,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,olabel,orig_index,label,prob_0,prob_1
0,22-oxacalcitriol,0,1,0,16,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,0,-1,0.9994956,0.0005043422
1,secondary hyperparathyroidism,2,4,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,1,-1,0.0007306917,0.9992693
2,low bone turnover,6,9,75,92,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,2,-1,0.0002668417,0.99973315
3,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,3,-1,0.0002126879,0.9997873
4,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,4,-1,0.99937797,0.0006219966
5,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,5,-1,0.9992455,0.000754497
6,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,6,-1,0.0002274776,0.9997725
8,suppression of bone turnover,27,31,180,208,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,8,-1,0.00026424238,0.9997358
9,lead,34,35,220,224,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,9,-1,0.0773473,0.9226527
10,adynamic bone disease,36,39,228,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,10,-1,0.0019180513,0.9980819
11,vitamin D,2,4,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,11,-1,0.99946254,0.000537492
12,22-oxacalcitriol,6,7,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,12,-1,0.99946827,0.00053180434
13,OCT,8,9,44,47,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,13,-1,0.99937904,0.00062091206
14,OCT,9,10,54,57,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,14,-1,0.999343,0.00065699115
15,impaired renal function,22,25,119,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,15,-1,0.00020783057,0.99979216
16,N,10,11,52,53,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,16,-1,0.6591502,0.34084985
17,N,19,20,84,85,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,17,-1,0.8078933,0.19210677
20,OCT,19,20,108,111,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,-1,20,-1,0.99904937,0.00095063215
22,OCT,26,27,156,159,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,-1,22,-1,0.9993782,0.00062174676
23,OCT,6,7,21,24,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,23,-1,0.99928373,0.0007163232
24,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,24,-1,0.00020965027,0.9997904
25,secondary hyperparathyroidism,2,4,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,25,-1,0.0001732383,0.99982685
26,OCT,5,6,48,51,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,26,-1,0.9992785,0.00072153326
28,hyperphosphatemia,9,10,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,-1,-1,28,-1,0.0005788104,0.99942124
29,OCT,7,8,39,42,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,-1,-1,-1,29,-1,0.99936,0.00063992804
30,OCT,4,5,12,15,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,30,-1,0.99933535,0.00066463096
31,abnormal bone formation,6,9,25,48,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,31,-1,0.00021136418,0.9997887
32,osteoid,13,14,64,71,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,32,-1,0.0002549471,0.9997451
34,OCT,3,4,13,16,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,-1,34,-1,0.9993299,0.00067008735
35,OCT,8,9,53,56,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,35,-1,0.9993031,0.00069685926
37,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,37,-1,0.0001982636,0.9998018
38,secondary hyperparathyroidism,33,35,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,38,-1,0.00020099919,0.9997991
39,low bone turnover,40,43,259,276,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,39,-1,0.0031910709,0.99680895
40,adynamic bone disease,53,56,323,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,40,-1,0.00020355891,0.99979645
49,ischemic cardiac disease,5,8,23,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,-1,-1,-1,49,-1,0.00020524903,0.9997948
50,hemoptysis,9,10,62,72,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,50,-1,0.0001982086,0.9998018
51,renal failure,13,15,94,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,51,-1,0.00020243764,0.9997975
52,hypoxemia,17,18,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,52,-1,0.00020077643,0.9997992
53,ventricular arrhythmia,7,9,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,-1,-1,53,-1,0.00019833715,0.9998017
54,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,54,-1,0.00020984506,0.99979013
56,IVMP,18,19,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,56,-1,0.9990526,0.00094736315
57,cardiac disease,4,6,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,57,-1,0.00020790927,0.99979216
58,ventricular arrhythmia,20,22,126,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,58,-1,0.00020838359,0.9997917
60,Parkinson's disease,4,7,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,-1,-1,60,-1,0.00018459279,0.9998154
66,postural hypotension,1,3,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,66,-1,0.0001953144,0.9998047
67,Parkinson's disease,4,7,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,67,-1,0.00024577172,0.99975425
68,Parkinson's Disease,5,8,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,68,-1,0.0004015775,0.99959844
69,Parkinson's disease,21,24,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,69,-1,0.00024458376,0.99975544
70,PD,25,26,148,150,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,70,-1,0.00023349847,0.9997665
71,mg selegiline,31,33,177,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,71,-1,0.999469,0.00053100305
77,PD,14,15,94,96,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,-1,-1,-1,77,-1,0.00021273151,0.9997873
80,PD,15,16,92,94,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,80,-1,0.00021451127,0.9997855
86,reduced the supine systolic and diastolic blood pressures,4,12,39,96,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,86,-1,0.0002484761,0.9997515
89,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,89,-1,0.9994553,0.0005447696
91,metamphetamine,20,21,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,91,-1,0.99948645,0.00051358534
94,Picloxydine,0,1,0,11,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,-1,-1,94,-1,0.9994647,0.0005353783
96,tetrandrine,2,3,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,96,-1,0.99949634,0.0005036009
97,fangchinoline,4,5,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,97,-1,0.9994942,0.0005057773
100,Tetrandrine,0,1,0,11,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,100,-1,0.999476,0.0005240586
101,TET,2,3,13,16,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,101,-1,0.99689037,0.0031096751
102,fangchinoline,5,6,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,102,-1,0.9994671,0.0005329265
103,FAN,7,8,37,40,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,103,-1,0.9991053,0.00089465355
104,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,104,-1,0.9994843,0.00051564886
105,TET,10,11,63,66,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,105,-1,0.00027953615,0.9997204
106,FAN,12,13,71,74,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,106,-1,0.00033963463,0.9996604
109,EP,23,24,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,109,-1,0.0002547384,0.9997453
112,TET,16,17,61,64,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,112,-1,0.00019081261,0.9998092
113,FAN,18,19,69,72,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,113,-1,0.99787104,0.0021289731
116,ASA,39,40,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,116,-1,0.99939454,0.0006054585
117,platelet aggregations,4,6,19,40,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,117,-1,0.00020429934,0.99979573
118,TET,14,15,80,83,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,118,-1,0.81861675,0.18138325
119,FAN,16,17,88,91,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,119,-1,0.9992455,0.00075453654
120,TET,4,5,21,24,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,120,-1,0.00025585122,0.9997441
121,FAN,6,7,29,32,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,121,-1,0.9847606,0.0152394315
122,TET,6,7,45,48,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,122,-1,0.00024156975,0.9997584
123,FAN,8,9,53,56,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,123,-1,0.9352444,0.06475564
124,tubular damage?BACKGROUND,6,8,51,76,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,124,-1,0.0062107593,0.99378926
125,renal tubular dysfunction,13,16,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,125,-1,0.00021577881,0.9997843
126,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,126,-1,0.9994487,0.00055128906
127,PAN,5,6,36,39,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,127,-1,0.99944705,0.0005529649
129,PAN,4,5,31,34,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,129,-1,0.080797456,0.9192025
130,protein excretion,40,42,226,243,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,130,-1,0.0036399495,0.99636
132,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,132,-1,0.012594462,0.9874055
134,cauda equina syndrome,18,21,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,134,-1,0.001108727,0.9988913
135,cauda equina syndrome,32,35,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,135,-1,0.008153518,0.9918465
138,mg,13,14,72,74,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,-1,-1,-1,138,-1,0.15316875,0.84683126
142,neurological deficits,4,6,30,51,All cases sustained permanent neurological deficits.,10225068_6,-1,-1,-1,142,-1,0.00020550635,0.99979454
144,mg,24,25,149,151,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,-1,144,-1,0.9985965,0.0014035212
149,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,-1,149,-1,0.00021413363,0.99978584
153,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,-1,153,-1,0.00021261755,0.9997874
155,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,-1,-1,155,-1,0.0002021869,0.9997979
162,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,-1,-1,162,-1,0.00022320832,0.9997768
164,capillary leak,7,9,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,164,-1,0.00021804136,0.999782
165,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,165,-1,0.00020816512,0.9997918
167,ACE inhibitors,3,5,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,-1,-1,167,-1,0.9994505,0.0005495206
172,thyroid disease,30,32,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,-1,172,-1,0.00023676771,0.9997632
173,Affective Disorders,2,4,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,-1,173,-1,0.00018671024,0.99981326
174,bipolar disorder,15,17,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,-1,174,-1,0.00020718656,0.9997929
182,thyroid illness,7,9,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,-1,182,-1,0.00021484552,0.9997851
193,thyroid illness,3,5,22,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,-1,193,-1,0.00020667199,0.99979335
197,mood disorder,1,3,16,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,197,-1,0.00020627982,0.9997937
198,psychiatric symptoms,7,9,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,198,-1,0.00020358434,0.99979645
199,mood disorders,17,19,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,-1,199,-1,0.00020276857,0.9997973
200,mood disorder,5,7,55,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,200,-1,0.00021640163,0.9997836
201,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,201,-1,0.0007715171,0.9992285
202,mood disorders,12,14,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,202,-1,0.00021416794,0.99978584
203,mood disorder,17,19,105,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,203,-1,0.00021552568,0.9997845
204,psychiatric symptoms,24,26,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,204,-1,0.00021414935,0.99978584
205,CIMD,4,5,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,-1,-1,-1,205,-1,0.00021605712,0.99978393
206,CIMD,6,7,40,44,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,206,-1,0.9821308,0.017869256
207,depressive disorders,15,17,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,207,-1,0.00020305491,0.9997969
208,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,208,-1,0.9993161,0.0006838685
209,mood disorder,15,17,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,209,-1,0.00020608953,0.99979395
210,CIMD,11,12,69,73,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,-1,210,-1,0.00024457465,0.99975544
211,fucoidan,2,3,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,211,-1,0.99943644,0.0005635349
212,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,212,-1,0.00020505967,0.9997949
215,Intracerebral hemorrhage,0,2,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,-1,-1,215,-1,0.00021016024,0.9997899
218,fucoidan,5,6,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,218,-1,0.999463,0.0005369287
220,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,220,-1,0.00020278172,0.9997973
221,fucoidan,9,10,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,-1,221,-1,0.9994518,0.0005481233
223,impaired blood clotting,5,8,44,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,223,-1,0.00022476348,0.99977523
224,hemodilution,9,10,72,84,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,224,-1,0.00020681905,0.99979323
225,hematomas,13,14,97,106,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,225,-1,0.00020999959,0.99979
229,white matter edema,1,4,6,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,229,-1,0.0060218144,0.99397814
230,neuronal loss,6,8,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,230,-1,0.00019891115,0.9998011
232,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,-1,232,-1,0.00020786168,0.99979216
234,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,-1,234,-1,0.99949145,0.0005085216
236,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,-1,236,-1,0.9995121,0.0004879683
238,hemolytic anemias,10,12,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,238,-1,0.00021080968,0.9997892
239,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,239,-1,0.99951684,0.00048313587
241,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,-1,241,-1,0.00020503897,0.999795
242,NSAIDs,9,10,71,77,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,-1,-1,-1,242,-1,0.99943393,0.00056600565
243,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,243,-1,0.0002157428,0.9997843
244,SAH,6,7,50,53,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,244,-1,0.0002157216,0.9997843
245,ketoprofen,13,14,89,99,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,245,-1,0.99952185,0.00047812107
246,mg,16,17,105,107,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,246,-1,0.9763373,0.023662731
247,ketoprofen,23,24,128,138,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,247,-1,0.9995235,0.0004764373
248,n,26,27,146,147,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,248,-1,0.74621916,0.25378078
249,NSAID,33,34,163,168,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,249,-1,0.99951315,0.00048681634
252,n,48,49,230,231,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,252,-1,0.92564136,0.07435861
253,aneurysmal SAH,58,60,281,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,253,-1,0.0002153447,0.99978465
255,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,255,-1,0.9994634,0.0005366412
256,ketoprofen,14,15,108,118,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,256,-1,0.9994875,0.00051240146
257,P,4,5,23,24,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,257,-1,0.14303307,0.856967
258,ketoprofen,10,11,39,49,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,258,-1,0.9994935,0.0005064773
260,contrast,1,2,3,11,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,260,-1,0.34813792,0.651862
264,P,25,26,174,175,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,264,-1,0.10170677,0.89829326
265,ketoprofen,4,5,19,29,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,-1,-1,265,-1,0.9994918,0.0005081306
267,Ketoprofen,0,1,0,10,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,267,-1,0.99947685,0.0005232311
269,SAH,10,11,77,80,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,269,-1,0.00021922331,0.99978083
270,ketoprofen,1,2,3,13,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,270,-1,0.9994803,0.0005197746
271,cerebral artery aneurysms,7,10,40,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,271,-1,0.00021705174,0.999783
273,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,273,-1,0.9994137,0.00058630615
274,flushing,11,12,79,87,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,274,-1,0.00037353163,0.9996264
275,respiratory arrest,1,3,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,275,-1,0.00021695117,0.9997831
276,desaturation,5,6,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,276,-1,0.0042644846,0.9957355
278,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,-1,-1,278,-1,0.00016703428,0.999833
281,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,-1,281,-1,0.000518598,0.9994814
286,mg,10,11,48,50,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,286,-1,0.99923813,0.00076186575
288,mg,15,16,71,73,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,288,-1,0.9992059,0.0007941547
290,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,290,-1,0.8523618,0.14763822
298,myocardial ischemia,8,10,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,-1,-1,298,-1,0.00019747383,0.99980253
299,Nitric oxide,0,2,0,12,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,-1,299,-1,0.9994276,0.00057235424
301,reactive oxygen species,4,7,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,301,-1,0.61498064,0.38501933
302,nitrotyrosine,26,27,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,302,-1,0.99939644,0.000603603
307,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,307,-1,0.99207956,0.0079205
308,lead,30,31,157,161,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,308,-1,0.9993692,0.0006308652
310,MDA,11,12,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,-1,-1,-1,310,-1,0.9991916,0.00080837705
311,rise in blood pressure,5,9,35,57,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,311,-1,0.00024373918,0.9997563
312,MDA,11,12,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,312,-1,0.99935895,0.0006410109
313,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,313,-1,0.9994247,0.00057538424
315,MDA,8,9,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,315,-1,0.99941564,0.0005843287
316,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,316,-1,0.999361,0.0006390206
317,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,317,-1,0.99863726,0.001362749
318,lead,11,12,76,80,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,-1,318,-1,0.9993672,0.0006328054
321,Glyceryl trinitrate,0,2,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,321,-1,0.99946624,0.00053378084
324,Migraine with,0,2,0,13,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,324,-1,0.28366473,0.7163353
325,aura,2,3,14,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,325,-1,0.12404297,0.8759571
327,aura,6,7,40,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,327,-1,0.23621526,0.7637847
330,aura,18,19,106,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,330,-1,0.000215271,0.99978477
331,migraine without,20,22,115,131,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,331,-1,0.036823213,0.9631768
332,aura,22,23,132,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,332,-1,0.09423407,0.90576595
333,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,333,-1,0.99943906,0.00056086574
335,migraine without aura,23,26,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,335,-1,0.00022738652,0.9997726
338,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,338,-1,0.9994709,0.0005291664
339,GTN,30,31,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,339,-1,0.9994294,0.0005706142
343,migraineurs,5,6,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,343,-1,0.00021432155,0.9997857
344,GTN,14,15,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,344,-1,0.989799,0.010201026
345,p=0.037,17,18,104,111,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,345,-1,0.350044,0.64995605
346,h,26,27,148,149,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,346,-1,0.99883956,0.0011604738
347,p,28,29,151,152,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,347,-1,0.49545383,0.50454617
349,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,-1,349,-1,0.00021146233,0.9997886
352,migraineurs,10,11,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,352,-1,0.00019157722,0.9998085
363,nonsmall cell lung carcinoma,4,8,32,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,-1,-1,363,-1,0.004853316,0.9951467
365,nonsmall cell lung carcinoma,6,10,39,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,365,-1,0.0018645099,0.99813545
366,NSCLC,11,12,69,74,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,366,-1,0.0002076034,0.9997924
369,VNB,10,11,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,369,-1,0.0003954197,0.99960464
371,GEM,15,16,89,92,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,371,-1,0.95375705,0.046242937
374,GEM,12,13,69,72,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,374,-1,0.9991654,0.0008346218
375,VNB,14,15,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,375,-1,0.84940034,0.1505997
376,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,376,-1,0.00021790856,0.99978215
378,NSCLC,6,7,43,48,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,-1,-1,-1,378,-1,0.00020198358,0.999798
381,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,381,-1,0.00030326904,0.99969673
382,GEM,11,12,49,52,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,382,-1,0.9936697,0.0063303313
390,P,28,29,151,152,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,-1,-1,390,-1,0.11366738,0.8863326
391,GEM,5,6,32,35,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,391,-1,0.9675749,0.032425098
392,VNB,7,8,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,392,-1,0.9942879,0.005712128
395,NSCLC,16,17,116,121,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,-1,395,-1,0.00021775941,0.99978226
397,calcium chloride,7,9,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,-1,-1,397,-1,0.99949694,0.00050304487
399,respiratory arrest,9,11,55,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,-1,-1,399,-1,0.00019436951,0.9998056
401,calcium chloride,3,5,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,-1,-1,401,-1,0.9994388,0.0005611797
405,calcium chloride,18,20,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,-1,-1,405,-1,0.99948263,0.00051737454
406,decreased renal function,2,5,14,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,406,-1,0.002664011,0.997336
407,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,407,-1,0.00021659031,0.99978346
408,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,408,-1,0.00021607174,0.99978393
409,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,409,-1,0.00021587592,0.9997842
410,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,410,-1,0.00021708569,0.999783
411,decreased renal function,48,51,350,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,411,-1,0.00022465829,0.99977535
412,reduction in renal function,8,12,55,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,412,-1,0.0002291217,0.99977094
413,CHF,15,16,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,413,-1,0.0002268285,0.9997732
414,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,414,-1,0.000218287,0.99978167
416,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,416,-1,0.00021960383,0.99978036
418,Decreased renal function,0,3,0,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,-1,-1,-1,418,-1,0.00021676796,0.9997832
421,mm Hg,30,32,192,197,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,421,-1,0.0042153434,0.9957846
424,diuretic,45,46,260,268,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,424,-1,0.99945873,0.000541247
426,decreased renal function,14,17,81,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,426,-1,0.00021698281,0.999783
427,P,20,21,121,122,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,427,-1,0.13880616,0.8611938
429,diuretic,14,15,78,86,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,429,-1,0.99937075,0.00062924146
431,decreased renal function,22,25,130,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,431,-1,0.00025772786,0.9997422
432,decreased renal function,10,13,59,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,-1,432,-1,0.00021117159,0.9997888
436,Diuretic,0,1,0,8,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,436,-1,0.99946445,0.0005355191
437,decreased renal function,10,13,64,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,437,-1,0.00022293885,0.999777
441,renal impairment,4,6,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,-1,441,-1,0.00022935185,0.9997707
443,decreased renal function,13,16,64,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,443,-1,0.00021489203,0.9997851
444,CHF,19,20,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,444,-1,0.00021848067,0.99978155
445,Diuretic,0,1,0,8,Diuretic use and advanced age increased this risk.,10539815_14,-1,-1,-1,445,-1,0.9994042,0.00059575896
447,renal impairment,8,10,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,447,-1,0.00020487538,0.99979514
448,CHF,14,15,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,448,-1,0.00020750328,0.9997925
452,psychotic disorder,13,15,73,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,452,-1,0.00019697381,0.999803
453,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,453,-1,0.00019850043,0.9998016
456,NRA0160,7,8,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,-1,-1,-1,456,-1,0.99307466,0.006925338
457,NRA0160,0,1,0,7,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,-1,457,-1,0.2240042,0.77599585
460,NRA0160,0,1,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,-1,-1,-1,460,-1,0.771528,0.22847204
463,NRA0160,0,1,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,463,-1,0.8857799,0.1142201
466,NRA0160,0,1,0,7,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,466,-1,0.99946195,0.00053807127
470,MAP,10,11,86,89,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,470,-1,0.9993856,0.00061440346
471,NRA0160,0,1,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,-1,471,-1,0.9994789,0.00052111025
473,NRA0160,0,1,0,7,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,-1,-1,473,-1,0.9994547,0.0005452951
476,NRA0160,0,1,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,-1,476,-1,0.9994253,0.0005747237
479,NRA0160,0,1,0,7,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,479,-1,0.9993956,0.00060443283
481,phencyclidine,6,7,50,63,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,481,-1,0.99950516,0.00049482036
482,NRA0160,4,5,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,482,-1,0.99885464,0.0011453698
483,antipsychotics,20,21,142,156,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,483,-1,0.99924064,0.0007594227
490,calcification of the artery,9,13,57,84,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,-1,-1,490,-1,0.00024403217,0.9997559
492,contrast,1,2,3,11,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,-1,-1,492,-1,0.9828295,0.017170463
496,ad,27,28,161,163,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,-1,-1,496,-1,0.9993857,0.000614308
498,calcification of the artery,11,15,81,108,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,498,-1,0.00021669711,0.99978334
499,ad,18,19,122,124,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,499,-1,0.9993563,0.00064363104
508,vitamin D,10,12,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,-1,-1,508,-1,0.9994648,0.000535204
511,vitamin D,3,5,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,511,-1,0.99945384,0.0005461937
512,calcification of the artery,9,13,43,70,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,512,-1,0.00023013055,0.99976987
513,vitamin K antagonist Warfarin,4,8,18,47,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,513,-1,0.99947256,0.0005274513
514,calcification of the artery,13,17,72,99,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,514,-1,0.0002282874,0.9997718
517,vitamin D,9,11,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,517,-1,0.99946445,0.0005355906
519,vitamin D,19,21,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,519,-1,0.9994672,0.0005327909
521,vitamin D,32,34,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,521,-1,0.99946696,0.00053301646
526,vitamin D,14,16,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,526,-1,0.9994553,0.0005447421
528,vitamin D,22,24,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,528,-1,0.9994517,0.00054831355
532,vitamin D,17,19,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,-1,532,-1,0.9994491,0.0005509382
537,dopamine agonist,4,6,28,44,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,-1,-1,-1,537,-1,0.9994319,0.00056809245
544,contrast,1,2,3,11,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,-1,544,-1,0.9632377,0.03676224
546,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,546,-1,0.99935704,0.00064290385
547,DA,6,7,32,34,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,547,-1,0.99937385,0.000626188
548,HVA,8,9,39,42,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,548,-1,0.9993606,0.0006393568
549,DA,10,11,43,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,549,-1,0.9993722,0.00062789296
551,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,-1,-1,551,-1,0.0095491195,0.9904509
553,acetazolamide,4,5,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,553,-1,0.9994648,0.00053524715
554,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,554,-1,0.00055691024,0.9994431
555,renal impairment,15,17,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,555,-1,0.00021150448,0.99978846
556,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,-1,556,-1,0.016663663,0.9833363
560,TAM,2,3,11,14,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,-1,560,-1,0.99943966,0.00056037825
563,TAM,6,7,35,38,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,-1,563,-1,0.9993832,0.0006167367
565,TAM,0,1,0,3,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,-1,-1,565,-1,0.9993086,0.0006913672
568,TAM,13,14,81,84,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,-1,-1,568,-1,0.9994665,0.0005334777
570,TAM,6,7,46,49,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,-1,570,-1,0.99929965,0.0007002985
571,hemolytic,1,2,4,13,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,571,-1,0.000208856,0.9997912
572,TAM,4,5,24,27,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,572,-1,0.9994816,0.0005184038
573,hydroxyl,24,25,158,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,573,-1,0.99948454,0.0005153988
577,TAM,6,7,34,37,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,577,-1,0.9992347,0.00076528935
578,AAPH,15,16,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,578,-1,0.008093214,0.99190676
580,TAM,3,4,20,23,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,-1,580,-1,0.9993736,0.0006264506
582,TAM,2,3,9,12,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,-1,582,-1,0.9993579,0.0006421339
583,TAM,9,10,68,71,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,-1,583,-1,0.9826111,0.017388865
585,tocopherols,9,10,60,71,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,585,-1,0.99948394,0.00051598914
586,TAM,15,16,98,101,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,586,-1,0.9994543,0.0005456837
588,TAM,13,14,100,103,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,-1,588,-1,0.9993456,0.0006543707
590,cytotoxicity,10,11,57,69,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,590,-1,0.0001884322,0.9998116
591,TAM,21,22,139,142,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,591,-1,0.99924755,0.0007524915
593,ATP,4,5,22,25,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,593,-1,0.9994191,0.00058089313
594,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,594,-1,0.9994373,0.0005626649
600,N(G)-nitro-L-arginine,34,35,222,243,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,-1,-1,-1,600,-1,0.9994629,0.0005371128
601,ATP,9,10,53,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,-1,601,-1,0.9993679,0.0006320947
603,ATP,30,31,165,168,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,603,-1,0.99937207,0.00062792795
622,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,-1,-1,-1,622,-1,0.9994468,0.00055314595
633,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,-1,-1,633,-1,0.00020428786,0.99979573
634,phosphodiesterase inhibitors,3,5,11,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,634,-1,0.9994727,0.0005272954
635,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,635,-1,0.9994814,0.0005187068
636,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,636,-1,0.00021087623,0.9997892
638,heart failure,4,6,31,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,638,-1,0.00021075823,0.9997893
640,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,640,-1,0.99949133,0.0005086598
642,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,642,-1,0.999493,0.00050701544
653,venous thromboembolism,10,12,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,-1,653,-1,0.00021341413,0.99978656
654,venous thromboembolism,8,10,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,654,-1,0.0001810578,0.999819
655,VTE,11,12,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,655,-1,0.00018668195,0.9998134
657,OC,19,20,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,657,-1,0.9992902,0.0007097942
658,OC,27,28,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,658,-1,0.9993044,0.0006955287
659,VTE,13,14,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,-1,659,-1,0.00021601388,0.99978405
660,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,-1,660,-1,0.0001925913,0.9998074
661,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,661,-1,0.00025049035,0.9997495
662,OC,12,13,68,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,662,-1,0.0003146698,0.9996854
663,VTE,14,15,92,95,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,-1,663,-1,0.00022242696,0.9997776
664,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,-1,664,-1,0.99923134,0.00076865364
676,mg,6,7,32,34,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,676,-1,0.9993006,0.0006993411
678,mg,23,24,114,116,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,678,-1,0.9994174,0.0005825823
696,CyA,14,15,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,-1,696,-1,0.9994573,0.0005426681
699,CyA.,15,16,104,108,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,-1,699,-1,0.04622971,0.9537703
702,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,702,-1,0.00022263212,0.9997774
703,IDDM,16,17,97,101,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,703,-1,0.005588891,0.99441105
705,gastrointestinal (GI) toxicity,27,32,128,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,705,-1,0.00026543625,0.9997346
708,IDDM,52,53,237,241,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,708,-1,0.0048994645,0.99510056
710,GI toxicity,62,64,268,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,710,-1,0.00022723632,0.9997727
712,lmphoproliferate disease,74,76,321,345,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,712,-1,0.0031669314,0.996833
713,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,713,-1,0.0004613,0.9995388
718,CyA,12,13,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,-1,-1,-1,718,-1,0.9994357,0.0005642384
726,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,-1,-1,726,-1,0.0001905239,0.99980944
727,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,-1,-1,727,-1,0.00019389084,0.9998061
728,iridocyclitis,10,11,49,62,Thirty-six of the 210 patients (17.2%) developed iridocyclitis.,1079693_2,-1,-1,-1,728,-1,0.015824545,0.9841755
729,Iridocyclitis,0,1,0,13,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,-1,-1,729,-1,0.016422862,0.9835772
731,uveitis,8,9,39,46,"However, 30% of the patients developed uveitis after 16 years of age.",1079693_4,-1,-1,-1,731,-1,0.0002076897,0.9997923
732,uveitis,17,18,87,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,-1,-1,-1,732,-1,0.00021282057,0.99978715
733,uveitis,6,7,40,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,733,-1,0.00019134792,0.9998087
734,uveitis,13,14,82,89,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,734,-1,0.00019178427,0.99980825
735,uveitis,5,6,36,43,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,735,-1,0.00021469152,0.99978536
736,signs or symptoms,11,14,73,90,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,736,-1,0.00022453345,0.99977547
737,ocular pain,20,22,109,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,737,-1,0.00021514748,0.9997849
738,decreased visual acuity,23,26,122,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,738,-1,0.0011364862,0.9988636
739,photophobia,28,29,150,161,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,739,-1,0.0017126088,0.9982874
740,uveitis,13,14,65,72,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,-1,-1,-1,740,-1,0.00020842969,0.99979156
742,uveitis,17,18,94,101,"Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.",1079693_9,-1,-1,-1,742,-1,0.00020346927,0.99979657
744,keratopathy,3,4,18,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,-1,-1,744,-1,0.00019124355,0.9998087
746,hydroxychloroquine,4,5,23,41,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,746,-1,0.9994978,0.000502268
747,chorioretinopathy,16,17,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,747,-1,0.000202104,0.9997979
750,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,750,-1,0.8408789,0.1591211
751,uveitis,8,9,61,68,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,751,-1,0.0002106662,0.9997893
752,uveitis,3,4,22,29,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,752,-1,0.00022060488,0.9997794
753,JRA,5,6,34,37,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,753,-1,0.00025270856,0.99974734
755,band keratopathy,5,7,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,-1,-1,755,-1,0.0026112949,0.9973888
759,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,-1,759,-1,0.00018568586,0.99981433
762,ruptured aneurysms,12,14,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,-1,762,-1,0.00019526189,0.9998048
764,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,-1,-1,764,-1,0.00020100284,0.9997991
767,P,19,20,108,109,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,-1,767,-1,0.06482267,0.9351773
770,mm,18,19,89,91,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,770,-1,0.0030788074,0.9969212
771,mm,24,25,110,112,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,771,-1,0.019484822,0.9805151
772,P,26,27,114,115,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,772,-1,0.12127421,0.87872577
773,P,5,6,21,22,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,773,-1,0.3377521,0.6622479
774,P,12,13,41,42,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,774,-1,0.33465025,0.6653497
777,aneurysmal rupture,5,7,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,-1,-1,777,-1,0.00019979657,0.99980026
780,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,-1,-1,780,-1,0.00021608247,0.99978393
783,reduction in blood pressure,19,23,134,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,783,-1,0.00023330796,0.99976665
784,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,784,-1,0.00020824434,0.9997918
786,n=100,22,23,130,135,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,786,-1,0.2072129,0.79278713
788,n=101,32,33,168,173,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,788,-1,0.23980395,0.76019603
790,n=94,43,44,210,214,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,790,-1,0.123147145,0.8768529
791,n=92,12,13,73,77,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,-1,-1,-1,791,-1,0.031446405,0.9685536
793,reduction in systolic BP,7,11,61,85,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,793,-1,0.0002301604,0.99976987
794,and,14,15,92,95,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,794,-1,0.000295864,0.99970406
795,BP,16,17,106,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,795,-1,0.00023225149,0.9997677
796,DBP reduction,8,10,60,73,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,796,-1,0.00023354297,0.9997664
797,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,797,-1,0.4740642,0.52593577
798,reduction,4,5,20,29,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,-1,798,-1,0.00022959798,0.99977046
802,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,802,-1,0.00021020952,0.9997898
806,visceral pain,14,16,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,-1,806,-1,0.00020957775,0.9997905
807,visceral pain,7,9,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,-1,807,-1,0.00018577084,0.9998142
809,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,809,-1,0.99911875,0.00088124454
810,acrolein,22,23,129,137,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,810,-1,0.9994537,0.0005462853
812,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,-1,-1,-1,812,-1,0.00035345697,0.99964654
815,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,-1,-1,-1,815,-1,0.00074762857,0.9992524
817,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,-1,817,-1,0.89208204,0.10791796
818,mg,5,6,15,17,i.p. and of 20 mg.,10840460_10,-1,-1,-1,818,-1,0.392796,0.60720396
819,acrolein,6,7,31,39,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,819,-1,0.99947184,0.000528149
820,mg,11,12,56,58,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,820,-1,0.95411927,0.045880754
821,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,-1,821,-1,0.042540736,0.9574593
823,behavioral disorders,4,6,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,-1,823,-1,0.00021648253,0.9997836
824,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,-1,824,-1,0.7130413,0.2869587
828,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,-1,-1,-1,828,-1,0.0058067203,0.99419326
829,mg,6,7,31,33,Administered at the dose of 20 mg.,10840460_20,-1,-1,-1,829,-1,0.9364301,0.06356993
830,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,830,-1,0.0002771742,0.9997228
831,acrolein,11,12,67,75,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,831,-1,0.99947435,0.0005256262
832,mg,14,15,83,85,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,832,-1,0.32942593,0.67057407
833,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,-1,-1,-1,833,-1,0.99909794,0.00090210844
834,acrolein,2,3,12,20,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,-1,834,-1,0.99945885,0.00054116605
836,visceral pain,23,25,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,836,-1,0.00019234412,0.99980766
837,painful syndromes,32,34,212,229,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,837,-1,0.00019093655,0.9998091
843,clonic fits,21,23,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,-1,-1,843,-1,0.0008238197,0.9991762
844,fits,1,2,4,8,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,-1,-1,844,-1,0.00026772136,0.9997323
850,emergency department,11,13,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,-1,-1,850,-1,0.0008692018,0.9991308
854,emergency department,26,28,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,-1,-1,854,-1,0.0025219617,0.99747807
855,fracture,32,33,164,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,855,-1,0.00021134966,0.9997887
856,dislocation,34,35,176,187,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,856,-1,0.00021150227,0.99978846
857,emergency department,37,39,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,857,-1,0.018949952,0.9810501
858,trauma,42,43,229,235,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,858,-1,0.00021245076,0.9997875
859,Ketamine hydrochloride,0,2,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,859,-1,0.99943024,0.0005696757
860,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,860,-1,0.003400093,0.9966
861,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,861,-1,0.009293097,0.9907069
865,fracture,14,15,93,101,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,865,-1,0.00018952975,0.9998105
866,dislocation,16,17,105,116,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,866,-1,0.00018887038,0.9998111
869,fracture,32,33,162,170,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,-1,869,-1,0.00021363341,0.99978644
870,fracture,1,2,9,17,Adequate fracture reduction was obtained in 111 of the children.,10901305_9,-1,-1,-1,870,-1,0.00017423356,0.9998258
872,emesis,10,11,56,62,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,872,-1,0.00022768245,0.99977237
874,clumsiness,21,22,109,119,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,874,-1,0.00023052344,0.9997695
875,ataxic,25,26,132,138,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,875,-1,0.9477804,0.0522196
876,dysphoric,33,34,171,180,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,876,-1,0.0002445292,0.99975544
880,emergency department,23,25,150,170,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,-1,-1,880,-1,0.00053010543,0.99946994
882,emergency department,11,13,59,79,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,-1,882,-1,0.0006825793,0.9993174
883,muscle dysfunction,1,3,21,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,-1,883,-1,0.00019657626,0.9998035
886,glucocorticoids,3,4,15,30,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,-1,-1,-1,886,-1,0.99934,0.0006599809
891,twitch,7,8,32,38,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,891,-1,0.0002096089,0.9997904
892,tetanic,10,11,49,56,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,892,-1,0.0002250607,0.999775
893,body weight gain,2,5,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,-1,-1,893,-1,0.00025545957,0.9997446
895,twitch,3,4,16,22,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,895,-1,0.00021277655,0.9997873
896,tetanic,5,6,27,34,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,896,-1,0.00043270408,0.99956733
897,neuromuscular dysfunction,5,7,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,897,-1,0.0002064331,0.9997936
899,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,899,-1,0.00020368511,0.99979633
900,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,-1,900,-1,0.00020827711,0.9997917
905,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,-1,905,-1,0.9994154,0.0005845791
908,immunoglobulin G,23,25,169,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,-1,908,-1,0.9994462,0.00055378163
912,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,-1,912,-1,0.8626372,0.13736276
914,TMA,12,13,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,-1,-1,-1,914,-1,0.9992963,0.00070372806
915,TMA,10,11,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,-1,-1,-1,915,-1,0.99941695,0.00058301527
918,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,-1,918,-1,0.99124384,0.008756175
921,TMA,13,14,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,-1,921,-1,0.34033254,0.6596675
924,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,924,-1,0.00023929618,0.9997607
925,TMA,22,23,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,925,-1,0.961321,0.03867901
927,Parkinson's disease,6,9,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,-1,927,-1,0.0002311983,0.9997688
929,Parkinson's disease,12,15,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,-1,929,-1,0.00022448483,0.99977547
930,Parkinson's disease,17,20,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,-1,930,-1,0.0001938169,0.9998062
936,dopamine agonists,35,37,209,226,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,-1,936,-1,0.99945694,0.0005430588
943,Parkinson's disease,12,15,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,-1,-1,-1,943,-1,0.00019538405,0.9998047
944,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,-1,944,-1,0.0007255162,0.99927455
945,increase in pupil diameter,14,18,78,104,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,-1,-1,-1,945,-1,0.00021519486,0.99978477
948,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,-1,-1,-1,948,-1,0.9994716,0.0005284517
949,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,-1,-1,-1,949,-1,0.99947673,0.00052325096
952,mg,12,13,58,60,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,-1,952,-1,0.99843735,0.0015626068
953,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,953,-1,0.9995034,0.00049666094
955,impairment in word recall,16,20,117,142,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,955,-1,0.00028882665,0.9997111
956,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,956,-1,0.9994886,0.0005113432
957,p,22,23,138,139,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,957,-1,0.15298562,0.8470144
958,p,30,31,175,176,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,-1,958,-1,0.0832466,0.9167534
959,impairment in word recall,12,16,81,106,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,959,-1,0.00022559566,0.9997744
960,p,25,26,152,153,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,960,-1,0.14221124,0.85778874
961,pupillary,6,7,36,45,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,961,-1,0.00019302533,0.99980694
963,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,963,-1,0.99948347,0.0005165273
969,opioid addicts,15,17,89,103,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,969,-1,0.0020619899,0.997938
970,MM,21,22,141,143,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,970,-1,0.9988017,0.0011982357
971,n,25,26,156,157,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,971,-1,0.7685323,0.23146774
972,n,37,38,220,221,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,972,-1,0.7610756,0.2389244
973,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,973,-1,0.00020173666,0.99979824
975,hydromorphone,32,33,188,201,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,975,-1,0.9994715,0.000528492
976,mg,34,35,204,206,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,976,-1,0.99934715,0.0006528841
977,ketorolac,40,41,244,253,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,977,-1,0.99946505,0.00053496636
978,mg,42,43,257,259,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,978,-1,0.9993562,0.0006438316
979,MM,3,4,20,22,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,979,-1,0.1222884,0.87771153
980,CP pain,10,12,71,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,980,-1,0.0002048092,0.99979526
981,MM,4,5,25,27,These data indicate that MM opioid abusers represent a pain-intolerant subset of clinical patients.,11027904_6,-1,-1,-1,981,-1,0.9993062,0.0006937965
988,NMDA,9,10,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,988,-1,0.99946624,0.00053378823
989,antagonists,11,12,76,87,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,989,-1,0.9994685,0.0005315282
991,analgesia,23,24,144,153,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,991,-1,0.00025200765,0.99974793
999,nausea and vomiting,10,13,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,999,-1,0.0002443907,0.99975556
1000,drowsiness,14,15,66,76,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1000,-1,0.00021824331,0.9997818
1007,mg,9,10,63,65,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,-1,-1,-1,1007,-1,0.9994318,0.00056816667
1008,drowsiness,3,4,25,35,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,-1,1008,-1,0.00018111234,0.99981886
1013,morphine analgesia,3,5,21,39,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,-1,-1,1013,-1,0.0059938263,0.99400616
1018,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,-1,-1,1018,-1,0.00021351386,0.99978656
1019,Spinal Cord Injury,5,8,30,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1019,-1,0.00019394631,0.9998061
1021,spinal cord injury,23,26,138,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1021,-1,0.00019200293,0.999808
1022,corticosteroid myopathy,13,15,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,-1,-1,1022,-1,0.0022442576,0.9977557
1026,damage to the muscle,7,11,38,58,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1026,-1,0.00041400717,0.99958605
1027,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1027,-1,0.00019484751,0.99980515
1028,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1028,-1,0.0022811443,0.9977189
1029,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1029,-1,0.0022313665,0.99776864
1031,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1031,-1,0.00019372159,0.99980634
1033,corticosteroid myopathy,21,23,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,-1,-1,1033,-1,0.0020449928,0.99795496
1035,RAPA,13,14,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1035,-1,0.93211603,0.067884
1037,CsA,20,21,117,120,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1037,-1,0.99940646,0.00059354916
1039,Tac,25,26,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1039,-1,0.9994166,0.00058346364
1042,RAPA,13,14,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,-1,-1,-1,1042,-1,0.9982607,0.0017393834
1043,CsA,6,7,40,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1043,-1,0.9990029,0.0009971799
1044,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1044,-1,0.0021989131,0.9978011
1045,CsA,15,16,78,81,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1045,-1,0.9990748,0.0009251508
1046,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1046,-1,0.0050520757,0.9949479
1047,facial dysmorphism,24,26,110,128,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1047,-1,0.00021776732,0.99978226
1048,posttransplant lymphoproliferative disorder,30,33,134,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1048,-1,0.0016132073,0.99838686
1049,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1049,-1,0.002532096,0.9974679
1053,P<0.05,25,26,162,168,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,-1,-1,1053,-1,0.04379993,0.9562
1054,dysmorphism,1,2,7,18,Facial dysmorphism improved in two patients.,11063349_7,-1,-1,-1,1054,-1,0.00020133062,0.9997987
1055,PTLD,3,4,14,18,No relapse of PTLD was observed.,11063349_8,-1,-1,-1,1055,-1,0.00021950755,0.9997805
1056,pneumonia,3,4,24,33,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1056,-1,0.00021843752,0.99978155
1057,Pneumocystis carinii pneumonia,6,9,39,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1057,-1,0.0013945876,0.99860543
1058,infectious mononucleosis,11,13,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1058,-1,0.00045640272,0.9995436
1059,PTLD,15,16,116,120,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1059,-1,0.00021568313,0.9997843
1060,bronchiolitis obliterans,22,24,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1060,-1,0.8834145,0.116585515
1062,RAPA,0,1,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1062,-1,0.99935454,0.00064545055
1063,pneumonia,9,10,51,60,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1063,-1,0.00021145064,0.9997886
1064,PTLD,13,14,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1064,-1,0.00022539636,0.99977463
1065,aphtous ulcers,19,21,91,105,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1065,-1,0.00020791382,0.99979216
1066,RAPA,0,1,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,-1,-1,-1,1066,-1,0.9985222,0.0014778473
1067,RAPA,2,3,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1067,-1,0.99934953,0.00065042527
1068,CsA,9,10,75,78,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1068,-1,0.99930835,0.00069170864
1069,RAPA,6,7,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1069,-1,0.9994369,0.00056308764
1070,Pneumocystis carinii pneumonia,19,22,133,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1070,-1,0.00087506697,0.99912494
1071,visual field constriction,15,18,142,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,-1,1071,-1,0.00022554987,0.9997745
1072,visual field constriction,3,6,21,46,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,-1,-1,-1,1072,-1,0.00020522457,0.9997948
1074,visual field loss,16,19,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,-1,1074,-1,0.00020915712,0.99979085
1076,visual field constriction,6,9,38,63,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,-1,-1,-1,1076,-1,0.00020827592,0.9997917
1077,visual field constriction,3,6,19,44,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,-1,1077,-1,0.00017111521,0.9998288
1080,Myocardial ischemia,0,2,0,19,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1080,-1,0.00020643172,0.9997936
1081,coronary artery spasm,4,7,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1081,-1,0.00020461789,0.9997954
1084,myocardial ischemia,14,16,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,-1,1084,-1,0.00021035608,0.99978966
1085,lesion in the coronary artery,12,17,57,86,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1085,-1,0.00028443793,0.9997155
1086,coronary artery stenosis,28,31,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1086,-1,0.0001929431,0.99980706
1087,myocardial ischemia,10,12,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,-1,-1,1087,-1,0.00018845807,0.9998116
1090,spastic angina,8,10,46,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1090,-1,0.00020486953,0.99979514
1091,coronary artery stenosis,14,17,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1091,-1,0.0002030135,0.99979705
1092,anginal attacks,3,5,17,32,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,-1,-1,1092,-1,0.00045262728,0.9995473
1096,coronary artery stenosis,13,16,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,-1,1096,-1,0.00020490588,0.99979514
1098,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1098,-1,0.00021608907,0.99978393
1099,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1099,-1,0.00021848899,0.99978155
1102,spastic angina,14,16,98,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,-1,-1,1102,-1,0.0002017303,0.99979824
1103,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1103,-1,0.00019872216,0.99980134
1104,coronary stenosis,13,15,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1104,-1,0.00019807406,0.99980193
1108,myocardial ischemia,11,13,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,-1,-1,-1,1108,-1,0.00021505643,0.999785
1111,technetium-99m sestamibi,14,17,89,113,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,-1,1111,-1,0.9994997,0.0005003225
1117,mg,29,30,176,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,-1,1117,-1,0.8831176,0.116882354
1119,predobutamine,7,8,42,55,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1119,-1,0.9994838,0.0005161552
1120,mg,20,21,123,125,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1120,-1,0.99943274,0.0005671997
1126,myocardial ischemia,13,15,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,-1,-1,-1,1126,-1,0.00021048552,0.99978954
1127,mg,2,3,11,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,-1,-1,-1,1127,-1,0.99938416,0.0006158703
1130,LID,36,37,216,219,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,-1,1130,-1,0.00032839764,0.9996716
1133,LID,52,53,360,363,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,-1,1133,-1,0.0005432348,0.9994568
1134,P,8,9,48,49,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1134,-1,0.1774283,0.82257164
1135,LID,31,32,145,148,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1135,-1,0.000215478,0.9997845
1141,LID,17,18,109,112,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,-1,1141,-1,0.00021590327,0.99978405
1147,LID,26,27,137,140,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,-1,-1,1147,-1,0.0002909487,0.99970907
1153,nonsmall cell lung carcinoma,15,19,126,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,-1,-1,1153,-1,0.0019565343,0.9980434
1154,nonsmall cell lung carcinoma,13,17,103,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1154,-1,0.0013624129,0.9986376
1155,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1155,-1,0.00021404219,0.99978596
1160,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,-1,1160,-1,0.00021053328,0.99978954
1161,NSCLC,7,8,66,71,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,-1,1161,-1,0.00019799081,0.99980205
1165,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,-1,-1,1165,-1,0.00023413223,0.9997658
1178,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,-1,1178,-1,0.00021639667,0.9997836
1179,Serotonergic antidepressants,0,2,0,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1179,-1,0.9994542,0.0005457412
1180,urinary incontinence,3,5,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1180,-1,0.00021866987,0.9997813
1181,serotonergic antidepressants,2,4,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,-1,-1,-1,1181,-1,0.99943274,0.0005671759
1182,urinary incontinence,1,3,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,-1,-1,1182,-1,0.000182396,0.99981767
1186,serotonin reuptake inhibitors paroxetine,17,21,114,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,-1,-1,1186,-1,0.99937207,0.00062794436
1189,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,-1,-1,1189,-1,0.9994654,0.00053457
1192,serotonergic antidepressants,7,9,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,-1,1192,-1,0.99947053,0.0005294408
1202,emergency department seizure,6,9,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,-1,-1,1202,-1,0.00051586615,0.99948406
1205,emergency department seizure,23,26,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,-1,-1,1205,-1,0.00041062772,0.9995894
1212,seizure disorder,9,11,68,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1212,-1,0.0002279809,0.999772
1215,amphetamine abuse,26,28,171,188,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1215,-1,0.015752198,0.9842478
1219,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1219,-1,0.015382261,0.9846177
1220,p,22,23,129,130,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1220,-1,0.87389106,0.12610888
1222,amphetamines,13,14,80,92,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,-1,-1,1222,-1,0.99943143,0.0005684987
1225,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1225,-1,0.9994529,0.00054705905
1226,syndrome of inappropriate secretion of antidiuretic hormone,6,13,40,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1226,-1,0.648941,0.351059
1227,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1227,-1,0.9994122,0.00058782194
1228,VPA,14,15,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1228,-1,0.00026159754,0.9997384
1229,syndrome of inappropriate secretion of antidiuretic hormone,21,28,119,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1229,-1,0.7747389,0.22526109
1230,SIADH,29,30,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1230,-1,0.9981614,0.0018386416
1231,VPA,4,5,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,-1,-1,1231,-1,0.9410681,0.058931816
1233,VPA,2,3,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,-1,-1,-1,1233,-1,0.99942076,0.00057926186
1236,SIADH,5,6,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1236,-1,0.0001909564,0.9998091
1237,weakness of the central nervous system,17,23,91,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1237,-1,0.00020228872,0.99979776
1238,VPA,28,29,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1238,-1,0.99940133,0.0005986882
1240,tizanidine,5,6,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,-1,1240,-1,0.9994916,0.00050845335
1243,alpha-2 adrenergic agonists,2,5,17,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1243,-1,0.9994703,0.0005297696
1244,spasticity,16,17,110,120,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1244,-1,0.00020081911,0.9997992
1245,disorders of the central nervous system,19,25,132,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1245,-1,0.00043635335,0.99956363
1246,spasticity,6,7,32,42,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,-1,1246,-1,0.00020240928,0.99979764
1248,enzyme inhibitors,6,8,55,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,-1,1248,-1,0.999401,0.0005989872
1250,lisinopril,9,10,63,73,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1250,-1,0.9994992,0.00050078245
1254,tizanidine,27,28,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1254,-1,0.9994998,0.0005002441
1255,spasticity,37,38,248,258,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1255,-1,0.00019879286,0.9998012
1256,tizanidine,4,5,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1256,-1,0.99950063,0.0004993258
1257,antihypertensive agents,7,9,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1257,-1,0.81839305,0.181607
1259,spasticity,22,23,153,163,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1259,-1,0.00021446178,0.9997856
1266,pentylenetetrazol,24,25,140,157,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1266,-1,0.9994754,0.0005245611
1267,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,-1,-1,1267,-1,0.9994061,0.00059396453
1269,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,-1,-1,-1,1269,-1,0.99942845,0.0005715065
1270,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1270,-1,0.00018986763,0.99981016
1272,ADR,27,28,158,161,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1272,-1,0.99945694,0.0005430831
1273,nitrite,12,13,68,75,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,-1,1273,-1,0.9992786,0.00072136713
1275,aminoguanidine,21,22,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1275,-1,0.9994367,0.00056334265
1276,AG,23,24,123,125,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1276,-1,0.9992261,0.0007739409
1277,ADR,11,12,75,78,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1277,-1,0.9994337,0.0005662782
1278,mesangial proliferation,16,18,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1278,-1,0.00021010534,0.9997899
1279,tubulointerstitial inflammation,20,22,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1279,-1,0.00025019416,0.99974984
1281,P,15,16,101,102,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,-1,1281,-1,0.08293206,0.917068
1282,nitrite,1,2,6,13,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1282,-1,0.9994081,0.00059194077
1283,P,11,12,80,81,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1283,-1,0.055192895,0.9448071
1286,AG,2,3,15,17,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1286,-1,0.99933976,0.0006602178
1287,nitrite,15,16,98,105,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1287,-1,0.9993073,0.00069266907
1289,melatonin,3,4,16,25,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1289,-1,0.9994387,0.00056127546
1290,narcosis,6,7,49,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1290,-1,0.0006882905,0.9993117
1291,Melatonin,0,1,0,9,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1291,-1,0.9993395,0.0006604522
1292,narcosis,17,18,108,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1292,-1,0.0002288346,0.9997712
1293,Sodium thiopenthal,0,2,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1293,-1,0.99943,0.00056992227
1294,melatonin,10,11,86,95,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1294,-1,0.9994074,0.00059258204
1295,Melatonin,0,1,0,9,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1295,-1,0.9994407,0.00055927655
1296,barbiturate narcosis,7,9,50,70,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1296,-1,0.035561975,0.9644381
1297,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,-1,1297,-1,0.0072098495,0.9927901
1298,contrast,1,2,3,11,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1298,-1,0.74224,0.25776
1299,melatonin,7,8,33,42,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1299,-1,0.9993955,0.0006044798
1300,narcosis,28,29,153,161,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1300,-1,0.017502217,0.98249775
1301,Melatonin,0,1,0,9,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1301,-1,0.9994764,0.00052369956
1302,narcosis,16,17,103,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1302,-1,0.0005721478,0.99942786
1303,melatonin,6,7,25,34,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1303,-1,0.9993919,0.00060809683
1304,narcosis,9,10,54,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1304,-1,0.999225,0.00077496254
1305,barbiturate,16,17,92,103,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1305,-1,0.99941945,0.0005805735
1312,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1312,-1,0.00022575747,0.9997743
1315,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1315,-1,0.0020404013,0.9979596
1317,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1317,-1,0.15494207,0.84505796
1318,MBC,9,10,61,64,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1318,-1,0.9993967,0.0006033188
1319,Myocet,26,27,162,168,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1319,-1,0.00023439535,0.9997656
1322,C,46,47,259,260,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1322,-1,0.980309,0.019690959
1323,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1323,-1,0.00023439043,0.9997656
1326,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1326,-1,0.00020678554,0.99979323
1327,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1327,-1,0.0002085561,0.99979144
1329,MC,5,6,24,26,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1329,-1,0.7984316,0.20156838
1330,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1330,-1,0.00020661997,0.99979335
1331,AC,18,19,80,82,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1331,-1,0.00020486035,0.99979514
1333,P,23,24,118,119,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1333,-1,0.556181,0.443819
1335,MC,13,14,76,78,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1335,-1,0.00040061146,0.9995994
1336,AC,19,20,102,104,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1336,-1,0.00027852392,0.99972147
1337,P,21,22,106,107,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1337,-1,0.07929909,0.9207009
1338,MC,0,1,0,2,MC patients also experienced less grade 4 neutropenia.,11230490_7,-1,-1,-1,1338,-1,0.9986971,0.0013029224
1340,MC,3,4,22,24,"Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months.",11230490_8,-1,-1,-1,1340,-1,0.997813,0.002187039
1341,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1341,-1,0.0005409399,0.9994591
1346,MBC,33,34,247,250,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1346,-1,0.9994616,0.0005384497
1348,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,-1,-1,1348,-1,0.9994772,0.0005228639
1356,contrast,1,2,3,11,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,-1,-1,1356,-1,0.46203038,0.5379696
1360,cyclophosphamide cytotoxicity,6,8,56,85,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,-1,1360,-1,0.017573286,0.98242676
1363,cytotoxicity,23,24,131,143,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,-1,-1,1363,-1,0.00020764658,0.9997924
1374,se,10,11,74,76,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,-1,1374,-1,0.015521133,0.9844789
1381,cytotoxicity,7,8,63,75,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,-1,1381,-1,0.00020953917,0.9997905
1396,Graves' disease,6,9,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1396,-1,0.00021460495,0.99978536
1397,febrile illness,11,13,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1397,-1,0.0001997478,0.99980026
1403,propylthio-,15,16,116,127,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1403,-1,0.9994696,0.00053047336
1404,propylthio-,15,16,116,127,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1404,-1,0.9994696,0.00053047336
1405,uracil,16,17,128,134,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1405,-1,0.99947244,0.0005275702
1408,propylthio-,13,14,101,112,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,-1,-1,1408,-1,0.9994685,0.0005315368
1411,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,-1,-1,1411,-1,0.000192163,0.9998079
1413,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1413,-1,0.00019324193,0.9998068
1414,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1414,-1,0.0001915825,0.9998085
1417,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1417,-1,0.00018942298,0.99981064
1418,pulmonary edema,8,10,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1418,-1,0.00019005727,0.9998099
1419,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,-1,1419,-1,0.88923526,0.11076477
1420,mg,7,8,35,37,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1420,-1,0.9993814,0.0006185967
1424,amine,24,25,137,142,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1424,-1,0.9994728,0.0005272125
1426,mg,18,19,90,92,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,-1,-1,1426,-1,0.9988533,0.0011466399
1429,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,-1,-1,1429,-1,0.00018659492,0.9998134
1430,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1430,-1,0.00020011113,0.9997999
1431,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1431,-1,0.00020418466,0.99979585
1432,diuretic,12,13,71,79,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1432,-1,0.0063380417,0.993662
1433,angiotensin II,4,6,23,37,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,-1,-1,-1,1433,-1,0.9994696,0.0005304016
1435,angiotensin II,8,10,46,60,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1435,-1,0.9994568,0.0005432346
1436,antagonist losartan,11,13,70,89,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1436,-1,0.9994622,0.00053778023
1437,renovascular disease,21,23,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1437,-1,0.00021448795,0.9997855
1438,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1438,-1,0.00020615711,0.9997938
1439,CIPS,5,6,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1439,-1,0.00028126125,0.9997187
1440,Bone pain,0,2,0,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,-1,-1,-1,1440,-1,0.0002162317,0.9997838
1443,oedema,6,7,52,58,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1443,-1,0.00019704257,0.999803
1444,painful,9,10,66,73,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1444,-1,0.00019709047,0.9998029
1446,foot pain,8,10,49,58,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1446,-1,0.00023291924,0.9997671
1447,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1447,-1,0.00020845192,0.99979156
1449,Morton's neuralgia,18,21,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1449,-1,0.00033728915,0.99966276
1450,gout,22,23,131,135,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1450,-1,0.003749102,0.9962509
1452,avascular necrosis,26,28,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1452,-1,0.00021664564,0.99978334
1453,intermittent claudication,29,31,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1453,-1,0.00021496805,0.999785
1454,foot deformities,33,35,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1454,-1,0.00025334107,0.9997466
1455,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1455,-1,0.0012564864,0.9987436
1456,hyperparathyroidism,40,41,250,269,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1456,-1,0.0003205051,0.99967957
1458,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,-1,-1,1458,-1,0.999466,0.0005339989
1460,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1460,-1,0.00022932036,0.9997707
1461,CIPS,6,7,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1461,-1,0.0008407319,0.9991592
1464,lead,6,7,41,45,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1464,-1,0.005374079,0.99462587
1465,CIPS,18,19,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1465,-1,0.00021037234,0.99978966
1466,haemorrhagic myocarditis,1,3,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,-1,1466,-1,0.00021350734,0.99978656
1468,Haemorrhagic myocarditis,0,2,0,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,-1,-1,-1,1468,-1,0.00020294031,0.99979705
1471,Anthracyclines,0,1,0,14,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1471,-1,0.9994436,0.00055639347
1472,antineoplastic drugs,3,5,29,49,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1472,-1,0.9994469,0.0005530447
1478,acute leukemia,29,31,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,-1,1478,-1,0.00022146874,0.99977857
1480,acute leukemia,3,5,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,-1,1480,-1,0.00019106951,0.99980897
1481,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,-1,-1,1481,-1,0.00020043596,0.99979955
1482,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,-1,-1,1482,-1,0.00020306051,0.9997969
1483,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1483,-1,0.00020759905,0.9997924
1484,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1484,-1,0.00020743265,0.99979264
1485,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1485,-1,0.0001985608,0.99980146
1486,DNR,16,17,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1486,-1,0.9989428,0.0010572558
1487,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1487,-1,0.9973755,0.0026245373
1488,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1488,-1,0.00019436172,0.9998056
1491,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,-1,1491,-1,0.00021500824,0.999785
1492,remodeling,4,5,39,49,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1492,-1,0.0002108541,0.9997892
1493,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1493,-1,0.00020946705,0.9997905
1494,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1494,-1,0.00020933388,0.9997907
1495,AF,15,16,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1495,-1,0.00022281986,0.99977714
1496,AF,20,21,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1496,-1,0.00023590359,0.99976414
1497,AF,8,9,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1497,-1,0.013544376,0.9864557
1501,nadolol,13,14,81,88,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,-1,-1,-1,1501,-1,0.99951196,0.00048799152
1502,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,-1,1502,-1,0.00021834343,0.99978167
1504,AF,4,5,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1504,-1,0.00017908891,0.9998209
1505,AF,14,15,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1505,-1,0.00017946876,0.99982053
1508,P<0.02,19,20,109,115,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1508,-1,0.22682364,0.7731764
1509,ms,27,28,142,144,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1509,-1,0.11967876,0.88032126
1510,AF,52,53,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1510,-1,0.00021689491,0.9997831
1512,AF,6,7,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1512,-1,0.00023664924,0.9997633
1513,AF,10,11,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1513,-1,0.00022290081,0.99977714
1515,n=5,24,25,136,139,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1515,-1,0.9282647,0.07173538
1517,AF,11,12,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,-1,-1,-1,1517,-1,0.00021227462,0.99978775
1521,AF,6,7,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,-1,-1,1521,-1,0.00026686437,0.99973315
1523,AF,4,5,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,-1,1523,-1,0.00024040553,0.9997596
1528,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1528,-1,0.9994572,0.0005428647
1530,primary headaches,13,15,64,81,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1530,-1,0.00020634002,0.9997937
1532,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1532,-1,0.9994554,0.00054458994
1533,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1533,-1,0.0005101723,0.9994898
1535,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1535,-1,0.9994449,0.0005551171
1536,GTN,22,23,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1536,-1,0.9517886,0.048211347
1538,GTN,9,10,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,-1,1538,-1,0.6333224,0.36667758
1540,GTN,11,12,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,-1,-1,1540,-1,0.92679954,0.07320051
1542,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1542,-1,0.9988544,0.0011455438
1543,GTN,15,16,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1543,-1,0.0031746347,0.99682534
1544,P=0.65,23,24,115,121,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1544,-1,0.09053262,0.9094674
1545,P=0.48,28,29,136,142,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1545,-1,0.08272409,0.91727597
1546,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1546,-1,0.8946809,0.10531908
1547,P=0.36,15,16,82,88,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1547,-1,0.02899169,0.97100836
1548,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1548,-1,0.0039706044,0.9960294
1549,GTN,16,17,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1549,-1,0.910728,0.089271985
1550,P,21,22,110,111,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1550,-1,0.13914676,0.86085325
1552,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,-1,1552,-1,0.00040335982,0.99959666
1553,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,-1,1553,-1,0.0003745776,0.99962544
1554,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1554,-1,0.00033904923,0.99966097
1555,TDP,12,13,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1555,-1,0.99914753,0.00085245736
1556,fluconazole,16,17,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1556,-1,0.99945265,0.00054740027
1557,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1557,-1,0.99925226,0.00074768724
1558,abscess,14,15,88,95,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1558,-1,0.00018578325,0.9998142
1559,TDP,16,17,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1559,-1,0.99943715,0.00056279165
1560,fluconazole,22,23,143,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1560,-1,0.99946684,0.0005331872
1561,TDP,31,32,197,200,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1561,-1,0.999438,0.00056204683
1562,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1562,-1,0.00017998356,0.99982005
1564,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1564,-1,0.00018475232,0.9998153
1565,fluconazole,56,57,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1565,-1,0.99946433,0.0005357195
1566,TDP,58,59,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1566,-1,0.9994555,0.0005444887
1567,TDP,1,2,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1567,-1,0.99945384,0.00054614036
1568,fluconazole,4,5,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1568,-1,0.9994641,0.0005358776
1569,premature ventricular contractions,15,18,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1569,-1,0.00021804406,0.999782
1571,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1571,-1,0.0003569516,0.9996431
1572,fluconazole,47,48,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1572,-1,0.9994661,0.00053387653
1573,TDP,52,53,347,350,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1573,-1,0.91474265,0.08525733
1576,QT prolongation,13,15,74,89,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1576,-1,0.00021410098,0.99978596
1577,TDP,16,17,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1577,-1,0.000221923,0.9997781
1578,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1578,-1,0.00021804695,0.9997819
1579,premature ventricular contractions,23,26,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1579,-1,0.00021470993,0.99978524
1580,fluconazole,39,40,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1580,-1,0.99947137,0.00052861037
1581,fluconazole,7,8,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1581,-1,0.999458,0.00054193696
1582,prolongation of the QT interval,16,21,87,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1582,-1,0.00023794091,0.9997621
1583,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1583,-1,0.9993913,0.0006086653
1584,fluconazole,7,8,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,-1,-1,1584,-1,0.99949515,0.0005048751
1588,renal failure,12,14,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1588,-1,0.00017780921,0.9998222
1589,cephalothin sodium,22,24,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1589,-1,0.9994795,0.0005205086
1590,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1590,-1,0.99945503,0.0005449246
1592,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,-1,-1,1592,-1,0.00020363597,0.99979633
1596,lung toxicity,17,19,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1596,-1,0.0030480728,0.99695194
1598,IH636 grape seed proanthocyanidin extract,25,30,207,248,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1598,-1,0.9995177,0.00048235134
1599,Grape seed extract,0,3,0,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1599,-1,0.9994337,0.0005663308
1600,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1600,-1,0.99945444,0.0005455032
1601,IH636 grape seed proanthocyanidin extract,6,11,35,76,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1601,-1,0.99950194,0.0004980336
1602,GSPE,12,13,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1602,-1,0.9994708,0.00052927894
1606,lung toxicity,22,24,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1606,-1,0.00023676072,0.9997632
1609,GSPE,13,14,71,75,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,-1,-1,-1,1609,-1,0.8989843,0.10101563
1610,GSPE,11,12,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,-1,1610,-1,0.9984497,0.0015502837
1611,AAP,7,8,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1611,-1,0.99924016,0.000759819
1612,h,13,14,64,65,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1612,-1,0.025030715,0.9749692
1613,AMI,15,16,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1613,-1,0.0076008756,0.99239916
1614,DOX,23,24,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1614,-1,0.9992586,0.0007413858
1615,h,29,30,121,122,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1615,-1,0.033316165,0.96668386
1616,BUN,11,12,63,66,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1616,-1,0.99806875,0.0019313048
1617,PAS,39,40,247,250,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1617,-1,0.9991357,0.0008643384
1618,GSPE,3,4,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1618,-1,0.9985285,0.0014714669
1619,AAP,7,8,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1619,-1,0.99929595,0.00070401677
1620,AMI,9,10,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1620,-1,0.9991346,0.00086541305
1621,DOX,11,12,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1621,-1,0.9992519,0.00074803655
1622,BUN,26,27,142,145,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1622,-1,0.99906176,0.00093821797
1623,tissue damage,13,15,94,107,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1623,-1,0.00019326329,0.9998067
1624,GSPE,30,31,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1624,-1,0.9994461,0.0005538566
1625,AAP,9,10,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1625,-1,0.9994374,0.0005625313
1626,AMI,11,12,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1626,-1,0.99939585,0.0006041509
1627,DOX,13,14,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1627,-1,0.999406,0.00059405685
1630,GSPE,31,32,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1630,-1,0.99944395,0.0005560142
1631,AAP,1,2,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1631,-1,0.9993654,0.00063461124
1632,AMI,3,4,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1632,-1,0.99930274,0.0006972117
1633,DOX,5,6,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1633,-1,0.99933296,0.00066697015
1634,GSPE,21,22,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1634,-1,0.99934906,0.00065092446
1636,GSPE,7,8,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,-1,1636,-1,0.9990996,0.0009004244
1637,Cutaneous leucocytoclastic vasculitis,0,3,0,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1637,-1,0.00033142552,0.9996686
1638,oxacillin,5,6,54,63,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1638,-1,0.9994604,0.00053958787
1639,oxacillin,7,8,39,48,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1639,-1,0.99945885,0.00054114126
1640,bacteremia,15,16,95,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1640,-1,0.0002114579,0.9997886
1641,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1641,-1,0.00021646562,0.9997836
1642,purpuric lesions,26,28,164,180,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1642,-1,0.00021890039,0.9997811
1644,leucocytoclastic vasculitis,6,8,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,-1,-1,1644,-1,0.00022139124,0.99977857
1645,Oxacillin,0,1,0,9,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,-1,1645,-1,0.9994529,0.0005470977
1648,Leucocytoclastic vasculitis,0,2,0,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1648,-1,0.005243655,0.99475634
1649,purpura,5,6,49,56,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1649,-1,0.9994091,0.00059090636
1650,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1650,-1,0.00021738517,0.9997826
1651,arthralgia,16,17,119,129,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1651,-1,0.00022028646,0.99977976
1652,renal involvement,19,21,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1652,-1,0.00021213076,0.99978787
1654,collagen vascular disease,10,13,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1654,-1,0.0030570521,0.99694294
1655,neoplasia,14,15,105,114,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1655,-1,0.00020669485,0.99979335
1656,corticosteroid,8,9,43,57,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,-1,1656,-1,0.9993831,0.00061685545
1658,Oxacillin,0,1,0,9,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1658,-1,0.9994654,0.00053456443
1659,leucocytoclastic vasculitis,10,12,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1659,-1,0.00021880378,0.9997812
1660,mania,1,2,23,28,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,-1,1660,-1,0.00017499579,0.99982506
1662,mania,9,10,58,63,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1662,-1,0.00024171975,0.9997583
1664,bipolar depression,25,27,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1664,-1,0.00021340638,0.99978656
1665,bipolar disorder,11,13,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1665,-1,0.00021875852,0.9997813
1667,Mania,32,33,216,221,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1667,-1,0.00022293758,0.999777
1669,hypomanic,6,7,36,45,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1669,-1,0.00022660197,0.99977344
1670,bipolar I,26,28,149,158,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1670,-1,0.005465489,0.9945345
1671,bipolar II,29,31,163,173,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1671,-1,0.005728861,0.99427116
1675,serotonin reuptake inhibitors,56,59,333,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1675,-1,0.99944264,0.0005573056
1676,SSRIs,60,61,364,369,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1676,-1,0.9993374,0.00066263234
1678,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1678,-1,0.00021312152,0.9997869
1679,mania,6,7,34,39,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1679,-1,0.00021567078,0.9997843
1680,N,15,16,73,74,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1680,-1,0.7707423,0.22925773
1681,SSRIs,31,32,134,139,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1681,-1,0.00027468137,0.9997253
1682,N,40,41,154,155,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1682,-1,0.9781004,0.021899616
1684,N,52,53,198,199,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1684,-1,0.9792475,0.020752525
1685,hypomanic,57,58,217,226,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1685,-1,0.00021874164,0.9997813
1686,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1686,-1,0.010204628,0.9897954
1687,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1687,-1,0.011441954,0.98855805
1688,contrast,1,2,3,11,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1688,-1,0.2726618,0.7273382
1691,p,31,32,142,143,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1691,-1,0.18251477,0.8174852
1693,p,37,38,236,237,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,-1,1693,-1,0.5556848,0.44431522
1696,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,-1,-1,1696,-1,0.00022262194,0.9997774
1697,transplant glomerulopathy,8,10,50,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1697,-1,0.0014294955,0.99857044
1698,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1698,-1,0.0002787965,0.9997212
1699,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1699,-1,0.33723265,0.66276735
1701,chronic allograft nephropathy,19,22,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1701,-1,0.00021647882,0.9997836
1702,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1702,-1,0.00021043755,0.99978954
1704,malignant hypertension,17,19,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1704,-1,0.00021913656,0.99978083
1707,TG,11,12,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1707,-1,0.00019962327,0.9998004
1708,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1708,-1,0.00019934936,0.9998006
1709,malignant hypertension,5,7,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1709,-1,0.00020641222,0.9997936
1711,lupus nephritis,11,13,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1711,-1,0.00020840165,0.99979156
1712,nephritis,15,16,113,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1712,-1,0.00020977347,0.99979025
1714,acute renal failure,22,25,175,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1714,-1,0.00020944708,0.9997906
1715,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1715,-1,0.00023758726,0.9997625
1716,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1716,-1,0.00021047487,0.99978954
1718,TG,17,18,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1718,-1,0.00023137472,0.9997687
1719,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1719,-1,0.00023578868,0.99976426
1720,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1720,-1,0.00020093174,0.9997991
1721,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1721,-1,0.00020843784,0.99979156
1722,injury,5,6,37,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1722,-1,0.00020556553,0.9997944
1723,immunologic injury,8,10,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1723,-1,0.0010499286,0.99895006
1724,renal pathology,1,3,4,19,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1724,-1,0.000192935,0.99980706
1725,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1725,-1,0.0001939417,0.9998061
1726,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,-1,1726,-1,0.00018770898,0.9998123
1728,cardiac arrhythmia,1,3,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,-1,1728,-1,0.00019781437,0.9998022
1729,mitral valve prolapse,7,10,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1729,-1,0.00019895518,0.9998011
1730,ventricular fibrillation,13,15,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1730,-1,0.00020382577,0.9997962
1732,BD1008,4,5,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1732,-1,0.99939656,0.0006034606
1733,oligodeoxynucleotide,8,9,63,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1733,-1,0.99943393,0.00056609337
1735,BD1018,17,18,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1735,-1,0.045913983,0.95408607
1736,"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",19,20,117,181,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1736,-1,0.9984281,0.0015719263
1737,BD1063,22,23,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1737,-1,0.04643193,0.9535681
1739,LR132,28,29,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1739,-1,0.76627547,0.2337246
1740,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1740,-1,0.99879813,0.0012018443
1741,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1741,-1,0.99879813,0.0012018443
1742,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1742,-1,0.99879813,0.0012018443
1744,NMDA,22,23,134,138,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,-1,-1,-1,1744,-1,0.9993678,0.0006321953
1745,BD1018,8,9,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1745,-1,0.9993955,0.00060452096
1746,BD1063,10,11,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1746,-1,0.9993923,0.0006077344
1747,LR132,13,14,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1747,-1,0.07273869,0.92726135
1749,LR132,4,5,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,-1,1749,-1,0.9994149,0.0005850652
1750,contrast,1,2,3,11,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1750,-1,0.7455877,0.25441232
1751,DTG,18,19,135,138,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1751,-1,0.99404764,0.0059523787
1752,BD1031,26,27,177,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1752,-1,0.9994123,0.0005877581
1753,"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",28,29,185,249,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1753,-1,0.99941325,0.0005868032
1756,BD1018,13,14,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1756,-1,0.99932444,0.00067562587
1757,BD1063,15,16,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1757,-1,0.9993824,0.00061764946
1758,LR132,17,18,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1758,-1,0.99935573,0.0006442828
1760,oligodeoxynucleotide,21,22,139,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,-1,1760,-1,0.9994286,0.0005713832
1767,allograft dysfunction,20,22,136,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,-1,1767,-1,0.00024807817,0.99975187
1768,eosinophilic,8,9,61,73,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,-1,1768,-1,0.0054281116,0.99457186
1769,Cholestatic jaundice,0,2,0,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1769,-1,0.0032758007,0.9967242
1770,metformin,7,8,48,57,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1770,-1,0.99937856,0.00062136166
1771,cholestatic jaundice,6,8,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1771,-1,0.00018119543,0.99981886
1772,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1772,-1,0.99943477,0.0005652135
1776,Metformin hydrochloride,0,2,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,-1,-1,-1,1776,-1,0.99943894,0.0005610524
1779,metformin,12,13,61,70,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,-1,-1,1779,-1,0.99936527,0.00063469104
1785,chronic liver disease,17,20,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,-1,-1,1785,-1,0.00018453332,0.9998155
1789,levobupivacaine,8,9,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1789,-1,0.9995104,0.00048964337
1790,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1790,-1,0.99952054,0.0004794334
1792,levobupivacaine,2,3,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1792,-1,0.9994904,0.00050956436
1793,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1793,-1,0.99950075,0.00049929065
1794,mg,13,14,72,74,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1794,-1,0.9093219,0.09067811
1797,mm Hg,13,15,84,89,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,-1,-1,-1,1797,-1,0.0019412886,0.99805874
1798,levobupivacaine,4,5,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1798,-1,0.9995154,0.00048460928
1799,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1799,-1,0.9995271,0.00047287537
1802,levobupivacaine,4,5,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1802,-1,0.9995203,0.00047967315
1803,dysrhythmias,7,8,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1803,-1,0.00020784602,0.99979216
1805,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1805,-1,0.99952734,0.00047263227
1808,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,-1,-1,-1,1808,-1,0.9994956,0.00050437107
1810,levobupivacaine,7,8,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1810,-1,0.9994854,0.00051458686
1811,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1811,-1,0.9995024,0.0004976296
1815,levobupivacaine,40,41,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1815,-1,0.99948835,0.00051167666
1816,rabbit syndrome,1,3,20,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,-1,-1,-1,1816,-1,0.0002012009,0.99979883
1818,Rabbit syndrome,0,2,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1818,-1,0.0020351743,0.99796486
1819,RS,3,4,17,19,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1819,-1,0.08431017,0.9156898
1820,neuroleptic,14,15,78,89,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1820,-1,0.8236107,0.17638925
1821,RS,7,8,46,48,"Here we present a case of withdrawal-emergent RS, which is the first of its kind to be reported.",11532387_2,-1,-1,-1,1821,-1,0.00021097818,0.99978906
1822,RS,3,4,22,24,The patient developed RS during dose reduction of risperidone.,11532387_3,-1,-1,-1,1822,-1,0.00028144472,0.9997185
1825,RS,5,6,48,50,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1825,-1,0.00037270694,0.99962723
1828,RS,37,38,261,263,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1828,-1,0.21639241,0.7836076
1829,E4031,6,7,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,-1,1829,-1,0.999453,0.00054704305
1833,Torsades de pointes,0,3,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1833,-1,0.0022252284,0.9977748
1834,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1834,-1,0.0035997888,0.99640024
1836,MAPD,24,25,156,160,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1836,-1,0.008649704,0.9913503
1837,TDP,0,1,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,-1,-1,-1,1837,-1,0.9965892,0.0034108348
1840,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,-1,1840,-1,0.00043069542,0.99956936
1841,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1841,-1,0.00019912711,0.99980086
1845,E4031,19,20,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1845,-1,0.6852004,0.31479964
1849,E4031,28,29,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,-1,1849,-1,0.9994147,0.0005853486
1850,TDP,5,6,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,-1,-1,-1,1850,-1,0.0002442652,0.9997557
1854,TDP,13,14,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,-1,1854,-1,0.9671934,0.032806594
1855,Amphotericin,0,1,0,12,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1855,-1,0.9994711,0.00052888604
1857,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1857,-1,0.12751962,0.87248033
1859,AIDS,21,22,130,134,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1859,-1,0.99941826,0.0005817034
1860,amphotericin B,24,26,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1860,-1,0.9994823,0.0005176656
1861,grand mal seizures,9,12,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1861,-1,0.00021086073,0.9997892
1862,amphotericin B,16,18,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1862,-1,0.9994572,0.0005428492
1865,hydroxyzine,7,8,57,68,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1865,-1,0.99948454,0.00051543856
1866,promethazine,9,10,70,82,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1866,-1,0.9994943,0.000505718
1870,lorazepam,5,6,40,49,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1870,-1,0.9995048,0.0004952002
1872,amphotercin B,14,16,99,112,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1872,-1,0.99951315,0.0004868681
1873,AIDS,2,3,12,16,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1873,-1,0.99889094,0.0011091089
1874,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1874,-1,0.0002071526,0.9997929
1876,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,-1,-1,1876,-1,0.005622348,0.9943777
1882,amphotericin B,7,9,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1882,-1,0.9994991,0.0005008889
1884,AIDS,17,18,94,98,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1884,-1,0.00019449188,0.9998055
1885,Amphotericin B,2,4,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,-1,-1,1885,-1,0.99949265,0.0005073224
1888,amphotericin B,10,12,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,-1,1888,-1,0.9994844,0.0005156101
1889,retention of urine,1,4,8,26,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,-1,1889,-1,0.00021585575,0.9997842
1894,wall rigidity,9,11,71,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1894,-1,0.00022418752,0.9997758
1896,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1896,-1,0.00021980684,0.99978024
1898,urinary bladder retention,5,8,17,42,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1898,-1,0.0002007322,0.9997993
1899,hydronephrosis,14,15,95,109,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1899,-1,0.00040892005,0.99959105
1902,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,-1,1902,-1,0.9994968,0.0005031648
1903,Calcineurin inhibitors,0,2,0,22,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,-1,-1,-1,1903,-1,0.99944526,0.000554768
1910,immunosuppressive agents,3,5,23,47,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1910,-1,0.8147307,0.18526934
1911,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1911,-1,0.99949014,0.00050982984
1915,myeloencephalopathy,1,2,6,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1915,-1,0.0004122888,0.9995877
1916,vincristin,6,7,56,66,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1916,-1,0.99947244,0.00052763335
1918,acute lymphoblastic leucemia,18,21,116,144,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1918,-1,0.00019522278,0.9998048
1919,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1919,-1,0.00020265221,0.9997974
1921,sensory and motor dysfunction,12,16,70,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,-1,-1,1921,-1,0.0002236201,0.9997764
1923,degeneration of myelin and axons,12,17,92,124,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,-1,-1,-1,1923,-1,0.00022038919,0.99977964
1926,Palpebral twitching,0,2,0,19,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,-1,-1,-1,1926,-1,0.00082220964,0.99917775
1932,palpebral twitching,18,20,117,136,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,-1,1932,-1,0.00020721617,0.99979275
1941,lymphadenitis,12,13,84,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1941,-1,0.0002022237,0.99979776
1942,eosinophilic,19,20,149,161,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1942,-1,0.011476086,0.9885239
1943,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1943,-1,0.00056596845,0.99943405
1945,autoimmunity,22,23,139,151,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1945,-1,0.00021783728,0.99978215
1947,hepatocellular necrosis,6,8,51,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1947,-1,0.00020755947,0.9997925
1948,hypersensitivity myocarditis,10,12,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1948,-1,0.00021009552,0.9997899
1949,nephritis,16,17,144,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1949,-1,0.0002113267,0.9997887
1950,bone marrow necrosis,19,22,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1950,-1,0.0019525301,0.9980475
1955,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,-1,1955,-1,0.00029383553,0.9997061
1956,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,-1,1956,-1,0.00025532514,0.9997447
1958,emergency department,13,15,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,-1,1958,-1,0.000271067,0.999729
1963,mg,7,8,49,51,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1963,-1,0.9989573,0.0010426729
1965,mg,23,24,145,147,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1965,-1,0.9994287,0.0005713103
1966,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,-1,1966,-1,0.0002291241,0.99977094
1967,Akathisia,0,1,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1967,-1,0.9964629,0.0035371652
1968,restlessness,9,10,56,68,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1968,-1,0.00022807503,0.9997719
1970,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1970,-1,0.9965301,0.0034698993
1971,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1971,-1,0.9965134,0.0034865853
1976,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,-1,1976,-1,0.00020144893,0.9997986
1979,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,-1,-1,1979,-1,0.00028190023,0.9997181
1984,nimesulide,2,3,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,-1,1984,-1,0.9994931,0.00050687965
1986,nimesulide,6,7,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1986,-1,0.99951077,0.0004891987
1988,NSAIDs,24,25,188,194,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1988,-1,0.9994899,0.00051010185
1989,nimesulide,9,10,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,-1,1989,-1,0.99949336,0.0005066531
1992,nimesulide,19,20,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,-1,-1,-1,1992,-1,0.999481,0.0005189748
1993,nimesulide,6,7,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1993,-1,0.99950254,0.0004974327
1995,urticaria/angioedema,19,20,144,164,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1995,-1,0.0002212661,0.9997787
1996,nimesulide,12,13,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,-1,-1,-1,1996,-1,0.9994981,0.0005018988
1998,nimesulide,6,7,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,-1,1998,-1,0.99948275,0.0005171694
2003,nimesulide,10,11,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2003,-1,0.9995005,0.0004995289
2005,NSAIDs,20,21,147,153,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2005,-1,0.99948186,0.0005182304
2017,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2017,-1,0.00022486573,0.9997751
2018,/-SD,17,18,110,114,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2018,-1,0.046196923,0.953803
2023,P,18,19,109,110,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,-1,-1,-1,2023,-1,0.15563557,0.84436446
2028,P,34,35,216,217,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,-1,2028,-1,0.24931286,0.7506872
2034,hepatitis C,10,12,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,-1,2034,-1,0.00027185483,0.99972814
2035,interferon,15,16,127,137,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2035,-1,0.999458,0.0005420245
2036,chronic hepatitis C,26,29,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2036,-1,0.015133513,0.98486644
2037,CHC,30,31,245,248,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2037,-1,0.18377379,0.8162262
2039,RIHA,15,16,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,-1,2039,-1,0.000209066,0.99979097
2040,RIHA,15,16,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2040,-1,0.00027434088,0.99972564
2041,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2041,-1,0.00029055204,0.9997094
2042,RIHA,17,18,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,-1,-1,-1,2042,-1,0.0004398312,0.9995602
2043,RIHA,10,11,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,-1,2043,-1,0.046220444,0.9537796
2044,RIHA,2,3,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,-1,2044,-1,0.012151463,0.9878485
2045,RIHA,7,8,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,-1,2045,-1,0.004304617,0.99569535
2047,RIHA,9,10,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,-1,2047,-1,0.006671856,0.9933281
2048,RIHA,24,25,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,-1,2048,-1,0.0005649913,0.999435
2050,RIHA,12,13,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,-1,2050,-1,0.00027510148,0.9997249
2051,RIHA,13,14,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,-1,-1,-1,2051,-1,0.4009423,0.59905773
2053,lactate,8,9,74,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2053,-1,0.99935967,0.0006403264
2054,AIDS,11,12,96,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2054,-1,0.0011299386,0.9988701
2056,CM,12,13,78,80,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2056,-1,0.000368941,0.99963105
2057,lactate,18,19,105,112,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2057,-1,0.9993524,0.000647563
2058,LA,20,21,114,116,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2058,-1,0.9991616,0.0008383759
2059,AIDS,23,24,121,125,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2059,-1,0.3348599,0.66514003
2061,AIDS,12,13,87,91,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2061,-1,0.00020288267,0.99979717
2062,TG,20,21,118,120,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2062,-1,0.00041472056,0.99958533
2066,CM,17,18,118,120,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2066,-1,0.0004202047,0.99957985
2067,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2067,-1,0.7532658,0.24673425
2068,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2068,-1,0.99906665,0.0009333721
2070,LA,41,42,251,253,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2070,-1,0.99936587,0.0006341554
2071,TG,5,6,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,-1,-1,-1,2071,-1,0.00022073617,0.9997793
2072,ANF,2,3,13,16,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,-1,2072,-1,0.9687563,0.031243738
2073,LA,2,3,15,17,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2073,-1,0.9987896,0.0012104104
2074,mM,10,11,44,46,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2074,-1,0.30189598,0.698104
2075,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2075,-1,0.3512224,0.64877766
2076,TG,13,14,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2076,-1,0.00022399375,0.99977607
2077,CM,7,8,56,58,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2077,-1,0.43098867,0.5690114
2078,LA,10,11,73,75,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2078,-1,0.99916136,0.00083865406
2079,AIDS,12,13,79,83,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2079,-1,0.0008452076,0.9991548
2081,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,-1,2081,-1,0.99941826,0.00058179296
2094,WR-2721,0,1,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,-1,-1,-1,2094,-1,0.96912885,0.030871162
2097,alkylating agents,13,15,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,-1,-1,-1,2097,-1,0.9994276,0.00057239213
2112,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,-1,-1,2112,-1,0.00023417601,0.9997658
2113,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,-1,2113,-1,0.00023018126,0.99976987
2114,Neurologic toxicity,0,2,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,-1,-1,2114,-1,0.00021846211,0.99978155
2122,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,-1,-1,2122,-1,0.00020902454,0.99979097
2124,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,-1,-1,2124,-1,0.00021606206,0.99978393
2125,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2125,-1,0.9994779,0.00052206777
2127,gestodene,19,20,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2127,-1,0.99949193,0.0005080105
2128,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2128,-1,0.9994879,0.0005120763
2131,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2131,-1,0.00019588527,0.9998041
2132,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2132,-1,0.00019741869,0.99980265
2133,factor V Leiden,3,6,16,31,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2133,-1,0.0019430409,0.99805695
2134,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2134,-1,0.0002030454,0.9997969
2139,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,-1,2139,-1,0.00020109331,0.99979895
2143,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,-1,-1,2143,-1,0.00020833431,0.9997917
2153,mg,38,39,242,244,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2153,-1,0.9991836,0.00081638014
2155,mg,49,50,306,308,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2155,-1,0.99917835,0.000821674
2157,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2157,-1,0.0002023678,0.99979764
2158,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2158,-1,0.00020763329,0.9997924
2163,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2163,-1,0.00020610093,0.99979395
2165,contrast,32,33,211,219,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2165,-1,0.556344,0.44365603
2172,renal disease,1,3,10,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2172,-1,0.00022338101,0.99977666
2173,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2173,-1,0.0002400267,0.99976
2174,calcineurin inhibitors cyclosporine,3,6,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,-1,-1,2174,-1,0.9994861,0.000513921
2177,renal disease,18,20,100,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2177,-1,0.00021405178,0.99978596
2178,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2178,-1,0.00023686257,0.9997632
2179,ESRD,9,10,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2179,-1,0.00019748286,0.99980253
2181,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2181,-1,0.000193975,0.9998061
2182,n=834,22,23,133,138,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,-1,2182,-1,0.15110615,0.8488939
2183,CRF,10,11,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2183,-1,0.00019434745,0.9998056
2184,ESRD,12,13,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2184,-1,0.00019907208,0.999801
2185,n=748,14,15,67,72,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2185,-1,0.15443824,0.8455618
2186,CRF,16,17,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2186,-1,0.00019436302,0.9998056
2188,n=41,25,26,118,122,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2188,-1,0.23154986,0.76845014
2189,ESRD,28,29,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2189,-1,0.00029365407,0.9997063
2190,n=45,30,31,134,138,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2190,-1,0.47861582,0.5213842
2191,ESRD,17,18,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2191,-1,0.0002468054,0.9997532
2192,ESRD,25,26,155,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2192,-1,0.00025585515,0.9997441
2194,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2194,-1,0.00023300163,0.999767
2195,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2195,-1,0.00033552697,0.9996644
2196,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2196,-1,0.00021832447,0.99978167
2197,ESRD,7,8,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2197,-1,0.00031589466,0.9996841
2199,hepatorenal syndrome,22,24,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2199,-1,0.00021534161,0.99978465
2202,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2202,-1,0.00022876656,0.9997713
2203,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2203,-1,0.00024313964,0.9997569
2204,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,-1,2204,-1,0.00023412601,0.99976593
2205,ESRD,2,3,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2205,-1,0.00023712082,0.99976283
2206,ESRD,10,11,62,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2206,-1,0.0002272582,0.9997727
2207,ESRD,26,27,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2207,-1,0.00023251718,0.9997675
2208,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2208,-1,0.0002569665,0.99974304
2209,ESRD,13,14,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2209,-1,0.00026673946,0.99973327
2210,ESRD,3,4,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,-1,2210,-1,0.0001977384,0.9998023
2211,ESRD,3,4,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2211,-1,0.00022938814,0.9997706
2213,hepatorenal syndrome,18,20,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2213,-1,0.00021669608,0.99978334
2215,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2215,-1,0.00018821385,0.9998118
2216,ESRD,20,21,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2216,-1,0.00019256101,0.9998074
2217,Epileptic seizures,0,2,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2217,-1,0.00022461009,0.99977535
2218,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2218,-1,0.9994722,0.00052782847
2219,fibrinolysis inhibitors,3,5,20,43,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2219,-1,0.0011543405,0.9988456
2220,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2220,-1,0.99947923,0.0005208178
2221,tAMCA,10,11,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2221,-1,0.99945813,0.0005418781
2222,tAMCA,2,3,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2222,-1,0.9994443,0.00055568037
2223,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2223,-1,0.00019762755,0.9998024
2224,tAMCA,5,6,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,-1,2224,-1,0.9993999,0.00060011866
2226,tAMCA,9,10,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,-1,-1,-1,2226,-1,0.9994442,0.0005558266
2227,tAMCA,4,5,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,-1,2227,-1,0.99941516,0.00058486895
2230,tAMCA,10,11,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,-1,-1,2230,-1,0.9994474,0.00055253785
2231,tAMCA,6,7,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2231,-1,0.99948597,0.0005140432
2232,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2232,-1,0.0002112753,0.9997887
2233,n=6,15,16,85,88,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2233,-1,0.5559473,0.44405264
2234,tAMCA,22,23,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2234,-1,0.9994832,0.00051676686
2236,contrast,1,2,3,11,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,-1,2236,-1,0.9710291,0.028970823
2237,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,-1,2237,-1,0.9994647,0.00053536246
2239,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,-1,2239,-1,0.9994025,0.0005974905
2243,thromboemboli,19,20,126,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,-1,-1,2243,-1,0.00020967428,0.9997904
2248,thromboembolism,9,10,63,78,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2248,-1,0.00021552856,0.9997845
2249,platelet factor 4,14,17,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2249,-1,0.9289499,0.07105009
2253,Thromboemboli,0,1,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2253,-1,0.04959992,0.95040005
2254,pulmonary emboli,9,11,47,63,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2254,-1,0.00021377622,0.9997862
2260,thromboembolism,17,18,142,157,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,-1,-1,2260,-1,0.00021324694,0.9997868
2263,dopamine agonist,6,8,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,-1,2263,-1,0.9994592,0.00054079527
2266,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2266,-1,0.0001947279,0.9998053
2267,delayed puberty,19,21,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2267,-1,0.00019743656,0.99980253
2270,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,-1,2270,-1,0.99950266,0.00049733697
2272,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,-1,-1,2272,-1,0.999485,0.00051492493
2273,Mental Disorders,17,19,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2273,-1,0.00019093692,0.9998091
2274,bipolar disorder,23,25,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2274,-1,0.00019399422,0.999806
2275,psychoses,26,27,133,142,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2275,-1,0.00021347376,0.99978656
2276,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2276,-1,0.99949515,0.0005048797
2277,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,-1,2277,-1,0.9994885,0.00051150407
2278,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,-1,2278,-1,0.9995135,0.00048654663
2280,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,-1,-1,-1,2280,-1,0.9994836,0.00051632884
2281,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,-1,2281,-1,0.9994765,0.0005235434
2283,cholestatic hepatitis,1,3,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,-1,2283,-1,0.009891496,0.9901085
2285,cholestatic hepatitis,8,10,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,-1,2285,-1,0.0011523399,0.9988476
2287,cholestatic hepatitis,11,13,68,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,-1,2287,-1,0.00022061709,0.9997794
2289,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2289,-1,0.99947613,0.0005239155
2290,analgesia,9,10,59,68,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2290,-1,0.00024515713,0.99975485
2293,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,-1,-1,-1,2293,-1,0.99948114,0.0005188329
2294,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,-1,2294,-1,0.017160054,0.98284
2296,cholestatic hepatitis,12,14,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,-1,2296,-1,0.000222484,0.9997775
2297,Torsade de pointes,0,3,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2297,-1,0.4206528,0.5793472
2299,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2299,-1,0.00023028486,0.99976975
2300,long QT syndrome,10,13,56,72,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2300,-1,0.00020894244,0.9997911
2301,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2301,-1,0.00028255515,0.9997174
2304,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2304,-1,0.00020464112,0.9997954
2305,torsade de pointes,15,18,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2305,-1,0.00021393689,0.9997861
2307,torsade de pointes,4,7,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2307,-1,0.0009773475,0.9990226
2309,erythromycin,10,11,66,78,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2309,-1,0.9994703,0.00052974577
2311,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,-1,2311,-1,0.0002766354,0.9997234
2313,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,-1,2313,-1,0.00024627443,0.9997538
2317,DA,2,3,10,12,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2317,-1,0.9994481,0.0005518463
2318,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2318,-1,0.00021516513,0.9997849
2319,Excitotoxicity,0,1,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2319,-1,0.00020855412,0.99979144
2322,DA,11,12,51,53,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2322,-1,0.9993327,0.0006672579
2327,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2327,-1,0.99945575,0.0005442018
2328,KA,12,13,75,77,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2328,-1,0.9992531,0.0007468976
2333,neuronal death,9,11,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2333,-1,0.00020618839,0.9997938
2334,KA,21,22,128,130,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2334,-1,0.99523795,0.0047620926
2338,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,-1,2338,-1,0.00016768758,0.9998323
2340,pregnenolone sulphate,10,12,87,108,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,-1,2340,-1,0.99945766,0.0005423602
2341,Pregnenolone sulphate,0,2,0,21,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2341,-1,0.9994266,0.0005734346
2342,PREGS,3,4,23,28,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2342,-1,0.99196786,0.008032146
2344,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,-1,2344,-1,0.07791853,0.9220814
2345,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2345,-1,0.404942,0.59505796
2346,NMDAR,11,12,63,68,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2346,-1,0.9993837,0.0006162428
2347,PREGS,18,19,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,-1,2347,-1,0.00042491683,0.9995751
2348,11-ketopregnenolone sulphate,5,7,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2348,-1,0.99946934,0.0005307354
2349,epipregnanolone,19,20,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2349,-1,0.9994765,0.0005234819
2350,sulphate,24,25,161,169,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2350,-1,0.9994504,0.0005496675
2351,PREGS,42,43,243,248,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2351,-1,0.9902294,0.009770497
2352,PREGS,49,50,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2352,-1,0.547232,0.452768
2353,PREGS,4,5,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,-1,2353,-1,0.34458783,0.65541214
2355,PREGS,1,2,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,-1,2355,-1,0.9993006,0.0006993632
2357,PREGS,6,7,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2357,-1,0.9960532,0.0039467863
2358,11-ketopregnenolone sulphate,8,10,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2358,-1,0.9994748,0.0005252128
2359,epipregnanolone sulphate,11,13,70,94,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2359,-1,0.9994962,0.00050375744
2361,NMDA,27,28,181,185,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2361,-1,0.9994474,0.0005526021
2362,PREGS,34,35,239,244,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2362,-1,0.9919327,0.008067293
2363,PREGS,10,11,72,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,-1,-1,2363,-1,0.0027424698,0.99725753
2366,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,-1,-1,2366,-1,0.00021567408,0.9997843
2367,damage,14,15,92,98,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2367,-1,0.00023469415,0.99976534
2368,dysfunction,21,22,131,142,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2368,-1,0.00023583588,0.99976414
2369,tissue injury,23,25,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2369,-1,0.0002309881,0.99976903
2372,DOX,14,15,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,-1,-1,2372,-1,0.99939597,0.0006039736
2375,PJ34,19,20,136,140,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2375,-1,0.99942493,0.0005750733
2377,DOX,36,37,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2377,-1,0.99942017,0.00057988055
2378,DOX,9,10,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,-1,2378,-1,0.99839765,0.0016023811
2379,DOX,3,4,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,-1,2379,-1,0.9994019,0.00059804576
2381,PJ34,9,10,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,-1,2381,-1,0.9994248,0.00057519256
2382,PJ34,3,4,17,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,-1,-1,2382,-1,0.99915504,0.00084497774
2384,PJ34,2,3,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2384,-1,0.99934846,0.0006515181
2385,lactate,11,12,77,84,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2385,-1,0.9993305,0.0006694637
2386,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2386,-1,0.9988048,0.0011951694
2388,DOX,9,10,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,-1,2388,-1,0.9992379,0.00076210324
2389,cardiac complications,11,13,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2389,-1,0.00021362076,0.99978644
2390,DOX,16,17,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2390,-1,0.99938226,0.0006177768
2392,amphotericin,11,12,57,69,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2392,-1,0.99948347,0.0005165477
2393,hypokalemia,13,14,80,91,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2393,-1,0.00021398485,0.9997861
2396,amphotericin B,25,27,168,182,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2396,-1,0.99948335,0.00051664544
2397,AmB,28,29,184,187,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2397,-1,0.9994567,0.0005433314
2400,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2400,-1,0.9983882,0.00161187
2402,tubular toxicity,30,32,205,221,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2402,-1,0.00020754957,0.9997925
2403,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2403,-1,0.012319485,0.98768055
2406,hypokalemia,51,52,342,353,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2406,-1,0.00020977166,0.99979025
2407,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2407,-1,0.0002113287,0.9997887
2408,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2408,-1,0.99943334,0.00056663126
2409,hematological disorders,9,11,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2409,-1,0.00020988549,0.99979013
2410,AmB,17,18,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2410,-1,0.9994604,0.00053958787
2411,AmB,20,21,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2411,-1,0.9994405,0.00055945094
2413,mg,25,26,163,165,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2413,-1,0.99944896,0.00055103266
2414,fungal infection,34,36,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2414,-1,0.00020836212,0.9997917
2415,AmB,5,6,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2415,-1,0.99939394,0.00060602394
2418,AmB,17,18,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2418,-1,0.9993162,0.00068380794
2419,P,20,21,144,145,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2419,-1,0.12993169,0.8700683
2420,AmB,3,4,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2420,-1,0.99945444,0.0005455563
2424,P,21,22,162,163,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2424,-1,0.07491148,0.92508847
2426,AmB,11,12,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2426,-1,0.9994456,0.00055434456
2428,AmB,17,18,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2428,-1,0.99942315,0.00057683326
2429,P,20,21,136,137,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2429,-1,0.13447627,0.86552376
2432,hypokalemia,13,14,96,107,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2432,-1,0.00058507296,0.9994149
2434,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2434,-1,0.00022164958,0.99977833
2435,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2435,-1,0.9993986,0.00060138036
2452,hemorrhaging,11,12,83,95,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,-1,2452,-1,0.00020663456,0.99979335
2457,circulatory failure,20,22,148,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2457,-1,0.0002080205,0.99979204
2458,hemorrhaging,23,24,175,187,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2458,-1,0.00020535728,0.99979466
2462,Erectile dysfunction,0,2,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2462,-1,0.00022041566,0.99977964
2464,of the,1,3,8,14,Lesions of the substantia nigra were confirmed by histology.,11890511_4,-1,-1,-1,2464,-1,0.025348505,0.9746515
2466,erectile dysfunction,9,11,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2466,-1,0.00018739764,0.99981266
2467,erectile dysfunction,21,23,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2467,-1,0.00019245216,0.99980754
2468,Parkinson's disease,24,27,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2468,-1,0.000352424,0.9996476
2469,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,-1,-1,2469,-1,0.00022127772,0.9997787
2473,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,-1,2473,-1,0.9994548,0.0005452444
2474,h,9,10,51,52,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,-1,-1,2474,-1,0.0051277517,0.9948723
2476,infarct,8,9,61,68,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2476,-1,0.00018064496,0.99981934
2477,h,10,11,72,73,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2477,-1,0.16777468,0.8322253
2479,contrast,7,8,42,50,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2479,-1,0.0012719071,0.9987281
2480,h,17,18,95,96,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2480,-1,0.6295004,0.3704996
2481,cardiac infarction,31,33,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2481,-1,0.00022730112,0.9997727
2494,mecamylamine,7,8,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,-1,2494,-1,0.99950564,0.00049435644
2508,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,-1,2508,-1,0.001900844,0.99809915
2512,Parkinson's disease,6,9,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,-1,2512,-1,0.00021356679,0.99978644
2513,Parkinson's disease,8,11,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2513,-1,0.00034061374,0.9996594
2516,LID,26,27,177,180,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2516,-1,0.0002378615,0.9997621
2517,Parkinson's disease,5,8,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2517,-1,0.00020605532,0.99979395
2518,Parkinson's disease,11,14,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2518,-1,0.0002107968,0.9997892
2519,LID,15,16,82,85,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2519,-1,0.00022485286,0.9997751
2520,n,17,18,87,88,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2520,-1,0.99607253,0.0039274693
2522,Parkinson's disease,26,29,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2522,-1,0.00021539441,0.99978465
2523,LID,30,31,159,162,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2523,-1,0.00025520247,0.99974483
2524,n,32,33,164,165,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2524,-1,0.9990501,0.0009498829
2525,Parkinson's Disease,6,9,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,-1,2525,-1,0.00028367533,0.99971634
2528,Parkinson's disease,10,13,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2528,-1,0.00018995581,0.99981004
2529,LID,14,15,80,83,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2529,-1,0.00021777645,0.99978226
2530,Parkinson's disease,1,4,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2530,-1,0.00028983847,0.99971014
2531,LID,5,6,25,28,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2531,-1,0.00038617657,0.9996138
2533,P,27,28,141,142,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2533,-1,0.30292025,0.6970798
2534,P,10,11,43,44,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2534,-1,0.14108154,0.8589184
2535,P,23,24,86,87,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2535,-1,0.26899835,0.7310017
2536,contrast,1,2,3,11,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2536,-1,0.9892307,0.010769286
2537,Parkinson's disease,9,12,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2537,-1,0.000288302,0.9997117
2538,LID,13,14,67,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2538,-1,0.00020161358,0.99979836
2539,P,9,10,38,39,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2539,-1,0.291043,0.708957
2540,Parkinson's disease,15,18,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2540,-1,0.00021699358,0.999783
2541,LID,19,20,80,83,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2541,-1,0.00026397218,0.999736
2542,Parkinson's disease,22,25,92,111,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2542,-1,0.00022277355,0.99977726
2543,LID,26,27,114,117,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2543,-1,0.0012054055,0.99879456
2545,P,20,21,113,114,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,-1,2545,-1,0.46299386,0.5370062
2546,LID,8,9,48,51,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,-1,-1,-1,2546,-1,0.024478458,0.9755215
2548,LID,4,5,23,26,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,-1,2548,-1,0.00048907066,0.9995109
2550,Zyban,2,3,11,16,Bupropion (Zyban) toxicity.,11928786_0,-1,-1,-1,2550,-1,0.9994653,0.0005346781
2555,Zyban,0,1,0,5,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2555,-1,0.9994435,0.0005565083
2556,bupropion hydrochloride,6,8,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2556,-1,0.99946624,0.0005338083
2561,drowsiness,5,6,38,48,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,-1,-1,2561,-1,0.00021884822,0.9997812
2571,Zyban,0,1,0,5,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2571,-1,0.9993988,0.0006011322
2572,cardiovascular toxicity,5,7,42,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2572,-1,0.00021531984,0.99978465
2576,PAN nephrosis,9,11,52,65,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,-1,-1,-1,2576,-1,0.00024380286,0.99975616
2578,glomerular injury,11,13,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,-1,2578,-1,0.00019758193,0.9998024
2579,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2579,-1,0.0115554845,0.98844445
2580,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2580,-1,0.9994624,0.0005375999
2581,PAN,13,14,114,117,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2581,-1,0.99939847,0.00060158334
2582,PAN,21,22,68,71,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,-1,2582,-1,0.9978173,0.0021827582
2586,p,42,43,177,178,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,-1,2586,-1,0.1650656,0.83493435
2587,p,23,24,111,112,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,-1,2587,-1,0.53741515,0.46258482
2588,contrast,1,2,3,11,"In contrast, podocalyxin did not change significantly at this time.",11961407_9,-1,-1,-1,2588,-1,0.9560425,0.04395745
2589,PAN,14,15,92,95,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,-1,-1,-1,2589,-1,0.9992481,0.0007519217
2590,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,-1,2590,-1,0.31650436,0.6834957
2591,dizocilpine,3,4,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2591,-1,0.99950266,0.0004973033
2592,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2592,-1,0.4060008,0.5939992
2593,NMDA,12,13,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2593,-1,0.9994758,0.0005242405
2595,behavioral,4,5,22,32,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2595,-1,0.00020820284,0.9997918
2596,Parkinson's disease,12,15,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2596,-1,0.00020294303,0.99979705
2597,tardive dyskinesia,17,19,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2597,-1,0.00020385162,0.9997962
2599,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2599,-1,0.0002343489,0.9997657
2600,tardive dyskinesia,34,36,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2600,-1,0.00022195137,0.9997781
2604,Parkinson's disease,12,15,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,-1,-1,2604,-1,0.00022007566,0.9997799
2605,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,-1,2605,-1,0.9994313,0.0005687017
2608,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,-1,2608,-1,0.99902,0.0009800228
2611,apomophine,15,16,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2611,-1,0.9995047,0.00049528043
2616,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,-1,-1,2616,-1,0.99943703,0.00056293095
2621,h,8,9,41,42,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2621,-1,0.09217329,0.90782666
2624,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2624,-1,0.99950397,0.0004960525
2627,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2627,-1,0.00020696307,0.9997931
2628,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2628,-1,0.0010366056,0.99896336
2629,NMDA,5,6,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,-1,2629,-1,0.9993918,0.0006082104
2632,visual disturbances,4,6,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2632,-1,0.0002046864,0.9997954
2634,LSD,14,15,110,113,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2634,-1,0.00020715377,0.9997929
2636,LSD,10,11,55,58,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2636,-1,0.00043289814,0.9995671
2637,EPS,17,18,98,101,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2637,-1,0.00902005,0.99097997
2638,antipsychotics,20,21,115,129,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2638,-1,0.9992267,0.0007733607
2640,visual disturbances,7,9,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,-1,-1,-1,2640,-1,0.00018291533,0.9998171
2642,visual disturbances,3,5,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2642,-1,0.00021054992,0.9997894
2643,LSD,14,15,99,102,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2643,-1,0.9821193,0.01788074
2645,visual disturbances,6,8,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,-1,-1,-1,2645,-1,0.00024310185,0.9997569
2646,visual disturbances,11,13,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,-1,2646,-1,0.0002249142,0.9997751
2648,Antithymocyte globulin,0,2,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,-1,-1,2648,-1,0.9993019,0.00069802976
2650,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,-1,2650,-1,0.97248995,0.02751003
2652,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,-1,-1,2652,-1,0.9991984,0.0008016355
2655,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2655,-1,0.99947315,0.0005268121
2656,refractory seizures,19,21,136,155,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2656,-1,0.0002293208,0.9997707
2658,lead,23,24,138,142,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2658,-1,0.39163703,0.60836303
2659,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2659,-1,0.0040756557,0.99592435
2661,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,-1,2661,-1,0.99945873,0.0005412697
2665,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,-1,2665,-1,0.9994512,0.00054875383
2666,charcoal,23,24,148,156,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2666,-1,0.9994537,0.00054631475
2668,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2668,-1,0.999476,0.00052404415
2671,P<0.05,16,17,102,108,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,-1,2671,-1,0.031711787,0.9682882
2674,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,-1,-1,2674,-1,0.999463,0.00053698506
2677,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2677,-1,0.9994773,0.0005226453
2678,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2678,-1,0.00019482651,0.99980515
2679,Ifosfamide encephalopathy,0,2,0,25,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,-1,-1,2679,-1,0.023200706,0.9767993
2681,antineoplastic,5,6,25,39,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2681,-1,0.99918264,0.0008173322
2683,IFX,9,10,58,61,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2683,-1,0.8538685,0.14613155
2684,neurological symptoms,18,20,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2684,-1,0.00023249943,0.9997675
2687,plasmacytoma,27,28,161,173,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,-1,-1,2687,-1,0.0021857729,0.9978142
2688,structural lesions of the brain,11,16,85,116,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2688,-1,0.0002925846,0.9997074
2689,metabolic abnormalities,17,19,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2689,-1,0.00020569003,0.9997943
2692,h,9,10,64,65,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,-1,-1,2692,-1,0.102173336,0.8978267
2697,IFX,41,42,265,268,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,-1,2697,-1,0.9994273,0.00057267695
2701,thymidine,6,7,37,46,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,-1,2701,-1,0.99940443,0.00059563183
2702,thymidine,18,19,150,159,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,-1,2702,-1,0.9994236,0.0005764002
2712,analgesia,11,12,85,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,-1,2712,-1,0.00023002151,0.99977
2713,h,11,12,70,71,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,-1,2713,-1,0.019569885,0.9804301
2716,adenovirus disease,5,7,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,-1,-1,-1,2716,-1,0.0002609292,0.9997391
2717,adenovirus disease,4,6,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,-1,2717,-1,0.0021570113,0.997843
2718,antiviral agents,4,6,22,38,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2718,-1,0.9622887,0.03771131
2719,adenovirus disease,14,16,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2719,-1,0.0003902646,0.99960977
2720,adenovirus disease,8,10,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,-1,2720,-1,0.003785749,0.9962142
2722,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,-1,-1,-1,2722,-1,0.99948466,0.0005153178
2724,guanosine,3,4,13,22,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,-1,2724,-1,0.99943346,0.00056655216
2726,respiratory syncytial virus infection,10,14,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2726,-1,0.0002088337,0.9997912
2727,interferon,20,21,129,139,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2727,-1,0.9994223,0.00057773845
2728,hepatitis C.,23,25,149,161,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2728,-1,0.0025845363,0.9974154
2730,infection with hemorrhagic fever viruses,33,38,215,255,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2730,-1,0.00023326883,0.99976677
2733,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2733,-1,0.9994417,0.00055827445
2734,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2734,-1,0.0044600796,0.99553996
2737,adenovirus disease,12,14,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,-1,-1,-1,2737,-1,0.00019562527,0.99980444
2739,adenovirus disease,18,20,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,-1,2739,-1,0.000232648,0.99976736
2740,hemorrhagic cystitis,4,6,34,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,-1,-1,2740,-1,0.00020212964,0.9997979
2741,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2741,-1,0.9994584,0.0005416537
2742,pneumonia,6,7,46,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2742,-1,0.00020982148,0.99979025
2743,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2743,-1,0.00021276764,0.9997873
2745,hemorrhagic cystitis,22,24,147,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2745,-1,0.00020896675,0.9997911
2746,pneumonia,30,31,216,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2746,-1,0.00021142604,0.9997886
2747,adenovirus disease,6,8,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,-1,-1,-1,2747,-1,0.00041780894,0.99958223
2749,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2749,-1,0.9994816,0.0005184389
2750,progressive renal failure,9,12,48,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2750,-1,0.00019835624,0.9998017
2752,adenovirus disease,19,21,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2752,-1,0.00020251682,0.9997975
2753,immunodeficiency,35,36,233,249,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2753,-1,0.00020916469,0.99979085
2755,adenovirus disease,11,13,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,-1,-1,2755,-1,0.0004906062,0.99950933
2757,adenovirus disease,15,17,96,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,-1,2757,-1,0.00022082374,0.99977916
2758,adenovirus disease,8,10,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,-1,2758,-1,0.0035431583,0.9964568
2760,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,-1,2760,-1,0.00030615376,0.9996939
2761,adenovirus disease,7,9,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,-1,2761,-1,0.0025422547,0.9974578
2763,asystolic cardiac arrest,1,4,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2763,-1,0.00020639983,0.9997936
2764,diltiazem overdose,5,7,39,57,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2764,-1,0.011263696,0.98873633
2770,isosorbide nitrate,21,23,96,114,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,-1,-1,2770,-1,0.9995029,0.00049713766
2773,charcoal,16,17,104,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,-1,2773,-1,0.99946886,0.0005311848
2777,asystolic,15,16,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,-1,-1,2777,-1,0.0002636422,0.99973637
2782,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,-1,2782,-1,0.011225078,0.9887749
2785,diltiazem overdose,11,13,63,81,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,-1,-1,2785,-1,0.012147891,0.9878521
2788,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2788,-1,0.9990656,0.0009344184
2789,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2789,-1,0.28276762,0.7172324
2791,LMWH,3,4,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2791,-1,0.99947053,0.00052949315
2792,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2792,-1,0.00051035616,0.99948967
2793,UH,23,24,151,153,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2793,-1,0.00060034584,0.99939966
2794,LMWH,20,21,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,-1,2794,-1,0.9981993,0.0018007065
2795,LMWH,11,12,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,-1,-1,-1,2795,-1,0.9994448,0.0005552574
2797,n,21,22,123,124,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2797,-1,0.42005733,0.57994264
2798,n,34,35,192,193,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2798,-1,0.8008403,0.19915968
2799,c,40,41,203,204,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2799,-1,0.7600957,0.23990427
2800,n,50,51,244,245,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2800,-1,0.7529588,0.24704127
2801,n,63,64,282,283,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2801,-1,0.38888374,0.61111623
2802,thromboembolism,4,5,22,37,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2802,-1,0.00019590899,0.9998041
2803,c,28,29,106,107,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2803,-1,0.97721463,0.022785366
2805,LMWH,10,11,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2805,-1,0.99939907,0.00060089596
2806,UH,15,16,103,105,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2806,-1,0.99779713,0.002202833
2807,LMWH,5,6,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,-1,2807,-1,0.9994282,0.00057181035
2808,LMWH,16,17,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,-1,2808,-1,0.99944514,0.0005548817
2816,mg,5,6,39,41,The patient received metoclopramide 10 mg i.v.,12139551_2,-1,-1,-1,2816,-1,0.99656504,0.0034349372
2821,mg,7,8,36,38,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,-1,-1,-1,2821,-1,0.99939597,0.000604047
2825,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,-1,-1,2825,-1,0.00056810223,0.9994319
2826,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2826,-1,0.99946946,0.00053058163
2828,arteritis,27,28,151,160,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2828,-1,0.00022849841,0.99977154
2829,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2829,-1,0.9994905,0.0005094662
2831,vasodilators,36,37,209,221,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2831,-1,0.9994653,0.000534751
2832,Arteritis,0,1,0,9,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2832,-1,0.00021137725,0.9997886
2833,vasodilators,5,6,29,41,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2833,-1,0.89305943,0.10694055
2834,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2834,-1,0.9994716,0.0005284134
2836,nitric oxide synthase,20,23,144,165,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2836,-1,0.99943656,0.00056345516
2838,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,-1,2838,-1,0.9994779,0.0005220459
2841,arteritis,31,32,172,181,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,-1,2841,-1,0.00022274106,0.99977726
2843,cholinergic agents,19,21,140,158,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,-1,-1,2843,-1,0.999411,0.00058900524
2849,neostigmine,8,9,50,61,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,-1,2849,-1,0.9995016,0.00049842615
2852,ACh,11,12,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,-1,-1,2852,-1,0.9993573,0.0006427686
2854,ACh,1,2,12,15,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,-1,-1,2854,-1,0.99929726,0.0007027606
2859,neostigmine,14,15,89,100,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,-1,2859,-1,0.99948657,0.00051336404
2860,ACh,13,14,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2860,-1,0.999097,0.0009030221
2861,mM KCl,17,19,87,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2861,-1,0.9994104,0.0005896119
2862,ACh,20,21,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2862,-1,0.99927086,0.00072915683
2863,ACh,7,8,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2863,-1,0.99875915,0.0012408209
2864,KCl,14,15,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2864,-1,0.99922895,0.00077101326
2865,ACh,2,3,17,20,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2865,-1,0.9993231,0.0006769077
2867,ACh,12,13,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2867,-1,0.99926275,0.00073724973
2868,convulsants,15,16,120,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,-1,2868,-1,0.7875115,0.21248849
2871,convulsants,10,11,65,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,-1,2871,-1,0.79514897,0.20485103
2872,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,-1,-1,2872,-1,0.00019560792,0.99980444
2873,painful temporomandibular disorders,3,6,23,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2873,-1,0.0011088791,0.9988912
2874,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2874,-1,0.00018063927,0.99981934
2875,nociceptive,8,9,52,63,This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw-stretch reflex and whether this process would be sensitive to length and velocity of the stretch.,12202650_2,-1,-1,-1,2875,-1,0.00019879229,0.9998012
2880,painful,17,18,106,113,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,-1,2880,-1,0.00019226728,0.9998078
2881,muscle pain,8,10,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,-1,-1,2881,-1,0.00019856042,0.99980146
2884,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,-1,2884,-1,0.00020948602,0.9997905
2885,AIDA,3,4,41,45,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,-1,2885,-1,0.0059644096,0.9940356
2886,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2886,-1,0.99944156,0.0005584254
2887,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2887,-1,0.00020837325,0.9997917
2888,contrast,1,2,3,11,"In contrast, 2R,4R-APDC injections were ineffective.",12231232_5,-1,-1,-1,2888,-1,0.4131693,0.58683074
2889,parkinsonian muscle rigidity,23,26,129,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,-1,-1,-1,2889,-1,0.0002035824,0.99979645
2893,GR 55562,21,23,128,136,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2893,-1,0.999388,0.0006119524
2894,CP 93129,31,33,176,184,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2894,-1,0.9993525,0.0006475238
2895,GR 55562,7,9,39,47,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2895,-1,0.99916255,0.00083745376
2896,CP 93129,16,18,72,80,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2896,-1,0.48371637,0.5162837
2898,GR 55562,0,2,0,8,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,-1,-1,2898,-1,0.99765295,0.0023471117
2901,GR 55562,12,14,71,79,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,-1,-1,-1,2901,-1,0.9994068,0.0005931968
2903,CP 93129,15,17,74,82,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,-1,2903,-1,0.011954766,0.9880453
2905,GR 55562,10,12,80,88,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,-1,-1,-1,2905,-1,0.9993705,0.00062947534
2907,hyperlocomotion,6,7,43,58,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2907,-1,0.00017806728,0.99982196
2908,GR 55562,37,39,255,263,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2908,-1,0.9994733,0.00052672933
2909,CP 93129,43,45,278,286,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2909,-1,0.8946481,0.10535194
2911,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,-1,2911,-1,0.00018914719,0.9998109
2915,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2915,-1,0.00020627785,0.9997937
2916,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2916,-1,0.00020659003,0.99979347
2917,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,-1,2917,-1,0.00019481573,0.99980515
2921,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,-1,2921,-1,0.00020006877,0.9997999
2924,renal cell cancer,15,18,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,-1,2924,-1,0.00021640577,0.9997836
2931,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,-1,2931,-1,0.0001972213,0.99980277
2933,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,-1,2933,-1,0.00022281053,0.99977726
2936,postoperative myalgia?This,5,7,45,71,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,-1,-1,2936,-1,0.012971729,0.98702824
2939,blind,17,18,99,104,"One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner.",12452237_1,-1,-1,-1,2939,-1,0.010732247,0.98926777
2940,PS,1,2,6,8,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2940,-1,0.7597366,0.24026343
2942,mg,13,14,76,78,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2942,-1,0.99686605,0.0031338898
2944,mg,23,24,113,115,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2944,-1,0.999065,0.0009349924
2946,mg,30,31,149,151,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2946,-1,0.9990539,0.0009461427
2947,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2947,-1,0.99949026,0.0005097694
2948,mg,43,44,205,207,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2948,-1,0.9988586,0.0011414858
2950,mg,2,3,13,15,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,-1,2950,-1,0.99245524,0.0075447303
2951,thiopental,7,8,40,50,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2951,-1,0.9994881,0.00051185087
2953,PS,15,16,90,92,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2953,-1,0.58616006,0.4138399
2954,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2954,-1,0.99950063,0.0004993839
2957,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2957,-1,0.00020279756,0.99979717
2958,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2958,-1,0.0002020828,0.9997979
2959,PS,29,30,170,172,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2959,-1,0.99841654,0.0015834492
2960,p,31,32,174,175,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2960,-1,0.28104585,0.7189542
2961,h,2,3,6,7,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2961,-1,0.99293435,0.007065624
2963,PS,12,13,54,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2963,-1,0.040164992,0.95983505
2964,p,20,21,82,83,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2964,-1,0.085913405,0.9140866
2966,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,-1,-1,2966,-1,0.00019721736,0.99980277
2969,postoperative myalgia,21,23,123,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,-1,-1,2969,-1,0.0003929997,0.999607
2971,mg,9,10,67,69,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,-1,2971,-1,0.9990632,0.0009367709
2976,mg,14,15,102,104,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2976,-1,0.99938166,0.0006183052
2978,mg,22,23,146,148,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2978,-1,0.9994741,0.000525889
2981,p,25,26,131,132,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,-1,-1,-1,2981,-1,0.25043583,0.7495642
2985,h,9,10,48,49,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,-1,2985,-1,0.5894105,0.41058955
2988,h,8,9,48,49,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2988,-1,0.011204763,0.9887953
2990,p,20,21,123,124,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2990,-1,0.2752163,0.72478366
2992,h,32,33,176,177,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2992,-1,0.07308429,0.92691576
2994,h,4,5,21,22,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2994,-1,0.052039284,0.94796073
2996,p,16,17,84,85,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2996,-1,0.37051967,0.62948036
3000,h,12,13,62,63,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,3000,-1,0.27696195,0.7230381
3001,p,35,36,185,186,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,3001,-1,0.20180611,0.79819393
3003,"nausea, vomiting",13,16,92,108,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3003,-1,0.00039988727,0.9996001
3004,phonophobia,17,18,110,121,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3004,-1,0.00022961372,0.99977034
3005,photophobia,19,20,125,136,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3005,-1,0.00021371631,0.9997863
3006,h,27,28,177,178,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3006,-1,0.451744,0.548256
3007,p,32,33,198,199,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3007,-1,0.8542288,0.14577124
3008,h,12,13,62,63,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3008,-1,0.09609402,0.903906
3010,h,24,25,115,116,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3010,-1,0.18729052,0.81270945
3011,p,33,34,166,167,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3011,-1,0.26604208,0.73395795
3022,sodium channels,17,19,109,124,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,-1,-1,-1,3022,-1,0.008955751,0.9910443
3024,sodium channels,34,36,219,234,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,-1,3024,-1,0.026794413,0.9732056
3025,contrast,1,2,3,11,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,-1,3025,-1,0.7983451,0.2016549
3031,glioblastomas,12,13,93,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,-1,-1,3031,-1,0.00022693342,0.9997731
3033,malignant tumor,5,7,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,-1,-1,3033,-1,0.00019009894,0.9998099
3041,glioblastomas,13,14,88,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,-1,3041,-1,0.00020611881,0.99979395
3043,visual disturbance,5,7,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3043,-1,0.0002098883,0.99979013
3044,h,12,13,71,72,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3044,-1,0.10743839,0.8925616
3045,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,-1,3045,-1,0.017705878,0.9822941
3047,glycerin,11,12,79,87,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,-1,3047,-1,0.99945396,0.00054600055
3049,ocular pain,13,15,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3049,-1,0.00021655767,0.99978346
3050,papilledema,18,19,142,153,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3050,-1,0.00021938157,0.9997806
3051,retinal detachment,21,23,168,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3051,-1,0.00021977519,0.99978024
3052,chorioretinal atrophy,7,9,32,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3052,-1,0.0004164599,0.99958354
3053,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3053,-1,0.00021397833,0.9997861
3068,absence seizures,4,6,37,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,-1,3068,-1,0.0002114692,0.9997886
3069,absence epilepsy,8,10,48,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,-1,-1,3069,-1,0.00017947184,0.99982053
3072,absence seizure,11,13,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,-1,3072,-1,0.00020411515,0.99979585
3073,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,-1,3073,-1,0.000204767,0.99979526
3074,absence seizure,4,6,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,-1,3074,-1,0.00020474337,0.99979526
3075,absence seizure,21,23,136,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,-1,-1,3075,-1,0.00020450984,0.9997955
3078,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3078,-1,0.00021021152,0.9997898
3080,absence seizures,24,26,168,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3080,-1,0.00021105183,0.99978894
3084,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,-1,3084,-1,0.00017688559,0.99982315
3093,deterioration of renal function,7,11,44,75,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,-1,-1,3093,-1,0.00036650058,0.99963343
3094,acute liver injury,7,10,57,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,-1,-1,3094,-1,0.00020835955,0.9997917
3105,acute liver insult,10,13,62,80,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,-1,3105,-1,0.00020287686,0.99979717
3108,pyeloureteritis cystica,3,5,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,-1,-1,3108,-1,0.0003731649,0.99962676
3113,thrombophlebitis,13,14,90,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,-1,-1,-1,3113,-1,0.00020793144,0.99979204
3114,pyeloureteritis cystica,15,17,98,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3114,-1,0.00020879228,0.9997912
3115,submucosal hemorrhage,18,20,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3115,-1,0.00020814114,0.9997919
3117,contrast medium,6,8,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,-1,-1,3117,-1,0.999424,0.0005760872
3119,contrast medium,2,4,20,35,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3119,-1,0.99944586,0.0005541941
3121,contrast medium,9,11,73,88,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3121,-1,0.9994499,0.0005501251
3123,contrast medium,24,26,152,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3123,-1,0.9994764,0.00052366115
3125,contrast medium,38,40,229,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3125,-1,0.99947315,0.0005268262
3126,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3126,-1,0.9995036,0.0004963528
3129,mg,15,16,97,99,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,-1,-1,3129,-1,0.99783045,0.0021695339
3132,mg,12,13,73,75,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3132,-1,0.8644526,0.1355474
3133,mg,22,23,118,120,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3133,-1,0.9766514,0.023348687
3138,mg,15,16,67,69,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3138,-1,0.96422344,0.035776608
3140,mg,24,25,116,118,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3140,-1,0.99673307,0.0032669136
3141,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3141,-1,0.99950635,0.0004936257
3142,P=0.001,32,33,155,162,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3142,-1,0.04584016,0.95415986
3144,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3144,-1,0.99950206,0.00049796124
3145,mg,45,46,231,233,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3145,-1,0.99613756,0.003862424
3148,mg,22,23,113,115,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3148,-1,0.97006017,0.02993987
3149,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3149,-1,0.9995016,0.000498434
3150,P=0.002,45,46,213,220,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3150,-1,0.087996975,0.9120031
3153,mg,9,10,54,56,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3153,-1,0.00092565914,0.99907434
3154,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3154,-1,0.9995009,0.00049912644
3156,mg,15,16,77,79,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3156,-1,0.9078873,0.09211275
3158,mg,24,25,126,128,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3158,-1,0.9968786,0.0031214224
3159,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3159,-1,0.9995116,0.00048840384
3160,P=0.003,32,33,165,172,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3160,-1,0.07258945,0.9274105
3162,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3162,-1,0.9995103,0.0004896904
3163,mg,48,49,247,249,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3163,-1,0.9856638,0.01433625
3165,contrast medium,5,7,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3165,-1,0.99941266,0.00058731815
3167,contrast medium,26,28,163,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3167,-1,0.999428,0.0005719689
3173,increase in blood pressure,15,19,101,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,-1,-1,3173,-1,0.00022755396,0.9997725
3176,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,-1,3176,-1,0.0038201548,0.9961798
3180,reduction in glomeruli,19,22,99,121,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3180,-1,0.00021649121,0.9997836
3181,P<0.05,31,32,165,171,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3181,-1,0.06145492,0.9385451
3183,elevated blood pressures,23,26,108,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,-1,3183,-1,0.00020991551,0.99979013
3192,reduction in glomeruli,8,11,48,70,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,-1,-1,3192,-1,0.00021411444,0.99978584
3196,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,-1,-1,-1,3196,-1,0.9993286,0.0006714708
3200,SRL,4,5,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3200,-1,0.99841034,0.0015896345
3201,calcineurin inhibitors,8,10,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3201,-1,0.9994306,0.0005694141
3203,SRL,5,6,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,-1,3203,-1,0.9993986,0.0006014535
3205,SRL,7,8,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,-1,3205,-1,0.9993723,0.0006276847
3207,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3207,-1,0.9994696,0.0005304461
3208,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3208,-1,0.999453,0.00054700306
3210,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3210,-1,0.99947983,0.0005202221
3211,SRL,37,38,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3211,-1,0.99945456,0.0005454674
3212,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3212,-1,0.99942625,0.00057373027
3213,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3213,-1,0.99947387,0.0005261387
3214,SRL,25,26,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3214,-1,0.9989994,0.0010006126
3215,Cr(EDTA,22,23,113,120,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,-1,3215,-1,0.99933165,0.0006682959
3219,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3219,-1,0.9994198,0.00058022665
3220,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3220,-1,0.9994444,0.00055561
3221,SRL,6,7,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3221,-1,0.99932444,0.0006756365
3222,CsA,6,7,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3222,-1,0.99941623,0.00058383076
3223,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3223,-1,0.99947876,0.0005212608
3224,SRL,13,14,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3224,-1,0.9994592,0.00054075476
3225,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3225,-1,0.9994831,0.0005168834
3226,SRL,27,28,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3226,-1,0.99947435,0.00052565517
3227,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3227,-1,0.9993049,0.00069508835
3228,SRL,13,14,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3228,-1,0.999129,0.0008709652
3229,P<0.001,15,16,94,101,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3229,-1,0.030159462,0.9698406
3231,P<0.02,45,46,274,280,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3231,-1,0.08695809,0.9130419
3232,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3232,-1,0.99943334,0.00056659186
3233,SRL,3,4,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3233,-1,0.9993761,0.0006238611
3235,P=0.05,18,19,109,115,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3235,-1,0.057743102,0.9422569
3237,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3237,-1,0.99943954,0.0005604244
3238,SRL,13,14,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3238,-1,0.99943453,0.0005654945
3239,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3239,-1,0.99946076,0.0005392871
3240,SRL,18,19,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3240,-1,0.99943537,0.00056455657
3241,troponin I,3,5,22,32,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,-1,-1,3241,-1,0.009314734,0.9906853
3244,myocardial cell injury,24,27,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,-1,3244,-1,0.0001955007,0.99980456
3248,cardiac disorders,38,40,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,-1,3248,-1,0.00020393367,0.9997961
3249,DOX,9,10,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,-1,-1,-1,3249,-1,0.99892944,0.0010705099
3250,LV,14,15,97,99,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3250,-1,0.00018146168,0.9998186
3251,DOX,26,27,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3251,-1,0.9993555,0.0006444538
3252,DOX,13,14,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,-1,3252,-1,0.9992674,0.00073261687
3253,DOX,5,6,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,-1,3253,-1,0.9990792,0.00092073326
3255,LV,9,10,41,43,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3255,-1,0.00021756352,0.9997825
3256,DOX,24,25,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3256,-1,0.9994261,0.00057390344
3257,p<0.001,27,28,142,149,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3257,-1,0.09838918,0.90161085
3258,DOX,8,9,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3258,-1,0.99932253,0.00067749183
3261,DOX,8,9,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3261,-1,0.9992397,0.00076029415
3262,p<0.05,23,24,121,127,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3262,-1,0.050434824,0.9495652
3263,DOX,16,17,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,-1,3263,-1,0.99811137,0.0018886549
3264,DOX,12,13,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3264,-1,0.3306902,0.6693098
3265,p=0.006,18,19,102,109,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3265,-1,0.21045326,0.7895467
3266,DOX,12,13,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,-1,3266,-1,0.99597436,0.0040256833
3267,LV,14,15,87,89,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3267,-1,0.00022656417,0.99977344
3268,LV,18,19,125,127,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,-1,3268,-1,0.00020581519,0.9997942
3269,ischemic injury,5,7,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3269,-1,0.00020306245,0.9997969
3270,DOX,8,9,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3270,-1,0.9991903,0.000809698
3272,DOX,13,14,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3272,-1,0.9993631,0.0006369026
3273,DOX,38,39,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3273,-1,0.99937576,0.0006242977
3275,hypoxemia,1,2,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,-1,-1,3275,-1,0.00021316194,0.9997868
3277,fistula,11,12,73,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3277,-1,0.00020434687,0.9997956
3278,necrotizing enterocolitis,13,15,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3278,-1,0.00020450106,0.9997955
3281,fistula,17,18,123,130,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,-1,-1,3281,-1,0.000214508,0.9997855
3282,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3282,-1,0.9994885,0.0005115563
3283,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3283,-1,0.0002015767,0.9997985
3284,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3284,-1,0.0001997339,0.99980026
3285,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3285,-1,0.99948287,0.000517147
3286,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3286,-1,0.9994842,0.0005157376
3287,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3287,-1,0.00024277388,0.99975723
3289,h,12,13,70,71,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3289,-1,0.018203916,0.9817961
3290,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3290,-1,0.9994831,0.00051683723
3291,n=8,17,18,88,91,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3291,-1,0.8217387,0.17826131
3292,n=6,22,23,104,107,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3292,-1,0.9840604,0.015939642
3293,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,-1,-1,-1,3293,-1,0.9994634,0.0005366223
3294,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3294,-1,0.9994836,0.00051634316
3295,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3295,-1,0.00020432136,0.99979573
3296,venous thromboembolism,3,5,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3296,-1,0.00021583495,0.9997842
3297,cyproterone acetate,8,10,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3297,-1,0.9994898,0.00051025307
3298,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3298,-1,0.9994875,0.00051249727
3299,Cyproterone acetate,2,4,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3299,-1,0.99947625,0.000523719
3300,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3300,-1,0.9994729,0.00052707933
3302,hirsutism,24,25,136,145,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3302,-1,0.00023538033,0.9997646
3303,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3303,-1,0.0014781244,0.99852186
3304,PCOS,36,37,208,212,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3304,-1,0.00025436925,0.99974567
3305,venous thromboembolism,8,10,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3305,-1,0.00021253934,0.9997875
3306,VTE,11,12,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3306,-1,0.00021894903,0.9997811
3307,combined oral contraceptives,19,22,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3307,-1,0.99947804,0.0005219882
3308,COCs,23,24,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3308,-1,0.99943835,0.0005616216
3310,hirsutism,31,32,184,193,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3310,-1,0.00025771756,0.9997423
3311,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3311,-1,0.0002722343,0.9997278
3312,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3312,-1,0.00027250146,0.9997274
3313,COCs,11,12,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,-1,3313,-1,0.00033864172,0.9996613
3314,oral contraception,10,12,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3314,-1,0.99939454,0.0006055131
3315,menopausal symptoms,18,20,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3315,-1,0.0002651557,0.9997348
3316,COCs,65,66,305,309,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3316,-1,0.71025336,0.2897466
3317,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3317,-1,0.00022859557,0.9997714
3319,hirsutism,21,22,113,122,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3319,-1,0.00021899017,0.9997811
3320,PCOS,23,24,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3320,-1,0.00022656201,0.99977344
3321,gum Arabic,5,7,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3321,-1,0.99944943,0.000550515
3322,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3322,-1,0.002151589,0.9978484
3323,gum Arabic,13,15,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3323,-1,0.9994491,0.00055096496
3324,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3324,-1,0.00019484527,0.99980515
3326,GM,23,24,126,128,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3326,-1,0.9994198,0.00058024575
3328,gum Arabic,22,24,95,105,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3328,-1,0.99942183,0.00057824474
3329,gum Arabic,35,37,150,160,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3329,-1,0.9994222,0.00057781744
3330,gum Arabic,46,48,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3330,-1,0.9994185,0.000581475
3331,GM,50,51,223,225,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3331,-1,0.99025005,0.00974997
3335,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3335,-1,0.9994518,0.0005481986
3336,GSH,18,19,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3336,-1,0.999395,0.00060493103
3337,gum Arabic,7,9,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3337,-1,0.9994642,0.0005358301
3338,GM,10,11,69,71,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3338,-1,0.9994313,0.0005686689
3341,cellulose,38,39,214,223,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3341,-1,0.9994529,0.0005470844
3342,GM,40,41,228,230,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3342,-1,0.9994259,0.00057408726
3343,GSH,48,49,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3343,-1,0.9994337,0.0005662301
3344,GM,61,62,314,316,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3344,-1,0.9994344,0.0005655158
3345,proximal tubular necrosis,66,69,339,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3345,-1,0.00018393657,0.9998161
3346,GM,78,79,415,417,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3346,-1,0.9994143,0.00058567553
3347,gum Arabic,81,83,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3347,-1,0.99946266,0.0005373286
3348,GM,87,88,463,465,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3348,-1,0.9994286,0.00057137694
3349,cellulose,89,90,470,479,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3349,-1,0.99944526,0.0005547749
3350,gum Arabic,5,7,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3350,-1,0.9994184,0.0005817007
3351,GM nephrotoxicity,22,24,136,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3351,-1,0.0015439682,0.998456
3353,venous thromboembolism,3,5,23,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,-1,-1,3353,-1,0.00019967945,0.9998004
3357,venous thromboembolism,8,10,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3357,-1,0.00020200593,0.999798
3358,VTE,11,12,70,73,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3358,-1,0.00020778103,0.9997923
3365,mg,29,30,182,184,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,-1,3365,-1,0.999148,0.00085201976
3368,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,-1,3368,-1,0.00023644783,0.99976355
3370,VTE,14,15,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3370,-1,0.00024443454,0.99975556
3373,VTE,31,32,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3373,-1,0.00024483245,0.9997552
3374,p=0.025,33,34,181,188,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3374,-1,0.91489536,0.08510466
3378,VTE,19,20,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,-1,-1,3378,-1,0.00021537922,0.99978465
3380,cholestatic hepatitis,1,3,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,-1,-1,3380,-1,0.00023061136,0.9997694
3381,cholestatic hepatitis,8,10,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,-1,3381,-1,0.00019661222,0.99980336
3382,cholestatic hepatitis,7,9,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,-1,-1,3382,-1,0.00024551712,0.9997545
3385,Cholestatic hepatitis,2,4,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,-1,3385,-1,0.001744398,0.99825555
3389,cholestatic hepatitis,16,18,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,-1,-1,3389,-1,0.00022278077,0.99977726
3391,adverse drug,7,9,52,64,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,-1,-1,-1,3391,-1,0.89225,0.107750006
3395,Cholestatic hepatitis,2,4,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,-1,3395,-1,0.0021473467,0.9978527
3400,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,-1,3400,-1,0.0002093303,0.9997907
3401,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,-1,3401,-1,0.00018987904,0.99981016
3406,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3406,-1,0.9994406,0.0005593717
3407,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3407,-1,0.00019969163,0.9998004
3411,PAN,26,27,173,176,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,-1,3411,-1,0.999281,0.0007190779
3415,PAN,11,12,51,54,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,-1,-1,-1,3415,-1,0.99928135,0.0007186579
3420,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,-1,3420,-1,0.0002001602,0.9997999
3422,GABA,4,5,33,37,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,-1,3422,-1,0.99945396,0.0005459995
3425,GABA,3,4,23,27,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3425,-1,0.9994205,0.00057946617
3426,GVG,5,6,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3426,-1,0.9926327,0.0073672896
3427,GABA,12,13,95,99,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,-1,3427,-1,0.99937695,0.0006230494
3428,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3428,-1,0.004213977,0.995786
3430,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3430,-1,0.00019802932,0.99980193
3431,GVG,35,36,218,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3431,-1,0.0006598397,0.9993401
3433,DA,47,48,289,291,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3433,-1,0.9994174,0.00058255624
3434,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,-1,3434,-1,0.000228897,0.99977106
3436,GVG,5,6,34,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3436,-1,0.00045061504,0.9995493
3438,oromandibular dystonia,1,3,17,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3438,-1,0.008879871,0.99112016
3439,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3439,-1,0.00023647648,0.99976355
3441,Parkinson's disease,6,9,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3441,-1,0.00020685019,0.9997931
3442,multiple system atrophy,10,13,75,98,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3442,-1,0.0002085394,0.99979144
3443,dystonias,1,2,8,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3443,-1,0.00022229148,0.99977773
3444,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3444,-1,0.000510165,0.9994898
3445,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3445,-1,0.00019921562,0.99980086
3446,Oromandibular dystonia,11,13,74,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3446,-1,0.00035273592,0.99964726
3447,OMD,14,15,98,101,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3447,-1,0.00025456698,0.9997454
3448,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3448,-1,0.00022922264,0.9997708
3449,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3449,-1,0.00022509074,0.9997749
3450,MR,0,1,0,2,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,-1,-1,3450,-1,0.9759616,0.024038324
3452,MR,6,7,39,41,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3452,-1,0.00026594487,0.999734
3453,neurologic symptoms,24,26,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3453,-1,0.00022235251,0.9997776
3455,MR,1,2,6,8,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3455,-1,0.27209574,0.7279043
3457,neurologic complications,20,22,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3457,-1,0.00021167919,0.99978834
3458,MR,9,10,53,55,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3458,-1,0.0003949126,0.9996051
3459,MR,14,15,75,77,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3459,-1,0.000362884,0.9996371
3460,MR,10,11,59,61,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,-1,3460,-1,0.035489604,0.9645104
3461,white matter abnormalities,11,14,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3461,-1,0.00023769328,0.99976236
3462,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3462,-1,0.015851526,0.9841485
3463,MR,35,36,142,144,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3463,-1,0.004704019,0.99529594
3464,white matter abnormalities,5,8,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3464,-1,0.00024332773,0.99975663
3465,MR,23,24,121,123,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3465,-1,0.00049412256,0.9995059
3466,cortical laminar necrosis,19,22,105,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,-1,3466,-1,0.00022866706,0.9997713
3471,mg,4,5,27,29,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,-1,3471,-1,0.719998,0.28000203
3473,P<0.05,16,17,113,119,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,-1,3473,-1,0.052970316,0.94702965
3474,mm Hg,10,12,56,61,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,-1,-1,-1,3474,-1,0.0038517101,0.99614835
3477,increases in blood pressure,4,8,34,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,-1,3477,-1,0.00022735009,0.9997726
3480,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,-1,3480,-1,0.000208475,0.99979156
3481,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3481,-1,0.000192361,0.99980766
3482,ICH,7,8,49,52,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3482,-1,0.00019675701,0.99980325
3484,ICH,10,11,77,80,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3484,-1,0.00021226834,0.99978775
3485,ICH,15,16,104,107,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3485,-1,0.00020876541,0.9997912
3486,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,-1,3486,-1,0.00021702236,0.999783
3491,ICH,21,22,144,147,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,-1,3491,-1,0.0001897433,0.9998103
3492,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3492,-1,0.00021961513,0.99978036
3495,ICH,18,19,119,122,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3495,-1,0.00022820142,0.9997718
3497,ICH,10,11,64,67,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3497,-1,0.00022191051,0.9997781
3498,ICH,20,21,109,112,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3498,-1,0.00022225543,0.99977773
3499,ICH,36,37,204,207,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3499,-1,0.00022665944,0.9997733
3500,Dexatrim,3,4,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3500,-1,0.9994916,0.0005084461
3501,Phenylpropanolamine,5,6,23,42,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3501,-1,0.9994916,0.00050836866
3502,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3502,-1,0.00020979666,0.99979025
3503,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3503,-1,0.9994197,0.0005803857
3504,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3504,-1,0.9991486,0.0008513555
3505,amine,7,8,43,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3505,-1,0.99938715,0.00061278406
3507,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,-1,3507,-1,0.00019650185,0.9998035
3508,PPA,7,8,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,-1,3508,-1,0.99899095,0.0010089955
3511,Dexatrim,7,8,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,-1,3511,-1,0.99944264,0.00055731804
3513,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,-1,3513,-1,0.99719316,0.0028069161
3515,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,-1,3515,-1,0.9941262,0.0058737686
3516,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3516,-1,0.99918944,0.0008105395
3517,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3517,-1,0.0001932598,0.9998068
3519,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3519,-1,0.00016776707,0.99983215
3520,SLE,12,13,70,73,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3520,-1,0.00018003845,0.99981993
3521,renal involvement,15,17,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3521,-1,0.00017440344,0.99982566
3525,CQ,5,6,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3525,-1,0.99937457,0.0006255163
3526,arthralgia,11,12,64,74,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3526,-1,0.0002345201,0.99976546
3527,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,-1,-1,-1,3527,-1,0.9991825,0.000817433
3528,Myositis,0,1,0,8,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,-1,3528,-1,0.00017880363,0.99982125
3530,muscular weakness,11,13,66,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3530,-1,0.0002078593,0.99979216
3531,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3531,-1,0.00021299373,0.99978703
3532,myositis,9,10,71,79,The neurological and electrophysiological findings were not typical of myositis.,12739036_8,-1,-1,-1,3532,-1,0.00019917439,0.99980086
3533,polymyositis,14,15,76,88,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,-1,3533,-1,0.00020116215,0.99979883
3536,affection of the musculoskeletal system,4,9,43,82,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3536,-1,0.00029087768,0.99970907
3537,SLE,19,20,155,158,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3537,-1,0.00020037539,0.99979967
3539,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,-1,-1,3539,-1,0.0001785978,0.9998215
3543,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,-1,3543,-1,0.00021202337,0.999788
3547,clonic seizure,13,15,76,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,-1,-1,3547,-1,0.00022279735,0.99977726
3549,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,-1,-1,3549,-1,0.00020589585,0.99979407
3552,hippocampal injury,3,5,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,-1,3552,-1,0.0001973959,0.99980265
3553,Estrogens,0,1,0,9,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3553,-1,0.9994462,0.0005537447
3554,hippocampal injury,5,7,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3554,-1,0.00021406871,0.99978596
3555,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3555,-1,0.00021356638,0.99978644
3556,SE,14,15,113,115,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3556,-1,0.000270028,0.99972993
3557,SE,16,17,130,132,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,-1,3557,-1,0.98030204,0.019697977
3558,oil,11,12,76,79,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,-1,3558,-1,0.9994148,0.0005851608
3559,SE,0,1,0,2,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3559,-1,0.99638176,0.0036181698
3560,h,4,5,18,19,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3560,-1,0.06683397,0.93316597
3561,h,12,13,68,69,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3561,-1,0.12775683,0.8722431
3562,SE,14,15,88,90,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,-1,3562,-1,0.5969421,0.40305787
3566,Postoperative myalgia,0,2,0,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,-1,-1,-1,3566,-1,0.0017179757,0.9982821
3569,postoperative myalgia,8,10,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,-1,3569,-1,0.0014699041,0.99853003
3576,n,20,21,159,160,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,-1,-1,3576,-1,0.5911027,0.4088973
3581,h,2,3,6,7,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,-1,-1,3581,-1,0.4726092,0.5273908
3589,postoperative myalgia,19,21,158,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,-1,-1,3589,-1,0.00020924848,0.9997907
3590,postoperative myalgia,8,10,59,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,-1,-1,3590,-1,0.0011438255,0.9988562
3593,postoperative myalgia,8,10,60,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,-1,-1,-1,3593,-1,0.001719527,0.9982805
3595,Pseudoacromegaly,0,1,0,16,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3595,-1,0.0041658804,0.9958341
3596,minoxidil,7,8,49,58,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3596,-1,0.99946314,0.0005368584
3597,Acromegaly,0,1,0,10,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3597,-1,0.0038186256,0.99618137
3598,endocrine disorder,3,5,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3598,-1,0.00020423273,0.99979573
3599,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3599,-1,0.88820344,0.111796595
3601,cutis verticis gyrata,30,33,172,193,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,-1,-1,3601,-1,0.036737956,0.963262
3602,Pseudoacromegaly,0,1,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3602,-1,0.0043638092,0.99563617
3603,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3603,-1,0.89934844,0.10065158
3604,pseudoacromegaly,5,6,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3604,-1,0.00020763389,0.9997924
3605,minoxidil,13,14,83,92,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3605,-1,0.999445,0.0005549237
3606,pseudoacromegaly,7,8,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3606,-1,0.00024520417,0.99975485
3607,minoxidil,13,14,70,79,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3607,-1,0.9994504,0.0005496641
3608,androgen,1,2,9,17,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,-1,-1,3608,-1,0.99934536,0.0006546149
3611,bone involvement,9,11,78,94,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,-1,-1,3611,-1,0.00021772807,0.99978226
3612,androgen,10,11,58,66,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3612,-1,0.9994011,0.00059888937
3615,bone involvement,19,21,133,149,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3615,-1,0.00020933889,0.9997907
3616,prostatic adenocarcinoma,8,10,60,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3616,-1,0.00019570364,0.9998043
3617,C,14,15,100,101,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3617,-1,0.6079115,0.3920885
3618,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3618,-1,0.9994678,0.0005322235
3619,mg,11,12,60,62,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3619,-1,0.99101186,0.00898816
3620,mg flutamide,20,22,104,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3620,-1,0.9994462,0.0005537259
3626,SE,24,25,100,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3626,-1,0.9992429,0.00075708044
3628,SE,47,48,191,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3628,-1,0.99920183,0.0007981985
3630,p,29,30,153,154,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,-1,3630,-1,0.09393455,0.90606546
3633,C,50,51,221,222,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,-1,3633,-1,0.17064682,0.82935315
3641,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,-1,3641,-1,0.0015707039,0.99842924
3643,3-methylcholanthrene,9,10,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3643,-1,0.99950194,0.00049803266
3644,MC,11,12,86,88,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3644,-1,0.99947983,0.0005202323
3648,PB,37,38,239,241,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3648,-1,0.99945074,0.000549254
3653,cobalt chloride,11,13,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3653,-1,0.9995159,0.0004840573
3657,se,27,28,186,188,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3657,-1,0.200246,0.79975396
3658,PB,33,34,218,220,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3658,-1,0.9994978,0.0005022262
3661,venous thromboembolism,5,7,34,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3661,-1,0.00017094024,0.99982905
3662,cyproterone acetate,11,13,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3662,-1,0.9994734,0.0005266141
3663,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3663,-1,0.9994837,0.0005163149
3664,venous thromboembolism,8,10,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3664,-1,0.0001678759,0.99983215
3665,VTE,11,12,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3665,-1,0.00017829526,0.9998217
3666,cyproterone acetate,16,18,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3666,-1,0.99949706,0.0005029064
3667,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3667,-1,0.9994906,0.0005093225
3668,combined oral contraceptives,28,31,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3668,-1,0.99948275,0.00051720324
3669,COCs,32,33,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3669,-1,0.9994468,0.00055318867
3670,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,-1,3670,-1,0.00028418313,0.99971575
3671,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,-1,3671,-1,0.9984124,0.0015876605
3672,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,-1,3672,-1,0.0006596571,0.99934036
3673,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3673,-1,0.00026534896,0.9997347
3674,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3674,-1,0.00041711846,0.9995828
3675,COCs,8,9,53,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,-1,-1,-1,3675,-1,0.017604085,0.9823959
3676,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3676,-1,0.00029784857,0.99970216
3677,COCs,24,25,106,110,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3677,-1,0.30928618,0.6907138
3678,COCs,43,44,197,201,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3678,-1,0.239138,0.76086193
3679,VTE,9,10,53,56,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3679,-1,0.00024465792,0.9997553
3680,COCs,14,15,79,83,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3680,-1,0.00026121622,0.99973875
3683,NSAIDs,11,12,81,87,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3683,-1,0.9994337,0.00056632515
3684,developmental anomalies,19,21,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3684,-1,0.0002090638,0.99979097
3685,NSAIDs,25,26,167,173,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3685,-1,0.99943453,0.00056539103
3688,ASA,5,6,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3688,-1,0.9994049,0.00059513305
3689,developmental anomalies,18,20,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3689,-1,0.00021341596,0.99978656
3690,CA,39,40,198,200,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3690,-1,0.84436315,0.15563682
3691,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,-1,3691,-1,0.00085728,0.99914265
3692,SD,12,13,80,82,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3692,-1,0.18733233,0.8126677
3693,ASA,18,19,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3693,-1,0.99809486,0.0019051806
3694,SD,43,44,247,249,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3694,-1,0.34206453,0.6579355
3695,gastrointestinal toxicity,53,55,297,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3695,-1,0.00019504917,0.9998049
3696,malformations,61,62,364,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3696,-1,0.00019628556,0.9998037
3697,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3697,-1,0.9990601,0.0009399152
3698,ASA,2,3,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3698,-1,0.99904376,0.0009562211
3699,SD,76,77,237,239,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3699,-1,0.015447162,0.98455286
3700,NSAIDs,7,8,50,56,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3700,-1,0.99931836,0.0006816887
3701,ventricular septal defects,9,12,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3701,-1,0.00018027038,0.9998198
3702,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3702,-1,0.0013873866,0.99861264
3703,MDs,19,20,119,122,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3703,-1,0.00018681979,0.99981326
3704,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3704,-1,0.00018615369,0.99981385
3705,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3705,-1,0.0014134787,0.99858654
3706,MDs,30,31,163,166,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3706,-1,0.00019326844,0.9998067
3707,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3707,-1,0.0016736231,0.99832636
3708,malformations,53,54,254,267,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3708,-1,0.00018321033,0.99981683
3709,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3709,-1,0.99924636,0.0007537188
3710,malformations,62,63,321,334,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3710,-1,0.00018346995,0.9998166
3711,DH,5,6,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3711,-1,0.0006140627,0.99938595
3712,MD,7,8,28,30,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3712,-1,0.00046782594,0.9995322
3713,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3713,-1,0.0005573363,0.99944264
3714,VSD,0,1,0,3,VSD also was noted following treatment on GD 11.,12852481_10,-1,-1,-1,3714,-1,0.0016646436,0.9983354
3715,contrast,1,2,3,11,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3715,-1,0.08830526,0.9116947
3716,DH,3,4,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3716,-1,0.9717704,0.028229553
3717,MD,5,6,20,22,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3717,-1,0.00029700465,0.999703
3718,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3718,-1,0.00038197264,0.99961805
3719,developmental anomalies,6,8,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3719,-1,0.00021529442,0.99978477
3720,SD,11,12,82,84,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3720,-1,0.8792086,0.12079136
3721,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3721,-1,0.00026622496,0.99973375
3722,SD,22,23,134,136,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3722,-1,0.59836805,0.4016319
3723,hydrocephalus,25,26,146,159,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3723,-1,0.00021464528,0.99978536
3724,malformations,2,3,15,28,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3724,-1,0.0002107791,0.9997892
3725,ASA,6,7,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3725,-1,0.99839395,0.0016060362
3726,malformations,17,18,85,98,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3726,-1,0.00022703514,0.99977297
3727,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3727,-1,0.9993492,0.00065080967
3729,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,-1,3729,-1,0.9994778,0.0005221907
3731,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3731,-1,0.9994967,0.00050329865
3734,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3734,-1,0.99949574,0.00050422683
3735,Flumazenil,0,1,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3735,-1,0.9994955,0.0005045292
3736,mg,6,7,28,30,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3736,-1,0.9991055,0.00089448225
3739,meperidine,41,42,201,211,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3739,-1,0.9994973,0.00050274824
3741,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,-1,3741,-1,0.99945873,0.00054130174
3742,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,-1,-1,-1,3742,-1,0.9994825,0.0005174979
3745,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3745,-1,0.99949324,0.00050673855
3748,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,-1,-1,-1,3748,-1,0.99946374,0.00053624343
3757,n,4,5,19,20,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3757,-1,0.06204663,0.9379534
3759,mg,46,47,198,200,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3759,-1,0.94136006,0.05863995
3764,MPEP,3,4,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,-1,3764,-1,0.9994685,0.0005314521
3772,h,25,26,143,144,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,-1,-1,-1,3772,-1,0.08635415,0.9136458
3774,MPEP,8,9,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,-1,3774,-1,0.9994286,0.0005713707
3777,MPEP,2,3,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3777,-1,0.9994778,0.0005222789
3781,veratridine,37,38,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3781,-1,0.9995061,0.00049390714
3784,MPEP,0,1,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,-1,-1,-1,3784,-1,0.9994357,0.0005643014
3786,MPEP,12,13,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,-1,3786,-1,0.9994367,0.0005632806
3788,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,-1,3788,-1,0.99944824,0.0005517898
3792,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,-1,3792,-1,0.00018153992,0.9998185
3795,fluvoxamine,14,15,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,-1,-1,-1,3795,-1,0.99949205,0.00050798873
3808,renal disease,12,14,97,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,-1,-1,3808,-1,0.00020047896,0.99979955
3812,psychiatric disorders,14,16,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,-1,-1,3812,-1,0.00019370255,0.99980634
3814,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,-1,3814,-1,0.0048168567,0.99518317
3819,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3819,-1,0.9995216,0.00047841604
3820,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3820,-1,0.9995278,0.00047218555
3821,ganaxolone,10,11,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3821,-1,0.99953604,0.00046398852
3822,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3822,-1,0.9995253,0.00047466304
3827,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3827,-1,0.99951804,0.00048201447
3828,ganaxolone,18,19,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3828,-1,0.9995208,0.00047926937
3829,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3829,-1,0.99949765,0.00050236785
3830,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3830,-1,0.9994948,0.0005051331
3831,ganaxolone,6,7,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3831,-1,0.9995023,0.0004977066
3838,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,-1,3838,-1,0.00021289811,0.99978715
3840,mg,14,15,78,80,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3840,-1,0.99684215,0.0031579083
3841,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3841,-1,0.99932516,0.00067481596
3842,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,-1,3842,-1,0.9992256,0.0007744352
3843,Renal function significantly deteriorated,0,4,0,41,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3843,-1,0.00031885196,0.9996811
3845,p,11,12,83,84,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3845,-1,0.07720168,0.92279834
3847,h,37,38,180,181,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3847,-1,0.09471004,0.90529
3848,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3848,-1,0.00022226817,0.99977773
3849,weight loss,5,7,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3849,-1,0.0004191557,0.9995808
3855,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,-1,3855,-1,0.00025967616,0.9997403
3859,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,-1,3859,-1,0.00020286602,0.99979717
3860,retinopathy,3,4,22,33,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3860,-1,0.00022028456,0.99977976
3861,thrombophlebitis,14,15,91,107,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3861,-1,0.00021676176,0.9997832
3862,thrombophlebitis,4,5,29,45,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3862,-1,0.00021739928,0.9997826
3870,mg,28,29,134,136,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3870,-1,0.99914694,0.00085310143
3871,rauwolscine,34,35,151,162,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3871,-1,0.9995047,0.0004952988
3872,mg,37,38,166,168,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3872,-1,0.9993505,0.0006495202
3874,MAP,16,17,94,97,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,-1,3874,-1,0.90686506,0.093134895
3875,MAP,2,3,10,13,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3875,-1,0.9992078,0.0007922711
3877,MAP,17,18,88,91,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3877,-1,0.06078818,0.93921185
3878,rauwolscine,20,21,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3878,-1,0.9994867,0.0005133254
3879,MAP,24,25,122,125,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3879,-1,0.032194167,0.9678058
3882,MAP,17,18,97,100,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3882,-1,0.005051802,0.99494815
3883,n,19,20,102,103,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3883,-1,0.99922013,0.0007798687
3884,rauwolscine,31,32,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3884,-1,0.9995103,0.00048966845
3885,MAP,38,39,169,172,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3885,-1,0.005404851,0.9945951
3886,n,40,41,174,175,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3886,-1,0.99937385,0.0006261605
3888,mg,13,14,60,62,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,-1,3888,-1,0.99891305,0.0010869591
3889,MAP,0,1,0,3,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3889,-1,0.0018133102,0.99818665
3891,n,18,19,95,96,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3891,-1,0.04354867,0.9564513
3894,mg,23,24,138,140,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,-1,-1,3894,-1,0.9994423,0.00055773545
3895,rauwolscine,4,5,30,41,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3895,-1,0.9994796,0.00052038854
3896,mg,7,8,45,47,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3896,-1,0.9992694,0.00073055486
3898,MAP,20,21,111,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3898,-1,0.99154013,0.008459878
3899,n,27,28,126,127,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3899,-1,0.096488014,0.90351194
3900,MAP,39,40,180,183,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3900,-1,0.8050733,0.19492672
3902,cirazoline,11,12,64,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3902,-1,0.99948514,0.00051479734
3903,Abbott-53693,25,26,129,141,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3903,-1,0.99942255,0.00057741685
3907,cirazoline,7,8,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3907,-1,0.99951243,0.00048753477
3909,n,16,17,103,104,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3909,-1,0.29100594,0.7089941
3910,n,27,28,144,145,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3910,-1,0.37478733,0.6252126
3911,Abbott-53693,9,10,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,-1,3911,-1,0.99943286,0.00056715996
3916,increase in locomotor activity,6,10,49,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,-1,3916,-1,0.00022620586,0.9997738
3917,increase in locomotor activity,8,12,57,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,-1,3917,-1,0.00021097578,0.99978906
3918,increase in locomotor activity,11,15,78,108,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,-1,3918,-1,0.0002083661,0.9997917
3921,physostigmine,10,11,84,97,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,-1,-1,3921,-1,0.999491,0.0005090129
3922,contrast,1,2,3,11,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3922,-1,0.9984983,0.0015017184
3923,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3923,-1,0.9995005,0.0004994291
3924,neostigmine,6,7,38,49,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3924,-1,0.9995053,0.00049473124
3939,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,-1,3939,-1,0.00020291746,0.99979705
3942,in,13,14,97,99,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,-1,-1,-1,3942,-1,0.00026697552,0.99973303
3945,Li,15,16,102,104,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,-1,3945,-1,0.9993156,0.0006843457
3950,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,-1,3950,-1,0.00021276194,0.9997873
3953,rise in blood pressure,4,8,23,45,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,-1,-1,-1,3953,-1,0.00024379494,0.99975616
3965,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3965,-1,0.00023229026,0.9997677
3966,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3966,-1,0.9994444,0.0005555162
3967,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3967,-1,0.9994536,0.00054636394
3968,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3968,-1,0.99943286,0.00056706835
3969,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3969,-1,0.9994386,0.0005614191
3970,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3970,-1,0.00021642908,0.9997836
3971,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3971,-1,0.99948466,0.0005152809
3972,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,-1,3972,-1,0.00024653494,0.9997534
3973,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3973,-1,0.9994568,0.00054320943
3974,mg,10,11,54,56,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3974,-1,0.9975405,0.0024595591
3975,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,-1,-1,-1,3975,-1,0.99943656,0.00056343875
3977,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3977,-1,0.9994611,0.0005389367
3978,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3978,-1,0.00021284432,0.99978715
3979,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3979,-1,0.9994468,0.0005531842
3980,inflammatory bowel disease,19,22,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3980,-1,0.00019414983,0.99980587
3981,Amnestic syndrome,0,2,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3981,-1,0.00019876858,0.9998012
3982,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3982,-1,0.022165246,0.97783476
3984,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,-1,3984,-1,0.023423871,0.9765761
3985,impairment of memory,7,10,50,70,Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.,1423339_2,-1,-1,-1,3985,-1,0.000196894,0.9998031
3986,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,-1,-1,3986,-1,0.0052009877,0.994799
3991,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,-1,3991,-1,0.99947685,0.0005231211
3992,glaucomatous,1,2,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,-1,3992,-1,0.00021585534,0.9997842
3996,blind,3,4,12,17,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3996,-1,0.0020695897,0.9979304
3999,p,28,29,180,181,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3999,-1,0.06749619,0.9325039
4000,betaxolol,4,5,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,-1,4000,-1,0.9994733,0.00052675395
4004,LY274614,11,12,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,-1,4004,-1,0.9994771,0.00052298175
4006,LY274614,0,1,0,8,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4006,-1,0.99903023,0.0009697824
4007,"3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid",2,6,10,88,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4007,-1,0.99859077,0.0014091756
4008,NMDA,18,19,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4008,-1,0.9994324,0.00056762615
4012,iprindole,18,19,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,-1,-1,-1,4012,-1,0.9994797,0.0005203285
4015,dizocilpine,11,12,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4015,-1,0.99952054,0.0004794199
4016,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4016,-1,0.37619957,0.6238004
4017,NMDA,19,20,125,129,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4017,-1,0.999453,0.00054700696
4018,LY274614,24,25,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4018,-1,0.99948716,0.0005127953
4019,NMDA,30,31,185,189,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4019,-1,0.99944717,0.00055284315
4020,LY274614,4,5,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,-1,4020,-1,0.9994344,0.00056561903
4021,LY274614,5,6,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,-1,-1,-1,4021,-1,0.9994844,0.000515516
4026,LY274614,10,11,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4026,-1,0.9994753,0.00052471785
4028,LY274614,19,20,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4028,-1,0.99948967,0.0005103003
4032,LY274614,24,25,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,-1,4032,-1,0.99948525,0.00051467324
4036,NMDA,19,20,144,148,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4036,-1,0.99944514,0.0005549032
4037,LY274614,23,24,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4037,-1,0.99948764,0.0005123612
4038,NMDA,26,27,183,187,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4038,-1,0.9994456,0.000554348
4041,penicillins,15,16,110,121,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,-1,4041,-1,0.9994344,0.0005656212
4044,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,-1,-1,4044,-1,0.9994823,0.0005177337
4045,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,-1,4045,-1,0.99948007,0.00051996834
4048,hemolytic,9,10,57,66,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,-1,-1,-1,4048,-1,0.00019776347,0.9998023
4050,neurologic sequelae,1,3,21,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,-1,4050,-1,0.00021210688,0.99978787
4051,weakness of extremities,4,7,29,52,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4051,-1,0.00024660406,0.9997534
4052,legs paralysis,8,10,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4052,-1,0.00020412334,0.99979585
4053,dysarthria,11,12,70,80,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4053,-1,0.00020674392,0.99979323
4055,h,15,16,94,95,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4055,-1,0.034229983,0.96577
4056,mg ketoconazole,20,22,119,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4056,-1,0.999488,0.0005119845
4057,mg ketoconazole,16,18,84,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4057,-1,0.9994584,0.0005416881
4058,adverse drug reactions,9,12,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,-1,-1,4058,-1,0.00055721845,0.99944276
4062,LIDs,3,4,30,34,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4062,-1,0.0002808079,0.9997192
4063,Parkinson's disease,14,17,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4063,-1,0.00023718143,0.99976283
4064,PD,18,19,113,115,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4064,-1,0.00022621275,0.9997738
4065,LIDs,24,25,155,159,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,-1,4065,-1,0.000283422,0.9997166
4068,LIDs,41,42,255,259,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,-1,4068,-1,0.00042470053,0.9995753
4069,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,-1,-1,4069,-1,0.99946517,0.0005348463
4073,contrast,1,2,3,11,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4073,-1,0.60400707,0.3959929
4074,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4074,-1,0.999421,0.00057907007
4076,LIDs,27,28,179,183,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4076,-1,0.0002589661,0.999741
4080,LIDs,10,11,69,73,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4080,-1,0.00031587356,0.9996841
4082,LIDs,38,39,254,258,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4082,-1,0.0003121691,0.9996879
4083,sugar dependency,3,5,17,33,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,-1,4083,-1,0.0044541573,0.99554586
4085,sugar,13,14,85,90,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4085,-1,0.9992079,0.00079216313
4086,drug dependency,24,26,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4086,-1,0.004834083,0.99516594
4087,sugar,11,12,70,75,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,-1,-1,-1,4087,-1,0.9993748,0.00062525645
4089,sucrose,30,31,155,162,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4089,-1,0.99943405,0.0005659771
4090,h,37,38,193,194,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4090,-1,0.9991092,0.0008908314
4091,h,41,42,213,214,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4091,-1,0.10426539,0.89573455
4092,ad,10,11,49,51,"Beginning on day 22, all rats were maintained on ad libitum chow.",14596845_5,-1,-1,-1,4092,-1,0.9991247,0.00087527954
4094,sucrose,6,7,40,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4094,-1,0.99941206,0.00058799115
4095,hyperactive,10,11,62,73,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4095,-1,0.00021005608,0.99979
4097,ad,21,22,136,138,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4097,-1,0.9993799,0.00062008563
4098,sucrose,25,26,151,158,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4098,-1,0.99943644,0.0005635413
4102,sucrose,50,51,298,305,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4102,-1,0.9994313,0.00056868186
4103,sugar,14,15,87,92,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,-1,4103,-1,0.99939203,0.0006079052
4104,sugar,21,22,132,137,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,-1,4104,-1,0.99939406,0.00060590217
4109,hemorrhagic cystitis,10,12,73,93,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,-1,-1,-1,4109,-1,0.00020127343,0.9997987
4110,Hemorrhagic cystitis,2,4,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4110,-1,0.0002069666,0.999793
4111,HC,5,6,27,29,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4111,-1,0.0002653368,0.9997347
4113,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4113,-1,0.9846699,0.015330024
4116,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,-1,4116,-1,0.00022582097,0.99977416
4118,h,33,34,122,123,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4118,-1,0.19607855,0.8039214
4119,IFS,41,42,155,158,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4119,-1,0.08464835,0.9153516
4125,h,4,5,26,27,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,-1,-1,4125,-1,0.03413944,0.96586055
4128,IFS,26,27,146,149,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,-1,-1,-1,4128,-1,0.00025752353,0.99974245
4129,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,-1,4129,-1,0.28674847,0.7132516
4135,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,-1,4135,-1,0.0002417755,0.9997582
4139,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,-1,4139,-1,0.0003580014,0.999642
4140,erythema nodosum,3,5,33,49,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4140,-1,0.0002183355,0.99978167
4141,acute promyelocytic leukemia,8,11,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4141,-1,0.00021791042,0.99978215
4142,Erythema nodosum,0,2,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4142,-1,0.00044866363,0.99955136
4143,ATRA,8,9,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4143,-1,0.00031699156,0.999683
4144,acute promyelocytic leukemia,11,14,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4144,-1,0.00021897284,0.9997811
4145,APL,15,16,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4145,-1,0.0002210913,0.9997789
4146,APL,6,7,39,42,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4146,-1,0.00020632861,0.9997937
4147,erythema nodosum,9,11,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4147,-1,0.00019755142,0.9998024
4148,ATRA,12,13,81,85,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4148,-1,0.00026211212,0.9997379
4150,painful erythematous,4,6,30,50,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4150,-1,0.00018811427,0.99981195
4151,ATRA,23,24,133,137,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4151,-1,0.99931276,0.0006872706
4152,erythema nodosum,10,12,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,-1,4152,-1,0.00021122214,0.9997888
4155,lesions,6,7,36,43,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,-1,-1,-1,4155,-1,0.00022252751,0.9997775
4156,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,-1,4156,-1,0.94407725,0.0559227
4157,ATRA,0,1,0,4,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4157,-1,0.7503425,0.24965751
4158,erythema nodosum,9,11,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4158,-1,0.00020659596,0.99979347
4160,erythema nodosum,9,11,60,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,-1,-1,-1,4160,-1,0.00020641006,0.9997936
4162,amphotericin B,5,7,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,-1,-1,4162,-1,0.9994636,0.00053640857
4164,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4164,-1,0.00020301118,0.99979705
4165,amphotericin B,19,21,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4165,-1,0.9994785,0.0005215316
4166,AmB,22,23,144,147,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4166,-1,0.9994529,0.0005470964
4167,coccidioidomycosis,26,27,166,184,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4167,-1,0.022542765,0.97745717
4168,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4168,-1,0.00021667955,0.99978334
4169,posaconazole,8,9,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4169,-1,0.999458,0.0005420447
4170,AmB.,12,13,102,106,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4170,-1,0.069855034,0.93014497
4172,AmB.,25,26,184,188,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4172,-1,0.016082082,0.98391795
4175,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,-1,-1,4175,-1,0.878716,0.12128394
4178,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4178,-1,0.16851252,0.8314875
4181,5-HT,26,27,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4181,-1,0.999498,0.000501939
4185,migraineurs,2,3,15,26,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4185,-1,0.00020107624,0.99979895
4187,mg,4,5,30,32,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,-1,-1,-1,4187,-1,0.98529804,0.014701914
4191,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4191,-1,0.9993931,0.00060686877
4192,P<0.01,6,7,51,57,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4192,-1,0.105408914,0.89459103
4195,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4195,-1,0.00021098743,0.99978906
4196,P<0.001,17,18,110,117,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4196,-1,0.1171403,0.8828597
4197,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,-1,-1,4197,-1,0.99729353,0.0027064413
4200,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4200,-1,0.99943525,0.0005647124
4201,5-HT,8,9,63,67,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4201,-1,0.9994487,0.00055132847
4204,P<0.01,6,7,52,58,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,-1,-1,4204,-1,0.143706,0.856294
4208,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4208,-1,0.9993524,0.0006476504
4209,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4209,-1,0.00020661365,0.99979335
4210,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4210,-1,0.9993364,0.0006635702
4212,contrast,1,2,3,11,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4212,-1,0.99912184,0.00087821524
4216,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4216,-1,0.6585965,0.3414035
4218,hemorrhagic cystitis,8,10,78,98,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,-1,-1,-1,4218,-1,0.00019835985,0.9998017
4219,hemorrhagic cystitis,6,8,32,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4219,-1,0.00019259278,0.9998074
4221,Wegener's granulomatosis,13,16,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4221,-1,0.0011694368,0.9988306
4222,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,-1,4222,-1,0.999456,0.00054406543
4226,hemorrhagic cystitis,17,19,106,126,"In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.",1468485_6,-1,-1,-1,4226,-1,0.0001966066,0.99980336
4227,psychosis,1,2,6,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,-1,-1,4227,-1,0.00020063196,0.99979943
4229,psychosis,3,4,19,28,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,-1,-1,4229,-1,0.00020656205,0.99979347
4231,psychosis,8,9,49,58,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4231,-1,0.00019336026,0.9998067
4233,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4233,-1,0.00018792727,0.99981207
4238,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4238,-1,0.7644192,0.23558077
4239,loreclezole,9,10,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4239,-1,0.008838645,0.99116135
4240,valproate,14,15,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4240,-1,0.9994504,0.00054959545
4241,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4241,-1,0.99945015,0.0005497948
4242,Loreclezole,0,1,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,-1,-1,4242,-1,0.015900563,0.9840994
4244,loreclezole,3,4,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4244,-1,0.99928707,0.0007129472
4245,valproate,9,10,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4245,-1,0.9994783,0.0005217041
4246,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4246,-1,0.9994771,0.00052295683
4249,BAY k-8644,9,11,74,84,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4249,-1,0.9949726,0.0050273547
4250,calcium channels,16,18,107,123,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4250,-1,0.023672858,0.9763272
4251,loreclezole,24,25,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4251,-1,0.9992836,0.00071637577
4252,valproate,30,31,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4252,-1,0.9994824,0.00051759504
4255,BAY k-8644,9,11,50,60,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4255,-1,0.999496,0.00050395605
4256,loreclezole,16,17,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4256,-1,0.99908197,0.00091796793
4257,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4257,-1,0.99951255,0.0004874769
4258,loreclezole,10,11,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4258,-1,0.017171348,0.9828287
4259,calcium channels,28,30,208,224,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4259,-1,0.9990551,0.0009448544
4260,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,-1,4260,-1,0.0030270333,0.9969729
4263,tubular lesions,13,15,113,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,-1,-1,4263,-1,0.00020771586,0.9997923
4264,mitochondrial injury,6,8,38,58,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,-1,-1,-1,4264,-1,0.00019708126,0.9998029
4266,mg,10,11,59,61,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,-1,4266,-1,0.9991374,0.0008625847
4267,h,11,12,58,59,Additional rats received a single dose either 6 days or 2 h prior to euthanasia.,14736955_4,-1,-1,-1,4267,-1,0.53864807,0.46135193
4268,Glomerular and tubular injury,0,4,0,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,-1,4268,-1,0.00022581925,0.99977416
4270,glomerular and tubular lesions,9,13,47,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4270,-1,0.0002167967,0.9997832
4272,NADH dehydrogenase,18,20,117,135,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4272,-1,0.99895716,0.0010427951
4273,citrate,28,29,181,188,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4273,-1,0.99938846,0.0006115778
4274,tubular lesions,9,11,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4274,-1,0.00021335656,0.9997867
4275,glomerular lesions,16,18,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4275,-1,0.0002168579,0.9997831
4276,glomerular and tubular injury,4,8,19,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4276,-1,0.00021986698,0.9997801
4277,Injury,30,31,215,221,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4277,-1,0.00021587346,0.9997842
4280,renal lesions,28,30,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,-1,4280,-1,0.00021865257,0.9997813
4285,sexually dysfunctional,1,3,9,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4285,-1,0.00023987681,0.9997601
4290,mg,30,31,207,209,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4290,-1,0.9994821,0.00051794347
4291,mg ephedrine,16,18,119,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,-1,-1,-1,4291,-1,0.99944514,0.00055485475
4294,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4294,-1,0.99944705,0.00055299525
4296,n=94,17,18,97,101,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4296,-1,0.04674542,0.9532546
4298,n=35,28,29,147,151,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4298,-1,0.091182366,0.90881765
4299,p=0.032,16,17,88,95,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4299,-1,0.12467736,0.87532264
4300,p=0.026,27,28,142,149,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4300,-1,0.15593427,0.8440657
4302,oestrogen,9,10,56,65,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,-1,-1,-1,4302,-1,0.9994418,0.00055819016
4304,leg cramps,13,15,85,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,-1,4304,-1,0.00018998643,0.99981004
4307,neurological complications,10,12,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,-1,4307,-1,0.00021770148,0.99978226
4315,heart failure,19,21,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,-1,4315,-1,0.00020028485,0.9997998
4316,propafenone overdose,5,7,57,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4316,-1,0.009129161,0.9908708
4317,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4317,-1,0.0019209224,0.99807906
4318,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4318,-1,0.0072238604,0.99277616
4320,cyanosis,36,37,245,253,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4320,-1,0.00019841525,0.9998016
4321,propafenone overdose,26,28,146,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,-1,4321,-1,0.009302367,0.99069756
4322,biventricular dysfunction,3,5,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,-1,4322,-1,0.00021875207,0.9997813
4324,contrast,12,13,74,82,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,-1,-1,4324,-1,0.9985453,0.0014547304
4325,cholestatic jaundice,1,3,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,-1,-1,4325,-1,0.00024705427,0.99975294
4326,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,-1,4326,-1,0.999456,0.0005439741
4328,itching,7,8,44,51,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4328,-1,0.00021537532,0.99978465
4329,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4329,-1,0.9995073,0.0004926475
4330,mg,15,16,92,94,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4330,-1,0.99928916,0.00071084715
4332,mg,22,23,120,122,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4332,-1,0.99907815,0.0009218789
4335,emergency department,4,6,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4335,-1,0.0029784346,0.9970215
4336,icterus,14,15,74,81,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4336,-1,0.00021120644,0.9997888
4338,hyperbilirubinemia,19,20,97,115,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4338,-1,0.00021433728,0.9997857
4342,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,-1,-1,-1,4342,-1,0.99948347,0.00051650364
4343,cholestatic jaundice,18,20,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,-1,-1,4343,-1,0.00023447229,0.9997656
4344,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,-1,-1,-1,4344,-1,0.99948585,0.0005141508
4345,vascular dysfunctions,20,22,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4345,-1,0.00019954923,0.9998005
4346,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4346,-1,0.002799151,0.99720085
4347,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4347,-1,0.0008410873,0.999159
4348,vascular disturbances,12,14,102,123,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4348,-1,0.00019921086,0.99980086
4350,mm,5,6,18,20,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4350,-1,0.99926835,0.0007316407
4351,increases in dural and cortical blood flow,14,21,62,104,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4351,-1,0.00034413856,0.99965584
4352,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,-1,-1,-1,4352,-1,0.9994831,0.0005168141
4353,increases in dural blood flow,2,7,11,40,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4353,-1,0.00027204436,0.9997279
4355,mm,17,18,106,108,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4355,-1,0.9979887,0.0020112868
4356,mm,30,31,152,154,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4356,-1,0.9986449,0.0013551564
4358,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,-1,-1,4358,-1,0.00018170616,0.99981827
4360,neuropathological damages,5,7,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,-1,-1,4360,-1,0.00020675437,0.99979323
4361,organophosphorus (OP) compounds,1,6,5,36,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4361,-1,0.9993761,0.00062395574
4362,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4362,-1,0.9994893,0.0005106194
4363,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4363,-1,0.99947184,0.00052818906
4364,sarin,12,13,74,79,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4364,-1,0.9994186,0.00058144686
4365,soman,14,15,84,89,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4365,-1,0.99945754,0.00054248923
4367,OPs,4,5,22,25,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4367,-1,0.010648546,0.98935145
4369,ACh,27,28,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4369,-1,0.99943,0.00056991517
4370,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4370,-1,0.99938655,0.0006134681
4371,pralidoxime-2-chloride,5,6,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4371,-1,0.9995047,0.0004952776
4372,2PAM,7,8,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4372,-1,0.9995011,0.00049885554
4374,N(6)-cyclopentyl adenosine,26,28,154,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4374,-1,0.99945396,0.0005460055
4375,CPA,29,30,182,185,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4375,-1,0.9992231,0.00077689206
4376,dizocilpine maleate,39,41,228,247,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4376,-1,0.99950814,0.0004918599
4377,-MK801 hydrogen maleate,43,46,250,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4377,-1,0.99947816,0.0005218778
4378,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4378,-1,0.9995022,0.0004978654
4379,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4379,-1,0.9994035,0.000596567
4380,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4380,-1,0.99946564,0.00053432037
4381,olive oil,11,13,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4381,-1,0.9994424,0.00055756164
4382,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4382,-1,0.9994017,0.00059826695
4383,h,6,7,35,36,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4383,-1,0.039271668,0.96072835
4384,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4384,-1,0.99941623,0.000583818
4386,CPA,1,2,5,8,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4386,-1,0.99944276,0.00055725296
4388,2PAM,5,6,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4388,-1,0.9994844,0.00051549653
4390,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,-1,4390,-1,0.011525966,0.9884741
4391,CPA,3,4,15,18,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4391,-1,0.99942183,0.00057819835
4393,2PAM,7,8,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4393,-1,0.99949145,0.00050858106
4397,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4397,-1,0.9994824,0.0005175879
4398,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4398,-1,0.00018425129,0.99981576
4399,gastric lymphoma,10,12,79,95,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4399,-1,0.00018466357,0.9998154
4400,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4400,-1,0.00018408586,0.9998159
4401,Steinert's disease).The,19,22,134,157,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4401,-1,0.0728572,0.9271428
4402,gastric lymphoma,30,32,222,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4402,-1,0.00018705311,0.999813
4403,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4403,-1,0.00018863875,0.99981135
4404,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4404,-1,0.00018363708,0.99981636
4405,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4405,-1,0.00018534092,0.9998147
4406,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,-1,4406,-1,0.00020894063,0.9997911
4412,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4412,-1,0.9994997,0.0005002822
4413,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4413,-1,0.99950063,0.0004993858
4416,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4416,-1,0.99939907,0.0006009228
4417,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4417,-1,0.9994234,0.000576601
4418,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,-1,-1,-1,4418,-1,0.96588033,0.034119688
4419,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,-1,-1,4419,-1,0.9994634,0.00053663127
4420,dilevalol antigens,16,18,120,138,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,-1,4420,-1,0.06449926,0.93550074
4422,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,-1,-1,4422,-1,0.00021827494,0.9997818
4423,Nephrotic syndrome,0,2,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,-1,-1,4423,-1,0.00021171352,0.99978834
4427,Na,4,5,32,34,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,-1,-1,4427,-1,0.99936956,0.00063045975
4429,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4429,-1,0.9994617,0.00053827587
4430,PAN,11,12,74,77,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4430,-1,0.9993451,0.0006549157
4431,PAN,4,5,14,17,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4431,-1,0.9954626,0.004537374
4433,hypoalbuminemia,10,11,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4433,-1,0.00020961132,0.9997904
4436,contrast,1,2,3,11,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,-1,4436,-1,0.79972595,0.20027405
4438,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,-1,4438,-1,0.00021967253,0.99978036
4440,behavioral disorder,2,4,23,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,-1,4440,-1,0.00018256268,0.99981743
4442,behavioral deterioration,4,6,22,46,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4442,-1,0.00020067728,0.9997993
4443,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4443,-1,0.00019546978,0.99980456
4445,sleeping difficulties,13,15,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4445,-1,0.00020432565,0.99979573
4447,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,-1,4447,-1,0.99948895,0.000511035
4450,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,-1,4450,-1,0.9994764,0.0005236756
4453,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,-1,4453,-1,0.00020828484,0.9997917
4454,pyridoxal,3,4,13,22,The level of pyridoxal in the blood was normal during the periods of relapse.,150790_6,-1,-1,-1,4454,-1,0.999491,0.0005089799
4455,kynurenine,7,8,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4455,-1,0.9994418,0.0005581383
4456,tryptophan,10,11,65,75,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4456,-1,0.99934965,0.000650345
4458,Parkinson's disease,15,18,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4458,-1,0.00023218864,0.99976784
4459,PD,19,20,127,129,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4459,-1,0.00020783136,0.99979216
4460,PD,8,9,62,64,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,-1,-1,4460,-1,0.00021557068,0.9997844
4461,PD,12,13,70,72,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4461,-1,0.00020810163,0.9997919
4464,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4464,-1,0.00021062906,0.9997894
4465,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,-1,4465,-1,0.00020093883,0.9997991
4468,hyper- or dyskinetic,7,10,49,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,-1,4468,-1,0.00025547974,0.9997445
4471,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4471,-1,0.00021291416,0.99978715
4472,SE,11,12,75,77,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4472,-1,0.012716194,0.9872838
4475,SE,40,41,276,278,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,-1,4475,-1,0.016746422,0.98325354
4476,SE,1,2,3,5,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4476,-1,0.9991116,0.0008884384
4477,glutamate receptor antagonists,37,40,207,237,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4477,-1,0.99942195,0.00057807745
4479,SE,28,29,170,172,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,-1,4479,-1,0.9660609,0.03393916
4482,Urinary bladder cancer,0,3,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4482,-1,0.00016738327,0.99983263
4483,Wegener's granulomatosis,4,7,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4483,-1,0.0028989632,0.997101
4487,Wegener's granulomatosis,21,24,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,-1,-1,4487,-1,0.0038045775,0.99619544
4488,Wegener's granulomatosis,17,20,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,-1,-1,4488,-1,0.0016344221,0.9983656
4494,Wegener's granulomatosis,10,13,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4494,-1,0.0038948078,0.9961052
4496,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4496,-1,0.0042208517,0.99577916
4498,n,11,12,70,71,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4498,-1,0.12315543,0.8768446
4499,n,18,19,92,93,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4499,-1,0.102679245,0.8973207
4503,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4503,-1,0.003499989,0.9965
4505,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4505,-1,0.003978442,0.99602157
4508,Wegener's granulomatosis,35,38,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,-1,4508,-1,0.0037640547,0.996236
4510,I1-imidazoline,7,8,61,75,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,-1,-1,4510,-1,0.9993686,0.00063144503
4516,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,-1,4516,-1,0.99950826,0.00049174647
4518,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4518,-1,0.99950635,0.000493593
4520,h,15,16,107,108,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4520,-1,0.21863888,0.78136104
4522,contrast,10,11,76,84,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4522,-1,0.13985395,0.86014605
4523,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4523,-1,0.021355115,0.97864485
4525,reduced locomotor activity,16,19,106,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,-1,4525,-1,0.000214924,0.9997851
4529,left ventricular systolic and diastolic dysfunction,2,8,18,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4529,-1,0.00021485721,0.9997851
4530,epinephrine overdose,12,14,99,119,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4530,-1,0.003036553,0.99696344
4533,contrast,1,2,3,11,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4533,-1,0.9968406,0.0031594066
4534,myocardial dysfunction,5,7,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4534,-1,0.00019141032,0.9998086
4536,mg,11,12,73,75,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4536,-1,0.9993954,0.00060466473
4538,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4538,-1,0.00020833511,0.9997917
4539,left ventricular systolic and diastolic dysfunction,30,36,206,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4539,-1,0.00021499634,0.999785
4540,myocardial necrosis,44,46,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4540,-1,0.00020437689,0.9997956
4541,tincture of Crataegus,3,6,27,48,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4541,-1,0.0045401985,0.99545974
4542,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4542,-1,0.00021161277,0.99978834
4543,Tincture of Crataegus,0,3,0,21,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4543,-1,0.0036126268,0.99638736
4544,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4544,-1,0.00028156658,0.99971837
4545,alcoholic extract of the berries of hawthorn,8,15,32,76,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4545,-1,0.9973732,0.0026267148
4546,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4546,-1,0.0001964951,0.9998035
4547,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4547,-1,0.00018812988,0.99981195
4548,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4548,-1,0.00022983168,0.9997702
4549,mg,37,38,206,208,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4549,-1,0.99856865,0.0014313189
4550,h,50,51,254,255,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4550,-1,0.071486235,0.9285137
4551,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,-1,4551,-1,0.00036015443,0.99963987
4553,TCR,0,1,0,3,TCR protected against pathological changes induced by isoproterenol in rat heart.,15233872_5,-1,-1,-1,4553,-1,0.00022829241,0.9997718
4555,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,-1,-1,-1,4555,-1,0.0002311194,0.9997689
4557,valdecoxib,6,7,51,61,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4557,-1,0.9994655,0.00053444976
4558,agents,10,11,99,105,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4558,-1,0.99943155,0.0005684789
4562,NSAIDs,24,25,192,198,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4562,-1,0.999453,0.00054699706
4563,valdecoxib,6,7,43,53,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4563,-1,0.9994727,0.00052738044
4564,osteoarthritis,17,18,122,136,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4564,-1,0.00021963714,0.99978036
4568,valdecoxib,23,24,160,170,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4568,-1,0.9995276,0.00047243678
4569,mg,28,29,178,180,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4569,-1,0.9995043,0.0004957079
4570,NSAID,33,34,202,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4570,-1,0.9995204,0.00047959818
4572,mg,37,38,223,225,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4572,-1,0.9995103,0.0004897231
4574,mg,42,43,245,247,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4574,-1,0.9994822,0.0005178134
4575,naproxen,46,47,256,264,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4575,-1,0.9995258,0.0004742312
4576,mg,48,49,269,271,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4576,-1,0.9994999,0.00050007435
4577,osteoarthritis,57,58,313,327,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4577,-1,0.00021496374,0.999785
4579,n,11,12,63,64,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4579,-1,0.20616998,0.79383
4580,mg,25,26,109,111,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4580,-1,0.9994179,0.0005820894
4582,n,30,31,128,129,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4582,-1,0.48419788,0.51580215
4584,n,39,40,163,164,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4584,-1,0.9369899,0.06301018
4586,valdecoxib,10,11,77,87,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4586,-1,0.9994758,0.00052423147
4587,NSAIDs,12,13,89,95,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4587,-1,0.99943393,0.00056601566
4589,valdecoxib,11,12,64,74,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4589,-1,0.99947745,0.0005225312
4593,valdecoxib,23,24,115,125,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4593,-1,0.9994666,0.00053344795
4594,NSAIDs,31,32,142,148,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4594,-1,0.99941754,0.000582444
4596,valdecoxib,17,18,91,101,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,-1,4596,-1,0.99947613,0.00052390475
4597,mg,10,11,66,68,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4597,-1,0.9993864,0.000613545
4598,mg,19,20,107,109,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4598,-1,0.9994197,0.00058029906
4599,valdecoxib,22,23,117,127,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4599,-1,0.99948645,0.000513504
4601,NSAIDs,37,38,227,233,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4601,-1,0.99946946,0.0005305374
4602,osteoarthritis,41,42,248,262,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4602,-1,0.00021623664,0.9997838
4604,Hypersensitivity myocarditis,0,2,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4604,-1,0.00023146607,0.99976856
4605,hypertrophic cardiomyopathy,3,5,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4605,-1,0.00022895331,0.99977106
4606,eosinophilic myocarditis,7,9,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4606,-1,0.00020328232,0.9997967
4607,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4607,-1,0.00019046053,0.99980956
4608,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4608,-1,0.00019811394,0.99980193
4609,biventricular failure,14,16,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4609,-1,0.00020138765,0.9997986
4611,ventricular dysfunction,8,10,55,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,-1,-1,4611,-1,0.00020640259,0.9997936
4613,hypertrophic cardiomyopathy,9,11,52,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,-1,-1,4613,-1,0.00020025372,0.9997998
4616,eosinophilic myocarditis,4,6,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,-1,-1,4616,-1,0.0002130835,0.9997869
4618,eosinophilic,7,8,40,52,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,-1,-1,4618,-1,0.0057995617,0.99420047
4621,Eosinophilic myocarditis,0,2,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,-1,-1,4621,-1,0.0020510617,0.99794894
4625,Idiopathic subjective tinnitus,0,3,0,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4625,-1,0.00020911783,0.99979085
4626,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4626,-1,0.53734505,0.46265495
4627,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,-1,4627,-1,0.0006225811,0.9993774
4633,vertigo,9,10,52,59,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4633,-1,0.002021956,0.99797803
4636,lead,43,44,247,251,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4636,-1,0.75073516,0.2492648
4639,hypolocomotion,14,15,111,125,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,-1,-1,4639,-1,0.00021281975,0.99978715
4645,ion channels,3,5,22,34,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,-1,-1,-1,4645,-1,0.009069241,0.99093074
4647,hypolocomotion,12,13,76,90,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,-1,-1,4647,-1,0.00020478302,0.99979526
4652,hypolocomotion,18,19,118,132,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,-1,-1,4652,-1,0.00022715292,0.99977285
4661,SD,7,8,35,37,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4661,-1,0.0055583557,0.9944417
4662,mg,14,15,56,58,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4662,-1,0.9943023,0.0056977025
4664,mg,34,35,155,157,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4664,-1,0.9966517,0.0033483591
4666,mg,9,10,37,39,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,-1,4666,-1,0.076412156,0.9235878
4672,rise in,1,3,4,11,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,-1,-1,-1,4672,-1,0.00028463546,0.9997154
4673,pressure,4,5,18,26,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,-1,-1,-1,4673,-1,0.00021782232,0.99978215
4680,Apamin,0,1,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4680,-1,0.9994729,0.00052715273
4681,potassium channels,7,9,49,67,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4681,-1,0.99392927,0.0060707224
4683,Apamin,0,1,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4683,-1,0.99939775,0.00060223986
4685,mg,23,24,97,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4685,-1,0.9935062,0.006493783
4688,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4688,-1,0.0055233217,0.99447674
4698,thiotepa,12,13,80,88,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,-1,4698,-1,0.9994753,0.0005247173
4703,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4703,-1,0.00021201103,0.999788
4704,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4704,-1,0.00021298541,0.99978703
4707,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4707,-1,0.0002074196,0.99979264
4708,anthracyclines,66,67,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4708,-1,0.9994005,0.0005995022
4709,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,-1,4709,-1,0.00023965303,0.9997603
4712,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4712,-1,0.00019809467,0.99980193
4713,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4713,-1,0.00020092234,0.9997991
4715,CHF,9,10,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,-1,-1,-1,4715,-1,0.00022532522,0.99977463
4722,obstructive lung disease,10,13,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,-1,-1,4722,-1,0.00017092704,0.99982905
4731,P,14,15,75,76,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,-1,-1,-1,4731,-1,0.20046057,0.79953945
4733,P,15,16,81,82,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,-1,-1,4733,-1,0.12267113,0.8773289
4735,P,13,14,86,87,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4735,-1,0.058002222,0.94199777
4740,sexual side effects,3,6,23,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4740,-1,0.00020972625,0.99979025
4743,impotence,21,22,140,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,-1,-1,-1,4743,-1,0.10932594,0.89067405
4745,sexual side effects,13,16,70,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,-1,-1,4745,-1,0.00021229566,0.99978775
4748,sexual side effects,9,12,54,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4748,-1,0.00021792663,0.99978215
4750,obsessive compulsive disorder,6,9,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4750,-1,0.0002149748,0.999785
4751,trichotillomania,10,11,64,80,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4751,-1,0.00024331798,0.99975663
4752,anxiety,12,13,82,89,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4752,-1,0.00021546279,0.9997845
4753,affective disorders,15,17,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4753,-1,0.00021352441,0.99978644
4754,sexual side effects,19,22,127,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4754,-1,0.00059604185,0.99940395
4761,sweating,6,7,45,53,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4761,-1,0.00022536154,0.99977463
4762,anxiety,9,10,65,72,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4762,-1,0.00022112588,0.9997789
4764,sexual side effects,17,20,100,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4764,-1,0.00021775236,0.99978226
4767,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,-1,-1,4767,-1,0.000233643,0.9997664
4768,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,-1,-1,-1,4768,-1,0.00021568147,0.9997843
4772,hemorrhagic cystitis,30,32,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,-1,4772,-1,0.00020102179,0.99979895
4773,hemorrhagic cystitis,11,13,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,-1,-1,-1,4773,-1,0.00019521348,0.9998048
4774,contrast,1,2,3,11,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4774,-1,0.99630874,0.0036912677
4776,hemorrhagic cystitis,19,21,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4776,-1,0.00021737379,0.9997826
4777,hemorrhagic cystitis,21,23,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,-1,-1,-1,4777,-1,0.00020241603,0.99979764
4778,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4778,-1,0.99949,0.0005099725
4779,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4779,-1,0.9994935,0.00050644955
4780,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,-1,-1,-1,4780,-1,0.99945194,0.0005480897
4783,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,-1,4783,-1,0.9994765,0.0005235019
4785,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,-1,-1,-1,4785,-1,0.9994822,0.0005178485
4786,venous thromboembolism,2,4,18,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4786,-1,0.00020884386,0.9997912
4789,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4789,-1,0.00021977183,0.99978024
4791,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4791,-1,0.9994873,0.00051272346
4792,venous thromboembolism,18,20,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4792,-1,0.00021910587,0.99978095
4793,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,-1,-1,-1,4793,-1,0.99947196,0.00052803475
4794,Raloxifene,0,1,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4794,-1,0.99947053,0.00052945374
4797,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4797,-1,0.00021804552,0.999782
4799,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4799,-1,0.9994821,0.00051793555
4800,venous thromboembolism,10,12,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4800,-1,0.00020620826,0.9997938
4803,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4803,-1,0.00021788695,0.99978215
4807,lead,45,46,264,268,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,-1,4807,-1,0.0013231762,0.99867684
4809,dopamine agonist,24,26,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,-1,-1,-1,4809,-1,0.99940145,0.0005986001
4810,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4810,-1,0.000215386,0.99978465
4812,psychosis,14,15,110,119,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4812,-1,0.00021814927,0.9997819
4813,sleep disturbances,16,18,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4813,-1,0.00021992884,0.9997801
4814,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4814,-1,0.00023634058,0.99976367
4815,Parkinson's disease,5,8,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,-1,-1,-1,4815,-1,0.00035973595,0.9996402
4816,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,-1,4816,-1,0.00019598674,0.9998041
4818,DFO,5,6,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,-1,-1,-1,4818,-1,0.9994879,0.00051207433
4820,SNHL,21,22,107,111,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,-1,-1,4820,-1,0.00026091558,0.9997391
4821,ototoxic,1,2,3,11,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4821,-1,0.00025039245,0.9997496
4822,DFO,6,7,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4822,-1,0.9993749,0.0006251081
4823,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,-1,4823,-1,0.0026797927,0.99732023
4824,SNHL,2,3,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4824,-1,0.0059252353,0.99407476
4825,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4825,-1,0.9993118,0.00068822165
4826,DFO,7,8,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4826,-1,0.999318,0.00068198564
4827,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4827,-1,0.0001961546,0.99980384
4828,thalassemic,7,8,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4828,-1,0.00021637522,0.9997837
4829,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4829,-1,0.00020768576,0.9997923
4831,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4831,-1,0.00019759833,0.9998024
4832,systemic sclerosis,21,23,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4832,-1,0.00019950188,0.9998005
4833,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4833,-1,0.00020092714,0.9997991
4834,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,-1,-1,4834,-1,0.00020665956,0.99979335
4839,anthracyclines,8,9,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4839,-1,0.99947864,0.00052144617
4841,heart damage,20,22,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4841,-1,0.00022138891,0.99977857
4842,systemic sclerosis,26,28,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4842,-1,0.00022127836,0.9997787
4843,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,-1,4843,-1,0.00019971255,0.99980026
4844,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4844,-1,0.9994444,0.00055561
4845,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4845,-1,0.00017868365,0.99982136
4846,diabetes?BACKGROUND,11,12,79,98,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4846,-1,0.019148955,0.98085105
4847,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4847,-1,0.99945384,0.0005461124
4848,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,-1,-1,4848,-1,0.99941826,0.0005817084
4851,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4851,-1,0.9994165,0.00058353704
4852,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4852,-1,0.00019159018,0.9998085
4853,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4853,-1,0.9994155,0.0005845399
4854,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4854,-1,0.00021999028,0.99978
4855,n,17,18,106,107,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4855,-1,0.395018,0.604982
4856,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4856,-1,0.0002209975,0.99977905
4857,n,26,27,141,142,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4857,-1,0.6173714,0.38262865
4859,n,34,35,163,164,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4859,-1,0.10935062,0.8906494
4861,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4861,-1,0.00018589347,0.9998141
4862,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4862,-1,0.00018688108,0.99981314
4865,folate,47,48,298,304,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4865,-1,0.99943584,0.0005640846
4866,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4866,-1,0.99945086,0.00054916425
4867,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4867,-1,0.00018738389,0.99981266
4868,P,76,77,444,445,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4868,-1,0.2618387,0.73816127
4869,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4869,-1,0.9994572,0.0005428186
4870,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4870,-1,0.00019682682,0.99980325
4871,P,19,20,89,90,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4871,-1,0.08000245,0.9199976
4873,P,40,41,161,162,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4873,-1,0.08765678,0.9123432
4874,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4874,-1,0.99945146,0.0005485221
4875,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4875,-1,0.9994524,0.00054755516
4876,Vitamin C,0,2,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4876,-1,0.99941313,0.00058685435
4877,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4877,-1,0.00021369309,0.9997863
4878,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4878,-1,0.9994222,0.0005777954
4879,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4879,-1,0.00020885063,0.9997912
4881,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,-1,-1,4881,-1,0.00020479475,0.99979526
4882,axonal degeneration,13,15,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4882,-1,0.00019164845,0.9998084
4883,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4883,-1,0.00019355392,0.99980646
4884,OCT,24,25,149,152,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4884,-1,0.99935454,0.0006454967
4885,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,-1,4885,-1,0.99945146,0.00054854224
4887,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4887,-1,0.9994665,0.0005335851
4888,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4888,-1,0.00021685769,0.9997831
4889,contrast,14,15,88,96,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4889,-1,0.98696727,0.013032777
4890,optic neuropathy,8,10,34,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,-1,-1,4890,-1,0.00019509887,0.9998049
4891,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4891,-1,0.9994246,0.0005754895
4892,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4892,-1,0.00022162043,0.99977845
4893,visual deficits,19,21,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4893,-1,0.00022401338,0.99977595
4894,contrast,34,35,237,245,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4894,-1,0.99813014,0.0018699302
4895,OCT,3,4,13,16,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4895,-1,0.9993098,0.0006902046
4896,OCT,5,6,18,21,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4896,-1,0.9993005,0.00069954654
4897,CA,12,13,52,54,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4897,-1,0.84329754,0.1567024
4898,OCT,0,1,0,3,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4898,-1,0.99934024,0.0006597703
4899,map,12,13,76,79,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4899,-1,0.00043761107,0.9995623
4900,OCT,20,21,123,126,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4900,-1,0.8945994,0.10540067
4901,n=661,22,23,128,133,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4901,-1,0.1418651,0.8581349
4902,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4902,-1,0.00019490473,0.99980515
4903,visual deficits,48,50,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4903,-1,0.0001983275,0.9998017
4904,C,56,57,282,283,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4904,-1,0.9184589,0.08154118
4905,visual deficits,60,62,298,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4905,-1,0.0001946464,0.9998054
4906,visual deficits,13,15,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4906,-1,0.0002067455,0.99979323
4907,C,19,20,92,93,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4907,-1,0.58003855,0.41996145
4908,OCT,3,4,17,20,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4908,-1,0.99899155,0.0010084737
4909,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4909,-1,0.00019988611,0.99980015
4910,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,-1,4910,-1,0.00021292876,0.99978703
4911,OCT,0,1,0,3,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4911,-1,0.99933165,0.0006683048
4912,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4912,-1,0.00018169718,0.9998184
4913,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4913,-1,0.00019693983,0.9998031
4914,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4914,-1,0.9994361,0.0005638843
4915,renal impairment,22,24,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4915,-1,0.0002004824,0.99979955
4921,n,19,20,96,97,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,-1,-1,4921,-1,0.3602812,0.6397188
4922,n,0,1,0,1,n = 9].,15572383_6,-1,-1,-1,4922,-1,0.7038649,0.2961352
4927,renal interstitial damage,11,14,74,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4927,-1,0.00021929773,0.9997807
4928,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4928,-1,0.00021662685,0.99978334
4931,focal glomerulosclerosis,7,9,42,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4931,-1,0.00020080227,0.9997992
4932,NS,14,15,78,80,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4932,-1,0.053251106,0.9467489
4936,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4936,-1,0.00021376745,0.9997862
4940,diseased kidney,14,16,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,-1,4940,-1,0.00018317033,0.99981683
4942,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,-1,-1,4942,-1,0.00020231301,0.99979776
4944,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,-1,4944,-1,0.99945813,0.0005419202
4946,tubulointerstitial injury,10,12,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,-1,-1,4946,-1,0.0031628024,0.99683714
4947,dUTP,16,17,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4947,-1,0.99937695,0.00062312256
4948,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4948,-1,0.00023038434,0.9997696
4950,glomerular diseases,13,15,103,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,-1,-1,4950,-1,0.00019839578,0.9998016
4953,interferon,13,14,96,106,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4953,-1,0.99941325,0.0005867573
4955,hepatitis C.BACKGROUND,18,20,133,155,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4955,-1,0.059084106,0.94091594
4957,interferon,35,36,239,249,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4957,-1,0.9994265,0.00057355757
4964,mg,14,15,72,74,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,-1,-1,-1,4964,-1,0.9538056,0.0461944
4968,P,26,27,96,97,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,-1,-1,4968,-1,0.09461998,0.90537995
4970,P,38,39,194,195,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,-1,-1,-1,4970,-1,0.4143642,0.5856358
4975,corticosteroid,17,18,97,111,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4975,-1,0.99930644,0.00069360516
4978,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4978,-1,0.00020935843,0.9997906
4980,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4980,-1,0.00021071744,0.9997893
4982,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4982,-1,0.00020670591,0.99979335
4984,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4984,-1,0.00020922594,0.99979085
4985,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,-1,-1,4985,-1,0.00021734413,0.9997826
4988,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4988,-1,0.00019389307,0.9998061
4989,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4989,-1,0.00019230925,0.99980766
4991,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,-1,4991,-1,0.00020366647,0.99979633
4994,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4994,-1,0.00021370144,0.9997863
4995,Cr,17,18,89,91,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4995,-1,0.9954146,0.004585328
4998,n,18,19,108,109,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4998,-1,0.9795337,0.020466357
4999,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4999,-1,0.000225307,0.99977475
5000,n,26,27,134,135,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,5000,-1,0.8998458,0.10015419
5005,n,38,39,240,241,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,-1,5005,-1,0.50979817,0.49020177
5006,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5006,-1,0.00019837669,0.9998017
5007,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5007,-1,0.0017891354,0.9982109
5009,thiazide,31,32,193,201,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5009,-1,0.9994904,0.00050957117
5011,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,-1,-1,5011,-1,0.00019957834,0.9998004
5016,HAL,17,18,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,-1,5016,-1,0.9994363,0.00056368986
5017,PRL,5,6,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,-1,-1,-1,5017,-1,0.00022092313,0.99977905
5019,PCNA,8,9,75,79,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,-1,-1,-1,5019,-1,0.99930024,0.00069973717
5020,PRL,12,13,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,-1,5020,-1,0.0002725683,0.9997274
5022,hyperplasia,9,10,70,81,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,5022,-1,0.00020321373,0.9997968
5023,PCNA,18,19,132,136,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,5023,-1,0.99244,0.0075600566
5024,contrast,7,8,55,63,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,5024,-1,0.999406,0.00059401436
5025,coronary stenosis,13,15,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,5025,-1,0.00020054051,0.99979943
5026,contrast,7,8,45,53,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5026,-1,0.9993315,0.00066858507
5027,coronary occlusion,21,23,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5027,-1,0.00020236836,0.99979764
5028,coronary stenoses,26,28,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5028,-1,0.0001993205,0.99980074
5029,hyperemic,32,33,233,242,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5029,-1,0.00020626289,0.9997937
5030,contrast,10,11,58,66,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5030,-1,0.9991272,0.000872772
5031,coronary stenosis,31,33,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5031,-1,0.00019483152,0.99980515
5032,coronary occlusion,6,8,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5032,-1,0.00020118384,0.99979883
5033,contrast,15,16,83,91,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5033,-1,0.9993369,0.000663134
5034,p,16,17,88,89,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,-1,-1,-1,5034,-1,0.25608924,0.74391073
5036,coronary stenosis,12,14,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5036,-1,0.00020840204,0.99979156
5037,contrast,21,22,129,137,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5037,-1,0.9994531,0.0005468761
5038,stenosis,9,10,47,55,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,-1,5038,-1,0.00021198922,0.999788
5040,stenosis,7,8,40,48,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5040,-1,0.00019161044,0.9998084
5042,contrast,44,45,251,259,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5042,-1,0.9994423,0.00055769057
5043,contrast,3,4,17,25,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5043,-1,0.99931324,0.00068676646
5044,coronary stenosis,23,25,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5044,-1,0.00019434911,0.9998056
5048,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,-1,-1,5048,-1,0.0002281951,0.9997718
5049,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5049,-1,0.00022366422,0.9997763
5050,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5050,-1,0.00020506926,0.9997949
5051,TD,13,14,106,108,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5051,-1,0.00024277157,0.99975723
5052,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,-1,-1,5052,-1,0.00019272578,0.9998073
5062,orofacial diskinesia,16,18,103,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,5062,-1,0.00039255887,0.9996075
5064,degeneration of,9,11,74,89,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5064,-1,0.00055262324,0.9994474
5066,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5066,-1,0.00020449345,0.9997955
5067,NMDA,16,17,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5067,-1,0.9994605,0.0005394567
5069,aortic occlusion,27,29,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5069,-1,0.00020558572,0.9997944
5070,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5070,-1,0.00019737256,0.99980265
5071,aortic occlusion,6,8,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5071,-1,0.00019895214,0.9998011
5072,C,11,12,50,51,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5072,-1,0.12799507,0.8720049
5073,n,13,14,53,54,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5073,-1,0.46249798,0.537502
5075,n,25,26,92,93,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5075,-1,0.6240939,0.37590608
5076,h,35,36,135,136,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5076,-1,0.06257956,0.9374204
5078,n,48,49,185,186,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5078,-1,0.4992499,0.50075006
5079,n,60,61,223,224,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5079,-1,0.5440419,0.45595816
5080,h,67,68,250,251,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5080,-1,0.051516794,0.94848317
5081,h,22,23,98,99,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,-1,-1,-1,5081,-1,0.038861085,0.9611389
5082,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5082,-1,0.99938905,0.00061092735
5083,spastic paraparesis,23,25,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5083,-1,0.0002065071,0.99979347
5086,C,23,24,134,135,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5086,-1,0.46425563,0.53574437
5087,P,25,26,137,138,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5087,-1,0.114124246,0.8858757
5088,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5088,-1,0.999418,0.0005819619
5089,spastic paraparesis,11,13,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5089,-1,0.00021515467,0.9997849
5091,spastic paraparesis,7,9,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5091,-1,0.00020001996,0.9998
5093,NMDA,21,22,132,136,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5093,-1,0.9993967,0.00060330186
5095,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5095,-1,0.00018814098,0.9998118
5096,NMDA,15,16,85,89,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5096,-1,0.99940145,0.0005985005
5097,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,-1,5097,-1,0.000433177,0.99956685
5100,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5100,-1,0.0002176301,0.9997824
5101,AF,13,14,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5101,-1,0.00021845233,0.99978155
5102,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5102,-1,0.00020635419,0.9997937
5103,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5103,-1,0.00021039121,0.99978966
5108,gallbladder dysfunction,9,11,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,-1,-1,5108,-1,0.00020365637,0.99979633
5116,psychosis,5,6,38,47,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5116,-1,0.0001983691,0.9998017
5118,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5118,-1,0.00019455883,0.9998055
5122,psychosis,30,31,217,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5122,-1,0.00020674136,0.99979323
5126,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5126,-1,0.00020163915,0.99979836
5127,HVA,0,1,0,3,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5127,-1,0.99925417,0.00074579404
5128,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5128,-1,0.00019035052,0.9998097
5130,stereotypies,18,19,121,133,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,-1,-1,5130,-1,0.0002106915,0.9997893
5131,Coronary aneurysm,0,2,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,-1,-1,-1,5131,-1,0.00017605771,0.999824
5132,coronary aneurysm,2,4,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5132,-1,0.00020298405,0.99979705
5135,vessel rupture,45,47,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5135,-1,0.00019935318,0.9998006
5136,coronary aneurysm,8,10,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,-1,-1,-1,5136,-1,0.00017321813,0.99982685
5139,mm,24,25,162,164,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,-1,-1,5139,-1,0.9761244,0.023875577
5140,Pheochromocytoma,0,1,0,16,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5140,-1,0.0018477926,0.9981522
5141,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5141,-1,0.99946564,0.0005343556
5142,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5142,-1,0.9994661,0.00053386326
5143,pheochromocytoma,7,8,40,56,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5143,-1,0.00015424479,0.99984574
5144,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5144,-1,0.9994388,0.0005611318
5145,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5145,-1,0.99594575,0.0040542283
5149,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5149,-1,0.9994506,0.0005493205
5150,mg,24,25,150,152,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5150,-1,0.99939895,0.0006010116
5151,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5151,-1,0.99932384,0.0006762082
5152,mg,28,29,170,172,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5152,-1,0.9993568,0.0006431797
5153,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,-1,-1,-1,5153,-1,0.9993498,0.0006501909
5155,pheochromocytoma,15,16,113,129,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,-1,-1,-1,5155,-1,0.00019941744,0.9998006
5156,pheochromocytoma,5,6,37,53,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5156,-1,0.00019469336,0.9998053
5157,benzamide,14,15,103,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5157,-1,0.999468,0.0005319952
5159,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5159,-1,0.88636816,0.113631845
5160,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5160,-1,0.9994537,0.0005463018
5162,pheochromocytoma,25,26,142,158,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,-1,-1,5162,-1,0.00019650745,0.9998035
5163,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5163,-1,0.99922204,0.0007779385
5164,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5164,-1,0.9988386,0.0011614038
5165,neurological dysfunction,1,3,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,-1,5165,-1,0.00021055032,0.9997894
5167,neurological dysfunction,9,11,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,-1,-1,-1,5167,-1,0.00019971922,0.99980026
5172,asphyxia,3,4,24,32,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5172,-1,0.00022695442,0.9997731
5173,malformations,5,6,34,47,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5173,-1,0.00022880513,0.9997712
5174,haemorrhage,17,18,123,134,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5174,-1,0.00022515321,0.9997749
5175,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5175,-1,0.00022999698,0.99977
5176,psychomotor retardation,28,30,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5176,-1,0.00022922133,0.9997708
5177,neurological dysfunctions,9,11,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,-1,5177,-1,0.00021164326,0.99978834
5178,p<0.01,15,16,91,97,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,-1,5178,-1,0.06601696,0.933983
5179,p<0.001,12,13,65,72,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,-1,5179,-1,0.05151764,0.94848233
5181,neurological dysfunctions,11,13,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,-1,-1,-1,5181,-1,0.00020308568,0.9997969
5183,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5183,-1,0.99944645,0.000553597
5184,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5184,-1,0.00018390079,0.9998161
5185,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5185,-1,0.9994537,0.00054629025
5186,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5186,-1,0.9994967,0.0005032989
5187,VPA,7,8,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5187,-1,0.9994704,0.0005296476
5188,15-F(2t)-isoprostane,33,34,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5188,-1,0.99948955,0.00051046564
5189,15-F(2t)-IsoP,35,36,195,208,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5189,-1,0.9994831,0.00051688903
5191,VPA,23,24,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,-1,5191,-1,0.999471,0.0005290598
5192,15-F(2t)-IsoP,11,12,72,85,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5192,-1,0.99940896,0.0005910596
5193,lipid hydroperoxides,13,15,87,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5193,-1,0.9990374,0.0009625912
5194,LPO,16,17,109,112,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5194,-1,0.9586459,0.041354053
5195,thiobarbituric acid reactive substances,20,24,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5195,-1,0.9992489,0.0007510486
5196,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5196,-1,0.9994692,0.00053078413
5197,15-F(2t)-IsoP,3,4,17,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5197,-1,0.9994648,0.0005351991
5198,VPA,14,15,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5198,-1,0.9796862,0.02031384
5199,LPO,1,2,6,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5199,-1,0.9182717,0.08172827
5200,p,16,17,86,87,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5200,-1,0.056053124,0.9439469
5201,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5201,-1,0.99847275,0.0015272159
5202,p,15,16,77,78,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5202,-1,0.063380726,0.93661934
5203,Liver toxicity,0,2,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,-1,-1,5203,-1,0.00019663358,0.99980336
5207,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,-1,5207,-1,0.00021274206,0.9997873
5208,VPA,7,8,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,-1,5208,-1,0.99939835,0.00060165377
5209,VPA,6,7,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5209,-1,0.99924743,0.0007526224
5210,15-F(2t)-IsoP,18,19,106,119,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5210,-1,0.9994272,0.00057286315
5212,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5212,-1,0.00022471955,0.99977523
5219,n=25,45,46,252,256,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,-1,5219,-1,0.1827107,0.8172893
5225,antiphospholipid syndrome,11,13,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5225,-1,0.004982601,0.99501747
5226,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5226,-1,0.00018954728,0.9998105
5236,DFU,15,16,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,-1,5236,-1,0.99935776,0.0006422805
5241,DFU,20,21,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5241,-1,0.9980572,0.0019428162
5242,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon",22,25,122,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5242,-1,0.9994753,0.00052469614
5243,phenyl-2(5H)-furanon,24,25,176,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5243,-1,0.9994591,0.00054091495
5244,COX-2 inhibitors,26,28,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5244,-1,0.99947506,0.00052493723
5246,DFU,18,19,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,-1,-1,-1,5246,-1,0.9983726,0.0016274049
5247,VSD,8,9,56,59,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5247,-1,0.00059347367,0.9994066
5248,MD,13,14,74,76,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5248,-1,0.00022834245,0.99977165
5250,COX-2,28,29,166,171,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5250,-1,0.99947184,0.00052819116
5252,growth retardation,6,8,41,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5252,-1,0.00018195598,0.999818
5253,increase of external and skeletal variations,10,16,65,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5253,-1,0.00018902676,0.999811
5255,DFU,10,11,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,-1,-1,5255,-1,0.9993863,0.00061371404
5257,teratogenicity,2,3,8,22,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,-1,5257,-1,0.00018925616,0.99981076
5259,COX inhibitors,4,6,35,49,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5259,-1,0.9994497,0.0005503619
5260,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5260,-1,0.00022260199,0.9997774
5261,MD,12,13,80,82,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5261,-1,0.00021659382,0.99978346
5262,COX-2 inhibitors,22,24,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5262,-1,0.9994704,0.00052955945
5263,COX-2 inhibitors,6,8,45,61,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,-1,-1,-1,5263,-1,0.99946064,0.00053935853
5264,DFU,1,2,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,-1,-1,-1,5264,-1,0.99943405,0.0005659741
5266,COX-2 inhibitors,4,6,31,47,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5266,-1,0.9994624,0.00053758343
5267,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5267,-1,0.0007267867,0.99927324
5268,rubella,6,7,40,47,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5268,-1,0.0011095755,0.99889046
5269,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5269,-1,0.0004087262,0.9995913
5270,rubella,12,13,84,91,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5270,-1,0.0046270117,0.99537295
5271,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5271,-1,0.08724099,0.91275907
5272,rubella,13,14,77,84,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5272,-1,0.00024733497,0.9997527
5273,hepatitis B vaccine,18,21,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5273,-1,0.16256668,0.83743334
5274,hepatitis B,29,31,173,184,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5274,-1,0.8964187,0.10358134
5275,hepatitis B,39,41,229,240,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5275,-1,0.88969797,0.11030201
5276,rubella,45,46,275,282,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5276,-1,0.994812,0.0051880046
5277,rubella vaccine,53,55,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5277,-1,0.046305306,0.9536947
5278,rubella,56,57,357,364,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5278,-1,0.48060834,0.51939166
5279,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5279,-1,0.0005024301,0.99949753
5280,rubella,13,14,62,69,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5280,-1,0.00027540274,0.99972457
5281,Hepatitis B vaccine,0,3,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,-1,5281,-1,0.9414595,0.05854059
5282,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5282,-1,0.78850204,0.21149804
5283,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5283,-1,0.69708467,0.30291533
5284,birth weight,11,13,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5284,-1,0.0009260888,0.99907386
5285,hepatitis B,17,19,122,133,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5285,-1,0.00023771956,0.99976224
5286,rubella,13,14,66,73,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,-1,5286,-1,0.0005324523,0.99946755
5287,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,-1,-1,-1,5287,-1,0.7363435,0.26365647
5288,hepatitis B,18,20,126,137,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5288,-1,0.00023100177,0.99976903
5289,rubella,21,22,142,149,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5289,-1,0.52632695,0.47367305
5290,masseter muscle rigidity,1,4,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,-1,-1,5290,-1,0.00023385137,0.9997662
5291,Masseter muscle rigidity,0,3,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5291,-1,0.0017030962,0.9982969
5292,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5292,-1,0.00019369129,0.99980634
5293,masseter muscle rigidity,19,22,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,-1,-1,-1,5293,-1,0.00021182939,0.9997882
5294,masseter muscle rigidity,8,11,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5294,-1,0.00024415014,0.9997558
5295,steel,14,15,68,73,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5295,-1,0.31766024,0.6823398
5297,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5297,-1,0.964803,0.035196964
5299,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,-1,-1,5299,-1,0.00019724689,0.99980277
5300,Dexrazoxane,0,1,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5300,-1,0.9994758,0.0005241874
5302,drugs etoposide,8,10,78,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5302,-1,0.99946517,0.0005348468
5305,anthracyclines daunorubicin,3,5,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5305,-1,0.99948186,0.0005181741
5307,epipodophyllotoxin etoposide,9,11,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5307,-1,0.9994947,0.00050531374
5310,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5310,-1,0.99945515,0.0005448919
5311,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5311,-1,0.9986253,0.0013747489
5313,hematologic toxicity,10,12,58,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5313,-1,0.00019543864,0.99980456
5314,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5314,-1,0.9994942,0.00050578837
5318,dexrazoxane,44,45,304,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5318,-1,0.999491,0.00050895655
5322,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,-1,5322,-1,0.99950004,0.00049995736
5323,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5323,-1,0.99947935,0.00052062667
5325,weight loss,9,11,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5325,-1,0.00025898017,0.999741
5328,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5328,-1,0.99947625,0.0005237325
5330,weight loss,34,36,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5330,-1,0.00031437923,0.99968565
5331,cytotoxicity,41,42,274,286,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5331,-1,0.00018633217,0.99981374
5333,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,-1,5333,-1,0.99948466,0.0005153502
5336,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,-1,-1,-1,5336,-1,0.999482,0.0005180909
5337,metastases,6,7,39,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5337,-1,0.00023037204,0.9997696
5338,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5338,-1,0.9994831,0.00051682343
5340,hematologic toxicity,24,26,166,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5340,-1,0.00022552362,0.9997745
5341,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,-1,5341,-1,0.0001761173,0.99982387
5343,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5343,-1,0.00020220327,0.99979776
5344,heart disease,7,9,57,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5344,-1,0.00020110195,0.99979895
5346,Thyroid disorders,0,2,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5346,-1,0.00022334713,0.99977666
5348,emergency department,13,15,66,86,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5348,-1,0.0047611655,0.9952388
5349,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5349,-1,0.00020300497,0.99979705
5355,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,-1,-1,-1,5355,-1,0.9381008,0.06189917
5373,BE,13,14,80,82,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,-1,-1,-1,5373,-1,0.3157938,0.68420625
5393,inability to repeat words,8,12,48,73,The mean highest BIS score corresponding to the inability to repeat words was 81.5 (95% CI = 78.1 to 84.8).,15930398_13,-1,-1,-1,5393,-1,0.0006037519,0.9993962
5394,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,-1,5394,-1,0.0002150271,0.999785
5395,Ro4368554,5,6,40,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5395,-1,0.9994894,0.00051053887
5396,memory deficiency,15,17,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5396,-1,0.00020586995,0.9997942
5399,ACh,19,20,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,-1,5399,-1,0.9993351,0.00066488056
5400,5-HT(6,11,12,80,86,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5400,-1,0.99950147,0.00049849786
5401,) antagonist Ro4368554,12,15,86,108,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5401,-1,0.9993863,0.0006136365
5402,3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole,16,17,110,164,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5402,-1,0.9995009,0.0004991631
5404,tryptophan,35,36,271,281,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5404,-1,0.9994735,0.0005265213
5405,TRP,37,38,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5405,-1,0.99946123,0.00053881237
5406,metrifonate,56,57,399,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5406,-1,0.99950874,0.0004912224
5407,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5407,-1,0.99951684,0.0004831953
5408,Ro4368554,33,34,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5408,-1,0.99950373,0.0004962464
5409,Ro4368554,2,3,6,15,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5409,-1,0.99937457,0.00062543753
5410,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5410,-1,0.9995028,0.0004971924
5411,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5411,-1,0.00018805849,0.99981195
5413,TRP,33,34,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5413,-1,0.9991423,0.00085766084
5414,Ro4368554,4,5,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5414,-1,0.99950993,0.0004900126
5415,retention deficit,10,12,65,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5415,-1,0.00019914762,0.99980086
5416,memory deficit,20,22,129,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5416,-1,0.00020100265,0.9997991
5417,Ro4368554,37,38,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5417,-1,0.9995074,0.00049261935
5418,Amiodarone pulmonary toxicity,0,3,0,29,Amiodarone pulmonary toxicity.,1595783_0,-1,-1,-1,5418,-1,0.011597701,0.9884023
5420,pneumonitis,18,19,122,133,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,-1,5420,-1,0.00020929158,0.9997907
5421,pulmonary toxicity,1,3,4,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5421,-1,0.00022054033,0.9997795
5423,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5423,-1,0.00021447038,0.9997856
5424,pulmonary toxicity,7,9,61,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,-1,-1,5424,-1,0.0002183532,0.99978167
5425,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,-1,-1,5425,-1,0.00020800305,0.99979204
5430,kainate receptor antagonists,7,10,43,71,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,-1,-1,5430,-1,0.9994221,0.0005779421
5432,Amino acids,0,2,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5432,-1,0.9993892,0.00061085285
5433,KA,12,13,64,66,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5433,-1,0.9993735,0.00062654255
5434,antagonists,14,15,76,87,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5434,-1,0.9993315,0.00066855835
5437,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5437,-1,0.00021096288,0.99978906
5438,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5438,-1,0.000209126,0.99979085
5444,pharyngitis,17,18,116,127,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,-1,-1,5444,-1,0.00020199823,0.999798
5447,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,-1,-1,5447,-1,0.9994968,0.00050317706
5458,macrolide,10,11,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,-1,-1,5458,-1,0.9994691,0.00053086056
5459,macrolides,36,37,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,-1,5459,-1,0.9994174,0.0005826053
5464,macrolide,2,3,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,-1,5464,-1,0.9994242,0.00057582173
5466,GNC92H2,6,7,50,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5466,-1,0.99943334,0.000566588
5467,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5467,-1,0.0029012782,0.9970987
5469,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,-1,5469,-1,0.0028049892,0.997195
5470,GNC92H2,7,8,54,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5470,-1,0.0640361,0.93596387
5471,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5471,-1,0.0029933455,0.9970067
5473,GNC92H2,23,24,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,-1,5473,-1,0.99908745,0.0009126007
5474,GNC92H2,0,1,0,7,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,-1,-1,-1,5474,-1,0.087351985,0.912648
5476,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5476,-1,0.0057944832,0.99420553
5477,GNC92H2,12,13,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5477,-1,0.99941516,0.0005848324
5480,GNC92H2,2,3,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5480,-1,0.9993567,0.0006432778
5482,GNC92H2,7,8,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5482,-1,0.99914944,0.00085055514
5483,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5483,-1,0.0029548893,0.9970451
5484,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,-1,5484,-1,0.008625646,0.9913743
5489,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5489,-1,0.00017983704,0.9998202
5490,metabolic alkalosis,11,13,64,83,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5490,-1,0.0001747815,0.9998253
5491,parathyroid hormone,16,18,93,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5491,-1,0.9760671,0.023932891
5492,"1,25-dihydroxyvitamin D",26,28,145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5492,-1,0.99947435,0.00052562467
5495,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5495,-1,0.99948454,0.0005154644
5496,mg,16,17,106,108,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5496,-1,0.99907327,0.0009267243
5499,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,-1,-1,-1,5499,-1,0.9994286,0.0005714268
5501,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,-1,5501,-1,0.9994011,0.0005989451
5504,vitamin D,12,14,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,-1,-1,-1,5504,-1,0.999448,0.000552032
5505,Pamidronate,0,1,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,-1,-1,5505,-1,0.9994697,0.0005302838
5513,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5513,-1,0.0002156412,0.9997844
5515,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5515,-1,0.00021649348,0.9997836
5516,leukocytoclastic vasculitis,1,3,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,-1,5516,-1,0.00021111201,0.99978894
5517,Leukocytoclastic vasculitis,0,2,0,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5517,-1,0.00059160346,0.99940836
5518,LV,3,4,29,31,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5518,-1,0.00021667105,0.99978334
5519,cutaneous small vessel vasculitis,8,12,48,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5519,-1,0.00020247916,0.9997975
5520,LV,6,7,37,39,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,-1,5520,-1,0.00017838334,0.9998216
5522,skin eruptions,5,7,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,-1,-1,-1,5522,-1,0.00021296427,0.99978703
5524,skin lesion,3,5,15,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5524,-1,0.00019016639,0.9998098
5525,LV Cutaneous lesions,13,16,77,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5525,-1,0.00018692687,0.99981314
5528,LV,0,1,0,2,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,-1,5528,-1,0.0002318212,0.9997682
5539,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,-1,5539,-1,0.00022258883,0.9997774
5541,Parkinson disease,23,25,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5541,-1,0.00020557219,0.9997944
5542,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5542,-1,0.00021182557,0.9997882
5545,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,-1,5545,-1,0.0002027709,0.9997973
5546,lipid bilayers,6,8,45,59,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,-1,5546,-1,0.015710173,0.9842898
5550,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,-1,5550,-1,0.043474104,0.9565259
5553,mg paclitaxel,8,10,42,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5553,-1,0.99945086,0.00054915325
5554,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5554,-1,0.00018376161,0.99981624
5555,mg paclitaxel,29,31,163,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5555,-1,0.99945015,0.00054978963
5556,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,-1,-1,5556,-1,0.00020718835,0.9997929
5558,Lamotrigine,0,1,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5558,-1,0.9994874,0.00051257684
5560,idiopathic generalized epilepsies,9,12,65,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5560,-1,0.00021513762,0.9997849
5561,idiopathic generalized epilepsies,3,6,19,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5561,-1,0.00021192091,0.9997881
5562,IGE,7,8,54,57,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5562,-1,0.31134787,0.68865216
5563,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5563,-1,0.9994568,0.000543196
5564,LTG,13,14,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5564,-1,0.9970566,0.0029434215
5566,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5566,-1,0.00024619696,0.9997538
5567,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5567,-1,0.0030108027,0.9969892
5568,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5568,-1,0.00026999734,0.99972993
5569,MJ,0,1,0,2,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5569,-1,0.0033327262,0.9966673
5570,LTG,3,4,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5570,-1,0.9992455,0.0007545578
5571,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5571,-1,0.9990042,0.0009957762
5572,MJ,6,7,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5572,-1,0.0002173916,0.9997826
5573,myoclonic status,16,18,78,94,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5573,-1,0.0002078944,0.99979216
5574,LTG,22,23,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5574,-1,0.9992716,0.00072842167
5577,thyrotropin,16,17,116,127,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,-1,5577,-1,0.9995105,0.00048948446
5578,penile erection,20,22,126,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,-1,5578,-1,0.0044484157,0.9955515
5580,psychiatric disorders,12,14,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,-1,-1,5580,-1,0.00018628367,0.99981374
5586,memory dissociation,4,6,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,-1,-1,-1,5586,-1,0.00020341456,0.99979657
5589,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5589,-1,0.999466,0.000533994
5590,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5590,-1,0.9994711,0.0005288957
5591,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,-1,5591,-1,0.00022128342,0.9997787
5593,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,-1,-1,-1,5593,-1,0.9994624,0.0005375811
5595,n,3,4,22,23,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,-1,5595,-1,0.16056676,0.8394332
5597,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5597,-1,0.99945575,0.0005443061
5598,amenorrhea,14,15,101,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5598,-1,0.00021067564,0.9997893
5599,P,16,17,113,114,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5599,-1,0.034672633,0.9653274
5600,venous thromboembolism,9,11,50,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5600,-1,0.00017184921,0.9998281
5601,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5601,-1,0.9994647,0.00053535507
5602,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,-1,-1,5602,-1,0.00020780142,0.99979216
5604,neurovascular complications,8,10,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,-1,5604,-1,0.00019427946,0.99980575
5607,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5607,-1,0.00019367078,0.99980634
5608,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5608,-1,0.0001960482,0.99980396
5610,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,-1,5610,-1,0.00022996844,0.99977
5612,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,-1,5612,-1,0.00019990614,0.99980015
5614,p,35,36,226,227,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,-1,5614,-1,0.33199725,0.6680028
5615,p,48,49,316,317,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,-1,5615,-1,0.15095799,0.849042
5617,aneurysmal SAH,29,31,209,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,-1,5617,-1,0.00020973785,0.99979025
5625,MAP,5,6,42,45,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,-1,-1,5625,-1,0.99918073,0.0008192819
5627,Aggressive behaviors,0,2,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5627,-1,0.00020741881,0.99979264
5628,psychiatric disorders,11,13,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5628,-1,0.00020357776,0.99979645
5630,METH,20,21,131,135,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5630,-1,0.99940467,0.00059534574
5631,METH,13,14,63,67,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,-1,5631,-1,0.99933124,0.0006687629
5635,MAP,14,15,112,115,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5635,-1,0.9908422,0.00915783
5636,METH,21,22,166,170,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5636,-1,0.99931574,0.000684323
5637,p<0.05,5,6,38,44,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5637,-1,0.08646766,0.9135323
5638,METH,32,33,153,157,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5638,-1,0.99936897,0.0006310302
5639,METH,10,11,66,70,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5639,-1,0.9993331,0.00066688115
5640,METH,23,24,134,138,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5640,-1,0.9993357,0.00066423486
5641,METH,22,23,129,133,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,-1,5641,-1,0.9993498,0.0006501785
5642,MAP,6,7,43,46,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5642,-1,0.9991653,0.00083476375
5643,aggressive behaviors,20,22,151,171,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5643,-1,0.0002128768,0.99978715
5644,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,-1,-1,5644,-1,0.99947554,0.0005244844
5646,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5646,-1,0.00030188035,0.99969816
5647,antipsychotics,8,9,53,67,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5647,-1,0.99943,0.00057002174
5650,ziprasidone,15,16,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5650,-1,0.99949896,0.00050099206
5651,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,-1,-1,-1,5651,-1,0.9995012,0.0004987417
5654,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5654,-1,0.99949336,0.0005066611
5655,mg,20,21,148,150,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5655,-1,0.9993968,0.00060322025
5656,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5656,-1,0.9994616,0.0005384581
5657,mg,15,16,95,97,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5657,-1,0.81839615,0.18160388
5658,psychosis,3,4,13,22,"However, her psychosis recurred after the dose reduction.",16225977_5,-1,-1,-1,5658,-1,0.00021445994,0.9997856
5659,mg,8,9,40,42,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5659,-1,0.99889106,0.0011089816
5660,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5660,-1,0.9994766,0.0005234685
5661,antipsychotics,22,23,162,176,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5661,-1,0.99946934,0.0005306823
5662,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5662,-1,0.9994947,0.0005052593
5664,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5664,-1,0.9994949,0.00050513074
5665,dysphonia,1,2,10,19,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5665,-1,0.00017908412,0.9998209
5666,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5666,-1,0.9450516,0.05494841
5667,dysphonia,9,10,45,54,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5667,-1,0.00018864864,0.99981135
5668,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5668,-1,0.9984415,0.001558467
5669,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,-1,5669,-1,0.98509,0.014909927
5670,dysphonia,11,12,62,71,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,-1,5670,-1,0.00019262584,0.9998074
5672,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5672,-1,0.00018254806,0.99981743
5673,blindness,6,7,46,55,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5673,-1,0.00018764456,0.9998124
5675,deterioration of vision,14,17,101,124,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5675,-1,0.00022336355,0.99977666
5676,fatiguability,19,20,131,144,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5676,-1,0.00022870372,0.9997713
5677,dyspnoea,21,22,146,154,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5677,-1,0.00022973111,0.9997702
5679,syncopal attacks,26,28,181,197,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5679,-1,0.00023562845,0.9997644
5680,chloroquine retinopathy,5,7,49,72,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5680,-1,0.01605097,0.983949
5681,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5681,-1,0.00021132609,0.9997887
5682,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5682,-1,0.00021268465,0.9997873
5683,right bundle branch block,21,25,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5683,-1,0.00079865573,0.99920136
5684,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5684,-1,0.00020813121,0.9997919
5685,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5685,-1,0.00020812823,0.9997919
5687,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,-1,5687,-1,0.0030944454,0.9969055
5688,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5688,-1,0.9994686,0.00053138885
5689,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5689,-1,0.0002239882,0.99977607
5693,ototoxic,11,12,60,68,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,-1,-1,5693,-1,0.00020333544,0.9997967
5696,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,-1,-1,5696,-1,0.00019101032,0.99980897
5697,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,-1,5697,-1,0.00021232077,0.99978775
5706,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5706,-1,0.00021106047,0.99978894
5708,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5708,-1,0.00021380457,0.9997862
5718,Cl,51,52,162,164,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,-1,-1,5718,-1,0.052477293,0.9475227
5722,tissue injury,27,29,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5722,-1,0.0002177669,0.99978226
5725,neurogenic hyperalgesia,6,8,60,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,-1,-1,5725,-1,0.0002063172,0.9997937
5732,mg,6,7,33,35,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,-1,-1,-1,5732,-1,0.99312145,0.006878554
5740,Mitochondrial abnormalities,0,2,0,27,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,-1,5740,-1,0.00020885003,0.9997912
5742,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5742,-1,0.00019975616,0.99980026
5743,c,30,31,195,196,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5743,-1,0.99944896,0.0005510689
5746,mitochondrial abnormalities,3,5,22,49,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,-1,5746,-1,0.00020431844,0.99979573
5747,suprofen,2,3,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,-1,5747,-1,0.9993974,0.00060261023
5748,suprofen,1,2,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5748,-1,0.9994124,0.00058762875
5749,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5749,-1,0.00018953426,0.9998105
5751,mg,10,11,54,56,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5751,-1,0.99940395,0.0005960396
5752,suprofen,12,13,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5752,-1,0.99936765,0.0006323831
5753,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5753,-1,0.9994473,0.00055276335
5756,suprofen,21,22,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,-1,5756,-1,0.99938536,0.0006146723
5757,contrast,1,2,3,11,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5757,-1,0.90536857,0.094631486
5758,suprofen,16,17,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5758,-1,0.9994399,0.000560087
5759,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5759,-1,0.9994487,0.00055128906
5760,suprofen,30,31,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5760,-1,0.9994485,0.00055153214
5761,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5761,-1,0.9994475,0.0005525234
5762,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5762,-1,0.99940073,0.0005992814
5763,suprofen,16,17,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5763,-1,0.9990427,0.00095730764
5764,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,-1,5764,-1,0.9993112,0.00068883516
5765,suprofen,3,4,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5765,-1,0.99934965,0.0006503478
5766,declines in renal function,6,10,34,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5766,-1,0.00017946858,0.99982053
5767,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5767,-1,0.9993837,0.0006163401
5768,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,-1,5768,-1,0.99949765,0.00050236256
5770,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,-1,5770,-1,0.99948406,0.00051588536
5773,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5773,-1,0.99945205,0.0005479431
5774,saline+DMSO,13,14,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5774,-1,0.9994554,0.0005446585
5776,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5776,-1,0.99949753,0.0005025082
5778,ritanserin,55,56,278,288,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5778,-1,0.99950635,0.0004936083
5779,injection)+ritanserin,56,57,289,310,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5779,-1,0.96522164,0.03477834
5780,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5780,-1,0.99943227,0.0005677157
5782,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,-1,5782,-1,0.9995334,0.00046662297
5783,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,-1,5783,-1,0.9994523,0.0005477609
5785,calcium channel blocker nitrendipine,4,8,22,58,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5785,-1,0.9994598,0.0005402023
5786,nephrosclerosis,9,10,62,77,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5786,-1,0.00020358434,0.99979645
5787,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5787,-1,0.00020270709,0.9997973
5788,calcium channel blocker nitrendipine,8,12,42,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5788,-1,0.9994785,0.00052156474
5792,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5792,-1,0.00021134502,0.9997887
5794,mm Hg,16,18,75,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5794,-1,0.000276508,0.9997235
5796,n,30,31,155,156,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5796,-1,0.65135634,0.34864366
5797,n,36,37,182,183,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5797,-1,0.9514776,0.048522353
5798,n,43,44,215,216,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5798,-1,0.7095888,0.2904112
5799,mm Hg,11,13,62,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5799,-1,0.00060142594,0.9993986
5800,n,14,15,69,70,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5800,-1,0.101783626,0.89821637
5801,sclerosis,10,11,67,76,Renal tissue was obtained for determination of glomerular size and sclerosis.,1639466_5,-1,-1,-1,5801,-1,0.00020363617,0.99979633
5806,contrast,1,2,3,11,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,-1,5806,-1,0.8935791,0.10642085
5813,torsades de pointes,2,5,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,-1,5813,-1,0.05695678,0.94304323
5815,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5815,-1,0.00019728733,0.99980277
5816,prolonged QT interval,12,15,72,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5816,-1,0.00019715288,0.9998029
5817,torsades de pointes,16,19,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5817,-1,0.00021650769,0.99978346
5818,TdP,20,21,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5818,-1,0.87549233,0.1245076
5820,fungal infection,28,30,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5820,-1,0.00019927279,0.99980074
5824,long QT syndrome,37,40,227,243,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,-1,5824,-1,0.00023660526,0.9997634
5826,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5826,-1,0.00020168589,0.99979836
5827,Graves' disease,9,12,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5827,-1,0.0002057112,0.9997943
5828,purpura,1,2,9,16,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,-1,-1,-1,5828,-1,0.9973622,0.002637844
5830,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5830,-1,0.00019695223,0.9998031
5831,Graves' disease,8,11,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5831,-1,0.00020548383,0.99979454
5832,purpuric lesions,15,17,86,102,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5832,-1,0.0002049725,0.999795
5835,PTU,36,37,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,-1,-1,5835,-1,0.9994779,0.00052207726
5842,Cerebral vasculitis,0,2,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5842,-1,0.00019730294,0.99980277
5843,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5843,-1,0.016428502,0.9835715
5844,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5844,-1,0.00020025163,0.9997998
5848,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,-1,-1,5848,-1,0.00019451005,0.9998055
5849,cerebral vasculitis,3,5,25,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5849,-1,0.00019844457,0.9998016
5850,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5850,-1,0.00020044876,0.99979955
5853,neurological symptoms,12,14,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,-1,-1,5853,-1,0.00020670709,0.99979335
5856,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,-1,5856,-1,0.99949574,0.00050419866
5861,ACh,22,23,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5861,-1,0.9993666,0.0006334172
5862,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5862,-1,0.00020881518,0.9997912
5863,AD,37,38,224,226,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5863,-1,0.9992454,0.0007546804
5864,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,-1,5864,-1,0.9994924,0.00050761213
5865,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,-1,5865,-1,0.99940073,0.000599205
5866,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5866,-1,0.99947995,0.00052005186
5867,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5867,-1,0.006024821,0.9939752
5870,contrast,3,4,10,18,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5870,-1,0.061400417,0.9385996
5871,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5871,-1,0.99948597,0.0005140239
5873,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,-1,-1,5873,-1,0.9994758,0.00052430265
5876,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5876,-1,0.00022249886,0.9997775
5877,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5877,-1,0.99949014,0.00050978106
5878,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5878,-1,0.00022694598,0.9997731
5879,OAB,19,20,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5879,-1,0.00053584157,0.9994642
5880,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5880,-1,0.99949133,0.00050858676
5881,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,-1,5881,-1,0.00062984746,0.99937016
5882,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5882,-1,0.99946326,0.00053674914
5883,mg,2,3,14,16,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5883,-1,0.9592315,0.040768534
5884,nocturia,3,4,14,22,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,-1,5884,-1,0.00020256295,0.9997974
5885,dry month,6,8,32,41,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,-1,-1,5885,-1,0.7041412,0.29585883
5887,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5887,-1,0.9994723,0.0005276675
5888,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5888,-1,0.001895717,0.9981042
5889,Remifentanil,0,1,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5889,-1,0.9994553,0.0005447592
5891,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5891,-1,0.99820054,0.0017994196
5892,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5892,-1,0.99949324,0.00050670496
5894,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5894,-1,0.9994869,0.00051305664
5895,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,-1,5895,-1,0.9994746,0.0005254887
5896,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5896,-1,0.9994856,0.0005143991
5897,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5897,-1,0.99943215,0.00056783523
5903,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5903,-1,0.999483,0.0005169767
5904,P,28,29,131,132,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5904,-1,0.05805653,0.9419435
5909,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,-1,5909,-1,0.9980975,0.0019025648
5910,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5910,-1,0.9994802,0.00051988836
5912,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5912,-1,0.051427294,0.9485727
5917,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,-1,-1,5917,-1,0.999426,0.0005740766
5918,MDMA,0,1,0,4,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5918,-1,0.9994204,0.0005796582
5919,impaired social and emotional judgement processes,10,16,85,134,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5919,-1,0.00023321788,0.99976677
5920,memory deficits,4,6,24,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5920,-1,0.00019091781,0.9998091
5921,MDMA,12,13,71,75,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5921,-1,0.999446,0.0005539954
5924,MDMA,9,10,48,52,"The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ""prefrontal"" mediated social and emotional judgement processes.",16574712_2,-1,-1,-1,5924,-1,0.9993468,0.00065324694
5926,MDMA,6,7,43,47,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,-1,5926,-1,0.9994511,0.0005488432
5930,MDMA,11,12,81,85,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,-1,5930,-1,0.99844295,0.0015570839
5932,MDMA,3,4,44,48,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5932,-1,0.99951446,0.00048560026
5935,5-HT,15,16,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5935,-1,0.9995109,0.0004891012
5936,5-HT neurotoxic lesions,33,36,214,237,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5936,-1,0.0055873445,0.9944127
5937,5-HT,40,41,260,264,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5937,-1,0.99950886,0.00049119064
5938,5-HT,1,2,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5938,-1,0.99944705,0.0005528882
5939,5-HT,12,13,75,79,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5939,-1,0.99944884,0.00055118976
5940,5-HT,30,31,185,189,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5940,-1,0.99944764,0.00055232254
5941,MDMA,43,44,263,267,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5941,-1,0.9994393,0.00056069717
5942,MDMA,14,15,74,78,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5942,-1,0.9992656,0.00073435484
5943,MDMA,29,30,158,162,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5943,-1,0.9993994,0.00060053606
5944,MDMA,2,3,17,21,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,-1,5944,-1,0.99946636,0.00053369533
5945,p,12,13,71,72,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5945,-1,0.45380363,0.54619634
5946,p,22,23,108,109,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5946,-1,0.537207,0.46279302
5947,p,30,31,154,155,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5947,-1,0.5086914,0.49130863
5948,contrast,1,2,3,11,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5948,-1,0.6245363,0.37546375
5950,MDMA,12,13,71,75,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5950,-1,0.99910504,0.00089488033
5951,MDMA,4,5,17,21,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5951,-1,0.9994517,0.0005482425
5952,impaired memory functioning,18,21,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5952,-1,0.00020287513,0.99979717
5953,MDMA,25,26,135,139,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5953,-1,0.99945337,0.00054668484
5954,lead,28,29,148,152,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5954,-1,0.859992,0.14000799
5955,memory impairments,32,34,169,187,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5955,-1,0.00020548362,0.99979454
5956,MDMA,10,11,54,58,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,-1,5956,-1,0.912668,0.08733199
5957,mangiferin,2,3,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5957,-1,0.99950767,0.0004923771
5958,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5958,-1,0.00021303212,0.99978703
5959,mangiferin,9,10,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5959,-1,0.9994993,0.00050069945
5960,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5960,-1,0.99948585,0.00051410473
5962,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5962,-1,0.00019125159,0.9998087
5963,MI,28,29,177,179,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5963,-1,0.00022902993,0.99977094
5964,ISPH,3,4,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5964,-1,0.94223374,0.057766307
5965,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5965,-1,0.011674366,0.9883257
5967,lactate,36,37,196,203,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5967,-1,0.99943906,0.0005608858
5969,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5969,-1,0.99943453,0.0005654155
5971,mangiferin,4,5,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5971,-1,0.9995073,0.0004927271
5972,triphenyl tetrazolium chloride,8,11,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5972,-1,0.99950373,0.0004962336
5973,TTC,12,13,82,85,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5973,-1,0.99949586,0.00050416
5974,ischemic,23,24,141,149,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5974,-1,0.00020660639,0.99979347
5975,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5975,-1,0.99947804,0.00052196055
5976,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5976,-1,0.9994728,0.00052723364
5977,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5977,-1,0.9994585,0.0005414738
5978,glutathione reductase,18,20,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5978,-1,0.9994646,0.0005354742
5979,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5979,-1,0.99949,0.0005099504
5980,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5980,-1,0.9994741,0.00052593066
5982,MI,39,40,272,274,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5982,-1,0.9985971,0.001402928
5983,mangiferin,3,4,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5983,-1,0.9994881,0.0005118264
5984,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5984,-1,0.0017548985,0.9982451
5985,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5985,-1,0.99947757,0.00052249373
5986,MI,23,24,138,140,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5986,-1,0.30986086,0.6901391
5987,mangiferin,14,15,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5987,-1,0.99947304,0.0005269271
5988,MI,20,21,168,170,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5988,-1,0.007743349,0.99225664
5989,mangiferin,8,9,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5989,-1,0.9994742,0.00052580587
5990,MI,15,16,103,105,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5990,-1,0.00020555376,0.9997944
5991,cardiac damage,29,31,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5991,-1,0.00020099344,0.9997991
5992,cyclooxygenase inhibitors,3,5,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5992,-1,0.999482,0.0005180061
5993,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5993,-1,0.00020675633,0.99979323
5996,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5996,-1,0.00020962927,0.9997904
5997,cyclooxygenase inhibitors,35,37,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5997,-1,0.9994795,0.0005205349
5998,Cyclooxygenase,0,1,0,14,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5998,-1,0.9994541,0.00054590346
5999,inhibitors,1,2,15,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5999,-1,0.999438,0.0005620083
6000,cyclooxygenase inhibitors,7,9,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,-1,6000,-1,0.9994369,0.0005631097
6001,cardiovascular toxicity,33,35,217,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,-1,-1,6001,-1,0.00023053223,0.9997695
6002,Pilocarpine seizures,0,2,0,20,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,6002,-1,0.01758845,0.98241156
6003,impairment in auditory location discrimination,4,9,41,87,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,6003,-1,0.00023235536,0.9997676
6004,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,-1,-1,6004,-1,0.0010643866,0.99893564
6006,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,6006,-1,0.0002104145,0.99978966
6007,deficits in auditory discrimination,7,11,46,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,6007,-1,0.00027921892,0.99972075
6008,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,-1,6008,-1,0.00019555085,0.99980444
6009,P,11,12,69,70,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,-1,-1,-1,6009,-1,0.19686562,0.8031344
6012,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,6012,-1,0.00021819898,0.9997818
6013,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,6013,-1,0.00022015984,0.9997799
6016,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,-1,6016,-1,0.0003652714,0.99963474
6017,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,-1,6017,-1,0.0011083558,0.99889165
6018,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,6018,-1,0.0002333854,0.99976665
6019,impairment in auditory discrimination,9,13,61,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,6019,-1,0.00021163338,0.99978834
6020,impaired auditory location discrimination,7,11,41,82,This impairment may explain one cause of impaired auditory location discrimination in humans.,16596970_11,-1,-1,-1,6020,-1,0.00021415832,0.99978584
6021,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6021,-1,0.8034879,0.19651206
6023,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6023,-1,0.00020805797,0.9997919
6024,NGF,2,3,9,12,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6024,-1,0.99928635,0.00071373145
6025,PGs,4,5,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6025,-1,0.99742377,0.0025762708
6026,NGF,5,6,35,38,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6026,-1,0.9984207,0.0015792806
6027,PGs,7,8,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6027,-1,0.025618603,0.9743814
6028,OAB,11,12,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6028,-1,0.99776626,0.0022337204
6029,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6029,-1,0.98624736,0.013752614
6030,bladder symptoms,15,17,82,98,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6030,-1,0.00024101761,0.999759
6031,NGF,0,1,0,3,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6031,-1,0.9993666,0.0006334682
6032,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6032,-1,0.99942786,0.0005720993
6033,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6033,-1,0.99946076,0.00053930125
6034,PGI2,6,7,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6034,-1,0.99945754,0.0005424703
6035,NGF,6,7,42,45,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6035,-1,0.9991487,0.0008512634
6036,PG,8,9,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6036,-1,0.9991365,0.0008635404
6037,OAB,16,17,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6037,-1,0.89262295,0.10737701
6038,NGF,3,4,17,20,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6038,-1,0.9993755,0.0006244983
6039,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6039,-1,0.9994085,0.00059157703
6040,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6040,-1,0.99943,0.0005699464
6041,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6041,-1,0.0013114454,0.9986885
6042,p,19,20,115,116,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6042,-1,0.08110301,0.91889703
6043,PGI2,3,4,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6043,-1,0.9990477,0.00095232064
6044,OAB,12,13,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6044,-1,0.08115087,0.9188491
6045,OAB,3,4,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6045,-1,0.99939084,0.00060914585
6046,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6046,-1,0.9993949,0.0006050734
6047,p,20,21,126,127,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6047,-1,0.3852587,0.61474127
6048,NGF,1,2,8,11,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6048,-1,0.9994393,0.0005606803
6049,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6049,-1,0.9950177,0.004982284
6050,PGI2,5,6,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6050,-1,0.99946517,0.00053488737
6051,OAB,15,16,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6051,-1,0.05972616,0.9402738
6052,NGF,2,3,13,16,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6052,-1,0.9992489,0.0007510705
6053,PGs,4,5,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6053,-1,0.9981019,0.001898141
6054,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6054,-1,0.00032944625,0.9996705
6055,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,-1,6055,-1,0.9964814,0.0035185684
6057,infected with hepatitis C virus,7,12,48,79,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,-1,-1,6057,-1,0.0006537078,0.9993463
6058,Chronic infection with hepatitis C virus (HCV,0,8,0,45,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6058,-1,0.00055952265,0.9994405
6062,HCV infection,5,7,31,44,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6062,-1,0.00017791621,0.9998221
6063,pegylated interferon,11,13,73,93,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6063,-1,0.99947983,0.00052020606
6068,HCV infection,20,22,138,151,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6068,-1,0.00021951884,0.9997805
6069,renal or cardiovascular disorders,28,32,188,221,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6069,-1,0.00022759517,0.99977237
6073,Viramidine,0,1,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6073,-1,0.9994906,0.0005094104
6077,hepatitis C.,29,31,189,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6077,-1,0.013119634,0.9868803
6081,growth impairment,11,13,80,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,-1,6081,-1,0.00020525334,0.9997948
6087,reduced cerebellar growth,11,14,87,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6087,-1,0.00022568836,0.9997743
6088,decreased cranial to body growth,17,22,124,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6088,-1,0.0002567613,0.9997433
6089,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,-1,-1,6089,-1,0.017168002,0.982832
6091,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6091,-1,0.9994043,0.00059574656
6092,CI-921,7,8,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6092,-1,0.9660411,0.033958934
6093,NSC 343499,9,11,49,59,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6093,-1,0.023274697,0.9767253
6094,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6094,-1,0.00021832572,0.99978167
6095,CI-921,0,1,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6095,-1,0.16072398,0.839276
6096,NSC 343499,2,4,8,18,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6096,-1,0.01596411,0.9840359
6097,"9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide",5,9,20,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6097,-1,0.99937266,0.0006273396
6098,topoisomerase,12,13,117,130,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6098,-1,0.725036,0.27496397
6099,II poison,13,15,131,140,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6099,-1,0.0023933472,0.99760664
6100,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6100,-1,0.00021541228,0.99978465
6101,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6101,-1,0.00022205168,0.999778
6102,squamous carcinoma,3,5,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6102,-1,0.00020075882,0.9997993
6103,adenocarcinoma,9,10,49,63,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6103,-1,0.00020408364,0.999796
6105,undifferentiated carcinoma,28,30,137,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6105,-1,0.00035045113,0.9996495
6108,grand mal seizures,21,24,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,-1,-1,6108,-1,0.00021199406,0.999788
6111,phlebitis,16,17,78,87,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6111,-1,0.00022529367,0.99977475
6112,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,-1,6112,-1,0.00017651793,0.9998235
6113,tumour,6,7,34,40,Further testing in this and other tumour types using multiple daily schedules is warranted.,1664218_8,-1,-1,-1,6113,-1,0.00022788269,0.99977213
6114,desipramine HCl,2,4,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6114,-1,0.999495,0.0005048948
6115,cinacalcet HCl,7,9,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6115,-1,0.9994917,0.0005083113
6120,mg,31,32,191,193,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6120,-1,0.99923193,0.00076810893
6122,mg,49,50,281,283,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6122,-1,0.99095577,0.009044188
6123,h,9,10,49,50,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,-1,6123,-1,0.067131616,0.93286836
6139,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,-1,-1,6139,-1,0.00021660436,0.99978346
6140,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,-1,6140,-1,0.99947935,0.0005206945
6143,hemianopia,8,9,50,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,-1,-1,6143,-1,0.9992472,0.0007528853
6144,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,-1,-1,6144,-1,0.00019280719,0.9998072
6145,"loss of central visual acuity, colour vision (Ishihara) and visual field",4,18,19,91,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6145,-1,0.00039672665,0.99960333
6146,visual field loss,1,4,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,-1,-1,6146,-1,0.00022970112,0.99977034
6147,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6147,-1,0.99947387,0.0005261415
6148,loss of visual function,8,12,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,-1,-1,-1,6148,-1,0.00024118058,0.9997588
6149,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,-1,6149,-1,0.9994733,0.0005266936
6151,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6151,-1,0.9994986,0.0005014068
6152,chiasmopathy,9,10,61,73,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6152,-1,0.00020778006,0.9997923
6153,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6153,-1,0.9994972,0.00050277164
6154,affect the,14,16,100,110,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6154,-1,0.012690072,0.98730993
6155,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,-1,-1,6155,-1,0.00057463505,0.9994254
6158,depressive symptoms,4,6,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6158,-1,0.00020539059,0.99979466
6160,insomnia,14,15,89,97,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6160,-1,0.00021012456,0.9997899
6161,loss of appetite,16,19,99,115,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6161,-1,0.00023615475,0.9997639
6163,mg paroxetine,10,12,54,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6163,-1,0.99943703,0.0005629132
6164,mg alprazolam,14,16,76,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6164,-1,0.999446,0.00055396114
6167,psychomotor retardation,14,16,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6167,-1,0.00021411241,0.99978596
6168,disorientation,17,18,110,124,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6168,-1,0.00021848067,0.99978155
6169,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6169,-1,0.00021568684,0.9997843
6172,C,8,9,38,39,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6172,-1,0.91800386,0.081996195
6173,mg mm Hg,19,22,96,104,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6173,-1,0.011889508,0.98811054
6178,BUN,28,29,155,158,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,-1,-1,-1,6178,-1,0.9993193,0.00068065256
6182,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6182,-1,0.00036187418,0.9996381
6183,NMS,10,11,72,75,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6183,-1,0.0054534962,0.99454653
6186,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6186,-1,0.00057432015,0.99942565
6187,symptoms,26,27,159,167,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6187,-1,0.0002233465,0.99977666
6188,NMS,4,5,25,28,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6188,-1,0.20223354,0.7977664
6192,malnutrition,20,21,129,141,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6192,-1,0.00022612434,0.9997739
6203,tricaine,6,7,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,-1,6203,-1,0.9995222,0.00047780285
6216,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,-1,6216,-1,0.002256859,0.9977431
6218,lidocaine seizures,3,5,37,55,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,-1,6218,-1,0.005682756,0.99431723
6223,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6223,-1,0.00023509882,0.99976486
6224,carbamylcholin,16,17,80,94,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,-1,6224,-1,0.99951375,0.00048628484
6227,mg,21,22,104,106,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,-1,-1,-1,6227,-1,0.9320325,0.0679675
6230,sweating,12,13,74,82,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,-1,6230,-1,0.00021762618,0.9997824
6238,hyperhidrosis,3,4,19,32,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6238,-1,0.0002965265,0.99970347
6239,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6239,-1,0.00025035974,0.9997496
6240,bronchorrhoea,7,8,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6240,-1,0.00021339176,0.9997867
6241,miosis,11,12,77,83,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6241,-1,0.00021303864,0.99978703
6243,mg,8,9,33,35,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,-1,6243,-1,0.8250531,0.17494689
6246,dyspnoea,3,4,19,27,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6246,-1,0.00021162549,0.99978834
6247,bronchospasm,5,6,32,44,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6247,-1,0.00021096873,0.99978906
6248,Respiratory insufficiency,0,2,0,25,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6248,-1,0.00021130411,0.9997887
6249,Proteus mirabilis infection,6,9,50,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6249,-1,0.0020793315,0.9979207
6250,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,-1,-1,6250,-1,0.00019613157,0.99980384
6254,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6254,-1,0.99938893,0.0006110584
6255,acute cardiovascular failure,17,20,105,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6255,-1,0.00020045755,0.99979955
6256,cognitive dysfunctions,12,14,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,-1,-1,-1,6256,-1,0.0001812317,0.99981874
6258,ethanolic extract of Daucus carota seeds,1,7,4,44,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6258,-1,0.99915016,0.00084980455
6259,DCE,8,9,46,49,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6259,-1,0.99940586,0.0005941327
6262,DCE,0,1,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,-1,6262,-1,0.99946195,0.00053809996
6263,DCE,7,8,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,-1,6263,-1,0.9994382,0.0005616998
6264,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,-1,6264,-1,0.9994635,0.0005365067
6268,Daucus carota extract,0,3,0,21,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,-1,-1,-1,6268,-1,0.9990638,0.0009362561
6270,DCE,10,11,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,-1,6270,-1,0.99944645,0.0005534893
6272,DCE,30,31,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,-1,6272,-1,0.9994455,0.0005544677
6273,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6273,-1,0.99947613,0.00052390125
6274,cognitive dysfunctions,14,16,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6274,-1,0.00020305239,0.9997969
6276,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,-1,6276,-1,0.99944335,0.0005565835
6277,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6277,-1,0.9994265,0.0005735502
6278,VPA,3,4,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6278,-1,0.99028486,0.009715196
6279,haemorrhagic pancreatitis,10,12,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,-1,-1,6279,-1,0.00020761527,0.9997924
6284,impaired consciousness,7,9,52,74,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,-1,-1,6284,-1,0.00020706255,0.999793
6287,VPA,9,10,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,-1,6287,-1,0.0002765774,0.9997234
6290,Atorvastatin,0,1,0,12,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,-1,-1,6290,-1,0.9994886,0.00051133585
6292,atorvastatin,6,7,37,49,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6292,-1,0.9994987,0.00050124613
6293,atorva,8,9,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6293,-1,0.99946994,0.0005301239
6296,atorva,22,23,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6296,-1,0.99946505,0.00053500227
6300,P,36,37,152,153,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,-1,6300,-1,0.072400644,0.92759943
6301,atorva,8,9,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6301,-1,0.9992594,0.0007405536
6303,P,37,38,169,170,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6303,-1,0.3085857,0.69141436
6304,Atorva,0,1,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6304,-1,0.99936634,0.0006336578
6306,P,17,18,81,82,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6306,-1,0.023198092,0.97680193
6309,atorva,37,38,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6309,-1,0.997719,0.002280975
6311,P,41,42,174,175,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6311,-1,0.27586448,0.7241355
6312,P,29,30,154,155,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,-1,6312,-1,0.26039857,0.73960143
6313,Atorva,0,1,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,-1,-1,-1,6313,-1,0.99943763,0.0005624102
6314,atorvastatin,2,3,6,18,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,-1,-1,6314,-1,0.9994931,0.0005068966
6317,cytosine arabinoside,5,7,42,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6317,-1,0.99948645,0.00051357696
6318,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6318,-1,0.00020075194,0.9997993
6319,central nervous system toxicity,1,5,4,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6319,-1,0.00019979582,0.99980026
6320,cytosine arabinoside,7,9,49,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6320,-1,0.9994848,0.000515193
6322,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6322,-1,0.9994831,0.0005169083
6323,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,-1,-1,6323,-1,0.00019441695,0.9998056
6324,cytosine arabinoside,9,11,60,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,-1,6324,-1,0.9994778,0.00052219845
6325,cytosine arabinoside,5,7,30,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6325,-1,0.99947757,0.00052247354
6326,numbness,28,29,159,167,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6326,-1,0.00021340598,0.99978656
6331,cytosine arabinoside,11,13,78,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6331,-1,0.99948263,0.000517341
6332,toxic to the peripheral nervous system,19,25,132,170,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6332,-1,0.00031650905,0.9996835
6337,free radicals,14,16,117,130,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,-1,6337,-1,0.044338074,0.9556619
6338,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6338,-1,0.000669449,0.9993305
6340,DFO,21,22,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6340,-1,0.99949753,0.0005024813
6343,h,12,13,50,51,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6343,-1,0.031338815,0.9686612
6344,DFO,21,22,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,-1,6344,-1,0.9994217,0.0005782741
6346,DA,5,6,32,34,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6346,-1,0.99937755,0.000622441
6348,DFO,25,26,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6348,-1,0.99943703,0.00056290114
6349,DFO,2,3,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,-1,6349,-1,0.99947506,0.00052497454
6351,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,-1,6351,-1,0.9994417,0.0005583352
6352,DFO,8,9,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,-1,-1,-1,6352,-1,0.999474,0.00052601285
6353,DFO,5,6,32,35,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,-1,6353,-1,0.99948186,0.0005181239
6356,cerebral haemorrhages,12,14,84,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6356,-1,0.00017481699,0.9998252
6363,p,27,28,102,103,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,-1,-1,-1,6363,-1,0.09840138,0.90159863
6364,haemorrhage,8,9,58,69,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6364,-1,0.00021256121,0.9997875
6367,cerebral haemorrhages,3,5,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6367,-1,0.00020448487,0.9997955
6368,cerebral haemorrhages,5,7,45,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,-1,-1,-1,6368,-1,0.00018372256,0.99981636
6370,thioperamide,3,4,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,-1,-1,-1,6370,-1,0.99945074,0.00054922997
6378,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6378,-1,0.9994677,0.0005323272
6379,thioperamide,11,12,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6379,-1,0.99948007,0.00051992247
6380,THP,13,14,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6380,-1,0.99945015,0.0005498777
6381,se,23,24,95,97,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6381,-1,0.7741649,0.22583503
6383,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6383,-1,0.99945,0.000549913
6384,h,14,15,54,55,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6384,-1,0.11723063,0.8827694
6387,P,28,29,139,140,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6387,-1,0.20806739,0.79193264
6388,RAMH,4,5,27,31,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6388,-1,0.9994054,0.0005946576
6389,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6389,-1,0.99933976,0.0006602445
6390,RAMH,0,1,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6390,-1,0.9993703,0.0006297505
6391,se,2,3,9,11,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6391,-1,0.99931264,0.00068739476
6392,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6392,-1,0.9993686,0.0006314324
6393,se,24,25,124,126,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6393,-1,0.99933136,0.0006686966
6395,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6395,-1,0.9994479,0.00055205566
6396,P,23,24,129,130,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6396,-1,0.21727808,0.78272194
6397,RAMH,2,3,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6397,-1,0.9993962,0.000603796
6398,THP,15,16,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6398,-1,0.34735024,0.65264976
6400,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,-1,6400,-1,0.9994091,0.00059088663
6401,RAMH,11,12,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,-1,-1,-1,6401,-1,0.9993931,0.00060686294
6402,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,-1,6402,-1,0.99947745,0.000522617
6405,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6405,-1,0.99942315,0.0005768376
6406,RAMH,7,8,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6406,-1,0.9994492,0.0005508321
6412,dopamine antagonists,4,6,25,45,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,-1,-1,-1,6412,-1,0.99940443,0.0005955313
6416,fluphenazine,4,5,23,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6416,-1,0.9995049,0.00049506687
6417,SCH 23390,8,10,52,61,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6417,-1,0.95968133,0.04031866
6420,fluphenazine,3,4,14,26,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,-1,6420,-1,0.9994905,0.0005094767
6422,SCH 23390,2,4,15,24,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,-1,-1,6422,-1,0.9994406,0.00055941526
6425,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6425,-1,0.99883336,0.0011667007
6426,quinpirole,9,10,40,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6426,-1,0.9995229,0.00047711906
6428,fluphenazine,15,16,86,98,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6428,-1,0.99952793,0.00047209422
6429,SCH 23390,17,19,100,109,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6429,-1,0.9995204,0.00047964163
6431,SKF 38393,2,4,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6431,-1,0.999448,0.0005519694
6432,quinpirole,5,6,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6432,-1,0.99948525,0.00051470706
6434,dopamine antagonists,16,18,109,129,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6434,-1,0.9994684,0.00053165614
6436,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,-1,-1,-1,6436,-1,0.016649209,0.9833508
6438,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,-1,6438,-1,0.00029063757,0.9997093
6440,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,-1,-1,-1,6440,-1,0.019740727,0.9802593
6441,cauda equina syndrome,7,10,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6441,-1,0.0007322109,0.99926776
6442,triamcinolone,16,17,97,110,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6442,-1,0.99948907,0.0005108843
6444,leg pain,11,13,63,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6444,-1,0.00024700738,0.99975294
6446,contrast medium,3,5,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,-1,6446,-1,0.99916816,0.0008318598
6449,numbness,8,9,46,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6449,-1,0.00021541906,0.99978465
6450,lower extremity weakness,10,13,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6450,-1,0.0002163117,0.9997837
6451,loss of sensation,4,7,35,52,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,-1,-1,-1,6451,-1,0.00024168748,0.9997583
6453,neurologic deterioration,6,8,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,-1,-1,-1,6453,-1,0.00022899087,0.99977106
6457,androgen,8,9,46,54,OBJECTIVES: To study the long-term effects of androgen treatment on atherosclerosis in postmenopausal women.,16938416_1,-1,-1,-1,6457,-1,0.99933785,0.0006620898
6464,n=11,14,15,79,83,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,-1,-1,6464,-1,0.23438296,0.7656171
6472,androgen,19,20,147,155,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,-1,-1,6472,-1,0.9993967,0.0006033453
6473,hepatitis B,8,10,63,74,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,-1,-1,6473,-1,0.06722944,0.93277055
6476,Hepatitis B virus (HBV) infection,0,7,0,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6476,-1,0.0009802652,0.99901974
6477,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6477,-1,0.00020639492,0.9997936
6481,hepatitis B surface antigen,3,7,15,42,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6481,-1,0.0038399457,0.99616003
6482,e,8,9,47,48,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6482,-1,0.99730253,0.0026974445
6485,cibenzoline,6,7,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,-1,-1,6485,-1,0.9994487,0.00055132137
6487,ventricular arrhythmia,11,13,93,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,-1,-1,6487,-1,0.00021752431,0.9997825
6488,Digitalis arrhythmia,0,2,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6488,-1,0.0017398671,0.9982602
6489,Na channel blockers,7,10,45,64,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6489,-1,0.9994573,0.0005426838
6491,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6491,-1,0.012500962,0.98749906
6492,Ca channel blockers,7,10,46,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6492,-1,0.9994537,0.0005463278
6496,SD,29,30,184,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6496,-1,0.020574974,0.979425
6497,n,31,32,188,189,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6497,-1,0.07566903,0.924331
6501,SD,29,30,185,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6501,-1,0.036997598,0.9630024
6502,n,31,32,189,190,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6502,-1,0.08423098,0.915769
6503,Na,21,22,141,143,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6503,-1,0.99936706,0.00063296675
6504,Ca,30,31,183,185,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6504,-1,0.9993192,0.00068084075
6506,gliomas,7,8,42,49,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,-1,-1,-1,6506,-1,0.00020948242,0.9997905
6508,brain edema,8,10,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6508,-1,0.00021266805,0.9997874
6509,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6509,-1,0.00021087965,0.9997892
6512,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,-1,-1,6512,-1,0.00019461672,0.9998054
6514,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6514,-1,0.0002203711,0.99977964
6515,metastases,26,27,120,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6515,-1,0.00022801285,0.999772
6516,meningioma,29,30,140,150,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6516,-1,0.00022441208,0.9997756
6517,edematous,8,9,46,55,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,-1,6517,-1,0.00022206779,0.999778
6519,glioma,25,26,144,150,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,-1,6519,-1,0.00021583455,0.9997842
6521,meningioma,1,2,3,13,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6521,-1,0.00019745651,0.99980253
6522,metastases,3,4,18,28,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6522,-1,0.00020346501,0.99979657
6525,gliomas,23,24,122,129,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,-1,6525,-1,0.00021574134,0.9997843
6528,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,-1,-1,6528,-1,0.00021121005,0.9997888
6529,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,-1,6529,-1,0.00020085167,0.9997992
6536,Ximelagatran,0,1,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6536,-1,0.99948967,0.00051027635
6537,direct thrombin inhibitor,4,7,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6537,-1,0.99949205,0.0005079383
6538,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6538,-1,0.99948657,0.00051337044
6539,embolic events,23,25,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6539,-1,0.00021308677,0.9997869
6540,abnormal liver function,33,36,188,211,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6540,-1,0.00021924774,0.9997807
6541,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6541,-1,0.8215884,0.17841159
6542,Irbesartan,8,9,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6542,-1,0.99948174,0.00051825657
6543,Vascular Events,12,14,86,101,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6543,-1,0.00020914874,0.99979085
6547,af embolic events,33,36,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6547,-1,0.00021878332,0.9997812
6548,Idraparinux,0,1,0,11,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6548,-1,0.99948287,0.00051707524
6549,Factor Xa,3,5,15,24,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6549,-1,0.9992124,0.0007876168
6550,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6550,-1,0.00021820252,0.9997818
6551,enzyme inhibitors,1,3,23,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6551,-1,0.99944264,0.0005573959
6552,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6552,-1,0.99944144,0.0005585915
6553,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6553,-1,0.00021309551,0.9997869
6554,cardiac remodelling,14,16,128,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6554,-1,0.00021184978,0.9997881
6557,EPS,6,7,52,55,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6557,-1,0.0018912246,0.99810874
6558,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6558,-1,0.99948114,0.00051883876
6559,bipolar mania,16,18,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6559,-1,0.00022494917,0.9997751
6561,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6561,-1,0.00036033816,0.99963963
6562,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6562,-1,0.9885018,0.011498162
6563,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6563,-1,0.9994616,0.000538376
6564,bipolar mania,18,20,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6564,-1,0.00021083762,0.9997892
6565,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6565,-1,0.9994916,0.00050842715
6566,n,12,13,65,66,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6566,-1,0.068055004,0.93194497
6567,n,19,20,90,91,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6567,-1,0.061179195,0.9388208
6570,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6570,-1,0.99947625,0.0005237974
6572,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6572,-1,0.9994754,0.00052459637
6573,QTP,21,22,114,117,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6573,-1,0.999196,0.0008040162
6574,n,26,27,129,130,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6574,-1,0.110301636,0.8896983
6575,PBO,37,38,179,182,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6575,-1,0.99945945,0.0005405147
6576,n,42,43,194,195,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6576,-1,0.093203984,0.906796
6578,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,-1,6578,-1,0.0002880421,0.99971193
6579,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6579,-1,0.00085181143,0.99914813
6580,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6580,-1,0.99949265,0.00050728634
6581,QTP,6,7,43,46,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6581,-1,0.9004231,0.09957695
6582,PBO,18,19,92,95,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6582,-1,0.999413,0.0005869429
6583,EPS,4,5,26,29,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6583,-1,0.91763115,0.08236879
6585,n,15,16,86,87,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6585,-1,0.820131,0.17986904
6587,n,30,31,155,156,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6587,-1,0.95882726,0.04117276
6588,EPS,40,41,213,216,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6588,-1,0.9969324,0.0030676124
6589,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6589,-1,0.001306911,0.99869305
6590,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6590,-1,0.99949384,0.0005061327
6591,QTP,24,25,111,114,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6591,-1,0.9991708,0.0008293032
6593,p,9,10,62,63,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6593,-1,0.10439127,0.8956087
6595,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6595,-1,0.9994772,0.0005228195
6601,p,7,8,54,55,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6601,-1,0.1300936,0.86990637
6602,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6602,-1,0.0003382097,0.9996618
6604,extrapyramidal syndrome,31,33,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6604,-1,0.00020727784,0.99979275
6605,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6605,-1,0.99949217,0.00050782703
6606,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,-1,6606,-1,0.999483,0.00051700533
6607,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,-1,-1,-1,6607,-1,0.9994808,0.00051923335
6608,bipolar mania,3,5,16,29,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6608,-1,0.00017437681,0.99982566
6609,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6609,-1,0.00019341924,0.9998066
6610,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6610,-1,0.00040072645,0.9995993
6611,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6611,-1,0.9994898,0.0005101533
6612,atorvastatin,3,4,24,36,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,-1,6612,-1,0.9994759,0.00052407157
6616,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6616,-1,0.9994529,0.00054710946
6618,O2-,20,21,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6618,-1,0.99945873,0.00054131105
6619,Atorvastatin,0,1,0,12,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6619,-1,0.99946135,0.00053868245
6620,Ato,2,3,14,17,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6620,-1,0.9994435,0.00055654434
6621,O2-,22,23,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6621,-1,0.99939513,0.00060480414
6623,Ato,16,17,70,73,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6623,-1,0.36724994,0.63275003
6624,O2-,30,31,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6624,-1,0.999099,0.0009010458
6625,SD,34,35,177,179,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6625,-1,0.25536776,0.7446322
6626,SD,3,4,8,10,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6626,-1,0.0012003594,0.9987997
6627,n,6,7,17,18,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6627,-1,0.097892,0.90210795
6628,Ato,13,14,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6628,-1,0.9993579,0.000642106
6629,drinking water,20,22,68,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6629,-1,0.9466149,0.053385038
6632,P,30,31,119,120,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,-1,6632,-1,0.22749078,0.7725092
6633,Ato,2,3,7,10,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6633,-1,0.99940324,0.0005967643
6635,P,29,30,106,107,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6635,-1,0.15933256,0.84066737
6637,P,48,49,192,193,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6637,-1,0.23705643,0.76294357
6639,Ato,12,13,84,87,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6639,-1,0.9992299,0.00077009655
6641,P,21,22,122,123,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6641,-1,0.21702299,0.78297704
6644,Ato,9,10,52,55,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6644,-1,0.9994185,0.00058157067
6646,P,20,21,110,111,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6646,-1,0.025842877,0.9741571
6647,Ato,2,3,15,18,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6647,-1,0.9994154,0.000584631
6649,SD,15,16,111,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6649,-1,0.00083537126,0.9991647
6651,hypothermic,6,7,38,49,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6651,-1,0.0005866135,0.9994134
6652,Chiari malformation,12,14,78,97,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6652,-1,0.0011670836,0.9988329
6653,hypothermic,9,10,67,78,"During anaesthesia and surgery, he inadvertently became moderately hypothermic.",17049862_1,-1,-1,-1,6653,-1,0.00025853535,0.9997415
6664,lead,9,10,63,67,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6664,-1,0.003280734,0.9967193
6665,cardiac event,13,15,82,95,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6665,-1,0.00021168221,0.99978834
6667,chorea,1,2,18,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6667,-1,0.00021184214,0.9997882
6669,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6669,-1,0.0059655285,0.99403447
6670,Nonketotic hyperglycinemia,0,2,0,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6670,-1,0.011437491,0.98856246
6671,disorder of amino acid metabolism,4,9,32,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6671,-1,0.0007305374,0.9992694
6674,neonatal apnea,7,9,37,51,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6674,-1,0.0002126506,0.9997874
6676,hypotonia,14,15,79,88,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6676,-1,0.00021295394,0.99978703
6677,psychomotor retardation,19,21,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6677,-1,0.000212998,0.99978703
6678,nonketotic,6,7,37,47,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6678,-1,0.011538826,0.98846114
6679,hyperglycinemia,7,8,48,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6679,-1,0.0005301974,0.9994698
6680,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6680,-1,0.0020156452,0.9979843
6681,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6681,-1,0.00020621592,0.9997938
6682,nonketotic hyperglycinemia,18,20,103,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6682,-1,0.0047757435,0.99522424
6684,chorea,27,28,187,193,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6684,-1,0.00021479576,0.99978524
6685,valproate,32,33,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6685,-1,0.9994382,0.0005617887
6686,citrate toxicity,1,3,7,23,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,-1,6686,-1,0.0061515667,0.9938485
6687,citrate toxicity,6,8,27,43,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,-1,6687,-1,0.0060181255,0.9939819
6689,hyperlipidemia,8,9,54,68,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,-1,-1,6689,-1,0.00020850005,0.99979156
6691,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,-1,-1,-1,6691,-1,0.9994905,0.0005094354
6694,the,14,15,80,83,"Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet.",17111419_5,-1,-1,-1,6694,-1,0.00080122234,0.99919873
6696,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6696,-1,0.99945146,0.00054859376
6697,muscle contractions,10,12,74,93,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6697,-1,0.00021620301,0.9997838
6701,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6701,-1,0.99946874,0.00053124735
6702,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6702,-1,0.8681188,0.13188113
6705,citrate toxicity,22,24,161,177,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,-1,-1,6705,-1,0.005150629,0.9948494
6708,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6708,-1,0.00020431573,0.99979573
6709,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6709,-1,0.0002032651,0.9997968
6711,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6711,-1,0.00020418837,0.99979585
6712,MCAO,16,17,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6712,-1,0.00021033364,0.99978966
6713,brain edema,19,21,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6713,-1,0.00020389029,0.9997961
6716,n,5,6,22,23,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6716,-1,0.27639678,0.7236032
6717,MAP,15,16,58,61,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6717,-1,0.00035424816,0.9996457
6719,n,5,6,27,28,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6719,-1,0.32960695,0.67039305
6720,MAP,11,12,39,42,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6720,-1,0.0005038903,0.9994961
6721,mm Hg,18,20,65,70,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6721,-1,0.00054556096,0.99945444
6722,h,22,23,83,84,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6722,-1,0.115832604,0.8841674
6723,MCAO,24,25,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6723,-1,0.00020182921,0.99979824
6724,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,-1,6724,-1,0.00027836065,0.9997216
6726,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,-1,6726,-1,0.00072787283,0.99927217
6727,ischemic,23,24,112,120,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,-1,-1,-1,6727,-1,0.00022711437,0.99977285
6728,neuronal injury,3,5,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6728,-1,0.00019193614,0.99980813
6729,"2,3,5-triphenyltetrazolium",8,9,48,74,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6729,-1,0.9995059,0.00049407803
6730,ischemic,2,3,7,15,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,-1,-1,-1,6730,-1,0.00018407324,0.999816
6731,ischemic,5,6,24,32,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6731,-1,0.0001961939,0.99980384
6734,P,34,35,162,163,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6734,-1,0.5485778,0.4514222
6736,P,36,37,154,155,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,-1,6736,-1,0.20745455,0.7925455
6738,h,8,9,71,72,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6738,-1,0.10767913,0.89232093
6739,MCAO,10,11,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6739,-1,0.36533692,0.63466305
6741,ischemic,17,18,116,124,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6741,-1,0.00019654325,0.9998035
6743,ischemic,29,30,178,186,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6743,-1,0.00019563611,0.99980444
6744,neuronal dysfunction,40,42,244,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6744,-1,0.00019322128,0.9998068
6750,chronic allograft nephropathy,15,18,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,-1,6750,-1,0.00020939737,0.9997906
6752,autoimmunity,8,9,47,59,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6752,-1,0.00020473303,0.99979526
6753,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6753,-1,0.00020297767,0.99979705
6754,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6754,-1,0.00020434434,0.9997956
6756,calcineurin inhibitors,12,14,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,-1,6756,-1,0.9994746,0.00052543933
6759,acute renal dysfunction,17,20,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,-1,6759,-1,0.00020178591,0.99979824
6760,chronic renal damage,10,13,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,-1,6760,-1,0.00019054463,0.99980944
6762,calcineurin inhibitor,19,21,143,164,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,-1,-1,6762,-1,0.99948573,0.0005142981
6764,acute renal dysfunction,1,4,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6764,-1,0.00022490731,0.9997751
6766,delayed graft function,11,14,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6766,-1,0.00022631437,0.9997737
6770,enzyme inhibitors,46,48,296,313,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6770,-1,0.99947065,0.00052931724
6771,angiotensin II receptor blockers,49,53,317,349,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6771,-1,0.9994729,0.00052709086
6777,SRL,2,3,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,-1,6777,-1,0.9994092,0.00059076725
6781,SRL,18,19,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,-1,-1,6781,-1,0.05989646,0.9401036
6782,SRL,13,14,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6782,-1,0.99944645,0.00055358355
6783,chronic allograft nephropathy,20,23,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6783,-1,0.00021462073,0.99978536
6784,CAN,24,25,120,123,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6784,-1,0.0022038354,0.9977962
6785,n,27,28,126,127,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6785,-1,0.9197608,0.080239154
6786,neoplasia,31,32,134,143,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6786,-1,0.00021575185,0.9997843
6787,n,33,34,145,146,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6787,-1,0.47754917,0.52245086
6788,Kaposi's sarcoma,37,40,153,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6788,-1,0.006871215,0.9931288
6789,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6789,-1,0.00022193951,0.9997781
6790,intestinal tumors,46,48,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6790,-1,0.00020730078,0.99979275
6791,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6791,-1,0.9330535,0.06694649
6793,n,59,60,263,264,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6793,-1,0.9806091,0.019390907
6794,SRL,0,1,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,-1,6794,-1,0.0016892408,0.9983108
6795,SRL,3,4,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,-1,6795,-1,0.49573404,0.50426596
6797,P,23,24,108,109,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,-1,6797,-1,0.14042994,0.8595701
6803,membranoproliferative glomerulopathy,11,13,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,-1,-1,6803,-1,0.00019993033,0.99980015
6806,SRL,3,4,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6806,-1,0.9982363,0.0017636796
6807,P,15,16,71,72,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6807,-1,0.07316117,0.9268389
6808,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,-1,6808,-1,0.00023995967,0.9997601
6809,P,29,30,131,132,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,-1,6809,-1,0.18939951,0.8106005
6811,P,15,16,89,90,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,-1,6811,-1,0.21925877,0.7807413
6813,SRL,8,9,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,-1,-1,6813,-1,0.9993754,0.00062467775
6815,glomerular pathology,5,7,27,47,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6815,-1,0.00020582872,0.9997942
6816,SRL,8,9,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6816,-1,0.99938023,0.0006196909
6822,5-HT,26,27,157,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6822,-1,0.99946505,0.00053496915
6824,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6824,-1,0.9994861,0.0005139369
6825,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6825,-1,0.9993082,0.0006918128
6830,5-HT,3,4,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6830,-1,0.9994522,0.0005478246
6831,5-hydroxyindoleacetic acid,8,10,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6831,-1,0.9994855,0.00051447185
6832,5-HIAA,11,12,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6832,-1,0.069018535,0.9309815
6833,PCPA,0,1,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6833,-1,0.99943954,0.00056047644
6834,5-HT,5,6,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6834,-1,0.999443,0.00055696594
6835,5-HIAA,7,8,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6835,-1,0.016280575,0.9837194
6836,T,1,2,8,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6836,-1,0.99931896,0.0006810526
6837,5-HT,5,6,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6837,-1,0.9994178,0.00058228173
6838,5-HIAA,7,8,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6838,-1,0.95305854,0.04694148
6839,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6839,-1,0.9994203,0.0005797562
6840,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,-1,6840,-1,0.99942136,0.0005786714
6845,5-HT,16,17,83,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,-1,6845,-1,0.998784,0.0012159547
6847,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6847,-1,0.010970163,0.9890298
6848,mesenchymal tumors,11,13,83,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6848,-1,0.0002079055,0.99979216
6849,malignant mesenchymal tumors,7,10,39,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6849,-1,0.0002213271,0.9997787
6851,Malignant Mesenchymal Tumor,28,31,199,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6851,-1,0.0002155302,0.9997845
6855,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6855,-1,0.9995018,0.00049818057
6856,IVA,23,24,120,123,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6856,-1,0.9857032,0.014296851
6859,glucosuria,11,12,78,88,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6859,-1,0.011151252,0.9888488
6861,aminoaciduria,15,16,103,116,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6861,-1,0.0110323215,0.9889677
6864,renal abnormalities,19,21,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,-1,-1,-1,6864,-1,0.00021524535,0.99978477
6866,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6866,-1,0.007842769,0.9921572
6867,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6867,-1,0.00024977158,0.9997502
6872,TDFS,8,9,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6872,-1,0.00022270728,0.99977726
6874,mesenchymal tumors,23,25,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6874,-1,0.00020318544,0.9997968
6875,UMB24,2,3,11,16,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,-1,-1,-1,6875,-1,0.9993574,0.00064260064
6879,contrast,1,2,3,11,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,-1,-1,-1,6879,-1,0.807104,0.19289604
6880,UMB24,8,9,48,53,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6880,-1,0.99943763,0.0005623845
6881,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6881,-1,0.9976037,0.002396357
6882,UMB24,5,6,40,45,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,-1,6882,-1,0.999371,0.00062902464
6883,UMB24,10,11,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,-1,-1,6883,-1,0.9994547,0.0005453364
6885,UMB24,18,19,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,-1,6885,-1,0.99947256,0.00052749756
6886,receptor antagonists,7,9,39,59,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,-1,-1,-1,6886,-1,0.999426,0.0005739655
6892,hyperCKaemia,7,8,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,-1,-1,6892,-1,0.00019723937,0.99980277
6895,muscle pathology,3,5,20,36,We investigated the muscle pathology in 8 such cases.,17241784_3,-1,-1,-1,6895,-1,0.00018175259,0.99981827
6917,antagonists,31,32,230,241,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,-1,-1,-1,6917,-1,0.99942833,0.00057158194
6919,contrast,8,9,49,57,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6919,-1,0.014341681,0.98565835
6920,adenosine-5'-triphosphate,10,11,70,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,-1,6920,-1,0.99947995,0.0005200896
6921,receptor antagonists atropine,2,5,15,44,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6921,-1,0.9995034,0.00049656
6922,4-DAMP,8,9,84,90,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6922,-1,0.9994972,0.00050281046
6923,methoctramine,16,17,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6923,-1,0.9995166,0.00048338645
6924,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6924,-1,0.99951863,0.00048142072
6925,4-DAMP,0,1,0,6,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6925,-1,0.9994795,0.00052049494
6926,methoctramine,10,11,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6926,-1,0.99948287,0.0005170699
6927,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6927,-1,0.9994825,0.0005174957
6928,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6928,-1,0.99948573,0.0005142466
6929,4-DAMP,24,25,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6929,-1,0.99943596,0.00056405127
6930,contrast,1,2,3,11,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6930,-1,0.08422997,0.91577
6931,methoctramine,5,6,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6931,-1,0.9994972,0.00050278124
6933,ATP,5,6,36,39,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,-1,6933,-1,0.999471,0.0005290164
6937,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6937,-1,0.00020508158,0.9997949
6939,coronary heart disease,20,23,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6939,-1,0.00020585858,0.9997942
6940,heart failure,26,28,183,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6940,-1,0.00021115447,0.9997888
6947,bradycardic,2,3,10,21,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,-1,6947,-1,0.00022019508,0.99977976
6951,bradycardic,12,13,84,95,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,-1,6951,-1,0.00017949581,0.99982053
6954,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,-1,-1,6954,-1,0.0001661514,0.9998338
6958,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6958,-1,0.00019914287,0.99980086
6959,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6959,-1,0.0002000682,0.9997999
6961,restlessness,18,19,106,118,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6961,-1,0.00020908476,0.99979097
6962,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6962,-1,0.9994783,0.00052171305
6964,anxiety,27,28,166,173,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,-1,6964,-1,0.00023143471,0.99976856
6970,mg,26,27,166,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,-1,-1,6970,-1,0.999424,0.00057603605
6971,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,-1,-1,6971,-1,0.00020595537,0.99979407
6977,ARB,13,14,89,92,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,-1,-1,6977,-1,0.9994267,0.0005733163
6981,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6981,-1,0.9994748,0.0005251542
6983,granulomas,14,15,108,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,-1,-1,6983,-1,0.00019981047,0.99980026
6985,cholestatic syndrome,21,23,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,-1,6985,-1,0.00021006068,0.99979
6986,granulomas,3,4,19,29,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,-1,-1,6986,-1,0.00019551638,0.99980456
6991,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,-1,-1,-1,6991,-1,0.9994752,0.0005247934
6994,atrioventricular block,6,8,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,-1,-1,6994,-1,0.0003606454,0.9996394
6997,sinus tachycardias,4,6,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6997,-1,0.00020260894,0.9997974
6998,carbamazepine overdose,12,14,75,97,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6998,-1,0.012002374,0.98799765
6999,bradyarrhythmias,13,14,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6999,-1,0.00021186615,0.9997881
7000,atrioventricular conduction delay,15,18,126,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,7000,-1,0.00021314857,0.9997869
7003,neurologic and psychiatric,10,13,62,88,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,-1,-1,-1,7003,-1,0.00020336415,0.9997967
7008,cardiac damage,9,11,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,-1,7008,-1,0.00021688457,0.9997831
7017,mm,17,18,116,118,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7017,-1,0.058876142,0.9411239
7018,mm,23,24,139,141,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7018,-1,0.06921974,0.9307803
7019,p,28,29,164,165,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7019,-1,0.16259946,0.83740056
7021,mm,22,23,157,159,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7021,-1,0.10152022,0.89847976
7022,mm,28,29,180,182,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7022,-1,0.17664249,0.82335746
7023,p,33,34,205,206,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7023,-1,0.16589147,0.83410853
7025,iodine-125-metaiodobenzylguanidine,11,12,99,133,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,-1,-1,7025,-1,0.9994856,0.00051430444
7026,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7026,-1,0.9994715,0.0005285479
7027,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7027,-1,0.9994671,0.0005328998
7029,NE,11,12,74,76,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7029,-1,0.9994289,0.0005710772
7031,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,-1,7031,-1,0.023090804,0.9769092
7032,vacuolar degeneration of myocardial cells,3,8,14,55,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,-1,-1,-1,7032,-1,0.00017371567,0.9998264
7034,p,39,40,202,203,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,-1,-1,-1,7034,-1,0.19153818,0.80846184
7035,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7035,-1,0.9994654,0.0005345909
7036,p,27,28,127,128,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7036,-1,0.13938938,0.86061066
7037,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7037,-1,0.99946433,0.00053573743
7038,p,27,28,127,128,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7038,-1,0.1418691,0.8581309
7039,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,-1,7039,-1,0.99949,0.00051001046
7041,myocardial impairment,13,15,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7041,-1,0.00021056861,0.9997894
7042,vacuolar degeneration,19,21,130,151,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7042,-1,0.00020899603,0.99979097
7049,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,-1,7049,-1,0.00020785116,0.99979216
7051,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,-1,-1,7051,-1,0.00020850086,0.99979156
7053,n=200,8,9,58,63,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7053,-1,0.27895373,0.72104627
7054,n=200,20,21,116,121,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7054,-1,0.3436968,0.6563032
7055,n=88,14,15,69,73,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7055,-1,0.01780443,0.98219556
7056,n=76,28,29,121,125,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7056,-1,0.1999357,0.8000643
7057,n=36,41,42,165,169,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7057,-1,0.32439047,0.67560947
7058,decreases of TEOAEs amplitudes at 4000Hz,14,20,89,129,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,-1,7058,-1,0.0043377583,0.9956623
7062,QT prolongation,2,4,12,27,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7062,-1,0.0002275314,0.9997725
7064,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7064,-1,0.011614291,0.9883857
7066,heroin,6,7,39,45,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,-1,-1,7066,-1,0.9994825,0.0005174924
7067,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7067,-1,0.0003135405,0.9996865
7068,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7068,-1,0.00024183039,0.9997582
7069,TdP,15,16,80,83,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7069,-1,0.0002239425,0.99977607
7071,heroin,1,2,3,9,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7071,-1,0.9994165,0.0005835332
7073,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7073,-1,0.9877121,0.0122879855
7075,heroin,19,20,113,119,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7075,-1,0.9994967,0.0005033303
7077,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7077,-1,0.99950254,0.0004974584
7082,p,14,15,79,80,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,-1,7082,-1,0.044919502,0.95508057
7083,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,-1,7083,-1,0.9994861,0.0005138408
7085,prolonged QTc interval,15,18,69,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,-1,7085,-1,0.00020766201,0.9997924
7086,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,-1,7086,-1,0.99949765,0.00050228834
7087,mg,2,3,5,7,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,-1,7087,-1,0.99943477,0.00056521856
7091,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7091,-1,0.00021616221,0.9997838
7093,heroin,17,18,109,115,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7093,-1,0.9990883,0.0009116694
7094,compartment syndrome,3,5,34,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7094,-1,0.00021380883,0.9997862
7095,myonecrosis,6,7,59,70,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7095,-1,0.000212547,0.9997875
7100,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7100,-1,0.00020214717,0.9997979
7101,myonecrosis,15,16,118,129,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7101,-1,0.00020233923,0.99979764
7103,arteriopathic,24,25,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,-1,-1,-1,7103,-1,0.00021354562,0.99978644
7104,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7104,-1,0.00048690036,0.99951315
7105,ziprasidone,5,6,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7105,-1,0.9994467,0.00055325456
7106,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7106,-1,0.00037756722,0.99962246
7107,NMS,4,5,32,35,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7107,-1,0.3748771,0.6251229
7108,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7108,-1,0.00019367338,0.99980634
7109,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7109,-1,0.00017021144,0.99982977
7110,NMS,9,10,54,57,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7110,-1,0.0034509955,0.996549
7111,ziprasidone,16,17,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7111,-1,0.99944705,0.000552895
7112,neuroleptics,2,3,22,34,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7112,-1,0.9993598,0.00064018177
7113,NMS,8,9,71,74,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7113,-1,0.9993468,0.0006532027
7114,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7114,-1,0.99939513,0.0006048717
7115,ziprasidone,14,15,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7115,-1,0.9994326,0.00056739355
7117,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7117,-1,0.00019762132,0.9998024
7118,NMS,17,18,102,105,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7118,-1,0.00023167185,0.9997683
7119,ziprasidone,30,31,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7119,-1,0.99950147,0.0004985454
7120,NMS,11,12,52,55,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7120,-1,0.004053125,0.99594694
7121,ziprasidone,14,15,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7121,-1,0.99944144,0.00055855874
7122,Neuroinflammation,0,1,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7122,-1,0.00021829178,0.99978167
7123,behavioral abnormalities,2,4,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7123,-1,0.00021480722,0.99978524
7125,autism,13,14,110,116,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7125,-1,0.00021466472,0.99978536
7126,Autism,0,1,0,6,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7126,-1,0.00020967668,0.9997904
7127,neurodevelopmental disorder,3,5,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7127,-1,0.00020411867,0.99979585
7128,deficits in communication and social skills,12,18,78,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7128,-1,0.00021479104,0.99978524
7129,repetitive behaviors,19,21,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7129,-1,0.0002062684,0.9997937
7130,autism,19,20,120,126,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,-1,7130,-1,0.0002212427,0.9997788
7132,preterm labor,8,10,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7132,-1,0.00022023478,0.99977976
7133,autism,18,19,123,129,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7133,-1,0.00022425916,0.9997757
7136,h,27,28,114,115,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,-1,7136,-1,0.11231481,0.8876852
7140,startle,37,38,210,217,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,-1,7140,-1,0.00029567565,0.9997043
7141,behavioral abnormalities,21,23,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7141,-1,0.00021747474,0.9997825
7142,autism,29,30,237,243,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7142,-1,0.00022062866,0.9997794
7143,autism spectrum disorders,13,16,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,-1,7143,-1,0.00019591497,0.9998041
7145,C219,41,42,239,243,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,-1,-1,-1,7145,-1,0.99948907,0.00051094417
7148,tariquidar,14,15,108,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,7148,-1,0.9994874,0.00051253184
7149,injury to the brain,10,14,67,86,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,-1,7149,-1,0.00024960804,0.99975044
7151,xanthine oxidase,2,4,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,-1,7151,-1,0.9292638,0.07073623
7154,xanthine oxidase,7,9,26,42,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7154,-1,0.99939215,0.0006078381
7155,reactive oxygen species,20,23,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7155,-1,0.0013253386,0.99867475
7159,allopurinol,21,22,114,125,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7159,-1,0.99947566,0.0005243774
7160,allopurinol,26,27,143,154,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7160,-1,0.9994766,0.0005234066
7162,urate,13,14,73,78,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,-1,7162,-1,0.99939156,0.00060847076
7164,P,15,16,45,46,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7164,-1,0.36536765,0.6346323
7165,decreased thymus (P,20,24,60,79,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7165,-1,0.032852974,0.96714705
7166,0.001,25,26,82,87,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7166,-1,0.09462826,0.9053718
7167,0.001,25,26,82,87,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7167,-1,0.09462826,0.9053718
7168,and bodyweights,27,29,89,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7168,-1,0.0003004837,0.9996996
7169,P,30,31,106,107,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7169,-1,0.7685193,0.23148072
7170,Allopurinol,0,1,0,11,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7170,-1,0.99946266,0.0005373816
7171,urate,3,4,28,33,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7171,-1,0.9993789,0.0006210746
7172,P,16,17,72,73,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7172,-1,0.049813528,0.95018643
7173,P,37,38,151,152,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7173,-1,0.044675354,0.9553246
7174,Allopurinol,2,3,3,14,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,-1,7174,-1,0.99946445,0.00053556584
7175,allopurinol,8,9,47,58,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,-1,-1,7175,-1,0.9994649,0.0005351234
7183,n,10,11,38,39,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7183,-1,0.28634903,0.713651
7186,n,37,38,175,176,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7186,-1,0.26741996,0.73258
7187,"nausea, vomiting",9,12,60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,-1,-1,7187,-1,0.00038638394,0.9996137
7189,postoperative emetic symptoms,8,11,44,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,-1,7189,-1,0.0010312236,0.99896884
7193,"nausea, vomiting",24,27,162,178,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,-1,-1,7193,-1,0.00028494548,0.99971503
7195,iron dextran,1,3,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7195,-1,0.99936956,0.00063049915
7196,degeneration of dopaminergic neurons,4,8,32,68,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7196,-1,0.0002192946,0.9997807
7198,Parkinson's disease,11,14,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,-1,-1,-1,7198,-1,0.00019411375,0.99980587
7199,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7199,-1,0.0055431,0.9944569
7200,SN,17,18,119,121,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7200,-1,0.00031781892,0.9996822
7203,degeneration of dopaminergic neurons,51,55,330,366,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7203,-1,0.00020829854,0.9997917
7205,SN,61,62,401,403,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7205,-1,0.00080097123,0.9991991
7206,iron dextran,63,65,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7206,-1,0.9994522,0.00054786506
7207,iron dextran,5,7,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7207,-1,0.999416,0.0005840743
7209,SN,23,24,160,162,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7209,-1,0.00021754838,0.9997825
7211,iron dextran,5,7,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7211,-1,0.9994179,0.00058211776
7213,SN,14,15,86,88,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7213,-1,0.0002575483,0.99974245
7215,degeneration of dopaminergic neurons,21,25,122,158,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7215,-1,0.00025905645,0.9997409
7216,iron overload,2,4,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7216,-1,0.0054636076,0.9945364
7217,iron overload,14,16,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7217,-1,0.005464735,0.9945353
7229,myocardial ischemia,13,15,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,-1,7229,-1,0.00019970228,0.99980026
7230,myocardial ischemia,11,13,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,-1,-1,-1,7230,-1,0.00019957342,0.9998005
7231,myocardial ischemia,36,38,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,-1,7231,-1,0.00020696897,0.999793
7236,myocardial ischemia,34,36,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,-1,7236,-1,0.00020650613,0.99979347
7237,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,-1,7237,-1,0.00019812639,0.99980193
7242,atherosclerotic obstruction,6,8,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7242,-1,0.00020969588,0.9997904
7243,coronary occlusion,9,11,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7243,-1,0.00021011935,0.9997899
7245,thrombus,17,18,109,117,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7245,-1,0.0002104283,0.99978954
7251,delusional parasitosis,5,7,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7251,-1,0.00018258861,0.99981743
7252,chronic hepatitis C,9,12,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7252,-1,0.0002447972,0.9997552
7253,pegylated interferon alpha-2b,14,17,89,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7253,-1,0.9995004,0.000499571
7255,chronic hepatitis C,3,6,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7255,-1,0.00032973124,0.99967027
7256,interferon,8,9,54,64,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7256,-1,0.9994029,0.0005971433
7259,psychosis,6,7,33,42,A minority of patients evolve to psychosis.,17511042_3,-1,-1,-1,7259,-1,0.00021289283,0.99978715
7260,psychogenic parasitosis,10,12,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7260,-1,0.00016462943,0.9998354
7261,interferon,14,15,83,93,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7261,-1,0.99881625,0.0011837701
7262,delusional parasitosis,8,10,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7262,-1,0.00017187791,0.9998281
7263,pegylated interferon alpha-2b,13,16,92,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7263,-1,0.99949276,0.00050724146
7265,pegylated interferon alpha-2b,6,9,46,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,-1,-1,-1,7265,-1,0.9994935,0.00050650095
7268,LID,3,4,27,30,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7268,-1,0.00022909832,0.99977094
7269,Parkinson's disease,13,16,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7269,-1,0.00021174156,0.9997882
7270,PD,17,18,100,102,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7270,-1,0.00021325426,0.9997868
7271,LID,14,15,73,76,"To this day, transcriptome analysis has been performed in a rat model of LID [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking.",17532790_2,-1,-1,-1,7271,-1,0.0004280007,0.999572
7272,PD,25,26,170,172,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7272,-1,0.00021195324,0.9997881
7274,MS,42,43,294,296,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7274,-1,0.0031392945,0.99686074
7275,LID,16,17,90,93,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,-1,7275,-1,0.00028095944,0.99971896
7276,LID,6,7,26,29,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7276,-1,0.16079892,0.8392011
7277,LID,14,15,86,89,"In conclusion, this study provides new insights into the protein changes occurring in LID.",17532790_8,-1,-1,-1,7277,-1,0.0025227054,0.99747723
7279,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,-1,7279,-1,0.00019680992,0.99980325
7280,contrast medium iopamidol,13,16,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7280,-1,0.99944514,0.00055479415
7281,contrast medium iodixanol,21,24,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7281,-1,0.99945945,0.0005405319
7284,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,-1,7284,-1,0.00020580477,0.9997942
7286,contrast,4,5,17,25,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7286,-1,0.7267129,0.27328718
7287,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7287,-1,0.00023541735,0.9997646
7290,P=0.39,31,32,131,137,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7290,-1,0.6119227,0.38807738
7291,P=0.44,53,54,217,223,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7291,-1,0.23156735,0.7684326
7295,P=0.11,35,36,148,154,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7295,-1,0.9561818,0.04381822
7296,P=0.37,55,56,226,232,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7296,-1,0.13804509,0.8619549
7302,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,-1,-1,7302,-1,0.00022600041,0.99977404
7303,Hepatonecrosis,0,1,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7303,-1,0.00065108517,0.99934894
7304,cholangitis,2,3,19,30,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7304,-1,0.00017285235,0.9998272
7307,PB,2,3,15,17,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7307,-1,0.9994123,0.0005877077
7308,chronic liver disease,31,34,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7308,-1,0.00021015463,0.9997899
7310,PB,15,16,82,84,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7310,-1,0.99931943,0.00068053126
7312,bronchopneumonia,31,32,161,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7312,-1,0.00020282425,0.99979717
7314,PB,4,5,29,31,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7314,-1,0.9991467,0.00085326313
7316,lead,15,16,87,91,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7316,-1,0.002144851,0.9978551
7317,hepatic enzyme dysfunction,18,21,126,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,-1,7317,-1,0.0002156521,0.9997844
7320,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,-1,-1,7320,-1,0.00021500885,0.999785
7323,amyloid beta peptide(1-42),10,16,67,93,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7323,-1,0.51379484,0.48620516
7325,H2O2,19,20,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7325,-1,0.9994692,0.0005307979
7327,reactive oxygen species,12,15,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7327,-1,0.0006567433,0.9993432
7328,c,17,18,128,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7328,-1,0.9993511,0.00064888876
7329,caspase 3,21,23,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7329,-1,0.99381727,0.006182727
7330,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7330,-1,0.0002284583,0.99977154
7332,decline of cognitive function,35,39,230,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7332,-1,0.00023849099,0.9997615
7335,terminal damage,12,14,98,113,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,-1,7335,-1,0.005054425,0.9949456
7337,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,-1,7337,-1,0.0053707007,0.9946293
7342,"3,4-dihydroxyphenylacetic acid",9,11,99,129,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,-1,7342,-1,0.9994765,0.0005235419
7346,"3,4-dihydroxyphenylacetic acid",30,32,190,220,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,-1,-1,-1,7346,-1,0.9994696,0.0005304873
7350,"3,4-dihydroxyphenylacetic acid",15,17,125,155,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,-1,7350,-1,0.99947053,0.00052947924
7354,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,-1,7354,-1,0.0051351995,0.99486476
7368,psychosis,11,12,79,88,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7368,-1,0.00021889308,0.9997811
7371,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7371,-1,0.00022347302,0.99977654
7374,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7374,-1,0.96670604,0.03329401
7377,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7377,-1,0.96285725,0.03714277
7379,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7379,-1,0.00021225821,0.99978775
7380,human immunodeficiency virus,8,11,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7380,-1,0.0015692031,0.9984308
7381,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7381,-1,0.00020843306,0.99979156
7382,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7382,-1,0.0002066306,0.99979335
7383,hyperlipidemia,20,21,132,146,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7383,-1,0.00021165881,0.99978834
7386,mg simvastatin,5,7,26,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7386,-1,0.9994493,0.0005506866
7388,mg,22,23,109,111,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7388,-1,0.9993685,0.0006315167
7389,mg,30,31,139,141,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7389,-1,0.99931693,0.0006831227
7390,mg atazanavir,41,43,185,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7390,-1,0.9994593,0.0005406716
7391,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,-1,-1,-1,7391,-1,0.0072335037,0.9927665
7398,human immunodeficiency virus,8,11,43,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,-1,7398,-1,0.00022172547,0.99977833
7399,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,-1,7399,-1,0.9933429,0.0066570616
7405,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,-1,-1,-1,7405,-1,0.9994356,0.0005643357
7409,fluvastatin,14,15,88,99,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7409,-1,0.99950194,0.0004980505
7410,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7410,-1,0.99951375,0.00048620996
7411,atorvastatin,26,27,162,174,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7411,-1,0.99950516,0.000494793
7418,fluoroquinolone,3,4,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,-1,-1,-1,7418,-1,0.9994498,0.0005502137
7430,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7430,-1,0.0001911577,0.99980885
7432,leukaemia,26,27,203,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7432,-1,0.00019334699,0.9998067
7433,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,-1,-1,7433,-1,0.00022774714,0.99977225
7437,carmofur,24,25,160,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,-1,7437,-1,0.9994979,0.00050206884
7439,lesions within the subcortical white matter of the cerebral hemispheres and the,13,25,87,166,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,-1,7439,-1,0.0077070636,0.9922929
7440,white matter abnormalities,13,16,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,-1,-1,-1,7440,-1,0.00022643157,0.99977356
7442,oedema,9,10,56,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,-1,7442,-1,0.0002034679,0.99979657
7446,serotonin reuptake inhibitor antidepressant,6,10,37,80,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,-1,-1,-1,7446,-1,0.99942976,0.0005701939
7455,P,32,33,194,195,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7455,-1,0.9147199,0.08528016
7456,P,46,47,263,264,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7456,-1,0.9756706,0.024329348
7458,P,26,27,161,162,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,-1,7458,-1,0.26151124,0.7384888
7460,P,18,19,101,102,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7460,-1,0.22204114,0.7779588
7461,P,30,31,167,168,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7461,-1,0.35585448,0.64414555
7463,P,29,30,179,180,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,-1,7463,-1,0.64109993,0.3589001
7464,contrast,3,4,16,24,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,-1,7464,-1,0.98286784,0.017132103
7470,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,-1,7470,-1,0.005844555,0.9941554
7471,loss of vision,8,11,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7471,-1,0.00020497561,0.999795
7472,headaches,16,17,97,106,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7472,-1,0.00020400016,0.999796
7473,paraesthesia,4,5,22,34,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7473,-1,0.0002197731,0.99978024
7474,numbness,6,7,40,48,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7474,-1,0.00020704833,0.999793
7475,scotomata,6,7,56,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,-1,-1,-1,7475,-1,0.00025679063,0.99974316
7479,lead,2,3,27,31,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,-1,-1,-1,7479,-1,0.013371922,0.9866281
7481,hepatitis B virus (HBV) infected,8,15,66,98,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7481,-1,0.0002376092,0.99976236
7482,hepatitis B virus,8,11,66,83,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7482,-1,0.00021566935,0.9997843
7483,human immunodeficiency virus,25,28,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7483,-1,0.0011974999,0.99880254
7484,HBV infected,4,6,30,42,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,-1,7484,-1,0.00021235213,0.9997876
7485,HBsAg,0,1,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,-1,7485,-1,0.0007054917,0.9992945
7486,C,32,33,209,210,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,-1,7486,-1,0.9991385,0.0008615326
7487,chronic hepatitis B,10,13,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,-1,7487,-1,0.00023432096,0.9997657
7488,Rabbit syndrome,0,2,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,-1,-1,-1,7488,-1,0.002372106,0.9976279
7490,rabbit syndrome,1,3,4,19,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7490,-1,0.001136929,0.9988631
7491,neuroleptic,11,12,77,88,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7491,-1,0.835182,0.16481802
7492,imipramine,8,9,47,57,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,-1,7492,-1,0.99947137,0.0005286209
7494,decreased basal ganglia,6,9,49,72,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7494,-1,0.00021520183,0.99978477
7495,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7495,-1,0.0002034685,0.99979657
7496,rabbit syndrome,25,27,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7496,-1,0.00023198902,0.99976796
7498,cholesteryl ester,2,4,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7498,-1,0.99947387,0.0005261048
7499,HIV protease inhibitor ritonavir,10,14,79,111,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7499,-1,0.9983778,0.001622132
7500,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,-1,-1,-1,7500,-1,0.99934274,0.0006572116
7504,atherosclerotic lesion,8,10,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,-1,7504,-1,0.00018393008,0.9998161
7505,cholesteryl ester,11,13,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,-1,-1,-1,7505,-1,0.9995085,0.00049146434
7507,HIV protease inhibitor ritonavir,24,28,160,192,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,-1,-1,-1,7507,-1,0.9953407,0.0046592564
7508,h,7,8,42,43,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7508,-1,0.01800677,0.9819932
7509,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7509,-1,0.999482,0.0005180644
7513,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7513,-1,0.9994661,0.0005338811
7514,cholesteryl esters,5,7,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7514,-1,0.99946517,0.0005348422
7518,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,-1,-1,-1,7518,-1,0.9994242,0.00057581597
7519,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,-1,7519,-1,0.99938333,0.0006166818
7520,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7520,-1,0.9993942,0.0006058629
7521,cholesteryl ester,22,24,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7521,-1,0.999469,0.0005310375
7526,antimicrobial agents,4,6,23,43,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7526,-1,0.9993419,0.00065806025
7528,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7528,-1,0.0005450256,0.99945503
7529,cm,13,14,63,65,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7529,-1,0.07388604,0.92611396
7530,Emergency Department,24,26,127,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7530,-1,0.0015994316,0.9984006
7532,malaise,39,40,201,208,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7532,-1,0.6254066,0.3745934
7536,upper respiratory tract infection,11,15,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7536,-1,0.00021654343,0.99978346
7539,alkaline phosphatase,34,36,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,-1,7539,-1,0.9986444,0.0013555506
7542,toxin,1,2,3,8,"No toxin, alcohol, or other drugs were reported.",17919553_6,-1,-1,-1,7542,-1,0.9990809,0.0009190872
7544,acute hepatitis,9,11,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,-1,-1,7544,-1,0.0002069666,0.999793
7547,hepatic dysfunction,10,12,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,-1,7547,-1,0.0002004977,0.99979955
7548,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7548,-1,0.0005354063,0.9994646
7550,acute hepatitis,21,23,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7550,-1,0.00020364588,0.99979633
7551,toxic hepatitis,32,34,200,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7551,-1,0.00020795425,0.99979204
7554,acute hepatitis,8,10,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,-1,7554,-1,0.00018036872,0.9998197
7556,uveitis,5,6,38,45,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7556,-1,0.00017175241,0.9998282
7557,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7557,-1,0.9994973,0.0005026723
7558,elevated intraocular pressure,9,12,53,82,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7558,-1,0.00019891362,0.9998011
7559,uveitis,18,19,106,113,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7559,-1,0.00019426538,0.99980575
7560,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7560,-1,0.99948764,0.00051228964
7561,FA,25,26,155,157,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7561,-1,0.9994497,0.00055034354
7562,FA,28,29,166,168,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,-1,7562,-1,0.99805176,0.0019482112
7563,mm Hg,18,20,88,93,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7563,-1,0.0058336766,0.99416625
7564,mm Hg,41,43,172,177,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7564,-1,0.0058690263,0.9941309
7565,mm Hg,47,49,190,195,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7565,-1,0.0052565723,0.99474347
7566,mm Hg,54,56,212,217,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7566,-1,0.005762191,0.9942378
7567,mm Hg,14,16,93,98,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,-1,7567,-1,0.0012151627,0.99878484
7568,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7568,-1,0.0001977795,0.9998023
7569,mm Hg,9,11,32,37,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7569,-1,0.005980452,0.9940196
7570,P,36,37,158,159,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7570,-1,0.19939338,0.8006066
7571,FA,10,11,64,66,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,-1,7571,-1,0.998995,0.0010049773
7600,DCM,5,6,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7600,-1,0.00021232966,0.9997876
7602,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7602,-1,0.0002096397,0.9997904
7603,acquired immunodeficiency syndrome,14,17,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7603,-1,0.00021342552,0.99978656
7604,AIDS,18,19,134,138,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7604,-1,0.00021982443,0.99978024
7605,and skeletal myopathies,29,32,184,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7605,-1,0.0006030451,0.9993969
7607,"3'-azido-2',3'-deoxythymidine",14,15,85,114,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7607,-1,0.99948347,0.0005164467
7608,AZT,16,17,116,119,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7608,-1,0.9994808,0.00051923166
7609,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7609,-1,0.00019769972,0.9998023
7610,Tg,45,46,296,298,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7610,-1,0.00020977245,0.99979025
7611,NTg,50,51,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7611,-1,0.0039140447,0.996086
7612,ad,55,56,345,347,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7612,-1,0.9278404,0.07215958
7613,AZT,61,62,395,398,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7613,-1,0.99947995,0.00052009505
7614,NTg,0,1,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7614,-1,0.9993587,0.0006413397
7615,Tg,4,5,23,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7615,-1,0.00023533274,0.9997646
7616,contrast,1,2,3,11,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7616,-1,0.99863005,0.001369947
7617,Tg,5,6,30,32,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7617,-1,0.00025931446,0.99974066
7618,cardiac dilation,8,10,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7618,-1,0.0002158823,0.9997842
7619,depressed cardiac function,11,14,69,95,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7619,-1,0.00022057627,0.9997794
7620,caspase 3,20,22,123,132,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,-1,-1,-1,7620,-1,0.998509,0.001490962
7621,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,-1,7621,-1,0.84839326,0.15160675
7623,cardiac dilation and dysfunction,33,37,221,253,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7623,-1,0.0002286381,0.9997714
7624,etoricoxib,3,4,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7624,-1,0.9994925,0.00050740334
7626,etoricoxib,12,13,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7626,-1,0.9994912,0.00050872663
7627,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7627,-1,0.9995009,0.0004990627
7628,etoricoxib,41,42,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7628,-1,0.99949384,0.00050612935
7631,RA,50,51,372,374,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7631,-1,0.0003632076,0.99963677
7632,RA,17,18,84,86,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7632,-1,0.00021984937,0.9997801
7633,etoricoxib,22,23,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7633,-1,0.99949026,0.0005097471
7634,mg,24,25,128,130,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7634,-1,0.9994479,0.0005521241
7635,n,27,28,138,139,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7635,-1,0.57446235,0.42553768
7637,mg,34,35,165,167,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7637,-1,0.99943143,0.0005686011
7638,n,38,39,181,182,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7638,-1,0.8135711,0.18642889
7641,SD,4,5,15,17,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7641,-1,0.0028826322,0.9971174
7642,etoricoxib,28,29,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7642,-1,0.9994974,0.00050257787
7644,GI AEs,6,8,43,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7644,-1,0.00023462389,0.99976534
7645,etoricoxib,12,13,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7645,-1,0.99946076,0.00053929223
7647,p,38,39,201,202,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7647,-1,0.089708164,0.91029185
7648,etoricoxib,13,14,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7648,-1,0.9986181,0.0013819154
7651,oedema,39,40,247,253,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7651,-1,0.00020447689,0.9997955
7652,Etoricoxib,0,1,0,10,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,-1,-1,-1,7652,-1,0.99947494,0.00052511593
7654,Etoricoxib,2,3,13,23,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7654,-1,0.9994822,0.0005178564
7655,mg,4,5,27,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7655,-1,0.9994363,0.00056368526
7656,GI AEs,15,17,105,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7656,-1,0.00020777073,0.9997923
7658,mg,21,22,141,143,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7658,-1,0.9994549,0.000545056
7659,AEs,12,13,91,94,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7659,-1,0.00019072423,0.9998093
7660,etoricoxib,18,19,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7660,-1,0.9994729,0.00052712334
7662,norfloxacin,5,6,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,-1,7662,-1,0.99948055,0.00051949697
7663,fluoroquinolones,7,8,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7663,-1,0.9994855,0.00051450817
7665,norfloxacin,12,13,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7665,-1,0.9994931,0.000506848
7666,anxious behaviour,11,13,86,103,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,-1,7666,-1,0.0002174426,0.9997826
7668,norfloxacin,15,16,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,-1,7668,-1,0.9994784,0.0005216554
7677,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,-1,7677,-1,0.00020208223,0.9997979
7683,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,-1,7683,-1,0.00017827452,0.9998217
7688,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,-1,-1,7688,-1,0.9994711,0.0005288374
7693,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,-1,7693,-1,0.99942553,0.0005745411
7695,Ce,17,18,124,126,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7695,-1,0.99921155,0.0007884715
7696,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7696,-1,0.9994642,0.0005358393
7698,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7698,-1,0.9994804,0.0005195668
7699,Ce,25,26,147,149,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7699,-1,0.34954953,0.6504505
7700,ng,28,29,155,157,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7700,-1,0.9944496,0.005550354
7701,ng,36,37,173,175,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7701,-1,0.9948449,0.005155031
7702,ng,45,46,194,196,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7702,-1,0.995455,0.004544912
7703,Ce,3,4,17,19,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,-1,-1,-1,7703,-1,0.15891694,0.8410831
7705,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,-1,7705,-1,0.9995003,0.0004996819
7711,P<0.001,17,18,76,83,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,-1,7711,-1,0.043286376,0.9567137
7714,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7714,-1,0.99948645,0.0005134974
7717,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7717,-1,0.99949086,0.00050915143
7718,Ce,33,34,233,235,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7718,-1,0.99942076,0.0005792381
7719,ng,36,37,241,243,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7719,-1,0.9974427,0.0025573303
7722,SD,10,11,47,49,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,-1,7722,-1,0.003952671,0.9960473
7723,n,6,7,23,24,"Of these, nearly half (n = 78)",18020536_4,-1,-1,-1,7723,-1,0.059925996,0.94007397
7724,n,10,11,55,56,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,-1,7724,-1,0.056562155,0.9434379
7725,n,12,13,60,61,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,-1,7725,-1,0.09336534,0.9066346
7726,oxazepam,5,6,37,45,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7726,-1,0.99949205,0.0005079095
7727,temazepam,7,8,47,56,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7727,-1,0.99948895,0.00051098067
7728,zopiclone,9,10,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7728,-1,0.99950194,0.0004979987
7729,SD,6,7,22,24,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,-1,7729,-1,0.01825575,0.9817442
7730,n,13,14,64,65,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,-1,7730,-1,0.16330229,0.83669776
7733,inability to sleep,10,13,56,74,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7733,-1,0.00024176927,0.9997582
7734,tiredness,18,19,102,111,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7734,-1,0.00023422157,0.9997658
7735,depressive symptoms,31,33,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7735,-1,0.00022262851,0.9997774
7736,temazepam,6,7,41,50,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,-1,7736,-1,0.99942744,0.0005725662
7737,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,-1,-1,7737,-1,0.00059128384,0.9994087
7740,disulfiram overdose,6,8,40,59,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7740,-1,0.008754867,0.9912451
7741,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7741,-1,0.00021179245,0.9997882
7742,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7742,-1,0.00021025565,0.9997898
7744,sensory loss,15,17,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7744,-1,0.00021360141,0.99978644
7745,paresthesia,19,20,116,127,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7745,-1,0.00021151011,0.99978846
7749,giddiness,21,22,104,113,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,-1,-1,7749,-1,0.00022258033,0.9997774
7751,and sensory dysfunction,7,10,54,77,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,-1,-1,-1,7751,-1,0.00022883808,0.9997712
7754,palsy,6,7,25,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,-1,-1,7754,-1,0.00020522848,0.9997948
7759,valproate,6,7,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,-1,-1,7759,-1,0.99948466,0.0005152873
7763,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7763,-1,0.00019376609,0.9998062
7764,LEV,15,16,106,109,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7764,-1,0.9992391,0.0007609109
7765,mg,18,19,116,118,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7765,-1,0.99921703,0.000782941
7766,valproate,22,23,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7766,-1,0.99943954,0.00056046236
7767,VPA,24,25,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7767,-1,0.99819916,0.0018008986
7768,mg,28,29,151,153,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7768,-1,0.9990602,0.00093974685
7770,"impaired word fluency, psychomotor speed and working memory",3,12,34,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,-1,-1,-1,7770,-1,0.00027838055,0.9997216
7771,LEV,5,6,38,41,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,-1,-1,7771,-1,0.03480027,0.96519977
7774,anxiety,11,12,105,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,-1,-1,-1,7774,-1,0.00021743702,0.9997826
7778,anxiety,29,30,184,191,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,-1,7778,-1,0.00021507629,0.9997849
7781,NE,24,25,134,136,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7781,-1,0.99942136,0.00057860906
7782,anxiety,44,45,245,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7782,-1,0.00022024318,0.99977976
7785,anxiety,1,2,16,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,-1,7785,-1,0.00019044473,0.99980956
7788,adrenergic antagonists,4,6,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,-1,7788,-1,0.9994729,0.00052708085
7792,anxiety,15,16,127,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,-1,-1,-1,7792,-1,0.00023412735,0.99976593
7793,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,-1,7793,-1,0.999483,0.0005170298
7794,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,-1,7794,-1,0.9994893,0.0005106564
7795,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,-1,7795,-1,0.9994887,0.00051131885
7796,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7796,-1,0.99948186,0.0005182057
7797,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7797,-1,0.00021536586,0.99978465
7798,myocardial ischaemia,49,51,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7798,-1,0.00021162974,0.99978834
7802,p,10,11,64,65,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,-1,-1,7802,-1,0.079947926,0.9200521
7803,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,-1,7803,-1,0.99948883,0.00051117607
7804,Myocardial infarction,0,2,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7804,-1,0.00019220826,0.9998078
7805,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7805,-1,0.99949,0.00050992315
7806,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7806,-1,0.99948287,0.00051712216
7807,CC,5,6,32,34,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7807,-1,0.8033527,0.19664727
7808,Thromboembolism,0,1,0,15,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7808,-1,0.00019762943,0.9998024
7809,CC,15,16,114,116,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7809,-1,0.95310956,0.046890434
7811,thromboembolism,4,5,35,50,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7811,-1,0.00020527703,0.9997948
7812,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7812,-1,0.00020535005,0.99979466
7813,MI,23,24,156,158,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7813,-1,0.00020678395,0.99979323
7814,CC,12,13,72,74,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7814,-1,0.27258313,0.7274169
7815,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7815,-1,0.00021284087,0.99978715
7816,myocardial infarction,8,10,56,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,-1,-1,7816,-1,0.00020355349,0.99979645
7817,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,-1,7817,-1,0.0010697712,0.99893016
7818,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,-1,7818,-1,0.00028759782,0.9997124
7819,CC,15,16,98,100,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7819,-1,0.00053208135,0.9994679
7820,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7820,-1,0.00020213737,0.9997979
7822,CC,9,10,57,59,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,-1,-1,7822,-1,0.50611097,0.493889
7823,ribonucleic acid,4,6,42,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7823,-1,0.99947065,0.0005294066
7824,hyperprolactinemic,12,13,92,110,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7824,-1,0.00023154418,0.99976844
7825,luteinizing hormone,16,18,135,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7825,-1,0.9994764,0.00052365364
7830,dopamine antagonist sulpiride,5,8,42,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,-1,-1,7830,-1,0.9994727,0.0005273865
7842,ventricular apical ballooning syndrome,4,8,25,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7842,-1,0.00017609919,0.999824
7843,Takotsubo cardiomyopathy,10,12,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7843,-1,0.00018121567,0.99981886
7845,apical ballooning syndrome,3,6,27,53,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7845,-1,0.00020916369,0.99979085
7846,Takotsubo cardiomyopathy,13,15,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7846,-1,0.0003805676,0.99961936
7847,akinesia,17,18,92,100,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7847,-1,0.00019656462,0.9998035
7848,apical ballooning,27,29,140,157,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7848,-1,0.010562656,0.98943734
7849,apical ballooning syndrome,21,24,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,-1,-1,-1,7849,-1,0.00019775666,0.9998023
7854,ADHD,21,22,157,161,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,-1,-1,-1,7854,-1,0.0002067739,0.99979323
7855,ADHD,13,14,72,76,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7855,-1,0.00025326936,0.99974674
7857,n,20,21,114,115,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7857,-1,0.971618,0.028382005
7859,n,27,28,140,141,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7859,-1,0.9233107,0.07668937
7862,n,36,37,180,181,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7862,-1,0.99890375,0.0010962036
7863,n,44,45,201,202,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7863,-1,0.9836113,0.016388651
7869,p,27,28,152,153,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,-1,7869,-1,0.10596455,0.89403546
7873,p,19,20,97,98,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,-1,7873,-1,0.34363222,0.6563678
7874,Drowsiness,0,1,0,10,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,-1,-1,-1,7874,-1,0.00018556125,0.99981445
7878,ADHD,17,18,105,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,-1,7878,-1,0.00020545462,0.99979454
7881,drowsiness,16,17,121,131,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,-1,-1,7881,-1,0.00021987893,0.9997801
7882,Renal Fanconi syndrome,0,3,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,-1,7882,-1,0.0012991608,0.99870086
7884,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,-1,7884,-1,0.00020141108,0.9997986
7886,MMF,2,3,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,-1,-1,-1,7886,-1,0.99943954,0.0005604501
7889,hepatitis B infection,7,10,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,-1,-1,-1,7889,-1,0.00035098562,0.99964905
7890,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7890,-1,0.0012537952,0.99874616
7892,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7892,-1,0.00056903024,0.99943095
7894,aminoaciduria,19,20,134,147,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7894,-1,0.011328507,0.98867154
7899,muscle weakness,1,3,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,-1,-1,-1,7899,-1,0.0002135161,0.99978656
7900,Fanconi syndrome,0,2,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7900,-1,0.017388375,0.98261154
7902,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7902,-1,0.0002102414,0.9997898
7903,tubular dysfunction,6,8,30,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,-1,-1,7903,-1,0.00020610231,0.99979395
7908,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7908,-1,0.99948114,0.0005189046
7909,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7909,-1,0.9994772,0.0005228003
7910,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7910,-1,0.9994765,0.0005235643
7912,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7912,-1,0.99949515,0.00050478126
7913,mg,25,26,135,137,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7913,-1,0.99946827,0.00053175824
7914,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7914,-1,0.99949956,0.00050045515
7915,mg,29,30,153,155,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7915,-1,0.99940586,0.0005940992
7916,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7916,-1,0.9994905,0.00050951145
7919,FDC,5,6,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,-1,7919,-1,0.9992643,0.0007356699
7920,in,6,7,43,45,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7920,-1,0.00028671187,0.99971324
7921,ie,26,27,146,148,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7921,-1,0.0021047809,0.99789524
7922,mm Hg,36,38,197,202,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7922,-1,0.0063067395,0.99369323
7923,P,50,51,198,199,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,-1,7923,-1,0.25517234,0.7448276
7924,P,23,24,87,88,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,-1,7924,-1,0.080661654,0.9193383
7926,cough,28,29,121,126,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7926,-1,0.00023136103,0.9997687
7934,HIT,15,16,112,115,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,-1,7934,-1,0.0002128376,0.99978715
7940,HIT,5,6,21,24,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,-1,7940,-1,0.00021938347,0.9997806
7945,HIT,10,11,63,66,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,-1,7945,-1,0.00024120173,0.9997588
7948,n,12,13,70,71,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7948,-1,0.06638728,0.9336127
7950,n,33,34,170,171,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7950,-1,0.13000089,0.8699991
7957,lymphomas,11,12,93,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7957,-1,0.00022008679,0.9997799
7958,Cancer and Leukemia,19,22,128,147,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7958,-1,0.0002501238,0.99974984
7959,B.Thalidomide,23,24,154,167,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7959,-1,0.99900264,0.0009973391
7960,multiple myeloma,32,34,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7960,-1,0.0003833709,0.9996166
7961,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7961,-1,0.00022186228,0.9997781
7962,lymphoplasmacytic lymphoma,39,41,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7962,-1,0.00021592758,0.99978405
7963,tumour,10,11,53,59,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,-1,7963,-1,0.00019627695,0.9998037
7964,lymphomas,12,13,80,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7964,-1,0.00018224926,0.9998178
7966,mg,16,17,115,117,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7966,-1,0.9994085,0.00059150474
7967,mg,22,23,147,149,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7967,-1,0.9994242,0.00057584833
7968,mg,38,39,209,211,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7968,-1,0.99940324,0.00059675635
7972,dyspnea,16,17,104,111,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,-1,-1,7972,-1,0.00023172176,0.9997683
7975,lymphomas,15,16,101,110,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7975,-1,0.00018167119,0.9998184
7976,contrast,17,18,115,123,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7976,-1,0.00023313028,0.9997669
7977,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7977,-1,0.99947006,0.0005299286
7978,NMDA,3,4,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7978,-1,0.99946874,0.00053130934
7982,acute pain,22,24,146,156,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7982,-1,0.00019450967,0.9998055
7983,acute pain,1,3,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7983,-1,0.00017464405,0.9998254
7984,NMDA,7,8,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7984,-1,0.9994573,0.00054269395
7987,acute pain,20,22,124,134,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,-1,7987,-1,0.00018977479,0.9998103
7990,acute pain,8,10,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,-1,7990,-1,0.00021243864,0.9997876
7991,NMDA,5,6,30,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7991,-1,0.99945694,0.0005430246
7992,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7992,-1,0.99947864,0.00052136707
7995,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7995,-1,0.9994603,0.0005397072
7996,acute pain,15,17,102,112,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7996,-1,0.00019586885,0.9998042
7997,NMDA antagonists,7,9,68,84,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7997,-1,0.9994229,0.0005771737
8000,acute pain,24,26,174,184,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,8000,-1,0.0002005604,0.99979943
8001,mental slowing,1,3,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,-1,8001,-1,0.00023427246,0.9997657
8005,blind,6,7,30,35,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,-1,8005,-1,0.013985249,0.9860147
8006,mg,4,5,30,32,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,8006,-1,0.99886596,0.0011340263
8007,mg trihexyphenidyl,7,9,40,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,8007,-1,0.999479,0.00052105956
8009,mental slowness,14,16,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,-1,-1,-1,8009,-1,0.00022170263,0.99977833
8010,mg trihexyphenidyl,9,11,60,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,8010,-1,0.99947685,0.0005231622
8011,mental slowness,16,18,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,8011,-1,0.00022546598,0.9997745
8012,mental slowing,13,15,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,-1,8012,-1,0.00022271108,0.99977726
8015,lead,3,4,34,38,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,-1,-1,8015,-1,0.0017908632,0.9982091
8017,sirolmus,7,8,38,46,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8017,-1,0.999466,0.00053405645
8018,Srl,9,10,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8018,-1,0.9994574,0.00054262934
8021,Srl,20,21,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8021,-1,0.9994635,0.00053650414
8023,Srl,10,11,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,-1,8023,-1,0.9992637,0.00073628087
8025,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,-1,-1,-1,8025,-1,0.9994904,0.0005095449
8028,p,29,30,136,137,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,-1,8028,-1,0.17091747,0.8290825
8030,p,24,25,114,115,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,-1,8030,-1,0.13490988,0.86509013
8031,ACE inhibitor,0,2,0,13,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8031,-1,0.9994586,0.0005413721
8032,ARB,6,7,49,52,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8032,-1,0.9994566,0.0005433808
8035,increased renal function,4,7,33,57,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8035,-1,0.0002145399,0.9997855
8036,p,13,14,81,82,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8036,-1,0.10971078,0.89028925
8038,decreased renal function,25,28,153,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8038,-1,0.00020865398,0.9997913
8039,p,39,40,225,226,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8039,-1,0.126059,0.87394094
8041,Srl,12,13,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,-1,8041,-1,0.99931157,0.0006883895
8042,Srl,0,1,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,-1,-1,8042,-1,0.9994437,0.00055632053
8045,Ginsenoside Rg1,0,2,0,15,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8045,-1,0.99540603,0.004593955
8046,of learning,5,7,40,51,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8046,-1,0.00020038075,0.99979967
8048,Rg1,0,1,0,3,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8048,-1,0.99909997,0.0009000642
8049,ginsenoside,4,5,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8049,-1,0.99943835,0.0005616249
8050,spatial learning impairment,12,15,69,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8050,-1,0.00021958606,0.9997805
8051,Rg1,5,6,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,-1,-1,-1,8051,-1,0.18056452,0.81943554
8053,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8053,-1,0.9746378,0.025362272
8054,learning impairment,13,15,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8054,-1,0.00021280796,0.99978715
8057,Rg1,23,24,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,-1,8057,-1,0.0021494422,0.99785054
8059,Rg1,14,15,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,-1,8059,-1,0.023321426,0.97667855
8061,Rg1,7,8,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8061,-1,0.99563617,0.0043638716
8063,NMDA,42,43,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8063,-1,0.9994535,0.00054649415
8064,MK801,46,47,295,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8064,-1,0.99944,0.00055998977
8065,Rg1,3,4,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,-1,8065,-1,0.012541165,0.9874588
8067,NMDA,3,4,15,19,This effect is NMDA receptor dependent.,18308784_10,-1,-1,-1,8067,-1,0.9993789,0.0006210713
8069,antagonists,7,8,73,84,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,-1,-1,-1,8069,-1,0.9993562,0.0006437979
8071,antagonists,7,8,61,72,A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described.,18329269_1,-1,-1,-1,8071,-1,0.99938214,0.0006177877
8073,Parkinson's disease,41,44,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,-1,8073,-1,0.00020763231,0.9997924
8078,dopamine receptor antagonists,24,27,161,190,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,-1,-1,-1,8078,-1,0.99945563,0.00054442394
8081,increase in locomotor activity,8,12,42,72,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,-1,8081,-1,0.0002121178,0.99978787
8083,mecamylamine,12,13,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,-1,-1,-1,8083,-1,0.99947673,0.00052328984
8086,SCH 23390,9,11,74,83,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8086,-1,0.99842936,0.0015705625
8087,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8087,-1,0.99949837,0.0005015864
8088,fluphenazine,21,22,149,161,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8088,-1,0.9995043,0.00049563154
8089,PHNO,5,6,33,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8089,-1,0.9994824,0.0005175279
8091,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8091,-1,0.9991955,0.0008045305
8096,vein occlusion,2,4,16,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,-1,8096,-1,0.00023561249,0.9997644
8097,vein occlusion,9,11,47,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8097,-1,0.0002169911,0.999783
8098,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8098,-1,0.9994917,0.0005082575
8099,CC,16,17,98,100,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8099,-1,0.0008211104,0.9991788
8100,infertility,8,9,50,61,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8100,-1,0.00021113473,0.9997888
8101,blurred vision,11,13,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8101,-1,0.00020862633,0.99979144
8102,CC,5,6,46,48,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,-1,8102,-1,0.9484082,0.051591754
8103,retinal vein occlusion,5,8,33,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8103,-1,0.00017692456,0.99982315
8104,CC,12,13,87,89,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8104,-1,0.9050586,0.094941385
8105,retinal vein occlusion,8,11,57,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8105,-1,0.00019688875,0.9998031
8106,CC,15,16,103,105,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8106,-1,0.0217965,0.97820354
8108,CC,10,11,66,68,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8108,-1,0.88798314,0.1120169
8109,visual disturbance,21,23,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8109,-1,0.00020684153,0.99979323
8110,CC,24,25,162,164,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8110,-1,0.98514634,0.01485362
8111,retinal vein occlusion,10,13,58,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8111,-1,0.00019426204,0.99980575
8112,CC,16,17,102,104,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8112,-1,0.90380216,0.09619788
8113,infertility,6,7,39,50,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8113,-1,0.0002236977,0.9997763
8114,CC,9,10,65,67,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8114,-1,0.40879658,0.59120345
8115,ipratropium bromide,4,6,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8115,-1,0.9994986,0.0005013761
8117,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8117,-1,0.00021508923,0.9997849
8118,ipratropium bromide,8,10,47,66,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8118,-1,0.9995146,0.0004854267
8120,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8120,-1,0.00019433042,0.99980575
8121,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,-1,8121,-1,0.9994659,0.0005340915
8123,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,-1,8123,-1,0.9994653,0.000534754
8125,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,-1,-1,-1,8125,-1,0.99947995,0.00052010076
8128,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8128,-1,0.9995036,0.00049637153
8130,airflow obstruction,17,19,116,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8130,-1,0.00021255451,0.9997875
8131,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,-1,8131,-1,0.005502538,0.9944975
8134,febrile neutropenia,13,15,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,-1,-1,8134,-1,0.00023477964,0.9997652
8143,P,22,23,129,130,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,-1,8143,-1,0.11070995,0.88929003
8144,P,19,20,114,115,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,-1,8144,-1,0.07953122,0.92046875
8146,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8146,-1,0.99949074,0.0005091914
8147,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8147,-1,0.99949515,0.0005048826
8148,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,-1,8148,-1,0.9994879,0.0005120573
8149,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,-1,-1,-1,8149,-1,0.9994892,0.0005107808
8150,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,-1,-1,-1,8150,-1,0.99947256,0.00052750757
8151,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,-1,-1,-1,8151,-1,0.9994868,0.00051322364
8152,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,-1,-1,-1,8152,-1,0.9994742,0.00052580785
8153,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8153,-1,0.99948335,0.00051661907
8154,P,30,31,177,178,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8154,-1,0.23911467,0.7608853
8156,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8156,-1,0.9994814,0.0005186291
8157,P,60,61,349,350,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8157,-1,0.207382,0.79261804
8158,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,-1,8158,-1,0.99949074,0.00050928444
8161,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,-1,8161,-1,0.9994905,0.0005094767
8162,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8162,-1,0.999479,0.00052107946
8163,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,-1,-1,-1,8163,-1,0.9994885,0.00051145477
8167,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8167,-1,0.00062495435,0.99937505
8168,ADRs,10,11,70,74,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8168,-1,0.01267506,0.98732495
8169,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8169,-1,0.0005322942,0.9994677
8170,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8170,-1,0.00018900512,0.999811
8171,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,-1,8171,-1,0.06240979,0.9375902
8174,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,-1,8174,-1,0.99943036,0.0005695565
8177,hepatic failure,7,9,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,-1,-1,-1,8177,-1,0.00019780059,0.9998022
8178,skin rash,4,6,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,-1,-1,8178,-1,0.0001932961,0.9998067
8188,METH,2,3,17,21,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8188,-1,0.9994282,0.00057175313
8190,DA,7,8,41,43,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8190,-1,0.99942434,0.00057565566
8191,neurodegeneration,22,23,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8191,-1,0.00020735255,0.99979264
8192,DA,24,25,151,153,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8192,-1,0.9972458,0.002754186
8193,CNS damage,2,4,12,22,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8193,-1,0.00020165877,0.99979836
8194,METH,6,7,33,37,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8194,-1,0.99947315,0.0005269136
8195,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8195,-1,0.9994868,0.0005131688
8196,DA,14,15,75,77,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8196,-1,0.9994579,0.00054215215
8199,METH,25,26,141,145,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,-1,8199,-1,0.9993749,0.0006251289
8201,METH,0,1,0,4,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8201,-1,0.99941146,0.0005885275
8202,DA,2,3,14,16,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8202,-1,0.99940753,0.0005925131
8203,METH,3,4,15,19,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,-1,8203,-1,0.9994136,0.0005863869
8204,METH,9,10,83,87,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,-1,8204,-1,0.999121,0.0008789632
8205,METH,22,23,152,156,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,-1,-1,-1,8205,-1,0.9993729,0.00062715076
8206,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,-1,8206,-1,0.00487499,0.995125
8207,METH,9,10,68,72,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,-1,8207,-1,0.99938047,0.00061952916
8208,nystagmus,1,2,17,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,-1,8208,-1,0.00021412749,0.99978584
8209,nystagmus,4,5,39,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8209,-1,0.00020074658,0.9997993
8210,NIN,6,7,50,53,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8210,-1,0.060846847,0.93915313
8211,NIN,14,15,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,-1,-1,-1,8211,-1,0.2420274,0.7579726
8213,NIN,0,1,0,3,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8213,-1,0.9994049,0.0005951075
8215,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8215,-1,0.99949634,0.0005036485
8222,GABA,29,30,182,186,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8222,-1,0.9994342,0.00056578126
8223,N-(2-propylpentanoyl)urea,32,33,191,216,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8223,-1,0.99944943,0.00055052136
8224,VPU,34,35,218,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8224,-1,0.9993943,0.0006057336
8225,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8225,-1,0.9994579,0.0005420819
8226,VPA,46,47,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8226,-1,0.9993844,0.00061558216
8227,VPU,0,1,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8227,-1,0.99946755,0.00053245865
8228,VPA,5,6,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8228,-1,0.99945575,0.0005442231
8230,VPA,30,31,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8230,-1,0.9994553,0.0005447634
8235,GABA,31,32,230,234,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,-1,8235,-1,0.9994222,0.0005778386
8236,VPU,3,4,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8236,-1,0.99877304,0.0012268983
8237,VPA,11,12,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8237,-1,0.0003307223,0.9996693
8240,GABA,14,15,85,89,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,-1,8240,-1,0.9993747,0.0006253294
8244,VPU,5,6,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8244,-1,0.07480982,0.9251902
8245,VPA,7,8,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8245,-1,0.9994523,0.0005476779
8250,VPA,3,4,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8250,-1,0.99944705,0.0005529496
8251,VPU,8,9,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8251,-1,0.99944407,0.0005559622
8255,atrioventricular block,1,3,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,-1,8255,-1,0.00037761344,0.99962234
8257,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,-1,-1,8257,-1,0.0001890556,0.999811
8259,atrioventricular (AV) block,6,11,30,57,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8259,-1,0.00038347946,0.9996165
8260,syncopal attacks,12,14,63,79,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8260,-1,0.00020549617,0.99979454
8263,syncopal attacks,12,14,79,95,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,-1,8263,-1,0.0002072822,0.99979275
8266,gastric hemorrhagic ulcers,5,8,34,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,-1,-1,8266,-1,0.00020653666,0.99979347
8268,gastric hemorrhage,5,7,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,-1,-1,8268,-1,0.00019547313,0.99980456
8271,lipid peroxide,20,22,106,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8271,-1,0.9994573,0.00054274366
8272,LPO,23,24,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8272,-1,0.9452288,0.054771215
8273,gastric hemorrhage,32,34,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8273,-1,0.00022006728,0.99978
8276,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8276,-1,0.99946743,0.0005325876
8280,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8280,-1,0.999453,0.0005470101
8281,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8281,-1,0.99946207,0.0005379025
8284,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,-1,-1,-1,8284,-1,0.99941695,0.00058308506
8285,h,10,11,57,58,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,-1,8285,-1,0.061970253,0.93802977
8286,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,-1,8286,-1,0.9374875,0.06251255
8293,gastric ulcers,1,3,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8293,-1,0.00022830893,0.99977165
8295,LPO,17,18,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8295,-1,0.00033913137,0.99966085
8297,gastric hemorrhage,8,10,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,-1,-1,8297,-1,0.00020490412,0.99979514
8300,hemorrhagic ulcer,1,3,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,-1,-1,8300,-1,0.0002196386,0.99978036
8303,gastric hemorrhagic ulcer,3,6,30,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8303,-1,0.0002121609,0.99978787
8304,LPO,13,14,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8304,-1,0.909271,0.090728976
8308,hepatitis B,5,7,33,44,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8308,-1,0.7196874,0.2803126
8309,HBSAG,14,15,96,101,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8309,-1,0.00023236779,0.9997676
8311,Hepatitis B virus (HBV),0,6,0,23,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8311,-1,0.0009422326,0.9990578
8312,chronic liver disease,13,16,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8312,-1,0.00020099652,0.9997991
8314,hepatic complication,11,13,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,-1,8314,-1,0.00020947524,0.9997905
8316,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8316,-1,0.00019179708,0.99980825
8317,HBV infection,14,16,90,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8317,-1,0.00018943599,0.99981064
8318,antiviral agent lamivudine,18,21,117,143,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8318,-1,0.9994242,0.0005758006
8321,lamivudin,2,3,17,26,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,-1,-1,-1,8321,-1,0.9994671,0.00053297123
8324,n=,5,6,22,24,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,-1,8324,-1,0.31611356,0.68388647
8329,p,21,22,109,110,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,-1,-1,8329,-1,0.13378379,0.8662162
8332,p,28,29,176,177,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,-1,8332,-1,0.0678278,0.9321722
8335,nucleoside,9,10,61,71,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8335,-1,0.99939966,0.00060031604
8336,nucleotide,11,12,75,85,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8336,-1,0.9993868,0.00061322347
8343,h,42,43,223,224,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,-1,8343,-1,0.1408784,0.8591216
8344,CYP,9,10,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8344,-1,0.9992446,0.0007554229
8345,h,13,14,71,72,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8345,-1,0.3439233,0.6560767
8346,CYP,20,21,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8346,-1,0.9992811,0.0007188754
8347,h,24,25,117,118,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8347,-1,0.5100708,0.4899292
8348,CYP,37,38,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8348,-1,0.9993144,0.0006856188
8349,h,41,42,187,188,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8349,-1,0.6158339,0.3841661
8350,CYP,47,48,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8350,-1,0.9992987,0.00070130476
8351,h,51,52,229,230,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8351,-1,0.6870295,0.3129705
8352,p,19,20,95,96,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,-1,-1,-1,8352,-1,0.036907483,0.9630925
8353,CYP,0,1,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8353,-1,0.99944574,0.00055426406
8354,p,4,5,29,30,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8354,-1,0.16805376,0.83194625
8355,CYP,34,35,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8355,-1,0.9994429,0.000557095
8356,p,39,40,206,207,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8356,-1,0.0822244,0.91777563
8357,bladder inflammation,9,11,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8357,-1,0.00017551145,0.99982446
8358,CYP,22,23,134,137,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8358,-1,0.99935395,0.0006460955
8359,bladder dysfunction,8,10,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8359,-1,0.00021788984,0.99978215
8360,bladder inflammation,15,17,92,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8360,-1,0.00021738435,0.9997826
8361,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,-1,8361,-1,0.99948347,0.00051648123
8367,hypokalemia,11,12,80,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,-1,8367,-1,0.00020239849,0.99979764
8370,mg,4,5,21,23,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8370,-1,0.9812676,0.018732445
8372,mg,30,31,136,138,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8372,-1,0.9721367,0.027863398
8375,mg,18,19,97,99,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,-1,-1,-1,8375,-1,0.9030567,0.09694336
8384,P,31,32,142,143,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8384,-1,0.23299244,0.7670075
8385,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,-1,8385,-1,0.00017605956,0.999824
8387,TAC,0,1,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,-1,8387,-1,0.99918884,0.00081118086
8390,headaches,6,7,39,48,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8390,-1,0.00022728313,0.9997727
8392,neurological deficits,11,13,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8392,-1,0.00021001762,0.99979
8393,myelitis,17,18,113,121,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8393,-1,0.00021192052,0.9997881
8394,brachial plexitis,20,22,132,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8394,-1,0.00020844955,0.99979156
8395,TAC,6,7,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,-1,-1,-1,8395,-1,0.9806253,0.019374752
8397,TAC,8,9,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,-1,-1,-1,8397,-1,0.9959577,0.0040422566
8406,blood loss,10,12,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,-1,8406,-1,0.00022368811,0.9997763
8409,in,10,11,67,69,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,-1,-1,8409,-1,0.0002685714,0.99973136
8412,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,-1,8412,-1,0.013995011,0.986005
8413,coagulation factors,11,13,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8413,-1,0.002296644,0.9977034
8415,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8415,-1,0.00021311297,0.9997869
8416,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,-1,8416,-1,0.99946636,0.0005335956
8417,hematological abnormalities,7,9,77,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,-1,8417,-1,0.00021297424,0.99978703
8419,hyperlipidemia,5,6,56,70,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,-1,-1,8419,-1,0.00021904905,0.99978095
8421,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,-1,-1,8421,-1,0.00019894911,0.9998011
8422,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,-1,-1,8422,-1,0.00019036523,0.9998097
8429,postoperative nausea and vomiting,15,19,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,-1,-1,-1,8429,-1,0.00033281904,0.99966717
8431,analgesia,17,18,97,106,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,-1,-1,-1,8431,-1,0.0002677936,0.9997322
8432,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8432,-1,0.00021819753,0.9997818
8434,h,21,22,131,132,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8434,-1,0.059787937,0.9402121
8440,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8440,-1,0.0002053287,0.99979466
8444,P,49,50,278,279,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8444,-1,0.035785276,0.9642147
8445,P,14,15,61,62,Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012).,18544179_6,-1,-1,-1,8445,-1,0.16760446,0.8323956
8447,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,-1,-1,8447,-1,0.0004967405,0.99950325
8449,postoperative nausea and vomiting,16,20,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8449,-1,0.00080701825,0.999193
8451,P,38,39,209,210,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8451,-1,0.9819692,0.01803086
8453,P,65,66,311,312,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8453,-1,0.9826722,0.01732772
8461,postoperative nausea and vomiting,5,9,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8461,-1,0.003232855,0.99676716
8462,postoperative pain,13,15,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8462,-1,0.0011252397,0.9988747
8465,Parkinson's disease,6,9,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,-1,8465,-1,0.0005206902,0.99947935
8467,Valvular heart abnormalities,0,3,0,28,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8467,-1,0.0002015146,0.9997985
8468,Parkinson's disease,9,12,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8468,-1,0.00032527518,0.9996748
8469,PD,13,14,86,88,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8469,-1,0.00020032532,0.99979967
8471,valvular heart abnormality,9,12,54,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,-1,8471,-1,0.00019678328,0.99980325
8472,PD,3,4,13,15,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,-1,8472,-1,0.00022318045,0.9997768
8474,PD,1,2,7,9,Thirty PD patients participated in the study.,18560792_6,-1,-1,-1,8474,-1,0.00022754855,0.9997725
8476,n=10,16,17,97,101,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,-1,8476,-1,0.12792118,0.8720788
8477,aortic regurgitation,6,8,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8477,-1,0.0002091258,0.99979085
8479,PD,41,42,153,155,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8479,-1,0.0002156626,0.9997844
8480,NS,46,47,177,179,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8480,-1,0.116699144,0.8833009
8481,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8481,-1,0.024734817,0.9752652
8482,n=2.8+/-1.09,15,16,81,93,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8482,-1,0.049219415,0.95078063
8483,p=0.008,20,21,108,115,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8483,-1,0.28851762,0.7114824
8486,valvular regurgitation,4,6,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8486,-1,0.00020431376,0.99979573
8488,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8488,-1,0.00020457109,0.9997955
8491,p=0.01,18,19,113,119,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8491,-1,0.26466897,0.73533106
8492,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8492,-1,0.00021112147,0.99978894
8493,valve regurgitation,8,10,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8493,-1,0.0001678874,0.99983203
8494,PD,11,12,77,79,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8494,-1,0.00017361598,0.9998264
8496,dopamine agonists,31,33,209,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8496,-1,0.99947697,0.00052301463
8498,Unfractionated heparin sodium,2,5,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8498,-1,0.99853873,0.0014612629
8499,UFH,6,7,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8499,-1,0.9994172,0.00058286334
8501,LMWH,13,14,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8501,-1,0.99941444,0.0005855818
8504,HIT,3,4,34,37,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,-1,8504,-1,0.0002133295,0.9997867
8506,HIT,3,4,19,22,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8506,-1,0.00024216979,0.9997578
8507,HIT,13,14,100,103,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8507,-1,0.00026419555,0.9997358
8508,LMWH,2,3,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8508,-1,0.9993419,0.00065807626
8509,UFH,17,18,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8509,-1,0.018420678,0.9815793
8510,UFH,3,4,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,-1,8510,-1,0.9987173,0.0012826798
8511,HIT,0,1,0,3,HIT antibody levels were measured the day before surgery and on POD 7 and 14.,18589141_7,-1,-1,-1,8511,-1,0.0004671401,0.99953294
8512,hepatic artery thrombosis,3,6,23,48,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8512,-1,0.00021169655,0.99978834
8513,HIT,17,18,100,103,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8513,-1,0.00024784007,0.9997521
8515,HIT,3,4,18,21,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,-1,8515,-1,0.00023323635,0.99976677
8516,HIT,6,7,52,55,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,-1,8516,-1,0.00026009814,0.99973994
8517,HIT,9,10,46,49,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,-1,-1,-1,8517,-1,0.0002155298,0.9997845
8519,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,-1,8519,-1,0.0001911484,0.99980885
8520,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,-1,-1,8520,-1,0.00020675555,0.99979323
8522,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8522,-1,0.00020145929,0.9997986
8524,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8524,-1,0.00019907036,0.999801
8526,3MA,4,5,26,29,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8526,-1,0.9994935,0.00050644326
8527,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8527,-1,0.00020970665,0.99979025
8529,3MA,20,21,140,143,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,-1,8529,-1,0.9994886,0.00051141856
8530,3MA,2,3,9,12,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8530,-1,0.9994568,0.0005431245
8531,mitochondrial injury,9,11,65,85,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8531,-1,0.00022571377,0.9997743
8533,3MA,11,12,74,77,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,-1,8533,-1,0.9995184,0.00048162357
8535,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,-1,-1,8535,-1,0.00017416263,0.9998259
8537,Mitochondrial injury,0,2,0,20,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8537,-1,0.00021948578,0.9997805
8538,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8538,-1,0.00021723784,0.99978274
8542,anthracycline doxorubicin,4,6,20,45,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8542,-1,0.9994542,0.00054580753
8543,DOX,7,8,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8543,-1,0.9994438,0.00055616786
8545,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8545,-1,0.00021839152,0.99978167
8548,DOX,0,1,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,-1,8548,-1,0.9992742,0.00072577473
8550,cardiac apoptosis,23,25,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,-1,8550,-1,0.0002435675,0.9997564
8551,DOX,1,2,3,6,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8551,-1,0.9994128,0.0005872799
8553,DOX,12,13,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8553,-1,0.9994018,0.00059822446
8554,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,-1,8554,-1,0.003984518,0.9960155
8555,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,-1,8555,-1,0.0012662382,0.9987338
8557,protein excretion,2,4,16,33,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8557,-1,0.0056876056,0.9943124
8558,calcineurin inhibitors,10,12,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8558,-1,0.99949205,0.0005079737
8561,chronic allograft nephropathy,30,33,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8561,-1,0.00047777122,0.9995222
8565,calcineurin inhibitors,11,13,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,-1,8565,-1,0.99951255,0.00048743738
8569,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,-1,-1,8569,-1,0.00020631817,0.9997937
8571,epileptiform activity,6,8,57,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,-1,8571,-1,0.00016977492,0.99983025
8574,epileptiform activity,14,16,92,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,-1,8574,-1,0.00018800185,0.99981207
8575,urethane,8,9,45,53,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,-1,8575,-1,0.99948955,0.00051041506
8578,epileptiform activity,8,10,57,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,-1,8578,-1,0.00021464773,0.99978536
8579,epileptiform activity,20,22,111,132,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8579,-1,0.00021492524,0.9997851
8580,epileptiform activity,43,45,269,290,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8580,-1,0.00021368779,0.9997863
8581,epilepsies,39,40,246,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,-1,8581,-1,0.00022268968,0.9997774
8585,psychoses,7,8,46,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8585,-1,0.03900496,0.960995
8586,anxiety neurosis,9,11,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8586,-1,0.00019840353,0.9998016
8588,neuropsychiatric,27,28,157,173,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,-1,8588,-1,0.00022161726,0.99977845
8590,malaria,5,6,35,42,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,-1,-1,-1,8590,-1,0.00021528805,0.99978477
8592,fat,1,2,5,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8592,-1,0.9994259,0.000574168
8593,obese,3,4,18,23,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8593,-1,0.00021440638,0.9997856
8599,triglycerides,10,11,79,92,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8599,-1,0.9992938,0.0007061421
8600,ATP,17,18,137,140,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8600,-1,0.9993268,0.00067325466
8601,fat,16,17,95,98,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8601,-1,0.9993968,0.0006032199
8602,obesity,24,25,125,132,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8602,-1,0.0002082114,0.9997918
8604,mg,6,7,17,19,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8604,-1,0.9994281,0.00057184196
8607,obese,37,38,186,191,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8607,-1,0.00022876021,0.9997713
8608,OB,39,40,193,195,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8608,-1,0.99941623,0.00058372616
8609,hepatic toxicity,50,52,245,261,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8609,-1,0.00021497154,0.999785
8612,doxorubicinol,11,12,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8612,-1,0.9994185,0.0005815019
8613,ND,21,22,146,148,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8613,-1,0.41782606,0.58217394
8614,OB,24,25,154,156,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8614,-1,0.9864737,0.013526391
8615,OB,4,5,34,36,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8615,-1,0.9994332,0.0005667252
8616,peroxisome proliferators,33,35,180,204,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8616,-1,0.99933213,0.0006678406
8617,ND,58,59,349,351,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8617,-1,0.0007663881,0.9992336
8618,OB,64,65,392,394,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8618,-1,0.9994368,0.0005632441
8619,ATP,85,86,480,483,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8619,-1,0.9994253,0.0005747632
8621,obese,4,5,27,32,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8621,-1,0.00020934668,0.9997907
8623,ATP,17,18,152,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8623,-1,0.99923563,0.0007644271
8626,PD,7,8,44,46,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,-1,8626,-1,0.0002868489,0.9997131
8630,PD,11,12,93,95,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,-1,8630,-1,0.00023483964,0.9997652
8631,PD,3,4,13,15,"In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex.",18703024_6,-1,-1,-1,8631,-1,0.00025464658,0.9997453
8632,PD,0,1,0,2,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,-1,-1,-1,8632,-1,0.00030525582,0.9996948
8634,PD,12,13,83,85,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,-1,-1,-1,8634,-1,0.00023304719,0.999767
8635,nutritional deficiency,13,15,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,-1,-1,8635,-1,0.002321068,0.99767894
8638,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,-1,-1,8638,-1,0.99949276,0.00050725765
8640,cranial nerve dysfunction,1,4,10,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,-1,-1,-1,8640,-1,0.00017903461,0.999821
8642,adverse effect on the auditory nerve,11,17,84,120,This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve.,18726058_3,-1,-1,-1,8642,-1,0.00028173038,0.99971825
8654,adverse effect on the proximal eighth nerve,14,21,98,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,-1,-1,8654,-1,0.00026659452,0.9997334
8655,cranial nerve deficits,4,7,35,57,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,-1,-1,8655,-1,0.00021043132,0.99978954
8657,hepatic failure,1,3,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,-1,-1,-1,8657,-1,0.00021883132,0.9997812
8658,coenzyme A,12,14,109,119,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,-1,-1,-1,8658,-1,0.9994795,0.00052061264
8661,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,-1,-1,8661,-1,0.9994947,0.0005053576
8665,mg-ezetimibe,25,26,188,200,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,-1,-1,-1,8665,-1,0.99946326,0.0005367287
8668,Simvastatinezetimibe,0,1,0,20,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8668,-1,0.9994998,0.0005002486
8669,escitalopram,2,3,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8669,-1,0.99950814,0.0004918616
8672,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,-1,-1,8672,-1,0.0054890923,0.9945109
8673,Ezetimibe,0,1,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8673,-1,0.99950933,0.00049069745
8674,uridine diphosphate,5,7,49,68,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8674,-1,0.99949515,0.00050481065
8675,simvastatin hydroxy acid,23,26,173,197,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8675,-1,0.9995079,0.00049213873
8678,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,-1,-1,8678,-1,0.00020676779,0.99979323
8681,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,-1,-1,8681,-1,0.9995196,0.00048040572
8684,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8684,-1,0.00021757178,0.9997824
8685,bisphosphonate,8,9,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8685,-1,0.9994843,0.00051564665
8686,alendronate,10,11,71,82,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8686,-1,0.9994917,0.0005082391
8687,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8687,-1,0.00021428088,0.9997857
8688,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8688,-1,0.00019923897,0.99980074
8689,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8689,-1,0.00020060345,0.99979943
8691,bisphosphonate,18,19,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8691,-1,0.9994655,0.0005344442
8692,alendronate sodium,20,22,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8692,-1,0.999476,0.00052400335
8693,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8693,-1,0.0001839315,0.9998161
8694,alendronate,4,5,29,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,-1,8694,-1,0.9994716,0.00052838976
8696,bisphosphonates,11,12,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8696,-1,0.9994261,0.00057389826
8698,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8698,-1,0.00021562228,0.9997844
8699,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,-1,8699,-1,0.00020464677,0.9997954
8702,volume retention,8,10,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,-1,-1,8702,-1,0.0025996594,0.9974004
8706,volume retention,13,15,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8706,-1,0.0015091224,0.9984908
8708,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8708,-1,0.00019644809,0.9998036
8712,mg,9,10,58,60,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8712,-1,0.9993279,0.0006721789
8713,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8713,-1,0.00022249545,0.9997775
8715,lipidemia,32,33,179,188,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8715,-1,0.005805961,0.9941941
8716,hypoalbuminemia,35,36,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8716,-1,0.00022393119,0.99977607
8720,body weight gain,39,42,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,-1,8720,-1,0.00025955093,0.9997404
8721,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8721,-1,0.00018218167,0.9998178
8723,uremia,24,25,150,156,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8723,-1,0.00017936714,0.99982065
8724,volume retention,9,11,62,78,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8724,-1,0.0017227975,0.9982772
8726,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8726,-1,0.00021179447,0.9997882
8728,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,-1,8728,-1,0.00019723861,0.99980277
8731,abdominal pain,7,9,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8731,-1,0.00020408715,0.999796
8734,urinary tract infection,21,24,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8734,-1,0.00020320366,0.9997968
8736,haemolysis,10,11,83,93,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,-1,-1,8736,-1,0.0002006109,0.99979943
8737,petechiae,4,5,36,45,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8737,-1,0.00022587828,0.99977416
8738,purpura,6,7,50,57,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8738,-1,0.99940586,0.0005941392
8739,haemorrhages,9,10,64,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,-1,-1,-1,8739,-1,0.00019656238,0.9998035
8740,bone marrow depression,3,6,12,34,No signs of bone marrow depression were found.,18791946_7,-1,-1,-1,8740,-1,0.00020553182,0.99979454
8742,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,-1,-1,8742,-1,0.00020510817,0.9997949
8745,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,-1,8745,-1,0.00018842626,0.9998116
8751,myocardial hyperactivity,21,23,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8751,-1,0.00019727662,0.99980277
8756,ischaemic injury,5,7,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,-1,-1,-1,8756,-1,0.00019138605,0.9998086
8758,mitochondrial damage,3,5,27,47,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,-1,-1,8758,-1,0.00022339443,0.99977666
8762,mitochondrial damage,14,16,110,130,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8762,-1,0.00020789876,0.99979216
8763,neurodegenerative,22,23,162,179,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8763,-1,0.00020540136,0.99979466
8767,axonal damage,11,13,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8767,-1,0.00020538097,0.99979466
8770,mitochondrial impairment,10,12,71,95,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8770,-1,0.00021122294,0.9997888
8772,mitochondrial toxicity,16,18,127,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,-1,-1,8772,-1,0.00021297098,0.99978703
8777,peripheral nerve toxicity,12,15,82,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,-1,8777,-1,0.00023457647,0.99976546
8780,5-(l-hexyloxy)-6-methoxy-4-methylquinoline,10,11,110,152,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8780,-1,0.9994802,0.0005198063
8783,8-aminoquinoline WR242511,5,7,26,51,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,-1,8783,-1,0.99943596,0.0005639674
8784,WR242511,6,7,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8784,-1,0.9994456,0.0005543306
8785,WR242511,34,35,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8785,-1,0.9994454,0.0005546326
8786,WR242511,6,7,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8786,-1,0.99942446,0.00057551195
8787,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8787,-1,0.0072384975,0.99276143
8788,hemoglobinuria,3,4,23,37,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8788,-1,0.00022729699,0.9997727
8789,WR242511,11,12,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8789,-1,0.96551514,0.034484893
8790,Myoglobinuria,0,1,0,13,Myoglobinuria was also observed following the 7.0 mg/kg dose.,18821488_7,-1,-1,-1,8790,-1,0.00039937202,0.9996006
8793,WR242511,4,5,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8793,-1,0.9891043,0.010895722
8796,liver tumors,6,8,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,-1,8796,-1,0.00019822297,0.9998018
8798,liver tumors,8,10,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8798,-1,0.00017717539,0.9998228
8799,oral contraceptive steroids,17,20,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8799,-1,0.9994492,0.0005507465
8800,Liver Tumors,3,5,17,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,-1,8800,-1,0.00020417511,0.99979585
8802,focal nodular hyperplasia,11,14,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8802,-1,0.00019234778,0.99980766
8803,adenoma,15,16,92,99,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8803,-1,0.0001947214,0.9998053
8804,hamartoma,17,18,101,110,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8804,-1,0.00019569373,0.9998043
8805,hepatoma,20,21,116,124,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8805,-1,0.00019472398,0.9998053
8806,oral contraceptive steroids,9,12,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,-1,8806,-1,0.99943167,0.0005683037
8808,liver rupture,3,5,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,-1,-1,8808,-1,0.00020999718,0.99979
8810,Parkinson's disease,8,11,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,-1,-1,8810,-1,0.00022886798,0.9997712
8812,Parkinson's disease,39,42,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8812,-1,0.00024275882,0.99975723
8813,PD,43,44,235,237,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8813,-1,0.0002161006,0.99978393
8814,PD,3,4,18,20,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,-1,8814,-1,0.00023184244,0.9997682
8820,PD,14,15,77,79,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,-1,8820,-1,0.00023027716,0.99976975
8822,PD,20,21,153,155,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,-1,8822,-1,0.0002390273,0.9997609
8841,priapism,8,9,63,71,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8841,-1,0.00021431009,0.9997857
8842,emergency department,11,13,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8842,-1,0.0015147966,0.99848527
8843,Priapism,0,1,0,8,Priapism is the prolonged erection of the penis in the absence of sexual arousal.,18996674_1,-1,-1,-1,8843,-1,0.009808594,0.99019134
8845,Emergency Department,13,15,71,91,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8845,-1,0.0004408867,0.9995591
8846,priapism,26,27,141,149,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8846,-1,0.0002452792,0.9997547
8855,ventricular ectopy,26,28,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,-1,8855,-1,0.0002139053,0.9997861
8856,cardiac disease,9,11,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8856,-1,0.00019138295,0.9998086
8858,bigeminy,16,17,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8858,-1,0.00019520584,0.9998048
8864,rheumatologic disorders,9,11,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,-1,8864,-1,0.0002041576,0.99979585
8866,hepatitis B virus surface antigen,20,25,138,171,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8866,-1,0.024220828,0.97577924
8867,HBs Ag,26,28,173,179,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8867,-1,0.002618331,0.9973816
8868,rheumatologic disease,32,34,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8868,-1,0.00020531361,0.99979466
8869,HBs Ag,8,10,35,41,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8869,-1,0.04581891,0.95418113
8870,rheumatologic diseases,13,15,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8870,-1,0.00021720164,0.99978286
8872,hepatitis B virus,4,7,22,39,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,-1,8872,-1,0.00025244968,0.9997476
8874,abnormal liver function,15,18,100,123,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,-1,-1,-1,8874,-1,0.00021586234,0.9997842
8878,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8878,-1,0.9994906,0.00050935365
8880,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8880,-1,0.00021214008,0.99978787
8882,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8882,-1,0.9994709,0.00052915333
8883,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8883,-1,0.00038596755,0.99961406
8885,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8885,-1,0.00021165477,0.99978834
8886,ISO,7,8,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8886,-1,0.99941766,0.0005823647
8887,h,23,24,91,92,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8887,-1,0.04293956,0.95706046
8888,P<0.05,28,29,115,121,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8888,-1,0.08325826,0.9167418
8889,weight,33,34,142,148,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8889,-1,0.0003359317,0.99966407
8890,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8890,-1,0.004302727,0.99569726
8892,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8892,-1,0.99947864,0.00052136654
8893,ISO,29,30,139,142,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8893,-1,0.99946266,0.00053739955
8894,P<0.05,41,42,191,197,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8894,-1,0.028118487,0.97188157
8895,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8895,-1,0.00037779892,0.9996222
8896,ISO,77,78,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8896,-1,0.9994609,0.00053914066
8898,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8898,-1,0.99947673,0.0005233148
8900,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8900,-1,0.9994161,0.0005838664
8901,ISO,14,15,92,95,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8901,-1,0.99876547,0.0012345623
8902,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8902,-1,0.00021505848,0.999785
8903,haemopericardium,1,2,6,22,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8903,-1,0.99944216,0.000557824
8904,gastrointestinal haemorrhage,3,5,27,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8904,-1,0.00018486122,0.99981517
8906,haemorrhage,7,8,35,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,-1,-1,-1,8906,-1,0.00020037426,0.99979967
8908,flavonoids,8,9,54,64,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,-1,8908,-1,0.99934226,0.000657748
8911,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,-1,-1,8911,-1,0.0005693315,0.9994306
8916,bupropion HCl,13,15,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,-1,8916,-1,0.9994937,0.00050626975
8919,bupropion HCl,22,24,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,-1,8919,-1,0.9994936,0.0005063341
8920,Bupropion HCl,0,2,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,-1,8920,-1,0.99944705,0.0005529499
8923,bupropion HCl,9,11,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,-1,8923,-1,0.9994821,0.0005179692
8925,p,10,11,74,75,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8925,-1,0.21224901,0.78775096
8926,bupropion HCl,26,28,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8926,-1,0.9994697,0.00053035404
8934,sinusoidal obstruction syndrome,14,17,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8934,-1,0.00020208453,0.9997979
8935,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8935,-1,0.00020131106,0.9997987
8936,calcineurin inhibitor,1,3,2,23,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8936,-1,0.99946684,0.000533163
8938,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8938,-1,0.00022556231,0.9997744
8943,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8943,-1,0.00021781339,0.99978215
8944,MDS,24,25,132,135,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8944,-1,0.00022505148,0.999775
8945,n,26,27,137,138,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8945,-1,0.99921024,0.0007897087
8946,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8946,-1,0.00021672541,0.99978334
8947,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8947,-1,0.00022394954,0.99977607
8948,n,37,38,177,178,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8948,-1,0.9991196,0.0008804229
8949,n,50,51,249,250,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8949,-1,0.99561846,0.004381613
8950,n,57,58,270,271,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8950,-1,0.99655044,0.0034495755
8952,GVHD,10,11,48,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8952,-1,0.00021397242,0.9997861
8953,GVHD,25,26,120,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8953,-1,0.00021349678,0.99978656
8954,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8954,-1,0.00019937997,0.9998006
8955,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8955,-1,0.99935955,0.000640508
8956,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8956,-1,0.00020188963,0.9997981
8957,sinusoidal obstruction syndrome,15,18,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8957,-1,0.00020977424,0.99979025
8958,SOS,19,20,119,122,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8958,-1,0.00021431134,0.9997857
8959,GVHD,14,15,90,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8959,-1,0.0002124538,0.9997875
8960,TMA,19,20,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8960,-1,0.0045528337,0.9954471
8961,SOS,21,22,121,124,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8961,-1,0.00022341337,0.99977654
8962,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8962,-1,0.99949384,0.00050609943
8964,colorectal adenomas,20,22,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8964,-1,0.00021833363,0.99978167
8965,adenomatous polyps,9,11,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8965,-1,0.00017101181,0.99982893
8966,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8966,-1,0.9994855,0.00051446864
8967,DFMO,19,20,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8967,-1,0.9994923,0.00050774403
8969,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8969,-1,0.00021629993,0.9997837
8971,DFMO,10,11,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8971,-1,0.9994325,0.0005674268
8972,DFMO,17,18,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8972,-1,0.999461,0.0005390582
8974,P,37,38,200,201,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8974,-1,0.19063744,0.80936253
8975,P,23,24,101,102,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,-1,8975,-1,0.22567837,0.7743216
8976,DFMO,11,12,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8976,-1,0.99944884,0.0005511671
8978,hearing reduction,33,35,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8978,-1,0.0002648639,0.9997352
8979,P,49,50,233,234,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8979,-1,0.056102768,0.9438972
8980,P,29,30,158,159,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,-1,8980,-1,0.5704145,0.42958546
8981,DFMO,12,13,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8981,-1,0.99947804,0.00052194216
8983,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8983,-1,0.00023138731,0.9997687
8985,P,26,27,123,124,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,-1,8985,-1,0.14461416,0.85538584
8986,DFMO,14,15,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,-1,8986,-1,0.9994667,0.000533284
8990,RPN,4,5,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,-1,-1,8990,-1,0.9441128,0.055887196
8993,to,16,17,115,117,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8993,-1,0.0003550551,0.999645
8994,RPN,27,28,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8994,-1,0.9991486,0.00085143384
8995,to the,15,17,108,114,The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla.,1919871_7,-1,-1,-1,8995,-1,0.0046571563,0.99534285
8998,ulcerative colitis,4,6,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8998,-1,0.00020630815,0.9997937
8999,pleural effusion,10,12,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8999,-1,0.00020442251,0.9997956
9001,urinary abnormalities,15,17,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,9001,-1,0.00020972984,0.99979025
9003,segmental necrotizing glomerulonephritis,7,10,45,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,-1,-1,9003,-1,0.00029660537,0.99970335
9004,pleural effusions,8,10,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,-1,-1,-1,9004,-1,0.00021981105,0.99978024
9007,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9007,-1,0.00020925685,0.9997907
9008,pleural effusions,25,27,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9008,-1,0.00021010253,0.9997899
9010,pleural effusion,50,52,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9010,-1,0.00020686361,0.9997931
9012,pleural effusion,7,9,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,-1,-1,-1,9012,-1,0.0001886695,0.99981135
9017,contrast,1,2,3,11,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,-1,9017,-1,0.8547535,0.14524648
9020,in,9,10,47,49,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,-1,-1,9020,-1,0.00047501113,0.99952495
9021,excretion,15,16,74,83,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,-1,-1,9021,-1,0.00025390575,0.99974614
9028,idiopathic Parkinson's disease,9,13,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,-1,-1,-1,9028,-1,0.00019674649,0.99980325
9029,idiopathic Parkinson's disease,20,24,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9029,-1,0.0002325287,0.9997675
9030,PD,25,26,177,179,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9030,-1,0.0002024066,0.99979764
9033,Parkinson's Disease,8,11,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9033,-1,0.000318005,0.99968207
9036,homonymous,11,12,60,70,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9036,-1,0.00022382168,0.9997762
9037,hemianopsia,12,13,71,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9037,-1,0.00020589466,0.99979407
9038,Valproate,33,34,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9038,-1,0.99949586,0.00050407153
9039,PD,22,23,137,139,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,-1,9039,-1,0.00022896379,0.99977106
9048,pains,4,5,29,34,Subjects also recalled their pains one week later.,19269743_5,-1,-1,-1,9048,-1,0.00022581108,0.99977416
9050,p<0.001,8,9,61,68,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,-1,9050,-1,0.044628613,0.9553714
9054,p<0.001,15,16,101,108,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,-1,9054,-1,0.07331688,0.9266831
9058,myeloma,21,22,166,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,-1,9058,-1,0.00022452853,0.99977547
9060,bortezomib,15,16,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9060,-1,0.9994802,0.000519783
9062,multiple myeloma,31,33,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9062,-1,0.0002643457,0.99973565
9063,MM,34,35,249,251,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9063,-1,0.16080074,0.83919924
9064,bortezomib,9,10,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9064,-1,0.99949527,0.0005047076
9066,mg,26,27,126,128,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9066,-1,0.9985965,0.00140354
9067,bortezomib,31,32,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9067,-1,0.99949765,0.00050227466
9070,CR,8,9,46,48,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9070,-1,0.0006437543,0.9993562
9071,CR,29,30,121,123,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9071,-1,0.155169,0.84483105
9074,bortezomib,4,5,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9074,-1,0.99949026,0.00050971104
9077,MM,25,26,176,178,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9077,-1,0.000856706,0.99914324
9080,captopril overdose,6,8,40,58,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,-1,-1,9080,-1,0.008798933,0.99120104
9082,inhibitors,9,10,77,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,-1,-1,-1,9082,-1,0.9994386,0.00056145526
9086,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,-1,9086,-1,0.009331266,0.9906687
9094,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,-1,9094,-1,0.99945587,0.00054418476
9097,critically ill,9,11,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,-1,-1,-1,9097,-1,0.00054578204,0.9994542
9099,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,-1,9099,-1,0.9994615,0.0005385815
9107,Pneumocystis pneumonia,10,12,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,-1,-1,9107,-1,0.00019217914,0.9998079
9108,Pneumocystis pneumonia,0,2,0,22,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9108,-1,0.00043442668,0.99956554
9109,PCP,3,4,24,27,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9109,-1,0.99610424,0.0038957773
9110,opportunistic infection,8,10,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9110,-1,0.00017888923,0.9998211
9111,intrahepatic cholestasis,14,16,99,123,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9111,-1,0.00020830768,0.9997917
9112,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9112,-1,0.00020928799,0.9997907
9113,PCP,34,35,243,246,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9113,-1,0.9994505,0.00054953835
9114,cm,9,10,44,46,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,-1,9114,-1,0.8510401,0.14895992
9115,apical ballooning syndrome,2,5,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,-1,-1,-1,9115,-1,0.00017014555,0.99982977
9116,apical ballooning syndrome,1,4,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9116,-1,0.00021730375,0.99978274
9117,ABS,5,6,32,35,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9117,-1,0.9986022,0.0013978534
9118,acute cardiac syndrome,12,15,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9118,-1,0.00021176497,0.9997882
9119,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9119,-1,0.00021900205,0.99978095
9120,epicardial coronary disease,38,41,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9120,-1,0.00021535804,0.99978465
9122,ABS,7,8,33,36,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,-1,9122,-1,0.00042337793,0.9995766
9124,ischemic chest pain,6,9,43,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,-1,-1,9124,-1,0.00020002492,0.9998
9125,fluorouracil,5,6,39,51,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9125,-1,0.999456,0.0005439939
9126,colorectal cancer,8,10,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9126,-1,0.00021251215,0.9997875
9128,akinesis,12,13,82,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,-1,-1,-1,9128,-1,0.00019396964,0.9998061
9129,cardiac complications,3,5,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9129,-1,0.00020501981,0.999795
9131,coronary vasospasm,11,13,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9131,-1,0.00020319998,0.9997968
9132,thrombus,18,19,154,162,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9132,-1,0.00020662863,0.99979335
9135,ABS,28,29,194,197,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,-1,9135,-1,0.9990145,0.0009854344
9137,antagonists,2,3,21,32,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9137,-1,0.9994869,0.000513072
9138,nitric oxide synthase inhibitors,4,8,37,69,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9138,-1,0.9994899,0.00051002135
9142,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9142,-1,0.00021702854,0.999783
9144,HOE 140,68,70,385,392,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9144,-1,0.99946326,0.00053677015
9145,des Arg10 HOE 140,76,80,412,429,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9145,-1,0.99946195,0.0005380036
9150,diabetic hyperalgesia,24,26,155,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,-1,-1,-1,9150,-1,0.00020494552,0.999795
9151,HOE 140,14,16,105,112,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9151,-1,0.999403,0.00059699244
9152,des Arg10 HOE 140,17,21,117,134,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9152,-1,0.9994491,0.000550904
9156,HOE 140,12,14,80,87,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9156,-1,0.9910142,0.008985849
9157,toxic neuropathy,18,20,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9157,-1,0.00021675661,0.9997832
9159,toxic neuropathy,23,25,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,-1,9159,-1,0.00020361153,0.99979645
9162,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,-1,9162,-1,0.6571011,0.34289888
9163,bradykinin receptor antagonists,8,11,56,87,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,-1,-1,9163,-1,0.9994629,0.0005370787
9164,inhibitors,14,15,104,114,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,-1,-1,9164,-1,0.9994466,0.0005534614
9167,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9167,-1,0.00051915395,0.9994809
9168,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9168,-1,0.9994568,0.00054315093
9170,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9170,-1,0.00047855472,0.9995215
9171,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9171,-1,0.99945265,0.0005473319
9172,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,-1,-1,9172,-1,0.0005245261,0.99947554
9174,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,-1,9174,-1,0.9994436,0.00055634225
9176,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,-1,-1,9176,-1,0.9994486,0.00055138627
9178,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,-1,-1,9178,-1,0.9994679,0.00053215475
9179,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,-1,9179,-1,0.00040815264,0.9995919
9181,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9181,-1,0.9994684,0.00053163304
9182,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9182,-1,0.0005271047,0.9994729
9184,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,-1,-1,9184,-1,0.0002112298,0.9997888
9185,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,-1,9185,-1,0.00020297612,0.99979705
9187,prothrombin complex concentrate,15,18,89,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9187,-1,0.026640195,0.9733599
9188,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9188,-1,0.00023029298,0.99976975
9191,h,12,13,59,60,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,-1,9191,-1,0.012939169,0.9870609
9192,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,-1,9192,-1,0.0017811855,0.99821883
9194,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9194,-1,0.0005672722,0.99943274
9195,n=12,20,21,96,100,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9195,-1,0.24447146,0.75552857
9199,P=0.015,22,23,139,146,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,-1,9199,-1,0.22186513,0.7781348
9200,hematomas,12,13,53,62,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,-1,9200,-1,0.00021468972,0.99978536
9201,contrast,1,2,3,11,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9201,-1,0.37973604,0.62026393
9202,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,-1,9202,-1,0.00020498423,0.999795
9204,inferior colliculus lesion,1,4,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,-1,9204,-1,0.00023665983,0.9997633
9206,inferior colliculus lesions,7,10,41,68,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,-1,9206,-1,0.00020051721,0.99979955
9211,map,26,27,146,149,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,-1,9211,-1,0.00043607972,0.9995639
9213,map,13,14,80,83,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9213,-1,0.044663817,0.95533615
9214,map,39,40,200,203,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9214,-1,0.99744934,0.0025506576
9215,callosal lesion,32,34,163,178,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,-1,9215,-1,0.006796598,0.9932034
9216,inferior colliculus lesions,3,6,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,-1,9216,-1,0.00019864089,0.99980134
9222,calcineurin inhibitor,19,21,125,146,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,-1,-1,9222,-1,0.9995061,0.0004938932
9249,PA,16,17,111,113,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,-1,9249,-1,0.99924195,0.0007580233
9250,memory impaired,9,11,60,75,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9250,-1,0.00018443164,0.99981564
9253,of,21,22,141,143,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9253,-1,0.00024017207,0.99975985
9254,PA,25,26,166,168,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9254,-1,0.9993211,0.00067896035
9258,HT,5,6,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9258,-1,0.08058511,0.9194149
9259,menopausal symptoms,12,14,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9259,-1,0.0017906484,0.99820936
9260,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9260,-1,0.0002140189,0.99978596
9263,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,-1,9263,-1,0.9990293,0.0009707897
9267,Menstrual Disorders,17,19,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9267,-1,0.00023529326,0.99976474
9268,Subfertility,20,21,127,139,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9268,-1,0.00023446578,0.9997656
9269,HT,7,8,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,-1,9269,-1,0.014890351,0.9851097
9270,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9270,-1,0.99905366,0.00094636576
9271,oestrogens,2,3,12,22,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9271,-1,0.9993911,0.0006089096
9272,progestogens,7,8,40,52,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9272,-1,0.9993968,0.00060323376
9273,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,-1,9273,-1,0.99873835,0.0012616586
9277,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,-1,9277,-1,0.999435,0.00056500855
9281,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9281,-1,0.999153,0.00084701844
9283,HT,17,18,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9283,-1,0.99919564,0.0008044117
9284,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9284,-1,0.00020874392,0.9997913
9285,HT,22,23,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,-1,9285,-1,0.62481916,0.37518084
9287,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9287,-1,0.00020166955,0.99979836
9288,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9288,-1,0.9516847,0.04831527
9289,HT,17,18,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9289,-1,0.9981694,0.0018305777
9290,HT,22,23,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9290,-1,0.9983901,0.0016099251
9291,HT,15,16,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,-1,-1,-1,9291,-1,0.0048364787,0.99516356
9292,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9292,-1,0.005048678,0.99495137
9293,disease,14,15,80,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9293,-1,0.0002083057,0.9997917
9294,HT,8,9,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,-1,9294,-1,0.9988067,0.0011933073
9302,painful,19,20,125,132,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,-1,9302,-1,0.00022174574,0.9997782
9307,salvianolic acid A,3,6,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9307,-1,0.9994838,0.0005160936
9308,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9308,-1,0.00021738124,0.9997826
9309,salvianolic acid A,11,14,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9309,-1,0.9994449,0.00055505097
9310,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9310,-1,0.00020497093,0.999795
9311,lactate,9,10,73,80,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9311,-1,0.9993987,0.0006012987
9313,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9313,-1,0.0057439166,0.9942561
9315,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9315,-1,0.35047823,0.64952177
9316,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9316,-1,0.99944407,0.0005559455
9317,respiratory dysfunction,4,6,27,50,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,-1,9317,-1,0.00019082954,0.9998092
9318,salvianolic acid A,2,5,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,-1,9318,-1,0.99920326,0.0007968078
9321,salvianolic acid A,4,7,23,41,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,-1,-1,9321,-1,0.999456,0.0005439614
9323,salvianolic acid A,7,10,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9323,-1,0.9993923,0.000607775
9324,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9324,-1,0.00021379805,0.9997862
9330,PAC,14,15,101,104,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9330,-1,0.9993197,0.0006803491
9332,amino acid glutamine,23,26,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9332,-1,0.9994153,0.0005846911
9333,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9333,-1,0.005845046,0.994155
9338,mg,37,38,226,228,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9338,-1,0.9980983,0.0019016565
9339,P,51,52,277,278,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9339,-1,0.3481701,0.65182996
9340,signs or symptoms,9,12,56,73,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9340,-1,0.00022359601,0.9997764
9343,P,44,45,291,292,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9343,-1,0.8159605,0.18403946
9344,P,21,22,118,119,Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%).,19473225_6,-1,-1,-1,9344,-1,0.07262152,0.92737854
9347,PAC,21,22,147,150,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9347,-1,0.00022980933,0.9997702
9348,myasthenia,3,4,22,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9348,-1,0.00021412056,0.99978584
9349,pegylated interferon,5,7,40,60,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9349,-1,0.9994979,0.0005021101
9351,hepatitis C.A,12,14,97,110,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9351,-1,0.018787725,0.9812122
9352,diplopia,18,19,147,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9352,-1,0.00021464957,0.99978536
9353,pegylated interferon (IFN) alpha-2b,25,31,191,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9353,-1,0.9995003,0.00049974537
9355,chronic hepatitis C,34,37,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9355,-1,0.00027811897,0.9997218
9356,CHC,38,39,266,269,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9356,-1,0.00055302994,0.9994469
9357,ptosis on the right upper lid,3,9,35,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9357,-1,0.009334585,0.99066544
9358,restricted right eye movement,10,14,69,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9358,-1,0.00046264523,0.99953735
9360,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,-1,-1,-1,9360,-1,0.9994735,0.00052653806
9361,pegylated IFN alpha-2b,12,15,90,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,-1,-1,-1,9361,-1,0.9994696,0.0005304223
9363,myasthenia,2,3,11,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9363,-1,0.00021027167,0.9997898
9364,pegylated IFN alpha-2b,8,11,61,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9364,-1,0.9994821,0.0005179588
9366,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9366,-1,0.00082030054,0.99917966
9367,IFN,35,36,213,216,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9367,-1,0.9994659,0.0005341876
9368,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,-1,9368,-1,0.00021863863,0.9997814
9377,hypoactivity,10,11,82,94,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,-1,9377,-1,0.00020661464,0.99979335
9382,hypoactivity,1,2,17,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,-1,9382,-1,0.00021383453,0.9997862
9388,Acute renal failure,0,3,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9388,-1,0.00021629436,0.9997837
9389,AIDS,6,7,37,41,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9389,-1,0.0018487745,0.99815124
9390,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9390,-1,0.9994717,0.00052834244
9392,osteomyelitis,15,16,103,116,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9392,-1,0.00021082535,0.9997892
9393,Renal failure,0,2,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9393,-1,0.00021924943,0.9997807
9395,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9395,-1,0.9994748,0.0005251905
9396,Tenofovir,0,1,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9396,-1,0.9994796,0.00052041386
9397,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9397,-1,0.017169222,0.98283076
9398,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9398,-1,0.00020923151,0.9997907
9399,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,-1,9399,-1,0.0022029402,0.99779713
9401,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9401,-1,0.9994741,0.00052591757
9402,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9402,-1,0.00023665352,0.9997633
9404,hydrogen cyanamide,3,5,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,-1,9404,-1,0.99946374,0.00053631753
9405,Hydrogen cyanamide,0,2,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,-1,9405,-1,0.99944097,0.0005589989
9406,aldehyde dehydrogenase,14,16,91,113,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9406,-1,0.99939966,0.00060034415
9407,acetaldehyde,19,20,129,141,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9407,-1,0.99941134,0.00058863265
9409,hydrogen cyanamide,18,20,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,-1,9409,-1,0.99947923,0.0005207771
9410,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9410,-1,0.9968951,0.0031049189
9411,hydrogen cyanamide,13,15,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9411,-1,0.9994487,0.0005512938
9414,malaise,13,14,65,72,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9414,-1,0.7905813,0.20941877
9415,flushing of the face,15,19,78,98,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9415,-1,0.0002755554,0.99972445
9417,dyspnea,23,24,117,124,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9417,-1,0.00020102103,0.99979895
9418,Dormex,12,13,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,-1,9418,-1,0.99931324,0.00068675075
9419,flushing,10,11,70,78,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9419,-1,0.00017423056,0.9998258
9423,Dormex,17,18,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,-1,-1,-1,9423,-1,0.9990175,0.0009824763
9424,dysosmia,1,2,10,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9424,-1,0.000175522,0.99982446
9425,pyrazinamide,4,5,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9425,-1,0.9994711,0.0005289428
9426,Pyrazinamide,0,1,0,12,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9426,-1,0.9994393,0.0005607301
9427,hepatic toxicity,7,9,46,62,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9427,-1,0.00022331711,0.99977666
9428,hyperuricemia,10,11,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9428,-1,0.00022218723,0.99977785
9429,digestive disorders,12,14,81,100,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9429,-1,0.0002256888,0.9997743
9430,pyrazinamide,14,15,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,-1,-1,-1,9430,-1,0.9994697,0.00053037604
9431,olfactory disorder,6,8,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9431,-1,0.00019549718,0.99980456
9432,pyrazinamide,10,11,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9432,-1,0.99947387,0.00052613945
9433,Dysosmia,0,1,0,8,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9433,-1,0.00022640543,0.99977356
9434,pyrazinamide,4,5,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9434,-1,0.99947387,0.00052612467
9435,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,-1,9435,-1,0.000218986,0.9997811
9438,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,-1,9438,-1,0.0002096165,0.9997904
9442,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,-1,9442,-1,0.00020022088,0.9997998
9445,prostaglandin,9,10,49,62,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9445,-1,0.99941325,0.00058671925
9446,PG,11,12,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9446,-1,0.9994062,0.0005937653
9448,prostaglandin E,14,16,100,115,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,-1,-1,9448,-1,0.9993686,0.00063143787
9449,LiCl,4,5,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,-1,9449,-1,0.9985959,0.0014040866
9451,PGE(2),12,14,87,93,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9451,-1,0.99928683,0.0007131796
9452,contrast,1,2,3,11,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9452,-1,0.99497604,0.00502394
9454,PGE(2),26,28,169,175,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9454,-1,0.996543,0.0034569649
9455,cAMP,29,30,180,184,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9455,-1,0.9993569,0.00064303563
9457,contrast,1,2,3,11,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,-1,9457,-1,0.97093415,0.029065797
9458,PGE(2),4,6,33,39,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,-1,-1,9458,-1,0.9993849,0.0006151453
9461,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,-1,-1,9461,-1,0.9994991,0.0005009314
9463,Fenoldopam mesylate,0,2,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,-1,-1,-1,9463,-1,0.999476,0.0005239742
9464,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,-1,-1,9464,-1,0.9994916,0.00050840556
9466,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,-1,9466,-1,0.9994997,0.0005003569
9469,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9469,-1,0.99949837,0.00050166016
9471,NS,41,42,221,223,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9471,-1,0.02352899,0.97647107
9475,P,29,30,170,171,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,-1,9475,-1,0.9176948,0.08230522
9478,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,-1,-1,9478,-1,0.9994808,0.0005192497
9489,Etodolac,0,1,0,8,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9489,-1,0.9994634,0.00053657475
9490,E,2,3,10,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9490,-1,0.7924732,0.20752673
9492,etodolac,8,9,56,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9492,-1,0.9994271,0.0005729798
9493,EAI,10,11,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9493,-1,0.00030479833,0.9996952
9495,Etodolac,0,1,0,8,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,-1,9495,-1,0.9994516,0.00054844265
9496,etodolac,8,9,26,34,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,-1,9496,-1,0.9994691,0.0005309406
9497,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9497,-1,0.9993942,0.00060582225
9498,writhing,11,12,91,99,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9498,-1,0.00020825746,0.9997918
9499,paw edema,19,21,141,150,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9499,-1,0.00020776063,0.9997923
9500,E,5,6,26,27,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9500,-1,0.9982981,0.0017018976
9501,p,16,17,109,110,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9501,-1,0.05139955,0.94860053
9502,etodolac,25,26,193,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,-1,-1,-1,9502,-1,0.9994499,0.0005501233
9509,fibrillation,20,21,142,154,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9509,-1,0.00021856857,0.9997814
9511,arrhythmic,32,33,217,227,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9511,-1,0.0002186036,0.9997814
9512,aconitine,5,6,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,-1,9512,-1,0.9994879,0.0005120443
9516,4-DAMP,9,10,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,-1,9516,-1,0.9994168,0.0005831492
9519,arrhythmic,9,10,71,81,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9519,-1,0.0002213537,0.9997787
9520,aconitine,17,18,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9520,-1,0.9994844,0.0005155388
9525,blind,9,10,66,71,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,-1,9525,-1,0.0034986471,0.9965013
9528,P,11,12,74,75,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9528,-1,0.32902658,0.6709734
9529,P,37,38,209,210,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9529,-1,0.7168053,0.2831947
9534,SSR103800,4,5,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,-1,9534,-1,0.9993925,0.0006074437
9538,NMDA,11,12,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9538,-1,0.99946433,0.00053562754
9539,NMDA,33,34,218,222,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9539,-1,0.99946445,0.000535538
9540,NMDA,32,33,204,208,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9540,-1,0.99931693,0.0006830615
9542,SSR103800,11,12,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9542,-1,0.9992899,0.0007101115
9543,NMDA,16,17,100,104,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9543,-1,0.99938345,0.0006164884
9545,NMDA,28,29,171,175,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9545,-1,0.9993911,0.0006089494
9546,SSR103800,10,11,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9546,-1,0.07621269,0.92378736
9548,ie,26,27,177,179,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9548,-1,0.015196912,0.9848031
9550,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9550,-1,0.9987476,0.0012523653
9551,ie,36,37,225,227,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9551,-1,0.025627034,0.974373
9552,NMDA,38,39,229,233,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9552,-1,0.99937433,0.00062575063
9553,SSR103800,3,4,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9553,-1,0.00025998388,0.99974006
9555,NMDA,18,19,102,106,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9555,-1,0.99946755,0.0005324338
9556,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9556,-1,0.99947864,0.00052136905
9558,NMDA,29,30,187,191,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9558,-1,0.9994649,0.00053513725
9559,contrast,1,2,3,11,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9559,-1,0.7677879,0.23221205
9560,SSR103800,3,4,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9560,-1,0.0012124169,0.9987876
9567,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9567,-1,0.99951017,0.00048987515
9568,antipsychotics,16,17,96,110,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9568,-1,0.99948907,0.00051095954
9570,SSR103800,6,7,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,-1,9570,-1,0.9990965,0.0009035295
9572,SSR103800,9,10,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,-1,9572,-1,0.99943405,0.0005659442
9573,Hibiscus rosa sinensis,2,5,10,32,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,-1,-1,-1,9573,-1,0.030055445,0.96994454
9574,Hibiscus rosa sinensis,5,8,32,54,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9574,-1,0.008640701,0.99135935
9575,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9575,-1,0.000222361,0.9997776
9578,Hibiscus rosa sinensis,15,18,125,147,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,-1,-1,-1,9578,-1,0.0008561098,0.99914384
9580,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9580,-1,0.0060327044,0.9939673
9581,glutathione reductase,28,30,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9581,-1,0.99943596,0.0005639671
9582,GSH,31,32,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9582,-1,0.99941385,0.00058615615
9583,GSH,18,19,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,-1,-1,-1,9583,-1,0.9992311,0.0007688657
9584,Hibiscus rosa sinensis,8,11,48,70,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9584,-1,0.007989839,0.99201024
9585,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9585,-1,0.00021627064,0.9997837
9586,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9586,-1,0.99950147,0.00049846485
9587,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9587,-1,0.0060069207,0.9939931
9588,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9588,-1,0.99945086,0.0005491682
9589,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9589,-1,0.999416,0.0005839952
9590,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,-1,9590,-1,0.9348725,0.06512757
9592,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,-1,9592,-1,0.99832433,0.001675656
9594,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9594,-1,0.88646877,0.1135312
9595,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9595,-1,0.00021268446,0.9997873
9596,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9596,-1,0.9941268,0.0058731395
9597,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9597,-1,0.0002180164,0.999782
9598,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,-1,9598,-1,0.00021350145,0.99978656
9600,PDTC,1,2,9,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9600,-1,0.99927944,0.0007206155
9601,lesions in the piriform cortex,7,12,57,87,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9601,-1,0.0002695642,0.9997304
9602,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,-1,9602,-1,0.0001986909,0.99980134
9603,PDTC,8,9,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9603,-1,0.99948525,0.00051468174
9604,neuronal loss,20,22,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9604,-1,0.00022632105,0.9997737
9605,reactive oxygen species,8,11,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,-1,-1,9605,-1,0.99906415,0.0009358155
9607,PDTC,14,15,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,-1,-1,-1,9607,-1,0.99606955,0.003930444
9608,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9608,-1,0.00079186354,0.99920815
9609,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9609,-1,0.00021826787,0.9997818
9610,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9610,-1,0.000463049,0.999537
9611,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9611,-1,0.0019545609,0.99804544
9614,human immunodeficiency virus infection,17,21,92,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,-1,-1,9614,-1,0.0009908585,0.99900913
9615,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,-1,-1,9615,-1,0.00021555484,0.9997844
9618,right heart failure,8,11,71,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,-1,9618,-1,0.000211543,0.99978846
9634,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9634,-1,0.00022207457,0.999778
9635,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9635,-1,0.00021896783,0.9997811
9636,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,-1,-1,9636,-1,0.00021898182,0.9997811
9637,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9637,-1,0.00024239894,0.9997576
9638,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9638,-1,0.0002392649,0.9997607
9639,n,39,40,235,236,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9639,-1,0.31741422,0.6825858
9640,n,55,56,319,320,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9640,-1,0.27990878,0.72009116
9641,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,-1,9641,-1,0.0002316504,0.9997683
9642,Sulfonamides,0,1,0,12,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9642,-1,0.99939823,0.00060176017
9644,hypoplastic left heart syndrome,27,31,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9644,-1,0.0002107134,0.9997893
9645,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9645,-1,0.0015940723,0.998406
9646,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9646,-1,0.0035529784,0.996447
9647,transverse limb deficiency,79,82,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9647,-1,0.00020521479,0.9997948
9648,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9648,-1,0.00021060917,0.9997894
9649,Nitrofurantoins,0,1,0,15,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9649,-1,0.9994561,0.00054387876
9650,anophthalmia,4,5,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9650,-1,0.00023891589,0.99976104
9651,microphthalmos,6,7,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9651,-1,0.9988243,0.0011757083
9652,hypoplastic left heart syndrome,21,25,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9652,-1,0.00022915729,0.9997708
9653,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9653,-1,0.00022619161,0.9997738
9654,cleft lip,57,59,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9654,-1,0.00023866,0.9997613
9655,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9655,-1,0.00023027672,0.99976975
9656,antibacterial agents,1,3,6,26,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9656,-1,0.98960716,0.01039282
9657,erythromycins,7,8,61,74,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9657,-1,0.99947566,0.0005244014
9658,penicillins,13,14,88,99,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9658,-1,0.9994511,0.0005488691
9660,quinolones,26,27,143,153,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9660,-1,0.99947876,0.0005212824
9661,penicillins,4,5,27,38,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9661,-1,0.99944884,0.00055110885
9662,erythromycins,6,7,40,53,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9662,-1,0.99946946,0.00053058664
9664,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9664,-1,0.00026421342,0.9997358
9665,Sulfonamides,0,1,0,12,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9665,-1,0.99948007,0.0005199696
9666,nitrofurantoins,2,3,17,32,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9666,-1,0.9994887,0.0005112686
9667,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9667,-1,0.00021447649,0.9997855
9668,hepatitis B virus e,15,19,106,125,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9668,-1,0.79713756,0.20286241
9669,hepatitis B virus,5,8,30,47,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,-1,9669,-1,0.00045480186,0.99954516
9671,LAM,40,41,274,277,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9671,-1,0.99942183,0.00057823915
9672,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9672,-1,0.00028114568,0.99971884
9673,LAM,9,10,60,63,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9673,-1,0.93141586,0.068584144
9674,HBsAg,5,6,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9674,-1,0.00025176464,0.9997483
9675,mutants,19,20,126,133,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9675,-1,0.00022806526,0.9997719
9676,HBsAg,7,8,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,-1,9676,-1,0.008834933,0.9911651
9677,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9677,-1,0.2124966,0.7875034
9678,LAM,16,17,78,81,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9678,-1,0.7328465,0.2671535
9679,LAM,8,9,46,49,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9679,-1,0.9994392,0.0005608145
9680,nucleotide analogues adefovir,13,16,76,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9680,-1,0.9994715,0.00052847463
9681,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9681,-1,0.99949265,0.0005073775
9682,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,-1,9682,-1,0.00019703523,0.999803
9683,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,-1,9683,-1,0.00019959433,0.9998004
9685,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,-1,9685,-1,0.99941397,0.0005860858
9689,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,-1,9689,-1,0.99944144,0.0005585292
9690,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,-1,9690,-1,0.99946076,0.00053927785
9691,myocardial hypertrophy,1,3,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,-1,-1,9691,-1,0.0001829333,0.9998171
9695,myocardial hypertrophy,4,6,29,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,-1,-1,9695,-1,0.00020895898,0.9997911
9699,myocardial hypertrophy,18,20,120,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,-1,-1,9699,-1,0.00021651162,0.99978346
9702,Myocardial hypertrophy,0,2,0,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,-1,-1,-1,9702,-1,0.00020941914,0.9997906
9705,myocardial hypertrophy,8,10,53,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,-1,-1,-1,9705,-1,0.00020411651,0.99979585
9707,cardiac involvement,17,19,123,142,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,-1,-1,-1,9707,-1,0.00021410242,0.99978596
9712,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,-1,-1,9712,-1,0.00020074523,0.9997993
9714,NIMO,7,8,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,-1,9714,-1,0.99948514,0.0005148948
9717,PA,6,7,32,34,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,-1,-1,-1,9717,-1,0.4276058,0.57239413
9718,PA,1,2,4,6,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,-1,9718,-1,0.9957563,0.004243705
9720,h,4,5,27,28,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,-1,9720,-1,0.04665286,0.9533471
9721,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9721,-1,0.08963095,0.91036904
9722,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9722,-1,0.8595485,0.14045148
9723,h,38,39,144,145,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9723,-1,0.15564246,0.84435755
9724,NTG,44,45,165,168,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9724,-1,0.9680369,0.03196313
9725,NIMO,46,47,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9725,-1,0.9993055,0.00069446827
9726,NIMO,55,56,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9726,-1,0.99937147,0.00062855514
9729,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9729,-1,0.99942183,0.0005781918
9730,NIMO,28,29,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9730,-1,0.9994424,0.0005575888
9731,NTG,32,33,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9731,-1,0.9987835,0.0012164413
9732,H,16,17,109,110,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9732,-1,0.01871283,0.9812872
9733,NTG,16,17,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9733,-1,0.99937683,0.0006231498
9734,n,18,19,87,88,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9734,-1,0.950986,0.0490139
9735,NTG,23,24,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9735,-1,0.9994221,0.0005778934
9736,NIMO,25,26,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9736,-1,0.9994522,0.000547845
9737,n,27,28,110,111,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9737,-1,0.99587834,0.0041217078
9738,mm Hg,43,45,183,188,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9738,-1,0.0036267599,0.99637324
9739,mm Hg,51,53,209,214,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9739,-1,0.0030072068,0.9969928
9740,mm Hg,60,62,241,246,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9740,-1,0.0028415218,0.9971585
9741,mm Hg,68,70,267,272,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9741,-1,0.0036540644,0.99634594
9742,NIMO,8,9,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9742,-1,0.9994784,0.0005216823
9743,mm Hg,16,18,89,94,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9743,-1,0.0007564509,0.9992436
9744,mm Hg,23,25,111,116,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9744,-1,0.0010305267,0.99896944
9745,P,7,8,57,58,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,-1,9745,-1,0.21854696,0.7814531
9746,mm Hg,8,10,36,41,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9746,-1,0.0008647339,0.9991353
9747,mm Hg,16,18,62,67,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9747,-1,0.0028198443,0.9971802
9748,NTG,21,22,79,82,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9748,-1,0.99938774,0.00061226747
9749,mm Hg,29,31,111,116,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9749,-1,0.0027149464,0.997285
9750,mm Hg,37,39,137,142,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9750,-1,0.0014488327,0.9985512
9751,NTG,42,43,154,157,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9751,-1,0.9993662,0.0006337363
9752,NIMO,44,45,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9752,-1,0.99942976,0.0005701988
9753,PA,4,5,17,19,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9753,-1,0.9988953,0.001104707
9754,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9754,-1,0.99935526,0.0006447964
9756,NIMO,0,1,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9756,-1,0.999416,0.0005840072
9757,NTG,11,12,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9757,-1,0.81890357,0.18109648
9759,NIMO,4,5,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,-1,9759,-1,0.9994617,0.0005383539
9765,peptic ulcer disease,12,15,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9765,-1,0.00018867814,0.99981135
9766,reflux esophagitis,16,18,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9766,-1,0.00019012796,0.9998099
9771,lethargy,5,6,32,40,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9771,-1,0.00018945856,0.9998105
9772,shortness of breath,8,11,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9772,-1,0.00019337262,0.9998067
9779,Parkinson's disease,12,15,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,-1,-1,-1,9779,-1,0.00020267039,0.9997974
9781,Parkinson's disease,23,26,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9781,-1,0.00024629247,0.99975365
9782,PD,27,28,195,197,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9782,-1,0.00021935295,0.9997807
9783,PD,28,29,163,165,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,-1,9783,-1,0.00022005448,0.99978
9784,"N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride",3,7,15,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9784,-1,0.9994747,0.00052535016
9785,AMN082,8,9,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9785,-1,0.9794836,0.02051644
9786,PD,28,29,185,187,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9786,-1,0.0002457816,0.99975425
9787,AMN082,20,21,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,-1,9787,-1,0.9989235,0.0010764365
9789,AMN082,0,1,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,-1,9789,-1,0.9953596,0.004640348
9792,PD,13,14,76,78,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9792,-1,0.0002113259,0.9997887
9793,AMN082,18,19,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9793,-1,0.8815189,0.118481115
9794,AMN082,3,4,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,-1,9794,-1,0.99406487,0.0059351893
9796,AMN082,3,4,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9796,-1,0.9959382,0.004061798
9797,PD,20,21,83,85,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9797,-1,0.0004972843,0.99950266
9798,motor dysfunction,10,12,74,91,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,-1,9798,-1,0.0002061249,0.99979395
9801,coronary artery spasm,6,9,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,-1,-1,9801,-1,0.00020716325,0.9997929
9802,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9802,-1,0.00019828948,0.9998017
9803,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9803,-1,0.00019801385,0.99980205
9805,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,-1,-1,9805,-1,0.00019643908,0.9998036
9807,Coronary artery spasm,0,3,0,21,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,-1,-1,9807,-1,0.0001656501,0.9998343
9809,nitrates,9,10,68,76,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,-1,-1,-1,9809,-1,0.9994411,0.000558911
9811,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9811,-1,0.99951327,0.0004867498
9812,angina,10,11,71,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9812,-1,0.0002222387,0.99977773
9813,coronary artery spasm,7,10,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,-1,-1,9813,-1,0.00019031749,0.9998097
9815,coronary artery spasm,16,19,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,-1,9815,-1,0.00019702208,0.999803
9817,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9817,-1,0.99943346,0.00056656677
9818,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9818,-1,0.99923635,0.000763702
9820,hippocampal damage,13,15,99,117,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9820,-1,0.00021331137,0.9997867
9821,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,-1,9821,-1,0.99947613,0.00052389875
9823,of neuronal cells,8,11,72,89,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9823,-1,0.00020669072,0.99979335
9824,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9824,-1,0.9994772,0.0005227884
9834,mg,10,11,61,63,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9834,-1,0.9992105,0.00078946305
9836,mg,18,19,90,92,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9836,-1,0.999374,0.0006260605
9838,mg,29,30,142,144,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9838,-1,0.9993901,0.0006098305
9840,mg,39,40,188,190,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9840,-1,0.99936384,0.0006362243
9841,MAP,48,49,230,233,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9841,-1,0.00030215998,0.9996979
9842,MAP,6,7,17,20,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9842,-1,0.029319191,0.97068083
9844,CO,17,18,58,60,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9844,-1,0.9994215,0.0005784971
9845,MAP,11,12,63,66,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9845,-1,0.0008557726,0.9991442
9846,CO,18,19,80,82,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9846,-1,0.99931073,0.00068931986
9848,MAP,5,6,39,42,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9848,-1,0.9926237,0.0073763654
9849,P,19,20,83,84,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9849,-1,0.054120127,0.94587994
9850,SD,26,27,103,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9850,-1,0.07676571,0.9232343
9851,P,24,25,68,69,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9851,-1,0.03323738,0.9667626
9852,CO,33,34,105,107,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9852,-1,0.99908006,0.0009199047
9854,increase in MAP,8,11,49,64,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9854,-1,0.00028448136,0.9997155
9855,P,23,24,93,94,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9855,-1,0.08741039,0.91258967
9856,CO,29,30,114,116,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9856,-1,0.99748707,0.0025128876
9860,CO,31,32,214,216,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,-1,9860,-1,0.9994392,0.0005607867
9861,tranexamic Acid,1,3,10,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,-1,9861,-1,0.99950325,0.0004967412
9863,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,-1,-1,9863,-1,0.00019934062,0.9998006
9864,tranexamic acid,11,13,74,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9864,-1,0.99948454,0.00051542337
9865,TXA,14,15,91,94,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9865,-1,0.9993357,0.00066425285
9866,TXA,19,20,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,-1,-1,9866,-1,0.3654351,0.63456494
9869,cerebral ischemic injury,13,16,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9869,-1,0.0002042904,0.99979573
9871,ischemic brain injury,23,26,126,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9871,-1,0.00020644865,0.9997936
9873,neurological abnormalities,8,10,50,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,-1,-1,9873,-1,0.00020292717,0.99979705
9875,TXA,9,10,53,56,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,-1,-1,9875,-1,0.9993511,0.00064894237
9876,ischemic,4,5,21,29,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,-1,-1,9876,-1,0.0002088753,0.9997911
9878,TXA,9,10,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,-1,9878,-1,0.9993123,0.000687743
9883,Direct thrombin inhibitors,2,5,12,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9883,-1,0.999448,0.00055194466
9884,DTIs,6,7,40,44,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9884,-1,0.00040481478,0.9995952
9886,HIT,23,24,160,163,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9886,-1,0.00024829165,0.99975175
9887,HIT,26,27,168,171,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9887,-1,0.00024310045,0.9997569
9889,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9889,-1,0.00026536206,0.9997346
9890,critically ill,7,9,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9890,-1,0.00027977503,0.99972016
9891,HITT,15,16,90,94,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9891,-1,0.00022542603,0.99977463
9893,recombinant Factor VIIa,34,37,183,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9893,-1,0.999456,0.0005439939
9898,hepatic impairment,54,56,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,-1,9898,-1,0.0002175861,0.9997824
9905,psychotropic drugs,8,10,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,-1,-1,9905,-1,0.9994598,0.0005401747
9906,psychotropic drugs,12,14,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9906,-1,0.99940133,0.0005986645
9907,phenothiazines,16,17,117,131,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9907,-1,0.9994948,0.0005051726
9909,Mellaril,8,9,53,61,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9909,-1,0.99949074,0.00050924654
9910,thioridazine,10,11,63,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9910,-1,0.99949706,0.00050298165
9912,Supraventricular tachycardia,0,2,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9912,-1,0.00020044569,0.99979955
9913,Thorazine,7,8,64,73,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9913,-1,0.9994848,0.00051523524
9915,Aventyl,0,1,0,7,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9915,-1,0.99948597,0.0005140089
9916,nortriptyline,2,3,9,22,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9916,-1,0.99950147,0.0004985264
9917,Elavil,5,6,28,34,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9917,-1,0.9994862,0.00051379
9919,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9919,-1,0.00020230627,0.99979776
9924,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,-1,-1,9924,-1,0.00022297245,0.999777
9925,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,-1,-1,9925,-1,0.0002016303,0.99979836
9927,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9927,-1,0.00020869794,0.9997913
9928,psychotropic drugs,19,21,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9928,-1,0.96318066,0.03681934
9929,cardiac complications,11,13,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9929,-1,0.00017889708,0.9998211
9930,phenothiazines,16,17,110,124,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9930,-1,0.99948066,0.00051932613
9933,immunodeficient,10,11,89,104,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,-1,-1,-1,9933,-1,0.00020964828,0.9997904
9934,anaemia,1,2,4,11,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9934,-1,0.00020312888,0.9997969
9935,3'-azido-3'dideoxythymidine,4,5,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9935,-1,0.999488,0.0005119914
9936,AZT,6,7,52,55,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9936,-1,0.9994936,0.0005063508
9937,AIDS,7,8,31,35,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9937,-1,0.00020084248,0.9997992
9939,leukaemia,17,18,89,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9939,-1,0.00019848964,0.9998016
9940,anaemia,27,28,141,148,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9940,-1,0.00020099115,0.9997991
9941,AZT,11,12,58,61,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9941,-1,0.99936587,0.00063420436
9942,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9942,-1,0.8454053,0.1545947
9943,AZT,0,1,0,3,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9943,-1,0.99945766,0.0005423095
9944,anaemia,2,3,13,20,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9944,-1,0.00022487451,0.9997751
9945,anaemia,2,3,12,19,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9945,-1,0.00020803773,0.9997919
9946,AZT,13,14,68,71,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9946,-1,0.9993905,0.0006094629
9947,AZT,18,19,113,116,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,-1,9947,-1,0.99941695,0.0005831162
9948,AZT,8,9,42,45,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,-1,-1,-1,9948,-1,0.99941885,0.0005812227
9949,anaemia,6,7,35,42,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9949,-1,0.00021224648,0.99978775
9950,phenylhydrazine,11,12,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9950,-1,0.9994642,0.0005358454
9951,PHZ,13,14,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9951,-1,0.99943775,0.00056221423
9952,AZT,15,16,97,100,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9952,-1,0.9991757,0.0008242083
9953,PHZ,17,18,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9953,-1,0.9992662,0.0007338229
9954,anaemia,24,25,146,153,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9954,-1,0.00020414687,0.99979585
9955,reticulocytosis,2,3,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9955,-1,0.00019598338,0.9998041
9956,anaemia,9,10,61,68,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9956,-1,0.00019331784,0.9998067
9957,AZT,12,13,81,84,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9957,-1,0.9994424,0.00055758056
9958,anaemia,2,3,23,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,-1,9958,-1,0.00020950261,0.9997905
9959,postoperative delirium,9,11,63,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9959,-1,0.00024403611,0.9997559
9960,hip fracture,15,17,117,129,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9960,-1,0.0002152238,0.99978477
9961,hip fracture,13,15,100,112,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9961,-1,0.0002100831,0.9997899
9962,postoperative delirium,24,26,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9962,-1,0.00022944174,0.9997706
9965,hip fracture,33,35,207,219,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,-1,9965,-1,0.0002091675,0.99979085
9968,Mental Disorders,12,14,87,103,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9968,-1,0.00021613028,0.99978393
9970,postoperative delirium,3,5,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9970,-1,0.0002204142,0.99977964
9971,P=.02,31,32,149,154,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9971,-1,0.588907,0.41109303
9973,SD,4,5,13,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9973,-1,0.017960448,0.9820395
9975,P=.01,32,33,171,176,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9975,-1,0.04772677,0.9522732
9977,postoperative delirium,12,14,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,-1,-1,9977,-1,0.00021143249,0.9997886
9978,postoperative delirium,18,20,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,-1,-1,9978,-1,0.00021893984,0.9997811
9981,serotonin reuptake inhibitor,14,17,90,118,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,-1,9981,-1,0.99863005,0.001370013
9984,SD,20,21,123,125,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9984,-1,0.00067625585,0.9993237
9985,selective serotonin reuptake inhibitor,25,29,140,178,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9985,-1,0.9994753,0.0005247268
9986,SSRI,30,31,180,184,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9986,-1,0.0026940347,0.997306
9987,SD,34,35,190,192,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9987,-1,0.0006346385,0.9993654
9988,SSRIs,40,41,220,225,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9988,-1,0.00062097993,0.99937904
9989,SSRI,18,19,106,110,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,-1,9989,-1,0.00023818738,0.99976176
9991,mg,10,11,52,54,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,-1,-1,-1,9991,-1,0.96282697,0.037173048
9992,Erectile Dysfunction,37,39,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,-1,9992,-1,0.00023845075,0.9997615
9993,sd,11,12,48,50,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9993,-1,0.008640272,0.99135965
9995,P=,47,48,193,195,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9995,-1,0.21368806,0.786312
9997,P=,20,21,94,96,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,-1,9997,-1,0.29688698,0.703113
9999,P=,29,30,133,135,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,-1,9999,-1,0.20667993,0.7933201
10001,P=,21,22,91,93,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,-1,10001,-1,0.19998814,0.8000118
10002,P=,9,10,49,51,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,-1,10002,-1,0.24175225,0.7582478
10003,SD,15,16,97,99,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,10003,-1,0.00026155886,0.9997384
10004,SSRI,19,20,109,113,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,10004,-1,0.00038255585,0.99961746
10006,SD,9,10,58,60,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,10006,-1,0.00025873558,0.99974126
10007,SSRIs,12,13,72,77,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,10007,-1,0.000234392,0.9997656
10013,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,10013,-1,0.00022408497,0.99977595
10014,SE,22,23,146,148,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,10014,-1,0.998911,0.0010889511
10015,Spontaneous recurrent seizures,0,3,0,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,10015,-1,0.00021288816,0.99978715
10016,SRS,4,5,32,35,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,10016,-1,0.0002095987,0.9997904
10019,SRS,11,12,72,75,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,-1,10019,-1,0.00021713908,0.99978286
10028,neuronal loss,15,17,91,104,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,-1,-1,-1,10028,-1,0.0002028935,0.99979717
10032,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,-1,-1,10032,-1,0.00020786366,0.99979216
10035,mg,13,14,95,97,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10035,-1,0.99806505,0.0019349552
10036,N=10,15,16,99,103,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10036,-1,0.45821378,0.5417862
10037,N=10,21,22,118,122,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10037,-1,0.68893766,0.31106237
10043,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,-1,10043,-1,0.00021597413,0.99978405
10045,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,-1,10045,-1,0.00020908075,0.99979097
10048,Midazolan,13,14,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10048,-1,0.99944526,0.00055468763
10049,MZ,15,16,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10049,-1,0.9923543,0.007645667
10050,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10050,-1,0.9994436,0.00055636454
10051,FL,20,21,100,102,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10051,-1,0.99908113,0.0009188767
10052,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,-1,10052,-1,0.03624336,0.9637566
10053,MZ,14,15,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,-1,-1,-1,10053,-1,0.91526914,0.084730834
10055,myocardiopathy,21,22,108,122,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10055,-1,0.0002064392,0.9997936
10056,MP,23,24,124,126,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10056,-1,0.9979189,0.002081121
10058,MR,34,35,173,175,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10058,-1,0.00021318065,0.9997868
10059,MZ,38,39,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10059,-1,0.99894327,0.0010568027
10060,MZ,4,5,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10060,-1,0.00028602552,0.99971396
10061,FL,6,7,25,27,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10061,-1,0.0004118216,0.9995882
10062,mg,9,10,43,45,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10062,-1,0.8437664,0.15623361
10063,mg,12,13,61,63,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10063,-1,0.9430856,0.056914408
10066,obstruction,29,30,128,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10066,-1,0.00021231227,0.99978775
10068,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10068,-1,0.99928445,0.0007156273
10070,MR,6,7,45,47,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10070,-1,0.00029277126,0.99970716
10071,MP,8,9,49,51,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10071,-1,0.016192194,0.98380774
10072,MZ,17,18,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10072,-1,0.0010517014,0.9989483
10073,mg,21,22,85,87,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10073,-1,0.5827417,0.41725838
10074,p<0.001,28,29,118,125,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10074,-1,0.101129666,0.89887035
10075,MP,10,11,34,36,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10075,-1,0.3482904,0.6517096
10076,MR,19,20,70,72,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10076,-1,0.00022600839,0.99977404
10077,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,-1,10077,-1,0.9994785,0.0005214978
10079,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10079,-1,0.99948895,0.0005110757
10081,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10081,-1,0.0002085402,0.99979144
10082,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10082,-1,0.00020691156,0.9997931
10083,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,-1,-1,-1,10083,-1,0.9994653,0.0005347148
10086,SD,25,26,114,116,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,-1,-1,10086,-1,0.18052036,0.81947964
10087,ischemic,5,6,29,37,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,-1,10087,-1,0.00021020712,0.9997898
10090,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,-1,10090,-1,0.9994893,0.00051066134
10095,cardiac dysrhythmias,23,25,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10095,-1,0.00022748063,0.9997725
10098,violent behavior,31,33,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10098,-1,0.00023816743,0.9997619
10100,xerostomia,11,12,76,86,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10100,-1,0.0003267889,0.99967325
10101,caries,14,15,96,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10101,-1,0.00024407917,0.9997559
10103,tooth wear,24,26,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10103,-1,0.00024608642,0.9997539
10106,bad breath,12,14,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,-1,-1,10106,-1,0.0002363852,0.99976367
10107,carious lesions,16,18,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,-1,-1,-1,10107,-1,0.0002093768,0.9997906
10109,carious episodes,15,17,89,105,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,-1,-1,-1,10109,-1,0.00023656081,0.9997634
10110,lead,15,16,98,102,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,-1,10110,-1,0.010650677,0.98934937
10112,oral manifestations,7,9,50,69,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10112,-1,0.00025789475,0.9997421
10114,methamphetamines,26,27,176,192,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10114,-1,0.99944884,0.0005511811
10117,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10117,-1,0.00020806491,0.9997919
10118,reactive oxygen species,21,24,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10118,-1,0.5067382,0.4932618
10125,DNA damage,16,18,100,110,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,-1,10125,-1,0.00023267306,0.99976736
10131,Metformin,0,1,0,9,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,-1,10131,-1,0.999419,0.00058109727
10133,metformin,3,4,22,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10133,-1,0.9994179,0.0005821633
10134,vascular dysfunction,16,18,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10134,-1,0.00022351886,0.99977654
10135,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,-1,10135,-1,0.004919312,0.9950807
10136,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10136,-1,0.20224907,0.79775095
10137,c,17,18,122,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10137,-1,0.9991722,0.0008277659
10139,Metformin,0,1,0,9,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10139,-1,0.99943286,0.0005671497
10140,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10140,-1,0.0002169154,0.9997831
10141,Metformin,0,1,0,9,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,-1,-1,-1,10141,-1,0.9993413,0.00065867894
10143,kidney dysfunction,5,7,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10143,-1,0.00021105484,0.99978894
10144,metformin,11,12,68,77,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10144,-1,0.9993468,0.0006532332
10146,c,10,11,79,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10146,-1,0.99936324,0.0006367092
10147,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10147,-1,0.15301877,0.8469812
10148,metformin,22,23,135,144,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10148,-1,0.99935573,0.00064423674
10149,metformin,9,10,53,62,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10149,-1,0.99934,0.00065994624
10150,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10150,-1,0.0022168811,0.9977831
10152,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,-1,10152,-1,0.99932563,0.000674448
10153,contrast,5,6,39,47,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10153,-1,0.99914277,0.0008571718
10155,CIN,9,10,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10155,-1,0.9957151,0.0042848554
10156,CIN,7,8,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10156,-1,0.39388895,0.606111
10157,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10157,-1,0.999366,0.0006340061
10158,CM,14,15,88,90,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10158,-1,0.99932337,0.0006766968
10159,iopromide,17,18,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10159,-1,0.99945587,0.0005441756
10160,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10160,-1,0.99947196,0.0005280514
10161,CM,43,44,239,241,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10161,-1,0.99920243,0.0007975906
10162,iopromide,9,10,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10162,-1,0.9994821,0.0005179578
10163,n,14,15,79,80,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10163,-1,0.4110358,0.58896416
10164,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10164,-1,0.999488,0.0005119889
10165,n,24,25,108,109,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10165,-1,0.49849546,0.50150454
10167,Na,3,4,14,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10167,-1,0.9993411,0.00065895397
10169,K,8,9,30,31,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10169,-1,0.99934024,0.00065976585
10171,Cr,14,15,50,52,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10171,-1,0.034593973,0.965406
10172,h,19,20,71,72,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10172,-1,0.0124932295,0.98750675
10173,CM,38,39,170,172,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10173,-1,0.9951584,0.0048416546
10174,Na,3,4,18,20,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10174,-1,0.9990534,0.00094658625
10175,Cr,5,6,25,27,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10175,-1,0.0003340801,0.999666
10176,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10176,-1,0.00020827274,0.9997918
10177,Injury to the kidney,5,9,23,43,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10177,-1,0.0005111909,0.99948883
10178,Failure of kidney function,10,14,45,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10178,-1,0.00021437652,0.9997856
10179,Loss of kidney function,15,19,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10179,-1,0.00022555693,0.9997744
10181,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10181,-1,0.9899498,0.010050158
10182,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,-1,10182,-1,0.009750537,0.99024945
10185,CIN,7,8,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10185,-1,0.99741936,0.0025806094
10186,CM,17,18,90,92,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10186,-1,0.9979748,0.0020251356
10187,CIN,40,41,217,220,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10187,-1,0.9971547,0.0028452314
10188,CM,47,48,257,259,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10188,-1,0.9985852,0.0014147566
10189,p,49,50,261,262,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10189,-1,0.38843194,0.6115681
10190,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10190,-1,0.99938035,0.0006196192
10191,congenital heart diseases,10,13,47,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10191,-1,0.00020007545,0.9997999
10192,p,28,29,161,162,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10192,-1,0.14979544,0.8502046
10193,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,-1,10193,-1,0.00023861974,0.9997614
10194,CM,13,14,73,75,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10194,-1,0.99608153,0.0039185164
10195,cyanosis,20,21,100,108,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10195,-1,0.0002045311,0.9997955
10196,CIN,24,25,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10196,-1,0.9991897,0.00081033487
10197,Antituberculosis,0,1,0,16,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,-1,-1,10197,-1,0.02220388,0.97779614
10199,Antituberculosis,0,1,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10199,-1,0.017844744,0.98215526
10201,ALF,13,14,102,105,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10201,-1,0.0011157687,0.99888426
10202,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,-1,10202,-1,0.00043094117,0.999569
10203,hepatitis virus infection,10,13,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,-1,10203,-1,0.00021923271,0.99978083
10205,icterus encephalopathy,7,9,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,-1,-1,10205,-1,0.00031546009,0.9996846
10206,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,-1,10206,-1,0.00023743598,0.9997626
10208,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,-1,-1,10208,-1,0.00017814708,0.99982184
10209,Gastrointestinal bleed,0,2,0,22,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10209,-1,0.008625169,0.9913748
10212,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10212,-1,0.00017878693,0.99982125
10213,hepatitis E virus (HEV,2,7,14,36,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10213,-1,0.00055857206,0.99944144
10214,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10214,-1,0.00021741565,0.9997826
10215,n,13,14,64,65,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,-1,10215,-1,0.0714676,0.9285324
10218,ALF,7,8,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,-1,10218,-1,0.00023272121,0.99976724
10221,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,-1,10221,-1,0.9994649,0.00053510553
10223,nitrous oxide,6,8,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,-1,-1,-1,10223,-1,0.99945766,0.00054239284
10233,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,-1,10233,-1,0.00021744447,0.9997826
10235,ACE) inhibitors,8,11,57,72,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10235,-1,0.99944454,0.00055549236
10236,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10236,-1,0.00020698042,0.999793
10238,ACE inhibitor enalapril,6,9,28,51,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,-1,-1,10238,-1,0.9994836,0.00051641377
10240,mg enalapril,4,6,25,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,-1,10240,-1,0.9992913,0.0007087073
10247,dysgenesis,1,2,10,20,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,-1,-1,-1,10247,-1,0.00016913992,0.99983084
10250,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,-1,-1,10250,-1,0.0001958552,0.9998042
10251,brainstem dysgenesis,11,13,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,-1,10251,-1,0.00018534128,0.9998147
10253,serotonin reuptake inhibitors,10,13,72,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,-1,-1,-1,10253,-1,0.9987754,0.001224537
10257,n,12,13,59,60,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,-1,10257,-1,0.1638777,0.83612233
10261,P,29,30,181,182,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,-1,10261,-1,0.86116815,0.1388319
10262,serotonin reuptake inhibitors,11,14,76,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10262,-1,0.99940264,0.00059740513
10263,SSRIs,15,16,107,112,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10263,-1,0.44264543,0.55735457
10264,P,28,29,172,173,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10264,-1,0.77591085,0.2240892
10265,P,41,42,218,219,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10265,-1,0.6632522,0.33674783
10268,SSRIs,10,11,61,66,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,-1,-1,10268,-1,0.0002311335,0.9997689
10271,SSRI,12,13,88,92,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,-1,10271,-1,0.0002308331,0.99976915
10272,fracture,20,21,135,143,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,-1,10272,-1,0.0002039037,0.9997961
10273,startle,1,2,17,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10273,-1,0.00026258986,0.99973744
10274,startle,6,7,49,56,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10274,-1,0.00025369134,0.99974626
10275,startle,6,7,45,52,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10275,-1,0.0003503842,0.99964964
10276,anxiety,15,16,90,97,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10276,-1,0.0002452834,0.9997547
10277,contrast,1,2,3,11,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10277,-1,0.64880353,0.35119647
10278,startle,5,6,34,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10278,-1,0.0002636598,0.99973637
10280,5-HT(2C,20,21,116,123,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10280,-1,0.9995148,0.00048524237
10281,m-chlorophenylpiperazine,24,25,142,166,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10281,-1,0.9995208,0.00047917914
10282,mCPP,26,27,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10282,-1,0.99943477,0.0005651509
10283,pentylenetetrazole,39,40,228,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10283,-1,0.99953127,0.00046879397
10284,PTZ,41,42,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10284,-1,0.9989097,0.0010902636
10285,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,-1,10285,-1,0.99940133,0.0005986259
10288,startle,5,6,42,49,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10288,-1,0.00024440215,0.99975556
10289,mCPP,12,13,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10289,-1,0.9086685,0.091331415
10290,startle,15,16,103,110,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10290,-1,0.00024147787,0.99975854
10291,PTZ,23,24,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10291,-1,0.9357911,0.06420894
10292,startle,26,27,163,170,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10292,-1,0.00024735948,0.9997526
10293,contrast,3,4,16,24,"CONCLUSIONS: In contrast to findings in the FPS paradigm, none of the drugs were able to exacerbate the LES response.",20394767_8,-1,-1,-1,10293,-1,0.05853164,0.9414683
10296,dermatitis eruptions,8,10,57,77,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10296,-1,0.00020136747,0.9997986
10298,facial dermatitis,20,22,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10298,-1,0.00021693711,0.9997831
10299,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,-1,-1,10299,-1,0.00021438878,0.9997856
10301,pimecrolimus,9,10,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,-1,10301,-1,0.9994831,0.0005168055
10303,Central nervous system complications,0,4,0,36,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,-1,-1,10303,-1,0.00019624532,0.9998037
10305,Central nervous system (CNS) complications,0,7,0,42,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10305,-1,0.00023809452,0.9997619
10307,neurological complications,6,8,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,-1,-1,-1,10307,-1,0.0002170236,0.999783
10308,leukemic infiltration,4,6,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10308,-1,0.00022306386,0.9997769
10311,neurocognitive defects,18,20,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10311,-1,0.00022473196,0.99977523
10313,n,8,9,78,79,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10313,-1,0.9993544,0.0006456179
10315,n,15,16,95,96,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10315,-1,0.99927753,0.0007224982
10317,n,24,25,127,128,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10317,-1,0.9994128,0.00058723
10318,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10318,-1,0.0056563695,0.99434364
10319,n,33,34,168,169,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10319,-1,0.9994129,0.000587117
10320,syndrome of inappropriate antidiuretic hormone secretion,38,44,176,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10320,-1,0.0009544425,0.99904555
10321,n,45,46,234,235,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10321,-1,0.9993938,0.0006061447
10322,n,55,56,273,274,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10322,-1,0.9993655,0.00063447934
10324,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,-1,-1,-1,10324,-1,0.999471,0.0005289854
10325,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,-1,10325,-1,0.005300964,0.994699
10326,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,-1,-1,10326,-1,0.0060601844,0.9939399
10327,nitric oxide synthase,8,11,56,77,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10327,-1,0.999159,0.0008410765
10328,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10328,-1,0.9994673,0.0005326683
10329,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10329,-1,0.004494448,0.9955056
10332,GSH,16,17,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10332,-1,0.99939096,0.00060900796
10333,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10333,-1,0.99941444,0.0005856125
10335,contrast,1,2,3,11,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10335,-1,0.35167238,0.64832765
10336,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10336,-1,0.9993888,0.0006111577
10338,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,-1,-1,-1,10338,-1,0.99950624,0.00049380166
10339,Coenzyme Q10,0,2,0,12,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10339,-1,0.99948066,0.00051935634
10340,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10340,-1,0.0020937985,0.9979062
10341,coenzyme Q10,4,6,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10341,-1,0.9994791,0.00052086887
10342,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10342,-1,0.00020511755,0.9997949
10344,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,-1,-1,-1,10344,-1,0.999483,0.0005169905
10346,Coenzyme Q10,0,2,0,12,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,-1,-1,-1,10346,-1,0.99946994,0.0005301161
10350,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10350,-1,0.99945503,0.0005449893
10351,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10351,-1,0.9994517,0.00054831407
10352,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10352,-1,0.9994259,0.00057412696
10353,tumor necrosis,28,30,208,222,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10353,-1,0.00020820899,0.9997918
10354,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10354,-1,0.9994362,0.0005638234
10355,platinum,35,36,254,262,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10355,-1,0.9994338,0.0005662075
10356,selenium,44,45,315,323,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10356,-1,0.9994242,0.00057575
10357,zinc,46,47,328,332,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10357,-1,0.9994342,0.00056579773
10359,renal tissue damage,3,6,24,43,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10359,-1,0.00020727942,0.99979275
10361,coenzyme Q10,12,14,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10361,-1,0.9995048,0.00049515394
10362,coenzyme Q10,4,6,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10362,-1,0.9994937,0.0005062818
10363,nitric oxide synthase,13,16,130,151,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10363,-1,0.011427622,0.98857236
10364,coenzyme Q10,4,6,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10364,-1,0.9994893,0.0005106414
10365,cisplatin nephrotoxicity,15,17,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10365,-1,0.0019978182,0.99800223
10367,bile duct injury,3,6,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,-1,-1,10367,-1,0.00022887955,0.9997712
10369,polymyositis,6,7,36,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,-1,-1,10369,-1,0.00019302846,0.99980694
10376,bile duct injury,19,22,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,-1,10376,-1,0.00022516889,0.9997749
10382,bipolar I disorder,24,27,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10382,-1,0.00046803354,0.999532
10383,psychotic,30,31,187,196,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10383,-1,0.00020664225,0.99979335
10386,mg,21,22,137,139,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10386,-1,0.99946815,0.00053192175
10388,mg,31,32,175,177,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10388,-1,0.99944633,0.0005536566
10390,mg,40,41,212,214,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10390,-1,0.9994572,0.00054281193
10392,mg,29,30,185,187,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10392,-1,0.99946755,0.00053244876
10395,mg,73,74,381,383,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10395,-1,0.99946827,0.0005318038
10398,mg,24,25,138,140,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10398,-1,0.9994388,0.00056111166
10400,mg,27,28,106,108,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,-1,-1,-1,10400,-1,0.9994531,0.00054689124
10404,mg,26,27,107,109,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,-1,-1,10404,-1,0.9994531,0.0005468871
10412,leukaemia,14,15,120,129,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10412,-1,0.00021595023,0.99978405
10413,lymphoma,16,17,134,142,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10413,-1,0.00021739845,0.9997826
10415,AraG,8,9,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10415,-1,0.9993538,0.0006462295
10417,VP,16,17,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10417,-1,0.00027931636,0.99972063
10419,CPM,21,22,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10419,-1,0.99905056,0.00094947766
10420,leukaemia,40,41,219,228,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10420,-1,0.00022368874,0.9997763
10421,lymphoma,42,43,232,240,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10421,-1,0.00022598232,0.99977404
10422,AraG,8,9,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10422,-1,0.9994041,0.00059591513
10423,sensory and motor neuropathy,14,18,77,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10423,-1,0.00023276871,0.99976724
10424,musculoskeletal pain,19,21,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10424,-1,0.0002249663,0.999775
10425,Haematological toxicity,0,2,0,23,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10425,-1,0.0002252507,0.99977475
10426,AraG,8,9,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10426,-1,0.99942005,0.0005800298
10427,AraG,7,8,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10427,-1,0.9994247,0.0005753134
10430,neurological toxicity,19,21,128,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10430,-1,0.00022914525,0.9997708
10434,DA,7,8,37,39,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10434,-1,0.9994172,0.0005828378
10437,DA,23,24,155,157,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10437,-1,0.99941075,0.0005893173
10439,DA,32,33,223,225,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10439,-1,0.9994061,0.00059392804
10441,DA,13,14,78,80,"However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.",20533999_2,-1,-1,-1,10441,-1,0.9989924,0.0010075781
10442,DA neurotoxicity,19,21,155,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,-1,10442,-1,0.005273407,0.9947266
10443,DA,13,14,75,77,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10443,-1,0.9992213,0.0007786898
10444,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10444,-1,0.005327231,0.99467283
10445,METH,25,26,140,144,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10445,-1,0.9993394,0.00066053116
10446,DA deficits,13,15,86,97,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10446,-1,0.005210557,0.9947895
10447,dopaminergic deficits,17,19,119,140,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10447,-1,0.0001942865,0.99980575
10448,DA,7,8,48,50,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10448,-1,0.99936026,0.00063976157
10450,DA,24,25,174,176,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10450,-1,0.9993599,0.0006401092
10461,and kidney injury,20,23,123,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,-1,10461,-1,0.0002446194,0.9997553
10463,C,9,10,49,50,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,-1,-1,10463,-1,0.99911326,0.00088677445
10464,cardiac and renal lesions,25,29,147,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,-1,10464,-1,0.00022286575,0.99977714
10467,atrial tachyarrhythmia,1,3,19,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,-1,10467,-1,0.00016391641,0.9998361
10469,atrial tachyarrhythmia,5,7,34,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,-1,-1,10469,-1,0.00021594857,0.99978405
10471,atenolol,6,7,43,51,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,-1,-1,10471,-1,0.99910563,0.0008943902
10473,atenolol,11,12,59,67,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,-1,-1,10473,-1,0.9620401,0.03795983
10475,atrial tachyarrhythmia,3,5,31,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10475,-1,0.00020466355,0.9997954
10476,SIAT,6,7,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10476,-1,0.99931777,0.0006822558
10477,SIAT,5,6,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,-1,-1,-1,10477,-1,0.00020244998,0.9997975
10478,SIAT,19,20,122,126,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,-1,10478,-1,0.00034491337,0.9996551
10480,SIAT,14,15,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,-1,10480,-1,0.00024011204,0.99975985
10482,SIAT,11,12,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,-1,-1,-1,10482,-1,0.0002519442,0.99974805
10485,atenolol,47,48,272,280,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,-1,-1,10485,-1,0.9625158,0.037484277
10486,diabetes mellitus.1,18,20,128,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,-1,10486,-1,0.096947856,0.9030521
10488,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,-1,10488,-1,0.0010182783,0.99898165
10490,ATP,22,23,139,142,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10490,-1,0.99941146,0.00058850023
10491,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10491,-1,0.9994809,0.0005191846
10493,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,-1,10493,-1,0.0012271543,0.9987728
10495,ATP,19,20,130,133,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10495,-1,0.9994236,0.000576379
10496,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10496,-1,0.9994804,0.00051963615
10498,NMDA,4,5,44,48,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,-1,10498,-1,0.9994387,0.0005613231
10505,glutamate NMDA,9,11,91,105,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10505,-1,0.9994617,0.00053829286
10506,antagonists,12,13,115,126,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10506,-1,0.999435,0.00056502037
10507,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10507,-1,0.9991671,0.00083290716
10508,AP7,23,24,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10508,-1,0.999421,0.0005789701
10509,NMDA,35,36,208,212,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10509,-1,0.9994442,0.00055575185
10510,NMDA,40,41,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10510,-1,0.99944204,0.0005579822
10511,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10511,-1,0.025440926,0.97455907
10512,AP7,9,10,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10512,-1,0.0002548844,0.9997451
10515,NMDA,5,6,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,-1,10515,-1,0.9993179,0.00068218587
10517,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,-1,10517,-1,0.014291671,0.98570836
10519,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10519,-1,0.014794052,0.98520595
10520,PAN,5,6,43,46,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10520,-1,0.9994392,0.0005608036
10523,PAN,2,3,13,16,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,-1,-1,10523,-1,0.9991702,0.0008298557
10525,PAN,13,14,78,81,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,-1,-1,-1,10525,-1,0.99833435,0.0016656623
10526,OCD,9,10,68,71,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10526,-1,0.00020844597,0.99979156
10527,stereotypies,23,24,161,173,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10527,-1,0.0005101045,0.9994899
10528,anxiety,25,26,177,184,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10528,-1,0.00021728301,0.99978274
10529,antidepressant clomipramine,9,11,55,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,-1,10529,-1,0.9994972,0.0005028
10531,anxiety,16,17,126,133,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10531,-1,0.00019854584,0.99980146
10532,behavioral inflexibility,26,28,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10532,-1,0.00019699127,0.999803
10534,hoarding,51,52,338,346,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10534,-1,0.00020064706,0.99979943
10535,corticostriatal dysfunction,54,56,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10535,-1,0.0031140638,0.99688596
10539,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,-1,10539,-1,0.00021005327,0.99979
10540,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10540,-1,0.00020241468,0.99979764
10541,psychiatric disorders,33,35,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10541,-1,0.00020212155,0.9997979
10542,aortic aneurysm,16,18,112,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,-1,10542,-1,0.00020629339,0.9997937
10543,thoracic aortic aneurysm,12,15,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10543,-1,0.00020863366,0.9997913
10544,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10544,-1,0.00028187278,0.9997181
10545,calcium chloride,19,21,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10545,-1,0.99942493,0.00057506264
10546,arterial injury,23,25,130,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10546,-1,0.00020650316,0.99979347
10547,matrix metalloproteinases,40,42,227,252,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10547,-1,0.99847454,0.00152541
10548,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10548,-1,0.042968918,0.9570311
10549,CaCl(2),13,15,72,79,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10549,-1,0.95075905,0.04924095
10550,NaCl,19,20,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10550,-1,0.99946076,0.00053919584
10551,n=12,12,13,80,84,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10551,-1,0.9913372,0.008662855
10552,n=12,19,20,120,124,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10552,-1,0.9884321,0.0115679
10553,aneurymal alteration,14,16,114,134,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10553,-1,0.00019986133,0.99980015
10554,n=6,17,18,136,139,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10554,-1,0.43920326,0.5607967
10555,media degeneration,23,25,147,165,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10555,-1,0.004439827,0.99556017
10556,n=12,39,40,259,263,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10556,-1,0.450289,0.549711
10557,p<0.01,16,17,94,100,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,-1,10557,-1,0.075965315,0.9240347
10558,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10558,-1,0.0002647697,0.9997352
10559,CaCl(2),10,12,63,70,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10559,-1,0.9994337,0.00056632573
10560,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10560,-1,0.00020955116,0.9997905
10565,organophosphorus (OP) poisons,13,18,105,134,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10565,-1,0.054368615,0.9456314
10568,OP compound,13,15,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,-1,-1,10568,-1,0.9989699,0.0010301013
10569,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,-1,-1,10569,-1,0.00019883153,0.9998012
10574,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10574,-1,0.00020329433,0.9997967
10575,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10575,-1,0.00020365171,0.99979633
10580,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10580,-1,0.99939156,0.00060842984
10581,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10581,-1,0.9993563,0.0006436562
10582,CHF,2,3,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,-1,10582,-1,0.00023878473,0.99976116
10586,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,-1,10586,-1,0.00023123312,0.9997688
10588,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,-1,10588,-1,0.00021439798,0.9997856
10592,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,-1,-1,10592,-1,0.00017758131,0.99982244
10595,drugs,2,3,18,23,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10595,-1,0.99947375,0.0005263148
10598,cognitive impairment,12,14,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10598,-1,0.0002191351,0.99978083
10599,cognitive impairment,16,18,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,-1,10599,-1,0.00019565194,0.9998043
10602,cognitive impairment,20,22,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,-1,-1,-1,10602,-1,0.00022147065,0.99977857
10609,reduced glutathione,16,18,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,-1,-1,-1,10609,-1,0.9994879,0.00051213143
10612,impairment of learning and memory,11,16,87,120,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,-1,-1,-1,10612,-1,0.0002265326,0.99977344
10614,cognitive impairment,5,7,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,-1,-1,-1,10614,-1,0.00021642432,0.9997836
10619,deterioration of cognitive functions,11,15,73,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,-1,10619,-1,0.00020827948,0.9997917
10625,cognitive impairment,22,24,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,-1,10625,-1,0.00021809664,0.9997819
10626,crocin,9,10,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10626,-1,0.9994659,0.00053410704
10627,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10627,-1,0.00022682139,0.9997732
10628,carotenoids,6,7,45,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10628,-1,0.999418,0.00058205344
10629,crocins,8,9,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10629,-1,0.9994253,0.0005746826
10630,crocins,8,9,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10630,-1,0.9994777,0.0005223593
10631,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10631,-1,0.00021204402,0.999788
10632,streptozocin,20,21,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10632,-1,0.99948776,0.00051227014
10633,STZ,22,23,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10633,-1,0.99948573,0.00051429396
10634,n,7,8,33,34,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10634,-1,0.053074155,0.9469259
10635,crocins,27,28,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10635,-1,0.9994784,0.00052161067
10636,STZ,37,38,124,127,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10636,-1,0.9993748,0.0006252678
10637,STZ,43,44,138,141,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10637,-1,0.9994641,0.0005359701
10638,crocins,45,46,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10638,-1,0.99946815,0.0005318659
10639,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,-1,10639,-1,0.00030706724,0.9996929
10640,STZ,1,2,3,6,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10640,-1,0.99943644,0.00056356256
10641,crocin,3,4,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10641,-1,0.99943584,0.00056415936
10642,crocin,7,8,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10642,-1,0.99943644,0.0005635193
10643,crocin,2,3,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,-1,-1,-1,10643,-1,0.99943644,0.0005635032
10644,crocin,7,8,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,-1,10644,-1,0.99944824,0.0005518032
10645,crocin,3,4,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,-1,10645,-1,0.99943334,0.0005666729
10647,crocin,10,11,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10647,-1,0.9994711,0.00052893144
10649,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10649,-1,0.00020017964,0.9997998
10650,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10650,-1,0.00027044205,0.9997296
10652,hemolytic anemia?BACKGROUND/AIMS,10,12,67,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10652,-1,0.008569982,0.99143
10654,angiogenesis inhibitors,25,27,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10654,-1,0.8682337,0.13176638
10655,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10655,-1,0.99948597,0.0005140153
10659,chronically infected with hepatitis C virus,4,10,27,70,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10659,-1,0.00042716655,0.9995728
10660,pegylated interferon alpha 2a,13,17,87,116,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10660,-1,0.99949706,0.0005029389
10662,contrast,1,2,3,11,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10662,-1,0.081218734,0.9187813
10663,pegylated interferon,16,18,102,122,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10663,-1,0.9994727,0.0005273231
10667,hepatitis C,24,26,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,-1,-1,10667,-1,0.12815456,0.8718454
10681,P,28,29,140,141,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,-1,10681,-1,0.14722717,0.85277283
10685,psychosis,8,9,69,78,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,-1,10685,-1,0.00023332774,0.99976665
10686,psychotic disorders,14,16,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,-1,10686,-1,0.00020195666,0.9997981
10689,antipsychotics,14,15,90,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,-1,10689,-1,0.9994654,0.0005345889
10693,phencyclidine,11,12,75,88,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,-1,10693,-1,0.9995264,0.00047363347
10695,psychotic disorders,28,30,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,-1,-1,10695,-1,0.00019755632,0.9998024
10697,psychosis,5,6,47,56,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10697,-1,0.00018908588,0.999811
10698,paranoid type schizophrenia,11,14,81,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10698,-1,0.0005416677,0.9994584
10699,psychosis,18,19,98,107,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10699,-1,0.00021471218,0.99978524
10700,psychosis,30,31,178,187,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,-1,10700,-1,0.0002300595,0.99977
10702,psychosis,7,8,52,61,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,-1,10702,-1,0.00022227663,0.99977773
10703,psychosis,31,32,185,194,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,-1,10703,-1,0.00022631025,0.9997737
10704,psychosis,13,14,83,92,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,-1,10704,-1,0.00021753716,0.9997825
10710,h,12,13,31,32,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,-1,10710,-1,0.082064345,0.9179356
10711,impairment of attention and memory,13,18,72,106,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,-1,-1,-1,10711,-1,0.00021110293,0.99978894
10714,Fluoropyrimidines,5,6,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10714,-1,0.9994741,0.00052592164
10716,5-FU,11,12,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10716,-1,0.9994765,0.0005235358
10718,head and neck cancers,30,34,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10718,-1,0.00024863917,0.9997514
10721,renal and kidney disease,27,31,154,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10721,-1,0.00022567462,0.9997743
10724,5-FU,10,11,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,-1,10724,-1,0.9993986,0.00060140074
10725,head and neck cancers,25,29,157,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,-1,-1,10725,-1,0.0005972588,0.99940276
10728,"nausea, vomiting",11,14,71,87,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,-1,-1,10728,-1,0.00023815107,0.9997619
10731,hepatic and renal dysfunctions,17,21,106,136,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,-1,-1,-1,10731,-1,0.00023624279,0.9997638
10732,psychosis,5,6,40,49,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10732,-1,0.00022531598,0.99977463
10733,NMDA,4,5,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,-1,-1,10733,-1,0.9994684,0.00053157524
10735,NMDA,11,12,80,84,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10735,-1,0.9994122,0.0005877989
10740,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,-1,10740,-1,0.0020052188,0.9979948
10742,psychosis,2,3,18,27,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10742,-1,0.00019114475,0.99980885
10747,NMDA,10,11,61,65,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10747,-1,0.99937797,0.00062199094
10748,dysfunction,12,13,75,86,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10748,-1,0.00019107353,0.99980897
10753,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,-1,10753,-1,0.00020817247,0.9997918
10761,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,-1,10761,-1,0.005166663,0.99483335
10764,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10764,-1,0.00019273203,0.9998073
10765,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10765,-1,0.00019725725,0.99980277
10767,Parkinson's disease,5,8,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,-1,10767,-1,0.00020963668,0.9997904
10769,Parkinson's disease,10,13,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,-1,-1,-1,10769,-1,0.00019418928,0.99980587
10773,Parkinson's disease,9,12,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10773,-1,0.0002225014,0.9997775
10774,dyskinetic movements,31,33,218,238,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10774,-1,0.00019717167,0.9998029
10779,parkinsonian catalepsy,6,8,55,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,-1,10779,-1,0.00021151858,0.99978846
10782,parkinsonian symptoms,13,15,98,119,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,-1,10782,-1,0.00019454195,0.9998055
10784,parkinsonian catalepsy,12,14,98,120,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,-1,-1,-1,10784,-1,0.00020803121,0.99979204
10787,neurotensin type-1 receptor antagonist SR48692,1,6,4,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,-1,10787,-1,0.9994566,0.0005433642
10790,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,-1,10790,-1,0.0021064058,0.99789363
10791,Organic mental disorder,0,3,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,-1,10791,-1,0.0027369813,0.9972631
10793,organic personality syndrome,17,20,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10793,-1,0.0002083049,0.9997917
10794,frontal lobe syndrome,34,37,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10794,-1,0.00020518407,0.9997948
10795,the,9,10,56,59,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,-1,-1,10795,-1,0.20981547,0.7901845
10796,the,17,18,108,111,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,-1,-1,10796,-1,0.0007549879,0.99924505
10798,organic personality syndrome,8,11,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,-1,-1,10798,-1,0.00019796702,0.99980205
10799,structural damage to the frontal lobe,6,12,28,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,-1,-1,10799,-1,0.00033393968,0.9996661
10801,Parkinson's disease,14,17,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,-1,10801,-1,0.00020408831,0.999796
10802,adenosine A(2A)/A(1,7,9,39,58,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10802,-1,0.9993223,0.00067774305
10803,Parkinson's disease,17,20,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10803,-1,0.00020132563,0.9997987
10804,Parkinson's disease,44,47,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10804,-1,0.00021500517,0.999785
10806,akinesia,60,61,316,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10806,-1,0.00021931612,0.9997807
10808,6-OHDA,65,66,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10808,-1,0.9994954,0.0005045617
10809,rotation,71,72,386,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10809,-1,0.0002196101,0.99978036
10824,n=10,3,4,12,16,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10824,-1,0.3721184,0.6278815
10825,n=10,14,15,62,66,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10825,-1,0.40555152,0.59444845
10826,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10826,-1,0.99941266,0.0005874131
10828,lead,8,9,52,56,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,-1,10828,-1,0.96973175,0.030268228
10832,CCNU,0,1,0,4,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10832,-1,0.9994591,0.00054088753
10833,lomustine,2,3,6,15,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10833,-1,0.9995073,0.0004926917
10835,gastrointestinal,26,27,142,158,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10835,-1,0.00018950572,0.9998105
10837,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,32,33,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10837,-1,0.99938273,0.0006172112
10838,CCNU,34,35,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10838,-1,0.99943143,0.00056857755
10839,CCNU,12,13,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,-1,10839,-1,0.99660337,0.0033966007
10840,CCNU,8,9,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,-1,10840,-1,0.99933785,0.00066214596
10842,CCNU,0,1,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10842,-1,0.99928826,0.00071182713
10843,lymphoma,9,10,48,56,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10843,-1,0.00020290435,0.99979717
10844,mast cell tumour,11,14,58,74,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10844,-1,0.00020135866,0.9997987
10845,brain tumour,15,17,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10845,-1,0.00020259077,0.9997974
10846,histiocytic tumours,18,20,90,109,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10846,-1,0.00020447669,0.9997955
10847,epitheliotropic lymphoma,21,23,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10847,-1,0.0012909361,0.9987091
10849,anaemia,13,14,79,86,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,-1,-1,10849,-1,0.00020921238,0.99979085
10851,Gastrointestinal toxicosis,0,2,0,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,-1,-1,10851,-1,0.00021151635,0.99978846
10855,hepatic failure,3,5,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,-1,-1,-1,10855,-1,0.00019472121,0.9998053
10861,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,-1,10861,-1,0.00020269105,0.9997973
10862,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,-1,-1,10862,-1,0.0002041064,0.99979585
10864,vein thrombosis,1,3,8,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10864,-1,0.00018705739,0.999813
10865,dipivalyl epinephrine,5,7,36,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10865,-1,0.9994874,0.00051259494
10866,vein thrombosis,11,13,64,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10866,-1,0.00019511503,0.9998049
10867,dipivalyl epinephrine,25,27,151,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10867,-1,0.999479,0.00052105385
10871,Pirarubicin,12,13,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,-1,10871,-1,0.9994893,0.0005106589
10873,renal and/or hepatic dysfunction,23,27,106,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10873,-1,0.00042650662,0.9995735
10874,granulocytopenia,7,8,59,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,-1,10874,-1,0.0002985078,0.99970144
10878,alopecia,12,13,76,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10878,-1,0.0020571875,0.99794275
10879,phlebitis,14,15,86,95,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10879,-1,0.00022079615,0.99977916
10882,hepatic dysfunction,6,8,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,-1,-1,10882,-1,0.00020352454,0.99979645
10883,Pirarubicin,6,7,49,60,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10883,-1,0.9994293,0.0005707061
10884,SE,14,15,85,87,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10884,-1,0.050298013,0.94970196
10885,Adriamycinol,0,1,0,12,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10885,-1,0.9994634,0.00053658284
10887,adriamycinone,4,5,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10887,-1,0.9994821,0.00051794347
10888,tetrahydropyranyladriamycinol,7,8,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10888,-1,0.9994918,0.00050816475
10890,Pirarubicin,3,4,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,-1,-1,-1,10890,-1,0.9994729,0.0005270613
10891,mesothelioma,4,5,22,34,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10891,-1,0.000211173,0.9997888
10892,leiomyosarcoma,6,7,36,50,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10892,-1,0.00021520695,0.99978477
10893,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10893,-1,0.00022158597,0.99977845
10897,audiovisual toxicity,29,31,169,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,-1,10897,-1,0.00022471997,0.99977523
10899,Visual toxicity,0,2,0,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10899,-1,0.00020948923,0.9997905
10900,dyschromatopsy,12,13,77,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10900,-1,0.00020535044,0.99979466
10901,loss of visual acuity,18,22,121,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10901,-1,0.00021857982,0.9997814
10902,retinal deposits,24,26,158,174,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10902,-1,0.45388725,0.5461128
10903,Auditory toxicity,0,2,0,17,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10903,-1,0.00020025697,0.9997998
10904,neurosensorial hearing loss,9,12,64,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10904,-1,0.0001974921,0.99980253
10906,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,-1,-1,10906,-1,0.00022273703,0.99977726
10909,aluminium,19,20,132,141,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,-1,10909,-1,0.99941146,0.0005886029
10910,audiovisual toxicity,4,6,23,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,-1,-1,10910,-1,0.00016637969,0.9998336
10912,Benzylacyclouridine,0,1,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10912,-1,0.9994808,0.00051921036
10913,marrow suppression,3,5,52,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10913,-1,0.00021864443,0.9997813
10914,immunodeficiency,9,10,104,120,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10914,-1,0.00021851712,0.99978155
10915,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10915,-1,0.9994605,0.0005395458
10916,Urd,6,7,51,54,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10916,-1,0.9994367,0.0005633636
10918,immunodeficiency virus,30,32,221,243,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10918,-1,0.00024136162,0.99975866
10920,Urd,8,9,59,62,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10920,-1,0.99946934,0.0005307268
10921,benzylacyclouridine,14,15,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10921,-1,0.99948967,0.00051025837
10922,BAU,16,17,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10922,-1,0.9994087,0.0005912864
10925,Urd,3,4,20,23,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10925,-1,0.99938476,0.0006151678
10926,Urd,15,16,87,90,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10926,-1,0.9993667,0.0006332717
10928,anemic,3,4,17,23,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10928,-1,0.00021015403,0.9997899
10929,leukopenic,5,6,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10929,-1,0.0002588155,0.99974114
10930,AZT,10,11,64,67,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10930,-1,0.99949837,0.0005015764
10931,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10931,-1,0.9965487,0.003451287
10932,AZT,26,27,143,146,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10932,-1,0.9995041,0.00049588556
10933,BAU,29,30,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10933,-1,0.9994986,0.0005013544
10936,P,43,44,236,237,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10936,-1,0.22591123,0.77408874
10937,P,57,58,299,300,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10937,-1,0.32574022,0.67425984
10938,megaloblastosis,71,72,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10938,-1,0.00020175667,0.99979824
10939,AZT,3,4,25,28,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10939,-1,0.9994698,0.00053018297
10940,BAU,11,12,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10940,-1,0.9994124,0.0005875771
10941,marrow toxicity,14,16,92,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10941,-1,0.00022593037,0.99977404
10942,BAU,10,11,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10942,-1,0.99944156,0.0005583737
10943,AZT,23,24,121,124,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10943,-1,0.99946326,0.0005367691
10946,hallucinosis,43,44,259,271,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,-1,-1,10946,-1,0.00055787934,0.99944216
10948,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,-1,-1,10948,-1,0.9994485,0.0005515305
10950,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,-1,10950,-1,0.012258055,0.98774195
10951,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10951,-1,0.9282874,0.071712606
10953,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10953,-1,0.0004335864,0.9995664
10955,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10955,-1,0.9145444,0.08545564
10956,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10956,-1,0.00047229655,0.9995277
10957,contractures,3,4,17,29,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10957,-1,0.00018524942,0.9998148
10960,P,28,29,138,139,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,-1,-1,10960,-1,0.9813928,0.018607194
10963,decreased appetite,6,8,47,65,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10963,-1,0.0002613627,0.99973863
10965,gastrointestinal symptoms,28,30,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10965,-1,0.00023231708,0.9997677
10971,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,-1,10971,-1,0.0007456061,0.9992544
10989,nalozone,29,30,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,-1,10989,-1,0.999493,0.00050701015
11001,halogenated hydroxyquinolines,2,4,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,-1,-1,11001,-1,0.9994541,0.00054586737
11003,halogenated hydroxyquinolines,12,14,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,-1,11003,-1,0.99945754,0.0005424794
11004,clioquinol,19,20,122,132,In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded.,230316_2,-1,-1,-1,11004,-1,0.9994655,0.00053446664
11005,clioquinol,7,8,36,46,"Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases.",230316_3,-1,-1,-1,11005,-1,0.9994778,0.0005221753
11006,neurological disturbance,7,9,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,11006,-1,0.00018957908,0.9998104
11008,clioquinol,25,26,157,167,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,11008,-1,0.99948716,0.00051277346
11009,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,-1,-1,11009,-1,0.00019727812,0.99980277
11010,clioquinol,13,14,70,80,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,11010,-1,0.99948335,0.00051665603
11011,acrodermatitis enteropathica,17,19,98,126,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,11011,-1,0.00021680932,0.9997832
11012,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,11012,-1,0.00020439092,0.9997956
11013,visual disturbance,10,12,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,11013,-1,0.0002018377,0.99979824
11015,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,-1,-1,11015,-1,0.00022204872,0.999778
11029,Myocardial infarction,0,2,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11029,-1,0.00018042719,0.9998196
11030,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11030,-1,0.9994671,0.00053297105
11032,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11032,-1,0.00019510108,0.9998049
11033,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11033,-1,0.99949086,0.0005090677
11034,mg,22,23,161,163,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11034,-1,0.9994728,0.0005272701
11036,myocardial ischemia,17,19,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11036,-1,0.0002053518,0.99979466
11037,coronary arterial stenosis,23,26,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11037,-1,0.00020286006,0.99979717
11038,acute coronary insufficiency,30,33,222,250,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11038,-1,0.0002063898,0.9997936
11042,impaired renal function,14,17,96,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,-1,-1,11042,-1,0.00020510152,0.9997949
11045,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,-1,-1,11045,-1,0.00020874014,0.9997913
11048,Postrenal failure,0,2,0,17,Postrenal failure was excluded by echography.,2320800_2,-1,-1,-1,11048,-1,0.0011679551,0.99883205
11049,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11049,-1,0.00020916491,0.99979085
11051,ascitis,19,20,118,125,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11051,-1,0.00020645969,0.9997936
11055,tubulopathies,8,9,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,-1,11055,-1,0.0002163385,0.9997837
11062,prostaglandin D2,7,9,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11062,-1,0.9994229,0.00057712424
11063,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11063,-1,0.999387,0.0006129868
11064,F2 alpha,13,15,86,94,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11064,-1,0.99902844,0.0009715238
11067,acetic acid writhing,20,23,134,154,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,-1,11067,-1,0.0042796247,0.99572045
11068,Prostaglandin D2,0,2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11068,-1,0.9994661,0.0005339167
11069,hyperalgesic,10,11,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11069,-1,0.00021357331,0.99978644
11070,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11070,-1,0.9994629,0.00053706183
11071,hyperalgesic,4,5,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11071,-1,0.00018618655,0.99981385
11072,pg,10,11,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11072,-1,0.99668497,0.003315021
11073,prostaglandin D2,29,31,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11073,-1,0.99947983,0.00052025466
11074,acetic acid writhing,5,8,33,53,Similar results were obtained by acetic acid writhing tests.,2322844_4,-1,-1,-1,11074,-1,0.0064426125,0.9935574
11075,hyperalgesic,1,2,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11075,-1,0.00018451801,0.9998155
11076,prostaglandin D2,4,6,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11076,-1,0.9994931,0.0005068883
11077,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11077,-1,0.9994789,0.0005210993
11078,ng,23,24,140,142,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11078,-1,0.86493516,0.13506489
11079,AH6809,28,29,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11079,-1,0.9994722,0.00052777864
11080,prostaglandin,2,3,12,25,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11080,-1,0.9994771,0.00052297476
11082,AH6809,8,9,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11082,-1,0.99948335,0.00051662076
11083,ng,16,17,102,104,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11083,-1,0.9756186,0.024381384
11084,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11084,-1,0.99949384,0.0005061901
11085,Prostaglandin F2 alpha,0,3,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,-1,-1,11085,-1,0.99946326,0.00053673587
11087,prostaglandin D2,5,7,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11087,-1,0.99948174,0.000518305
11088,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11088,-1,0.9994844,0.0005155494
11090,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,-1,-1,11090,-1,0.00018366823,0.99981636
11091,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11091,-1,0.00020621768,0.9997938
11092,organ involvement,6,8,49,66,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11092,-1,0.00021129345,0.9997887
11093,lesions,17,18,123,130,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11093,-1,0.0002056969,0.9997943
11094,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,-1,-1,11094,-1,0.00017928849,0.99982077
11095,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,-1,11095,-1,0.00016126632,0.9998387
11096,cutaneous lesions,13,15,76,93,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,-1,-1,-1,11096,-1,0.00020889223,0.9997911
11097,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11097,-1,0.00021262749,0.9997874
11099,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11099,-1,0.00021379539,0.9997862
11100,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,-1,-1,11100,-1,0.00020190678,0.9997981
11102,analgesia,5,6,35,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,-1,-1,-1,11102,-1,0.0002341202,0.99976593
11105,mg,6,7,32,34,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11105,-1,0.9990972,0.0009027412
11107,mg,23,24,128,130,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11107,-1,0.99941766,0.00058241416
11108,carbon dioxide,7,9,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,-1,11108,-1,0.99945027,0.00054973847
11109,P,3,4,18,19,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11109,-1,0.9011679,0.09883205
11111,P,12,13,56,57,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11111,-1,0.9181718,0.08182813
11113,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11113,-1,0.00019327803,0.9998067
11114,P,9,10,55,56,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11114,-1,0.4033587,0.59664124
11115,ventricular ectopic beats,15,18,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11115,-1,0.00019462357,0.9998054
11116,P,19,20,104,105,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11116,-1,0.7375842,0.26241586
11118,sinus thrombosis,1,3,9,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11118,-1,0.00021067284,0.9997893
11119,menorrhagia,11,12,81,92,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11119,-1,0.00057672,0.99942327
11121,menorrhagia,21,22,165,176,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,-1,11121,-1,0.0018223397,0.99817765
11122,menorrhagia,9,10,56,67,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11122,-1,0.0011558931,0.998844
11124,sinus thrombosis,16,18,126,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11124,-1,0.00020016954,0.9997999
11126,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,-1,11126,-1,0.9994836,0.0005163454
11127,cerebral vascular accident,8,11,46,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11127,-1,0.00020911683,0.99979085
11128,CVA,12,13,74,77,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11128,-1,0.00021500229,0.999785
11129,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11129,-1,0.00020914932,0.99979085
11130,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11130,-1,0.00021284999,0.99978715
11137,ventricular fibrillation,8,10,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11137,-1,0.00021133796,0.9997887
11138,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11138,-1,0.00021095021,0.99978906
11140,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,-1,-1,11140,-1,0.00019649154,0.9998035
11141,cardiac disturbances,9,11,68,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11141,-1,0.00019351036,0.99980646
11142,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11142,-1,0.00019309936,0.99980694
11144,ventricular fibrillation,6,8,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11144,-1,0.00020757034,0.9997924
11145,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11145,-1,0.00020790966,0.99979216
11146,ventricular fibrillation,1,3,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,-1,-1,-1,11146,-1,0.00020835655,0.9997917
11148,ventricular fibrillation,7,9,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11148,-1,0.00021049776,0.99978954
11150,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11150,-1,0.9994363,0.00056367886
11151,carbon dioxide,31,33,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11151,-1,0.99943644,0.0005635483
11152,CO2,34,35,190,193,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11152,-1,0.99943537,0.0005645598
11153,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11153,-1,0.0002044494,0.9997956
11154,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11154,-1,0.00020233556,0.99979764
11155,mm Hg,17,19,90,95,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11155,-1,0.0048344084,0.9951656
11156,mm Hg,24,26,110,115,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11156,-1,0.0070931534,0.9929068
11158,ventricular fibrillation,38,40,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11158,-1,0.00020084326,0.9997992
11160,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,-1,-1,11160,-1,0.00019691954,0.9998031
11163,Trental,2,3,16,23,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,-1,-1,11163,-1,0.9995109,0.0004891493
11165,peripheral vascular disease,12,15,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,-1,11165,-1,0.00022764053,0.99977237
11167,Trental,8,9,50,57,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11167,-1,0.9994783,0.00052177056
11168,methylxanthine,12,13,62,76,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11168,-1,0.99949205,0.0005079679
11169,intermittent claudication,17,19,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11169,-1,0.00021253283,0.9997875
11172,methylxanthines,8,9,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11172,-1,0.99952555,0.0004744887
11174,hyperemic,5,6,26,35,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,-1,-1,-1,11174,-1,0.00020733062,0.99979264
11180,p,2,3,16,17,pentoxifylline (p less than 0.002).,2348231_7,-1,-1,-1,11180,-1,0.3237792,0.67622083
11184,p,21,22,166,167,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,-1,11184,-1,0.8791404,0.12085967
11185,pentoxyifylline,3,4,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11185,-1,0.9995035,0.0004965021
11188,Parkinson's disease,6,9,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11188,-1,0.0006948433,0.9993051
11189,haemorrhage,16,17,89,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11189,-1,0.00018966335,0.9998104
11191,haemorrhage,9,10,52,63,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11191,-1,0.00020125095,0.9997987
11192,Parkinson's disease,17,20,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11192,-1,0.00020239926,0.99979764
11194,pneumonia,6,7,33,42,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11194,-1,0.0002117222,0.99978834
11195,bronchitis,8,9,47,57,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11195,-1,0.00021109669,0.99978894
11196,neoplasms,15,16,77,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11196,-1,0.000215478,0.9997845
11197,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11197,-1,0.00021481789,0.99978524
11198,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11198,-1,0.00021875039,0.9997813
11199,septicaemia,35,36,150,161,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11199,-1,0.00021619168,0.9997838
11206,Parkinson's disease,14,17,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,-1,11206,-1,0.0002620976,0.9997379
11212,cardiorespiratory arrest,3,5,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,-1,-1,11212,-1,0.00022478426,0.99977523
11214,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,-1,-1,-1,11214,-1,0.99947625,0.00052374694
11216,cardiorespiratory arrest,8,10,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,-1,11216,-1,0.0001746504,0.9998254
11220,Myasthenia gravis,0,2,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,-1,-1,11220,-1,0.00034331947,0.9996567
11223,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11223,-1,0.00020682655,0.99979323
11224,quadriplegic,14,15,89,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11224,-1,0.0002408143,0.99975914
11226,preeclampsia,20,21,148,160,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11226,-1,0.00020735769,0.99979264
11229,neuromuscular blockade,23,25,160,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,-1,11229,-1,0.00021420224,0.99978584
11233,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,-1,11233,-1,0.00017385634,0.99982613
11235,disorder of neuromuscular transmission,18,22,123,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,-1,-1,-1,11235,-1,0.00020412703,0.99979585
11239,hepatocellular carcinomas,5,7,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,-1,-1,11239,-1,0.00021351081,0.99978656
11242,hepatocellular carcinomas,7,9,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,-1,-1,-1,11242,-1,0.00017702546,0.99982303
11255,mm Hg,32,34,192,197,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11255,-1,0.0032699024,0.9967301
11256,h,41,42,221,222,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11256,-1,0.53941786,0.46058214
11258,"5,7-dihydroxytryptamine",51,52,290,313,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11258,-1,0.9994892,0.00051073235
11259,"5,7-DHT",53,54,315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11259,-1,0.99949265,0.0005072803
11260,"5,7-DHT",5,6,34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,-1,11260,-1,0.9994692,0.00053078186
11263,"5,7-DHT",2,3,9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11263,-1,0.9994917,0.00050823303
11266,in,31,32,175,177,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11266,-1,0.00024757232,0.99975246
11267,serotonin methyldopa,39,41,222,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11267,-1,0.99948186,0.000518221
11273,Liver enlargement,0,2,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11273,-1,0.00017657064,0.9998235
11274,muscle wastage,3,5,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11274,-1,0.00017824292,0.99982184
11277,cibenzoline,4,5,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,-1,-1,11277,-1,0.99946886,0.00053116225
11280,cibenzoline,16,17,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,-1,11280,-1,0.99948186,0.0005181355
11282,Cibenzoline,0,1,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11282,-1,0.9994795,0.0005205761
11285,digitalis,24,25,167,176,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11285,-1,0.0012393731,0.9987606
11287,n,86,87,368,369,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11287,-1,0.1121888,0.8878112
11291,tocainide,10,11,67,76,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,-1,-1,11291,-1,0.9994671,0.00053292577
11292,cibenzoline,1,2,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,-1,11292,-1,0.9994338,0.0005661816
11300,pentylenetrazol,21,22,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11300,-1,0.9995129,0.0004871139
11301,PTZ,23,24,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11301,-1,0.99948895,0.0005110328
11302,h,26,27,163,164,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11302,-1,0.22582228,0.77417773
11304,h,39,40,254,255,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11304,-1,0.12466769,0.8753323
11305,h,19,20,101,102,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,-1,11305,-1,0.030388428,0.9696116
11306,h,23,24,143,144,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,-1,11306,-1,0.46690863,0.53309137
11308,PTZ,4,5,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11308,-1,0.11487522,0.88512474
11310,PTX,8,9,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11310,-1,0.99744034,0.0025596519
11312,3-mercaptopropionic acid,20,22,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11312,-1,0.999508,0.00049197365
11313,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11313,-1,0.9994881,0.0005118362
11315,BCC,28,29,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11315,-1,0.0004094958,0.99959046
11316,DMCM,34,35,218,222,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11316,-1,0.9994153,0.00058467995
11317,strychnine,38,39,228,238,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11317,-1,0.8231293,0.17687073
11318,STR,40,41,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11318,-1,0.00025181362,0.9997482
11319,pentylenetetrazol,5,6,21,38,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,-1,11319,-1,0.9994831,0.0005168801
11321,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11321,-1,0.9989706,0.0010293331
11322,BCC,2,3,5,8,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11322,-1,0.0006998112,0.9993001
11323,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11323,-1,0.19122538,0.80877465
11324,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11324,-1,0.00041062396,0.9995894
11326,PTZ,14,15,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11326,-1,0.99898523,0.0010147387
11327,PTX,16,17,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11327,-1,0.9940204,0.0059795245
11328,h,18,19,114,115,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11328,-1,0.22104399,0.778956
11330,h,16,17,92,93,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11330,-1,0.08631738,0.91368264
11331,chloride,24,25,144,152,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11331,-1,0.99941444,0.0005855416
11333,Argentine hemorrhagic fever,9,12,61,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,-1,-1,11333,-1,0.005648809,0.99435115
11335,Argentine hemorrhagic fever,12,15,75,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11335,-1,0.0056635,0.99433655
11336,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11336,-1,0.00021397283,0.9997861
11338,viremia,8,9,60,67,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11338,-1,0.00021141837,0.9997886
11339,interferon,14,15,93,103,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11339,-1,0.9991528,0.00084724603
11343,AHF,16,17,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,-1,-1,11343,-1,0.00025414623,0.9997459
11346,AHF,11,12,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,-1,-1,-1,11346,-1,0.00027150413,0.9997285
11347,fluorouracil,5,6,44,56,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,-1,11347,-1,0.99944645,0.0005535455
11349,fluorouracil,11,12,79,91,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11349,-1,0.9994734,0.00052663044
11350,5-FU,13,14,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11350,-1,0.9994721,0.00052797043
11351,5-FU,11,12,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11351,-1,0.9994266,0.00057339575
11353,ischemic,25,26,170,178,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11353,-1,0.00019271567,0.9998073
11354,5-FU,10,11,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11354,-1,0.9994406,0.0005593907
11355,5-FU,20,21,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11355,-1,0.9994437,0.0005562476
11356,Anginal,0,1,0,7,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11356,-1,0.10331425,0.8966857
11357,angina,9,10,49,55,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11357,-1,0.0002045352,0.9997955
11358,5-FU,12,13,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11358,-1,0.9994462,0.00055375975
11359,mm,12,13,61,63,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11359,-1,0.6999625,0.3000375
11360,5-FU,31,32,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11360,-1,0.99948066,0.00051933114
11361,5-FU,40,41,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11361,-1,0.99947673,0.00052326993
11362,P,43,44,185,186,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11362,-1,0.4610126,0.5389874
11363,ischemic,3,4,17,25,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,-1,11363,-1,0.00022276846,0.99977726
11364,5-FU,3,4,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11364,-1,0.99944013,0.0005598499
11365,5-FU,11,12,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11365,-1,0.99944025,0.0005596821
11366,P,14,15,66,67,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11366,-1,0.081191145,0.9188088
11367,5-FU,36,37,165,169,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11367,-1,0.99942845,0.0005714785
11368,5-FU,48,49,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11368,-1,0.9994367,0.00056330505
11369,P,50,51,226,227,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11369,-1,0.12623046,0.8737696
11370,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,-1,-1,11370,-1,0.0001921652,0.9998079
11372,5-FU,3,4,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11372,-1,0.99945885,0.00054117094
11374,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11374,-1,0.00019889903,0.9998011
11375,scabies,4,5,20,27,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11375,-1,0.00021594159,0.99978405
11376,scabies,7,8,52,59,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11376,-1,0.00021180275,0.9997882
11378,gamma benzene,19,21,130,143,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11378,-1,0.99949074,0.00050923275
11379,hexachloride,21,22,144,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11379,-1,0.99949396,0.0005060107
11382,toxic to the central nervous system,7,13,45,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11382,-1,0.0004982107,0.9995018
11383,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11383,-1,0.00020503701,0.999795
11387,biogenic amines,9,11,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,-1,-1,-1,11387,-1,0.99943,0.00056993554
11388,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11388,-1,0.99946517,0.00053480087
11389,biogenic amines,29,31,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11389,-1,0.99929714,0.00070284226
11391,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,-1,11391,-1,0.017043162,0.9829569
11395,suppression of motility,26,29,173,196,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,-1,11395,-1,0.00023776627,0.99976224
11398,"3,4-dihydroxyphenylacetic acid",15,17,97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,-1,11398,-1,0.9994816,0.0005183514
11399,normetanephrine,3,4,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,-1,11399,-1,0.99945885,0.0005411818
11403,biogenic amines,5,7,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11403,-1,0.9994118,0.000588221
11405,monoamine oxidase,22,24,152,169,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11405,-1,0.9994398,0.00056020165
11407,behavioral depression,37,39,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11407,-1,0.00021126,0.9997887
11409,Chloroacetaldehyde,0,1,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,-1,11409,-1,0.9994542,0.0005458234
11412,chloroacetaldehyde,7,8,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11412,-1,0.99946815,0.00053186365
11413,CAA,9,10,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11413,-1,0.99943966,0.0005603277
11414,CAA,32,33,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11414,-1,0.9994698,0.0005302262
11415,hemorrhagic cystitis,37,39,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11415,-1,0.00020126345,0.9997987
11416,CAA,4,5,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11416,-1,0.0059822234,0.9940177
11417,bladder damage,13,15,79,93,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11417,-1,0.00021398872,0.9997861
11418,CAA,7,8,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,-1,11418,-1,0.9994299,0.0005700521
11424,blind,37,38,229,234,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,-1,11424,-1,0.96473765,0.035262324
11436,leukemoid reaction,6,8,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11436,-1,0.00089699874,0.99910307
11438,erythroderma,11,12,86,98,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11438,-1,0.02574044,0.9742596
11439,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11439,-1,0.00021677789,0.9997832
11442,generalized erythroderma,11,13,77,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11442,-1,0.9693225,0.03067749
11443,leukemoid reaction,16,18,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11443,-1,0.00044673102,0.99955326
11446,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11446,-1,0.00020995973,0.99979
11449,HIV disease,30,32,161,172,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,-1,11449,-1,0.0001992458,0.99980074
11454,megaloblastosis,8,9,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,-1,-1,11454,-1,0.00017245953,0.9998275
11456,hepatitis B virus,9,12,68,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11456,-1,0.00019406137,0.999806
11457,infection by hepatitis B virus (HBV),24,32,162,198,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11457,-1,0.0003972247,0.99960285
11458,hepatitis B surface antigen,18,22,116,143,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11458,-1,0.0029434771,0.9970565
11459,HBsAg,23,24,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11459,-1,0.000288266,0.9997117
11460,hepatitis B e antigen,26,30,156,177,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11460,-1,0.048719976,0.95128006
11461,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11461,-1,0.00039768423,0.9996024
11462,hepatitis B,8,10,49,60,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11462,-1,0.90267795,0.097322084
11463,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11463,-1,0.9434493,0.056550656
11464,HBsAg,11,12,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,-1,11464,-1,0.00024952667,0.99975044
11465,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11465,-1,0.6040674,0.39593264
11466,HBsAg,5,6,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11466,-1,0.00023452367,0.99976546
11467,HBsAg,1,2,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,-1,-1,-1,11467,-1,0.67053896,0.32946107
11468,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,-1,-1,11468,-1,0.00028816322,0.9997118
11470,obsessive compulsive disorder,8,11,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11470,-1,0.00019786644,0.9998022
11472,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11472,-1,0.00020206413,0.999798
11473,restlessness,5,6,43,55,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11473,-1,0.00022681811,0.9997732
11474,anxiety,20,21,129,136,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11474,-1,0.00021806774,0.9997819
11475,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11475,-1,0.90215266,0.097847275
11476,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11476,-1,0.17634015,0.82365984
11477,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11477,-1,0.98241204,0.017588027
11478,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,-1,-1,11478,-1,0.999226,0.0007740098
11481,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11481,-1,0.99933016,0.0006699111
11482,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11482,-1,0.9990815,0.0009185196
11483,analgesia,7,8,52,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,-1,-1,-1,11483,-1,0.00021682172,0.9997832
11485,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11485,-1,0.99948347,0.00051656127
11486,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide",15,18,98,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11486,-1,0.9994814,0.00051860244
11487,prostaglandin,18,19,116,129,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,-1,11487,-1,0.9994455,0.0005545135
11491,pertussis toxin,17,19,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,-1,11491,-1,0.99947065,0.00052938535
11494,8-bromo cyclic adenosine monophosphate,11,15,61,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,-1,-1,11494,-1,0.99948657,0.0005134679
11495,cyclic adenosine monophosphate,36,39,221,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,-1,11495,-1,0.9994604,0.000539627
11498,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,-1,11498,-1,0.011748382,0.9882516
11503,mm Hg,20,22,104,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11503,-1,0.0021618002,0.9978382
11504,P,28,29,126,127,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11504,-1,0.93702805,0.062971935
11505,mm Hg,47,49,201,206,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11505,-1,0.0010420235,0.998958
11506,P,50,51,208,209,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11506,-1,0.9930005,0.006999462
11510,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,-1,11510,-1,0.011257153,0.9887428
11514,P,33,34,150,151,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,-1,11514,-1,0.23792058,0.7620794
11516,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,-1,-1,11516,-1,0.00020190503,0.9997981
11517,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,-1,11517,-1,0.00022408497,0.99977595
11520,CO2,10,11,68,71,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,-1,-1,-1,11520,-1,0.99941075,0.0005892346
11522,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,-1,11522,-1,0.00020015656,0.9997999
11525,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,-1,11525,-1,0.00019694828,0.9998031
11527,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11527,-1,0.99949944,0.00050051
11528,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11528,-1,0.00020346772,0.99979657
11529,alpha-2 adrenergic agonist dexmedetomidine,2,6,21,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11529,-1,0.99948335,0.00051661266
11530,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11530,-1,0.00021098866,0.99978906
11531,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,-1,-1,11531,-1,0.00022025095,0.99977976
11533,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,-1,-1,11533,-1,0.00020310139,0.9997969
11535,n,2,3,9,10,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11535,-1,0.10788933,0.8921107
11536,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11536,-1,0.99949837,0.0005016027
11537,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11537,-1,0.9994979,0.0005020847
11538,DG-5128,76,77,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11538,-1,0.999421,0.0005790637
11540,ALF,8,9,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,-1,-1,-1,11540,-1,0.15513411,0.84486586
11541,ALF,0,1,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,-1,11541,-1,0.9935434,0.0064565637
11542,contrast,1,2,3,11,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11542,-1,0.9991918,0.000808171
11543,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11543,-1,0.00022627314,0.9997737
11545,startle,12,13,65,72,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,-1,-1,11545,-1,0.00021286178,0.99978715
11546,acute hepatitis,1,3,20,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,-1,-1,11546,-1,0.00020649469,0.99979347
11547,acute hepatitis,9,11,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11547,-1,0.00019146873,0.9998086
11548,hepatocellular necrosis,13,15,77,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11548,-1,0.00018964996,0.9998104
11549,clotiazepam,24,25,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11549,-1,0.99948454,0.0005154745
11550,thienodiazepine,27,28,163,178,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11550,-1,0.9994869,0.0005130867
11551,Clotiazepam,0,1,0,11,Clotiazepam withdrawal was followed by prompt recovery.,2572625_2,-1,-1,-1,11551,-1,0.9994622,0.0005378508
11553,clotiazepam,9,10,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,-1,11553,-1,0.99945146,0.0005485948
11555,clotiazepam,4,5,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11555,-1,0.9994634,0.0005365905
11556,acute hepatitis,7,9,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11556,-1,0.00018803445,0.99981195
11558,clotiazepam,18,19,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11558,-1,0.99946386,0.00053612405
11560,fluvoxamine,7,8,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,-1,11560,-1,0.99944836,0.0005516283
11561,fluvoxamine,8,9,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11561,-1,0.9994947,0.00050535204
11563,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11563,-1,0.9994956,0.00050432415
11564,fluvoxamine,4,5,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,-1,-1,11564,-1,0.99950004,0.0005000055
11567,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11567,-1,0.99950063,0.00049938296
11568,fluvoxamine,10,11,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11568,-1,0.9994993,0.00050069037
11569,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11569,-1,0.99948007,0.00051991653
11570,fluvoxamine,16,17,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11570,-1,0.99947935,0.0005206311
11571,fluvoxamine,3,4,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,-1,11571,-1,0.999493,0.00050700724
11572,fluvoxamine,4,5,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11572,-1,0.9994837,0.0005162794
11577,carcinogens,5,6,48,59,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,-1,-1,-1,11577,-1,0.99946004,0.0005399055
11578,carcinogenic process,19,21,112,132,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11578,-1,0.00018672128,0.99981326
11580,5-AzC,24,25,149,154,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11580,-1,0.9995012,0.00049872574
11581,carcinogens,51,52,277,288,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11581,-1,0.9166326,0.08336747
11582,benzo[a]-pyrene,53,54,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11582,-1,0.9995017,0.00049833785
11584,"1,2-DMH",67,68,380,387,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11584,-1,0.9994791,0.0005208947
11586,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11586,-1,0.9994462,0.00055379356
11587,carcinogens,8,9,50,61,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11587,-1,0.9993838,0.00061613624
11588,5-AzC,12,13,81,86,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11588,-1,0.9994717,0.0005283494
11589,5-AzC,30,31,191,196,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11589,-1,0.9994703,0.0005297498
11590,"1,2-DMH",9,10,81,88,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11590,-1,0.9994141,0.0005859665
11591,cytosine,17,18,124,132,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11591,-1,0.9994473,0.00055275514
11592,5-AzC,31,32,216,221,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11592,-1,0.99948126,0.0005188134
11593,5-AzC,7,8,34,39,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,-1,11593,-1,0.9994461,0.00055386504
11594,se,8,9,52,54,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,-1,-1,-1,11594,-1,0.9904579,0.009542069
11595,BN 52021,9,11,71,79,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11595,-1,0.9994266,0.00057342695
11596,cardiovascular impairments,14,16,104,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11596,-1,0.00020871128,0.9997913
11598,decrease of mean arterial blood pressure,20,26,101,141,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,-1,-1,-1,11598,-1,0.00023368954,0.9997663
11600,BN 52021,11,13,82,90,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,-1,11600,-1,0.99945694,0.0005430919
11602,contrast,1,2,3,11,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11602,-1,0.10615357,0.8938464
11603,BN 52021,7,9,30,38,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11603,-1,0.999371,0.00062898005
11605,BN 52021,1,3,5,13,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,-1,11605,-1,0.9994252,0.0005748262
11607,BN 52021,15,17,107,115,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,-1,11607,-1,0.8294722,0.17052786
11608,BN 52021,4,6,28,36,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11608,-1,0.9994081,0.0005919379
11609,BN 52021,34,36,173,181,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11609,-1,0.9994246,0.0005755016
11610,cardiovascular toxicity,45,47,241,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11610,-1,0.00021151332,0.99978846
11611,cardiovascular alterations,17,19,102,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,-1,11611,-1,0.00022632926,0.9997737
11612,flank pain,5,7,30,40,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11612,-1,0.00018730013,0.9998128
11613,suprofen,9,10,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11613,-1,0.9992262,0.0007737391
11614,Suprofen,0,1,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,-1,11614,-1,0.99941134,0.0005887048
11615,flank pain,7,9,50,60,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,-1,11615,-1,0.000184413,0.99981564
11616,hay fever,26,28,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11616,-1,0.0032429225,0.9967571
11617,asthma,29,30,121,127,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11617,-1,0.00022474678,0.99977523
11618,p,75,76,316,317,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11618,-1,0.8159897,0.18401036
11620,agents,12,13,76,82,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11620,-1,0.9994011,0.0005988736
11622,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11622,-1,0.00023190034,0.9997681
11623,kidney stones,25,27,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11623,-1,0.00022655725,0.99977344
11624,gout,31,32,175,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11624,-1,0.0002331841,0.99976677
11625,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,-1,11625,-1,0.9993969,0.0006031096
11626,Antihypertensive drugs,0,2,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,-1,-1,11626,-1,0.80670303,0.19329701
11634,depressions,9,10,50,61,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11634,-1,0.00020504328,0.999795
11635,methyl,12,13,75,81,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11635,-1,0.99942905,0.00057088124
11636,dopa,13,14,82,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11636,-1,0.99943656,0.0005634581
11639,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11639,-1,0.99949145,0.00050855655
11640,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11640,-1,0.99947244,0.0005276076
11641,Voltarol,3,4,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11641,-1,0.9994815,0.00051849696
11643,abnormalities of liver function,5,9,48,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,-1,-1,11643,-1,0.00021884989,0.9997812
11647,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11647,-1,0.99948466,0.00051532115
11650,Cushing's syndrome,5,8,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,-1,-1,11650,-1,0.00020159918,0.9997985
11656,deoxycorticosterone,7,8,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,-1,11656,-1,0.9994931,0.000506898
11658,deoxycorticosterone,11,12,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,-1,11658,-1,0.99945766,0.000542333
11665,and renal insufficiency,13,16,82,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11665,-1,0.00022464994,0.99977535
11666,intravascular coagulation,18,20,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11666,-1,0.00021841357,0.99978155
11667,intravascular coagulation,2,4,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11667,-1,0.00021853669,0.9997814
11668,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11668,-1,0.99948823,0.00051174866
11669,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11669,-1,0.99948335,0.00051666907
11670,pulmonary and renal insufficiency,24,28,147,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11670,-1,0.00021865737,0.9997813
11671,trauma,32,33,213,219,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11671,-1,0.00021707533,0.999783
11675,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,-1,-1,11675,-1,0.00022186799,0.9997781
11680,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,-1,-1,-1,11680,-1,0.9994023,0.00059767446
11682,Angiotension II,27,29,151,166,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11682,-1,0.9994728,0.0005272729
11683,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11683,-1,0.9994821,0.00051793555
11686,kidney damage,48,50,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,-1,11686,-1,0.00020324279,0.9997968
11691,SD,9,10,38,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,-1,11691,-1,0.03920609,0.9607939
11695,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11695,-1,0.00021079037,0.9997892
11696,cerebral vasculitis,18,20,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11696,-1,0.00020731542,0.99979275
11697,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11697,-1,0.00021511219,0.9997849
11698,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11698,-1,0.00021394853,0.9997861
11699,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11699,-1,0.00022035892,0.99977964
11707,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11707,-1,0.00020003445,0.9998
11708,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11708,-1,0.0002021333,0.9997979
11710,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11710,-1,0.00020060517,0.99979943
11711,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11711,-1,0.0002030793,0.9997969
11717,reductions in mean arterial blood pressure,12,18,88,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11717,-1,0.00021797587,0.999782
11719,p,8,9,58,59,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11719,-1,0.11084526,0.8891548
11720,increase in heart rate and cardiac output,13,20,76,117,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11720,-1,0.00021261755,0.9997874
11724,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,-1,11724,-1,0.99798644,0.00201356
11728,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,-1,11728,-1,0.0021562304,0.99784374
11729,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11729,-1,0.00019903903,0.999801
11730,DM,7,8,60,62,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11730,-1,0.99924433,0.0007556508
11732,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11732,-1,0.00019588508,0.9998041
11733,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11733,-1,0.00019978933,0.99980026
11734,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11734,-1,0.0022269886,0.997773
11736,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11736,-1,0.99947554,0.00052451534
11737,P,24,25,176,177,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11737,-1,0.99943167,0.0005682977
11738,DM,0,1,0,2,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11738,-1,0.99652267,0.0034773084
11740,P,13,14,63,64,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11740,-1,0.9986565,0.0013435144
11741,P,3,4,9,10,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11741,-1,0.99919754,0.0008024208
11742,P,7,8,27,28,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11742,-1,0.9990491,0.0009508872
11743,P,19,20,65,66,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11743,-1,0.99913603,0.00086400704
11746,DM,35,36,130,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11746,-1,0.99931693,0.0006830325
11750,P,4,5,12,13,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11750,-1,0.9993523,0.00064773066
11752,SE,18,19,75,77,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11752,-1,0.9993113,0.00068872626
11755,P,4,5,13,14,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11755,-1,0.9992787,0.00072127924
11756,P,19,20,85,86,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11756,-1,0.9990326,0.00096744584
11758,P,18,19,86,87,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,-1,11758,-1,0.16906096,0.83093905
11765,analgesia,9,10,70,79,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,-1,-1,11765,-1,0.00020986507,0.99979013
11771,cataleptic,22,23,169,179,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,-1,-1,-1,11771,-1,0.99936956,0.0006304943
11783,cataleptic,4,5,31,41,Naloxone inhibited the induced cataleptic effects.,2716967_6,-1,-1,-1,11783,-1,0.94899553,0.051004484
11795,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11795,-1,0.0012758777,0.99872404
11796,p,23,24,124,125,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11796,-1,0.7970768,0.20292316
11797,increased cardiac output,32,35,162,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11797,-1,0.00028648402,0.9997135
11798,p,46,47,219,220,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11798,-1,0.6716197,0.32838026
11799,mm,9,10,60,62,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11799,-1,0.013274962,0.986725
11800,p,17,18,87,88,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11800,-1,0.27455378,0.7254463
11801,mm,26,27,166,168,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11801,-1,0.9991115,0.0008885641
11802,p,47,48,259,260,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11802,-1,0.5924968,0.40750322
11806,p,53,54,288,289,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,-1,11806,-1,0.3343972,0.6656028
11810,rise in resting blood pressure,1,6,4,34,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11810,-1,0.00027093987,0.9997291
11812,increased cardiac output,12,15,77,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11812,-1,0.00020552673,0.99979454
11813,blood,20,21,131,136,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11813,-1,0.05430817,0.9456918
11814,Neuromuscular blockade,0,2,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11814,-1,0.00019450596,0.9998055
11815,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11815,-1,0.9994499,0.0005500404
11818,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11818,-1,0.0002024722,0.9997975
11819,mg,12,13,92,94,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11819,-1,0.9994288,0.00057113165
11820,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11820,-1,0.9994843,0.00051570055
11829,CBZ,5,6,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11829,-1,0.99948907,0.0005109242
11831,CBZ,28,29,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11831,-1,0.99949026,0.0005097198
11832,CBZ,2,3,13,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,-1,11832,-1,0.9994711,0.00052884314
11835,CBZ,1,2,8,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,-1,11835,-1,0.9994294,0.0005705865
11836,CBZ,1,2,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,-1,11836,-1,0.99938786,0.00061217934
11838,CBZ,2,3,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,-1,-1,11838,-1,0.9993936,0.0006064441
11840,CBZ,4,5,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,-1,11840,-1,0.9993963,0.00060364325
11843,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,-1,11843,-1,0.999433,0.0005670438
11844,CBZ,5,6,32,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,-1,11844,-1,0.98660606,0.0133939395
11847,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,-1,11847,-1,0.007709664,0.9922903
11849,amphotericin B,4,6,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,-1,11849,-1,0.9994655,0.0005344959
11850,amphotericin B,4,6,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,-1,11850,-1,0.9994779,0.00052215665
11852,contrast,1,2,3,11,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,-1,-1,-1,11852,-1,0.29210067,0.70789933
11855,amphotericin B,2,4,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,-1,-1,-1,11855,-1,0.99947447,0.00052550214
11856,amphotericin B,9,11,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,-1,11856,-1,0.99946946,0.000530508
11858,amphotericin B,9,11,60,74,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11858,-1,0.99950814,0.00049179734
11859,amphotericin B,14,16,102,116,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11859,-1,0.9995091,0.00049095496
11862,venous thrombosis,5,7,39,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,-1,11862,-1,0.00019958404,0.9998004
11863,venous thrombosis,8,10,56,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,-1,11863,-1,0.00019803386,0.99980193
11865,hypokalemia,1,2,29,40,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11865,-1,0.00021400911,0.99978596
11866,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11866,-1,0.99948657,0.000513461
11867,hypokalemia,8,9,77,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,-1,11867,-1,0.00020008958,0.9997999
11868,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11868,-1,0.99949193,0.00050800154
11869,hypokalemia,10,11,77,88,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11869,-1,0.00019481035,0.99980515
11870,mg,7,8,38,40,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11870,-1,0.9992536,0.0007464593
11872,mg oxprenolol,29,31,158,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11872,-1,0.99946755,0.0005324909
11877,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,-1,-1,-1,11877,-1,0.9994918,0.0005081262
11880,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11880,-1,0.99950516,0.0004948246
11881,hypokalemia,11,12,81,92,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11881,-1,0.00021829075,0.99978167
11882,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11882,-1,0.00021331465,0.9997867
11884,ACTH,20,21,90,94,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11884,-1,0.9994111,0.00058894913
11885,NE,36,37,170,172,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11885,-1,0.9994159,0.00058417086
11887,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11887,-1,0.00020520166,0.9997948
11888,c,79,80,430,431,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11888,-1,0.8480167,0.1519833
11891,ACC-9089,2,3,11,19,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,-1,11891,-1,0.96760744,0.032392543
11899,contrast,1,2,3,11,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,-1,11899,-1,0.9992724,0.0007275427
11901,supraventricular tachyarrhythmia,8,10,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,-1,-1,11901,-1,0.00020106818,0.99979895
11902,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11902,-1,0.00020106186,0.99979895
11904,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11904,-1,0.0002019374,0.9997981
11909,h,14,15,92,93,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,-1,11909,-1,0.015044198,0.98495585
11922,Phentolamine,0,1,0,12,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,-1,11922,-1,0.99949,0.00051001506
11924,phentolamine,5,6,32,44,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,-1,-1,-1,11924,-1,0.9994821,0.00051793805
11926,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,-1,11926,-1,0.00020515395,0.9997949
11931,h,26,27,194,195,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11931,-1,0.10349402,0.89650595
11932,h,29,30,202,203,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11932,-1,0.1293244,0.8706756
11934,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11934,-1,0.30118603,0.6988139
11935,h,1,2,4,5,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,-1,11935,-1,0.60888183,0.3911181
11938,h,2,3,5,6,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,-1,11938,-1,0.5895816,0.4104184
11941,h,13,14,87,88,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11941,-1,0.05300313,0.94699687
11943,adenoma,19,20,126,133,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11943,-1,0.00020598542,0.99979407
11945,GABA,0,1,0,4,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11945,-1,0.99947816,0.00052182324
11947,respiratory paralysis,7,9,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11947,-1,0.00020842232,0.99979156
11948,thiopental,11,12,83,93,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11948,-1,0.9994887,0.0005112335
11949,respiratory paralysis,7,9,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11949,-1,0.00017327908,0.9998267
11950,CNS depressants,11,13,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11950,-1,0.8835283,0.11647168
11952,respiratory paralysis,5,7,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11952,-1,0.00020788587,0.99979216
11953,thiopental,9,10,65,75,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11953,-1,0.99949026,0.0005096727
11954,thiopental,5,6,15,25,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11954,-1,0.999458,0.00054198166
11955,GABA,14,15,91,95,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11955,-1,0.99935204,0.0006480184
11959,thiosemicarbazide,4,5,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11959,-1,0.9994825,0.0005174103
11960,thiopental,20,21,139,149,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11960,-1,0.9994831,0.0005168476
11961,thiopental,5,6,15,25,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11961,-1,0.99945027,0.0005497658
11962,respiratory arrest,7,9,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11962,-1,0.0001783099,0.9998217
11963,GABA,13,14,79,83,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11963,-1,0.9994043,0.0005956795
11965,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11965,-1,0.99940693,0.0005931154
11967,respiratory paralysis,9,11,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11967,-1,0.00023234078,0.9997677
11969,GABA,14,15,73,77,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11969,-1,0.99943143,0.00056855445
11971,respiratory paralysis,5,7,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11971,-1,0.00021505561,0.999785
11972,thiopental,9,10,71,81,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11972,-1,0.9994916,0.0005084378
11973,GABA,12,13,95,99,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11973,-1,0.9994747,0.00052531745
11978,mg,8,9,45,47,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,-1,11978,-1,0.9993747,0.00062532345
11986,chloride channels,25,27,171,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,-1,11986,-1,0.057094626,0.9429054
11989,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,-1,11989,-1,0.00020716364,0.9997929
11990,Pneumonitis,0,1,0,11,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11990,-1,0.00021613708,0.99978393
11991,pleural effusions,3,5,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11991,-1,0.00021345339,0.99978656
11992,cardiac tamponade,9,11,72,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11992,-1,0.0002192112,0.99978083
11994,ulcerative colitis,29,31,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11994,-1,0.00020980765,0.99979025
11997,lupus,8,9,59,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11997,-1,0.00020310331,0.9997969
11998,serositis,13,14,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11998,-1,0.003066908,0.9969331
11999,pulmonary parenchymal involvement,15,18,102,135,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11999,-1,0.0002003666,0.99979967
12000,joint symptoms,22,24,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,12000,-1,0.0002011238,0.99979895
12002,inflammatory bowel disease,8,11,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,12002,-1,0.00019593608,0.9998041
12003,lupus syndrome,19,21,137,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,12003,-1,0.00020248689,0.9997975
12005,hypokalaemia,4,5,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12005,-1,0.00021077633,0.9997893
12006,chlorthalidone,6,7,47,61,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12006,-1,0.9994916,0.0005084099
12007,essential hypertension,11,13,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12007,-1,0.00021007168,0.9997899
12010,hypokalaemia,9,10,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12010,-1,0.00019951843,0.9998005
12011,diuretic,16,17,111,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12011,-1,0.0057045547,0.9942954
12012,essential hypertension,27,29,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12012,-1,0.00019923136,0.99980074
12013,hypokalaemia,32,33,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12013,-1,0.00019744183,0.99980253
12014,diuretic,36,37,250,258,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12014,-1,0.9994031,0.0005968479
12015,Chlorthalidone,0,1,0,14,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,12015,-1,0.9994598,0.000540208
12016,mg,3,4,19,21,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,12016,-1,0.97108096,0.028919104
12018,K,11,12,58,59,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,-1,12018,-1,0.99808717,0.0019128032
12019,bromide,6,7,34,41,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,-1,12019,-1,0.9992787,0.0007212324
12031,buspirone,5,6,27,36,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,-1,12031,-1,0.9995105,0.0004894405
12034,buspirone,6,7,41,50,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12034,-1,0.99949586,0.0005040788
12035,5-hydroxytryptaminergic agonists,9,11,61,93,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12035,-1,0.9991604,0.00083960546
12039,5-HT,5,6,30,34,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,-1,-1,-1,12039,-1,0.9994332,0.0005668001
12040,5-HT,5,6,36,40,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,-1,-1,12040,-1,0.99946207,0.0005379792
12042,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12042,-1,0.99943644,0.0005634859
12043,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12043,-1,0.9994099,0.00059009873
12044,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12044,-1,0.9994795,0.00052057335
12045,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12045,-1,0.9994678,0.00053227606
12046,mg,30,31,184,186,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12046,-1,0.99933594,0.00066404534
12047,P,9,10,63,64,Significant differences between the four groups were detected (P less than 0.001).,2917114_2,-1,-1,-1,12047,-1,0.25388002,0.74612
12048,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12048,-1,0.9994837,0.00051621615
12049,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12049,-1,0.99948525,0.00051471515
12050,bradycardias,26,27,177,189,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12050,-1,0.00020636167,0.9997937
12051,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,-1,-1,-1,12051,-1,0.9994886,0.00051142584
12054,folate,17,18,96,102,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,-1,-1,12054,-1,0.9994273,0.0005727122
12055,Folate,0,1,0,6,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,-1,-1,-1,12055,-1,0.9993013,0.00069864036
12057,CBZ,2,3,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,-1,12057,-1,0.9994236,0.00057641615
12058,CBZ,11,12,60,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12058,-1,0.9993861,0.00061389414
12059,folate,14,15,77,83,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12059,-1,0.9993135,0.0006864942
12060,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12060,-1,0.99946743,0.0005325556
12062,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12062,-1,0.002801974,0.997198
12064,hexafluorodiethyl ether,3,5,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12064,-1,0.9994655,0.0005344386
12065,HFDE,6,7,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12065,-1,0.99930847,0.0006914805
12066,CBZ,20,21,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12066,-1,0.9994624,0.0005375684
12068,CBZ,3,4,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12068,-1,0.99938977,0.0006102665
12069,h,10,11,60,61,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12069,-1,0.070917286,0.92908275
12071,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12071,-1,0.0007402537,0.99925977
12072,CBZ,1,2,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,-1,-1,-1,12072,-1,0.9994517,0.0005483334
12073,CBZ,3,4,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12073,-1,0.99944955,0.00055040384
12074,folate,10,11,58,64,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12074,-1,0.99942243,0.00057754345
12075,folate,21,22,109,115,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12075,-1,0.9994234,0.00057668076
12076,myocardial ischemia,1,3,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,-1,-1,-1,12076,-1,0.00021303924,0.99978703
12077,Angina,0,1,0,6,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12077,-1,0.00021437061,0.9997856
12078,ischemic,2,3,11,19,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12078,-1,0.00021210447,0.99978787
12081,myocardial ischemia,21,23,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12081,-1,0.0002132951,0.9997867
12082,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12082,-1,0.0002110826,0.99978894
12084,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,-1,12084,-1,0.74724734,0.25275266
12088,p,37,38,155,156,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12088,-1,0.079587445,0.9204126
12089,p,48,49,184,185,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12089,-1,0.09654031,0.9034597
12090,p,61,62,217,218,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12090,-1,0.06426217,0.93573785
12093,contrast,92,93,381,389,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12093,-1,0.019035669,0.98096436
12095,hydralazine,98,99,427,438,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12095,-1,0.9995159,0.00048417182
12098,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12098,-1,0.8495494,0.15045057
12099,p,34,35,170,171,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12099,-1,0.41714832,0.5828517
12100,p,53,54,252,253,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12100,-1,0.5062222,0.49377784
12101,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12101,-1,0.7223437,0.27765635
12102,n,16,17,95,96,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12102,-1,0.12696598,0.87303394
12103,n,31,32,151,152,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12103,-1,0.24393243,0.7560676
12104,n,42,43,182,183,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12104,-1,0.16840836,0.8315916
12105,iopentol,3,4,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12105,-1,0.9995148,0.00048519677
12106,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12106,-1,0.99951017,0.0004898688
12107,metrizoate,7,8,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12107,-1,0.99951947,0.0004804884
12108,ventricular fibrillation,2,4,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,-1,-1,-1,12108,-1,0.00020574279,0.9997943
12109,iopentol,14,15,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12109,-1,0.9994636,0.00053643156
12110,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12110,-1,0.9994765,0.0005235351
12111,metrizoate,18,19,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12111,-1,0.99947804,0.00052194565
12112,iopentol,1,2,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12112,-1,0.9995055,0.0004944615
12113,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12113,-1,0.99950933,0.00049069553
12114,metrizoate,9,10,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12114,-1,0.9995129,0.0004870895
12115,ventricular fibrillation,2,4,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12115,-1,0.00017656795,0.9998235
12116,p,8,9,66,67,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12116,-1,0.14351283,0.85648715
12117,iopentol,14,15,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12117,-1,0.9994784,0.00052157755
12118,iohexol,20,21,108,115,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12118,-1,0.99948347,0.00051656424
12119,metrizoate,27,28,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12119,-1,0.999476,0.0005240601
12120,Iopentol,0,1,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12120,-1,0.9994742,0.00052582263
12121,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12121,-1,0.9994918,0.0005082261
12122,decrease in,7,9,54,65,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12122,-1,0.00021430477,0.9997857
12123,blood,10,11,73,78,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12123,-1,0.00019727962,0.99980277
12124,metrizoate,13,14,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12124,-1,0.9994906,0.0005093876
12126,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,-1,-1,12126,-1,0.00018872027,0.99981135
12133,euthyroid,6,7,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,-1,-1,12133,-1,0.00021973789,0.99978024
12137,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,-1,12137,-1,0.01721682,0.9827832
12141,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,-1,-1,-1,12141,-1,0.9994404,0.00055963366
12144,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,-1,12144,-1,0.9994388,0.00056118506
12152,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,-1,-1,12152,-1,0.999471,0.00052902725
12153,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12153,-1,0.99949765,0.00050234824
12154,THC,18,19,125,128,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12154,-1,0.99947125,0.00052880996
12156,6-OHDA,28,29,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12156,-1,0.99949396,0.00050601334
12158,6-OHDA,34,35,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12158,-1,0.9994875,0.00051240245
12159,THC,4,5,29,32,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12159,-1,0.9994778,0.0005222594
12160,6-OHDA,12,13,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12160,-1,0.99950206,0.00049797166
12161,of the locus,18,21,112,124,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12161,-1,0.00030431748,0.99969566
12163,6-OHDA,30,31,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12163,-1,0.99950755,0.0004924102
12166,6-OHDA,18,19,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12166,-1,0.99950826,0.0004916965
12167,6-OHDA,25,26,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12167,-1,0.9995079,0.0004920592
12169,THC,17,18,118,121,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,-1,-1,12169,-1,0.9994498,0.00055015105
12172,azelastine,12,13,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12172,-1,0.9994814,0.00051860494
12173,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12173,-1,0.9994823,0.0005176796
12174,spring allergic rhinitis,22,25,149,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12174,-1,0.00020783869,0.99979216
12175,Azelastine,0,1,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12175,-1,0.9994653,0.0005347183
12176,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12176,-1,0.9994655,0.0005344987
12177,spring allergic rhinitis,22,25,144,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12177,-1,0.00033472184,0.99966526
12178,spring allergic rhinitis,19,22,87,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,-1,12178,-1,0.00022750752,0.9997725
12179,azelastine,8,9,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12179,-1,0.99948955,0.0005104598
12180,mg,17,18,89,91,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12180,-1,0.99822634,0.0017736354
12181,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12181,-1,0.99948955,0.0005104737
12182,mg,37,38,205,207,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12182,-1,0.9992999,0.0007001291
12183,body weights,3,5,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,-1,12183,-1,0.028268397,0.9717316
12184,azelastine,10,11,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12184,-1,0.9994856,0.0005143245
12185,mg,13,14,84,86,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12185,-1,0.9971413,0.0028586646
12186,azelastine,3,4,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,-1,-1,-1,12186,-1,0.9994655,0.00053447223
12187,contrast,1,2,3,11,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12187,-1,0.19250031,0.8074997
12188,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12188,-1,0.99947566,0.0005243779
12189,Drowsiness,0,1,0,10,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12189,-1,0.0001803921,0.9998196
12190,altered taste perception,2,5,15,39,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12190,-1,0.00017510762,0.99982494
12191,azelastine,14,15,104,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12191,-1,0.99945,0.0005499109
12192,Azelastine,0,1,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12192,-1,0.9994654,0.0005346419
12193,seasonal allergic rhinitis,10,13,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12193,-1,0.00020179283,0.99979824
12194,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12194,-1,0.00020902154,0.99979097
12195,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12195,-1,0.00021011615,0.9997899
12197,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12197,-1,0.00019620884,0.99980384
12198,deterioration of renal function,20,24,113,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12198,-1,0.00020400969,0.999796
12201,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,-1,12201,-1,0.00021405995,0.99978596
12202,HMG CoA,0,2,0,7,HMG CoA reductase inhibitors.,3076126_0,-1,-1,-1,12202,-1,0.99945956,0.0005404258
12205,HMG CoA,16,18,103,110,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,-1,12205,-1,0.99947697,0.00052307
12210,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,-1,-1,-1,12210,-1,0.34455827,0.6554417
12212,myoglobinuria,7,8,40,53,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12212,-1,0.00037974515,0.9996202
12213,renal failure,15,17,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12213,-1,0.00018622701,0.99981385
12215,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12215,-1,0.9994893,0.00051066274
12216,gemfibrozil,33,34,205,216,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12216,-1,0.9995003,0.0004997296
12217,niacin,35,36,220,226,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12217,-1,0.99948895,0.00051108445
12221,hypercholesterolaemia,18,19,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,-1,12221,-1,0.00021250345,0.9997875
12225,RA,6,7,48,50,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12225,-1,0.00021664564,0.99978334
12228,HLA antigens,30,32,196,208,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12228,-1,0.99925154,0.0007484437
12229,nephritis,7,8,44,53,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12229,-1,0.0002101779,0.9997899
12231,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12231,-1,0.99951994,0.000480113
12233,gold thiosulphate,30,32,180,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12233,-1,0.9995048,0.00049518346
12234,B35,33,34,202,205,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12234,-1,0.99950814,0.00049181
12235,RA,13,14,81,83,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12235,-1,0.00037876714,0.99962115
12236,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12236,-1,0.9994444,0.0005555755
12237,nephritis,19,20,117,126,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12237,-1,0.00020411321,0.99979585
12238,contralateral rotation,1,3,10,32,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12238,-1,0.00081038347,0.99918956
12239,substantia nigra lesion,5,8,54,77,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12239,-1,0.0003971535,0.99960285
12241,6-OHDA,2,3,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12241,-1,0.99944884,0.0005511154
12242,SN lesion,4,6,36,45,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12242,-1,0.00021630715,0.9997837
12243,contralateral rotation,11,13,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12243,-1,0.00021719727,0.99978286
12244,ipsilateral circling,20,22,137,157,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12244,-1,0.00021865798,0.9997813
12245,contralateral rotation,9,11,47,69,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12245,-1,0.0002070345,0.999793
12246,rotational behavior,27,29,169,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12246,-1,0.000210667,0.9997893
12247,contralateral rotation,1,3,5,27,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12247,-1,0.000309685,0.9996903
12248,DA,11,12,89,91,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12248,-1,0.9992311,0.0007689578
12249,DA,18,19,128,130,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12249,-1,0.9992219,0.00077810086
12251,contralateral rotation,29,31,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,-1,12251,-1,0.0002257495,0.9997743
12253,rotation,26,27,161,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,-1,12253,-1,0.00018800561,0.99981207
12256,DA,12,13,86,88,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12256,-1,0.9994343,0.00056563783
12257,contralateral rotation,16,18,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12257,-1,0.00022198372,0.999778
12265,hepatocellular injury,8,10,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,-1,-1,-1,12265,-1,0.00019761492,0.9998024
12266,contrast,1,2,3,11,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,-1,-1,12266,-1,0.9253875,0.07461247
12268,Allergic,0,1,0,8,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,-1,-1,12268,-1,0.00022658618,0.99977344
12281,sulfonylureas,12,13,87,100,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,-1,12281,-1,0.9994542,0.0005457924
12282,glyburide,1,2,4,13,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12282,-1,0.9994716,0.0005284199
12283,sulfonylurea,5,6,35,47,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12283,-1,0.9994779,0.0005221195
12285,type II diabetes mellitus,3,7,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12285,-1,0.0032460315,0.996754
12286,glyburide,16,17,112,121,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12286,-1,0.99948066,0.00051940244
12287,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,-1,12287,-1,0.00020957795,0.9997905
12289,glyburide,6,7,47,56,Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow-up period of 1 year.,3107448_5,-1,-1,-1,12289,-1,0.9994461,0.0005538922
12290,Glyburide,0,1,0,9,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,-1,-1,-1,12290,-1,0.9994754,0.00052462233
12291,Mitomycin C,0,2,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,-1,-1,12291,-1,0.9994836,0.00051639654
12293,Mitomycin C,0,2,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12293,-1,0.999485,0.00051499397
12295,HUS,7,8,50,53,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12295,-1,0.00020773687,0.9997923
12296,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12296,-1,0.00020271231,0.9997973
12298,progressive renal failure,9,12,71,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12298,-1,0.00020434125,0.99979573
12299,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12299,-1,0.99947566,0.0005244104
12300,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12300,-1,0.00021392303,0.9997861
12301,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12301,-1,0.99947935,0.00052063755
12302,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12302,-1,0.00021380803,0.9997862
12303,pulmonary edema,27,29,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12303,-1,0.00021125155,0.9997888
12304,Renal lesions,0,2,0,13,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12304,-1,0.00021244044,0.9997876
12305,idiopathic HUS,8,10,43,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12305,-1,0.00020954876,0.9997905
12307,ischemic,24,25,158,166,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12307,-1,0.00021792311,0.99978215
12308,gastric adenocarcinoma,14,16,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12308,-1,0.00020383783,0.9997962
12309,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12309,-1,0.0002065794,0.99979347
12311,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12311,-1,0.9994838,0.0005160993
12312,pulmonary edema,31,33,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12312,-1,0.00020641873,0.9997936
12313,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12313,-1,0.99946433,0.0005356996
12314,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12314,-1,0.00022354996,0.9997764
12315,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12315,-1,0.99949265,0.0005072892
12317,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12317,-1,0.00017563767,0.99982435
12320,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,-1,12320,-1,0.9994665,0.00053357845
12321,Chlordiazepoxide,0,1,0,16,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,-1,-1,12321,-1,0.9994966,0.0005034335
12325,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,-1,-1,12325,-1,0.9995055,0.00049449573
12328,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12328,-1,0.9995103,0.0004897423
12330,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12330,-1,0.9995159,0.00048409335
12331,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,-1,12331,-1,0.00020858715,0.99979144
12332,serotonin antagonists,3,5,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12332,-1,0.99944454,0.00055548496
12334,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12334,-1,0.00021396078,0.9997861
12335,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,-1,12335,-1,0.99938715,0.00061283755
12336,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12336,-1,0.99948454,0.00051541504
12337,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12337,-1,0.999488,0.0005120348
12339,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,-1,12339,-1,0.99942905,0.00057097164
12342,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,-1,12342,-1,0.99942696,0.00057302014
12343,Chorea,0,1,0,6,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12343,-1,0.00019529856,0.9998047
12344,oral contraception,3,5,23,41,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12344,-1,0.9993617,0.00063834427
12345,chorea,3,4,25,31,Three patients developed chorea while receiving oral contraceptives.,3123611_1,-1,-1,-1,12345,-1,0.00019162598,0.9998084
12347,chorea,5,6,30,36,Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued.,3123611_2,-1,-1,-1,12347,-1,0.00022226604,0.99977773
12348,chorea,6,7,48,54,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12348,-1,0.00022799135,0.999772
12349,oral contraception,9,11,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12349,-1,0.13163327,0.8683668
12350,chorea,11,12,71,77,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12350,-1,0.00020256855,0.9997974
12351,chorea,19,20,115,121,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12351,-1,0.00020460658,0.9997954
12352,rheumatic fever,21,23,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12352,-1,0.00020453676,0.9997955
12356,normocarbia,7,8,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12356,-1,0.9994584,0.00054164545
12357,SE,20,21,96,98,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12357,-1,0.9726149,0.027385157
12363,metocurine,10,11,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,-1,-1,12363,-1,0.999432,0.00056795875
12367,retinyl acetate,3,5,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12367,-1,0.9994679,0.0005320989
12369,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12369,-1,0.9994783,0.000521735
12370,retinyl acetate,5,7,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12370,-1,0.9994461,0.00055387506
12371,RA,8,9,51,53,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12371,-1,0.9994118,0.0005882019
12372,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12372,-1,0.9994423,0.00055768393
12373,tumorigenesis,16,17,113,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12373,-1,0.0002176992,0.99978226
12374,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12374,-1,0.014816162,0.98518384
12375,drinking water,25,27,112,126,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12375,-1,0.99935776,0.00064224674
12376,RA,29,30,145,147,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12376,-1,0.9993754,0.00062465394
12377,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12377,-1,0.9964132,0.0035868254
12378,RA,25,26,148,150,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12378,-1,0.99941254,0.00058743265
12379,P,28,29,166,167,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12379,-1,0.46883854,0.5311615
12381,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12381,-1,0.00017216116,0.99982786
12385,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12385,-1,0.99938154,0.00061839743
12386,RA,7,8,22,24,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12386,-1,0.9993856,0.0006143542
12387,epithelial hyperplasia,32,34,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12387,-1,0.00020754918,0.9997925
12389,papillomas,3,4,12,22,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12389,-1,0.00020769583,0.9997923
12390,RA,17,18,64,66,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12390,-1,0.00040733092,0.9995927
12391,RA,29,30,99,101,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12391,-1,0.06948394,0.93051606
12392,RA,0,1,0,2,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,-1,-1,-1,12392,-1,0.9993339,0.00066610664
12393,RA,4,5,29,31,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12393,-1,0.99917114,0.0008289065
12394,BHA,11,12,64,67,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12394,-1,0.9048467,0.09515324
12397,mitomycin C.Since,11,13,72,89,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12397,-1,0.7892278,0.21077222
12398,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12398,-1,0.99948394,0.0005160519
12399,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12399,-1,0.99946433,0.00053564645
12402,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12402,-1,0.00018784452,0.9998122
12403,mg,9,10,55,57,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12403,-1,0.9993343,0.0006656541
12404,MMC,11,12,62,65,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12404,-1,0.001779506,0.9982205
12405,mg,15,16,79,81,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12405,-1,0.9992866,0.0007134217
12407,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,-1,12407,-1,0.00019585858,0.9998042
12410,mg,29,30,174,176,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,-1,12410,-1,0.99935967,0.00064038933
12413,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,-1,-1,12413,-1,0.00020673091,0.99979323
12417,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,-1,12417,-1,0.00021164205,0.99978834
12426,cerebral lesions,1,3,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12426,-1,0.0001878773,0.9998122
12427,tiazofurin,5,6,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12427,-1,0.99945825,0.00054175383
12428,MR,8,9,62,64,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12428,-1,0.62682056,0.37317947
12429,Tiazofurin,0,1,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,-1,12429,-1,0.99944526,0.0005547773
12430,MR,8,9,47,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12430,-1,0.001257849,0.99874216
12431,cerebral abnormalities,13,15,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12431,-1,0.00020753652,0.9997925
12432,MR,3,4,21,23,The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.,3183120_3,-1,-1,-1,12432,-1,0.00084167864,0.9991584
12433,MR,3,4,15,17,The utility of MR in the evaluation of patients receiving this new agent is illustrated.,3183120_4,-1,-1,-1,12433,-1,0.012936526,0.98706347
12435,head and neck carcinoma,5,9,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12435,-1,0.00024521,0.99975485
12436,esophageal carcinoma,10,12,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12436,-1,0.00021661754,0.99978334
12437,5-FU,13,14,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,-1,-1,-1,12437,-1,0.999433,0.0005670138
12438,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,-1,12438,-1,0.00020074696,0.9997993
12440,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,-1,12440,-1,0.00019774782,0.9998023
12442,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12442,-1,0.0002019503,0.9997981
12443,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12443,-1,0.00020544267,0.99979454
12444,ventricular fibrillation,4,6,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12444,-1,0.00019842434,0.9998016
12445,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12445,-1,0.00019932658,0.99980074
12446,5-FU,6,7,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12446,-1,0.99946886,0.0005311113
12447,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12447,-1,0.00021681967,0.9997832
12448,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12448,-1,0.00021407606,0.99978596
12450,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,-1,-1,12450,-1,0.00019363662,0.99980634
12451,choriocarcinoma,16,17,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,-1,12451,-1,0.00034974137,0.99965024
12455,Actomycin-D,14,15,89,100,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,-1,-1,-1,12455,-1,0.9994671,0.0005329034
12460,pulmonary obstruction,16,18,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,-1,-1,-1,12460,-1,0.00020480041,0.99979526
12461,tumor necrosis,9,11,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,-1,12461,-1,0.0002058892,0.9997942
12465,embolism,18,19,103,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,-1,-1,12465,-1,0.00020983926,0.99979013
12475,DA,41,42,255,257,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,-1,12475,-1,0.9994392,0.00056081795
12477,DA,27,28,180,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,-1,12477,-1,0.9994685,0.00053156365
12480,DA,26,27,187,189,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12480,-1,0.99943477,0.0005652655
12481,DA,32,33,226,228,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12481,-1,0.99943167,0.0005683202
12485,cm H2O,5,7,33,39,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12485,-1,0.99947244,0.00052755483
12486,P,10,11,60,61,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12486,-1,0.120271064,0.879729
12487,decreased arterial blood pressure,15,19,77,110,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12487,-1,0.00022374126,0.9997763
12488,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12488,-1,0.9994748,0.00052519573
12490,decrease in arterial blood pressure,10,15,65,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12490,-1,0.0002184065,0.99978155
12491,increased heart rate,17,20,119,139,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12491,-1,0.00023384579,0.9997662
12492,decreased cardiac output,21,24,144,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12492,-1,0.00022661149,0.99977344
12494,decreases in arterial blood pressure and systemic vascular resistance,3,12,33,102,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12494,-1,0.0002702933,0.9997297
12495,increases in,13,15,107,119,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12495,-1,0.00029849212,0.99970144
12496,rate,16,17,126,130,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12496,-1,0.0002200914,0.9997799
12497,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,-1,12497,-1,0.99947053,0.00052952574
12499,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,-1,12499,-1,0.9994973,0.0005026566
12502,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12502,-1,0.9994572,0.00054279744
12503,decreases in arterial blood pressure and cardiac output,31,39,172,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12503,-1,0.000223309,0.99977666
12504,hypokalemia,3,4,39,50,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,-1,-1,-1,12504,-1,0.00019440398,0.9998056
12507,hypokalemia,12,13,66,77,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12507,-1,0.00021377174,0.9997862
12508,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12508,-1,0.99950373,0.0004962118
12512,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,-1,12512,-1,0.9994924,0.00050755695
12515,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,-1,-1,12515,-1,0.99947196,0.00052799756
12516,ergot,6,7,31,36,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12516,-1,0.99891555,0.0010844728
12517,gangrene,15,16,87,95,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12517,-1,0.00019472658,0.9998053
12518,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12518,-1,0.00018945077,0.9998105
12519,calcium channel blockers,4,7,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12519,-1,0.99942327,0.000576811
12520,ergot,11,12,80,85,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12520,-1,0.9994399,0.0005600661
12536,mm Hg,7,9,43,48,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12536,-1,0.003428675,0.9965713
12538,HEM,16,17,86,89,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12538,-1,0.0002297403,0.9997702
12539,n,18,19,91,92,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12539,-1,0.9126896,0.08731041
12541,SNP,30,31,149,152,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12541,-1,0.99943525,0.00056475494
12542,n,32,33,154,155,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12542,-1,0.9921376,0.007862366
12544,SNP,19,20,140,143,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,-1,-1,12544,-1,0.00021178376,0.9997882
12546,mm Hg,9,11,44,49,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12546,-1,0.0005896414,0.9994104
12547,HEM,13,14,57,60,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12547,-1,0.00021413894,0.99978584
12548,mm Hg,22,24,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12548,-1,0.001307772,0.9986922
12549,SNP,26,27,107,110,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12549,-1,0.13472067,0.8652793
12550,P,29,30,118,119,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12550,-1,0.56600964,0.43399036
12551,mm Hg,27,29,117,122,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12551,-1,0.0016435423,0.9983564
12552,HEM,31,32,130,133,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12552,-1,0.00034241308,0.99965763
12553,SNP,33,34,138,141,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12553,-1,0.99907863,0.0009213468
12555,P,41,42,184,185,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12555,-1,0.77277863,0.22722131
12557,hypovolemia,7,8,45,56,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,-1,-1,12557,-1,0.00019679585,0.99980325
12559,Ventricular tachyarrhythmias,0,2,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12559,-1,0.00017504033,0.99982494
12560,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12560,-1,0.9994765,0.0005235391
12561,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12561,-1,0.9994973,0.0005026859
12562,preterm labor,8,10,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12562,-1,0.00022748085,0.9997725
12563,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12563,-1,0.9994978,0.0005022338
12564,cardiovascular complications,6,8,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12564,-1,0.00019645259,0.9998036
12565,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12565,-1,0.9994947,0.0005052615
12571,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,-1,12571,-1,0.023115898,0.97688407
12572,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,-1,12572,-1,0.020986302,0.9790137
12579,Ethopropazine,0,1,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12579,-1,0.99949276,0.00050725933
12580,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12580,-1,0.9995011,0.0004989324
12582,ethopropazine,5,6,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12582,-1,0.99949014,0.0005098228
12583,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12583,-1,0.99948907,0.0005108594
12587,Ethopropazine,0,1,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12587,-1,0.99947006,0.0005299205
12588,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12588,-1,0.99947935,0.00052065845
12590,procyclidine,18,19,129,141,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12590,-1,0.99948585,0.0005141682
12591,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12591,-1,0.99950314,0.0004968698
12592,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12592,-1,0.00020366201,0.99979633
12593,procyclindine,17,18,122,135,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12593,-1,0.9995111,0.0004889032
12594,anxiety,23,24,170,177,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12594,-1,0.00020928259,0.9997907
12596,ethopropazine,27,28,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12596,-1,0.99950564,0.00049434166
12597,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12597,-1,0.999474,0.0005260274
12598,parkinsonian symptoms,16,18,113,134,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12598,-1,0.00020189022,0.9997981
12601,renal and hepatic failure,6,10,49,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12601,-1,0.0002186826,0.9997813
12603,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12603,-1,0.00019770199,0.9998023
12604,hepatic failure,10,12,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12604,-1,0.00019977942,0.99980026
12611,osteoarthritis,16,17,116,130,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12611,-1,0.00019819499,0.9998018
12612,spondyloarthropathy,18,19,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12612,-1,0.00020098579,0.9997991
12614,Sexual dysfunctions,0,2,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12614,-1,0.00022496609,0.999775
12615,Impotence,0,1,0,9,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,-1,12615,-1,0.9978927,0.0021073462
12617,Depressed mood,0,2,0,14,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12617,-1,0.00020496782,0.999795
12618,sexual difficulties,12,14,78,97,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12618,-1,0.00020094478,0.9997991
12619,impotence,18,19,112,121,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12619,-1,0.00035970626,0.9996402
12622,Quinidine,0,1,0,9,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12622,-1,0.99948114,0.0005188912
12623,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12623,-1,0.01829912,0.98170096
12624,Laotian,7,8,36,43,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12624,-1,0.999403,0.00059697026
12625,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12625,-1,0.00088189356,0.99911815
12626,quinidine phenylethylbarbiturate,25,27,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12626,-1,0.9994423,0.0005577137
12627,Quinidine,0,1,0,9,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12627,-1,0.99946946,0.0005305014
12628,phenylethylbarbiturate,3,4,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12628,-1,0.99947387,0.0005260996
12629,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12629,-1,0.0008706133,0.99912935
12631,urothelial cancer,3,5,23,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12631,-1,0.00020263328,0.9997974
12632,renal papillary necrosis?The,6,9,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12632,-1,0.00049621303,0.99950373
12640,ureteric cancer,31,33,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,-1,-1,12640,-1,0.00020584013,0.9997942
12641,contrast,1,2,3,11,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12641,-1,0.92236733,0.07763264
12645,cancer of the ureter,32,36,199,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12645,-1,0.00032175757,0.99967825
12646,myocardial ischemia,2,4,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,-1,-1,12646,-1,0.00019304687,0.99980694
12650,myocardial ischemia,6,8,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12650,-1,0.00018128651,0.99981874
12651,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12651,-1,0.00017912683,0.9998209
12656,myocardial ischemia,5,7,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12656,-1,0.00020618466,0.9997938
12658,angina,14,15,101,107,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12658,-1,0.00020669584,0.99979335
12659,myocardial ischemia,5,7,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,-1,-1,-1,12659,-1,0.00018817706,0.9998118
12661,myocardial ischemia,1,3,17,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,-1,12661,-1,0.00020175011,0.99979824
12666,hemoglobin E,10,12,73,85,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,-1,12666,-1,0.3527348,0.6472652
12667,hemoglobin E,4,6,23,35,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12667,-1,0.3983058,0.60169417
12668,leprosy,11,12,51,58,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12668,-1,0.0002550402,0.99974495
12672,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12672,-1,0.9994142,0.0005857794
12673,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12673,-1,0.9993574,0.0006425857
12674,GSH,23,24,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12674,-1,0.9993709,0.0006291233
12675,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,-1,-1,-1,12675,-1,0.9994911,0.0005089062
12677,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12677,-1,0.9993455,0.0006545126
12678,GSH,21,22,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12678,-1,0.99935097,0.0006490809
12679,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,-1,-1,-1,12679,-1,0.9994825,0.00051744166
12683,thymidylate synthase,7,9,49,69,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12683,-1,0.9994541,0.00054589385
12684,"N10-propargyl-5,8-dideazafolic acid",10,12,80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12684,-1,0.9994961,0.0005038396
12685,"N10-propargyl-5,8-dideazafolic acid",17,19,135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12685,-1,0.99948835,0.0005116001
12686,thymidylate synthase,25,27,204,224,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12686,-1,0.97996324,0.020036684
12687,TS,28,29,226,228,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12687,-1,0.037704837,0.9622952
12688,cytotoxicity,31,32,236,248,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12688,-1,0.00022214698,0.99977785
12689,CB 3717,10,12,74,81,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,-1,12689,-1,0.99945694,0.0005430371
12690,CB 3717,24,26,133,140,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,-1,12690,-1,0.99951315,0.0004868017
12691,TS,5,6,32,34,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12691,-1,0.00028100584,0.99971896
12692,CB 3717,7,9,36,43,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12692,-1,0.9994997,0.0005003306
12693,CB 3717,27,29,130,137,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12693,-1,0.9995023,0.0004976414
12694,CB 3717 cytotoxicity,44,47,220,240,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12694,-1,0.016644487,0.9833556
12695,CB 3717,5,7,31,38,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12695,-1,0.9994873,0.000512722
12698,hepatoma,19,20,97,105,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12698,-1,0.00020870511,0.9997913
12699,mesothelioma,22,23,111,123,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12699,-1,0.00020670077,0.99979335
12702,malaise,4,5,36,43,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,-1,-1,12702,-1,0.8101455,0.1898545
12704,CB 3717,23,25,124,131,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,-1,12704,-1,0.9994598,0.00054019946
12705,CB 3717,12,14,60,67,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,-1,12705,-1,0.9994431,0.0005568277
12709,malaise,2,3,19,26,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,-1,-1,12709,-1,0.83384085,0.16615915
12710,CB 3717,10,12,80,87,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,-1,12710,-1,0.99936134,0.000638694
12711,Type B hepatitis,0,3,0,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12711,-1,0.0077876556,0.99221236
12712,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12712,-1,0.84894234,0.15105765
12713,Hepatitis B,0,2,0,11,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12713,-1,0.89199764,0.10800238
12714,type B hepatitis,29,32,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12714,-1,0.004639586,0.99536043
12715,hepatitis B surface antigen,36,40,215,242,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12715,-1,0.9580616,0.04193847
12717,P,16,17,76,77,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12717,-1,0.17655438,0.8234457
12718,P,37,38,167,168,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12718,-1,0.16854176,0.8314583
12719,e,12,13,65,66,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12719,-1,0.9936114,0.0063885874
12720,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12720,-1,0.0002739446,0.999726
12721,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,-1,12721,-1,0.00024430783,0.9997557
12722,Hepatitis B,0,2,0,11,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12722,-1,0.8735801,0.12641989
12723,type B hepatitis,11,14,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12723,-1,0.00083276513,0.9991672
12724,type B hepatitis,6,9,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,-1,-1,12724,-1,0.0011513951,0.99884856
12726,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,-1,12726,-1,0.99947685,0.0005231732
12729,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12729,-1,0.00018467379,0.9998154
12731,AV block,0,2,0,8,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12731,-1,0.00022056447,0.9997794
12733,impairment of ventricular function,7,11,34,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12733,-1,0.00025539304,0.9997446
12735,mg,14,15,77,79,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12735,-1,0.99765116,0.002348879
12736,mg,20,21,100,102,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12736,-1,0.9989182,0.0010819039
12738,mg,7,8,40,42,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,-1,-1,-1,12738,-1,0.9972946,0.0027054276
12743,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,-1,12743,-1,0.9995221,0.00047796938
12745,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,-1,12745,-1,0.0005909157,0.9994091
12748,prostate adenocarcinomas,15,17,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12748,-1,0.00022323964,0.9997768
12749,PAs,18,19,101,104,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12749,-1,0.99938464,0.00061537395
12750,testosterone propionate,34,36,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12750,-1,0.99944705,0.0005528898
12751,TP,38,39,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12751,-1,0.99917597,0.0008240577
12752,PA,12,13,67,69,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12752,-1,0.00020837344,0.9997917
12753,TP,17,18,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12753,-1,0.9911908,0.008809243
12754,TP,4,5,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,-1,12754,-1,0.9910993,0.008900714
12757,bromperidol,8,9,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12757,-1,0.99947125,0.0005287179
12758,blind,22,23,112,117,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12758,-1,0.004473903,0.99552613
12760,mg,17,18,82,84,The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets.,347884_2,-1,-1,-1,12760,-1,0.9972377,0.0027622445
12761,mg,8,9,32,34,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12761,-1,0.98201466,0.017985292
12762,mg,20,21,76,78,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12762,-1,0.92554474,0.07445523
12763,extrapyramidal concomitant symptoms,6,9,41,76,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,-1,-1,12763,-1,0.0002077428,0.9997923
12764,blind,3,4,14,19,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12764,-1,0.003302146,0.9966979
12766,psychotic syndromes,20,22,114,133,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12766,-1,0.00019669623,0.99980336
12768,bromperidol,17,18,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,-1,12768,-1,0.9994473,0.0005527354
12770,acute hepatitis,4,6,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,-1,12770,-1,0.00021413015,0.99978584
12774,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12774,-1,0.99945885,0.0005411109
12775,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12775,-1,0.00047806962,0.999522
12779,alkaline phosphatase,19,21,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,-1,-1,12779,-1,0.9994628,0.0005371678
12783,acute hepatitis,9,11,91,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,-1,12783,-1,0.00019872728,0.99980134
12784,auditory neurotoxicity,3,5,18,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,-1,-1,12784,-1,0.00020298948,0.99979705
12786,auditory neurotoxicity,2,4,11,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,-1,-1,12786,-1,0.00018862597,0.99981135
12790,abnormal audiograms,7,9,46,65,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12790,-1,0.00020130146,0.9997987
12791,"deficits mostly in the high frequency range of 4,000 to 8,000 Hz",10,22,71,135,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12791,-1,0.0103748925,0.98962516
12794,auditory abnormality,41,43,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,-1,-1,12794,-1,0.00021238111,0.9997876
12802,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,-1,-1,12802,-1,0.00021212104,0.99978787
12803,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,-1,12803,-1,0.00020376689,0.9997962
12805,netilmicin,5,6,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,-1,12805,-1,0.9995048,0.00049513363
12807,netilmicin sulfate,8,10,53,71,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12807,-1,0.99952495,0.00047505257
12808,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12808,-1,0.99953127,0.00046877452
12809,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12809,-1,0.99952376,0.0004762153
12812,netilmicin,10,11,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,-1,12812,-1,0.9995085,0.0004914451
12815,netilmicin,10,11,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12815,-1,0.99951446,0.00048553475
12816,piperacillin,12,13,57,69,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12816,-1,0.9994998,0.00050020753
12818,netilmicin,10,11,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,-1,12818,-1,0.999532,0.00046803826
12820,netilmicin,34,35,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,-1,12820,-1,0.9995065,0.00049357396
12823,netilmicin,13,14,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,-1,-1,12823,-1,0.9994948,0.000505149
12828,bradyarrhythmias,16,17,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,-1,-1,-1,12828,-1,0.00019364012,0.99980634
12830,Flurbiprofen,0,1,0,12,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12830,-1,0.9994973,0.0005026612
12831,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12831,-1,0.00057936815,0.99942064
12832,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12832,-1,0.00020608127,0.99979395
12833,flurbiprofen,11,12,79,91,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12833,-1,0.999498,0.00050194375
12835,tender joints,7,9,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12835,-1,0.00021320423,0.9997868
12836,swelling,13,14,71,79,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12836,-1,0.00021041128,0.99978966
12837,tenderness,15,16,84,94,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12837,-1,0.00021200822,0.999788
12838,stiffness,28,29,146,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12838,-1,0.0002207229,0.9997793
12839,fecal occult blood,7,10,45,63,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12839,-1,0.000294002,0.999706
12840,gastrointestinal (GI) bleeding,25,30,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12840,-1,0.0002442717,0.9997557
12842,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,-1,-1,12842,-1,0.00021212448,0.99978787
12846,antiinflammatory agents,10,12,76,99,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12846,-1,0.9993955,0.00060447084
12847,NSAID,13,14,101,106,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12847,-1,0.9994473,0.00055266166
12850,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,-1,12850,-1,0.9994873,0.000512731
12859,NSAID,19,20,123,128,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,-1,12859,-1,0.99941707,0.00058299117
12862,sodium pentothal,9,11,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12862,-1,0.9994653,0.00053477346
12863,ischaemia,17,18,123,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12863,-1,0.00021580429,0.9997842
12865,gangrene,4,5,34,42,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,-1,-1,12865,-1,0.87929124,0.12070876
12878,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,-1,12878,-1,0.008147871,0.9918521
12879,Cephalosporin,0,1,0,13,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12879,-1,0.9994784,0.000521583
12880,hematologic disturbances,6,8,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12880,-1,0.00020707952,0.999793
12881,blood dyscrasias,12,14,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,-1,12881,-1,0.0009291034,0.9990709
12889,cytopenias,9,10,58,68,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,-1,-1,12889,-1,0.00046535875,0.9995346
12892,cytopenias,2,3,10,20,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,-1,-1,-1,12892,-1,0.00024118194,0.9997588
12893,cephalosporin,4,5,29,42,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12893,-1,0.99949825,0.0005017481
12894,hematologic syndrome,7,9,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12894,-1,0.0001883063,0.9998117
12896,hemolytic,22,23,117,126,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12896,-1,0.00020863645,0.9997913
12897,cytopenia,38,39,241,250,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12897,-1,0.00068592525,0.99931407
12900,hematotoxicity,16,17,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12900,-1,0.00020126114,0.9997987
12901,blood dyscrasias,21,23,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12901,-1,0.0012964304,0.9987036
12902,injury to,8,10,54,63,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12902,-1,0.0007950542,0.99920493
12903,regions of the kidney,11,15,74,95,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12903,-1,0.00089882273,0.99910116
12905,hexachloro-1:3-butadiene,24,25,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12905,-1,0.9994991,0.0005008958
12906,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12906,-1,0.11227238,0.8877276
12907,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12907,-1,0.99948347,0.00051652826
12908,PAN,32,33,207,210,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12908,-1,0.9994661,0.00053386326
12909,2-bromoethylamine,36,37,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12909,-1,0.99949586,0.00050417345
12910,BEA,38,39,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12910,-1,0.24757212,0.7524279
12912,phosphatase,9,10,67,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12912,-1,0.06437196,0.93562806
12913,protein excretion,18,20,142,159,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12913,-1,0.0047095907,0.9952904
12914,Tubular damage,0,2,0,14,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12914,-1,0.00019626273,0.9998037
12915,HCBD,4,5,27,31,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12915,-1,0.0058682305,0.99413174
12916,BEA,6,7,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12916,-1,0.9993436,0.0006564573
12917,glomerular damage,14,16,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12917,-1,0.00019741738,0.99980265
12918,PAN,18,19,130,133,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12918,-1,0.99904925,0.00095070555
12919,protein excretion,9,11,57,74,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12919,-1,0.0032182597,0.9967817
12920,Da,20,21,138,140,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12920,-1,0.9325917,0.06740835
12921,contrast,1,2,3,11,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12921,-1,0.9979755,0.0020244766
12922,protein excretion,3,5,13,30,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12922,-1,0.004810663,0.9951893
12923,tubular damage,6,8,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12923,-1,0.00019858315,0.99980146
12924,excretion,15,16,95,104,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12924,-1,0.00021046122,0.99978954
12925,proteins,17,18,108,116,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12925,-1,0.99903405,0.0009660256
12926,Proximal tubular damage,0,3,0,23,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12926,-1,0.0002184944,0.99978155
12927,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12927,-1,0.00021337345,0.9997867
12928,papillary damage,7,9,43,59,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12928,-1,0.00021555237,0.9997844
12929,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12929,-1,0.9989613,0.0010387173
12930,Alkaline phosphatase,0,2,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12930,-1,0.99947125,0.0005288115
12932,proximal tubular damage,10,13,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12932,-1,0.00022109677,0.9997789
12933,papillary damage,20,22,165,181,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12933,-1,0.00021266236,0.9997874
12935,Reye,4,5,15,19,A catch in the Reye.,3670965_0,-1,-1,-1,12935,-1,0.000915359,0.9990846
12936,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,-1,12936,-1,0.00016830173,0.9998317
12937,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,-1,12937,-1,0.00020008346,0.9997999
12939,salicylate,2,3,11,21,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,-1,-1,-1,12939,-1,0.9994999,0.0005000813
12943,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,-1,-1,12943,-1,0.0001997457,0.99980026
12944,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,-1,12944,-1,0.0002414735,0.99975854
12945,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,-1,12945,-1,0.0002525385,0.99974746
12949,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12949,-1,0.0024825186,0.99751747
12950,salicylates,14,15,90,101,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12950,-1,0.9994442,0.00055584335
12953,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,-1,-1,12953,-1,0.0002099013,0.99979013
12956,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,-1,12956,-1,0.00020041302,0.99979955
12957,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,-1,12957,-1,0.00019843057,0.9998016
12959,nitrous oxide,15,17,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,-1,12959,-1,0.9985216,0.0014783377
12962,MAP,5,6,37,40,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12962,-1,0.00020798123,0.99979204
12963,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12963,-1,0.0010689124,0.9989311
12968,psychosis,1,2,11,20,Postpartum psychosis induced by bromocriptine.,3686155_0,-1,-1,-1,12968,-1,0.00018929009,0.99981076
12971,psychosis,12,13,86,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12971,-1,0.00021570885,0.9997843
12973,inhibition of lactation,18,21,131,154,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12973,-1,0.00022214232,0.99977785
12975,psychosis,9,10,59,68,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12975,-1,0.00020183576,0.99979824
12976,Parkinson's disease,16,19,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12976,-1,0.0001991913,0.99980086
12978,psychosis,7,8,53,62,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,-1,-1,-1,12978,-1,0.00020380906,0.9997962
12979,mania,5,6,46,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,-1,12979,-1,0.00023408672,0.99976593
12981,triazolam,3,4,15,24,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12981,-1,0.99946743,0.00053256983
12982,mania,9,10,62,67,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12982,-1,0.004726388,0.99527365
12984,organic mental disorder,2,5,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,-1,-1,12984,-1,0.0026214235,0.9973786
12987,triazolam,10,11,63,72,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,-1,-1,12987,-1,0.9994623,0.0005377493
12988,triazolo,5,6,33,41,The possible contribution of the triazolo group to changes in affective status is discussed.,3693336_4,-1,-1,-1,12988,-1,0.9994704,0.00052963075
12989,Hyperglycemic,0,1,0,13,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,-1,-1,12989,-1,0.00020849667,0.99979156
12993,lethargy,10,11,65,73,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12993,-1,0.00021604949,0.99978393
12996,polyphagia,17,18,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12996,-1,0.0002216297,0.99977833
13000,hyperglycemia,13,14,77,90,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,-1,-1,13000,-1,0.0002279257,0.99977213
13002,lactic acidosis,1,3,11,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13002,-1,0.00017777766,0.9998222
13003,ketosis,8,9,50,57,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13003,-1,0.00398581,0.99601424
13004,lactate,13,14,80,87,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13004,-1,0.9993075,0.000692479
13005,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,-1,-1,13005,-1,0.00021742209,0.9997826
13006,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,-1,13006,-1,0.0039435746,0.99605644
13008,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,-1,13008,-1,0.99942833,0.0005715855
13010,CSA,4,5,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,-1,-1,-1,13010,-1,0.9994253,0.0005747281
13011,CSA,4,5,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13011,-1,0.99945515,0.0005448802
13014,amphothericin B,23,25,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13014,-1,0.99947995,0.0005200412
13016,CSA,40,41,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13016,-1,0.9994522,0.0005478219
13019,CSA nephrotoxicity,8,10,46,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,-1,13019,-1,0.0021563792,0.9978436
13021,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,-1,13021,-1,0.9993474,0.00065255276
13023,neuropathic damage,8,10,75,93,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,-1,13023,-1,0.00019422907,0.99980575
13024,neuropathic damage,3,5,24,42,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13024,-1,0.00020180881,0.99979824
13027,Mipafox,24,25,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13027,-1,0.99950516,0.0004948732
13028,"N, N'-diisopropylphosphorodiamidofluoridate",26,29,164,207,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13028,-1,0.9994925,0.00050749263
13029,neurotoxic organophosphate,32,34,212,238,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13029,-1,0.9071512,0.09284872
13030,Mipafox,19,20,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,-1,13030,-1,0.99947256,0.00052744144
13031,cord damage,8,10,63,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,-1,13031,-1,0.00019464623,0.9998054
13032,cord,50,51,242,246,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,-1,-1,13032,-1,0.00019299703,0.99980706
13033,contrast,1,2,3,11,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13033,-1,0.35035762,0.6496424
13034,Mipafox,5,6,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13034,-1,0.99945873,0.0005412408
13035,cord damage,43,45,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13035,-1,0.00019123046,0.99980885
13036,Mipafox,18,19,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13036,-1,0.99948055,0.0005194905
13037,neuropathic damage,22,24,141,159,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13037,-1,0.00020507044,0.9997949
13041,angioneurotic edema,5,7,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13041,-1,0.00019916016,0.99980086
13043,carcinoma of the oral cavity,18,23,140,168,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13043,-1,0.71611506,0.28388494
13045,impaired renal function,28,31,203,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13045,-1,0.00019777044,0.9998023
13046,diphenhydramine,1,2,5,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,-1,-1,13046,-1,0.9995022,0.00049776526
13049,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,-1,-1,13049,-1,0.00021192899,0.9997881
13050,Diuretics,0,1,0,9,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13050,-1,0.9982658,0.0017341856
13053,hypertensive coronary disease,6,9,40,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13053,-1,0.00021513559,0.9997849
13056,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,-1,-1,13056,-1,0.00019318241,0.9998068
13057,essential hypertension,11,13,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13057,-1,0.00020483008,0.99979514
13058,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13058,-1,0.00020493714,0.99979514
13059,diuretic,26,27,188,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13059,-1,0.999488,0.0005119699
13061,diuretic,37,38,252,260,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13061,-1,0.9994838,0.0005161387
13062,chlorthalidone,39,40,262,276,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13062,-1,0.9994966,0.0005034027
13064,chlorthalidone,11,12,74,88,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,-1,-1,-1,13064,-1,0.9994822,0.0005177623
13069,chlorthalidone,6,7,37,51,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13069,-1,0.99946004,0.0005399702
13070,ventricular ectopic beats,15,18,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13070,-1,0.00022113833,0.9997789
13071,diuretic,7,8,57,65,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13071,-1,0.9994324,0.0005675647
13072,ischaemic heart disease,17,20,139,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13072,-1,0.00021541906,0.99978465
13074,Myasthenia gravis,0,2,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,-1,-1,13074,-1,0.00033689677,0.9996631
13078,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,-1,-1,13078,-1,0.00019872161,0.99980134
13083,Wernicke's encephalopathy,4,7,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,-1,13083,-1,0.0003523314,0.9996476
13085,Wernicke's encephalopathy,16,19,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13085,-1,0.0004706313,0.99952936
13086,tolazamide,22,23,152,162,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13086,-1,0.9994978,0.00050216814
13087,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13087,-1,0.99948287,0.00051711476
13088,TPP,42,43,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13088,-1,0.9994704,0.0005295767
13090,Wernicke's encephalopathy,19,22,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,-1,13090,-1,0.0003124135,0.99968755
13092,Wernicke's encephalopathy,16,19,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13092,-1,0.00034093586,0.99965906
13093,TPP,28,29,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13093,-1,0.99944454,0.00055543677
13094,Wernicke's encephalopathy,14,17,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,-1,13094,-1,0.0037931076,0.9962069
13096,trihexyphenidyl hydrochloride,3,5,19,48,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,-1,-1,13096,-1,0.99947506,0.0005249986
13098,trihexyphenidyl hydrochloride,11,13,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,-1,13098,-1,0.9994916,0.00050836895
13105,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,-1,13105,-1,0.0001664319,0.9998336
13109,diethylnitrosamine,7,8,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,-1,-1,-1,13109,-1,0.9994802,0.0005197808
13111,PB,15,16,85,87,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13111,-1,0.9993309,0.0006691581
13112,mg,18,19,92,94,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13112,-1,0.9965616,0.0034383861
13114,diethylnitrosamine,33,34,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13114,-1,0.9994721,0.00052788586
13115,DEN,35,36,203,206,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13115,-1,0.99929225,0.00070775027
13116,DEN,9,10,36,39,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13116,-1,0.9993548,0.0006451676
13117,DEN,13,14,52,55,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13117,-1,0.9993362,0.0006637979
13118,PB,15,16,58,60,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13118,-1,0.99934846,0.00065148546
13119,hepatocarcinogenesis,28,29,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13119,-1,0.00020611114,0.99979395
13120,PAS,14,15,67,70,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13120,-1,0.00021061601,0.9997894
13121,preneoplastic foci,16,18,80,98,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13121,-1,0.00041450333,0.99958545
13122,PB,22,23,130,132,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13122,-1,0.999193,0.00080693205
13123,DEN,27,28,163,166,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13123,-1,0.9991573,0.00084265997
13124,micronuclei,7,8,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13124,-1,0.00085954973,0.9991404
13125,DEN,14,15,104,107,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13125,-1,0.99936086,0.0006391765
13126,DEN,22,23,158,161,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13126,-1,0.99939287,0.00060711143
13127,PB,24,25,164,166,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13127,-1,0.9993918,0.00060818286
13128,PB,11,12,54,56,"When the treatment last only 2 weeks, the presence of PB did not change significantly the last parameters.",3780814_5,-1,-1,-1,13128,-1,0.9992162,0.00078383205
13129,DEN,1,2,3,6,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13129,-1,0.99941707,0.0005830009
13130,PB,3,4,9,11,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13130,-1,0.9993925,0.000607512
13132,DEN,23,24,128,131,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13132,-1,0.9993992,0.0006008307
13133,PB,4,5,21,23,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13133,-1,0.99914765,0.0008523068
13135,DEN,13,14,83,86,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13135,-1,0.99892247,0.001077523
13136,DEN,24,25,159,162,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13136,-1,0.9992461,0.00075392134
13137,precancerous lesions,17,19,88,108,This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.,3780814_8,-1,-1,-1,13137,-1,0.00020637976,0.9997936
13138,PB,14,15,95,97,Biochemical investigations are in progress to obtain more information about this 'paradoxical' PB effect.,3780814_9,-1,-1,-1,13138,-1,0.99814224,0.0018577699
13139,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,-1,-1,13139,-1,0.00018321838,0.99981683
13141,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,-1,-1,13141,-1,0.00017621946,0.99982387
13146,h,13,14,63,64,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,-1,-1,13146,-1,0.019123973,0.980876
13152,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13152,-1,0.00022023752,0.99977976
13153,K,28,29,158,159,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13153,-1,0.99931085,0.0006891717
13163,molindone,6,7,43,52,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,-1,-1,13163,-1,0.9994791,0.00052088924
13166,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,-1,-1,13166,-1,0.00025172334,0.9997483
13170,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13170,-1,0.00018550607,0.99981457
13171,molindone,18,19,130,139,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13171,-1,0.9994879,0.00051211927
13172,molindone,3,4,25,34,Physicians who prescribe molindone should be aware of this reaction.,3782049_4,-1,-1,-1,13172,-1,0.9994629,0.00053706235
13173,Compression neuropathy,0,2,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13173,-1,0.00021547842,0.9997845
13174,fibrous myopathy,9,11,70,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13174,-1,0.00020847342,0.99979156
13175,Fibrous myopathy,0,2,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,-1,-1,13175,-1,0.00017623557,0.99982375
13177,compression neuropathy,2,4,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,-1,-1,13177,-1,0.00020678947,0.99979323
13179,fibrous myopathy,7,9,59,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13179,-1,0.00019778666,0.9998023
13180,fibrous myopathy,49,51,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13180,-1,0.00019813036,0.99980193
13181,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13181,-1,0.0001744801,0.99982554
13182,amphotericin,6,7,46,58,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13182,-1,0.9994728,0.0005272437
13184,sporotrichosis,7,8,54,68,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13184,-1,0.0011042041,0.99889576
13185,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13185,-1,0.00019641098,0.9998036
13186,amphotericin B,17,19,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13186,-1,0.99947804,0.00052198773
13187,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,-1,-1,13187,-1,0.00019587445,0.9998042
13189,amphotericin,3,4,16,28,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13189,-1,0.99947995,0.00052012375
13190,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13190,-1,0.0002168147,0.9997832
13191,Cerebral infarction,0,2,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13191,-1,0.00018627246,0.99981374
13192,phenylpropanolamine,8,9,47,66,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13192,-1,0.9994715,0.000528524
13193,Phenylpropanolamine,0,1,0,19,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13193,-1,0.9994369,0.0005631008
13194,PPA,2,3,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13194,-1,0.99934524,0.0006547715
13197,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13197,-1,0.00021232422,0.99978775
13198,neuropsychiatric symptoms,14,16,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13198,-1,0.00021758341,0.9997824
13199,cerebral infarction,19,21,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13199,-1,0.0002148574,0.9997851
13200,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13200,-1,0.00018880088,0.99981123
13201,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13201,-1,0.012916801,0.9870832
13202,optic neuropathy,1,3,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13202,-1,0.0002200442,0.99978
13203,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13203,-1,0.9994898,0.000510236
13205,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,-1,-1,-1,13205,-1,0.9994797,0.0005203365
13207,retrobulbar neuropathy,2,4,12,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13207,-1,0.016214361,0.9837856
13208,scotoma,10,11,81,88,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13208,-1,0.0002027535,0.9997973
13209,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,-1,-1,-1,13209,-1,0.9994863,0.00051369646
13211,optic nerve toxicity,3,6,15,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13211,-1,0.00018643381,0.9998136
13212,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13212,-1,0.9994758,0.00052423344
13213,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,-1,-1,-1,13213,-1,0.99948597,0.00051403634
13215,meningeal leukemia,3,5,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,-1,-1,-1,13215,-1,0.00020028581,0.9997998
13218,meningeal disease,8,10,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,13218,-1,0.00017022002,0.99982977
13222,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,-1,13222,-1,0.99949074,0.0005092832
13230,hemiparesis,7,8,45,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,-1,-1,13230,-1,0.00021774985,0.99978226
13233,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13233,-1,0.9994765,0.00052353484
13234,antineoplastic agents,5,7,34,55,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13234,-1,0.999466,0.0005340557
13236,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13236,-1,0.9995009,0.00049908453
13237,leukemia,16,17,103,111,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13237,-1,0.00019602837,0.99980396
13239,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13239,-1,0.99949884,0.0005011841
13240,leukemic infiltration of bone marrow,14,19,109,145,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13240,-1,0.0002076717,0.9997924
13242,hyperbilirubinemia,10,11,65,83,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13242,-1,0.00033530983,0.99966466
13243,antineoplastic,21,22,130,144,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13243,-1,0.011574945,0.988425
13245,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,-1,-1,-1,13245,-1,0.99940693,0.000593083
13251,thrombophlebitis,2,3,19,35,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,-1,13251,-1,0.00022247827,0.9997775
13256,Thrombophlebitis,0,1,0,16,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,-1,-1,13256,-1,0.0001889882,0.999811
13269,P,16,17,108,109,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,-1,-1,13269,-1,0.22004975,0.7799502
13271,contrast,1,2,3,11,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13271,-1,0.19831227,0.8016877
13272,P,14,15,92,93,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13272,-1,0.12252464,0.8774753
13274,P,25,26,120,121,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,-1,13274,-1,0.10830366,0.8916963
13275,contrast,1,2,3,11,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,-1,13275,-1,0.28479803,0.715202
13278,angina,6,7,32,38,Report of a case of spontaneous angina.,3952818_1,-1,-1,-1,13278,-1,0.00017542246,0.9998246
13279,colon carcinoma,8,10,35,50,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13279,-1,0.00019688086,0.9998031
13280,liver metastasis,11,13,55,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13280,-1,0.00019695186,0.9998031
13281,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13281,-1,0.00019856571,0.99980146
13283,5-FU,20,21,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13283,-1,0.9994849,0.00051507173
13284,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13284,-1,0.0068166167,0.99318343
13285,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13285,-1,0.00020445527,0.9997956
13289,5-FU,14,15,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13289,-1,0.9994912,0.0005088164
13290,calcium antagonists,18,20,96,115,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13290,-1,0.99948126,0.00051881117
13291,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13291,-1,0.0056998287,0.9943001
13295,TOTP,3,4,27,31,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13295,-1,0.99940467,0.00059537473
13296,"0,0'-diisopropyl phosphorofluoridate",12,14,53,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13296,-1,0.9975545,0.0024455567
13297,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13297,-1,0.99943286,0.00056711456
13299,signs and lesions,6,9,49,66,Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared.,3961813_2,-1,-1,-1,13299,-1,0.00022898085,0.99977106
13303,TOTP,35,36,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13303,-1,0.99945205,0.00054792693
13304,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13304,-1,0.9994555,0.00054445706
13306,TOTP,6,7,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13306,-1,0.99940884,0.00059118465
13307,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13307,-1,0.9994398,0.00056022895
13309,TOTP,6,7,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13309,-1,0.99917704,0.0008229461
13310,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13310,-1,0.99938107,0.0006188588
13311,Degenerating myelinated fibers,0,3,0,30,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13311,-1,0.00017979844,0.9998202
13312,TOTP,16,17,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13312,-1,0.9993456,0.0006543491
13313,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13313,-1,0.9994111,0.0005889171
13317,tachyarrhythmias,12,13,85,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,-1,-1,13317,-1,0.00018718158,0.9998129
13319,cholestatic hepatitis,3,5,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,-1,-1,13319,-1,0.00096894574,0.99903107
13325,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13325,-1,0.00020584483,0.9997942
13326,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13326,-1,0.0004995044,0.9995005
13327,cholestatic hepatitis,23,25,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13327,-1,0.004683876,0.99531615
13328,cirrhosis of the liver,27,31,194,216,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13328,-1,0.00025408444,0.9997459
13330,cholestatic injury,8,10,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,-1,-1,13330,-1,0.00061628607,0.9993837
13333,fat,6,7,48,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13333,-1,0.9994023,0.0005977004
13335,adenocarcinomas,20,21,96,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,-1,13335,-1,0.00023191405,0.9997681
13340,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13340,-1,0.99940324,0.0005967683
13341,fat,24,25,139,142,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13341,-1,0.9993869,0.00061312236
13343,SD,4,5,24,26,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,-1,-1,13343,-1,0.10072372,0.89927626
13345,SD,1,2,13,15,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13345,-1,0.0940469,0.90595305
13347,prostatitis,12,13,81,92,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13347,-1,0.00021464158,0.99978536
13349,neoplasms,2,3,13,22,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,-1,13349,-1,0.00019907321,0.999801
13351,Immunosuppressive drugs,0,2,0,23,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,-1,-1,13351,-1,0.80309176,0.19690822
13354,chlorambucil,7,8,49,61,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13354,-1,0.9994855,0.0005145138
13355,alkylating agents,9,11,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13355,-1,0.99934846,0.0006515339
13357,purine,15,16,97,103,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13357,-1,0.99946815,0.00053187937
13359,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13359,-1,0.99947816,0.0005218613
13360,synovitis,10,11,67,76,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,-1,13360,-1,0.00019815227,0.9998018
13361,alkylating agents,3,5,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13361,-1,0.99947625,0.00052374124
13362,nonlymphocytic leukemia,13,15,87,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13362,-1,0.00020949062,0.9997905
13363,alkylating agents,18,20,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13363,-1,0.9994802,0.0005198953
13365,lymphoma,30,31,209,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13365,-1,0.00020950261,0.9997905
13374,immunosuppressive drugs,26,28,156,179,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13374,-1,0.99904233,0.0009576269
13375,alkylating agents,30,32,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13375,-1,0.99941635,0.00058363937
13377,hypaque 76.Sequential,8,10,47,68,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13377,-1,0.0029251056,0.99707484
13378,hypaque 76,34,36,208,218,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13378,-1,0.92275673,0.07724327
13379,QTC prolongation,1,3,12,28,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13379,-1,0.0005714461,0.9994286
13381,elevation of cardiac output,16,20,109,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13381,-1,0.00021438919,0.9997856
13383,femoral nerve palsy,5,8,54,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,-1,-1,13383,-1,0.00024209893,0.99975795
13385,muscle tear,16,18,91,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13385,-1,0.0001927254,0.9998073
13387,contracture,25,26,147,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13387,-1,0.00019868863,0.99980134
13389,femoral nerve entrapment,7,10,56,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13389,-1,0.00020849369,0.99979156
13390,femoral nerve palsy,14,17,97,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13390,-1,0.00020732469,0.99979264
13391,loss of quadriceps functions,19,23,129,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13391,-1,0.00022207647,0.999778
13392,femoral nerve palsy,1,4,22,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13392,-1,0.00020795563,0.99979204
13395,motor and sensory impairment,28,32,195,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13395,-1,0.00021960548,0.99978036
13396,contracture,35,36,237,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13396,-1,0.00021733419,0.9997826
13397,Pneumonitis,0,1,0,11,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13397,-1,0.00022310897,0.9997769
13398,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13398,-1,0.00022098234,0.99977905
13401,sinuatrial disease,3,5,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13401,-1,0.0015906072,0.99840945
13403,mg,16,17,105,107,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13403,-1,0.9992391,0.0007608939
13404,mg,21,22,130,132,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13404,-1,0.9994086,0.0005914222
13405,supraventricular tachyarrhythmias,31,33,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13405,-1,0.00020263251,0.9997974
13406,pneumonitis,2,3,13,24,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13406,-1,0.00021721033,0.99978286
13407,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13407,-1,0.0002195624,0.9997805
13408,proximal motor neuropathy,12,15,81,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13408,-1,0.00021919384,0.99978083
13411,amiodarone pneumonitis,14,16,87,109,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,-1,-1,-1,13411,-1,0.00686423,0.9931358
13414,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,-1,13414,-1,0.009885277,0.9901147
13415,sinoatrial block,2,4,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13415,-1,0.005758914,0.9942411
13417,primary cardiomyopathy,14,16,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13417,-1,0.00021997099,0.99978
13418,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13418,-1,0.00021742146,0.9997826
13420,sinoatrial block,12,14,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,-1,-1,13420,-1,0.0038865397,0.9961134
13427,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13427,-1,0.99949896,0.00050104124
13428,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13428,-1,0.99950457,0.0004954332
13429,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13429,-1,0.99948514,0.0005148199
13431,degeneration of the extraocular muscles,5,10,39,78,All three anesthetics produced massive degeneration of the extraocular muscles.,4038130_4,-1,-1,-1,13431,-1,0.00024309674,0.9997569
13432,Muscle degeneration,0,2,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,-1,13432,-1,0.00020500299,0.999795
13433,muscle damage,3,5,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13433,-1,0.00017964802,0.9998204
13434,mepivacaine,19,20,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13434,-1,0.99949384,0.0005061006
13437,diplopia,12,13,67,75,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13437,-1,0.00020411087,0.99979585
13438,damage to the extraocular,25,29,163,188,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13438,-1,0.00033143818,0.9996686
13439,muscles,29,30,189,196,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13439,-1,0.00021272278,0.9997873
13440,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,-1,13440,-1,0.004507332,0.9954927
13441,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,-1,-1,13441,-1,0.00017062969,0.9998293
13446,PAS,5,6,31,34,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13446,-1,0.998684,0.0013159597
13448,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,-1,13448,-1,0.00021329206,0.9997867
13449,renal failure,8,10,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13449,-1,0.00018638847,0.9998136
13453,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13453,-1,0.99847287,0.0015271127
13456,oliguria,22,23,152,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,-1,13456,-1,0.0002105373,0.99978954
13458,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,-1,13458,-1,0.00021762244,0.9997824
13460,tumours,7,8,46,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,-1,-1,-1,13460,-1,0.00019583615,0.9998042
13462,Papillomas,0,1,0,10,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13462,-1,0.00020353464,0.99979645
13463,bladder carcinomas,18,20,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13463,-1,0.00020287241,0.99979717
13464,bladder tumours,5,7,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,-1,-1,-1,13464,-1,0.00016851707,0.99983144
13465,hyperplasia,10,11,62,73,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13465,-1,0.00021003204,0.99979
13466,bladder calculi,24,26,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13466,-1,0.9487694,0.05123064
13467,tumours,4,5,15,22,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,-1,-1,-1,13467,-1,0.00020323678,0.9997968
13469,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,-1,13469,-1,0.56701833,0.43298167
13475,tender hepatomegaly,2,4,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13475,-1,0.00020583815,0.9997942
13476,malaise,10,11,67,74,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13476,-1,0.8099915,0.19000848
13477,anorexia,12,13,76,84,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13477,-1,0.00020687052,0.9997931
13478,nausea and vomiting,14,17,86,105,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13478,-1,0.0002198481,0.9997801
13479,upper abdominal pain,21,24,127,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13479,-1,0.00020352688,0.99979645
13480,hepatocellular necrosis,5,7,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13480,-1,0.00020519207,0.9997948
13482,fatty change,22,24,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13482,-1,0.005653058,0.9943469
13483,hepatocellular necrosis,26,28,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13483,-1,0.0002102039,0.9997898
13484,hepatic necrosis,30,32,225,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13484,-1,0.0002077743,0.9997923
13485,acute hepatitis,6,8,40,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13485,-1,0.00020971145,0.99979025
13488,hepatic failure,7,9,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,-1,-1,-1,13488,-1,0.00020379467,0.9997962
13490,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,-1,13490,-1,0.0008730457,0.999127
13493,hepatic dysfunction,16,18,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,-1,13493,-1,0.00021168303,0.99978834
13495,hemiparesis,1,2,10,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13495,-1,0.00021347683,0.99978656
13496,diphenylhydantoin toxicity,7,9,47,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13496,-1,0.030773563,0.9692264
13497,diphenylhydantoin,6,7,33,50,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13497,-1,0.9994844,0.00051555404
13498,DPH,8,9,52,55,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13498,-1,0.9994861,0.00051384675
13500,cerebellar dysfunction,21,23,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13500,-1,0.0002105923,0.9997894
13501,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13501,-1,0.00018848073,0.9998116
13502,DPH overdose,10,12,71,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13502,-1,0.006864158,0.9931358
13503,DPH,5,6,30,33,Both had brain surgery before DPH treatment.,430165_5,-1,-1,-1,13503,-1,0.99738413,0.0026158504
13504,cerebral damage,7,9,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13504,-1,0.0001992631,0.99980074
13505,DPH toxicity,13,15,77,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13505,-1,0.005915817,0.9940842
13507,fasciculations,5,6,41,55,Suxamethonium infusion rate and observed fasciculations.,435349_0,-1,-1,-1,13507,-1,0.00023010619,0.99976987
13508,Suxamethonium chloride,0,2,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13508,-1,0.99947447,0.0005255485
13509,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13509,-1,0.08733565,0.9126643
13510,mg,18,19,88,90,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13510,-1,0.99466646,0.005333602
13511,mg,22,23,101,103,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13511,-1,0.9983841,0.001615838
13512,tetanic,12,13,76,83,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13512,-1,0.43974087,0.5602591
13513,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13513,-1,0.9932041,0.0067958767
13514,mg,22,23,131,133,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13514,-1,0.99908435,0.0009156356
13515,Fasciculations,0,1,0,14,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,-1,-1,13515,-1,0.00020947964,0.9997905
13518,twitch,6,7,34,40,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13518,-1,0.00021461867,0.99978536
13519,tetanus,9,10,57,64,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13519,-1,0.00021201144,0.999788
13520,Fasciculations,0,1,0,14,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,-1,-1,13520,-1,0.00020811553,0.9997919
13523,Tiapride,0,1,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13523,-1,0.99947315,0.0005269242
13524,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13524,-1,0.00021063509,0.9997894
13525,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13525,-1,0.9994935,0.0005065437
13526,benzamide,4,5,24,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13526,-1,0.9994856,0.0005143216
13528,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13528,-1,0.00022024823,0.99977976
13529,idiopathic Parkinson's disease,21,25,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13529,-1,0.00022060279,0.9997794
13531,akinesia,13,14,98,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13531,-1,0.00020874334,0.9997913
13532,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,-1,13532,-1,0.9994824,0.0005175684
13544,Quinidine hepatitis,0,2,0,19,Quinidine hepatitis.,48362_0,-1,-1,-1,13544,-1,0.011680283,0.98831975
13545,quinidine,3,4,28,37,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13545,-1,0.9992724,0.0007275871
13546,lactic acid,15,17,112,123,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13546,-1,0.99918514,0.0008148456
13547,alkaline phosphatase,20,22,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13547,-1,0.005821626,0.9941784
13549,quinidine,2,3,18,27,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,-1,-1,-1,13549,-1,0.9994615,0.00053850684
13550,quinidine,4,5,20,29,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13550,-1,0.9993906,0.0006094043
13551,phosphatase,15,16,94,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13551,-1,0.0002890812,0.99971086
13552,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13552,-1,0.99934715,0.000652894
13553,quinidine hepatotoxicity,6,8,35,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,-1,-1,13553,-1,0.005673417,0.99432653
13554,hepatic toxicity,12,14,73,89,"This report also suggests that, even after long-term administration, the hepatic toxicity is reversible.",48362_6,-1,-1,-1,13554,-1,0.00020335251,0.9997967
13555,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,-1,13555,-1,0.000713094,0.99928695
13557,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13557,-1,0.00050168874,0.99949825
13558,adenocarcinoma,16,17,103,117,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13558,-1,0.00019140265,0.9998086
13560,Angiosarcoma,0,1,0,12,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,-1,-1,-1,13560,-1,0.0005695671,0.99943036
13561,intraarterial,4,5,25,38,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,-1,-1,13561,-1,0.00029097337,0.99970895
13563,thromboembolism,1,2,9,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,-1,13563,-1,0.00019729316,0.99980277
13566,thromboembolism,1,2,9,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,-1,-1,-1,13566,-1,0.00020787159,0.99979216
13568,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13568,-1,0.00019893298,0.9998011
13573,and,9,10,70,73,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13573,-1,0.00034719086,0.99965286
13574,ischemic,16,17,117,125,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13574,-1,0.00020914694,0.99979085
13576,thromboembolism,4,5,27,42,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,-1,-1,13576,-1,0.00021097799,0.99978906
13580,sodium warfarin,11,13,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,-1,-1,-1,13580,-1,0.9994369,0.00056304305
13581,Galanthamine,0,1,0,12,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13581,-1,0.9995183,0.00048178155
13583,(Hyoscine).Galanthamine,18,19,123,146,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13583,-1,0.9995049,0.00049510156
13585,hyoscine,42,43,304,312,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13585,-1,0.99953234,0.00046772338
13586,overdosage,44,45,314,324,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13586,-1,0.00022967374,0.99977034
13587,physostigmine,5,6,25,38,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13587,-1,0.99947685,0.00052312383
13589,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,-1,-1,-1,13589,-1,0.9994917,0.0005082684
13590,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13590,-1,0.99949753,0.0005024744
13591,mg,6,7,30,32,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13591,-1,0.517908,0.48209202
13592,mg,13,14,71,73,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,-1,-1,-1,13592,-1,0.99933916,0.00066078897
13595,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,-1,-1,-1,13595,-1,0.99949896,0.00050099613
13596,h,10,11,61,62,The drug was still present in measurable quantities after 24 h even with the smallest dose.,6103707_11,-1,-1,-1,13596,-1,0.11136566,0.8886344
13597,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13597,-1,0.9989876,0.0010123888
13598,chlorpropanol,5,6,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13598,-1,0.99948055,0.000519445
13599,Tobanum,7,8,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13599,-1,0.99945515,0.00054479763
13600,GYKI-41 099,2,4,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,-1,13600,-1,0.9909279,0.009072051
13603,pindolol,8,9,67,75,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13603,-1,0.9995123,0.0004877063
13604,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13604,-1,0.01749583,0.9825042
13605,GYKI-41 900,0,2,0,11,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,-1,13605,-1,0.9992925,0.00070751895
13606,14C-41 099,12,14,78,88,There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs.,6111982_5,-1,-1,-1,13606,-1,0.995201,0.0047989707
13607,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,-1,-1,13607,-1,0.99950254,0.00049750454
13612,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,-1,13612,-1,0.99947566,0.0005243879
13614,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13614,-1,0.99950325,0.00049676275
13615,impotence,9,10,69,78,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13615,-1,0.050082497,0.94991744
13616,impotence,12,13,84,93,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13616,-1,0.037608568,0.96239144
13618,impaired glucose tolerance,9,12,71,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13618,-1,0.0005751885,0.9994248
13619,gout,17,18,119,123,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13619,-1,0.00022585028,0.99977416
13620,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13620,-1,0.99869066,0.0013092951
13621,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13621,-1,0.0029890682,0.99701095
13622,dyspnoea,31,32,203,211,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13622,-1,0.00023467444,0.99976534
13624,corneal disease,1,3,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,-1,-1,-1,13624,-1,0.00020631759,0.9997937
13628,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13628,-1,0.9994425,0.00055744714
13629,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13629,-1,0.9994692,0.0005307384
13632,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,-1,13632,-1,0.9994531,0.0005468349
13635,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,-1,13635,-1,0.99949026,0.0005096897
13637,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,-1,-1,13637,-1,0.99945253,0.0005474691
13641,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,-1,-1,-1,13641,-1,0.9994791,0.0005208619
13643,MK-212,12,13,55,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13643,-1,0.9994905,0.0005095282
13644,muscimol,21,22,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13644,-1,0.9995023,0.0004976872
13646,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,-1,-1,13646,-1,0.9994986,0.0005013862
13649,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,-1,-1,-1,13649,-1,0.9994542,0.0005458586
13650,5-HTP,4,5,26,31,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,-1,13650,-1,0.99948883,0.00051112095
13654,MK-212,8,9,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,-1,-1,13654,-1,0.9994821,0.0005179469
13656,ischaemic heart disease,3,6,20,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13656,-1,0.00020651518,0.99979347
13657,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13657,-1,0.00020827196,0.9997918
13663,inflammatory bowel disease,8,11,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13663,-1,0.00019145668,0.9998086
13665,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13665,-1,0.0001999532,0.9998
13666,ulcerative colitis,8,10,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13666,-1,0.00018938397,0.99981064
13667,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13667,-1,0.0004232032,0.99957675
13668,ventricular septal defect,25,28,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13668,-1,0.0001897498,0.9998103
13669,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,-1,13669,-1,0.00023017752,0.99976987
13670,uterine cornu,18,20,94,107,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,-1,-1,13670,-1,0.15205552,0.8479445
13671,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13671,-1,0.00367621,0.9963238
13672,hypoplastic lungs,15,17,63,80,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13672,-1,0.00021010553,0.9997899
13673,absent kidneys and ureters,18,22,82,108,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13673,-1,0.00023904009,0.9997609
13674,talipes equinovarus,24,26,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13674,-1,0.028149918,0.97185016
13676,teratogenic,13,14,76,87,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,-1,-1,-1,13676,-1,0.00021473964,0.99978524
13681,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,-1,13681,-1,0.0002065987,0.99979347
13688,impotence,9,10,55,64,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,-1,-1,-1,13688,-1,0.74807096,0.25192904
13694,hematologic toxicity,36,38,165,185,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13694,-1,0.00021885887,0.9997812
13695,gastrin,42,43,210,217,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13695,-1,0.99948186,0.00051818596
13706,generalized seizures,9,11,54,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,-1,-1,-1,13706,-1,0.00021394588,0.9997861
13711,epileptic foci,16,18,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,-1,-1,13711,-1,0.00021593994,0.99978405
13713,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13713,-1,0.0002109474,0.99978906
13714,antineoplastic,7,8,61,75,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13714,-1,0.99923825,0.0007617511
13717,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13717,-1,0.00021442253,0.9997856
13718,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13718,-1,0.00021494615,0.9997851
13721,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13721,-1,0.9994746,0.00052547315
13722,vinca alkaloid,30,32,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13722,-1,0.9994752,0.0005248176
13723,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,-1,13723,-1,0.19172409,0.8082759
13724,intravascular coagulation,9,11,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,-1,-1,-1,13724,-1,0.00019559488,0.99980444
13727,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13727,-1,0.00022893235,0.99977106
13728,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13728,-1,0.0022357416,0.9977642
13735,ISO,19,20,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13735,-1,0.9993767,0.00062333216
13736,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13736,-1,0.90694606,0.093053915
13737,hydroxyproline,20,21,93,107,"A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.",6203632_2,-1,-1,-1,13737,-1,0.9994286,0.0005714415
13738,h,9,10,50,51,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,-1,13738,-1,0.1427187,0.85728127
13739,hydroxyproline,4,5,21,35,The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.,6203632_6,-1,-1,-1,13739,-1,0.9994673,0.00053273584
13740,hypertrophic,16,17,75,87,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,-1,13740,-1,0.00020787714,0.99979216
13742,P,12,13,73,74,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,-1,13742,-1,0.10307833,0.8969217
13743,ISO,8,9,50,53,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13743,-1,0.99922943,0.0007705289
13744,hypertrophic,12,13,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13744,-1,0.00020604944,0.99979395
13746,hyperplasia,21,22,119,130,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,-1,-1,13746,-1,0.00019063678,0.99980944
13750,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,-1,13750,-1,0.00021168485,0.99978834
13756,gastrointestinal problems,8,10,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,-1,-1,13756,-1,0.0002192764,0.9997807
13760,Skin rashes,0,2,0,11,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13760,-1,0.0002677252,0.9997323
13762,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13762,-1,0.00019963451,0.9998004
13763,polymyositis,9,10,56,68,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13763,-1,0.00020036584,0.99979967
13764,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13764,-1,0.00020107049,0.99979895
13767,skin lesion,1,3,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13767,-1,0.00020268274,0.9997973
13768,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13768,-1,0.9065579,0.09344213
13769,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13769,-1,0.00026930476,0.99973065
13773,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,-1,-1,13773,-1,0.00022138155,0.9997787
13775,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,-1,13775,-1,0.00017899332,0.999821
13777,contrast,15,16,100,108,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,-1,13777,-1,0.016458495,0.98354155
13779,cardiomegaly,3,4,17,29,"In patients with cardiomegaly, the increase in heart size was similar in both groups.",6229975_6,-1,-1,-1,13779,-1,0.00021223797,0.99978775
13781,hypercalcaemia,4,5,18,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13781,-1,0.0001857613,0.9998142
13784,bicarbonate,23,24,165,176,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13784,-1,0.999426,0.0005740465
13785,Vitamin D3 toxicity,0,3,0,19,Vitamin D3 toxicity in dairy cows.,6286738_0,-1,-1,-1,13785,-1,0.016522612,0.9834774
13786,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13786,-1,0.99947065,0.00052932336
13787,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13787,-1,0.9994735,0.00052651623
13789,hyperphosphatemia,23,24,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13789,-1,0.00057315535,0.99942684
13790,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13790,-1,0.9994665,0.00053355045
13792,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,-1,13792,-1,0.99945515,0.0005448086
13793,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,-1,13793,-1,0.999464,0.0005360855
13796,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13796,-1,0.016924096,0.98307586
13797,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13797,-1,0.01686837,0.98313165
13800,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13800,-1,0.99945253,0.0005475036
13801,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13801,-1,0.9994535,0.0005465505
13804,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13804,-1,0.9994524,0.0005476442
13806,Diseases of peripheral nerves,0,4,0,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,-1,-1,-1,13806,-1,0.00021643589,0.9997836
13807,peripheral nerve disease,6,9,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,-1,-1,-1,13807,-1,0.00018732387,0.99981266
13809,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,-1,13809,-1,0.00020549302,0.99979454
13811,nutritional deficiency,4,6,29,51,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13811,-1,0.00061369414,0.9993863
13812,thiamine,7,8,55,63,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13812,-1,0.9994759,0.0005240748
13813,riboflavin,9,10,68,78,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13813,-1,0.99948335,0.00051665923
13815,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,-1,-1,13815,-1,0.00019482967,0.99980515
13820,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,-1,-1,13820,-1,0.00020290184,0.99979717
13823,connective tissue disorders,2,5,19,46,Heredofamilial and connective tissue disorders were rare.,6287825_10,-1,-1,-1,13823,-1,0.00019683245,0.99980325
13824,neuropathies,13,14,81,93,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,-1,-1,-1,13824,-1,0.00019105658,0.99980897
13825,Doxorubicin cardiomyopathy,0,2,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13825,-1,0.0055985465,0.9944015
13826,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13826,-1,0.00019281049,0.9998072
13827,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13827,-1,0.00016440699,0.9998356
13828,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13828,-1,0.009670134,0.99032986
13832,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,-1,13832,-1,0.00019198847,0.999808
13835,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,-1,13835,-1,0.00020951379,0.9997905
13842,DA,15,16,100,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13842,-1,0.9993375,0.0006625238
13843,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13843,-1,0.9993345,0.0006654562
13845,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,-1,13845,-1,0.004554267,0.9954457
13847,sodium acetylsalicylate,12,14,89,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,-1,-1,-1,13847,-1,0.9994568,0.0005431432
13851,salicylates,1,2,8,19,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,-1,-1,13851,-1,0.9994497,0.0005503273
13868,pentylenetetrezol,30,31,161,178,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,-1,13868,-1,0.9994677,0.0005323181
13871,ATP,16,17,103,106,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,-1,-1,-1,13871,-1,0.99935967,0.00064034166
13874,Naloxazone,0,1,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,-1,13874,-1,0.99947363,0.00052634435
13877,naloxazone,18,19,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,-1,13877,-1,0.9994955,0.000504509
13878,naloxazone,2,3,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13878,-1,0.9994816,0.0005184078
13879,morphine analgesia,5,7,51,69,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13879,-1,0.74169284,0.25830716
13882,naloxazone,2,3,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13882,-1,0.999476,0.00052405486
13884,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13884,-1,0.00020582559,0.9997942
13889,NH4Ac,5,6,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13889,-1,0.99948406,0.0005159543
13890,incoordination,28,29,172,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13890,-1,0.00023440922,0.9997656
13892,NH4Ac,33,34,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13892,-1,0.99948597,0.00051405054
13897,mM NH4Ac,21,23,140,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13897,-1,0.999476,0.00052404613
13898,mM NH4Ac,35,37,222,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13898,-1,0.9994741,0.00052594993
13902,acetaldehyde,16,17,117,129,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13902,-1,0.9994704,0.00052960496
13903,NH4Ac,21,22,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13903,-1,0.99946886,0.00053115544
13904,ammonia,4,5,29,36,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13904,-1,0.99927956,0.00072051596
13905,calcium channels,6,8,44,60,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13905,-1,0.011759909,0.9882401
13906,NH4Ac,5,6,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,-1,-1,-1,13906,-1,0.9994729,0.0005271246
13910,NH4Ac,9,10,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13910,-1,0.99946946,0.000530547
13912,muscular incoordination,16,18,104,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13912,-1,0.00019411281,0.99980587
13914,NH4Ac,28,29,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13914,-1,0.99947375,0.0005263163
13915,metrazol,34,35,246,254,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13915,-1,0.99949086,0.00050911965
13918,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,-1,13918,-1,0.7835483,0.21645167
13922,choreic,13,14,86,93,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13922,-1,0.00082972285,0.9991703
13923,dystonic,17,18,108,116,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13923,-1,0.0002342142,0.9997658
13925,thalamic lesions,5,7,43,59,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,-1,-1,13925,-1,0.00019748192,0.99980253
13927,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13927,-1,0.99949026,0.00050976017
13928,major depressive disorder,15,18,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13928,-1,0.00018187464,0.99981815
13929,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,-1,13929,-1,0.9994973,0.00050265784
13932,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13932,-1,0.9995066,0.00049335003
13934,depressive illness,11,13,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13934,-1,0.00021107959,0.99978894
13935,blurred vision,12,14,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13935,-1,0.00020974924,0.99979025
13937,drowsiness,19,20,103,113,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13937,-1,0.00020931673,0.9997907
13938,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13938,-1,0.9995161,0.00048384906
13940,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,-1,13940,-1,0.99950564,0.0004942966
13941,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,-1,13941,-1,0.9994899,0.00051012135
13947,panic disorder,9,11,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,-1,-1,13947,-1,0.00022099014,0.99977905
13950,mg,12,13,57,59,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13950,-1,0.99919647,0.00080355204
13952,mg,31,32,139,141,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13952,-1,0.9993956,0.000604383
13953,panic disorders,49,51,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13953,-1,0.00021110778,0.99978894
13955,impaired immediate free recall,2,6,11,41,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,-1,-1,-1,13955,-1,0.0004091747,0.9995908
13958,Delayed free recall was also impaired,0,6,0,37,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13958,-1,0.0004061414,0.9995939
13963,h,11,12,48,49,"After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance.",6387529_5,-1,-1,-1,13963,-1,0.03954858,0.9604515
13964,behavioral impairment,8,10,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,-1,-1,-1,13964,-1,0.00020857342,0.99979144
13965,urothelial toxicity,3,5,32,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13965,-1,0.00021350857,0.99978656
13966,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13966,-1,0.99948597,0.000514029
13968,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13968,-1,0.00021815866,0.9997819
13969,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13969,-1,0.99946254,0.0005375007
13970,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13970,-1,0.9994647,0.00053532724
13972,urothelial toxicity,17,19,118,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13972,-1,0.00021070235,0.9997893
13974,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13974,-1,0.0002162589,0.9997837
13976,haematuria,17,18,99,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13976,-1,0.00020149809,0.9997985
13977,haematuria,23,24,135,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13977,-1,0.0002021092,0.9997979
13979,haematuria,24,25,121,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13979,-1,0.00021081067,0.9997892
13980,bladder irritation,28,30,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13980,-1,0.00021153835,0.99978846
13982,pollakisuria,33,34,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13982,-1,0.008276496,0.9917235
13987,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,-1,-1,13987,-1,0.00022306258,0.9997769
13996,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,-1,13996,-1,0.011046044,0.98895395
13997,prostaglandin,2,3,10,23,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,-1,-1,13997,-1,0.9994203,0.00057976285
14000,PGs,7,8,51,54,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14000,-1,0.999466,0.00053395133
14002,PG,17,18,97,99,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14002,-1,0.99948114,0.0005189393
14004,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14004,-1,0.99950635,0.0004936447
14006,pentetrazol,28,29,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14006,-1,0.99950624,0.00049371674
14007,PTZ,30,31,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14007,-1,0.99948704,0.0005129529
14011,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14011,-1,0.9994947,0.0005053289
14012,meclofenamic acid,10,12,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14012,-1,0.9995022,0.00049776095
14013,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14013,-1,0.99948907,0.0005109025
14014,PTZ,19,20,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14014,-1,0.008322356,0.99167764
14017,PGs,4,5,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,-1,14017,-1,0.8254148,0.17458524
14020,ammonia,4,5,23,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,14020,-1,0.99928975,0.0007102692
14021,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,14021,-1,0.99941695,0.00058311346
14022,Valproic acid,0,2,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,14022,-1,0.9994467,0.0005533406
14023,VPA,3,4,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,14023,-1,0.71507794,0.28492203
14025,VPA,5,6,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,-1,14025,-1,0.8876712,0.11232885
14026,Ammonia,0,1,0,7,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14026,-1,0.9993569,0.0006430927
14027,NH3,2,3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14027,-1,0.9993808,0.00061912957
14028,drowsiness,16,17,83,93,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14028,-1,0.00020522437,0.9997948
14029,VPA,33,34,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14029,-1,0.9993081,0.0006919163
14030,NH3,6,7,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,14030,-1,0.9993705,0.00062947266
14031,VPA,22,23,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,14031,-1,0.99937624,0.0006237922
14038,renal abnormality,6,8,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,-1,14038,-1,0.00019154395,0.9998085
14044,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,-1,14044,-1,0.99949515,0.0005048479
14049,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,-1,-1,14049,-1,0.01648104,0.9835189
14050,ketone,2,3,9,15,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,-1,14050,-1,0.9994765,0.0005235358
14069,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14069,-1,0.00019419965,0.99980587
14070,trazodone,8,9,48,57,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14070,-1,0.9994825,0.00051748945
14071,trazodone,9,10,56,65,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14071,-1,0.99949205,0.0005078788
14072,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14072,-1,0.00021506668,0.999785
14073,trazodone,12,13,67,76,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14073,-1,0.9994733,0.0005267328
14075,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14075,-1,0.9994748,0.0005251531
14076,DTIC,7,8,56,60,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14076,-1,0.0084068775,0.9915931
14077,melanoma,10,11,66,74,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14077,-1,0.00022315238,0.9997769
14078,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14078,-1,0.99947244,0.0005276225
14079,DTIC,14,15,84,88,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14079,-1,0.013534453,0.9864655
14080,melanoma,18,19,102,110,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14080,-1,0.00019526375,0.9998048
14082,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,-1,-1,14082,-1,0.00019374632,0.9998062
14084,Eosinophilic,0,1,0,12,Eosinophilic infiltrations were found around the vessels.,6503301_5,-1,-1,-1,14084,-1,0.0077848923,0.9922151
14086,neurologic impairment,5,7,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,-1,-1,14086,-1,0.00019920479,0.99980086
14090,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,-1,-1,14090,-1,0.00022158555,0.99977845
14094,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,-1,-1,14094,-1,0.00023415145,0.9997658
14096,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,-1,-1,14096,-1,0.0002496097,0.99975044
14098,Ebstein's anomaly,4,7,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,-1,-1,14098,-1,0.0054820557,0.994518
14099,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,-1,-1,14099,-1,0.0019462894,0.9980538
14101,cardiac malformations,24,26,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,-1,14101,-1,0.0002071676,0.9997929
14102,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,-1,14102,-1,0.00020538822,0.99979466
14103,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,-1,14103,-1,0.00017129643,0.9998287
14104,infarcts,3,4,18,26,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,-1,14104,-1,0.00017116206,0.9998288
14105,sedentary-isoproterenols,11,12,56,80,Elevations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls.,6534871_4,-1,-1,-1,14105,-1,0.97474325,0.025256755
14106,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,-1,-1,14106,-1,0.000197954,0.99980205
14108,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,-1,14108,-1,0.023297256,0.97670275
14110,PEG 400,13,15,70,77,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14110,-1,0.99947923,0.00052082253
14112,ADR,30,31,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14112,-1,0.99946946,0.0005305558
14113,PEG 400,0,2,0,7,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,-1,14113,-1,0.99943715,0.0005628821
14114,cardiac morphological alterations,9,12,79,112,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,-1,14114,-1,0.00020766618,0.9997924
14115,ADR,6,7,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14115,-1,0.99932563,0.0006743428
14116,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14116,-1,0.0030201785,0.9969798
14117,Ehrlich ascites tumor,14,17,84,105,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14117,-1,0.00020831425,0.9997917
14118,amine,2,3,11,16,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14118,-1,0.99939847,0.00060148694
14119,ketamine catatonia,5,7,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14119,-1,0.0027680947,0.9972319
14121,catatonia,16,17,114,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,-1,14121,-1,0.0002049135,0.99979514
14123,catatonia,12,13,83,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14123,-1,0.00020378262,0.9997962
14129,melatonin,22,23,121,130,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,-1,14129,-1,0.99942255,0.00057749636
14132,melatonin,22,23,132,141,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,-1,-1,14132,-1,0.9993931,0.0006069136
14135,amines,13,14,78,84,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,-1,14135,-1,0.99929,0.00070995174
14137,melatonin,20,21,111,120,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,-1,-1,-1,14137,-1,0.9993678,0.0006322912
14139,ketamine catatonia,15,17,93,111,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,-1,-1,-1,14139,-1,0.003693481,0.99630654
14147,falling platelet count,5,8,34,56,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,-1,-1,-1,14147,-1,0.00016419531,0.9998357
14157,Ventricular fibrillation,0,2,0,24,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14157,-1,0.00017951085,0.99982053
14158,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14158,-1,0.9994543,0.0005456624
14159,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14159,-1,0.99942076,0.0005792992
14161,Renografin 76%,3,6,16,30,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14161,-1,0.44918346,0.55081654
14162,Hypaque 76%,11,14,57,68,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14162,-1,0.0054303315,0.9945696
14163,Renografin,0,1,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14163,-1,0.9994584,0.00054163486
14164,chelating agents sodium citrate,3,7,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14164,-1,0.99918944,0.0008105225
14165,disodium edetate,8,10,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14165,-1,0.9994653,0.0005347178
14166,Hypaque,12,13,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14166,-1,0.00022945202,0.9997706
14167,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14167,-1,0.99944025,0.0005596829
14169,Ventricular fibrillation,0,2,0,24,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14169,-1,0.0002172304,0.99978274
14170,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14170,-1,0.9994899,0.00051012135
14171,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14171,-1,0.99944156,0.0005584584
14173,quaternary ammonium,4,6,29,48,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14173,-1,0.9994797,0.0005203543
14174,N,11,12,86,87,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14174,-1,0.99944776,0.0005521898
14175,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14175,-1,0.00020588997,0.9997942
14176,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14176,-1,0.9994062,0.0005937596
14177,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14177,-1,0.9994062,0.0005937596
14182,ventricular fibrillation,12,14,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,-1,-1,14182,-1,0.00022205804,0.999778
14185,VT,14,15,100,102,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14185,-1,0.00021952993,0.9997805
14186,n,17,18,105,106,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14186,-1,0.20299725,0.7970027
14188,n,26,27,135,136,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14188,-1,0.9980683,0.0019317054
14190,VT,14,15,104,106,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14190,-1,0.00022234934,0.9997776
14191,ventricular fibrillation,16,18,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14191,-1,0.00022130493,0.9997787
14192,VF,19,20,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14192,-1,0.00022355058,0.9997764
14193,VT,10,11,57,59,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,-1,14193,-1,0.00021117501,0.9997888
14195,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,-1,-1,14195,-1,0.00055510784,0.9994449
14201,anorexia,17,18,86,94,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14201,-1,0.00023365545,0.9997663
14202,visual halos or blurring,23,27,101,125,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14202,-1,0.00024176466,0.9997582
14203,thyroid function abnormalities,32,35,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14203,-1,0.00023551974,0.9997645
14204,pulmonary interstitial infiltrates,40,43,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14204,-1,0.0002448892,0.9997551
14206,VT,11,12,81,83,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14206,-1,0.00020867187,0.9997913
14207,VF,13,14,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14207,-1,0.00020648881,0.99979347
14209,VT,23,24,122,124,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14209,-1,0.00022956559,0.99977046
14210,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14210,-1,0.00022827042,0.9997718
14213,bladder carcinoma,5,7,41,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,-1,-1,-1,14213,-1,0.00021080424,0.9997892
14214,transitional cell carcinoma,10,13,67,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,-1,-1,-1,14214,-1,0.00019974132,0.99980026
14216,h,11,12,67,68,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14216,-1,0.027917521,0.9720825
14217,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14217,-1,0.00022504311,0.999775
14221,angiopathy,1,2,24,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,-1,14221,-1,0.00020310216,0.9997969
14222,D-pen,8,9,60,65,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,-1,-1,-1,14222,-1,0.9994759,0.0005241816
14223,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,-1,14223,-1,0.99944013,0.00055988174
14224,EACA,5,6,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,-1,-1,14224,-1,0.056507166,0.9434928
14227,EACA,12,13,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14227,-1,0.0008061981,0.99919385
14228,subarachnoid haemorrhage,21,23,119,143,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14228,-1,0.00020207743,0.999798
14229,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14229,-1,0.00021224082,0.99978775
14231,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14231,-1,0.65404254,0.3459575
14232,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14232,-1,0.65404254,0.3459575
14233,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14233,-1,0.65404254,0.3459575
14235,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14235,-1,0.99950266,0.00049733795
14236,FANFT,7,8,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14236,-1,0.9994804,0.00051958684
14237,bladder carcinomas,18,20,149,167,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14237,-1,0.0002601599,0.9997398
14239,FANFT,12,13,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14239,-1,0.99942565,0.0005743371
14242,FANFT,40,41,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14242,-1,0.9994311,0.00056892796
14245,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14245,-1,0.011310405,0.9886896
14247,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14247,-1,0.9993505,0.0006495249
14249,Cerebral hemorrhage,0,2,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14249,-1,0.00018801975,0.99981195
14250,phenylpropanolamine,4,5,36,55,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14250,-1,0.9994665,0.0005335662
14252,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14252,-1,0.9994325,0.0005674468
14253,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14253,-1,0.9992994,0.00070057996
14256,lead,7,8,42,46,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,-1,-1,14256,-1,0.0054806774,0.9945193
14259,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,-1,14259,-1,0.00020280915,0.99979717
14261,lead,8,9,49,53,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,-1,14261,-1,0.9991406,0.00085930823
14264,lead,6,7,44,48,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14264,-1,0.029098134,0.9709019
14265,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14265,-1,0.00019578537,0.9998042
14267,papillary necrosis,1,3,6,24,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14267,-1,0.00018226665,0.9998178
14268,naproxen,5,6,32,40,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14268,-1,0.9994599,0.00054010114
14271,fenoprofen calcium,15,17,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14271,-1,0.9995121,0.0004879218
14272,salicylates,20,21,122,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14272,-1,0.9995066,0.0004934046
14273,gold salts,22,24,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14273,-1,0.9994978,0.0005022032
14275,RPN,30,31,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14275,-1,0.9994253,0.0005747424
14276,naproxen,37,38,221,229,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14276,-1,0.9995173,0.0004827011
14277,RPN,5,6,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,-1,14277,-1,0.00033186053,0.9996681
14279,naproxen,4,5,29,37,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,-1,-1,-1,14279,-1,0.9994703,0.0005297344
14280,RPN,5,6,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,-1,-1,14280,-1,0.004659434,0.9953406
14283,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,-1,14283,-1,0.00019007103,0.9998099
14285,Abnormal involuntary movements,0,3,0,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14285,-1,0.0002065345,0.99979347
14287,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14287,-1,0.00020466979,0.9997954
14288,mg,30,31,187,189,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14288,-1,0.9994567,0.00054330187
14290,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,-1,14290,-1,0.00020265454,0.9997974
14295,netilmicin,9,10,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14295,-1,0.9995004,0.0004995927
14300,netilmicin,2,3,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,-1,-1,-1,14300,-1,0.99947864,0.0005213793
14306,netilmicin,4,5,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,-1,14306,-1,0.99943143,0.0005685566
14310,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14310,-1,0.7559621,0.24403793
14311,of,14,15,104,106,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14311,-1,0.0002970324,0.999703
14312,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14312,-1,0.00018167967,0.9998184
14313,androgen,12,13,74,82,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14313,-1,0.9994135,0.0005865043
14314,syndrome of obstructive sleep apnea,25,30,167,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14314,-1,0.00020549617,0.99979454
14315,androgens,34,35,238,247,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14315,-1,0.999423,0.00057694624
14316,androgens,2,3,9,18,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,-1,-1,-1,14316,-1,0.99930215,0.0006978719
14317,androgen,3,4,19,27,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14317,-1,0.9993299,0.0006700899
14318,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14318,-1,0.00017187397,0.9998281
14319,androgens,7,8,40,49,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14319,-1,0.999401,0.0005990486
14320,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14320,-1,0.00019067257,0.9998093
14321,androgens,6,7,53,62,Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.,6732043_6,-1,-1,-1,14321,-1,0.999315,0.0006849339
14322,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14322,-1,0.0002068104,0.99979323
14323,androgen,15,16,97,105,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14323,-1,0.99929965,0.00070032023
14324,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14324,-1,0.99930274,0.0006972902
14325,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14325,-1,0.00018290906,0.9998171
14326,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14326,-1,0.9988488,0.0011511517
14328,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14328,-1,0.000206305,0.9997937
14329,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,-1,14329,-1,0.99946207,0.0005379405
14330,astrocytomas,7,8,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,-1,14330,-1,0.00020993633,0.99979013
14334,astrocytomas,8,9,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14334,-1,0.0001990698,0.999801
14335,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14335,-1,0.999406,0.00059408066
14336,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,-1,-1,-1,14336,-1,0.99376065,0.006239343
14337,loss of vision,9,12,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14337,-1,0.00019603866,0.99980396
14338,retinal vasculitis,15,17,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14338,-1,0.00018343757,0.9998166
14344,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,-1,-1,14344,-1,0.00018565504,0.99981433
14346,myocardial lesions,3,5,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,-1,-1,14346,-1,0.00019686867,0.9998031
14348,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,-1,-1,14348,-1,0.0001837439,0.99981624
14351,leukemia,18,19,98,106,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,-1,-1,-1,14351,-1,0.00022874495,0.9997713
14354,diabetic autonomic neuropathy?The,7,10,56,89,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14354,-1,0.0004908543,0.9995091
14365,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,-1,-1,14365,-1,0.9993611,0.0006389243
14368,Tricuspid valve regurgitation,0,3,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14368,-1,0.001961496,0.9980385
14369,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14369,-1,0.011681069,0.9883189
14370,tricuspid regurgitation,4,6,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14370,-1,0.00019963014,0.9998004
14371,atrial flutter,7,9,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14371,-1,0.045893535,0.95410645
14372,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14372,-1,0.00019651477,0.9998035
14374,tricuspid regurgitation,8,10,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14374,-1,0.00019733568,0.99980265
14375,atrial flutter,11,13,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14375,-1,0.00019779323,0.9998022
14376,cardiac disease,20,22,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14376,-1,0.00019501126,0.99980503
14377,lithium compounds,26,28,169,186,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14377,-1,0.99945015,0.00054984674
14378,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14378,-1,0.999376,0.0006240354
14379,congenital heart disease,11,14,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14379,-1,0.00020339379,0.99979657
14381,cyanosis,6,7,38,46,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14381,-1,0.00023322368,0.99976677
14382,cardiac arrhythmia,9,11,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14382,-1,0.00022452552,0.99977547
14383,aniracetam,5,6,30,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14383,-1,0.99947983,0.00052014703
14384,Ro 13-5057,7,11,42,52,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14384,-1,0.2663036,0.7336964
14385,learning and memory,14,17,68,87,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14385,-1,0.00022579987,0.99977416
14386,aniracetam,3,4,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14386,-1,0.9995059,0.0004941119
14387,Ro 13-5057,5,9,26,36,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14387,-1,0.99900216,0.0009978971
14388,1-anisoyl-2-pyrrolidinone,10,11,38,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14388,-1,0.9995129,0.0004870937
14389,impaired cognitive functions,19,22,112,140,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14389,-1,0.00021174035,0.9997882
14390,hypercapnia,55,56,324,335,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14390,-1,0.00021730603,0.99978274
14394,chloramphenicol,130,131,781,796,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14394,-1,0.99951684,0.00048311212
14396,h,149,150,903,904,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14396,-1,0.34468612,0.6553139
14398,hypercapnia,197,198,1178,1189,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14398,-1,0.0002159564,0.99978405
14399,h,205,206,1239,1240,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14399,-1,0.114515804,0.8854842
14400,impaired cognitive functions,5,8,40,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14400,-1,0.00017416515,0.9998259
14401,aniracetam,12,13,87,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14401,-1,0.9994616,0.0005383708
14402,aniracetam,6,7,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,-1,14402,-1,0.9994517,0.00054829573
14403,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14403,-1,0.999501,0.00049902155
14404,pyrrolidinone,3,4,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14404,-1,0.9995003,0.0004997432
14405,aniracetam,16,17,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,-1,-1,-1,14405,-1,0.99944097,0.0005589686
14406,aniracetam,4,5,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,-1,-1,-1,14406,-1,0.99946946,0.00053051027
14408,Sodium chloride,0,2,0,15,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,-1,14408,-1,0.9994351,0.00056484865
14419,adenohypophyseal tumors,3,5,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,-1,-1,14419,-1,0.0009575311,0.99904245
14420,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14420,-1,0.00017148648,0.99982846
14422,DES,14,15,96,99,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14422,-1,0.9199641,0.08003591
14423,mg,19,20,106,108,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14423,-1,0.9366441,0.063355915
14424,DES,9,10,30,33,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,-1,14424,-1,0.999035,0.0009650348
14425,PRL,17,18,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14425,-1,0.00028899027,0.999711
14426,PRL,28,29,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14426,-1,0.00027240353,0.99972755
14427,acriflavine,51,52,340,351,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14427,-1,0.9994809,0.00051915983
14428,PRL,1,2,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14428,-1,0.00024745762,0.9997526
14429,PRL,13,14,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14429,-1,0.0002402859,0.99975973
14430,DES,31,32,178,181,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14430,-1,0.99374443,0.0062555303
14431,DES,4,5,17,20,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,-1,14431,-1,0.9970824,0.002917583
14432,PRL,5,6,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14432,-1,0.00023862656,0.9997614
14433,PRL,14,15,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14433,-1,0.00022516503,0.9997749
14434,DES,4,5,21,24,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,-1,14434,-1,0.9988192,0.0011808376
14436,PRL,20,21,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,-1,14436,-1,0.00020218054,0.9997979
14437,calcium chloride,2,4,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14437,-1,0.99947065,0.0005293879
14439,eserine,12,13,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14439,-1,0.99948114,0.00051891006
14440,calcium chloride,3,5,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14440,-1,0.99948007,0.000519921
14441,mydriasis,41,42,233,242,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14441,-1,0.00020713876,0.9997929
14445,eserine,51,52,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14445,-1,0.9994962,0.0005037169
14446,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14446,-1,0.011364928,0.98863506
14448,eserine,15,16,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14448,-1,0.9994791,0.0005208624
14449,mydriasis,5,6,19,28,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14449,-1,0.00019815454,0.9998018
14453,eserine,15,16,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14453,-1,0.99950373,0.0004962376
14454,calcium chloride,21,23,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14454,-1,0.999498,0.000501938
14455,calcium chloride,4,6,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14455,-1,0.99947375,0.0005262894
14456,mydriasis,20,21,123,132,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14456,-1,0.00021180941,0.9997882
14460,eserine,30,31,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14460,-1,0.9994849,0.00051509775
14461,Calcium chloride,0,2,0,16,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14461,-1,0.99948776,0.000512253
14463,eserine,11,12,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14463,-1,0.9995053,0.00049475906
14465,Thiazide,0,1,0,8,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14465,-1,0.9994609,0.0005391594
14466,hypokalemia,3,4,20,31,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14466,-1,0.0005874959,0.99941254
14468,Thiazide,0,1,0,8,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,-1,14468,-1,0.9994665,0.00053351023
14469,Hypokalemia,0,1,0,11,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14469,-1,0.00058620167,0.99941385
14470,thiazide,9,10,71,79,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14470,-1,0.99943155,0.000568425
14472,hydrochlorothiazide,18,19,97,116,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14472,-1,0.9994797,0.0005203658
14473,HCTC,20,21,118,122,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14473,-1,0.8921551,0.10784489
14474,mg,4,5,20,22,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14474,-1,0.999079,0.0009209948
14475,mg,15,16,78,80,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14475,-1,0.99871504,0.0012850307
14476,mg,18,19,86,88,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14476,-1,0.9989963,0.0010036937
14477,mg,21,22,97,99,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14477,-1,0.99879813,0.0012018913
14478,K,2,3,10,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14478,-1,0.9992933,0.0007066854
14479,mg HCTZ,22,24,87,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14479,-1,0.99918896,0.00081100076
14480,K,5,6,37,38,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,-1,14480,-1,0.0011581801,0.9988418
14481,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14481,-1,0.99942553,0.0005744718
14482,mg,12,13,60,62,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14482,-1,0.99918884,0.00081120245
14483,PVC,19,20,91,94,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14483,-1,0.00021820064,0.9997818
14484,PVC,8,9,37,40,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,-1,14484,-1,0.00020921376,0.99979085
14485,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14485,-1,0.44643208,0.55356795
14486,mg,6,7,46,48,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14486,-1,0.96664685,0.033353146
14487,PVC,3,4,18,21,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14487,-1,0.00022628717,0.9997737
14488,p,18,19,94,95,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14488,-1,0.21418315,0.78581685
14489,thiazide,5,6,28,36,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14489,-1,0.999474,0.00052608957
14490,hypokalemia,8,9,53,64,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14490,-1,0.00020742277,0.99979264
14492,hypokalemia,3,4,18,29,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14492,-1,0.0001945568,0.9998055
14493,PVC,13,14,80,83,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14493,-1,0.00021590204,0.99978405
14494,acute hepatic necrosis,4,7,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,-1,-1,14494,-1,0.00022001147,0.99978
14495,phosphatase,15,16,101,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,-1,14495,-1,0.00021860526,0.9997814
14497,cathepsin D,3,5,15,26,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14497,-1,0.99946505,0.0005349064
14499,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14499,-1,0.011496921,0.98850304
14501,viral hepatitis,42,44,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14501,-1,0.0002053947,0.99979466
14502,cathepsin D,17,19,103,114,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,-1,14502,-1,0.92555016,0.074449874
14518,or kidney disease,33,36,161,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,-1,-1,14518,-1,0.00021390896,0.9997861
14522,6-thioguanine,5,6,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,-1,-1,-1,14522,-1,0.99947554,0.00052450434
14523,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14523,-1,0.00019514667,0.9998049
14524,6-thioguanine,23,24,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14524,-1,0.99948347,0.0005164758
14526,6-thioguanine,31,32,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,-1,-1,-1,14526,-1,0.9994623,0.0005377334
14527,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,-1,-1,14527,-1,0.00021333071,0.9997867
14529,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14529,-1,0.9994831,0.00051680475
14530,Diabenese,10,11,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14530,-1,0.9523587,0.04764133
14531,optic neuropathy,15,17,98,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14531,-1,0.00021812078,0.9997819
14532,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14532,-1,0.99948466,0.0005152939
14534,diabetics,4,5,22,31,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,-1,-1,14534,-1,0.00021189566,0.9997881
14535,optic neuropathy,5,7,34,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14535,-1,0.00019395798,0.9998061
14537,diabetics,18,19,120,129,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14537,-1,0.0001974006,0.99980265
14538,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14538,-1,0.0001636005,0.9998363
14539,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14539,-1,0.99945027,0.00054972485
14540,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14540,-1,0.0001903743,0.9998097
14541,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14541,-1,0.99947256,0.00052740244
14542,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14542,-1,0.00018909814,0.9998109
14543,se,26,27,186,188,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14543,-1,0.9994522,0.0005477671
14544,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14544,-1,0.999471,0.0005289609
14545,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14545,-1,0.9994585,0.00054152904
14546,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14546,-1,0.00020492953,0.99979514
14549,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14549,-1,0.999482,0.0005181116
14550,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14550,-1,0.9994935,0.00050649175
14551,cholesteryl esters,19,21,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14551,-1,0.99948585,0.0005141466
14553,lipoproteinuria,4,5,27,42,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,-1,-1,14553,-1,0.0044188355,0.9955812
14555,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,-1,14555,-1,0.9994349,0.0005650618
14558,chloramphenicol,8,9,69,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,-1,-1,14558,-1,0.9994703,0.0005297478
14561,chloramphenicol,20,21,137,152,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,-1,-1,14561,-1,0.9994752,0.00052484794
14562,pancytopenia,4,5,19,31,The first signs of pancytopenia began within one month of the surgery.,7072798_2,-1,-1,-1,14562,-1,0.00020757805,0.9997924
14564,chloramphenicol,13,14,84,99,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,-1,14564,-1,0.9994899,0.00051009504
14566,chloramphenicol,13,14,81,96,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14566,-1,0.9994702,0.00052986195
14567,bone marrow hypoplasia,23,26,153,175,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14567,-1,0.00020191929,0.9997981
14569,chloramphenicol,11,12,79,94,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14569,-1,0.99947065,0.0005293208
14572,atrial tachycardia,14,16,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14572,-1,0.0001970852,0.9998029
14573,intraventricular conduction abnormalities,21,24,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14573,-1,0.00019580964,0.9998042
14574,atrial tachycardia,5,7,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,-1,14574,-1,0.00020690427,0.9997931
14576,atrial flutter,10,12,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,-1,-1,-1,14576,-1,0.00023949839,0.99976045
14578,clear cell adenocarcinoma,2,5,15,40,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,-1,14578,-1,0.0024758338,0.9975242
14579,clear cell adenocarcinoma,3,6,13,38,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,-1,14579,-1,0.00025516012,0.99974483
14587,mg nitrazepam,10,12,57,70,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,-1,14587,-1,0.999451,0.00054902583
14597,EPS,7,8,46,49,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,-1,-1,-1,14597,-1,0.00092708727,0.9990729
14602,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14602,-1,0.99941885,0.00058114866
14603,benzodiazepine lorazepam,5,7,32,56,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14603,-1,0.9994585,0.00054150063
14604,EPS,16,17,102,105,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,-1,-1,-1,14604,-1,0.00021507342,0.9997849
14611,chloroprocaine,28,29,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,-1,14611,-1,0.9994754,0.0005245646
14614,chloroprocaine,20,21,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,-1,-1,-1,14614,-1,0.9994842,0.0005157952
14617,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,-1,-1,14617,-1,0.00020481057,0.99979526
14620,chloroprocaine,29,30,133,147,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,-1,-1,14620,-1,0.9995128,0.00048723348
14623,REM sleep deprivation,0,3,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,-1,14623,-1,0.0028839207,0.9971161
14624,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14624,-1,0.0014738139,0.9985262
14625,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14625,-1,0.0016668066,0.99833316
14627,head twitches,14,16,104,117,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14627,-1,0.00022075113,0.9997793
14628,REMD,3,4,18,22,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14628,-1,0.00061271543,0.99938726
14630,REMD,15,16,114,118,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14630,-1,0.0022997207,0.9977003
14631,REMD,25,26,160,164,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14631,-1,0.0021834176,0.99781656
14632,twitches,29,30,189,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14632,-1,0.00023993243,0.9997601
14636,N,22,23,109,110,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14636,-1,0.6259348,0.37406525
14637,N,29,30,139,140,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14637,-1,0.65735734,0.34264264
14638,N,43,44,179,180,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14638,-1,0.4817104,0.5182896
14639,N,52,53,206,207,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14639,-1,0.5796682,0.4203318
14648,mg,15,16,111,113,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,-1,-1,14648,-1,0.9991303,0.0008697411
14652,premature ventricular contractions,14,17,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14652,-1,0.00020808596,0.9997919
14653,atrial flutter,18,20,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14653,-1,0.00021349189,0.99978656
14659,ventricular fibrillation,9,11,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,-1,-1,14659,-1,0.00020811592,0.9997919
14664,enlargement of the liver,1,5,23,47,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14664,-1,0.00021480826,0.99978524
14665,carbon,12,13,80,86,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14665,-1,0.99947184,0.00052813493
14667,cirrhosis of the liver,4,8,20,42,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14667,-1,0.00035872962,0.9996413
14669,splenomegaly,33,34,179,191,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14669,-1,0.00020384132,0.9997962
14670,testicular atrophy,41,43,214,232,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14670,-1,0.00020199169,0.999798
14671,carbon tetrachloride,52,54,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14671,-1,0.9994979,0.0005021375
14672,carbon tetrachloride,77,79,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14672,-1,0.9995004,0.0004996515
14673,enlargement of the liver,85,89,499,523,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14673,-1,0.00022981613,0.9997702
14675,body weight,36,38,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,-1,-1,-1,14675,-1,0.019093836,0.98090625
14676,carbon tetrachloride,8,10,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,-1,-1,-1,14676,-1,0.9994698,0.0005302409
14682,allopurinol,14,15,74,85,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,-1,-1,14682,-1,0.9994629,0.000537113
14687,Triamterene nephrolithiasis,0,2,0,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14687,-1,0.007704974,0.992295
14688,dyazide,3,4,41,48,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14688,-1,0.999511,0.0004890137
14689,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,-1,14689,-1,0.007290582,0.9927094
14691,triamterene,10,11,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14691,-1,0.9994869,0.0005130278
14692,uric acid salts,14,17,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14692,-1,0.9994636,0.00053639314
14693,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,-1,14693,-1,0.0074928654,0.99250716
14694,hemorrhagic cystitis,1,3,17,37,Busulfan-induced hemorrhagic cystitis.,7269015_0,-1,-1,-1,14694,-1,0.00021387571,0.9997861
14695,hemorrhage cystitis,5,7,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,-1,-1,-1,14695,-1,0.00019562678,0.99980444
14696,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,-1,14696,-1,0.008452077,0.9915479
14700,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,-1,14700,-1,0.0055006146,0.9944993
14702,CM,3,4,20,22,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14702,-1,0.99650687,0.0034931244
14704,DXR,12,13,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14704,-1,0.9994331,0.0005668695
14706,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14706,-1,0.00020529835,0.99979466
14707,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,-1,14707,-1,0.9994398,0.00056021556
14708,DXR,11,12,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,-1,-1,-1,14708,-1,0.99942964,0.0005703472
14710,DXR,13,14,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,-1,14710,-1,0.999463,0.00053702266
14712,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,-1,14712,-1,0.017581545,0.9824185
14714,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,-1,14714,-1,0.017710716,0.98228925
14718,cerebral edema,1,3,8,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14718,-1,0.00020066254,0.9997993
14720,acetaminophen overdose,9,11,68,90,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14720,-1,0.008802002,0.991198
14721,Cerebral edema,0,2,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,-1,-1,14721,-1,0.000199633,0.9998004
14724,signs and symptoms,12,15,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14724,-1,0.00021051722,0.99978954
14725,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14725,-1,0.00020177495,0.99979824
14733,SNP,15,16,77,80,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,-1,14733,-1,0.99898463,0.0010152869
14735,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,-1,-1,-1,14735,-1,0.9994542,0.0005457693
14736,SNP,4,5,15,18,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14736,-1,0.00020053152,0.99979943
14737,SNP,2,3,11,14,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14737,-1,0.9994362,0.00056380243
14738,increase in blood pressure,10,14,71,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14738,-1,0.00020382539,0.9997962
14739,SNP,3,4,29,32,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,-1,14739,-1,0.00020219655,0.9997979
14741,SNP,16,17,106,109,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,-1,14741,-1,0.5872957,0.41270432
14745,SNP,19,20,135,138,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,-1,14745,-1,0.0011602052,0.9988398
14747,digoxin,11,12,87,94,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,-1,-1,14747,-1,0.9994338,0.0005661892
14748,digoxin,9,10,58,65,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14748,-1,0.9994742,0.0005257757
14751,luteinizing hormone,27,29,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14751,-1,0.9994716,0.0005284535
14752,digoxin,13,14,91,98,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14752,-1,0.9994522,0.00054784544
14753,digoxin,23,24,146,153,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14753,-1,0.9994529,0.00054715975
14756,digoxin,10,11,53,60,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14756,-1,0.9994568,0.0005431874
14757,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14757,-1,0.00021532644,0.99978465
14758,digoxin,6,7,44,51,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,-1,-1,-1,14758,-1,0.99942976,0.0005701575
14765,Gentamicin sulfate,0,2,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14765,-1,0.9994733,0.00052678504
14766,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14766,-1,0.9994993,0.000500677
14769,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14769,-1,0.999491,0.0005090234
14770,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14770,-1,0.99950767,0.00049235276
14771,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14771,-1,0.0002174575,0.9997825
14772,reduction in renal function,49,53,302,329,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14772,-1,0.00022138219,0.9997787
14773,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,-1,-1,14773,-1,0.00022718932,0.99977285
14774,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,-1,14774,-1,0.00023457558,0.99976546
14776,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,-1,14776,-1,0.00018761486,0.9998124
14778,Endometrial carcinoma,0,2,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14778,-1,0.00021095485,0.99978906
14779,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14779,-1,0.00020820522,0.9997918
14780,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14780,-1,0.00018653907,0.9998135
14781,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14781,-1,0.00018628633,0.99981374
14782,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14782,-1,0.00020770516,0.9997923
14783,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14783,-1,0.00020361872,0.99979645
14784,estrogens,16,17,113,122,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14784,-1,0.9993629,0.0006370661
14786,estrogens,4,5,27,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14786,-1,0.99902666,0.00097331183
14787,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14787,-1,0.00023093061,0.99976903
14789,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14789,-1,0.0002257379,0.9997743
14790,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,-1,14790,-1,0.007862864,0.99213713
14794,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,-1,14794,-1,0.9993467,0.0006532886
14795,phophorylcreatine,13,14,79,96,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,-1,14795,-1,0.9919293,0.0080707595
14797,mM adenosine,4,6,18,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14797,-1,0.9994186,0.0005814174
14798,ATP,14,15,86,89,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14798,-1,0.99937576,0.00062424835
14799,ATP,24,25,164,167,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14799,-1,0.9993868,0.00061324745
14810,Streptomycin sulfate,0,2,0,20,Streptomycin sulfate (300 mg/kg s.c.) was injected for various periods into preweanling rats and for 3 weeks into weanling rats.,7444978_1,-1,-1,-1,14810,-1,0.99940383,0.0005961785
14811,Abnormal movements,0,2,0,18,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14811,-1,0.00020012945,0.9997999
14812,deafness,3,4,23,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14812,-1,0.00019905345,0.999801
14815,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,-1,14815,-1,0.0022188493,0.9977812
14826,LiCl,35,36,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,-1,14826,-1,0.99941623,0.000583798
14828,h,16,17,77,78,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,-1,14828,-1,0.7424832,0.25751674
14829,h,1,2,2,3,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,-1,-1,-1,14829,-1,0.65692055,0.34307945
14832,h,2,3,6,7,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,-1,14832,-1,0.99911314,0.000886806
14843,Cardiovascular complications,0,2,0,28,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14843,-1,0.00020597361,0.99979407
14845,preterm labor,7,9,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14845,-1,0.00021088446,0.9997892
14846,cardiovascular complications,1,3,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14846,-1,0.00020845231,0.99979156
14848,preterm labor,13,15,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14848,-1,0.0002069019,0.9997931
14849,corticosteroid,1,2,11,25,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,-1,14849,-1,0.99932325,0.00067679747
14851,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14851,-1,0.9807904,0.019209627
14853,benzylthiouracil,16,17,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14853,-1,0.9994715,0.0005285731
14854,hepatic adverse effects,11,14,64,87,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14854,-1,0.00018896154,0.9998111
14855,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14855,-1,0.9986463,0.0013537292
14857,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14857,-1,0.00019864732,0.99980134
14858,cholestatic hepatitis,4,6,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14858,-1,0.00019100393,0.99980897
14860,N,10,11,65,66,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14860,-1,0.99944764,0.0005523088
14861,cholestatic,6,7,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,-1,-1,14861,-1,0.0005480628,0.99945194
14865,Benzylthiouracil,14,15,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14865,-1,0.99948114,0.0005189207
14866,ne,18,19,118,120,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14866,-1,0.9994407,0.0005592974
14871,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14871,-1,0.99939203,0.0006079475
14872,haematological disturbances,17,19,102,129,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14872,-1,0.0002018246,0.99979824
14874,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,-1,-1,14874,-1,0.9967051,0.003294897
14875,Na,8,9,59,61,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14875,-1,0.999416,0.0005840802
14876,Ca,10,11,66,68,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14876,-1,0.9994185,0.00058151106
14878,mM Na,5,7,39,44,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14878,-1,0.9991997,0.0008003116
14879,mM Ca,9,11,54,59,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14879,-1,0.99862516,0.0013748981
14880,N,12,13,61,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14880,-1,0.9940995,0.0059005544
14881,mM,13,14,50,52,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14881,-1,0.99539596,0.004603979
14882,mM,29,30,109,111,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14882,-1,0.9977831,0.0022169433
14883,mM,34,35,131,133,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14883,-1,0.9987923,0.0012076924
14884,mM,49,50,182,184,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14884,-1,0.9983411,0.0016589296
14885,mM,55,56,214,216,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14885,-1,0.9983631,0.0016369505
14886,mM,7,8,33,35,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14886,-1,0.9404932,0.05950676
14887,mM,13,14,54,56,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14887,-1,0.97137827,0.028621737
14888,mM,29,30,118,120,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14888,-1,0.96768534,0.032314632
14891,Na,6,7,40,42,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14891,-1,0.9993143,0.0006857187
14892,Ca,8,9,47,49,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14892,-1,0.9993845,0.0006154073
14893,N,42,43,203,204,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14893,-1,0.9982455,0.0017545258
14896,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14896,-1,0.9994873,0.00051271566
14897,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14897,-1,0.9994778,0.0005221885
14898,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14898,-1,0.9994783,0.00052178866
14899,CsA,3,4,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14899,-1,0.9994566,0.0005433699
14900,Fujimycine,9,10,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14900,-1,0.99949753,0.000502466
14901,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14901,-1,0.99948525,0.00051472324
14902,macrolide,21,22,83,92,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14902,-1,0.99948955,0.0005104749
14905,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14905,-1,0.99942756,0.0005724691
14906,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14906,-1,0.011184585,0.9888154
14907,Cyclophilin A,0,2,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14907,-1,0.9994673,0.0005327379
14908,CsA,11,12,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14908,-1,0.99944955,0.0005503904
14909,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14909,-1,0.9994696,0.0005303836
14910,immunosuppressants CsA,19,21,121,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14910,-1,0.9993864,0.0006135743
14911,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14911,-1,0.9994727,0.00052729616
14913,CsA,11,12,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14913,-1,0.99941814,0.0005819012
14914,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14914,-1,0.9994672,0.0005328593
14917,CsA,8,9,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14917,-1,0.999451,0.0005490277
14918,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14918,-1,0.999464,0.00053600164
14919,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,-1,-1,14919,-1,0.00018367244,0.99981636
14922,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,-1,-1,14922,-1,0.00020188809,0.9997981
14924,rhabdomyosarcoma,16,17,114,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,-1,-1,-1,14924,-1,0.00021108081,0.99978894
14925,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,-1,-1,14925,-1,0.00019815359,0.9998018
14928,Triniol,7,8,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,-1,14928,-1,0.9994572,0.00054280594
14931,conjunctivitis,19,20,97,111,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,-1,-1,14931,-1,0.00020535532,0.99979466
14934,Triniol,5,6,41,48,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,-1,14934,-1,0.9994167,0.00058335974
14941,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14941,-1,0.9994824,0.0005175955
14942,beraprost,9,10,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14942,-1,0.9994804,0.0005196257
14943,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14943,-1,0.999488,0.000511935
14944,prostacyclin,10,11,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14944,-1,0.9994962,0.0005037279
14945,beraprost,12,13,81,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14945,-1,0.99949133,0.0005086787
14946,BPT,14,15,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14946,-1,0.9989409,0.0010590652
14947,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14947,-1,0.9994904,0.0005096387
14948,CLZ,23,24,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14948,-1,0.9991905,0.0008094597
14949,cAMP,38,39,250,254,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14949,-1,0.99945706,0.0005429548
14950,"cyclic adenosine 3',5'-monophosphate",40,43,256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14950,-1,0.9994648,0.0005352127
14951,BPT,13,14,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14951,-1,0.8093699,0.19063005
14952,CLZ,31,32,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14952,-1,0.9988973,0.0011026905
14953,mg,34,35,164,166,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14953,-1,0.9329472,0.067052774
14955,cAMP,19,20,137,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,-1,14955,-1,0.9990553,0.0009447339
14957,facial flush,12,14,79,91,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14957,-1,0.0002074295,0.99979264
14959,CLZ,25,26,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14959,-1,0.99937785,0.00062215637
14960,cAMP,1,2,14,18,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,-1,14960,-1,0.9993729,0.00062707654
14964,coenzyme A,18,20,123,133,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14964,-1,0.9994942,0.00050583034
14965,diabetes mellitus,10,12,69,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,-1,-1,14965,-1,0.00019338513,0.9998066
14972,thyroiditis,10,11,72,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,-1,-1,14972,-1,0.00019894398,0.9998011
14977,ammonia coma,2,4,12,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,-1,14977,-1,0.0055743563,0.99442565
14978,Ammonia coma,0,2,0,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14978,-1,0.0038478991,0.9961521
14979,NH4CL,17,18,101,106,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14979,-1,0.9993268,0.000673222
14981,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,-1,14981,-1,0.9994785,0.0005215526
14982,ammonia,13,14,71,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14982,-1,0.9993741,0.00062596245
14984,ammonia,28,29,149,156,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14984,-1,0.9993906,0.00060940837
14988,ammonia coma,18,20,116,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14988,-1,0.004986255,0.9950138
14989,ammonia,26,27,160,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14989,-1,0.9992054,0.0007945884
14990,ammonia,12,13,84,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14990,-1,0.9993228,0.0006771864
14991,ammonia coma,15,17,100,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14991,-1,0.0053034667,0.9946965
14992,ammonia,8,9,39,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14992,-1,0.9993729,0.0006271077
14993,ammonia coma,13,15,69,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14993,-1,0.005429896,0.9945701
14995,encephalopathic,13,14,91,106,These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.,761833_7,-1,-1,-1,14995,-1,0.00020006363,0.9997999
14996,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,-1,-1,14996,-1,0.00020949701,0.9997905
14997,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14997,-1,0.000187794,0.9998122
14999,coronary heart disease,21,24,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14999,-1,0.00018891397,0.9998111
15000,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,15000,-1,0.9994947,0.0005053118
15002,hematologic toxicity,13,15,80,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,15002,-1,0.000202879,0.99979717
15004,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,-1,15004,-1,0.9995079,0.0004921467
15008,human immunodeficiency virus,1,4,13,41,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15008,-1,0.00043264485,0.99956733
15009,ZDV,18,19,132,135,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15009,-1,0.9994267,0.0005732903
15010,mg,21,22,141,143,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15010,-1,0.9994349,0.0005650785
15011,n,29,30,167,168,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15011,-1,0.28069916,0.71930087
15013,mg,41,42,215,217,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15013,-1,0.99942386,0.0005761195
15014,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15014,-1,0.9994931,0.000506914
15015,n,57,58,292,293,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15015,-1,0.264773,0.73522705
15017,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,15017,-1,0.9994611,0.0005388696
15018,folate,7,8,34,40,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,15018,-1,0.9994456,0.0005543885
15019,hematologic toxicity,1,3,7,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,-1,15019,-1,0.00023026422,0.99976975
15020,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,15020,-1,0.9994661,0.00053391367
15021,folate,8,9,48,54,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,15021,-1,0.9994543,0.00054570974
15023,Vitamin B12,0,2,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15023,-1,0.9994616,0.0005384299
15025,ZDV,7,8,48,51,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15025,-1,0.98403555,0.015964432
15026,myelotoxicity,18,19,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15026,-1,0.00022453986,0.99977547
15031,Halothane hepatitis,0,2,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,-1,-1,-1,15031,-1,0.018539907,0.9814601
15032,trifluoroacetyl,9,10,67,82,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,15032,-1,0.9994673,0.0005326439
15033,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,15033,-1,0.01673366,0.98326635
15044,halothane hepatitis,23,25,159,178,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,-1,-1,-1,15044,-1,0.015806355,0.9841936
15047,echothiophate iodide,7,9,59,79,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15047,-1,0.9994777,0.0005223497
15048,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15048,-1,0.9994593,0.00054062105
15049,muscle weakness,19,21,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15049,-1,0.0001980635,0.99980193
15050,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15050,-1,0.0002113273,0.9997887
15053,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,-1,-1,15053,-1,0.9994838,0.00051614584
15054,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15054,-1,0.99947363,0.0005263439
15056,antagonist,5,6,40,50,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15056,-1,0.9994622,0.0005378025
15057,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15057,-1,0.00023234739,0.9997676
15063,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,-1,-1,-1,15063,-1,0.9994822,0.00051783636
15065,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,-1,-1,15065,-1,0.9992312,0.0007687676
15066,neuroblastoma,9,10,55,68,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,-1,15066,-1,0.00021845609,0.99978155
15067,neuroblastoma,4,5,22,35,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,-1,15067,-1,0.00021460025,0.99978536
15068,neuroblastoma,7,8,52,65,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,-1,15068,-1,0.00020779789,0.9997923
15070,neuroblastoma,29,30,182,195,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,-1,15070,-1,0.00021932031,0.9997807
15072,DLT,13,14,77,80,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,-1,-1,15072,-1,0.0002585659,0.9997414
15075,n,13,14,88,89,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15075,-1,0.9986071,0.0013929703
15077,n,20,21,102,103,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15077,-1,0.9992829,0.00071707205
15078,n,28,29,151,152,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15078,-1,0.99926156,0.00073842285
15080,metastases,7,8,49,59,Three complete responses were observed in marrow metastases.,7707116_10,-1,-1,-1,15080,-1,0.0002100212,0.99979
15081,neuroblastoma,7,8,43,56,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,-1,15081,-1,0.00021615335,0.9997838
15085,oxypurines,6,7,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15085,-1,0.99948066,0.0005193704
15086,nucleosides,9,10,59,70,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15086,-1,0.99945956,0.000540465
15087,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15087,-1,0.00020901636,0.99979097
15088,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,-1,-1,15088,-1,0.00020054624,0.99979943
15092,oxypurines,19,20,148,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15092,-1,0.9994437,0.0005562877
15093,nucleosides,22,23,164,175,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15093,-1,0.9994043,0.00059564656
15095,oxypurines,8,9,53,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15095,-1,0.9994423,0.0005577102
15096,nucleosides,10,11,68,79,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15096,-1,0.9994186,0.0005814157
15098,SD,17,18,100,102,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15098,-1,0.46119624,0.53880376
15100,SD,44,45,240,242,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15100,-1,0.41315338,0.58684665
15102,acetylsalicylate,29,30,184,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,-1,15102,-1,0.9994967,0.00050325354
15109,oxypurines,10,11,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15109,-1,0.9994677,0.0005323295
15110,nucleosides,13,14,85,96,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15110,-1,0.9994356,0.0005644288
15111,ischemic,30,31,195,203,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15111,-1,0.00021278953,0.9997873
15114,cyanoacrylate,6,7,56,69,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15114,-1,0.9994948,0.0005051839
15118,DX,10,11,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,-1,15118,-1,0.999361,0.00063903944
15120,DX,16,17,94,96,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,-1,-1,15120,-1,0.999433,0.0005669451
15122,DX,14,15,81,83,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15122,-1,0.99930274,0.0006973021
15123,p,16,17,85,86,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15123,-1,0.100076966,0.899923
15125,DX,10,11,68,70,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15125,-1,0.99940515,0.0005948844
15126,contrast,17,18,94,102,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15126,-1,0.043697454,0.95630246
15128,p,15,16,68,69,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,15128,-1,0.13644448,0.86355555
15130,DX,16,17,101,103,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,-1,15130,-1,0.9994087,0.0005913112
15133,Prostaglandin,0,1,0,13,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15133,-1,0.99943453,0.0005653889
15134,bladder hyperactivity,2,4,25,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15134,-1,0.00022841172,0.99977165
15135,tachykinins?In,12,13,89,103,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15135,-1,0.0045649023,0.99543506
15136,prostaglandin (PG) E2,23,28,190,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15136,-1,0.99944633,0.000553641
15137,"RP 67,580",11,13,72,81,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15137,-1,0.9575981,0.042401955
15138,"SR 48,968",19,21,124,133,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15138,-1,0.99295855,0.0070415125
15139,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15139,-1,0.99941146,0.00058856024
15140,PG,19,20,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15140,-1,0.99936515,0.0006349071
15141,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15141,-1,0.9993374,0.0006625496
15142,"RP 67,580",11,13,73,82,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15142,-1,0.0044260724,0.9955739
15143,"SR 48,968",14,16,86,95,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15143,-1,0.03597119,0.96402884
15144,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15144,-1,0.99933535,0.0006646316
15145,PG,40,41,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15145,-1,0.99911636,0.00088359375
15146,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,-1,-1,15146,-1,0.9994593,0.000540725
15147,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15147,-1,0.99947804,0.00052196876
15148,tachykinins,12,13,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15148,-1,0.00060190994,0.9993981
15149,tachykinins,1,2,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,-1,-1,-1,15149,-1,0.94117963,0.058820307
15150,Prostanoids,0,1,0,11,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15150,-1,0.9994087,0.00059131574
15151,tachykinins,6,7,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15151,-1,0.95738924,0.04261078
15152,bladder hyperactivity,13,15,73,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15152,-1,0.00022503667,0.999775
15153,cardiogenic shock,1,3,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15153,-1,0.00022727468,0.9997727
15154,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15154,-1,0.00022484598,0.9997751
15157,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,-1,15157,-1,0.00020533241,0.99979466
15162,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,-1,-1,15162,-1,0.00018315775,0.99981683
15166,calcium chloride,8,10,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15166,-1,0.99944896,0.00055098324
15168,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15168,-1,0.00021307275,0.9997869
15169,misoprostol,3,4,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,-1,-1,15169,-1,0.99945575,0.000544219
15172,misoprostol,9,10,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,-1,15172,-1,0.99948406,0.0005159341
15174,NSAID,20,21,130,135,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15174,-1,0.99948114,0.00051890087
15177,misoprostol,42,43,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15177,-1,0.99950314,0.00049683306
15180,BUN,13,14,79,82,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,-1,15180,-1,0.99918944,0.0008105766
15182,BUN,17,18,82,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15182,-1,0.4176875,0.58231246
15184,p,52,53,237,238,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15184,-1,0.062017214,0.9379828
15186,K,2,3,11,12,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15186,-1,0.99940014,0.0005998488
15187,p,29,30,114,115,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15187,-1,0.050852608,0.94914734
15188,BUN,4,5,23,26,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15188,-1,0.99824166,0.0017583669
15190,K,9,10,44,45,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15190,-1,0.9991122,0.0008878079
15193,misoprostol,2,3,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15193,-1,0.9994758,0.00052427995
15194,renal impairment,6,8,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15194,-1,0.00021115568,0.9997888
15198,panic disorder,5,7,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,-1,15198,-1,0.00020995532,0.99979
15201,panic disorder,7,9,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,-1,15201,-1,0.00020966868,0.9997904
15203,panic disorder,13,15,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,-1,15203,-1,0.00018423091,0.99981576
15207,mg,7,8,36,38,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,-1,-1,-1,15207,-1,0.9993923,0.0006076701
15210,enuresis,21,22,112,120,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15210,-1,0.0029289452,0.997071
15213,impaired memory,36,38,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15213,-1,0.00022388784,0.99977607
15214,weight loss,39,41,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15214,-1,0.0037662992,0.99623376
15217,Cognitive deterioration,0,2,0,23,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15217,-1,0.00017915177,0.9998209
15218,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15218,-1,0.9994173,0.0005826878
15219,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15219,-1,0.99945086,0.00054915773
15220,DM,2,3,18,20,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15220,-1,0.4794766,0.5205234
15222,restlessness,17,18,82,94,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15222,-1,0.00023089937,0.99976915
15223,insomnia,19,20,96,104,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15223,-1,0.00022126675,0.9997787
15225,nystagmus,26,27,133,142,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15225,-1,0.0002185213,0.99978155
15226,inattention,34,35,184,195,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15226,-1,0.00026415449,0.9997359
15227,disorientation,36,37,197,211,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15227,-1,0.00023739455,0.9997626
15229,al,43,44,247,249,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15229,-1,0.9979819,0.0020181187
15230,al,58,59,314,316,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15230,-1,0.9865384,0.013461562
15231,al,74,75,389,391,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15231,-1,0.9963831,0.0036168827
15232,DM,8,9,50,52,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,-1,15232,-1,0.99915016,0.00084982684
15233,cognitive deterioration,6,8,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15233,-1,0.00020374882,0.9997962
15234,DM,13,14,88,90,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15234,-1,0.92051375,0.079486206
15237,coronary artery disease,13,16,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,-1,15237,-1,0.00020319474,0.9997968
15238,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,-1,-1,15238,-1,0.00018783234,0.9998122
15239,digitalis glycosides,3,5,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15239,-1,0.9987348,0.0012652364
15241,coronary artery disease,20,23,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15241,-1,0.00019405768,0.999806
15243,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15243,-1,0.8499671,0.15003282
15244,coronary artery disease,26,29,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15244,-1,0.00021331361,0.9997867
15245,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15245,-1,0.00021726375,0.99978274
15248,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15248,-1,0.09816207,0.90183794
15249,mm Hg,12,14,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15249,-1,0.0017339404,0.99826604
15250,P,15,16,93,94,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15250,-1,0.16635564,0.83364433
15251,P,32,33,191,192,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15251,-1,0.19232094,0.80767906
15252,h,38,39,211,212,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15252,-1,0.046314005,0.953686
15254,P,15,16,120,121,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,-1,15254,-1,0.16740146,0.83259857
15258,coronary artery disease,7,10,42,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15258,-1,0.00018918651,0.9998109
15259,congestive heart failure,15,18,90,114,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15259,-1,0.00019327286,0.9998067
15265,pulmonary tuberculosis,9,11,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,-1,15265,-1,0.00020434144,0.99979573
15270,pulmonary tuberculosis,11,13,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15270,-1,0.00021772411,0.99978226
15271,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15271,-1,0.00022100868,0.99977905
15277,ocular hypertension,1,3,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,-1,-1,-1,15277,-1,0.00020561807,0.9997944
15278,lead,5,6,43,47,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15278,-1,0.0063893446,0.9936107
15279,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15279,-1,0.00020420548,0.99979585
15280,corticosteroid glaucoma,13,15,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15280,-1,0.0055334354,0.9944666
15283,mm Hg,30,32,170,175,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,-1,15283,-1,0.00029692677,0.999703
15286,contrast,1,2,3,11,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15286,-1,0.9936614,0.006338549
15287,hypertensive eyes,5,7,39,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15287,-1,0.00018730707,0.99981266
15289,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,-1,15289,-1,0.0002001783,0.9997998
15291,corticosteroid glaucoma,15,17,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15291,-1,0.005598637,0.9944014
15292,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15292,-1,0.00020185941,0.9997981
15293,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15293,-1,0.0054672207,0.9945328
15294,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15294,-1,0.00018902928,0.999811
15298,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15298,-1,0.99946576,0.000534296
15302,gastric adenocarcinoma,26,28,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15302,-1,0.000220083,0.9997799
15304,disorientation,9,10,60,74,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,-1,-1,15304,-1,0.00021376235,0.9997862
15314,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15314,-1,0.022200039,0.9777999
15315,fluoroacetate,14,15,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15315,-1,0.9995117,0.00048833963
15316,fluorocitrate,16,17,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15316,-1,0.9995053,0.0004947208
15317,thiamine,18,19,122,130,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15317,-1,0.99951637,0.0004836381
15318,dihydrouracil,22,23,146,159,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15318,-1,0.9995166,0.00048340397
15321,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15321,-1,0.99947816,0.000521877
15322,neuroleptics,11,12,75,87,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15322,-1,0.9994562,0.0005438296
15324,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15324,-1,0.9995142,0.00048580047
15326,organic psychotic,13,15,111,128,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15326,-1,0.005381384,0.99461854
15330,neuroleptics,21,22,92,104,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,-1,-1,15330,-1,0.00021566157,0.9997844
15332,contrast,11,12,57,65,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15332,-1,0.9983536,0.001646476
15333,carbamazepine oxcarbazepine,13,15,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15333,-1,0.99945563,0.00054435385
15334,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15334,-1,0.99944156,0.00055844354
15338,h,23,24,104,105,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,-1,-1,-1,15338,-1,0.0919758,0.9080242
15339,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,-1,-1,15339,-1,0.00018179092,0.99981827
15341,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,-1,-1,15341,-1,0.00021220603,0.99978787
15343,Reactive oxygen species,0,3,0,23,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15343,-1,0.99919945,0.00080059574
15344,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15344,-1,0.99946123,0.00053879694
15348,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15348,-1,0.99945754,0.0005424794
15349,PAN,13,14,76,79,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15349,-1,0.9993856,0.0006143882
15350,N,32,33,178,179,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15350,-1,0.3241121,0.67588794
15351,thiobarbituric acid reactive substances,17,21,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,-1,15351,-1,0.99918514,0.000814895
15353,proteinuric injury,11,13,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15353,-1,0.0025210383,0.997479
15354,PAN nephropathy,14,16,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15354,-1,0.00043990123,0.99956006
15355,gall bladder stones,2,5,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15355,-1,0.0023342052,0.99766576
15357,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15357,-1,0.9994849,0.00051506236
15359,acromegaly,6,7,39,49,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15359,-1,0.004346967,0.99565303
15360,gall bladder stones,9,12,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15360,-1,0.0014841501,0.9985159
15362,acromegalic,30,31,192,203,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15362,-1,0.0028217994,0.9971782
15363,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15363,-1,0.004615459,0.9953845
15364,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,-1,-1,15364,-1,0.0039975434,0.9960025
15370,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15370,-1,0.99948007,0.0005199046
15371,UDCA,10,11,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15371,-1,0.9994696,0.0005303823
15372,UDCA,25,26,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15372,-1,0.9994816,0.0005183734
15373,n,16,17,88,89,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15373,-1,0.30962497,0.69037503
15374,n,23,24,108,109,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15374,-1,0.5348337,0.46516624
15375,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15375,-1,0.9209768,0.079023175
15377,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,-1,-1,15377,-1,0.12621912,0.87378085
15379,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15379,-1,0.005928539,0.9940714
15381,gall stone disease,22,25,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15381,-1,0.0031295787,0.99687046
15382,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15382,-1,0.0059621283,0.99403787
15384,SC-48334,8,9,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15384,-1,0.9666558,0.03334423
15386,HIV-1 infection,15,17,107,122,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15386,-1,0.0003177547,0.9996823
15387,SC-48334,43,44,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15387,-1,0.9922964,0.0077035306
15391,SC-48334,19,20,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15391,-1,0.9994723,0.00052767125
15392,mg,22,23,121,123,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15392,-1,0.9952218,0.004778224
15393,h,25,26,132,133,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15393,-1,0.081574045,0.918426
15395,mg,31,32,155,157,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15395,-1,0.99850273,0.0014972334
15396,h,34,35,166,167,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15396,-1,0.077474326,0.92252564
15400,p,25,26,120,121,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,-1,-1,-1,15400,-1,0.1922795,0.8077205
15401,SC-48334,2,3,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15401,-1,0.9993781,0.0006218344
15402,human immunodeficiency virus,21,24,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15402,-1,0.0002823723,0.99971765
15404,p,24,25,136,137,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,-1,15404,-1,0.44778514,0.5522148
15408,p,32,33,143,144,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15408,-1,0.39685592,0.60314405
15409,p,52,53,194,195,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15409,-1,0.33648202,0.66351795
15411,flatulence,2,3,10,20,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15411,-1,0.0031866843,0.99681336
15412,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15412,-1,0.0001791687,0.9998209
15413,weight loss,8,10,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15413,-1,0.0010944972,0.99890554
15415,nondepolarizing neuromuscular blocking agents,4,8,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,-1,15415,-1,0.9665226,0.033477377
15417,nondepolarizing neuromuscular blocking agents,4,8,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15417,-1,0.98603314,0.013966896
15418,muscle weakness,20,22,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15418,-1,0.00020961229,0.9997904
15419,respiratory insufficiency,13,15,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,-1,-1,15419,-1,0.0001885751,0.9998115
15423,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,-1,-1,-1,15423,-1,0.9994691,0.0005309003
15425,pathology at both the neuromuscular junction,8,14,41,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15425,-1,0.00055605493,0.99944395
15426,and muscle,21,23,115,125,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15426,-1,0.0003496437,0.99965036
15428,Hepatic dysfunction,0,2,0,19,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,-1,-1,15428,-1,0.00021163076,0.99978834
15430,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15430,-1,0.8869392,0.113060795
15431,hypersensitivity myocarditis,3,5,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15431,-1,0.00021025565,0.9997898
15433,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15433,-1,0.6868748,0.31312525
15434,hypersensitivity myocarditis,10,12,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15434,-1,0.00019322534,0.9998068
15438,septicemia,15,16,96,106,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,-1,-1,-1,15438,-1,0.00020179496,0.99979824
15439,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15439,-1,0.69946146,0.3005385
15440,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15440,-1,0.00021996973,0.99978
15445,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,-1,15445,-1,0.8094131,0.19058698
15450,Hypersensitivity myocarditis,2,4,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15450,-1,0.00019710569,0.9998029
15451,allergy,11,12,83,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15451,-1,0.0001985928,0.99980146
15452,penicillins,13,14,94,105,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15452,-1,0.9994318,0.00056819746
15453,sleep disturbance,1,3,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,-1,-1,-1,15453,-1,0.00022194692,0.9997781
15454,sleep disturbance,10,12,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15454,-1,0.0002082096,0.9997918
15456,PRL,25,26,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15456,-1,0.00024022839,0.99975973
15457,n,19,20,117,118,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15457,-1,0.68651056,0.3134894
15458,n,32,33,162,163,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15458,-1,0.7773295,0.22267051
15459,mg,6,7,34,36,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,-1,15459,-1,0.9993444,0.0006556314
15461,PRL,1,2,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,-1,15461,-1,0.7267349,0.2732651
15462,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,-1,15462,-1,0.0002270477,0.99977297
15464,PRL,5,6,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15464,-1,0.00020720511,0.99979275
15465,sleep disturbance,46,48,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15465,-1,0.00020401864,0.999796
15466,se,56,57,275,277,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15466,-1,0.15275829,0.8472417
15468,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,-1,-1,-1,15468,-1,0.9994721,0.0005279366
15469,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,-1,-1,-1,15469,-1,0.9994815,0.0005185662
15470,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15470,-1,0.99948645,0.0005134796
15471,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15471,-1,0.9994967,0.0005032473
15472,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,-1,-1,-1,15472,-1,0.9993338,0.00066622026
15473,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,-1,-1,-1,15473,-1,0.99947244,0.00052759505
15474,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15474,-1,0.99948055,0.0005194638
15475,mg,13,14,74,76,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15475,-1,0.85121465,0.14878538
15477,exanthema,22,23,99,108,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15477,-1,0.00023379317,0.9997662
15478,urtication,24,25,110,120,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15478,-1,0.002739114,0.9972609
15479,itchiness,26,27,122,131,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15479,-1,0.009493145,0.9905069
15484,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15484,-1,0.9995066,0.0004933893
15485,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15485,-1,0.9994925,0.00050744764
15486,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15486,-1,0.9995079,0.00049206626
15490,pulmonary edema,12,14,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15490,-1,0.00021084686,0.9997892
15491,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15491,-1,0.00020848395,0.99979156
15492,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15492,-1,0.00020719448,0.9997929
15493,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15493,-1,0.00021693877,0.9997831
15495,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15495,-1,0.00021302055,0.99978703
15497,lisinopril,6,7,37,47,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,-1,-1,15497,-1,0.9995004,0.00049964525
15498,enzyme inhibitors,6,8,59,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,-1,-1,-1,15498,-1,0.9994332,0.0005667263
15503,diphenhydramine hydrochloride,9,11,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,-1,-1,15503,-1,0.99949145,0.00050858274
15512,Water intoxication,0,2,0,18,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15512,-1,0.0030641742,0.99693584
15514,abortion,8,9,81,89,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15514,-1,0.0002092024,0.99979085
15515,water intoxication,3,5,14,32,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15515,-1,0.003040365,0.9969597
15517,abortions,12,13,98,107,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15517,-1,0.00020250272,0.9997975
15518,water intoxication,3,5,17,35,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,-1,-1,-1,15518,-1,0.0027505558,0.9972494
15520,abortions,4,5,52,61,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15520,-1,0.00022505492,0.999775
15521,water intoxication,28,30,184,202,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15521,-1,0.0028857777,0.9971142
15522,asthenia,45,46,287,295,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15522,-1,0.00020394784,0.9997961
15524,headaches,51,52,323,332,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15524,-1,0.00022434577,0.9997757
15526,lactate,8,9,45,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15526,-1,0.999418,0.00058205344
15527,lactate,15,16,81,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15527,-1,0.99941206,0.0005878992
15528,dextrose,21,22,106,114,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15528,-1,0.9994259,0.00057416776
15539,tuberculous,8,9,35,46,as well as of those of seven other tuberculous patients.,804391_4,-1,-1,-1,15539,-1,0.0002258115,0.99977416
15541,KF17837,0,1,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,-1,-1,-1,15541,-1,0.99940395,0.0005960404
15543,KF17837,0,1,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,-1,-1,-1,15543,-1,0.99943596,0.00056402065
15545,KF17837,3,4,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15545,-1,0.9966372,0.003362738
15546,cataleptic,15,16,88,98,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15546,-1,0.9991586,0.0008413401
15548,CGS 21680,28,30,197,206,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15548,-1,0.9994603,0.0005397566
15549,KF17837,0,1,0,7,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,-1,-1,15549,-1,0.99945694,0.000543014
15553,KF17837,2,3,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15553,-1,0.88039947,0.11960059
15554,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15554,-1,0.9994796,0.00052041386
15555,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15555,-1,0.999493,0.0005069298
15556,KF17837,4,5,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15556,-1,0.9768281,0.02317192
15558,antagonist,12,13,82,92,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15558,-1,0.99946576,0.0005342359
15560,antagonists,28,29,198,209,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15560,-1,0.9994733,0.00052675843
15561,KF17837,2,3,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,-1,-1,15561,-1,0.9993724,0.0006275974
15565,teratogenic,17,18,82,93,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,-1,15565,-1,0.00026309906,0.99973685
15566,teratogenic,2,3,10,21,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15566,-1,0.00023377802,0.9997662
15567,arthrogryposis,5,6,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15567,-1,0.0002176822,0.9997824
15569,arthrogryposis,7,8,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15569,-1,0.00020954118,0.9997905
15570,teratogenic,16,17,89,100,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15570,-1,0.00022599718,0.99977404
15575,deformations,3,4,22,34,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,-1,15575,-1,0.00021376745,0.9997862
15576,nicotine sulfate,3,5,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,-1,15576,-1,0.99948066,0.0005193876
15578,deformations,1,2,4,16,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15578,-1,0.00020916588,0.99979085
15581,excessive flexion or extension of one or more toes,10,19,66,116,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15581,-1,0.0003051755,0.9996948
15582,cranial hemorrhage,25,27,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,-1,15582,-1,0.00020834545,0.9997917
15584,P,6,7,39,40,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,-1,15584,-1,0.031592935,0.96840703
15588,arthrogryposis,16,17,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,-1,15588,-1,0.00019240721,0.99980766
15592,allergic,27,28,159,167,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15592,-1,0.00022752098,0.9997725
15593,allergic,34,35,219,227,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15593,-1,0.00021154158,0.99978846
15595,AX,39,40,254,256,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15595,-1,0.9991873,0.00081267324
15597,benzylpenicilloate,10,11,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15597,-1,0.99947375,0.00052624807
15598,benzylpenicillin,12,13,94,110,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15598,-1,0.99947673,0.0005232607
15599,PG,14,15,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15599,-1,0.9985298,0.0014702352
15601,AMP,19,20,129,132,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15601,-1,0.99941313,0.0005868652
15602,AX,23,24,139,141,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15602,-1,0.0037194393,0.9962806
15603,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15603,-1,0.8098086,0.19019146
15604,PG,22,23,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15604,-1,0.9934465,0.006553421
15605,AX,26,27,155,157,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15605,-1,0.3887683,0.61123174
15606,allergic,8,9,42,50,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,-1,-1,-1,15606,-1,0.00021691828,0.9997831
15607,AX allergy,11,13,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15607,-1,0.00019022587,0.9998098
15608,PG,17,18,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15608,-1,0.29179618,0.7082038
15612,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15612,-1,0.9908722,0.009127811
15613,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15613,-1,0.003397859,0.9966022
15614,PG,32,33,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15614,-1,0.14614657,0.85385346
15615,AX,3,4,16,18,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,-1,15615,-1,0.00023669077,0.9997633
15616,AX,4,5,22,24,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15616,-1,0.0002437996,0.99975616
15617,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15617,-1,0.00032071906,0.9996793
15618,AX,8,9,40,42,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15618,-1,0.0002431044,0.9997569
15619,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15619,-1,0.30938265,0.6906173
15620,AX,3,4,21,23,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15620,-1,0.00022538434,0.99977463
15622,AX,22,23,121,123,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15622,-1,0.00021662768,0.99978334
15623,AX,38,39,175,177,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15623,-1,0.00022070145,0.9997793
15624,PG,0,1,0,2,PG was well tolerated by all 54 patients.,8092427_14,-1,-1,-1,15624,-1,0.8878586,0.112141415
15625,PG,11,12,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,-1,15625,-1,0.0023414097,0.9976586
15634,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15634,-1,0.00028464766,0.9997154
15636,mm Hg,27,29,165,170,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15636,-1,0.0031722276,0.9968278
15637,P,30,31,172,173,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15637,-1,0.063253745,0.9367463
15638,mm Hg,15,17,70,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15638,-1,0.0011817197,0.9988182
15639,P,18,19,77,78,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15639,-1,0.040960763,0.9590393
15640,P,14,15,77,78,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,-1,-1,-1,15640,-1,0.13905832,0.8609417
15643,mm Hg,17,19,108,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15643,-1,0.004491417,0.99550855
15644,P,20,21,115,116,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15644,-1,0.10371119,0.8962888
15645,mm Hg,39,41,206,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15645,-1,0.005719254,0.9942807
15646,P,42,43,213,214,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15646,-1,0.21635884,0.78364116
15647,P,53,54,273,274,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15647,-1,0.55263245,0.44736755
15653,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,-1,-1,15653,-1,0.9993755,0.0006245025
15656,dyskinetic movements,22,24,135,155,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,-1,-1,15656,-1,0.0002224227,0.9997776
15658,physostigmine,6,7,36,49,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15658,-1,0.9995003,0.0004997177
15659,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15659,-1,0.9994924,0.00050756667
15660,5-MDOT,10,11,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15660,-1,0.9507345,0.049265493
15662,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15662,-1,0.99950063,0.0004993437
15663,dyskinetic movements,20,22,119,139,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15663,-1,0.00021835696,0.99978167
15666,meperidine,4,5,23,33,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15666,-1,0.9995221,0.0004778869
15667,dyskinetic movements,8,10,60,80,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15667,-1,0.00020438839,0.9997956
15668,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15668,-1,0.9994649,0.0005350961
15669,dystonic,10,11,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15669,-1,0.00019900942,0.999801
15672,dystonic,3,4,23,31,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15672,-1,0.00021972448,0.99978024
15673,chorea,6,7,47,53,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15673,-1,0.00021468561,0.99978536
15688,hallucinatory,22,23,148,161,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,-1,-1,15688,-1,0.00022163308,0.99977833
15690,neuroleptics,6,7,42,54,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,-1,-1,15690,-1,0.9994161,0.0005838931
15693,neuromuscular disorders,7,9,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,-1,-1,15693,-1,0.00020141972,0.9997986
15696,myotonia,14,15,109,117,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15696,-1,0.00020555298,0.9997944
15697,acetazolamide,3,4,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15697,-1,0.9994808,0.0005192297
15698,renal calculi,9,11,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15698,-1,0.00048033387,0.9995197
15699,calculus,6,7,56,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15699,-1,0.00022591572,0.99977404
15700,calculus,15,16,111,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15700,-1,0.00022712498,0.99977285
15702,acetazolamide,5,6,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,-1,-1,15702,-1,0.9994417,0.00055825984
15703,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,-1,15703,-1,0.99947006,0.0005299839
15705,calcium channel blockers,11,14,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,-1,15705,-1,0.999456,0.0005440727
15707,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15707,-1,0.99943894,0.00056099513
15711,n,45,46,222,223,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15711,-1,0.027690874,0.9723092
15713,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,-1,15713,-1,0.99942744,0.00057260034
15715,calcium channel blockers,10,13,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,-1,-1,15715,-1,0.9994804,0.00051955594
15718,telangiectasia,3,4,43,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,-1,-1,15718,-1,0.00022157036,0.99977845
15720,Adalat,6,7,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15720,-1,0.9994597,0.0005403591
15721,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15721,-1,0.0002193799,0.9997806
15722,flushing,6,7,50,58,Neither patient complained of photosensitivity or flushing.,8251368_2,-1,-1,-1,15722,-1,0.00022782183,0.99977213
15723,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15723,-1,0.9994742,0.0005257923
15724,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15724,-1,0.00021795716,0.999782
15725,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,-1,15725,-1,0.00019536469,0.9998047
15730,RPGN,11,12,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,-1,-1,15730,-1,0.00019990442,0.99980015
15734,antiplatelet agents,12,14,81,100,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,-1,15734,-1,0.90013313,0.09986682
15735,RPGN,4,5,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,-1,-1,15735,-1,0.00022012372,0.9997799
15737,polymyositis,3,4,10,22,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15737,-1,0.00015905836,0.999841
15738,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15738,-1,0.00015780177,0.99984217
15739,rheumatologic diseases,7,9,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,-1,-1,15739,-1,0.00020692161,0.9997931
15741,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15741,-1,0.00019499211,0.99980503
15742,polymyositis,11,12,66,78,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15742,-1,0.00019328871,0.9998067
15751,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,-1,-1,15751,-1,0.00020078121,0.9997992
15753,neuralgia,5,6,29,38,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,-1,-1,-1,15753,-1,0.00020037597,0.99979967
15757,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15757,-1,0.28832272,0.71167725
15758,trimethaphan,7,8,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15758,-1,0.999491,0.00050900195
15760,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15760,-1,0.9994493,0.0005507329
15761,PGE1,8,9,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15761,-1,0.999443,0.00055696804
15762,trimethaphan,11,12,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15762,-1,0.9994709,0.00052910135
15763,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15763,-1,0.99945146,0.0005485922
15766,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15766,-1,0.1329683,0.8670317
15767,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15767,-1,0.99934477,0.0006551622
15768,MAP,42,43,243,246,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15768,-1,0.0033913208,0.99660873
15770,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15770,-1,0.99941266,0.0005873487
15771,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15771,-1,0.99937695,0.0006230263
15772,MAP,6,7,28,31,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15772,-1,0.02968249,0.9703175
15773,P,21,22,122,123,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15773,-1,0.13105541,0.86894464
15775,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15775,-1,0.99942005,0.0005800304
15776,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15776,-1,0.98936325,0.010636803
15777,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15777,-1,0.9993937,0.00060625473
15778,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15778,-1,0.9994036,0.0005964212
15779,P,10,11,35,36,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,-1,15779,-1,0.012063265,0.9879367
15780,P,10,11,33,34,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,-1,15780,-1,0.01962833,0.98037165
15781,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15781,-1,0.9993936,0.0006063585
15782,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15782,-1,0.99941504,0.00058494334
15784,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15784,-1,0.99940753,0.00059243065
15786,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,-1,15786,-1,0.00022560083,0.9997744
15788,AIDS,24,25,143,147,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15788,-1,0.00026397698,0.999736
15789,Kaposi's sarcoma,26,29,156,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15789,-1,0.0002318853,0.9997681
15790,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,-1,15790,-1,0.002001277,0.99799865
15791,oedema,7,8,39,45,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,-1,15791,-1,0.00020956354,0.9997905
15793,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,-1,15793,-1,0.002165798,0.99783427
15795,haematological toxicity,5,7,33,56,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,-1,-1,15795,-1,0.00020372514,0.99979633
15799,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,-1,15799,-1,0.00022465014,0.99977535
15800,Dup 753,0,2,0,7,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,-1,-1,15800,-1,0.9994992,0.0005008245
15802,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15802,-1,0.00017327396,0.9998267
15804,hypoalbuminemia,9,10,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15804,-1,0.00017228698,0.99982774
15806,in blood nitrogen urea,14,18,110,132,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15806,-1,0.90481013,0.09518983
15807,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15807,-1,0.9994759,0.00052412605
15808,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15808,-1,0.99947816,0.0005218964
15810,angiotensin II,42,44,269,283,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15810,-1,0.99945813,0.0005418509
15812,hearing loss,9,11,72,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,-1,-1,15812,-1,0.00021361811,0.99978644
15813,hearing loss,17,19,110,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,-1,-1,15813,-1,0.000201564,0.9997985
15816,hearing loss,16,18,100,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,-1,-1,15816,-1,0.00021633458,0.9997837
15818,Lymphoma,5,6,34,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15818,-1,0.0002068563,0.9997931
15820,mg,17,18,110,112,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15820,-1,0.97197264,0.028027322
15822,neuropathic symptoms,7,9,47,67,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,-1,-1,-1,15822,-1,0.00020555807,0.9997944
15824,neuropathic symptoms,3,5,31,51,Twenty-seven patients reported neuropathic symptoms.,8384253_4,-1,-1,-1,15824,-1,0.00020638804,0.9997936
15825,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,-1,-1,15825,-1,0.00021597907,0.99978405
15826,Neuropathic,0,1,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,-1,15826,-1,0.00019870681,0.99980134
15828,signs and symptoms,11,14,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15828,-1,0.00021671694,0.99978334
15829,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15829,-1,0.016793502,0.9832065
15830,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15830,-1,0.9994178,0.00058221375
15832,erectile dysfunction,10,12,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15832,-1,0.00021003523,0.99979
15835,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,-1,15835,-1,0.9994373,0.00056267605
15836,impotence,12,13,68,77,A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml.,8386779_2,-1,-1,-1,15836,-1,0.0006720962,0.9993279
15837,mg,8,9,31,33,of a combination of 3 drugs: 6 mg.,8386779_3,-1,-1,-1,15837,-1,0.99822897,0.0017710347
15839,phentolamine,0,1,0,12,phentolamine and 10 micrograms.,8386779_5,-1,-1,-1,15839,-1,0.9994481,0.0005518984
15840,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15840,-1,0.989754,0.010245961
15841,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15841,-1,0.9994449,0.0005551208
15842,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15842,-1,0.9994412,0.0005588115
15844,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15844,-1,0.9994404,0.00055957783
15849,ddI,7,8,36,39,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15849,-1,0.9992478,0.00075224054
15851,(AZT)One,16,17,103,111,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15851,-1,0.99146163,0.008538411
15853,AZT,25,26,169,172,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15853,-1,0.99948764,0.0005123643
15855,ddI,30,31,195,198,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15855,-1,0.8230509,0.17694908
15856,opportunistic infections,4,6,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15856,-1,0.00017165123,0.99982834
15857,AIDS,14,15,96,100,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15857,-1,0.00017625943,0.99982375
15858,AIDS,12,13,68,72,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,-1,15858,-1,0.00025811465,0.99974185
15860,diarrhoea,5,6,32,41,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,-1,-1,15860,-1,0.0002050286,0.999795
15862,pancreatitis,7,8,50,62,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,-1,-1,15862,-1,0.00020342697,0.99979657
15863,abdominal pain,8,10,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,-1,-1,15863,-1,0.00021623293,0.9997838
15864,glucose tolerance curves,3,6,25,49,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,-1,-1,-1,15864,-1,0.002886195,0.9971138
15867,adenomas,1,2,8,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15867,-1,0.000206671,0.99979335
15868,focal nodular hyperplasia,3,6,21,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15868,-1,0.00020537041,0.99979466
15870,adenoma,4,5,21,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15870,-1,0.00017258374,0.9998274
15871,focal nodular hyperplasia,8,11,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15871,-1,0.00016877292,0.9998312
15873,adenoma,7,8,65,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15873,-1,0.00020474844,0.99979526
15874,focal nodular hyperplasia,9,12,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15874,-1,0.00020326664,0.9997968
15875,neurofilament proteins,5,7,47,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15875,-1,0.95815665,0.041843336
15876,axonal damage,8,10,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15876,-1,0.00020486387,0.99979514
15877,neurofilament,5,6,56,69,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15877,-1,0.87301415,0.12698586
15878,axonal injury,26,28,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15878,-1,0.00021927075,0.9997807
15879,injury in the cortex,1,5,6,26,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15879,-1,0.00037509727,0.99962485
15880,lactate,10,11,55,62,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15880,-1,0.99934393,0.0006561008
15881,Infarcts,0,1,0,8,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15881,-1,0.00023145857,0.99976856
15882,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15882,-1,0.0002031897,0.9997968
15883,axonal damage,11,13,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15883,-1,0.0002028229,0.99979717
15884,traumatic,16,17,105,114,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15884,-1,0.00020414377,0.99979585
15885,ischemic lesions,18,20,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15885,-1,0.00020279987,0.99979717
15888,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,-1,15888,-1,0.9994242,0.0005757616
15893,neuronal degeneration,9,11,71,92,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15893,-1,0.000203046,0.9997969
15894,glial fibrillary acidic protein,17,21,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15894,-1,0.6976841,0.30231583
15895,neuronal loss,36,38,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15895,-1,0.00020429274,0.99979573
15896,GABA,12,13,89,93,Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.,8410199_9,-1,-1,-1,15896,-1,0.99886286,0.0011371045
15897,confusion.15,9,10,83,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,-1,15897,-1,0.013181784,0.9868182
15900,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15900,-1,0.00020159074,0.9997985
15901,P,10,11,55,56,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15901,-1,0.12041181,0.8795882
15903,P,27,28,150,151,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15903,-1,0.45445314,0.5455469
15908,hepatic dysfunction,17,19,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,-1,-1,15908,-1,0.00021397363,0.9997861
15911,gallstone,16,17,107,116,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15911,-1,0.00537871,0.9946213
15912,acromegalic,20,21,138,149,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15912,-1,0.0021173751,0.99788254
15913,acromegaly,17,18,120,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,-1,15913,-1,0.00087136024,0.99912864
15916,gallstones,12,13,71,81,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15916,-1,0.0026586093,0.99734145
15917,cholecystitis,18,19,105,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15917,-1,0.00022659355,0.99977344
15920,gallstones,8,9,54,64,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,-1,-1,-1,15920,-1,0.998889,0.0011109462
15921,gallstones,9,10,48,58,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,-1,-1,15921,-1,0.0029688382,0.9970311
15923,gallstones,20,21,127,137,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15923,-1,0.00022467971,0.99977535
15924,cholecystitis,23,24,143,156,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15924,-1,0.00021310485,0.9997869
15926,acromegalic,29,30,194,205,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15926,-1,0.002710267,0.9972898
15928,acromegalic,17,18,116,127,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,-1,-1,-1,15928,-1,0.00021951235,0.9997805
15929,Parkinson,2,3,12,21,Increase of Parkinson disability after fluoxetine medication.,8423889_0,-1,-1,-1,15929,-1,0.0001974663,0.99980253
15932,Parkinson's disease,7,10,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,-1,-1,15932,-1,0.0004611898,0.9995388
15934,idiopathic Parkinson's disease,12,16,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15934,-1,0.0001638075,0.9998362
15935,antidepressant fluoxetine,20,22,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15935,-1,0.9994461,0.00055384974
15937,Parkinson's disease,11,14,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,-1,-1,-1,15937,-1,0.00023974763,0.9997602
15950,anxiety,37,38,214,221,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,-1,15950,-1,0.00026806057,0.99973196
15955,Sinus arrest,0,2,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,-1,15955,-1,0.0001852669,0.9998148
15958,bradyarrhythmias,15,16,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,-1,15958,-1,0.00020908454,0.99979097
15959,leukemia,4,5,23,31,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15959,-1,0.00020152153,0.9997985
15960,cardiac disease,9,11,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15960,-1,0.00019827322,0.9998017
15961,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15961,-1,0.00020166283,0.99979836
15966,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,-1,15966,-1,0.00018786995,0.9998122
15969,erosive rheumatoid arthritis,12,15,78,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15969,-1,0.0001965215,0.9998035
15970,RA,16,17,108,110,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15970,-1,0.00019737182,0.99980265
15972,gold,12,13,65,69,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,-1,-1,15972,-1,0.9994198,0.00058022444
15973,RA,26,27,140,142,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,-1,15973,-1,0.005753014,0.99424696
15974,RA,6,7,40,42,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,-1,15974,-1,0.00019646945,0.9998036
15975,synovitis,20,21,129,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,-1,-1,-1,15975,-1,0.00020633293,0.9997937
15978,fluvoxamine,6,7,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15978,-1,0.99949443,0.0005055276
15979,phenothiazines,8,9,53,67,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15979,-1,0.99949145,0.0005084707
15980,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,-1,-1,15980,-1,0.9994802,0.00051978324
15982,Pentamidine isethionate,0,2,0,23,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15982,-1,0.99914193,0.000858083
15983,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15983,-1,0.00020031272,0.99979967
15984,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15984,-1,0.00023646407,0.99976355
15985,torsade de pointes,1,4,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15985,-1,0.00040973927,0.9995902
15987,hypomagnesemia,12,13,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15987,-1,0.00022175885,0.9997782
15988,Torsade de pointes,0,3,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15988,-1,0.00042886307,0.99957114
15989,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15989,-1,0.9994485,0.0005514798
15990,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,-1,-1,15990,-1,0.99946433,0.0005356942
15991,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15991,-1,0.0061958726,0.9938041
15992,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15992,-1,0.9994293,0.00057063426
15993,QTc interval prolongation,1,4,5,30,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,-1,-1,-1,15993,-1,0.00038341508,0.9996165
16001,mg,40,41,234,236,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,16001,-1,0.99916315,0.0008369058
16002,mg,48,49,261,263,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,16002,-1,0.9988317,0.0011683617
16003,n,4,5,17,18,PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers.,8480959_4,-1,-1,-1,16003,-1,0.1508661,0.84913385
16005,triglycerides,20,21,111,124,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,-1,16005,-1,0.999032,0.00096802716
16007,P,23,24,108,109,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,16007,-1,0.2580769,0.74192303
16009,triglycerides,39,40,166,179,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,16009,-1,0.99934584,0.0006541892
16014,symptoms,5,6,28,36,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16014,-1,0.00020050324,0.99979955
16015,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16015,-1,0.9994585,0.00054154324
16017,mg,34,35,200,202,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16017,-1,0.9989986,0.0010014285
16025,hypokalemia,3,4,21,32,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,16025,-1,0.00021089733,0.99978906
16027,hypomagnesemia,7,8,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,16027,-1,0.00021526217,0.99978477
16028,hypokalemia,2,3,13,24,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16028,-1,0.0005801998,0.9994198
16029,muscle weakness,5,7,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16029,-1,0.00020685275,0.9997931
16030,hypomagnesemia,9,10,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16030,-1,0.00020833928,0.9997917
16031,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16031,-1,0.00020594652,0.99979407
16035,diuretic,1,2,14,22,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16035,-1,0.99896896,0.0010310832
16036,obese,16,17,101,106,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16036,-1,0.00020328115,0.9997967
16037,edematous,18,19,110,119,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16037,-1,0.00020468581,0.9997954
16038,hypokalemia,1,2,12,23,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,-1,16038,-1,0.00039603966,0.9996039
16046,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,-1,-1,16046,-1,0.00018671702,0.99981326
16049,Allergic interstitial nephritis,0,3,0,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,-1,16049,-1,0.0001948436,0.99980515
16050,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,-1,16050,-1,0.00021284554,0.99978715
16059,p,25,26,123,124,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16059,-1,0.039522648,0.9604773
16062,p,36,37,148,149,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,-1,-1,-1,16062,-1,0.09825313,0.9017469
16066,p,35,36,148,149,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,-1,-1,16066,-1,0.051494688,0.94850534
16067,Swelling,0,1,0,8,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,-1,16067,-1,0.00022721186,0.99977285
16075,uremia,14,15,83,89,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16075,-1,0.00020601132,0.99979395
16076,se,16,17,94,96,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16076,-1,0.99891126,0.0010887266
16078,macrolide,13,14,92,101,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16078,-1,0.99947804,0.0005220026
16079,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16079,-1,0.9994987,0.0005012476
16080,renal disease,10,12,52,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16080,-1,0.00019706156,0.999803
16081,ESRD,13,14,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16081,-1,0.0002793542,0.99972063
16082,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16082,-1,0.9994665,0.0005335306
16084,aluminum,23,24,145,153,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16084,-1,0.99942577,0.0005742835
16087,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,-1,16087,-1,0.0002317719,0.9997682
16088,preneoplastic,4,5,26,39,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16088,-1,0.009180194,0.99081975
16089,hepatoma,7,8,50,58,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16089,-1,0.00017244292,0.9998275
16090,hepatomas,2,3,15,24,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16090,-1,0.0001927686,0.9998073
16091,liver lesions,6,8,56,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16091,-1,0.00019450596,0.9998055
16092,hepatomas,4,5,21,30,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,-1,16092,-1,0.00021518215,0.9997849
16095,hepatomas,17,18,96,105,"These cells proliferated further, replacing the most part of the nodules, and with this process hepatomas appeared to have been formed.",85485_6,-1,-1,-1,16095,-1,0.00020538118,0.99979466
16097,squamous cell esophageal carcinoma,7,11,44,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,-1,16097,-1,0.00022060152,0.9997794
16101,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16101,-1,0.9994337,0.00056624797
16102,squamous cell esophageal carcinoma,36,40,230,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16102,-1,0.00018580363,0.9998142
16104,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,-1,16104,-1,0.98797673,0.012023268
16105,CR,16,17,73,75,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,-1,16105,-1,0.0002447734,0.9997552
16106,DI,4,5,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,-1,-1,-1,16106,-1,0.40154997,0.59845
16107,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,-1,16107,-1,0.90458816,0.095411815
16109,granulocytopenia,9,10,37,53,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,-1,-1,16109,-1,0.00017047489,0.99982953
16112,peripheral neurotoxicity,7,9,34,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,-1,-1,16112,-1,0.00021812557,0.9997819
16113,VNB,6,7,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16113,-1,0.9974081,0.0025918568
16114,esophageal squamous cell carcinoma,13,17,74,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16114,-1,0.00019865794,0.99980134
16116,VNB,12,13,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,-1,-1,16116,-1,0.72556,0.27444
16120,sodium chloride,30,32,202,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,-1,16120,-1,0.9994748,0.00052517216
16122,sodium chloride,25,27,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16122,-1,0.99948263,0.0005173521
16123,sodium chloride,33,35,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16123,-1,0.99948406,0.000515907
16127,in MAP,12,14,89,95,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16127,-1,0.18183358,0.81816643
16129,increase in MAP,20,23,148,163,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16129,-1,0.11447264,0.8855274
16130,central nervous system alpha2-adrenergic receptor agonist clonidine,3,10,16,83,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16130,-1,0.96407187,0.035928175
16131,reduction in MAP,15,18,111,127,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16131,-1,0.00019786625,0.9998022
16132,sodium chloride,34,36,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16132,-1,0.99947864,0.00052144594
16133,sodium chloride,22,24,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,-1,16133,-1,0.9994764,0.0005236277
16134,aponidine hydrochloride,5,7,35,58,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,-1,-1,16134,-1,0.9994844,0.0005155069
16135,apraclonidine,7,8,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16135,-1,0.9994823,0.00051768287
16136,apraclonidine,20,21,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16136,-1,0.99947983,0.00052016164
16137,ocular hypotensive,1,3,4,22,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16137,-1,0.000223136,0.9997769
16138,apraclonidine,29,30,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16138,-1,0.9994968,0.0005031202
16139,Decreases in systolic blood pressure,0,5,0,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,-1,-1,-1,16139,-1,0.0002161587,0.9997838
16140,Conjunctival blanching,0,2,0,22,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16140,-1,0.00029391175,0.9997061
16141,mydriasis,3,4,27,36,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16141,-1,0.00022211054,0.99977785
16142,lid,1,2,6,9,Upper lid retraction was frequently noted.,8590259_7,-1,-1,-1,16142,-1,0.87187266,0.12812735
16143,lid,6,7,34,37,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16143,-1,0.00034528153,0.99965477
16144,mm,16,17,83,85,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16144,-1,0.19338194,0.80661803
16145,entropion,31,32,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16145,-1,0.00024107759,0.9997589
16146,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16146,-1,0.00021515426,0.9997849
16153,C,3,4,18,19,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16153,-1,0.43755224,0.5624478
16155,mg,21,22,81,83,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16155,-1,0.34956336,0.6504366
16157,mg,34,35,124,126,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16157,-1,0.7802387,0.2197613
16159,Loss of consciousness,0,3,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16159,-1,0.00019823316,0.9998018
16160,SD,16,17,78,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16160,-1,0.0017931748,0.99820685
16161,C,42,43,170,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16161,-1,0.99134266,0.008657313
16162,P,50,51,187,188,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16162,-1,0.22665027,0.7733497
16163,P,14,15,64,65,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16163,-1,0.07533849,0.9246615
16164,C,21,22,88,89,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16164,-1,0.99442697,0.0055730236
16166,P,24,25,121,122,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,-1,16166,-1,0.2686395,0.7313605
16167,C,7,8,44,45,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,-1,16167,-1,0.46348268,0.5365173
16174,droperidol,3,4,27,37,Angioedema associated with droperidol administration.,8599504_0,-1,-1,-1,16174,-1,0.9994723,0.0005277052
16176,angioneurotic edema,5,7,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16176,-1,0.00020138093,0.9997986
16177,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16177,-1,0.0102687515,0.98973125
16179,drug allergies,13,15,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16179,-1,0.0029624177,0.99703765
16181,swelling,21,22,131,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16181,-1,0.00019684463,0.9998031
16182,droperidol,37,38,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16182,-1,0.99947745,0.000522528
16184,bone tumor,7,9,52,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,-1,-1,16184,-1,0.000211615,0.99978834
16185,bone tumors,9,11,66,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16185,-1,0.0001826473,0.99981743
16186,Rosen's T5,16,19,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16186,-1,0.84330237,0.1566976
16187,T10,20,21,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16187,-1,0.99927074,0.00072922977
16192,ventricular dilation,31,33,172,192,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,-1,-1,16192,-1,0.00022736331,0.9997726
16193,cardiac abnormalities,3,5,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16193,-1,0.0001988046,0.9998012
16194,P,11,12,75,76,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16194,-1,0.0721263,0.9278737
16204,n,4,5,29,30,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16204,-1,0.6284909,0.37150908
16205,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16205,-1,0.0037909085,0.99620914
16206,mm Hg,30,32,144,149,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16206,-1,0.0049742716,0.9950257
16207,n,3,4,19,20,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16207,-1,0.2146247,0.7853753
16209,mm Hg,19,21,102,107,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16209,-1,0.0005823727,0.99941766
16211,mm Hg,23,25,120,125,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16211,-1,0.0041962345,0.9958038
16212,p,26,27,127,128,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16212,-1,0.34165075,0.6583492
16217,hypertensives,34,35,219,232,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,-1,16217,-1,0.00020773945,0.9997923
16219,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,-1,-1,16219,-1,0.0002194023,0.9997806
16221,cognitive impairment,9,11,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,-1,16221,-1,0.00020825845,0.9997918
16227,mg,12,13,65,67,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,-1,16227,-1,0.9652416,0.03475834
16230,Impairment of cognitive function,2,6,9,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,-1,16230,-1,0.00022320855,0.9997768
16238,cognitive impairment,8,10,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,-1,-1,-1,16238,-1,0.00021634427,0.9997837
16241,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,-1,-1,16241,-1,0.9994493,0.0005506374
16243,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16243,-1,0.8149935,0.18500653
16244,NMBAs,4,5,31,36,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16244,-1,0.99942183,0.00057817687
16246,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,-1,-1,16246,-1,0.999479,0.0005210494
16248,Atracurium besylate,0,2,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16248,-1,0.99949336,0.00050657825
16249,benzylisoquinolinium NMBA,5,7,36,61,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16249,-1,0.9994824,0.0005175748
16254,carotid artery thrombosis,7,10,50,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16254,-1,0.00016734243,0.99983263
16258,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16258,-1,0.00020555592,0.9997944
16262,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16262,-1,0.00021685954,0.9997831
16263,DM,3,4,19,21,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16263,-1,0.20644708,0.7935529
16264,hemorrhagic infarct,4,6,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,-1,-1,16264,-1,0.00020306419,0.9997969
16265,occlusion of the,4,7,31,47,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,-1,-1,16265,-1,0.0052615833,0.9947384
16266,carotid artery,9,11,62,76,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,-1,-1,16266,-1,0.00020485683,0.99979514
16267,venous sinus thrombosis,15,18,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,-1,-1,16267,-1,0.00020971945,0.99979025
16270,DM,17,18,98,100,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,-1,-1,16270,-1,0.9993437,0.00065631344
16272,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,-1,-1,16272,-1,0.0001937585,0.9998062
16275,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16275,-1,0.9994912,0.0005087864
16276,antineoplastic,15,16,93,107,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16276,-1,0.00066682306,0.9993332
16280,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16280,-1,0.00022856245,0.9997714
16281,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16281,-1,0.00023683503,0.9997632
16286,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,-1,16286,-1,0.0002297837,0.9997702
16287,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,-1,16287,-1,0.00026864262,0.99973136
16289,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,-1,-1,16289,-1,0.0002232209,0.9997768
16290,Hematologic toxicities,0,2,0,22,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,-1,-1,16290,-1,0.00021760541,0.9997824
16299,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,-1,16299,-1,0.00020948882,0.9997905
16303,head and neck cancers,12,16,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,-1,16303,-1,0.00022692521,0.9997731
16304,head and neck carcinomas,5,9,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,-1,16304,-1,0.00023578464,0.99976426
16306,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16306,-1,0.9994784,0.00052165816
16307,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16307,-1,0.0006977684,0.99930227
16312,head and neck carcinoma,32,36,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,-1,16312,-1,0.00023630043,0.99976367
16320,factor,11,12,78,84,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,-1,-1,-1,16320,-1,0.98362154,0.016378472
16321,Alopecia,0,1,0,8,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16321,-1,0.0027327633,0.99726725
16322,paresthesias,2,3,10,22,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16322,-1,0.000214755,0.99978524
16324,hematologic toxicity,2,4,17,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,-1,-1,16324,-1,0.00021761538,0.9997824
16325,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,-1,16325,-1,0.00023096606,0.99976903
16331,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,-1,16331,-1,0.99948704,0.00051298575
16341,granulocytopenia,11,12,80,96,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,-1,-1,16341,-1,0.00021212104,0.99978787
16344,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,-1,-1,16344,-1,0.00020974866,0.99979025
16351,Parkinson's disease,7,10,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,-1,-1,16351,-1,0.0002183278,0.99978167
16352,Parkinson's disease,4,7,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16352,-1,0.00020724525,0.99979275
16353,PD,8,9,51,53,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16353,-1,0.00020694413,0.9997931
16361,PD,18,19,135,137,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,-1,16361,-1,0.00023658497,0.9997634
16366,C,15,16,85,86,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16366,-1,0.9982767,0.0017232674
16368,triamcinolone,24,25,116,129,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16368,-1,0.9994968,0.00050317607
16369,reduction of food,45,48,225,242,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16369,-1,0.035547536,0.9644525
16370,loss in body weight,6,10,35,54,This was associated with a similar loss in body weight.,8665051_4,-1,-1,-1,16370,-1,0.00048247617,0.99951756
16372,C,9,10,52,53,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16372,-1,0.9991579,0.00084209366
16373,NS,48,49,172,174,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16373,-1,0.022472354,0.9775277
16375,tetanic,20,21,111,118,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,-1,16375,-1,0.00027066618,0.99972934
16377,p,22,23,130,131,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,-1,16377,-1,0.13318413,0.86681587
16382,C,14,15,54,55,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16382,-1,0.9910102,0.008989808
16383,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16383,-1,0.0002149502,0.999785
16388,muscle necrosis,50,52,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16388,-1,0.00020851177,0.99979156
16395,renal disease,26,28,173,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16395,-1,0.00021326829,0.9997868
16396,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16396,-1,0.0002238428,0.9997762
16400,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,-1,16400,-1,0.000391392,0.9996086
16403,ESRD,14,15,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,-1,-1,-1,16403,-1,0.00018453808,0.9998155
16409,ESRD,12,13,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,-1,-1,-1,16409,-1,0.00022898868,0.99977106
16411,hemorrhagic cystitis,8,10,78,98,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,-1,16411,-1,0.000220231,0.99977976
16412,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,-1,-1,16412,-1,0.0001874382,0.99981254
16420,emesis,34,35,223,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,-1,16420,-1,0.0002353202,0.99976474
16426,cardiovascular toxicities,6,8,43,68,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,-1,-1,-1,16426,-1,0.00020241199,0.99979764
16430,critically ill,4,6,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,-1,-1,16430,-1,0.000272315,0.99972767
16437,Leg and back pain,0,4,0,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,-1,-1,16437,-1,0.00030535538,0.9996947
16442,p,6,7,36,37,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16442,-1,0.40120053,0.59879947
16443,p,20,21,93,94,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16443,-1,0.30624366,0.6937564
16448,Leg and/or back pain,0,4,0,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,-1,16448,-1,0.0003181251,0.99968195
16453,cuprolinic blue,33,35,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,-1,16453,-1,0.99949837,0.0005015841
16454,heparan sulphate,1,3,4,20,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16454,-1,0.9994925,0.0005074989
16455,cuprolinic blue,6,8,40,55,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16455,-1,0.99949527,0.0005047724
16457,p<0.001,33,34,202,209,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,-1,16457,-1,0.22279255,0.77720743
16461,h,13,14,82,83,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16461,-1,0.07483747,0.92516255
16462,contrast,18,19,102,110,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16462,-1,0.00628183,0.99371815
16463,h,31,32,155,156,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16463,-1,0.15528563,0.8447144
16464,p<0.002,33,34,158,165,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16464,-1,0.055843506,0.9441565
16465,heparan sulphate,8,10,32,48,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16465,-1,0.9993974,0.0006026533
16466,heparan sulphate,15,17,104,120,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,-1,16466,-1,0.9994779,0.0005220501
16469,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,-1,16469,-1,0.9995043,0.0004956167
16473,FLA-63,0,1,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,-1,-1,16473,-1,0.99944514,0.0005548436
16476,Pimozide,0,1,0,8,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,-1,-1,-1,16476,-1,0.99948955,0.000510461
16480,5-HTP,0,1,0,5,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,-1,-1,16480,-1,0.9994856,0.00051431917
16486,Microangiopathic hemolytic anemia,0,3,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16486,-1,0.00021032941,0.99978966
16487,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16487,-1,0.99947625,0.0005237375
16489,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16489,-1,0.00021372263,0.9997863
16490,MAHA,9,10,61,65,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16490,-1,0.00028143774,0.9997185
16491,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16491,-1,0.9994772,0.00052284665
16493,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16493,-1,0.9994898,0.0005101923
16497,MAHA,28,29,173,177,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16497,-1,0.007599735,0.9924003
16498,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16498,-1,0.9994554,0.0005446507
16499,MAHA,12,13,67,71,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16499,-1,0.002833626,0.99716634
16500,MAHA,1,2,17,21,FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.,8701950_4,-1,-1,-1,16500,-1,0.00053234096,0.9994677
16501,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16501,-1,0.99945945,0.0005405147
16502,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16502,-1,0.9994491,0.0005509604
16503,CyA,19,20,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16503,-1,0.99944013,0.0005598505
16504,MAHA,29,30,163,167,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16504,-1,0.007027853,0.99297214
16505,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,-1,16505,-1,0.009137585,0.9908625
16509,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,-1,16509,-1,0.0059382874,0.99406165
16510,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,-1,16510,-1,0.999493,0.0005069898
16512,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,-1,16512,-1,0.99946886,0.0005311435
16513,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16513,-1,0.9994795,0.00052059273
16514,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16514,-1,0.9994836,0.0005163828
16515,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16515,-1,0.9994821,0.00051792816
16516,deoxycholate,4,5,22,34,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16516,-1,0.99948657,0.0005133739
16517,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16517,-1,0.9994758,0.00052429124
16518,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16518,-1,0.9994875,0.0005124205
16519,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16519,-1,0.99949324,0.0005067383
16520,Ethinyl estradiol,0,2,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16520,-1,0.99947685,0.0005231729
16521,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16521,-1,0.9994797,0.0005203003
16522,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16522,-1,0.99948186,0.0005182309
16523,P,32,33,182,183,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16523,-1,0.20214051,0.79785943
16524,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,-1,16524,-1,0.9994708,0.00052930316
16525,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16525,-1,0.9994831,0.0005168129
16526,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16526,-1,0.9994842,0.0005158102
16527,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16527,-1,0.9994661,0.00053387013
16528,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16528,-1,0.99946445,0.0005355454
16529,anticancer drugs,3,5,15,31,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,-1,-1,-1,16529,-1,0.9993973,0.000602682
16532,anticancer drugs,4,6,26,42,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16532,-1,0.999448,0.00055195676
16533,nitrogranulogen,8,9,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16533,-1,0.99941003,0.00058994745
16534,NG,10,11,68,70,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16534,-1,0.06769268,0.93230736
16536,MTX,15,16,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16536,-1,0.9994436,0.00055642077
16538,5-FU,20,21,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16538,-1,0.9994784,0.00052163453
16540,CY,25,26,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16540,-1,0.99942136,0.00057869236
16541,MTX,33,34,179,182,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16541,-1,0.99945325,0.0005466999
16542,5-FU,35,36,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16542,-1,0.9994703,0.00052966847
16543,CY,37,38,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16543,-1,0.99943334,0.0005666337
16546,MTX,1,2,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16546,-1,0.99933136,0.00066861627
16547,p,7,8,49,50,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16547,-1,0.06806018,0.9319398
16549,p,20,21,119,120,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16549,-1,0.125668,0.874332
16551,NG,4,5,28,30,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16551,-1,0.53878313,0.4612168
16552,5-FU,6,7,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16552,-1,0.99943596,0.0005639685
16553,CY,8,9,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16553,-1,0.99936646,0.0006335942
16556,CMF,5,6,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16556,-1,0.99664813,0.0033519047
16557,p,13,14,90,91,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16557,-1,0.026767261,0.9732327
16560,CY,0,1,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16560,-1,0.99944144,0.0005585598
16561,hemorrhagic cystitis,2,4,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16561,-1,0.00020347296,0.99979657
16562,5-FU,20,21,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16562,-1,0.99946827,0.00053180027
16563,MTX,22,23,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16563,-1,0.99944574,0.00055430346
16564,MTX,10,11,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16564,-1,0.9994286,0.0005714238
16565,CY,12,13,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16565,-1,0.9993988,0.0006011096
16566,NG,14,15,81,83,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16566,-1,0.00027810544,0.9997218
16567,5-FU,23,24,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16567,-1,0.9994562,0.0005437891
16568,MTX,28,29,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16568,-1,0.999426,0.0005739994
16569,5-FU,30,31,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16569,-1,0.9994497,0.0005503104
16570,CY,32,33,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16570,-1,0.999326,0.00067406136
16572,MTX,6,7,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16572,-1,0.99945456,0.00054544216
16573,5-FU,8,9,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16573,-1,0.9994717,0.00052826357
16574,CY,10,11,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16574,-1,0.9994148,0.00058520294
16576,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,-1,16576,-1,0.9994485,0.00055154134
16577,p,8,9,61,62,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16577,-1,0.3955819,0.60441816
16578,locomotor hypoactivity,21,23,110,132,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16578,-1,0.00020609188,0.99979395
16580,mg,28,29,157,159,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16580,-1,0.99934334,0.0006567017
16583,p,15,16,120,121,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,-1,16583,-1,0.18810315,0.8118968
16586,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,-1,16586,-1,0.008409156,0.99159086
16587,nicotinic acid amide,8,11,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,-1,-1,16587,-1,0.99946123,0.0005387605
16590,NAD,13,14,75,78,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16590,-1,0.9992974,0.0007026112
16591,AAP,27,28,139,142,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16591,-1,0.9992581,0.0007418398
16594,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,-1,16594,-1,0.00025324087,0.99974674
16595,AAP,1,2,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16595,-1,0.99945885,0.0005411026
16597,nicotinic acid amide,28,31,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16597,-1,0.99946886,0.00053118553
16598,NAA,32,33,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16598,-1,0.9994716,0.0005284149
16599,NAD,48,49,278,281,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16599,-1,0.9994425,0.0005574458
16600,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,-1,16600,-1,0.99941504,0.0005849375
16605,NAA,11,12,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,-1,-1,16605,-1,0.99943286,0.0005671089
16608,NAA,23,24,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16608,-1,0.99942243,0.00057754735
16609,NAD,33,34,205,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16609,-1,0.9993924,0.0006076394
16610,NAA,6,7,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,-1,16610,-1,0.9994273,0.0005727027
16613,cognitive and functional deficits,1,5,19,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16613,-1,0.00021816259,0.9997819
16614,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16614,-1,0.99948114,0.0005188635
16616,bipolar disorder,14,16,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,-1,16616,-1,0.00019800253,0.99980205
16622,loss of creativity,33,36,189,207,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16622,-1,0.00022397816,0.99977607
16623,functional impairments,38,40,213,235,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16623,-1,0.0026823834,0.9973176
16626,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16626,-1,0.99948055,0.0005194663
16627,cognitive and functional impairments,17,21,120,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16627,-1,0.00022312258,0.9997769
16629,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16629,-1,0.999474,0.000526068
16630,"cognitive, motivational, or creative deficits",25,32,150,195,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16630,-1,0.00028303883,0.99971694
16633,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16633,-1,0.9994831,0.00051681465
16637,loss of creativity,22,25,149,167,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16637,-1,0.0002328677,0.9997671
16638,functional impairments,27,29,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16638,-1,0.00029946186,0.99970055
16640,tramadol,7,8,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,-1,-1,16640,-1,0.99946994,0.00053002813
16642,Tramadol,0,1,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16642,-1,0.9994837,0.00051626714
16643,cancer pain,17,19,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16643,-1,0.00022911713,0.99977094
16644,malignant pain,22,24,138,152,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16644,-1,0.0002193889,0.9997806
16646,dosulepine hydrochloride,9,11,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16646,-1,0.9995115,0.00048856245
16647,tetraparetic,13,14,89,101,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16647,-1,0.00021427905,0.9997857
16648,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16648,-1,0.00020848375,0.99979156
16650,tramadol,21,22,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,-1,-1,16650,-1,0.9994764,0.00052366464
16654,calcium chloride,2,4,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16654,-1,0.9994758,0.0005242417
16655,4-aminopyridine,5,6,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16655,-1,0.9994923,0.00050770503
16656,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16656,-1,0.016164683,0.98383534
16658,antidepressant overdose,11,13,73,96,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,-1,-1,16658,-1,0.0029872921,0.99701273
16665,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16665,-1,0.99946994,0.00053007813
16666,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16666,-1,0.999491,0.0005090461
16667,antidepressant desipramine,5,7,41,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,-1,16667,-1,0.99947244,0.00052756694
16670,CaCl2,6,7,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16670,-1,0.9994337,0.0005662793
16671,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16671,-1,0.9994406,0.00055941736
16672,antidepressant desipramine,8,10,48,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16672,-1,0.99948406,0.00051591295
16673,4-aminopyridine,16,17,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16673,-1,0.999511,0.00048896304
16674,NaHCO3,2,3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,-1,16674,-1,0.9994448,0.00055524043
16676,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16676,-1,0.9994887,0.0005112092
16677,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16677,-1,0.9994986,0.0005014304
16679,p,6,7,42,43,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16679,-1,0.05113399,0.94886595
16681,p,13,14,67,68,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16681,-1,0.036433328,0.96356666
16682,CaCl2,19,20,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16682,-1,0.99946433,0.00053563755
16683,CaCl2,5,6,34,39,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16683,-1,0.9994821,0.0005179198
16684,4-aminopyridine,7,8,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16684,-1,0.9994911,0.00050893234
16686,CaCl2,0,1,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16686,-1,0.99944323,0.00055674865
16687,central nervous system toxicity,8,12,58,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16687,-1,0.00021632778,0.9997837
16706,comatose,5,6,32,40,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16706,-1,0.8091645,0.19083546
16707,stuporous,7,8,44,53,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16707,-1,0.00020161261,0.99979836
16708,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16708,-1,0.0002001222,0.9997999
16709,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16709,-1,0.999483,0.0005169614
16710,alcohol withdrawal symptoms,8,11,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16710,-1,0.002955006,0.997045
16712,nitrazepam,19,20,123,133,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16712,-1,0.9994918,0.0005082062
16713,nitrazepam overdose,3,5,17,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16713,-1,0.0053462144,0.9946538
16714,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16714,-1,0.9994666,0.0005333603
16716,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,-1,16716,-1,0.99944896,0.0005510944
16717,neurological sequelae,5,7,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,-1,-1,-1,16717,-1,0.00022942181,0.9997706
16720,hypoxaemia,21,22,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,-1,16720,-1,0.00019351499,0.99980646
16721,Valsartan,0,1,0,9,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16721,-1,0.99947864,0.0005214407
16722,angiotensin II antagonist,4,7,17,42,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16722,-1,0.99946254,0.00053748896
16723,essential hypertension,11,13,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16723,-1,0.0001767984,0.9998233
16724,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16724,-1,0.99948835,0.0005116038
16725,angiotensin II antagonist,10,13,61,86,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16725,-1,0.9994511,0.0005489086
16726,valsartan,14,15,88,97,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16726,-1,0.99948335,0.0005166558
16727,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16727,-1,0.99949014,0.00050977955
16729,mg valsartan,24,26,165,177,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16729,-1,0.99949515,0.00050484214
16730,mg amlodipine,28,30,183,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16730,-1,0.99948174,0.0005183255
16731,mg amlodipine,15,17,84,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,-1,-1,-1,16731,-1,0.9994253,0.00057474565
16732,valsartan,3,4,14,23,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16732,-1,0.99947685,0.0005232066
16733,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16733,-1,0.9994837,0.00051621295
16734,mm Hg,8,10,48,53,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16734,-1,0.0013160777,0.99868387
16735,valsartan,13,14,66,75,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16735,-1,0.9994254,0.0005745863
16736,p,15,16,77,78,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16736,-1,0.02709643,0.97290355
16737,valsartan,9,10,42,51,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16737,-1,0.9994773,0.0005226912
16738,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16738,-1,0.99948955,0.0005104895
16739,p,16,17,78,79,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16739,-1,0.38959196,0.610408
16741,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16741,-1,0.9995177,0.0004822775
16742,mg,20,21,120,122,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16742,-1,0.9994338,0.00056620373
16743,mg valsartan,28,30,144,156,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16743,-1,0.999456,0.0005439635
16744,mg amlodipine,35,37,169,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16744,-1,0.9994917,0.0005083077
16745,valsartan,41,42,191,200,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16745,-1,0.9995183,0.00048172276
16746,mg amlodipine,44,46,208,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16746,-1,0.9994511,0.0005488453
16747,mg amlodipine,51,53,236,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16747,-1,0.9994962,0.00050375215
16748,valsartan,6,7,32,41,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16748,-1,0.99947673,0.0005232729
16749,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16749,-1,0.99947315,0.0005269121
16751,valsartan,4,5,22,31,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16751,-1,0.9994747,0.0005252876
16752,dihydropyridine calcium antagonists,25,28,150,185,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16752,-1,0.9994741,0.0005258953
16753,pupillary oscillation,3,5,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16753,-1,0.00020817982,0.9997918
16754,paranoia,10,11,66,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16754,-1,0.00021173913,0.9997882
16755,paranoia,1,2,16,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16755,-1,0.0002224013,0.9997776
16756,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16756,-1,0.015701033,0.98429894
16757,paranoia,12,13,85,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16757,-1,0.00021333357,0.9997867
16758,pupillary oscillation,2,4,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16758,-1,0.0001744254,0.99982566
16759,crack cocaine,13,15,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16759,-1,0.9894196,0.010580438
16760,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16760,-1,0.9983931,0.0016068156
16761,n,20,21,136,137,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16761,-1,0.9898281,0.010171856
16762,crack,28,29,166,171,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16762,-1,0.9963881,0.0036119302
16763,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16763,-1,0.9985316,0.0014684106
16764,n,35,36,201,202,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16764,-1,0.936774,0.06322595
16766,phenytoin overdosages,10,12,75,96,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,-1,16766,-1,0.0059392783,0.9940607
16768,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,-1,-1,16768,-1,0.00020873777,0.9997913
16772,phenytoin overdosage,3,5,17,37,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16772,-1,0.0058700917,0.9941299
16773,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16773,-1,0.00020172837,0.99979824
16775,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16775,-1,0.0002020071,0.999798
16776,cerebellar disorders,13,15,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,-1,16776,-1,0.00018186147,0.99981815
16777,Serotonin syndrome,0,2,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,-1,16777,-1,0.006067219,0.9939328
16780,shivering,15,16,106,115,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16780,-1,0.00021575966,0.9997843
16781,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16781,-1,0.00021267758,0.9997874
16782,salivation,20,21,134,144,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16782,-1,0.00021683186,0.9997832
16786,monoamine oxidase,12,14,67,84,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,-1,-1,-1,16786,-1,0.99944,0.0005600202
16792,serotonin syndrome,9,11,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16792,-1,0.0017184681,0.9982816
16793,tranylcypromine,18,19,115,130,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16793,-1,0.99949825,0.0005016811
16798,shivering,17,18,90,99,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16798,-1,0.00022939165,0.9997706
16801,salivation,24,25,128,138,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16801,-1,0.00024568834,0.99975437
16802,diaphoresis,26,27,143,154,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16802,-1,0.009679719,0.99032027
16803,mm,4,5,18,20,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,-1,-1,-1,16803,-1,0.8245499,0.17545013
16804,mm Hg,7,9,40,45,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16804,-1,0.003553299,0.99644667
16805,mg,24,25,124,126,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16805,-1,0.9994282,0.0005717719
16807,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16807,-1,0.00021444606,0.9997856
16808,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16808,-1,0.00020329647,0.9997967
16809,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16809,-1,0.00020934347,0.9997907
16812,neuromuscular paralysis,11,13,74,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,-1,-1,-1,16812,-1,0.00020172051,0.99979836
16815,HUS,10,11,53,56,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,-1,16815,-1,0.0001769576,0.99982303
16820,HUS,6,7,42,45,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16820,-1,0.00020250928,0.9997975
16821,oliguria,18,19,115,123,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16821,-1,0.00020020656,0.9997998
16822,HUS,7,8,41,44,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16822,-1,0.00020976545,0.99979025
16824,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16824,-1,0.00020900002,0.99979097
16828,urothelial cancer,15,17,102,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,-1,-1,16828,-1,0.00018949939,0.9998105
16832,transitional cell carcinoma,9,12,38,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,-1,-1,16832,-1,0.00020801711,0.99979204
16835,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,-1,-1,16835,-1,0.00019940031,0.9998006
16836,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,-1,-1,16836,-1,0.0002065526,0.99979347
16838,valproate,11,12,96,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,-1,16838,-1,0.9994261,0.0005738654
16839,sodium valproate,7,9,61,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16839,-1,0.9994555,0.0005445422
16840,neurological disorders,40,42,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16840,-1,0.00021624139,0.9997838
16841,cerebellum damage,43,45,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16841,-1,0.00021740155,0.9997826
16842,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16842,-1,0.017492004,0.982508
16847,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,-1,16847,-1,0.017806407,0.9821936
16848,intracranial bleeding,1,3,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,-1,-1,16848,-1,0.00019773781,0.9998023
16851,pulmonary edema,23,25,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16851,-1,0.00019620996,0.99980384
16852,wheezing,26,27,147,155,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16852,-1,0.00020868919,0.9997913
16853,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,-1,-1,16853,-1,0.00018070612,0.99981934
16857,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,-1,-1,16857,-1,0.00022552685,0.9997745
16869,Hoe-140,24,25,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,-1,16869,-1,0.99930704,0.00069294905
16874,antipurine,7,8,32,42,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16874,-1,0.999483,0.00051697623
16875,lometrexol,9,10,54,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16875,-1,0.9994869,0.00051305734
16876,DDATHF,11,12,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16876,-1,0.99946016,0.00053982995
16877,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16877,-1,0.99948573,0.0005142449
16878,Lometrexol,0,1,0,10,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16878,-1,0.9994825,0.0005174535
16880,purine,19,20,129,135,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16880,-1,0.99947625,0.0005238129
16881,lometrexol,9,10,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16881,-1,0.9994893,0.0005107202
16882,tumours,13,14,97,104,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16882,-1,0.00021816135,0.9997819
16884,lometrexol,7,8,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,-1,-1,16884,-1,0.99946624,0.0005337315
16887,lometrexol,8,9,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16887,-1,0.9995092,0.0004908338
16888,folic acid,15,17,101,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16888,-1,0.99950814,0.0004919099
16889,lometrexol,9,10,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16889,-1,0.99952054,0.00047949835
16890,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16890,-1,0.9995167,0.0004832229
16892,lometrexol,22,23,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16892,-1,0.9995208,0.00047925182
16893,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16893,-1,0.9995178,0.00048219407
16898,folate,13,14,83,89,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,-1,-1,16898,-1,0.99929786,0.00070212263
16899,lometrexol,4,5,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16899,-1,0.9995098,0.0004901911
16900,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16900,-1,0.9995116,0.0004884183
16902,lometrexol,24,25,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16902,-1,0.99951315,0.00048689643
16906,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,-1,16906,-1,0.005269209,0.99473083
16909,EDDs,11,12,73,77,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,-1,-1,16909,-1,0.00018353206,0.9998165
16911,EDDs,19,20,90,94,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16911,-1,0.00019934747,0.9998006
16912,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16912,-1,0.0028590672,0.997141
16914,EDDs,4,5,24,28,"Compared with controls, EDDs were more frequently black, male, and younger.",8988571_3,-1,-1,-1,16914,-1,0.00020503036,0.999795
16917,EDDs,0,1,0,4,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,-1,-1,-1,16917,-1,0.97582346,0.024176495
16925,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,-1,16925,-1,0.0002254359,0.9997745
16927,preterm,7,8,46,53,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,-1,16927,-1,0.0001975424,0.99980253
16928,preterm infants,2,4,10,25,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16928,-1,0.0001990901,0.999801
16929,sensorineural,28,29,145,158,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16929,-1,0.0060651633,0.9939348
16931,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16931,-1,0.00019648705,0.9998035
16932,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,-1,-1,16932,-1,0.00020239288,0.99979764
16934,ototoxic,13,14,92,100,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,-1,16934,-1,0.00019375444,0.9998062
16937,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,-1,-1,16937,-1,0.00019872123,0.99980134
16938,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16938,-1,0.99943656,0.00056337804
16939,choreoathetosis,3,4,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16939,-1,0.001093697,0.99890625
16940,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16940,-1,0.9994848,0.0005152377
16941,oxazolidine,5,6,27,38,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16941,-1,0.9994684,0.00053166604
16942,amphetamines,12,13,86,98,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16942,-1,0.99948114,0.00051884766
16943,attention deficit disorder,19,22,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16943,-1,0.00020684193,0.99979323
16944,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16944,-1,0.9994647,0.0005353604
16945,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16945,-1,0.00019119873,0.99980885
16946,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16946,-1,0.9994894,0.0005106041
16947,choreoathetosis,13,14,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16947,-1,0.0011887375,0.99881124
16948,emergency department,14,16,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16948,-1,0.00021644084,0.9997836
16949,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16949,-1,0.9994684,0.0005315912
16950,attention deficit disorder,8,11,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,-1,16950,-1,0.0002011282,0.99979883
16952,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,-1,-1,-1,16952,-1,0.99943846,0.0005615588
16953,choreoathetoid movements,1,3,4,28,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16953,-1,0.002249574,0.99775046
16954,h,8,9,47,48,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16954,-1,0.06169899,0.938301
16955,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16955,-1,0.00021078515,0.9997892
16956,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16956,-1,0.00021047407,0.99978954
16958,choreoathetoid movements,17,19,130,154,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,-1,-1,-1,16958,-1,0.0017551507,0.9982449
16959,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,-1,16959,-1,0.0013463612,0.99865365
16960,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16960,-1,0.99946314,0.00053686835
16961,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16961,-1,0.00019328026,0.9998067
16962,choreoathetoid movements,3,5,19,43,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16962,-1,0.0017987936,0.99820113
16963,pemoline overdose,12,14,94,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16963,-1,0.005620218,0.9943798
16965,venlafaxine overdose,4,6,25,45,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,-1,-1,16965,-1,0.015001467,0.9849985
16966,venlafaxine overdose,7,9,31,51,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,-1,-1,-1,16966,-1,0.01606222,0.9839378
16973,venlafaxine overdose,13,15,65,85,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,-1,-1,16973,-1,0.014515035,0.985485
16976,venlafaxine overdose,3,5,17,37,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16976,-1,0.014899853,0.9851001
16977,generalized seizure,14,16,85,104,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16977,-1,0.00020934745,0.9997906
16978,elevated intraocular pressure,12,15,65,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16978,-1,0.00020921037,0.99979085
16979,corticosteroid,21,22,121,135,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16979,-1,0.9993808,0.0006192037
16980,IOP rise,3,5,30,38,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16980,-1,0.00020341107,0.99979657
16982,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,-1,-1,16982,-1,0.99941874,0.00058128807
16985,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16985,-1,0.99943775,0.00056223193
16988,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16988,-1,0.00025110584,0.9997489
16990,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16990,-1,0.01103072,0.9889693
16991,paracetamol overdose,14,16,76,96,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16991,-1,0.010713672,0.98928636
16992,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16992,-1,0.00045670013,0.9995433
16993,ALF,15,16,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16993,-1,0.00629138,0.9937086
16995,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16995,-1,0.9994247,0.0005753151
16996,ALF,6,7,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16996,-1,0.7854843,0.21451573
16997,ALF,13,14,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16997,-1,0.9944687,0.005531342
16998,P,24,25,174,175,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16998,-1,0.12040063,0.87959933
16999,P,12,13,72,73,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,-1,-1,-1,16999,-1,0.09376863,0.9062314
17001,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17001,-1,0.9994795,0.00052056165
17002,fMLP,11,12,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17002,-1,0.9994106,0.0005894158
17003,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17003,-1,0.018913604,0.98108643
17004,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,17004,-1,0.00065055786,0.9993494
17005,P,15,16,102,103,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,17005,-1,0.14326437,0.85673565
17006,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,17006,-1,0.00026048577,0.99973947
17007,paracetamol overdose,10,12,60,80,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,17007,-1,0.009649014,0.990351
17008,Cholesteryl hemisuccinate,0,2,0,25,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17008,-1,0.99947697,0.00052300014
17011,carbon tetrachloride,14,16,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17011,-1,0.99949265,0.0005073645
17012,chloroform,17,18,128,138,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17012,-1,0.9994641,0.00053587166
17013,galactosamine,19,20,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17013,-1,0.9994998,0.0005001365
17014,cholesteryl hemisuccinate,11,13,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17014,-1,0.9987871,0.0012128673
17015,tris salt,14,16,91,100,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17015,-1,0.9994331,0.00056685973
17016,CS,17,18,102,104,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17016,-1,0.99934644,0.0006535327
17018,carbon tetrachloride,32,34,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17018,-1,0.99943334,0.00056665885
17019,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17019,-1,0.99942005,0.00057994766
17020,CS,8,9,49,51,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17020,-1,0.99827325,0.0017267452
17021,CS,21,22,125,127,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17021,-1,0.99935716,0.00064288307
17022,ether,25,26,153,158,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17022,-1,0.99948525,0.00051467126
17023,CS,28,29,167,169,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17023,-1,0.99248964,0.007510279
17024,tris salt,33,35,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17024,-1,0.99949443,0.0005055197
17025,CSE,36,37,216,219,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17025,-1,0.99950516,0.0004948451
17026,carbon,43,44,258,264,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17026,-1,0.9994942,0.0005058152
17028,CS,13,14,64,66,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17028,-1,0.9904254,0.009574545
17030,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17030,-1,0.9994568,0.00054321776
17031,CHCl3,32,33,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17031,-1,0.9994874,0.0005126165
17033,galactosamine,36,37,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17033,-1,0.99948454,0.00051539094
17036,h,10,11,82,83,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,-1,17036,-1,0.16139983,0.83860016
17037,CS,4,5,24,26,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,-1,17037,-1,0.21589755,0.78410244
17039,CS,3,4,17,19,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,17039,-1,0.9989899,0.0010100896
17040,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,17040,-1,0.0057149176,0.99428505
17041,CS,15,16,78,80,"However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.",9067481_8,-1,-1,-1,17041,-1,0.99890316,0.0010968628
17042,CS,16,17,101,103,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17042,-1,0.99927646,0.00072356354
17043,CSE,20,21,131,134,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17043,-1,0.9992835,0.00071651913
17044,CS,25,26,156,158,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17044,-1,0.999228,0.0007719679
17045,prostaglandin,4,5,30,43,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,-1,-1,17045,-1,0.9994261,0.00057388406
17048,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,-1,-1,17048,-1,0.9994568,0.0005432333
17051,n,16,17,79,80,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17051,-1,0.9981805,0.0018195646
17053,n,32,33,153,154,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17053,-1,0.99918956,0.0008103928
17055,C,43,44,203,204,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17055,-1,0.9991549,0.0008450489
17056,n,45,46,206,207,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17056,-1,0.9991634,0.00083664624
17060,C,5,6,30,31,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,-1,17060,-1,0.9947896,0.005210463
17063,C,6,7,39,40,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17063,-1,0.9992914,0.00070854457
17064,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17064,-1,0.99941695,0.00058306474
17065,ketone,3,4,31,37,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,-1,17065,-1,0.99946684,0.0005332167
17066,C,20,21,115,116,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,-1,17066,-1,0.67769253,0.32230753
17071,impairment of hepatic function,20,24,137,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,-1,17071,-1,0.00044569574,0.99955434
17072,adenomyosis,4,5,18,29,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17072,-1,0.00019311077,0.99980694
17074,fluoxetine hydrochloride,12,14,76,100,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17074,-1,0.99947006,0.00052995334
17075,serotonin reuptake inhibitor,17,20,114,142,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17075,-1,0.9994295,0.00057048915
17076,adenomyosis,22,23,147,158,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17076,-1,0.00019303933,0.99980694
17079,adenomyosis,26,27,170,181,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,-1,17079,-1,0.00020155845,0.9997985
17081,serotonin reuptake inhibitor,5,8,22,50,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,-1,-1,17081,-1,0.9994574,0.00054263143
17084,adenomyosis,6,7,42,53,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,-1,17084,-1,0.00017531693,0.9998247
17087,adenomyosis,5,6,39,50,This invasion eventually progresses to adenomyosis.,9098464_10,-1,-1,-1,17087,-1,0.00021048069,0.99978954
17088,Cardiovascular alterations,0,2,0,26,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17088,-1,0.00017313572,0.99982685
17089,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17089,-1,0.99940825,0.000591758
17091,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17091,-1,0.9994843,0.0005156622
17092,cardiovascular alterations,17,19,104,130,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17092,-1,0.00022005154,0.99978
17093,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17093,-1,0.9994271,0.0005730019
17094,cardiovascular malformations,16,18,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17094,-1,0.00020166454,0.99979836
17095,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,-1,-1,-1,17095,-1,0.9986463,0.0013536374
17099,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17099,-1,0.9994394,0.0005605868
17100,cardiovascular malformations,26,28,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17100,-1,0.00021108122,0.99978894
17101,cardiovascular malformations,4,6,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17101,-1,0.00021299129,0.99978703
17102,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17102,-1,0.999482,0.00051805656
17105,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,-1,17105,-1,0.8929287,0.10707135
17107,ventricular septal defect,1,4,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,-1,17107,-1,0.00021352606,0.99978644
17109,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,-1,17109,-1,0.00020304251,0.9997969
17112,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,-1,-1,17112,-1,0.00023122254,0.9997688
17115,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,-1,-1,17115,-1,0.0002172132,0.99978274
17117,deoxycorticosterone,12,13,96,115,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,-1,-1,17117,-1,0.9995147,0.00048530387
17122,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17122,-1,0.00017963123,0.9998204
17124,benzodiazepine clonazepam,10,12,73,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17124,-1,0.9994824,0.0005175393
17125,pilocarpine seizures,15,17,121,141,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17125,-1,0.01601473,0.98398525
17128,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17128,-1,0.999481,0.0005189919
17133,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,-1,17133,-1,0.9994993,0.00050070084
17137,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,-1,-1,17137,-1,0.00021340516,0.99978656
17139,NMDA,8,9,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17139,-1,0.9993581,0.0006419176
17140,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17140,-1,0.0052355803,0.99476445
17143,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17143,-1,0.00021151999,0.99978846
17144,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17144,-1,0.00021067906,0.9997893
17145,nephrotic syndrome,10,12,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,-1,17145,-1,0.00020012964,0.9997999
17146,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17146,-1,0.00020972405,0.99979025
17147,NS,18,19,127,129,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17147,-1,0.0002712997,0.99972874
17148,ribonucleic acid,5,7,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,-1,17148,-1,0.99934655,0.0006534623
17150,NS,0,1,0,2,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17150,-1,0.98082536,0.019174589
17151,PAN,11,12,68,71,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17151,-1,0.99940276,0.0005972953
17152,PAN,17,18,100,103,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17152,-1,0.9959021,0.00409793
17153,NS,21,22,120,122,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17153,-1,0.063007936,0.93699205
17154,PAN,36,37,155,158,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,-1,17154,-1,0.99896836,0.001031649
17155,NS,19,20,118,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17155,-1,0.47848287,0.5215171
17156,PAN,22,23,132,135,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17156,-1,0.9991301,0.0008698894
17157,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,-1,-1,-1,17157,-1,0.00034841883,0.99965155
17159,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,-1,-1,17159,-1,0.000639835,0.99936014
17162,benzisoxazole,3,4,15,28,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17162,-1,0.9995004,0.00049963436
17163,serotonin 5-HT2,9,11,64,79,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17163,-1,0.99949527,0.0005047007
17167,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,-1,-1,17167,-1,0.00019531327,0.9998047
17168,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,-1,17168,-1,0.00022188935,0.9997781
17171,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,-1,-1,-1,17171,-1,0.999483,0.0005169274
17174,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,-1,-1,17174,-1,0.0003888601,0.9996112
17176,Atypical sensations,0,2,0,19,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,-1,-1,-1,17176,-1,0.00021723434,0.99978274
17178,tingling,5,6,32,40,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17178,-1,0.00021645322,0.9997836
17179,burning sensations,7,9,44,62,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17179,-1,0.00020767112,0.9997924
17180,sunburn,16,17,100,107,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17180,-1,0.00022037972,0.99977964
17184,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,-1,-1,17184,-1,0.00046215332,0.9995378
17186,amikacin retinal toxicity,8,11,39,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17186,-1,0.023869513,0.97613055
17189,streptococcal endophthalmitis,19,21,135,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17189,-1,0.0049922746,0.99500775
17190,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,-1,-1,17190,-1,0.0010780179,0.998922
17192,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,-1,-1,17192,-1,0.00021508882,0.9997849
17193,retinal toxicity,9,11,75,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17193,-1,0.00022984459,0.9997701
17194,ischaemia,13,14,104,113,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17194,-1,0.00022907757,0.99977094
17195,retinal toxicity,5,7,39,55,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,-1,17195,-1,0.00029814034,0.9997018
17196,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,-1,-1,17196,-1,0.9994887,0.0005113179
17198,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17198,-1,0.0008398856,0.9991602
17199,neuroleptic,23,24,149,160,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17199,-1,0.9797793,0.020220673
17201,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17201,-1,0.9920655,0.007934517
17203,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17203,-1,0.96364903,0.036351
17204,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17204,-1,0.99950755,0.0004924165
17207,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17207,-1,0.99949646,0.0005034845
17208,Carteolol,0,1,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17208,-1,0.9995184,0.0004816608
17210,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17210,-1,0.99950516,0.00049484207
17212,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17212,-1,0.9994911,0.0005089367
17214,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17214,-1,0.99945456,0.0005454888
17215,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17215,-1,0.9994499,0.00055009313
17217,hyperlocomotion,13,14,107,122,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17217,-1,0.0002344233,0.9997656
17218,Carteolol,0,1,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,-1,-1,-1,17218,-1,0.9994894,0.0005105094
17220,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17220,-1,0.99950314,0.0004968946
17221,twitch,25,26,182,188,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17221,-1,0.000238584,0.9997614
17222,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,-1,17222,-1,0.999509,0.00049106916
17223,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17223,-1,0.9994923,0.0005076891
17225,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17225,-1,0.9994486,0.00055141415
17226,antipsychotic effects,28,30,235,256,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17226,-1,0.0064743976,0.9935256
17228,Granulosa cell tumor of the ovary,0,6,0,33,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,-1,17228,-1,0.0036114426,0.99638855
17239,granulosa cell tumor of the ovary,19,25,104,137,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,-1,-1,17239,-1,0.00033085726,0.9996692
17240,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17240,-1,0.00020718656,0.9997929
17241,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17241,-1,0.0002069153,0.9997931
17244,AZT,7,8,48,51,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17244,-1,0.9994954,0.00050462346
17245,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17245,-1,0.00021628218,0.9997837
17246,AZT,0,1,0,3,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17246,-1,0.9994281,0.0005719131
17247,macrocytic anemia,4,6,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17247,-1,0.00021142041,0.9997886
17248,AIDS,7,8,39,43,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17248,-1,0.00021832988,0.99978167
17249,AZT,12,13,66,69,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17249,-1,0.999433,0.00056700973
17250,AZT,13,14,75,78,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17250,-1,0.99943393,0.00056605745
17251,thymidine,20,21,106,115,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17251,-1,0.9994367,0.00056335016
17252,phosphate hydroxyl,24,26,136,154,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17252,-1,0.99943,0.0005700288
17253,AZT,5,6,28,31,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17253,-1,0.99946564,0.0005343844
17254,H2O,8,9,43,46,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17254,-1,0.9994797,0.00052035233
17255,H2O,27,28,126,129,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17255,-1,0.99948287,0.00051708217
17256,AZT,36,37,170,173,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17256,-1,0.99948347,0.0005165255
17257,mg,47,48,224,226,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17257,-1,0.9993309,0.0006691808
17258,mg,9,10,39,41,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,-1,-1,-1,17258,-1,0.99891496,0.0010850457
17260,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17260,-1,0.00020466765,0.9997954
17261,MDS,17,18,125,128,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17261,-1,0.00020560318,0.9997944
17262,myelodysplasia,6,7,37,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17262,-1,0.00020417238,0.99979585
17263,myelodysplastic granulocytosis,12,14,81,111,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17263,-1,0.00020711722,0.9997929
17264,myelosis,31,32,224,232,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17264,-1,0.0002072733,0.99979275
17265,hyperplastic marrow,35,37,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17265,-1,0.00020549989,0.99979454
17266,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17266,-1,0.0002124546,0.9997875
17267,hypocellular,41,42,294,306,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17267,-1,0.00021441557,0.9997856
17268,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17268,-1,0.00020570551,0.9997943
17269,dyserythropoiesis,49,50,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17269,-1,0.0002054084,0.99979466
17270,hemosiderosis,51,52,370,383,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17270,-1,0.00057410286,0.9994259
17271,AZT,2,3,16,19,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17271,-1,0.99943477,0.00056517386
17272,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17272,-1,0.00020055774,0.99979943
17276,mg,10,11,56,58,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,-1,17276,-1,0.99940836,0.00059168186
17281,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,-1,17281,-1,0.0002116009,0.99978846
17283,Estrogens,0,1,0,9,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,-1,17283,-1,0.99942684,0.0005731663
17287,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,-1,17287,-1,0.0052766562,0.9947233
17290,factor VIII,27,29,155,166,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,-1,17290,-1,0.9993917,0.00060832174
17291,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,-1,-1,-1,17291,-1,0.9994887,0.0005112306
17293,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,-1,17293,-1,0.9992719,0.0007280914
17294,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,-1,17294,-1,0.99936146,0.0006385828
17295,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,-1,17295,-1,0.99934083,0.0006591813
17298,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,-1,17298,-1,0.00020993093,0.99979013
17301,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,-1,-1,17301,-1,0.00018432579,0.99981564
17302,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,-1,17302,-1,0.00020040329,0.99979967
17304,polyuric,4,5,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17304,-1,0.0068586078,0.99314135
17307,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17307,-1,0.90060157,0.099398404
17309,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,-1,-1,17309,-1,0.0001993448,0.9998006
17312,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,-1,-1,17312,-1,0.00020356046,0.99979645
17313,NIK-247,2,3,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,-1,17313,-1,0.99934715,0.0006528685
17315,NIK-247,3,4,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17315,-1,0.99623704,0.003762989
17317,cholinesterase inhibitors tacrine,21,24,151,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17317,-1,0.99945873,0.0005412558
17318,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17318,-1,0.99931467,0.00068535353
17319,NIK-247,0,1,0,7,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17319,-1,0.9994061,0.0005938697
17320,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17320,-1,0.99945253,0.000547473
17321,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17321,-1,0.99944144,0.00055853743
17322,NIK-247,3,4,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17322,-1,0.94865197,0.05134797
17323,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17323,-1,0.9994671,0.00053288
17324,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17324,-1,0.90521526,0.09478476
17325,NIK-247,6,7,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,-1,-1,-1,17325,-1,0.9994235,0.0005764988
17328,NIK-247,4,5,28,35,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,-1,-1,17328,-1,0.9992644,0.00073555287
17330,NIK-247,4,5,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17330,-1,0.9992999,0.00070008135
17331,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17331,-1,0.00020772478,0.9997923
17333,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,-1,-1,17333,-1,0.00018827882,0.9998117
17335,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,-1,-1,17335,-1,0.00020228754,0.99979776
17341,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,-1,17341,-1,0.9994599,0.00054012355
17346,cardiovascular,25,26,159,173,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,-1,-1,-1,17346,-1,0.00021190455,0.9997881
17349,atrioventricular reentrant tachycardia,3,6,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17349,-1,0.0006605201,0.9993394
17351,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17351,-1,0.00022446559,0.9997756
17352,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17352,-1,0.00025763232,0.9997423
17353,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17353,-1,0.00020907618,0.99979097
17354,atrioventricular reentrant tachycardia,12,15,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17354,-1,0.00024910874,0.9997509
17355,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17355,-1,0.00021553248,0.9997845
17357,AVRT,24,25,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,-1,17357,-1,0.90188897,0.09811107
17359,A-86929,11,12,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,-1,17359,-1,0.9734668,0.026533123
17362,DA,6,7,34,36,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17362,-1,0.9994603,0.00053973345
17363,agonists,10,11,50,58,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17363,-1,0.99945945,0.0005405603
17364,Parkinson's disease,15,18,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17364,-1,0.00020656205,0.99979347
17365,PD,19,20,100,102,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17365,-1,0.00020808974,0.9997919
17366,DA,5,6,33,35,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17366,-1,0.9994772,0.00052282575
17367,receptor agonists,7,9,39,56,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17367,-1,0.9994418,0.0005582064
17368,SKF-82958,11,12,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17368,-1,0.10300055,0.8969995
17369,"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide",13,16,76,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17369,-1,0.99949133,0.0005086365
17370,A-77636,18,19,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17370,-1,0.813955,0.18604502
17371,"[1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride",20,28,180,275,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17371,-1,0.99944824,0.00055177556
17372,SKF-82958,43,44,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17372,-1,0.14138518,0.8586148
17373,A-77636,53,54,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17373,-1,0.89175516,0.10824479
17374,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10,11,69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17374,-1,0.99951303,0.00048694815
17376,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17376,-1,0.00020333233,0.9997967
17377,A-86929,39,40,301,308,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17377,-1,0.20815106,0.7918489
17378,DA,54,55,439,441,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17378,-1,0.99949515,0.00050477934
17380,DA,3,4,17,19,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17380,-1,0.9994654,0.0005346572
17381,LY-171555,8,9,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17381,-1,0.99939406,0.00060593965
17382,hydrochloride,14,15,134,147,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17382,-1,0.99945253,0.00054745027
17383,A-86929,3,4,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17383,-1,0.9994024,0.0005975942
17386,LY-171555,14,15,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17386,-1,0.99950016,0.0004998549
17388,LY-171555,31,32,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17388,-1,0.9994874,0.0005126267
17390,DA,4,5,29,31,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17390,-1,0.99947244,0.0005275958
17392,DA,37,38,230,232,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17392,-1,0.9994723,0.00052765943
17393,DA,1,2,7,9,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17393,-1,0.999335,0.00066500297
17394,agents,4,5,22,28,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17394,-1,0.99872226,0.0012777355
17395,A-86929,13,14,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17395,-1,0.63148814,0.3685118
17396,PD,28,29,166,168,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17396,-1,0.0004976296,0.9995024
17398,hydrochlorofluorocarbons,6,7,36,60,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17398,-1,0.999469,0.000531038
17399,chlorofluorocarbons,12,13,98,117,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17399,-1,0.99947876,0.00052130304
17400,Hydrochlorofluorocarbons,2,3,12,36,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17400,-1,0.9994622,0.00053776946
17401,HCFCs,4,5,38,43,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17401,-1,0.9994079,0.0005921592
17402,chlorofluorocarbons,15,16,114,133,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17402,-1,0.9994653,0.00053474127
17403,CFCs,17,18,135,139,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17403,-1,0.9994375,0.00056250533
17407,HCFC 123,23,25,165,173,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17407,-1,0.9994721,0.0005279865
17409,HCFC,29,30,215,219,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17409,-1,0.99948066,0.00051935046
17412,trifluoroacetyl,16,17,118,133,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17412,-1,0.9994716,0.0005284648
17415,HCFCs,5,6,25,30,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,-1,-1,17415,-1,0.99496245,0.0050375164
17417,trifluoroacetyl,16,17,109,124,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,-1,17417,-1,0.999445,0.00055492984
17418,hepatocellular necrosis,7,9,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,-1,17418,-1,0.00022584079,0.99977416
17420,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,-1,17420,-1,0.017255599,0.9827444
17421,HCFCs,8,9,53,58,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,-1,17421,-1,0.9993767,0.00062329235
17424,duct hamartoma,1,3,5,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,-1,-1,17424,-1,0.014071379,0.9859286
17426,hamartoma,7,8,30,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,-1,-1,17426,-1,0.009144759,0.9908552
17428,liver mass,5,7,26,36,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,-1,-1,-1,17428,-1,0.00021603898,0.99978393
17432,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,-1,17432,-1,0.9767786,0.02322136
17435,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17435,-1,0.00020675988,0.99979323
17438,TLE,33,34,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17438,-1,0.9926756,0.0073244604
17439,Parkinson's disease,5,8,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,-1,17439,-1,0.0003216889,0.9996784
17440,Parkinson's disease,13,16,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,-1,-1,-1,17440,-1,0.00020654571,0.99979347
17441,Parkinson's disease,5,8,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,-1,17441,-1,0.00022407812,0.99977595
17446,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,-1,17446,-1,0.00021397833,0.9997861
17449,Parkinson's disease,4,7,27,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17449,-1,0.00042119104,0.9995788
17452,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17452,-1,0.9994874,0.0005125666
17453,macrolide,5,6,35,44,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17453,-1,0.999482,0.00051801355
17454,erythromycin,3,4,16,28,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17454,-1,0.99941325,0.00058670744
17455,hydroxyl,10,11,60,68,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17455,-1,0.99936944,0.0006305922
17456,erythromycin,5,6,36,48,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17456,-1,0.99945885,0.0005411826
17457,gastroenteritis,10,11,75,90,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17457,-1,0.00021485536,0.9997851
17458,macrolides,27,28,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17458,-1,0.9994618,0.00053817895
17460,erythromycin,11,12,87,99,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17460,-1,0.99945873,0.00054131803
17461,macrolides,20,21,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17461,-1,0.9994568,0.00054322294
17462,ventricular dysrhythmias,5,7,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17462,-1,0.00019779343,0.9998022
17463,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17463,-1,0.9994869,0.00051301526
17464,dysrhythmias,1,2,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,-1,-1,-1,17464,-1,0.00018832658,0.9998117
17465,erectile dysfunction,6,8,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,-1,17465,-1,0.00022821796,0.9997718
17467,erectile dysfunction,18,20,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,-1,17467,-1,0.00021700372,0.999783
17471,gynecomastia,20,21,115,127,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,-1,-1,17471,-1,0.00021687259,0.9997831
17473,erectile dysfunction,15,17,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,-1,17473,-1,0.00020142144,0.9997986
17475,gynecomastia,17,18,117,129,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17475,-1,0.00021434118,0.9997857
17476,testosterone heptylate,4,6,31,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17476,-1,0.9994861,0.000513847
17477,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17477,-1,0.99948275,0.0005171871
17478,hypogonadism,11,12,90,102,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17478,-1,0.00021545826,0.9997845
17483,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,-1,-1,17483,-1,0.00021509742,0.9997849
17486,hypothalamic dysfunction,12,14,75,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17486,-1,0.00021590658,0.99978405
17487,luteinizing hormone,18,20,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17487,-1,0.9994235,0.00057649304
17488,erectile dysfunction,30,32,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17488,-1,0.00021595518,0.99978405
17489,androgen,45,46,263,271,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17489,-1,0.9994098,0.00059022027
17493,androgen,33,34,199,207,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,-1,-1,17493,-1,0.99940836,0.0005916531
17495,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,-1,-1,17495,-1,0.00020684095,0.99979323
17499,erectile dysfunction,13,15,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,-1,17499,-1,0.00021733419,0.9997826
17500,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,-1,-1,17500,-1,0.00020597794,0.99979407
17504,gynecomastia,12,13,67,79,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,-1,-1,17504,-1,0.00017177533,0.9998282
17509,antipsychotic drug,3,5,18,36,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17509,-1,0.9994367,0.0005633553
17511,serotonin 5-HT2,12,14,75,90,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17511,-1,0.999432,0.0005679801
17514,neuroleptics,33,34,241,253,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,-1,17514,-1,0.94473124,0.05526876
17517,n,40,41,254,255,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17517,-1,0.9992494,0.0007505836
17519,n,47,48,278,279,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17519,-1,0.99764997,0.0023500056
17530,5-FU,15,16,118,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17530,-1,0.9995022,0.0004978378
17531,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17531,-1,0.99950826,0.0004917566
17532,MFL,19,20,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17532,-1,0.9994973,0.00050267536
17537,5-FU,8,9,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17537,-1,0.99948597,0.0005139506
17538,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17538,-1,0.99949074,0.0005092043
17539,MFL,13,14,92,95,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17539,-1,0.99947375,0.0005263128
17542,5-FU,30,31,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17542,-1,0.99947995,0.0005200583
17543,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17543,-1,0.9994991,0.00050094817
17544,h,44,45,246,247,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17544,-1,0.008811738,0.9911883
17545,metastasis,13,14,69,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,-1,-1,-1,17545,-1,0.00021260051,0.9997874
17547,MFL,5,6,28,31,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,-1,17547,-1,0.0010802725,0.9989197
17553,MFL,1,2,4,7,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,-1,17553,-1,0.99932003,0.00068004016
17556,impaired heart function,17,20,110,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,-1,-1,17556,-1,0.00019045472,0.99980956
17559,Agranulocytosis,0,1,0,15,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,-1,17559,-1,0.002666072,0.997334
17563,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,-1,-1,-1,17563,-1,0.99937266,0.0006273273
17565,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,-1,17565,-1,0.00021309286,0.9997869
17566,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17566,-1,0.9994444,0.00055561523
17567,AVP,6,7,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17567,-1,0.9993411,0.00065892446
17570,LiCl,9,10,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,-1,17570,-1,0.99929726,0.00070276664
17573,AVP,3,4,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17573,-1,0.9970824,0.0029175247
17574,AVP,7,8,47,50,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17574,-1,0.9978103,0.002189694
17576,AVP,19,20,131,134,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17576,-1,0.9848378,0.015162174
17577,AVP,24,25,159,162,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17577,-1,0.99929154,0.00070846966
17578,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17578,-1,0.18507648,0.8149236
17579,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,-1,-1,17579,-1,0.9994789,0.00052111095
17581,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17581,-1,0.9994692,0.0005307738
17583,sphincter of Oddi dyskinesia,24,28,162,190,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17583,-1,0.00020994311,0.99979
17585,mg prostigmine,13,15,88,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17585,-1,0.99945587,0.0005440851
17586,mg morphine,18,20,126,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17586,-1,0.99947125,0.0005287843
17587,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17587,-1,0.99945027,0.0005497193
17588,Nitrolingual,10,11,71,83,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17588,-1,0.9992156,0.00078433286
17590,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17590,-1,0.9994716,0.0005284267
17591,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17591,-1,0.999471,0.00052902667
17592,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,-1,17592,-1,0.9994524,0.0005475442
17594,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17594,-1,0.9994579,0.000542055
17596,sphincter of Oddi dyskinesia,23,27,128,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17596,-1,0.00020845192,0.99979156
17597,mg,23,24,182,184,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17597,-1,0.9828864,0.017113656
17598,mg,31,32,202,204,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17598,-1,0.996349,0.0036509617
17599,mg,39,40,222,224,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17599,-1,0.9963469,0.0036531757
17601,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17601,-1,0.9995054,0.00049458974
17602,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17602,-1,0.9994966,0.00050340855
17604,hemicholinium-3,24,25,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17604,-1,0.99949086,0.0005091487
17606,quinpirole,49,50,403,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17606,-1,0.99949396,0.0005060092
17608,2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride,54,59,451,531,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17608,-1,0.99950624,0.00049378804
17610,hydrobromide,64,65,626,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17610,-1,0.9994881,0.0005119118
17611,polyamines,67,68,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17611,-1,0.9994906,0.000509313
17613,mg,5,6,18,20,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17613,-1,0.99863535,0.0013646212
17616,mg,20,21,86,88,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17616,-1,0.9992761,0.00072386244
17617,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17617,-1,0.99950147,0.0004984846
17618,mg,29,30,119,121,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17618,-1,0.9993507,0.0006492596
17620,glomerular disease,3,5,41,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,-1,17620,-1,0.00022087153,0.99977916
17623,mesangial,20,21,136,145,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,-1,-1,17623,-1,0.00022615732,0.9997738
17625,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,-1,17625,-1,0.00025029533,0.9997497
17636,burning painful,15,17,93,108,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,-1,-1,17636,-1,0.00020829814,0.9997917
17638,acute pain,21,23,124,134,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,-1,-1,17638,-1,0.00020163915,0.99979836
17642,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,-1,-1,17642,-1,0.0005899666,0.99941003
17643,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,-1,-1,17643,-1,0.0002147212,0.99978524
17644,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,-1,-1,17644,-1,0.00019468243,0.9998054
17646,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17646,-1,0.00018449512,0.9998155
17647,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17647,-1,0.0001877992,0.9998122
17651,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17651,-1,0.00021362852,0.99978644
17653,P,27,28,126,127,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17653,-1,0.13957864,0.8604214
17654,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,-1,-1,17654,-1,0.0001874039,0.99981266
17657,hearing loss,7,9,46,58,None of the patients complained of subjective hearing loss.,9522143_7,-1,-1,-1,17657,-1,0.00020485019,0.99979514
17658,neurological deficit,2,4,12,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,-1,17658,-1,0.00021649576,0.9997836
17660,neurological deficit,6,8,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17660,-1,0.000206752,0.99979323
17661,mg,16,17,110,112,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17661,-1,0.99921465,0.00078532053
17663,hypoaesthesia,19,20,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17663,-1,0.00021318471,0.9997868
17664,loss of pinprick,32,35,178,194,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17664,-1,0.9398237,0.06017628
17665,lead,49,50,304,308,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17665,-1,0.0009893177,0.9990107
17666,neurological deficit,53,55,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17666,-1,0.00021538968,0.99978465
17667,Transient neurologic symptoms,0,3,0,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,-1,-1,-1,17667,-1,0.00017849955,0.9998215
17671,transient neurologic symptoms,6,9,42,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17671,-1,0.00022324837,0.9997768
17672,TNSs,10,11,73,77,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17672,-1,0.0004332838,0.99956673
17681,TNSs,24,25,164,168,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,-1,17681,-1,0.00032580216,0.9996742
17688,TNSs,12,13,67,71,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,-1,17688,-1,0.00022744942,0.9997726
17690,TNSs,9,10,61,65,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17690,-1,0.0031320285,0.99686795
17692,P,18,19,106,107,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17692,-1,0.037603162,0.96239686
17694,TNSs,33,34,176,180,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17694,-1,0.0044867536,0.99551326
17698,P,37,38,190,191,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,-1,-1,-1,17698,-1,0.3138234,0.6861766
17701,TNSs,25,26,154,158,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,-1,17701,-1,0.00029810224,0.9997019
17703,iron dextran,16,18,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17703,-1,0.9994911,0.0005088817
17704,blind,21,22,143,148,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17704,-1,0.99942696,0.000573091
17705,iron dextran,12,14,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,-1,-1,-1,17705,-1,0.99939394,0.00060607924
17707,MP,23,24,148,150,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,-1,17707,-1,0.99944276,0.00055719906
17708,mg,29,30,129,131,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,-1,-1,-1,17708,-1,0.99925584,0.0007441375
17709,MP,0,1,0,2,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17709,-1,0.49367625,0.50632375
17710,mg,13,14,49,51,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17710,-1,0.9354764,0.06452354
17711,MP,0,1,0,2,MP before and after TDI (group 3).,9523850_6,-1,-1,-1,17711,-1,0.17615913,0.82384086
17712,MP,6,7,46,48,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,-1,-1,-1,17712,-1,0.7828632,0.21713676
17713,mg,4,5,21,23,We conclude that 125 mg i.v.,9523850_12,-1,-1,-1,17713,-1,0.92639196,0.07360805
17714,MP,0,1,0,2,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17714,-1,0.0023242945,0.9976757
17715,iron dextran,10,12,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17715,-1,0.9994252,0.0005748681
17716,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,-1,17716,-1,0.00029902908,0.999701
17718,gastrointestinal motility disorders,18,21,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,-1,-1,17718,-1,0.00020551107,0.99979454
17719,Prolongation of QT interval,0,4,0,27,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17719,-1,0.00019744577,0.99980253
17720,torsades de pointes,5,8,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17720,-1,0.0002627123,0.9997373
17721,sudden cardiac death,10,13,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17721,-1,0.0001802817,0.9998197
17722,erythromycin,20,21,132,144,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17722,-1,0.99950004,0.00049996405
17723,azole antifungal agents,22,25,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17723,-1,0.99949515,0.00050480344
17725,gastroesophageal reflux disorder,14,17,89,121,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,-1,-1,17725,-1,0.00021883863,0.9997812
17736,n,47,48,288,289,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17736,-1,0.76164085,0.23835912
17738,n,59,60,346,347,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17738,-1,0.9828455,0.017154464
17739,dyskinetic parkinsonian,1,3,4,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,-1,17739,-1,0.00020475099,0.99979526
17741,hyperkinetic abnormal involuntary movement,9,13,57,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,-1,17741,-1,0.00019928627,0.99980074
17744,sinusitis,10,11,75,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,-1,17744,-1,0.00019823278,0.9998018
17746,mg,12,13,66,68,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17746,-1,0.99930537,0.0006946858
17747,sinusitis,29,30,157,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17747,-1,0.00020346655,0.99979657
17748,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,-1,-1,17748,-1,0.00026144346,0.9997385
17751,flatulence,9,10,59,69,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,-1,-1,17751,-1,0.00022895136,0.99977106
17754,mg,11,12,69,71,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17754,-1,0.9994543,0.0005456231
17755,sinusitis,23,24,138,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17755,-1,0.00020497992,0.999795
17756,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,-1,17756,-1,0.00018747628,0.99981254
17767,n,9,10,59,60,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,-1,17767,-1,0.66345006,0.3365499
17771,p,26,27,152,153,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,-1,17771,-1,0.31906188,0.6809381
17772,p,15,16,94,95,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17772,-1,0.4321892,0.5678108
17774,p,27,28,152,153,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17774,-1,0.61455244,0.3854475
17775,p,18,19,95,96,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,-1,17775,-1,0.17302042,0.8269796
17777,p,14,15,82,83,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17777,-1,0.50997907,0.49002096
17778,p,27,28,132,133,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17778,-1,0.62905675,0.37094322
17779,p,35,36,167,168,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17779,-1,0.7203462,0.2796538
17782,disease,12,13,78,85,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,-1,-1,17782,-1,0.00020352028,0.99979645
17788,Endometrial cancers,0,2,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,-1,-1,17788,-1,0.00021093935,0.99978906
17798,hyperkalaemia,16,17,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,-1,-1,17798,-1,0.00019984799,0.99980015
17805,hyperkalaemia,30,31,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,-1,-1,-1,17805,-1,0.00020299683,0.99979705
17810,Acute hepatitis,0,2,0,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17810,-1,0.00021984245,0.9997801
17812,erythroblastocytopenia,8,9,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17812,-1,0.008354814,0.99164516
17814,acute hepatitis,4,6,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,-1,-1,17814,-1,0.0001818261,0.99981815
17816,beta lactam,10,12,80,91,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17816,-1,0.99946123,0.0005387764
17819,erythroblastocytopenia,35,36,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17819,-1,0.008548888,0.9914511
17821,beta lactam,20,22,122,133,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,-1,-1,17821,-1,0.9994585,0.0005414849
17823,NMDA,6,7,36,40,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,-1,17823,-1,0.99932766,0.0006723333
17825,NMDA,16,17,83,87,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,-1,-1,17825,-1,0.9993255,0.0006744826
17826,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,-1,-1,17826,-1,0.00020407664,0.999796
17829,"5,7-DCKA",3,4,28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17829,-1,0.99948895,0.00051104673
17831,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17831,-1,0.00022045115,0.9997795
17832,"5,7-DCKA",0,1,0,8,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,-1,17832,-1,0.9994616,0.0005384037
17835,NMDA,11,12,65,69,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,-1,17835,-1,0.9993286,0.00067141856
17837,on the peripheral nervous system,3,8,26,58,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,-1,-1,-1,17837,-1,0.00034501284,0.999655
17839,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17839,-1,0.9973803,0.0026196737
17841,CDDP,15,16,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17841,-1,0.0058325627,0.99416745
17843,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17843,-1,0.999461,0.00053902244
17845,peripheral nervous system damage,27,31,177,209,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17845,-1,0.00021959338,0.9997805
17846,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,-1,17846,-1,0.9994443,0.0005556764
17848,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17848,-1,0.9994863,0.00051368226
17849,peripheral neurotoxicity,6,8,53,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17849,-1,0.00022818249,0.9997718
17851,CDDP,23,24,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,-1,17851,-1,0.9992112,0.00078882545
17852,platinum,5,6,33,41,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17852,-1,0.999387,0.0006129155
17853,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17853,-1,0.9994554,0.000544632
17854,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17854,-1,0.9990331,0.0009668726
17856,CDDP,25,26,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17856,-1,0.99938893,0.0006110112
17858,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,-1,-1,-1,17858,-1,0.9994516,0.0005484356
17860,thyrotoxicosis,7,8,36,50,Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.,9653867_0,-1,-1,-1,17860,-1,0.0018366937,0.9981633
17861,Eating disorders,0,2,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,-1,-1,17861,-1,0.0002053234,0.99979466
17863,eating disorders,14,16,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17863,-1,0.0002042125,0.99979585
17864,metabolic disturbances,23,25,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17864,-1,0.00020444726,0.9997956
17865,diuretic,26,27,173,181,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17865,-1,0.9993666,0.0006334015
17866,eating disorders,14,16,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17866,-1,0.0002006224,0.99979943
17867,thyrotoxicosis,24,25,148,162,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17867,-1,0.00020026689,0.9997998
17869,trimipramine,1,2,9,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,-1,17869,-1,0.9994717,0.000528285
17871,Trimipramine,0,1,0,12,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17871,-1,0.9994942,0.00050573534
17872,TRI,2,3,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17872,-1,0.99948657,0.0005133577
17874,imipramine,16,17,93,103,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17874,-1,0.99950075,0.0004991887
17878,TRI,11,12,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,-1,17878,-1,0.99930286,0.0006971087
17880,TRI,0,1,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,-1,17880,-1,0.9993007,0.0006992866
17881,TRI,4,5,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17881,-1,0.99945265,0.0005474029
17882,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17882,-1,0.01650994,0.9834901
17884,twitches,25,26,148,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17884,-1,0.00023121548,0.9997688
17885,TRI,0,1,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17885,-1,0.9995029,0.0004970559
17887,quinpirole,13,14,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17887,-1,0.9995122,0.00048778247
17889,stereotypies,1,2,4,16,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17889,-1,0.00020523847,0.9997948
17891,TRI,11,12,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17891,-1,0.99939775,0.00060223934
17896,TRI,13,14,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,-1,-1,-1,17896,-1,0.9994393,0.00056072365
17901,irritable bowel syndrome,13,16,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,-1,17901,-1,0.0002115321,0.99978846
17902,Irritable bowel syndrome,2,5,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17902,-1,0.00021594632,0.99978405
17903,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17903,-1,0.00020919481,0.99979085
17904,disordered gastrointestinal motility,19,22,110,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17904,-1,0.00021738745,0.9997826
17906,motility and symptoms,20,23,117,138,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17906,-1,0.00022156612,0.99977845
17907,irritable bowel syndrome,25,28,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17907,-1,0.00020853661,0.99979144
17908,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17908,-1,0.00021335289,0.9997867
17909,IBS,5,6,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17909,-1,0.00020925824,0.9997907
17910,n,9,10,67,68,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17910,-1,0.94776016,0.0522398
17911,n,15,16,98,99,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17911,-1,0.8841902,0.1158098
17913,mg,35,36,201,203,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17913,-1,0.9994061,0.00059392717
17914,n,40,41,223,224,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17914,-1,0.9399628,0.060037117
17915,n,47,48,243,244,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17915,-1,0.9516272,0.048372757
17917,mm Hg,20,22,128,133,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17917,-1,0.00082374824,0.9991762
17919,mm Hg,38,40,200,205,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17919,-1,0.0006794034,0.9993206
17922,IBS,11,12,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,-1,17922,-1,0.0002045974,0.9997954
17924,IBS,13,14,113,116,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17924,-1,0.00020181805,0.99979824
17925,mm,27,28,160,162,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17925,-1,0.9386797,0.06132023
17927,P,33,34,190,191,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17927,-1,0.11825751,0.8817425
17928,mm,44,45,225,227,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17928,-1,0.9879743,0.01202572
17929,IBS,1,2,22,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17929,-1,0.00020850443,0.99979156
17932,mm,23,24,118,120,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17932,-1,0.9987472,0.0012527574
17934,P,29,30,148,149,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17934,-1,0.060922958,0.939077
17935,mm,40,41,183,185,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17935,-1,0.99921274,0.00078724534
17937,IBS,11,12,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,-1,-1,17937,-1,0.00021721817,0.99978274
17948,mg,7,8,46,48,"Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years.",9672273_5,-1,-1,-1,17948,-1,0.99942124,0.00057877676
17959,vascular events,13,15,77,92,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17959,-1,0.00020677113,0.99979323
17960,hypertriglyceridaemia,16,17,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17960,-1,0.00039428007,0.9996057
17970,postoperative pain,9,11,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,-1,-1,17970,-1,0.00021238759,0.9997876
17972,analgesia,13,14,102,111,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17972,-1,0.00022528098,0.99977475
17973,postoperative pain,21,23,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17973,-1,0.00026324333,0.9997367
17974,h,1,2,13,14,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,-1,-1,17974,-1,0.47495636,0.5250436
17977,norpethidine,4,5,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,-1,17977,-1,0.99948573,0.00051418995
17981,norpethidine,17,18,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,-1,17981,-1,0.99947125,0.0005287381
17983,analgesia,12,13,68,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,-1,-1,17983,-1,0.00022206694,0.999778
17984,mepivacaine,8,9,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,-1,-1,-1,17984,-1,0.99947566,0.00052439584
17986,increase in blood pressure,1,5,3,29,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17986,-1,0.00080768525,0.9991923
17987,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17987,-1,0.00020870651,0.9997913
17989,loss of consciousness,16,19,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17989,-1,0.00021057182,0.9997894
17990,mepivacaine,43,44,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17990,-1,0.9994918,0.0005081613
17991,mg,45,46,283,285,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17991,-1,0.99945587,0.00054408563
17993,mg,49,50,314,316,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17993,-1,0.99940646,0.0005935135
17994,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17994,-1,0.000569334,0.9994306
17998,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,-1,-1,17998,-1,0.00021365356,0.9997863
17999,mepivacaine,18,19,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,-1,17999,-1,0.99949145,0.0005085439
18001,vanishing bile duct,2,5,28,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,-1,18001,-1,0.00034913406,0.99965084
18002,vanishing bile duct syndrome,1,5,6,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,-1,-1,18002,-1,0.0004970635,0.9995029
18005,drug or infection,16,19,128,145,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,-1,18005,-1,0.008401481,0.9915985
18006,vanishing bile duct syndrome,12,16,76,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,-1,18006,-1,0.00019260948,0.9998074
18008,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,18008,-1,0.99949753,0.0005024004
18011,cholestatic disease,13,15,80,99,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,18011,-1,0.0002354683,0.9997645
18013,vanishing bile duct syndrome,5,9,39,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,18013,-1,0.00076313916,0.9992368
18014,vanishing bile duct syndrome,27,31,190,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,18014,-1,0.0008395239,0.9991605
18018,appetite suppressant drugs,20,23,122,148,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,-1,18018,-1,0.99944454,0.0005553917
18022,fenfluramines,11,12,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,18022,-1,0.9994677,0.00053230335
18023,p<0.0001,27,28,150,158,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,18023,-1,0.07427546,0.9257245
18029,lead,9,10,67,71,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,-1,-1,18029,-1,0.22716157,0.7728385
18034,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,-1,18034,-1,0.00022023416,0.99977976
18037,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,-1,-1,18037,-1,0.00021207616,0.999788
18044,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18044,-1,0.9994937,0.0005062673
18045,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18045,-1,0.9994993,0.0005006973
18046,ethosuximide,14,15,84,96,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18046,-1,0.9995003,0.0004997482
18047,Choreoathetoid movements,0,2,0,24,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,-1,18047,-1,0.0063970834,0.99360293
18049,hyperkinesias,1,2,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18049,-1,0.00016263741,0.9998373
18050,movement abnormalities,7,9,54,76,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18050,-1,0.00016563365,0.9998343
18052,choreoathetoid movements,8,10,38,62,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18052,-1,0.001574892,0.9984251
18054,heroine,28,29,197,204,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18054,-1,0.99948597,0.00051406305
18056,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18056,-1,0.99950147,0.0004985475
18057,SLE,8,9,56,59,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18057,-1,0.00021640163,0.9997836
18058,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18058,-1,0.99950397,0.00049606035
18059,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18059,-1,0.0077336896,0.99226624
18061,birth defects,39,41,262,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18061,-1,0.00021197971,0.999788
18063,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,-1,-1,18063,-1,0.9994584,0.000541646
18065,cleft,7,8,45,50,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,-1,-1,18065,-1,0.0002279068,0.99977213
18069,folic acid,11,13,81,91,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,-1,-1,18069,-1,0.9995036,0.0004963301
18070,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18070,-1,0.00028520531,0.9997148
18071,systemic lupus erythematodes,8,11,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18071,-1,0.7275979,0.27240208
18072,stillbirth,4,5,25,35,Her pregnancy ended with stillbirth.,9758264_7,-1,-1,-1,18072,-1,0.00028510965,0.9997149
18074,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18074,-1,0.00020717569,0.9997929
18075,lupus,12,13,88,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18075,-1,0.00020856327,0.99979144
18076,mg,29,30,173,175,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18076,-1,0.9991671,0.000832927
18077,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18077,-1,0.999481,0.0005190498
18079,mg,5,6,23,25,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18079,-1,0.9962339,0.00376609
18080,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18080,-1,0.99947804,0.0005219668
18082,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18082,-1,0.0002183957,0.99978167
18083,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18083,-1,0.00021635584,0.9997837
18084,antipsychotics,5,6,32,46,Adverse effects of the atypical antipsychotics.,9766615_0,-1,-1,-1,18084,-1,0.99840575,0.0015942727
18085,antipsychotics,3,4,19,33,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18085,-1,0.9992094,0.00079053885
18086,lead,5,6,40,44,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18086,-1,0.006201504,0.99379843
18087,antipsychotics,7,8,41,55,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18087,-1,0.9989196,0.0010803698
18088,neuroleptics,16,17,109,121,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18088,-1,0.018312331,0.9816877
18090,EPS,15,16,116,119,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18090,-1,0.002484514,0.99751544
18091,tardive dyskinesia,18,20,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18091,-1,0.00022538046,0.99977463
18094,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18094,-1,0.0047620083,0.99523795
18095,EPS,9,10,47,50,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18095,-1,0.99940324,0.00059677346
18096,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18096,-1,0.0051014107,0.9948986
18100,agranulocytosis,44,45,257,272,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18100,-1,0.0005675747,0.9994324
18102,lead,27,28,175,179,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18102,-1,0.003738813,0.9962612
18103,antipsychotic,38,39,253,266,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18103,-1,0.9992704,0.0007296702
18115,emergency department,25,27,143,163,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,-1,18115,-1,0.00029728367,0.99970263
18126,psychosis,9,10,74,83,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18126,-1,0.000211047,0.99978894
18127,disruptive behaviors,11,13,88,108,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18127,-1,0.00021182072,0.9997882
18128,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18128,-1,0.00021380986,0.9997862
18130,psychosis,26,27,139,148,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18130,-1,0.00020201133,0.999798
18131,disruptive behaviors,28,30,153,173,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18131,-1,0.00020678947,0.99979323
18132,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18132,-1,0.00020808556,0.9997919
18135,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,-1,18135,-1,0.00022835967,0.99977165
18141,psychosis,31,32,197,206,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18141,-1,0.000228149,0.9997719
18142,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18142,-1,0.00022667025,0.9997733
18143,extrapyramidal signs,17,19,84,104,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,-1,18143,-1,0.0001858786,0.9998141
18146,extrapyramidal signs,26,28,156,176,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,-1,18146,-1,0.00036968547,0.99963033
18148,neuroleptics,12,13,80,92,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18148,-1,0.93814456,0.061855435
18149,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18149,-1,0.00021643176,0.9997836
18150,psychosis,20,21,135,144,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18150,-1,0.00021584197,0.9997842
18151,disruptive behaviors,22,24,149,169,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18151,-1,0.00021825539,0.9997818
18152,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18152,-1,0.0001858148,0.9998142
18153,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18153,-1,0.99943346,0.00056657783
18154,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,-1,-1,18154,-1,0.00020963949,0.9997904
18155,renal failure,5,7,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18155,-1,0.0001973752,0.99980265
18156,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18156,-1,0.99945956,0.0005404634
18157,renal lesions,6,8,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,-1,-1,-1,18157,-1,0.00019465607,0.9998054
18166,radiocalcium,15,16,79,91,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,-1,18166,-1,0.99945337,0.000546688
18168,Gm,13,14,91,93,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,-1,18168,-1,0.017873881,0.98212606
18169,calcium chloride,2,4,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,-1,18169,-1,0.9994099,0.0005900391
18172,radiocalcium,1,2,14,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,-1,18172,-1,0.99947184,0.0005281964
18178,mg,13,14,74,76,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18178,-1,0.014729514,0.9852705
18179,Gm,17,18,86,88,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18179,-1,0.35385787,0.64614207
18184,SM-5887,9,10,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,-1,18184,-1,0.4466541,0.55334586
18187,SM-5887,11,12,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18187,-1,0.4934416,0.5065584
18188,SM-5887,18,19,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18188,-1,0.99669206,0.003307868
18192,SM-5887,29,30,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,-1,-1,-1,18192,-1,0.4833865,0.5166135
18194,of blood pressure,17,20,114,131,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18194,-1,0.00022573833,0.9997743
18196,SM-5887,33,34,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18196,-1,0.999445,0.00055499014
18198,SM-5887,8,9,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,-1,-1,18198,-1,0.020318517,0.9796815
18202,SM-5887,18,19,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,-1,18202,-1,0.0044263876,0.99557364
18205,SM-5887,5,6,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,-1,-1,18205,-1,0.99638784,0.0036121462
18207,SM-5887,3,4,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,-1,-1,18207,-1,0.7081298,0.29187018
18211,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,-1,-1,-1,18211,-1,0.99947995,0.0005200665
18213,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,-1,-1,-1,18213,-1,0.9994673,0.00053268403
18214,n,16,17,80,81,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18214,-1,0.9946425,0.0053574615
18215,n=5,26,27,111,114,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18215,-1,0.9981268,0.0018732045
18216,n,31,32,124,125,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18216,-1,0.98146075,0.018539267
18217,IgA nephropathy,37,39,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18217,-1,0.003242867,0.9967571
18218,n,40,41,158,159,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18218,-1,0.9986395,0.0013604291
18219,n,48,49,182,183,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18219,-1,0.9976776,0.0023223867
18220,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18220,-1,0.010711792,0.9892882
18221,n,58,59,229,230,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18221,-1,0.9923056,0.0076944125
18222,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18222,-1,0.010849462,0.9891506
18223,n,68,69,270,271,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18223,-1,0.9903527,0.009647356
18224,FK506 nephropathy,14,16,87,104,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,-1,18224,-1,0.010346056,0.989654
18225,FK506 nephropathy,1,3,8,25,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18225,-1,0.011662769,0.9883372
18226,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18226,-1,0.0002169969,0.999783
18227,interstitial fibrosis,39,41,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18227,-1,0.00020932671,0.9997907
18229,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18229,-1,0.01138163,0.9886184
18230,P,32,33,215,216,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18230,-1,0.3582093,0.6417906
18231,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18231,-1,0.0117928935,0.98820716
18232,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18232,-1,0.011684163,0.9883158
18233,lead,34,35,245,249,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18233,-1,0.006521381,0.99347866
18237,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18237,-1,0.99947673,0.00052330137
18238,EE,11,12,69,71,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18238,-1,0.99941766,0.0005824047
18240,contrast,1,2,3,11,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,-1,18240,-1,0.96127284,0.038727142
18241,EE,1,2,6,8,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,-1,18241,-1,0.4617732,0.5382268
18242,EE,25,26,151,153,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,-1,-1,-1,18242,-1,0.9993907,0.0006092739
18244,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18244,-1,0.9995084,0.000491612
18245,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18245,-1,0.99951136,0.00048868236
18246,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18246,-1,0.99949324,0.00050679897
18247,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18247,-1,0.9994929,0.00050712563
18248,valvular disease,22,24,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18248,-1,0.002867129,0.9971329
18249,valvular abnormalities,10,12,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18249,-1,0.00018098857,0.999819
18250,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18250,-1,0.99948394,0.0005160457
18251,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18251,-1,0.999488,0.0005119455
18252,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18252,-1,0.99950016,0.0004998737
18253,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18253,-1,0.9995054,0.0004945516
18254,valvulopathy,7,8,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18254,-1,0.00022000498,0.99978
18256,aortic regurgitation,39,41,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18256,-1,0.00021366334,0.9997863
18259,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18259,-1,0.002465641,0.9975344
18260,aortic regurgitation,8,10,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18260,-1,0.00021412547,0.99978584
18261,aortic insufficiency,6,8,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,-1,-1,-1,18261,-1,0.000199017,0.999801
18263,nerve growth factor,6,9,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18263,-1,0.8087297,0.19127028
18265,PG-9,17,18,130,134,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18265,-1,0.99946636,0.0005336114
18267,nerve growth factor,31,34,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18267,-1,0.8078378,0.19216219
18268,NGF,35,36,253,256,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18268,-1,0.99941397,0.00058609614
18269,PG-9,6,7,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18269,-1,0.999491,0.0005089731
18272,S-(-)-ET-126,40,41,228,240,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18272,-1,0.99843985,0.0015601597
18273,PG-9,6,7,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,18273,-1,0.99945647,0.00054354663
18275,PG-9,6,7,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,-1,18275,-1,0.9994848,0.00051522494
18276,PG-9,0,1,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18276,-1,0.9994435,0.00055656617
18277,NGF,9,10,45,48,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18277,-1,0.9993992,0.0006008129
18278,NGF,2,3,12,15,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18278,-1,0.99942327,0.0005767423
18279,PG-9,6,7,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18279,-1,0.9994584,0.0005415933
18280,PG-9,12,13,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,-1,-1,-1,18280,-1,0.9994381,0.00056187436
18281,PG-9,7,8,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18281,-1,0.99945086,0.0005491721
18282,NGF,19,20,125,128,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18282,-1,0.99940634,0.0005936442
18283,PG-9,2,3,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18283,-1,0.99946755,0.0005325079
18285,tobramicyn,15,16,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,-1,18285,-1,0.00039739397,0.9996026
18288,n,3,4,10,11,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18288,-1,0.3717902,0.6282098
18290,TD,15,16,69,71,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18290,-1,0.0010202636,0.99897975
18291,n,17,18,73,74,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18291,-1,0.20967287,0.79032713
18293,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18293,-1,0.0052172793,0.99478275
18294,TD,19,20,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18294,-1,0.00071097934,0.99928904
18295,P,22,23,91,92,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18295,-1,0.08913382,0.91086614
18296,TD,15,16,108,110,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18296,-1,0.0011875626,0.99881244
18297,P,17,18,112,113,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18297,-1,0.09015489,0.9098451
18298,TD,14,15,84,86,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18298,-1,0.0040273354,0.9959727
18299,h,26,27,132,133,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18299,-1,0.017296115,0.98270386
18300,TD,28,29,137,139,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18300,-1,0.00489708,0.9951029
18301,Vd,31,32,142,144,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18301,-1,0.021183062,0.9788169
18302,TD,41,42,193,195,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18302,-1,0.006160286,0.9938397
18303,Cl,44,45,198,200,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18303,-1,0.40911543,0.5908845
18304,TD,54,55,259,261,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18304,-1,0.003966895,0.99603313
18306,TD,18,19,91,93,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,-1,-1,18306,-1,0.00022672235,0.9997733
18308,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18308,-1,0.0007645754,0.9992354
18309,decreased auditory function,7,10,38,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18309,-1,0.0001997777,0.99980026
18310,auditory loss,17,19,98,111,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18310,-1,0.00019728621,0.99980277
18311,decreased auditory function,32,35,174,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18311,-1,0.00020003483,0.9998
18317,vasodilators,8,9,56,68,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18317,-1,0.9085544,0.09144558
18320,GABA,29,30,215,219,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18320,-1,0.99947137,0.0005286792
18326,pindolol,7,8,65,73,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18326,-1,0.99952495,0.00047504372
18328,atenolol,11,12,89,97,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18328,-1,0.93859977,0.061400257
18332,methylatropine,8,9,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,-1,-1,-1,18332,-1,0.9994942,0.00050582405
18335,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,18335,-1,0.99946684,0.0005331514
18336,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,-1,-1,18336,-1,0.9994405,0.0005594572
18340,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18340,-1,0.9994764,0.0005236162
18341,nitric oxide synthase,41,44,231,252,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18341,-1,0.013654844,0.9863452
18342,FR 139317,13,15,78,87,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,-1,-1,18342,-1,0.99945873,0.00054122275
18344,FK,0,1,0,2,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18344,-1,0.9994184,0.00058167905
18345,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,-1,18345,-1,0.00048442336,0.99951553
18346,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,-1,-1,-1,18346,-1,0.9994837,0.0005162897
18347,FR 139317,3,5,22,31,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18347,-1,0.98856467,0.011435361
18349,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,-1,-1,-1,18349,-1,0.999461,0.0005390466
18350,Structural and functional impairment of mitochondria,0,6,0,52,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18350,-1,0.00033332675,0.9996667
18352,c,15,16,125,126,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18352,-1,0.9993957,0.0006042891
18354,ADR,5,6,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18354,-1,0.99948126,0.0005188005
18356,cardiovascular toxicity,17,19,90,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18356,-1,0.00021231794,0.99978775
18357,ADR,3,4,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18357,-1,0.99939847,0.00060152484
18358,c,8,9,70,71,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18358,-1,0.9993969,0.00060302444
18359,ADR,22,23,143,146,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18359,-1,0.9994215,0.000578528
18360,ADR,40,41,256,259,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18360,-1,0.99942553,0.00057451945
18361,ADR,10,11,53,56,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18361,-1,0.9994412,0.0005587712
18362,cardiovascular arrhythmias,12,14,64,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18362,-1,0.00020758757,0.9997924
18364,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18364,-1,0.99934465,0.0006553033
18365,swelling,51,52,295,303,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18365,-1,0.00021122699,0.9997888
18366,ADR,31,32,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,-1,18366,-1,0.9994461,0.00055385765
18367,ADR,21,22,126,129,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18367,-1,0.9993555,0.00064452295
18368,structural and functional impairment,27,31,179,215,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18368,-1,0.00034530286,0.99965465
3131,creatinine,8,9,41,51,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,3131,-1,0.9993957,0.0006043058
6755,sirolimus,1,2,8,17,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0,-1,0,6755,-1,0.99947673,0.0005233283
15904,cimetidine,7,8,40,50,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0,-1,0,15904,-1,0.99947816,0.0005218076
13703,enflurane,4,5,16,25,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,0,-1,0,13703,-1,0.9994505,0.00054945244
13783,calcium,21,22,139,146,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,0,-1,0,13783,-1,0.99943274,0.0005672622
7887,steroids,5,6,21,29,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0,-1,0,7887,-1,0.9994035,0.000596567
10008,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0,10008,-1,0.99943846,0.0005615098
16438,lignocaine,11,12,67,77,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0,-1,0,16438,-1,0.9994814,0.0005186252
7459,fluoxetine,3,4,10,20,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,0,-1,0,7459,-1,0.99948055,0.0005194435
2284,isoflurane,6,7,46,56,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,0,-1,0,2284,-1,0.9993487,0.00065132655
10961,Mazindol,0,1,0,8,Mazindol did not benefit strength at any point in the study.,2266990_5,0,-1,0,10961,-1,0.999468,0.000532028
14154,heparin,15,16,85,92,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,0,-1,0,14154,-1,0.99928975,0.00071023474
1110,dobutamine,10,11,58,68,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0,1110,-1,0.9995134,0.00048659922
15821,vincristine,35,36,193,204,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0,15821,-1,0.9995034,0.0004966202
1475,anthracycline,4,5,35,48,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0,-1,0,1475,-1,0.99942964,0.00057036843
10788,neurotensin,16,17,127,138,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0,10788,-1,0.9994036,0.00059641065
14350,adriamycin,4,5,25,35,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0,-1,0,14350,-1,0.99948895,0.00051098265
6119,desipramine,28,29,175,186,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0,-1,0,6119,-1,0.9994898,0.0005101923
4996,spironolactone,13,14,72,86,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,0,-1,0,4996,-1,0.99947506,0.000524958
17609,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,17609,-1,0.99945897,0.00054098683
17183,aminoglycosides,4,5,34,49,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,0,-1,0,17183,-1,0.99945253,0.00054746965
8690,steroid,17,18,126,133,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,0,-1,0,8690,-1,0.9994324,0.00056753826
6656,phenytoin,1,2,10,19,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,0,-1,0,6656,-1,0.9994849,0.0005150319
1928,citalopram,7,8,49,59,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0,-1,0,1928,-1,0.9994721,0.0005279961
3172,dexamethasone,11,12,62,75,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,0,-1,0,3172,-1,0.99942315,0.00057687284
1905,tacrolimus,7,8,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,1905,-1,0.9994611,0.00053894724
515,Warfarin,17,18,103,111,"In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.",10669626_11,0,-1,0,515,-1,0.99942636,0.0005736937
14831,lithium,14,15,75,82,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,14831,-1,0.9994609,0.0005391566
11501,enalapril,12,13,64,73,Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril.,2559236_3,0,-1,0,11501,-1,0.99947125,0.0005287156
7006,Doxorubicin,0,1,0,11,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,0,-1,0,7006,-1,0.99935204,0.00064801157
17931,cisapride,9,10,65,74,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0,17931,-1,0.99949276,0.00050720875
5869,scopolamine,2,3,14,25,Injections of scopolamine into mice resulted in impaired performance on Y-maze tests (a 37% decreases in alternation behavior).,16428827_6,0,-1,0,5869,-1,0.9994709,0.00052916666
190,calcium,4,5,25,32,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0,190,-1,0.99936014,0.0006398326
1999,paracetamol,26,27,131,142,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0,-1,0,1999,-1,0.99949205,0.00050788844
18031,appetite suppressants,2,4,10,31,Intake of appetite suppressants may accelerate the progression of the disease.,9727773_10,0,-1,0,18031,-1,0.9994229,0.00057709886
1734,Cocaine,0,1,0,7,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,0,-1,0,1734,-1,0.9993919,0.0006081168
18123,amphetamine,5,6,26,37,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,0,-1,0,18123,-1,0.9994954,0.00050462154
545,Dopamine,0,1,0,8,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0,-1,0,545,-1,0.99937904,0.0006208775
11521,fentanyl,15,16,103,111,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,0,-1,0,11521,-1,0.9994709,0.00052914774
13634,benzodiazepines,3,4,20,35,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0,-1,0,13634,-1,0.999485,0.0005149323
10099,methamphetamine,3,4,24,39,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,0,-1,0,10099,-1,0.9994313,0.00056861195
10995,naloxone,29,30,158,166,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0,-1,0,10995,-1,0.99949336,0.0005066512
12799,deferoxamine,18,19,105,117,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0,-1,0,12799,-1,0.99945086,0.00054910063
12871,calcitonin,12,13,76,86,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,0,-1,0,12871,-1,0.99949455,0.00050544407
7059,smoking,8,9,42,49,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,0,-1,0,7059,-1,0.9993919,0.0006080597
11534,alfentanil,19,20,118,128,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0,-1,0,11534,-1,0.99947447,0.0005255327
16628,lithium,9,10,53,60,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,0,-1,0,16628,-1,0.9994537,0.00054625905
5719,nicotine,4,5,21,29,CONCLUSION: The 4-mg nicotine lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions.,16330293_18,0,-1,0,5719,-1,0.9994815,0.0005184717
3811,steroids,1,2,12,20,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,0,-1,0,3811,-1,0.99937963,0.00062028033
18068,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0,18068,-1,0.99950445,0.00049557164
7758,levetiracetam,3,4,26,39,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0,-1,0,7758,-1,0.999483,0.0005170322
592,sodium,2,3,11,17,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0,-1,0,592,-1,0.9994367,0.00056329434
7221,apomorphine,3,4,21,32,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0,7221,-1,0.99944025,0.0005597603
1334,doxorubicin,2,3,18,29,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,0,-1,0,1334,-1,0.9994357,0.00056421285
2198,creatinine,13,14,84,94,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0,2198,-1,0.9994267,0.0005733455
5390,propofol,12,13,83,91,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0,-1,0,5390,-1,0.99935156,0.0006484585
15712,bupivacaine,2,3,8,19,dose of bupivacaine.,8231633_3,0,-1,0,15712,-1,0.9994765,0.00052353786
2098,cisplatin,16,17,108,117,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2098,-1,0.9993229,0.000677121
13426,antidepressants,3,4,23,38,Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly.,4027862_3,0,-1,0,13426,-1,0.99929523,0.00070468924
2120,cisplatin,18,19,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2120,-1,0.99941885,0.0005811886
16834,Cyclophosphamide,2,3,13,29,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,0,-1,0,16834,-1,0.99949324,0.0005067782
15040,Enflurane,0,1,0,9,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,0,-1,0,15040,-1,0.99944013,0.00055981014
14598,haloperidol,16,17,93,104,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,0,-1,0,14598,-1,0.9994678,0.0005321795
17472,testosterone,22,23,131,143,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,0,-1,0,17472,-1,0.9994135,0.0005865071
13631,potassium,6,7,32,41,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0,13631,-1,0.9994431,0.0005569323
14750,testosterone,25,26,157,169,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0,-1,0,14750,-1,0.9994541,0.00054590846
9473,sodium,25,26,128,134,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,0,-1,0,9473,-1,0.99951315,0.0004868444
159,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0,159,-1,0.999463,0.00053702656
17086,steroids,20,21,128,136,CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.,9098464_9,0,-1,0,17086,-1,0.99930763,0.00069233647
7408,pravastatin,12,13,75,86,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,7408,-1,0.99950373,0.0004962542
8647,papaverine,3,4,14,24,The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings.,18726058_6,0,-1,0,8647,-1,0.99949026,0.0005097203
7341,dopamine,7,8,86,94,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0,7341,-1,0.99946815,0.00053186214
13992,carbamazepine,2,3,9,22,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,0,-1,0,13992,-1,0.99949193,0.0005081011
8643,papaverine,20,21,150,160,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,0,-1,0,8643,-1,0.99948895,0.00051106303
8058,morphine,38,39,198,206,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,0,-1,0,8058,-1,0.9994035,0.00059654255
13913,verapamil,26,27,192,201,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0,13913,-1,0.9994925,0.0005074777
9541,glycine,3,4,15,22,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0,-1,0,9541,-1,0.9994011,0.0005989336
14168,sodium citrate,19,21,133,147,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0,14168,-1,0.9994598,0.0005402178
8828,Mesna,29,30,174,179,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0,8828,-1,0.9994547,0.00054534944
2973,Rizatriptan,0,1,0,11,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0,-1,0,2973,-1,0.99947363,0.00052635116
10770,dopamine,7,8,35,43,"However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.",20880751_2,0,-1,0,10770,-1,0.9993832,0.0006167676
1320,doxorubicin,32,33,189,200,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1320,-1,0.9994677,0.0005322912
18193,doxorubicin,7,8,43,54,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,0,-1,0,18193,-1,0.99942267,0.0005773536
13841,calcitonin,1,2,9,19,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,0,-1,0,13841,-1,0.99942243,0.0005775831
15551,haloperidol,7,8,46,57,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0,-1,0,15551,-1,0.99948883,0.00051118335
8582,mefloquine,7,8,47,57,Neuropsychiatric side effects after the use of mefloquine.,1867351_0,0,-1,0,8582,-1,0.99946386,0.0005361141
12969,bromocriptine,4,5,32,45,Postpartum psychosis induced by bromocriptine.,3686155_0,0,-1,0,12969,-1,0.999479,0.0005210273
12940,paracetamol,19,20,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0,12940,-1,0.99950767,0.00049236725
4729,Salbutamol,2,3,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0,-1,0,4729,-1,0.9994764,0.0005236012
2790,heparin,1,2,21,28,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,0,-1,0,2790,-1,0.9994497,0.0005502761
15819,vincristine,8,9,56,67,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0,15819,-1,0.9995073,0.00049268507
4030,dopamine,4,5,27,35,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,0,-1,0,4030,-1,0.99944276,0.0005572599
3897,prazosin,14,15,70,78,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0,-1,0,3897,-1,0.9994779,0.0005221076
15899,cimetidine,36,37,205,215,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,0,-1,0,15899,-1,0.9994481,0.0005518405
2014,timolol,34,35,174,181,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0,2014,-1,0.9995078,0.0004922565
11908,epinephrine,8,9,47,58,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,0,-1,0,11908,-1,0.999423,0.00057704776
1350,diazepam,35,36,142,150,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0,-1,0,1350,-1,0.99946815,0.0005318089
14515,cimetidine,20,21,129,139,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,0,-1,0,14515,-1,0.9994979,0.0005020799
13442,gentamicin,18,19,105,115,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,0,-1,0,13442,-1,0.9994229,0.0005771495
8963,sulindac,15,16,114,122,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,0,-1,0,8963,-1,0.9994917,0.000508256
16058,midazolam,17,18,93,102,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,0,-1,0,16058,-1,0.99949443,0.0005055744
17724,cisapride,12,13,75,84,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0,-1,0,17724,-1,0.9995303,0.00046964508
16040,magnesium,27,28,131,140,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,0,-1,0,16040,-1,0.9993992,0.0006008373
14215,Adriamycin,0,1,0,10,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0,-1,0,14215,-1,0.9994721,0.0005279497
15649,nitroglycerin,8,9,54,67,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,0,-1,0,15649,-1,0.9994955,0.00050446455
3197,tacrolimus,12,13,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,3197,-1,0.99948114,0.00051886577
14517,cimetidine,10,11,52,62,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,0,-1,0,14517,-1,0.99951696,0.00048309195
5790,enalapril,18,19,126,135,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0,5790,-1,0.99949646,0.00050346943
16188,doxorubicin,25,26,151,162,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,0,-1,0,16188,-1,0.9993781,0.0006218324
15366,cholesterol,34,35,195,206,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,0,-1,0,15366,-1,0.99935824,0.00064171286
5092,glutamate,15,16,100,109,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0,-1,0,5092,-1,0.99939907,0.000600879
2146,adenosine,6,7,47,56,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,0,-1,0,2146,-1,0.9994357,0.0005642804
2421,spironolactone,5,6,33,47,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,0,-1,0,2421,-1,0.999482,0.0005180877
16424,acetaminophen,7,8,36,49,"Through 30 years of widespread use, acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages.",8682684_1,0,-1,0,16424,-1,0.9994536,0.0005464059
8473,pergolide,11,12,57,66,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0,-1,0,8473,-1,0.99945563,0.0005443318
2503,morphine,14,15,111,119,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,2503,-1,0.9994609,0.0005391463
4179,serotonin,22,23,136,145,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0,4179,-1,0.99948174,0.00051832275
16496,dipyridamole,23,24,139,151,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0,16496,-1,0.9995042,0.0004958237
13693,ranitidine,18,19,81,91,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0,13693,-1,0.99950576,0.0004942747
15156,metoprolol,11,12,77,87,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,0,-1,0,15156,-1,0.99950314,0.0004968807
10979,scopolamine,3,4,20,31,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0,10979,-1,0.9995167,0.00048327592
18129,haloperidol,19,20,95,106,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,0,-1,0,18129,-1,0.9994697,0.0005303475
7657,diclofenac,19,20,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0,-1,0,7657,-1,0.9994937,0.0005063185
5618,cocaine,33,34,240,247,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,0,-1,0,5618,-1,0.9993563,0.00064364634
4137,mesna,16,17,78,83,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,4137,-1,0.99945134,0.00054860313
14679,indomethacin,1,2,9,21,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,0,-1,0,14679,-1,0.99944586,0.000554081
630,dopamine,27,28,167,175,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0,630,-1,0.9994728,0.0005271967
2242,heparin,10,11,73,80,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,0,-1,0,2242,-1,0.9994117,0.000588258
2026,timolol,12,13,61,68,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0,-1,0,2026,-1,0.99948895,0.0005110138
13946,propranolol,5,6,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0,13946,-1,0.9995159,0.0004840624
5347,alcohol,11,12,60,67,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,0,-1,0,5347,-1,0.99937975,0.000620226
15838,papaverine,0,1,0,10,"papaverine, 100 micrograms.",8386779_4,0,-1,0,15838,-1,0.9994524,0.00054757897
2977,ergotamine,18,19,117,127,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0,-1,0,2977,-1,0.9995061,0.0004938916
6887,cocaine,20,21,126,133,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,0,-1,0,6887,-1,0.99943084,0.00056917104
8987,sulindac,16,17,82,90,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,0,-1,0,8987,-1,0.9994821,0.0005179618
11824,carbamazepine,1,2,8,21,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0,11824,-1,0.99947566,0.00052433036
1170,gemcitabine,36,37,152,163,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1170,-1,0.9983911,0.001608913
8456,Fentanyl,0,1,0,8,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,0,-1,0,8456,-1,0.9994167,0.00058335974
852,ketamine,14,15,75,83,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,0,-1,0,852,-1,0.9993549,0.0006451031
665,ketamine,5,6,50,58,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,0,-1,0,665,-1,0.9994497,0.0005502926
3775,methamphetamine,22,23,142,157,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0,-1,0,3775,-1,0.9994634,0.000536588
6010,pilocarpine,20,21,100,111,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0,-1,0,6010,-1,0.9994832,0.0005167491
14833,lithium,12,13,53,60,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,0,-1,0,14833,-1,0.9993656,0.0006343421
10723,Capecitabine,4,5,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0,-1,0,10723,-1,0.9994117,0.0005883367
2399,potassium,12,13,86,95,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,0,-1,0,2399,-1,0.9994331,0.0005668938
13527,metoclopramide,9,10,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0,13527,-1,0.9994947,0.00050534453
11469,fluoxetine,3,4,24,34,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,0,-1,0,11469,-1,0.9994616,0.0005384489
15246,ouabain,26,27,169,176,"Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted.",783197_4,0,-1,0,15246,-1,0.99948126,0.0005187718
17010,adriamycin,12,13,94,104,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0,-1,0,17010,-1,0.9995091,0.0004909566
17410,"1-bromo-1-chloro-2,2,2-trifluoroethane",9,10,50,88,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0,17410,-1,0.9994461,0.0005539321
10706,scopolamine,7,8,66,77,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,0,-1,0,10706,-1,0.9995117,0.00048830424
7512,ritonavir,7,8,38,47,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,0,-1,0,7512,-1,0.9995023,0.00049767864
6890,Statins,0,1,0,7,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,0,-1,0,6890,-1,0.9993631,0.0006368427
11983,diazepam,3,4,13,21,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0,-1,0,11983,-1,0.9995192,0.00048080573
11905,flestolol,4,5,21,30,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0,-1,0,11905,-1,0.9994618,0.0005382108
2166,adenosine,37,38,239,248,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0,2166,-1,0.99942636,0.0005736636
17096,nifedipine,10,11,66,76,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0,17096,-1,0.9994814,0.00051865465
15267,rifampin,17,18,124,132,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,0,-1,0,15267,-1,0.99941707,0.00058295776
8801,Oral Contraceptives,7,9,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0,-1,0,8801,-1,0.999466,0.00053401286
670,lidocaine,11,12,71,80,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0,670,-1,0.99944407,0.00055591826
5846,methylphenidate,12,13,64,79,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,0,-1,0,5846,-1,0.99947315,0.00052686565
12471,nicotine,22,23,123,131,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,0,-1,0,12471,-1,0.99948394,0.0005160098
12793,deferoxamine,9,10,53,65,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0,-1,0,12793,-1,0.99947613,0.00052386255
10583,amiodarone,4,5,21,31,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,0,-1,0,10583,-1,0.9994166,0.00058346085
10241,prazosin,8,9,45,53,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,0,-1,0,10241,-1,0.9994773,0.0005226977
15869,oral contraceptives,13,15,78,97,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0,-1,0,15869,-1,0.9994522,0.0005478011
14734,saralasin,17,18,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0,14734,-1,0.99948645,0.00051357015
7478,Disulfiram,0,1,0,10,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,0,-1,0,7478,-1,0.9994789,0.000521102
11892,Flestolol,0,1,0,9,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0,-1,0,11892,-1,0.99944526,0.00055469817
619,isoproterenol,5,6,52,65,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,0,-1,0,619,-1,0.999501,0.0004989613
5429,steroid,4,5,30,37,Dose reduction or concomitant steroid therapy may have a role in selected patients.,1595783_6,0,-1,0,5429,-1,0.99932706,0.000672932
3209,tacrolimus,32,33,183,193,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,3209,-1,0.9994783,0.00052176986
2493,naloxone,5,6,44,52,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0,2493,-1,0.99949455,0.000505465
8187,Methamphetamine,0,1,0,15,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,0,-1,0,8187,-1,0.99943215,0.0005678721
9767,omeprazole,4,5,34,44,"Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug.",1992636_3,0,-1,0,9767,-1,0.99947554,0.00052450737
16862,bradykinin,4,5,22,32,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,0,-1,0,16862,-1,0.9993679,0.000632105
11604,bupivacaine,2,3,13,24,injection of bupivacaine were ineffective.,2594614_4,0,-1,0,11604,-1,0.9994981,0.0005018
2024,Timolol,0,1,0,7,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0,-1,0,2024,-1,0.9995042,0.00049577025
13957,propranolol,14,15,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0,13957,-1,0.999479,0.0005209937
15460,clomipramine,9,10,45,57,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,0,-1,0,15460,-1,0.99950635,0.00049364945
12948,acetaminophen,32,33,151,164,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0,12948,-1,0.9994659,0.0005341106
2626,reserpine,4,5,24,33,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,0,-1,0,2626,-1,0.99944514,0.0005548135
16659,antidepressants,5,6,35,50,Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues.,8800187_2,0,-1,0,16659,-1,0.9994236,0.00057636393
4253,bicuculline,5,6,19,30,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0,4253,-1,0.9995142,0.00048577847
4552,oxygen,17,18,126,132,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,0,-1,0,4552,-1,0.9994435,0.0005564778
12456,Cisplatin,17,18,106,115,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,12456,-1,0.999416,0.00058397016
7639,aspirin,6,7,44,51,Use of gastroprotective agents and low-dose aspirin was allowed.,17965424_2,0,-1,0,7639,-1,0.9993622,0.0006378468
14760,testosterone,12,13,80,92,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,0,-1,0,14760,-1,0.9993782,0.00062175776
7936,heparin,31,32,213,220,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,0,-1,0,7936,-1,0.9993343,0.0006657423
4537,epinephrine,13,14,79,90,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,0,-1,0,4537,-1,0.99942183,0.0005781565
6083,alcohol,3,4,21,28,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,0,-1,0,6083,-1,0.99935347,0.00064651127
192,calcium,9,10,60,67,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,0,-1,0,192,-1,0.99937636,0.0006236412
13246,vancomycin,8,9,57,67,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,0,-1,0,13246,-1,0.9993284,0.0006717092
10616,phenobarbitone,14,15,104,118,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0,10616,-1,0.99948055,0.0005194492
16867,dextran,11,12,92,99,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0,-1,0,16867,-1,0.99946135,0.0005386008
16044,ciprofloxacin,3,4,31,44,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,0,-1,0,16044,-1,0.99939394,0.0006060439
14513,cimetidine,22,23,122,132,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0,14513,-1,0.9995011,0.00049890624
11803,norepinephrine,8,9,68,82,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0,11803,-1,0.999432,0.00056793814
3893,prazosin,20,21,124,132,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,0,-1,0,3893,-1,0.9995055,0.0004945257
15529,oxytocin,8,9,47,55,The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.,803783_5,0,-1,0,15529,-1,0.99931514,0.00068484456
14292,aminoglycoside,3,4,23,37,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0,-1,0,14292,-1,0.9994306,0.00056939776
5327,etoposide,14,15,102,111,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,5327,-1,0.9994779,0.0005221609
9523,oxycodone,16,17,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0,-1,0,9523,-1,0.99948126,0.0005187231
187,Magnesium,0,1,0,9,Magnesium levels in patients on lithium treatment were unchanged from baseline levels.,10354657_11,0,-1,0,187,-1,0.9993573,0.00064269005
15406,zidovudine,17,18,96,106,"For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively.",7905523_6,0,-1,0,15406,-1,0.9994869,0.0005131048
8094,nicotine,8,9,45,53,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0,-1,0,8094,-1,0.9994435,0.0005565728
6022,prostaglandins,4,5,24,38,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,0,-1,0,6022,-1,0.99925333,0.00074664026
3943,lithium,41,42,258,265,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0,-1,0,3943,-1,0.9994342,0.00056585256
11871,terbutaline,11,12,62,73,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0,-1,0,11871,-1,0.99948716,0.00051284564
13100,trihexyphenidyl,5,6,29,44,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0,-1,0,13100,-1,0.99946517,0.0005348509
11183,theophylline,19,20,152,164,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,0,-1,0,11183,-1,0.9992361,0.0007638489
13844,calcitonin,11,12,57,67,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,0,-1,0,13844,-1,0.99946994,0.00053011783
13626,potassium,2,3,11,20,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0,13626,-1,0.9994254,0.00057458953
13662,sulphasalazine,3,4,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0,-1,0,13662,-1,0.9994673,0.0005326799
4093,amphetamine,15,16,84,95,Nine days later locomotor activity was measured in response to a single low dose of amphetamine (0.5 mg/kg).,14596845_6,0,-1,0,4093,-1,0.99947315,0.0005268794
7273,bromocriptine,32,33,204,217,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0,-1,0,7273,-1,0.99949825,0.0005017938
7965,thalidomide,14,15,99,110,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,0,-1,0,7965,-1,0.99948776,0.00051224645
1163,cisplatin,41,42,241,250,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1163,-1,0.9993849,0.0006151212
10348,creatinine,9,10,65,75,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,10348,-1,0.999421,0.0005790002
3785,dopamine,14,15,96,104,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,0,-1,0,3785,-1,0.9994004,0.0005996573
4592,aspirin,13,14,84,91,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,0,-1,0,4592,-1,0.99940383,0.00059611397
15626,phenylephrine,2,3,12,25,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,0,-1,0,15626,-1,0.9994991,0.0005009111
5543,apomorphine,46,47,291,302,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,0,-1,0,5543,-1,0.999483,0.0005170295
467,clozapine,2,3,12,21,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,0,-1,0,467,-1,0.99950325,0.0004967405
6899,statins,4,5,32,39,These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.,17241784_7,0,-1,0,6899,-1,0.9993318,0.0006681882
16544,creatinine,4,5,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,16544,-1,0.9993705,0.0006295126
1177,gemcitabine,10,11,59,70,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1177,-1,0.99937755,0.00062252185
10041,modafinil,23,24,151,160,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0,-1,0,10041,-1,0.9995117,0.00048833404
2566,bupropion,30,31,165,174,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0,-1,0,2566,-1,0.99950874,0.0004911995
17406,"1,1-dichloro-2,2,2-trifluoroethane",21,22,129,163,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0,17406,-1,0.9994234,0.000576653
3175,dexamethasone,12,13,81,94,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,0,-1,0,3175,-1,0.9993374,0.00066263176
18120,cocaine,15,16,95,102,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,0,-1,0,18120,-1,0.99941707,0.0005829962
16607,ethanol,12,13,84,91,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0,-1,0,16607,-1,0.99939775,0.00060228584
3366,docetaxel,35,36,213,222,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,3366,-1,0.999421,0.0005789845
13261,vancomycin,3,4,17,27,"We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.",3934126_6,0,-1,0,13261,-1,0.99934334,0.00065660686
6235,epinephrine,9,10,79,90,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,0,-1,0,6235,-1,0.9994758,0.0005243044
17676,Prilocaine,0,1,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0,17676,-1,0.9994388,0.0005611791
259,acetaminophen,15,16,68,81,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,0,-1,0,259,-1,0.99949384,0.0005061994
14994,dopamine,27,28,145,153,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,0,-1,0,14994,-1,0.9993899,0.0006100586
543,apomorphine,3,4,9,20,"In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage.",10683478_6,0,-1,0,543,-1,0.99946266,0.00053739623
7861,methylphenidate,34,35,163,178,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0,7861,-1,0.99949455,0.00050543464
6818,serotonin,13,14,90,99,Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.,17194457_0,0,-1,0,6818,-1,0.9994123,0.00058775273
12747,testosterone,13,14,112,124,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,0,-1,0,12747,-1,0.9994469,0.00055310596
6251,carbachol,13,14,72,81,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0,-1,0,6251,-1,0.9994716,0.00052839576
1868,prochlorperazine,14,15,104,120,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,0,-1,0,1868,-1,0.9995053,0.00049466424
10231,enalapril,9,10,51,60,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,0,-1,0,10231,-1,0.9994924,0.00050761335
7840,estradiol,2,3,15,24,"Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.",18162529_11,0,-1,0,7840,-1,0.9993025,0.0006975138
11377,lindane,17,18,121,128,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,0,-1,0,11377,-1,0.9994981,0.000501839
14938,paramethasone,3,4,31,44,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0,-1,0,14938,-1,0.999423,0.00057698664
14921,Carboplatin,0,1,0,11,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0,-1,0,14921,-1,0.9994815,0.0005185402
10812,succinylcholine,11,12,78,93,BACKGROUND: patients undergoing electroconvulsive therapy (ECT) often receive succinylcholine as part of the anesthetic procedure.,21029050_1,0,-1,0,10812,-1,0.9994541,0.0005458983
8270,histamine,17,18,87,96,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0,-1,0,8270,-1,0.9994273,0.0005727267
9708,Nimodipine,0,1,0,10,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,0,-1,0,9708,-1,0.99950635,0.00049361296
17838,carboplatin,6,7,33,44,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,17838,-1,0.9994635,0.0005364985
5731,gabapentin,3,4,12,22,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,0,-1,0,5731,-1,0.99946517,0.00053487206
9564,haloperidol,5,6,29,40,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,9564,-1,0.9995096,0.0004904465
14863,carbimazole,12,13,71,82,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,0,-1,0,14863,-1,0.9995029,0.0004970625
10234,angiotensin,4,5,26,37,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,0,-1,0,10234,-1,0.9994418,0.0005581891
10610,phenobarbitone,3,4,22,36,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0,-1,0,10610,-1,0.9995035,0.0004965287
8082,nicotine,4,5,24,32,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,8082,-1,0.99944264,0.00055739534
15943,labetalol,12,13,102,111,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,0,-1,0,15943,-1,0.99944705,0.0005529533
8382,metoprolol,5,6,26,36,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0,8382,-1,0.9994904,0.00050964794
7993,morphine,18,19,128,136,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,0,-1,0,7993,-1,0.99946135,0.00053863006
2815,metoclopramide,3,4,21,35,The patient received metoclopramide 10 mg i.v.,12139551_2,0,-1,0,2815,-1,0.9994723,0.0005276894
1607,doxorubicin,26,27,183,194,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0,-1,0,1607,-1,0.999488,0.0005119223
8119,theophylline,17,18,108,120,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,0,-1,0,8119,-1,0.99951386,0.00048614005
14585,scopolamine,4,5,30,41,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0,14585,-1,0.99949217,0.00050780864
10981,cycloheximide,16,17,120,133,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0,10981,-1,0.9995167,0.00048332426
906,cyclosporine,13,14,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0,-1,0,906,-1,0.9994467,0.00055327354
11237,phenobarbital,9,10,57,70,An experiment was performed to test whether inclusion of phenobarbital in a choline-devoid diet would increase the hepatocarcinogenicity of the diet.,2396046_1,0,-1,0,11237,-1,0.9994469,0.0005530743
8423,fentanyl,1,2,9,17,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0,8423,-1,0.99947363,0.00052636187
11252,methyldopa,9,10,68,78,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0,-1,0,11252,-1,0.99949276,0.0005072523
2487,Morphine,0,1,0,8,Morphine but not nicotine induced a dose-dependent catalepsy.,11900788_2,0,-1,0,2487,-1,0.99943095,0.0005690419
16691,tacrolimus,11,12,80,90,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0,-1,0,16691,-1,0.99949265,0.0005073828
1151,cisplatin,2,3,12,21,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1151,-1,0.9994254,0.00057461637
14684,Indomethacin,0,1,0,12,Indomethacin was first given four weeks prior to the onset of symptoms.,7263204_3,0,-1,0,14684,-1,0.99947935,0.00052068924
14130,ketamine,25,26,147,155,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0,14130,-1,0.9994281,0.00057184603
16806,diazepam,26,27,130,138,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,0,-1,0,16806,-1,0.99948287,0.0005171554
9831,ephedrine,7,8,44,53,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,0,-1,0,9831,-1,0.99949,0.00050998904
11044,cisplatin,11,12,76,85,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,11044,-1,0.9994704,0.00052960316
12872,calcitonin,16,17,103,113,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,0,-1,0,12872,-1,0.9994748,0.00052515964
6418,sulpiride,13,14,80,89,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0,6418,-1,0.99950135,0.00049868657
2373,anthracycline,21,22,124,137,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0,-1,0,2373,-1,0.99943453,0.0005654255
14414,noradrenaline,18,19,139,152,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,0,-1,0,14414,-1,0.9994752,0.0005248239
5372,benzoylecgonine,11,12,63,78,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0,-1,0,5372,-1,0.999464,0.0005359886
6205,cocaine,3,4,19,26,Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.,16725121_4,0,-1,0,6205,-1,0.99941826,0.0005817739
15262,oxygen,36,37,198,204,"Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption.",783197_11,0,-1,0,15262,-1,0.9992931,0.0007068962
3890,prazosin,6,7,35,43,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,0,-1,0,3890,-1,0.99947935,0.0005206679
2137,oral contraceptives,40,42,227,246,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0,2137,-1,0.9994599,0.00054013083
6507,mannitol,5,6,23,31,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,0,-1,0,6507,-1,0.9994031,0.00059683365
8930,bupropion,21,22,128,137,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0,-1,0,8930,-1,0.9994832,0.0005167161
7178,gentamicin,8,9,71,81,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0,-1,0,7178,-1,0.9994536,0.0005463626
18287,tobramycin,10,11,63,73,MATERIALS AND METHODS: Patients undergoing treatment with i.v. tobramycin (4 mg/kg/day) were randomised to two groups.,9875685_2,0,-1,0,18287,-1,0.999481,0.0005189594
14278,Sulindac,0,1,0,8,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,0,-1,0,14278,-1,0.9994642,0.0005358485
10029,modafinil,3,4,23,32,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0,-1,0,10029,-1,0.99948126,0.0005187844
6118,desipramine,17,18,93,104,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0,-1,0,6118,-1,0.9994862,0.0005137145
11663,angiotensin,5,6,27,38,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0,-1,0,11663,-1,0.9994543,0.00054563273
3017,sodium,1,2,8,14,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0,-1,0,3017,-1,0.99940884,0.00059114746
13145,morphine,6,7,30,38,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,0,-1,0,13145,-1,0.999361,0.0006390706
1123,metoprolol,9,10,63,73,No significant differences were found in any parameter between metoprolol and metoprolol-glucagon.,11079278_11,0,-1,0,1123,-1,0.9994703,0.00052978017
14763,gentamicin,5,6,42,52,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,0,-1,0,14763,-1,0.99942786,0.00057210313
12964,isoflurane,19,20,94,104,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,0,-1,0,12964,-1,0.99942505,0.00057499605
15487,fluorescein,31,32,206,217,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0,-1,0,15487,-1,0.9994808,0.00051930017
15178,creatinine,7,8,46,56,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0,15178,-1,0.9993382,0.0006618113
6445,steroid,17,18,99,106,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,0,-1,0,6445,-1,0.9993118,0.00068815204
3185,dexamethasone,3,4,17,30,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,0,-1,0,3185,-1,0.9994055,0.00059453264
11117,morphine,26,27,129,137,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,0,-1,0,11117,-1,0.9993999,0.0006001405
2991,rizatriptan,27,28,140,151,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0,-1,0,2991,-1,0.9995214,0.00047862725
17230,tamoxifen,13,14,87,96,BACKGROUND: Increased attention has been focused recently on the estrogenic effects of tamoxifen.,9205462_1,0,-1,0,17230,-1,0.99935883,0.0006411679
6943,clonidine,7,8,37,46,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,0,-1,0,6943,-1,0.99948525,0.00051476405
1321,cyclophosphamide,44,45,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1321,-1,0.9994935,0.00050653477
480,clozapine,2,3,12,21,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,0,-1,0,480,-1,0.9995096,0.000490451
12052,carbamazepine,1,2,8,21,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,0,-1,0,12052,-1,0.99947697,0.0005230545
12165,desipramine,16,17,105,116,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0,-1,0,12165,-1,0.9995146,0.00048546464
2610,Reserpine,0,1,0,9,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0,-1,0,2610,-1,0.99949837,0.00050159695
18160,hydrocortisone,8,9,51,65,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,18160,-1,0.9994717,0.000528256
13294,phosphate,1,2,16,25,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0,-1,0,13294,-1,0.99945205,0.00054798863
5317,doxorubicin,41,42,288,299,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,5317,-1,0.9994623,0.0005376565
16147,Thiopentone,0,1,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,16147,-1,0.9994677,0.00053230743
6960,clonidine,16,17,92,101,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,0,-1,0,6960,-1,0.99948186,0.00051813305
8408,oxytocin,4,5,27,35,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,0,-1,0,8408,-1,0.99931395,0.00068601617
5970,iron,56,57,316,320,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0,5970,-1,0.9994265,0.0005735603
17385,levodopa,12,13,95,103,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0,-1,0,17385,-1,0.99950266,0.00049730187
14596,haloperidol,5,6,37,48,Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.,7161250_0,0,-1,0,14596,-1,0.99943405,0.00056589453
13277,5-fluorouracil,3,4,20,34,Cardiac toxicity of 5-fluorouracil.,3952818_0,0,-1,0,13277,-1,0.9994704,0.00052957766
13870,adenosine,14,15,88,97,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,0,-1,0,13870,-1,0.9994085,0.00059154996
5249,piroxicam,23,24,127,136,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,0,-1,0,5249,-1,0.99860436,0.0013956625
2019,timolol,52,53,271,278,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0,-1,0,2019,-1,0.9994931,0.0005068038
10374,Azathioprine,0,1,0,12,Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities.,2051906_4,0,-1,0,10374,-1,0.9994962,0.0005037116
13080,chloroquine,16,17,113,124,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,0,-1,0,13080,-1,0.9995079,0.0004921231
6662,phenytoin,2,3,18,27,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,0,-1,0,6662,-1,0.9994868,0.0005131982
3476,cortisol,75,76,434,442,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,3476,-1,0.9994301,0.00056991255
8487,pergolide,12,13,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0,-1,0,8487,-1,0.99948263,0.0005172848
1994,paracetamol,8,9,72,83,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0,-1,0,1994,-1,0.9995011,0.0004989215
462,dopamine,16,17,100,108,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,0,-1,0,462,-1,0.99944514,0.0005548772
1159,gemcitabine,25,26,131,142,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1159,-1,0.99937373,0.0006262822
16871,dextran,12,13,101,108,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0,16871,-1,0.99943286,0.0005670708
14940,paramethasone,14,15,73,86,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,0,-1,0,14940,-1,0.99940073,0.00059931475
16068,Smoking,0,1,0,7,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,0,-1,0,16068,-1,0.9994173,0.0005827534
3864,oral contraceptive,19,21,109,127,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0,-1,0,3864,-1,0.9994611,0.0005389341
3070,carbamazepine,13,14,89,102,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0,3070,-1,0.9994861,0.0005138757
13774,timolol,4,5,24,31,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,0,-1,0,13774,-1,0.9994863,0.0005136734
4013,dopamine,25,26,143,151,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,0,-1,0,4013,-1,0.9994599,0.0005400885
3655,lindane,22,23,150,157,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0,3655,-1,0.9995215,0.0004784792
7835,estradiol,18,19,120,129,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0,-1,0,7835,-1,0.9993825,0.0006174395
2845,alcohol,10,11,75,82,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,0,-1,0,2845,-1,0.9992834,0.0007166468
5098,amiodarone,8,9,57,67,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,0,-1,0,5098,-1,0.99948955,0.0005104087
2089,cisplatin,15,16,111,120,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2089,-1,0.99937695,0.0006231261
16210,caffeine,11,12,75,83,Participants were then tested on 2 occasions after 12-hour abstinence from caffeine in each of 2 protocols; this required a total of 4 laboratory visits.,8607407_5,0,-1,0,16210,-1,0.9993098,0.0006902326
16274,Paclitaxel,0,1,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0,16274,-1,0.9994754,0.00052464334
922,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,922,-1,0.99945384,0.0005461427
3101,bupropion,11,12,79,88,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3101,-1,0.99950016,0.0004998449
2641,risperidone,17,18,125,136,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,0,-1,0,2641,-1,0.9994666,0.0005334314
11166,pentoxifylline,6,7,34,48,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,0,-1,0,11166,-1,0.9994993,0.00050064165
6086,alcohol,1,2,4,11,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,0,-1,0,6086,-1,0.9994149,0.0005850917
13143,morphine,7,8,48,56,Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.,3780846_2,0,-1,0,13143,-1,0.99942636,0.000573721
12327,alfentanil,36,37,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,12327,-1,0.99950635,0.00049369084
7865,methylphenidate,14,15,78,93,Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing).,18182964_4,0,-1,0,7865,-1,0.99945086,0.0005491745
7300,iopamidol,23,24,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,7300,-1,0.9994722,0.0005278645
10976,morphine,9,10,67,75,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0,10976,-1,0.9994493,0.0005507397
12474,dopamine,39,40,245,253,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,0,-1,0,12474,-1,0.99944586,0.0005541602
7435,methotrexate,13,14,88,100,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,7435,-1,0.99945027,0.0005497285
1985,paracetamol,4,5,31,42,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0,-1,0,1985,-1,0.99949896,0.0005009701
13757,mexiletine,16,17,113,123,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,0,-1,0,13757,-1,0.9994727,0.0005273281
1073,vigabatrin,11,12,77,87,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0,-1,0,1073,-1,0.99948514,0.00051486585
7340,lipopolysaccharide,2,3,14,32,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0,7340,-1,0.9994868,0.0005131126
10170,creatinine,12,13,38,48,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0,10170,-1,0.99935037,0.0006495871
12125,lithium,6,7,56,63,Thyroid function and urine-concentrating ability during lithium treatment.,3001299_0,0,-1,0,12125,-1,0.9993861,0.00061395834
9380,cannabis,13,14,92,100,Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.,19631624_7,0,-1,0,9380,-1,0.9994248,0.000575186
10343,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0,10343,-1,0.9993272,0.0006728442
5461,azithromycin,9,10,53,65,Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.,15985056_10,0,-1,0,5461,-1,0.99949765,0.0005023904
10680,lidocaine,16,17,100,109,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,-1,0,10680,-1,0.9993942,0.00060583116
8766,cisplatin,34,35,206,215,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,8766,-1,0.9994172,0.0005828423
4123,mesna,17,18,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,4123,-1,0.99944586,0.0005541687
525,calcium,11,12,67,74,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0,525,-1,0.99943346,0.0005665557
6177,alanine,20,21,115,122,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0,6177,-1,0.9993782,0.0006217592
2008,timolol,6,7,44,51,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,0,-1,0,2008,-1,0.9994892,0.00051080366
17479,bromocriptine,13,14,107,120,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0,17479,-1,0.9994942,0.00050581206
11826,cocaine,11,12,87,94,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0,11826,-1,0.99943644,0.0005634929
14505,cimetidine,11,12,44,54,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0,14505,-1,0.99949896,0.00050103123
15519,Oxytocin,0,1,0,8,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,0,-1,0,15519,-1,0.99944407,0.00055592065
2116,cisplatin,5,6,32,41,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2116,-1,0.9994394,0.0005605545
4951,ribavirin,3,4,19,28,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,0,-1,0,4951,-1,0.9994899,0.0005100882
16220,sertraline,4,5,21,31,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,0,-1,0,16220,-1,0.9994803,0.00051977835
16905,cocaine,4,5,33,40,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,0,-1,0,16905,-1,0.9993556,0.00064435153
10665,ribavirin,18,19,116,125,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,0,-1,0,10665,-1,0.99940085,0.00059917
14749,estrogen,19,20,117,125,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0,-1,0,14749,-1,0.9994299,0.0005701369
8378,metoprolol,11,12,65,75,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,8378,-1,0.9994898,0.0005101826
16384,steroids,12,13,64,72,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0,16384,-1,0.99931693,0.0006830817
12853,potassium,6,7,28,37,In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac.,3560096_4,0,-1,0,12853,-1,0.9993917,0.0006082678
14241,aspirin,32,33,164,171,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0,-1,0,14241,-1,0.99943846,0.00056155375
16125,captopril,3,4,18,27,RESULTS: Lifetime captopril treatment significantly lowered mean arterial pressure in both groups.,8586822_4,0,-1,0,16125,-1,0.99947804,0.0005220394
11562,serotonin,12,13,79,88,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0,-1,0,11562,-1,0.9994704,0.00052957685
14575,amiodarone,3,4,18,28,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,0,-1,0,14575,-1,0.9994885,0.00051147037
14915,rapamycin,17,18,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0,14915,-1,0.99941516,0.0005848539
15827,vincristine,8,9,46,57,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,0,-1,0,15827,-1,0.9994986,0.0005013728
673,capsaicin,26,27,165,174,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0,673,-1,0.9994772,0.00052280055
15939,labetalol,6,7,45,54,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,0,-1,0,15939,-1,0.9994831,0.0005168139
13384,warfarin,10,11,52,60,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,0,-1,0,13384,-1,0.9993492,0.00065085996
15108,malondialdehyde,8,9,52,67,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0,-1,0,15108,-1,0.9994567,0.00054324616
1531,calcitonin,21,22,116,126,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0,-1,0,1531,-1,0.99947065,0.0005293889
13876,morphine,9,10,63,71,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0,-1,0,13876,-1,0.9994541,0.00054591236
10483,salbutamol,21,22,111,121,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0,-1,0,10483,-1,0.9994823,0.00051766186
4205,nitroglycerin,9,10,66,79,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,0,-1,0,4205,-1,0.9994708,0.0005292888
8591,mefloquine,10,11,74,84,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,0,-1,0,8591,-1,0.9994842,0.00051577477
697,tacrolimus,2,3,17,27,"We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.",10743694_2,0,-1,0,697,-1,0.9994466,0.000553445
6399,apomorphine,4,5,29,40,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,0,-1,0,6399,-1,0.99944884,0.00055120216
17689,lidocaine,7,8,39,48,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0,17689,-1,0.99943787,0.00056211976
5737,gabapentin,29,30,209,219,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0,5737,-1,0.9994351,0.00056488573
2851,acetylcholine,9,10,69,82,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,0,-1,0,2851,-1,0.9993661,0.0006339273
7392,blood urea nitrogen,10,13,68,87,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,7392,-1,0.99117154,0.008828433
2117,amifostine,7,8,46,56,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2117,-1,0.9994659,0.0005340846
2049,ribavirin,7,8,43,52,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,0,-1,0,2049,-1,0.99948335,0.0005166706
5265,piroxicam,3,4,12,21,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,0,-1,0,5265,-1,0.9985996,0.001400433
10786,haloperidol,17,18,141,152,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0,-1,0,10786,-1,0.9994294,0.00057058025
14507,creatinine,35,36,214,224,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0,14507,-1,0.99942976,0.00057020807
7646,diclofenac,14,15,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0,-1,0,7646,-1,0.9994748,0.0005251967
18314,isoniazid,10,11,86,95,Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.,9915601_0,0,-1,0,18314,-1,0.999493,0.000506983
4174,calcitonin,8,9,54,64,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0,4174,-1,0.9994536,0.0005463559
4011,amphetamine,14,15,86,97,Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole-treated rats is reported.,1436384_2,0,-1,0,4011,-1,0.99948406,0.000515893
379,cisplatin,33,34,171,180,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0,-1,0,379,-1,0.99935347,0.0006464894
18174,dipyridamole,13,14,115,127,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0,18174,-1,0.99949265,0.0005073638
15045,halothane,30,31,209,218,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0,15045,-1,0.9995048,0.0004951955
17523,risperidone,12,13,90,101,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0,-1,0,17523,-1,0.99949396,0.0005060406
12647,epinephrine,6,7,45,56,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,0,-1,0,12647,-1,0.99937063,0.00062934967
10962,mazindol,4,5,29,37,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0,10962,-1,0.9994887,0.0005112696
16200,caffeine,5,6,40,48,Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.,8607407_1,0,-1,0,16200,-1,0.9993753,0.00062471017
7417,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0,7417,-1,0.999456,0.0005440273
5222,cyclosporine,14,15,75,87,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,5222,-1,0.99947375,0.000526242
11601,bupivacaine,21,22,117,128,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0,11601,-1,0.9994905,0.00050945894
18228,creatinine,2,3,10,20,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0,-1,0,18228,-1,0.9994424,0.0005575994
717,tacrolimus,1,2,5,15,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,0,-1,0,717,-1,0.9994443,0.0005557307
4127,dexamethasone,16,17,78,91,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0,4127,-1,0.99940586,0.0005941797
4760,yohimbine,3,4,16,25,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0,-1,0,4760,-1,0.9995079,0.00049213687
14248,aspirin,16,17,80,87,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,0,-1,0,14248,-1,0.99929523,0.00070475717
911,tacrolimus,6,7,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0,-1,0,911,-1,0.99945456,0.0005454971
4714,cyclophosphamide,5,6,41,57,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0,-1,0,4714,-1,0.99946326,0.0005367246
15953,labetalol,7,8,49,58,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,0,-1,0,15953,-1,0.99946946,0.0005305108
9931,antidepressant,19,20,138,152,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,0,-1,0,9931,-1,0.99944574,0.00055422337
5629,methamphetamine,18,19,114,129,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,0,-1,0,5629,-1,0.999413,0.0005870152
14503,aspartate,27,28,170,179,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0,-1,0,14503,-1,0.9994566,0.00054336217
13402,amiodarone,11,12,75,85,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,0,-1,0,13402,-1,0.9994887,0.0005112928
17763,tamoxifen,9,10,68,77,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,0,-1,0,17763,-1,0.9993894,0.0006105152
16620,lithium,25,26,140,147,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,0,-1,0,16620,-1,0.9993806,0.000619394
16548,creatinine,14,15,75,85,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,16548,-1,0.9993309,0.0006691837
2292,bilirubin,15,16,92,101,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0,2292,-1,0.99935216,0.00064784416
13908,verapamil,11,12,66,75,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0,-1,0,13908,-1,0.9994966,0.0005033886
17824,glycine,13,14,67,74,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,0,-1,0,17824,-1,0.9993318,0.00066815765
3846,creatinine,23,24,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0,3846,-1,0.9994406,0.0005593534
1690,lithium,24,25,122,129,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,0,-1,0,1690,-1,0.99940133,0.0005986282
5736,gabapentin,4,5,29,39,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0,5736,-1,0.99943715,0.00056285504
12883,cefonicid,10,11,69,78,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0,12883,-1,0.9994986,0.0005014407
16858,Epinephrine,0,1,0,11,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,0,-1,0,16858,-1,0.9993544,0.0006455991
9623,lithium,2,3,14,21,Less frequent lithium administration and lower urine volume.,1987816_0,0,-1,0,9623,-1,0.99937433,0.00062564027
17773,tamoxifen,24,25,132,141,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,0,-1,0,17773,-1,0.99934095,0.00065899786
13567,heparin,8,9,66,73,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,0,-1,0,13567,-1,0.9993242,0.0006758384
7516,Ritonavir,0,1,0,9,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0,-1,0,7516,-1,0.9994685,0.00053146755
15035,isoflurane,10,11,77,87,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,0,-1,0,15035,-1,0.9994704,0.0005295511
3402,sodium,6,7,44,50,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,0,-1,0,3402,-1,0.9993305,0.00066947076
1520,verapamil,4,5,34,43,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,0,-1,0,1520,-1,0.9994912,0.00050872256
6475,lamivudine,15,16,120,130,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,0,-1,0,6475,-1,0.9995029,0.0004971062
13579,heparin,6,7,53,60,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,0,-1,0,13579,-1,0.99940646,0.00059357466
10715,5-fluorouracil,9,10,58,72,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0,-1,0,10715,-1,0.9994778,0.0005222375
7102,simvastatin,15,16,102,113,Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin.,17344566_2,0,-1,0,7102,-1,0.9994454,0.00055464427
15648,phenylephrine,6,7,37,50,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,0,-1,0,15648,-1,0.9994879,0.00051205774
17753,levofloxacin,9,10,52,64,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0,-1,0,17753,-1,0.9994917,0.000508265
16268,estradiol,11,12,52,61,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,0,-1,0,16268,-1,0.99938154,0.000618457
814,naloxone,13,14,86,94,i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg.,10840460_6,0,-1,0,814,-1,0.9994753,0.0005247629
610,isoproterenol,31,32,180,193,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0,-1,0,610,-1,0.99950576,0.00049424527
3816,cocaine,35,36,233,240,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,3816,-1,0.9994374,0.00056263997
9220,Sirolimus,2,3,12,21,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0,-1,0,9220,-1,0.9995146,0.00048547555
5533,Cocaine,0,1,0,7,"Cocaine generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects.",1610717_4,0,-1,0,5533,-1,0.9993783,0.0006216869
7907,lamivudine,24,25,162,172,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0,7907,-1,0.99949086,0.00050916773
1498,verapamil,19,20,106,115,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0,-1,0,1498,-1,0.99950397,0.00049599336
5451,Corticosteroids,0,1,0,15,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0,5451,-1,0.9994584,0.000541599
8884,isoproterenol,37,38,217,230,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,8884,-1,0.9994803,0.00051976147
16984,superoxide,2,3,11,21,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,0,-1,0,16984,-1,0.9994293,0.00057073357
1663,antidepressants,12,13,80,95,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,0,-1,0,1663,-1,0.9993718,0.0006281922
17659,bupivacaine,11,12,82,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0,-1,0,17659,-1,0.99948776,0.0005122687
916,cyclosporine,16,17,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,916,-1,0.99945134,0.00054868107
15859,didanosine,5,6,43,53,Adverse reactions possibly attributable to didanosine were common.,8387218_7,0,-1,0,15859,-1,0.99948466,0.00051532657
13481,hepatic injury,13,15,117,131,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1,13481,-1,0.00020724346,0.99979275
9203,hemorrhagic,18,19,110,121,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,1,1,9203,-1,0.00019029806,0.9998097
4801,cataracts,20,21,125,134,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,4801,-1,0.00021895069,0.9997811
7951,thrombosis,51,52,249,259,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1,7951,-1,0.00022820054,0.9997718
11270,hypotensive,31,32,205,216,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,-1,1,1,11270,-1,0.00018764546,0.9998124
730,arthritis,23,24,132,141,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,1,1,730,-1,0.00019477228,0.9998053
12706,nephrotoxicity,12,13,69,83,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1,12706,-1,0.0002037863,0.9997962
2238,convulsive,6,7,44,54,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,1,1,2238,-1,0.0001918439,0.99980813
16860,allergic reaction,21,23,123,140,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,16860,-1,0.00021315587,0.9997869
15090,ischemia,33,34,152,160,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,1,1,15090,-1,0.00022297158,0.999777
9762,Hemolytic anemia,0,2,0,16,Hemolytic anemia associated with the use of omeprazole.,1992636_0,-1,1,1,9762,-1,0.00018174187,0.99981827
18209,cardiotoxicity,17,18,125,139,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,1,1,18209,-1,0.00021490699,0.9997851
17038,death,20,21,117,122,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,1,1,17038,-1,0.00022435049,0.9997757
3912,bradycardia,21,22,112,123,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,1,1,3912,-1,0.00022553653,0.9997745
13371,cancers,24,25,167,174,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1,13371,-1,0.00020414297,0.99979585
9186,stroke,11,12,73,79,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,1,1,9186,-1,0.0002014301,0.9997986
6181,fever,5,6,18,23,"7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).",16720068_7,-1,1,1,6181,-1,0.00019405916,0.999806
17624,hyperactivity,22,23,151,164,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,1,1,17624,-1,0.0002215492,0.99977845
13352,rheumatoid arthritis,16,18,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,1,1,13352,-1,0.0001835072,0.9998165
2161,pain,7,8,41,45,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2161,-1,0.00020606986,0.99979395
15797,cardiotoxicity,5,6,25,39,There was no evidence of cardiotoxicity.,8305357_10,-1,1,1,15797,-1,0.00020504679,0.999795
10578,coma,1,2,9,13,Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment.,20635749_3,-1,1,1,10578,-1,0.00020167936,0.99979836
1936,fever,9,10,60,65,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1936,-1,0.000196559,0.9998035
1422,anuria,14,15,71,77,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,1,1,1422,-1,0.00022472147,0.99977523
12787,anemia,14,15,108,114,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,1,1,12787,-1,0.00018831204,0.9998117
12462,tumor,30,31,162,167,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1,12462,-1,0.0002071107,0.9997929
1591,nephrotoxicity,16,17,94,108,Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity.,1130930_2,-1,1,1,1591,-1,0.00020448642,0.9997955
14968,hypercholesterolemia,9,10,46,66,He assumed pravastatin (20 mg/day) because of hypercholesterolemia.,7604176_4,-1,1,1,14968,-1,0.00019408858,0.999806
12634,cancer,16,17,120,126,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1,12634,-1,0.00020514593,0.9997949
16271,thrombosis,28,29,177,187,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,1,1,16271,-1,0.00020371367,0.99979633
17528,breast cancer,5,7,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,17528,-1,0.00021347153,0.99978656
10590,weakness,28,29,190,198,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,1,1,10590,-1,0.00021712064,0.99978286
13450,hyperkalemia,11,12,61,73,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1,13450,-1,0.0001834311,0.9998166
6283,encephalopathy,5,6,33,47,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1,6283,-1,0.00020844935,0.99979156
2000,urticaria,11,12,58,67,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1,2000,-1,0.0025713816,0.9974286
12441,cardiotoxicity,5,6,25,39,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,1,1,12441,-1,0.00020236683,0.99979764
18062,epileptic,4,5,15,24,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,1,1,18062,-1,0.0002141667,0.99978584
131,proteinuria,16,17,91,102,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,-1,1,1,131,-1,0.00022849426,0.99977154
6718,hypertensive,2,3,7,19,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,1,1,6718,-1,0.00019381358,0.9998062
15736,proteinuria,26,27,166,177,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,1,1,15736,-1,0.00022220165,0.99977785
6725,ischemia,11,12,76,84,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,1,1,6725,-1,0.00019372214,0.99980634
2822,cardiac arrest,6,8,33,47,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,-1,1,1,2822,-1,0.00020435583,0.9997956
15952,hypotension,4,5,26,37,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,-1,1,1,15952,-1,0.0002066984,0.99979335
17785,endometrial cancer,9,11,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,17785,-1,0.00019890963,0.9998011
4171,toxicity,23,24,172,180,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,1,1,4171,-1,0.00021720452,0.99978286
13147,rigidity,29,30,152,160,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,1,1,13147,-1,0.00020964188,0.9997904
11373,ischemia,18,19,118,126,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,1,1,11373,-1,0.00019995663,0.9998
4211,migraine,26,27,166,174,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,1,1,4211,-1,0.00020640691,0.9997936
11677,Renal damage,0,2,0,12,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,1,1,11677,-1,0.00018067681,0.99981934
1881,seizure,7,8,41,48,"However, these other potential causes of seizure were ruled out.",11573852_7,-1,1,1,1881,-1,0.00023956393,0.99976045
8792,toxicity,9,10,72,80,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,-1,1,1,8792,-1,0.00021751663,0.9997825
11930,prolactinoma,23,24,173,185,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,11930,-1,0.00021266988,0.9997874
13802,milk fever,25,27,140,150,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13802,-1,0.0042377845,0.9957623
12665,hemolytic anemia,3,5,30,46,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,1,1,12665,-1,0.00021330224,0.9997867
9280,breast cancer,40,42,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1,9280,-1,0.0002024585,0.9997975
4033,neurotoxic,7,8,42,52,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,1,1,4033,-1,0.00018833808,0.9998117
8085,hyperactivity,1,2,17,30,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,1,1,8085,-1,0.00018857168,0.9998115
1586,Nephrotoxicity,0,1,0,14,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,-1,1,1,1586,-1,0.00018572446,0.99981433
15325,schizophrenic,11,12,94,107,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,1,1,15325,-1,0.0002168511,0.9997832
1193,seizures,2,3,22,30,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,-1,1,1,1193,-1,0.00019575366,0.9998043
16117,hypertensive,12,13,111,123,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,1,1,16117,-1,0.00020278849,0.9997973
16190,cardiac toxicity,9,11,37,53,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1,16190,-1,0.00022328562,0.9997768
15931,Depression,0,1,0,10,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,1,1,15931,-1,0.00019189934,0.99980813
2090,nephrotoxicity,19,20,128,142,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2090,-1,0.00021041931,0.99978966
12478,locomotor hyperactivity,8,10,65,88,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,1,1,12478,-1,0.00020148714,0.9997985
5507,hypercalcemia,16,17,111,124,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,1,1,5507,-1,0.00020827987,0.9997917
4716,Tremor,0,1,0,6,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,-1,1,1,4716,-1,0.00018634956,0.9998136
2335,seizures,10,11,50,58,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,-1,1,1,2335,-1,0.00018376425,0.99981624
4435,ascites,19,20,128,135,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,1,1,4435,-1,0.00021489285,0.9997851
17062,hypotension,1,2,11,22,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,1,1,17062,-1,0.00021233452,0.9997876
9376,hyperactivity,7,8,49,62,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,1,1,9376,-1,0.0002087069,0.9997913
11000,Neurotoxicity,0,1,0,13,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,1,1,11000,-1,0.00018420843,0.99981576
3654,convulsions,15,16,100,111,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,1,1,3654,-1,0.0002036317,0.99979633
9901,coagulopathy,32,33,230,242,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,-1,1,1,9901,-1,0.00021268082,0.9997874
9328,peripheral neuropathy,1,3,6,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,1,1,9328,-1,0.00023131847,0.9997687
5729,neuropathic pain,17,19,83,99,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,1,1,5729,-1,0.00019419871,0.99980587
16651,pain,9,10,47,51,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,-1,1,1,16651,-1,0.00019528645,0.9998047
17808,hypersensitivity,9,10,46,62,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,-1,1,1,17808,-1,0.00019829725,0.9998017
16323,myalgia,18,19,109,116,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,1,1,16323,-1,0.0002063054,0.9997937
6478,hepatocellular carcinoma,13,15,68,92,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1,6478,-1,0.00020532616,0.99979466
18097,sexual dysfunction,29,31,167,185,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1,18097,-1,0.0003425334,0.9996575
680,pain,6,7,41,45,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1,680,-1,0.00021130775,0.9997887
1355,convulsions,23,24,118,129,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,-1,1,1,1355,-1,0.00021603961,0.99978393
10243,hypotension,11,12,104,115,Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).,2024540_5,-1,1,1,10243,-1,0.0002260045,0.99977404
15692,nephrolithiasis,1,2,22,37,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,1,1,15692,-1,0.00023006431,0.99977
13883,hypotension,7,8,67,78,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,13883,-1,0.00020721697,0.99979275
1409,anuria,2,3,19,25,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,1,1,1409,-1,0.00022747868,0.9997725
3065,visual hallucinations,6,8,37,58,None of the patients had experienced visual hallucinations before this event.,12523465_5,-1,1,1,3065,-1,0.00019403658,0.999806
8816,dyskinesia,14,15,108,118,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,-1,1,1,8816,-1,0.0002210405,0.9997789
17285,tumor,17,18,97,102,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,1,1,17285,-1,0.00020867506,0.9997913
4194,migraine,21,22,138,146,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,1,1,4194,-1,0.00020334378,0.9997967
12353,rigidity,5,6,58,66,Intracranial pressure increases during alfentanil-induced rigidity.,3125768_0,-1,1,1,12353,-1,0.0002266791,0.9997733
14391,amnesia,79,80,467,474,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,1,1,14391,-1,0.00021644331,0.9997836
16845,hepatic damage,5,7,30,44,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1,16845,-1,0.00019938263,0.9998006
10378,schizophrenia,17,18,119,132,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,-1,1,1,10378,-1,0.00021132971,0.9997887
6556,extrapyramidal symptoms,3,5,27,50,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,1,1,6556,-1,0.00022518628,0.9997749
10105,pain,10,11,70,74,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,1,1,10105,-1,0.00022172715,0.99977833
13472,liver disease,3,5,21,34,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,-1,1,1,13472,-1,0.00017202055,0.999828
13344,prostate cancer,10,12,52,67,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,1,1,13344,-1,0.00020062123,0.99979943
3744,vomiting,8,9,48,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1,3744,-1,0.00020943652,0.9997906
637,hypotension,23,24,160,171,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,1,1,637,-1,0.00021241451,0.9997876
17626,pain,2,3,21,25,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,-1,1,1,17626,-1,0.000180181,0.9998198
3327,nephrotoxicity,25,26,130,144,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,1,1,3327,-1,0.00019457015,0.9998055
18186,cardiotoxic,8,9,51,62,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,1,1,18186,-1,0.00021275504,0.9997873
10119,diabetic nephropathy,13,15,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,-1,1,1,10119,-1,0.00020625896,0.9997937
11135,seizure,13,14,94,101,Both patients had received maximum doses of other beta-lactam antibiotics without evidence of seizure activity.,2343592_4,-1,1,1,11135,-1,0.00021863508,0.9997814
3762,Delirium,2,3,13,21,"CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.",12905102_6,-1,1,1,3762,-1,0.00019017218,0.9998098
7971,neuropathy,14,15,89,99,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1,7971,-1,0.00022989216,0.9997701
530,calcification,42,43,249,262,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,1,1,530,-1,0.00023267174,0.99976736
141,neurotoxicity,7,8,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,-1,1,1,141,-1,0.00021208789,0.999788
7361,myocarditis,12,13,75,86,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,-1,1,1,7361,-1,0.00016494193,0.999835
17978,toxicity,6,7,30,38,No other risk factors for CNS toxicity were identified.,9672936_4,-1,1,1,17978,-1,0.00021477262,0.99978524
7625,rheumatoid arthritis,5,7,47,67,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,7625,-1,0.00019654493,0.9998035
14178,ventricular tachycardia,3,5,28,51,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,1,1,14178,-1,0.0002114466,0.9997886
4819,sensorineural hearing loss,17,20,79,105,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,1,1,4819,-1,0.00022198034,0.999778
13487,cholestasis,14,15,100,111,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,1,1,13487,-1,0.00020740656,0.99979264
11493,hyperalgesia,8,9,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,1,1,11493,-1,0.00016891508,0.9998311
4310,coma,23,24,166,170,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,1,1,4310,-1,0.00021948911,0.9997805
4237,seizures,26,27,168,176,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1,4237,-1,0.00020544385,0.99979454
14199,ataxia,9,10,61,67,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1,14199,-1,0.00023149652,0.99976856
11500,albuminuria,18,19,101,112,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,-1,1,1,11500,-1,0.00021712894,0.99978286
13819,Migraine,0,1,0,8,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1,13819,-1,0.00020670018,0.99979335
8328,hepatitis,6,7,44,53,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,1,1,8328,-1,0.00020828782,0.9997917
2268,hyperprolactinemia,14,15,102,120,These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.,11838826_3,-1,1,1,2268,-1,0.00019694828,0.9998031
3107,hepatotoxic,20,21,132,143,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,1,1,3107,-1,0.0002068861,0.9997931
16045,cancer,3,4,19,25,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,1,1,16045,-1,0.00019427687,0.99980575
10964,dry mouth,13,15,73,82,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,1,1,10964,-1,0.0002751293,0.9997248
180,Hypothyroidism,2,3,9,23,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,-1,1,1,180,-1,0.0002052786,0.9997948
17134,seizures,40,41,221,229,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,1,1,17134,-1,0.00021178699,0.9997882
7841,hyperprolactinemia,11,12,66,84,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,1,1,7841,-1,0.00039650474,0.99960357
3580,myalgia,34,35,206,213,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1,3580,-1,0.00020687882,0.9997931
1878,seizures,18,19,96,104,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,1,1,1878,-1,0.00020719328,0.9997929
3015,nausea,32,33,154,160,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,-1,1,1,3015,-1,0.00022168105,0.99977833
10304,acute lymphoblastic leukemia,7,10,57,85,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,1,1,10304,-1,0.00019467408,0.9998054
13102,rigidity,1,2,15,23,Post-operative rigidity after fentanyl administration.,3780697_0,-1,1,1,13102,-1,0.00019608655,0.99980396
14680,aplastic anemia,10,12,65,80,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,-1,1,1,14680,-1,0.0001844559,0.9998155
3579,myalgia,22,23,140,147,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1,3579,-1,0.00020635243,0.9997937
340,migraine,43,44,227,235,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,1,1,340,-1,0.00019650054,0.9998035
17549,toxicities,1,2,6,16,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1,17549,-1,0.00022394591,0.99977607
4463,rigidity,29,30,134,142,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,1,1,4463,-1,0.00021385594,0.9997862
13445,anuria,9,10,65,71,The serum gentamicin concentration had reached toxic levels when anuria developed.,4069770_2,-1,1,1,13445,-1,0.00022974797,0.9997702
7640,thrombotic,8,9,56,66,"General safety was also assessed, including adjudicated thrombotic cardiovascular event data.",17965424_4,-1,1,1,7640,-1,0.00019113491,0.99980885
7153,hypertension,1,2,23,35,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,1,1,7153,-1,0.00021134643,0.9997887
2103,neuropathy,20,21,142,152,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2103,-1,0.00022222959,0.99977773
16964,Seizure,0,1,0,7,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,1,1,16964,-1,0.00022479928,0.99977523
1795,asystole,1,2,5,13,"When asystole was recorded, drug infusion was stopped and a resuscitation sequence was begun.",11524350_6,-1,1,1,1795,-1,0.00024836883,0.9997516
723,aggressiveness,21,22,144,158,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,-1,1,1,723,-1,0.00021407095,0.99978596
16149,pain,5,6,48,52,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,-1,1,1,16149,-1,0.00023817923,0.9997619
3048,glaucoma,10,11,84,92,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,1,1,3048,-1,0.00021644167,0.9997836
13732,cardiac hypertrophy,3,5,37,56,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,-1,1,1,13732,-1,0.00021169696,0.99978834
10115,diabetic nephropathy,7,9,54,74,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,-1,1,1,10115,-1,0.00020655044,0.99979347
11215,depression,17,18,138,148,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,1,1,11215,-1,0.00022224295,0.99977773
12324,rigidity,4,5,23,31,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,1,1,12324,-1,0.0002265754,0.99977344
27,hypercalcemia,7,8,46,59,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,1,1,27,-1,0.00020957914,0.9997905
1962,vomiting,15,16,87,95,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1,1962,-1,0.00024129396,0.99975866
15212,irritability,34,35,198,210,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1,15212,-1,0.00023094229,0.99976903
4502,bladder cancer,4,6,22,36,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,4502,-1,0.00020629044,0.9997937
5949,memory impairment,6,8,28,45,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,1,1,5949,-1,0.00021488896,0.9997851
4644,death,30,31,184,189,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,-1,1,1,4644,-1,0.00024193554,0.99975806
7116,schizophrenia,10,11,52,65,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,1,1,7116,-1,0.00018586371,0.9998142
9926,cardiac arrhythmias,1,3,6,25,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,1,1,9926,-1,0.00020987107,0.99979013
4046,hemolysis,12,13,90,99,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1,4046,-1,0.0002034753,0.99979657
5506,hypocalcemia,8,9,63,75,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,1,1,5506,-1,0.0002041792,0.99979585
5481,death,4,5,31,36,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,1,1,5481,-1,0.00025199328,0.99974805
2783,asystole,24,25,149,157,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,1,1,2783,-1,0.00020935205,0.9997906
285,hypotensive,19,20,114,125,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,-1,1,1,285,-1,0.00021021334,0.9997898
5694,sensorineural hearing loss,33,36,198,224,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,5694,-1,0.0031149876,0.996885
334,pain,20,21,112,116,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,1,1,334,-1,0.00021270839,0.9997873
4802,gallbladder disease,22,24,136,155,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,4802,-1,0.00021493055,0.9997851
7385,fatigue,26,27,180,187,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1,7385,-1,0.000216933,0.9997831
10492,Diabetes,0,1,0,8,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,1,1,10492,-1,0.0002044681,0.9997955
5724,Secondary hyperalgesia,0,2,0,22,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,5724,-1,0.0010988718,0.9989011
18236,cholestasis,6,7,35,46,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,18236,-1,0.0002055816,0.9997944
402,tetany,10,11,70,76,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,1,1,402,-1,0.00021613193,0.99978393
4619,myocarditis,9,10,54,65,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,1,1,4619,-1,0.00021353949,0.99978644
13731,bone marrow suppression,39,42,255,278,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1,13731,-1,0.00024824194,0.99975175
4728,Tremor,0,1,0,6,Tremor was measured simultaneously by two independent observers.,15338796_11,-1,1,1,4728,-1,0.0002118787,0.9997881
3813,seizures,4,5,30,38,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,1,1,3813,-1,0.00021344953,0.99978656
4720,Tremor,2,3,9,15,METHODS: Tremor was measured using a laser pointer technique.,15338796_4,-1,1,1,4720,-1,0.0002010471,0.99979895
16293,polyneuropathy,19,20,92,106,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,16293,-1,0.00020970147,0.9997904
4659,convulsions,6,7,50,61,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,-1,1,1,4659,-1,0.00019481443,0.99980515
11231,paralysis,1,2,9,18,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,1,1,11231,-1,0.00018080419,0.9998192
12798,ototoxicity,29,30,242,253,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,-1,1,1,12798,-1,0.00023896716,0.99976104
9079,hypotension,3,4,21,32,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,1,1,9079,-1,0.0002100076,0.99979
18098,seizure,36,37,212,219,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1,18098,-1,0.00022139146,0.99977857
2814,asystole,13,14,96,104,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,-1,1,1,2814,-1,0.0002156227,0.9997844
5384,seizures,6,7,35,43,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,1,1,5384,-1,0.00021086034,0.9997892
11043,breast cancer,5,7,37,50,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1,11043,-1,0.00020239867,0.99979764
7893,glycosuria,16,17,118,128,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,7893,-1,0.00021430459,0.9997857
5605,vasculitis,15,16,120,130,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,1,1,5605,-1,0.00019732458,0.99980265
13084,diabetic,12,13,77,85,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,1,1,13084,-1,0.00021531472,0.99978465
4124,Cystitis,0,1,0,8,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,1,1,4124,-1,0.00021604392,0.99978393
10124,renal damage,14,16,96,108,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,-1,1,1,10124,-1,0.00021646809,0.9997836
11515,glomerular sclerosis,9,11,56,76,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,-1,1,1,11515,-1,0.00016365186,0.9998363
1835,ventricular tachycardia,10,12,49,72,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,1,1,1835,-1,0.00021309774,0.9997869
8325,hepatitis,17,18,65,74,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,1,1,8325,-1,0.00019551955,0.99980456
1172,thrombocytopenia,9,10,52,68,"World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively.",11135224_10,-1,1,1,1172,-1,0.00017820553,0.99982184
6690,depression,11,12,74,84,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,1,1,6690,-1,0.00021073793,0.9997893
1940,rheumatoid arthritis,28,30,177,197,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1940,-1,0.0001983014,0.9998017
8299,atherosclerotic,17,18,100,115,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,1,1,8299,-1,0.00020244827,0.9997975
15684,Hallucinations,2,3,13,27,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,-1,1,1,15684,-1,0.00018672075,0.99981326
9465,hypotension,9,10,55,66,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,1,1,9465,-1,0.00020413694,0.99979585
14701,cardiomyopathy,1,2,4,18,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,1,1,14701,-1,0.00020825012,0.9997918
9486,seizures,6,7,43,51,RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.,19707748_5,-1,1,1,9486,-1,0.00020689006,0.9997931
7575,bruising,15,16,81,89,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,1,1,7575,-1,0.00016912782,0.99983084
9228,proteinuria,15,16,98,109,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,-1,1,1,9228,-1,0.00021773511,0.99978226
8570,proteinuria,12,13,88,99,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,-1,1,1,8570,-1,0.00020214563,0.9997979
2451,exencephaly,6,7,52,63,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,2451,-1,0.00020398907,0.999796
166,Angioedema,0,1,0,10,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,1,1,166,-1,0.00016842519,0.99983156
12955,hypotension,13,14,99,110,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,1,1,12955,-1,0.00020299315,0.99979705
11421,migraine,7,8,44,52,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,1,1,11421,-1,0.00017405489,0.999826
5536,Hypersensitivity,0,1,0,16,"Hypersensitivity to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.",1610717_7,-1,1,1,5536,-1,0.00021097457,0.99978906
13188,renal dysfunction,20,22,124,141,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,1,1,13188,-1,0.00019712807,0.9998029
10524,proteinuria,15,16,98,109,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,1,1,10524,-1,0.00021389489,0.9997861
2617,catalepsy,8,9,49,58,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,1,1,2617,-1,0.00021182717,0.9997882
5021,hypertrophy,6,7,43,54,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,1,1,5021,-1,0.00020267925,0.9997973
15171,renal dysfunction,7,9,57,74,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,1,1,15171,-1,0.00020343045,0.99979657
12986,Manic,0,1,0,5,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,1,1,12986,-1,0.0054760226,0.994524
13257,nephrotoxicity,9,10,74,88,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1,13257,-1,0.00018617765,0.99981385
1253,hypotension,22,23,157,168,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,1,1,1253,-1,0.00020310505,0.9997969
8090,hyperactivity,8,9,64,77,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,1,1,8090,-1,0.0002172451,0.99978274
2229,seizures,4,5,20,28,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,1,1,2229,-1,0.00017349086,0.9998265
1800,seizures,9,10,70,78,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,1,1,1800,-1,0.00023130127,0.9997687
9027,renal injury,8,10,64,76,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1,9027,-1,0.0002064766,0.9997936
5581,amnesia,4,5,23,30,Learning of rats under amnesia caused by pentobarbital.,1616457_0,-1,1,1,5581,-1,0.00016967976,0.99983025
1886,seizures,12,13,66,74,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,1,1,1886,-1,0.0001971352,0.9998029
3914,bradycardia,3,4,17,28,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,-1,1,1,3914,-1,0.00020873795,0.9997913
17758,Cancer,12,13,54,60,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,17758,-1,0.00021861026,0.9997814
7686,pain,2,3,13,17,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,1,1,7686,-1,0.00018149371,0.9998185
8931,convulsions,26,27,154,165,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,-1,1,1,8931,-1,0.0002304285,0.9997696
2083,breast carcinoma,13,15,71,87,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2083,-1,0.00021360793,0.99978644
16618,polyuria,19,20,107,115,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1,16618,-1,0.00021046543,0.99978954
5439,hiccups,2,3,33,40,Possible azithromycin-associated hiccups.,15985056_0,-1,1,1,5439,-1,0.00022161768,0.99977845
14658,arrhythmia,5,6,21,31,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,1,1,14658,-1,0.0002101436,0.9997899
10020,epileptic,18,19,109,118,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1,10020,-1,0.00021840545,0.99978155
760,cocaine abuse,9,11,66,79,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,1,1,760,-1,0.0054711453,0.99452883
3802,hemolytic anemia,12,14,97,113,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,3802,-1,0.00021729214,0.99978274
14582,carcinoma,9,10,48,57,"In both instances, suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix.",7088431_3,-1,1,1,14582,-1,0.00020713639,0.9997929
7800,bradycardia,21,22,76,87,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1,7800,-1,0.00022163033,0.99977833
13089,diabetic,13,14,68,76,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,1,1,13089,-1,0.00019948132,0.9998005
2240,thrombocytopenia,2,3,30,46,Delayed-onset heparin-induced thrombocytopenia.,11827497_0,-1,1,1,2240,-1,0.00021472469,0.99978524
9246,dementia,6,7,44,52,Components of lemon essential oil attenuate dementia induced by scopolamine.,19356307_0,-1,1,1,9246,-1,0.00017450389,0.99982554
5462,hiccups,15,16,95,102,Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.,15985056_10,-1,1,1,5462,-1,0.00020445313,0.9997956
11204,cerebral haemorrhage,4,6,21,41,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1,11204,-1,0.00020142682,0.9997986
7146,seizures,12,13,85,93,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,1,1,7146,-1,0.00020373426,0.99979633
5478,seizures,28,29,149,157,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,1,1,5478,-1,0.00022055398,0.9997794
10132,nephropathy,4,5,51,62,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,1,1,10132,-1,0.00021456242,0.9997855
15273,glomerulonephritis,6,7,45,63,Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out.,7834920_4,-1,1,1,15273,-1,0.0003593276,0.9996407
868,pain,30,31,150,154,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1,868,-1,0.0002205773,0.9997794
605,depressed,9,10,75,84,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,1,1,605,-1,0.00022175969,0.9997782
6467,diabetes,7,8,57,65,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,-1,1,1,6467,-1,0.00022082374,0.99977916
9243,proteinuria,7,8,58,69,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,-1,1,1,9243,-1,0.00020901755,0.99979097
6315,hypertension,7,8,64,76,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,1,1,6315,-1,0.00021350167,0.99978656
5592,osteoporosis,8,9,61,73,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,1,1,5592,-1,0.00022884311,0.9997712
10848,neutropenia,8,9,48,59,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,1,1,10848,-1,0.00021049153,0.99978954
17750,diarrhea,7,8,49,57,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,1,1,17750,-1,0.00022043328,0.9997795
11164,hyperemia,9,10,72,81,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,1,1,11164,-1,0.00022922919,0.9997708
12226,toxicity,10,11,66,74,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1,12226,-1,0.00021173953,0.9997882
16386,atrophy,32,33,183,190,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,16386,-1,0.00021258835,0.9997874
14619,seizures,22,23,109,117,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,1,1,14619,-1,0.00021108583,0.99978894
4519,hypotension,9,10,72,83,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,1,1,4519,-1,0.00021619251,0.9997838
8338,cystitis,17,18,145,153,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,-1,1,1,8338,-1,0.0002059917,0.99979407
12911,nephrotoxicity,4,5,30,44,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,1,1,12911,-1,0.00020687505,0.9997931
15061,Overdose,0,1,0,8,Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.,7651879_3,-1,1,1,15061,-1,0.00022106474,0.9997789
2324,seizures,6,7,34,42,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1,2324,-1,0.00017698173,0.99982303
13367,carcinoma,6,7,47,56,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,-1,1,1,13367,-1,0.00022403432,0.99977595
8411,hypotension,13,14,80,91,Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia.,18513945_8,-1,1,1,8411,-1,0.00020093634,0.9997991
17732,parkinsonian,4,5,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1,17732,-1,0.00021759815,0.9997824
8598,cardiotoxicity,13,14,103,117,"Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.",18674790_2,-1,1,1,8598,-1,0.0002000272,0.9998
4979,hyperkalemia,4,5,47,59,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,1,1,4979,-1,0.0002068232,0.99979323
10018,epileptic,7,8,38,47,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1,10018,-1,0.00021458657,0.9997855
10151,nephropathy,2,3,8,19,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,1,1,10151,-1,0.00018354149,0.9998165
9874,seizures,4,5,21,29,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,1,1,9874,-1,0.00021348087,0.99978656
5378,seizures,1,2,11,19,BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.,1592014_6,-1,1,1,5378,-1,0.00017359015,0.9998265
2288,hepatitis,13,14,68,77,"There was no evidence for viral, autoimmune, or metabolic causes of hepatitis.",11847945_3,-1,1,1,2288,-1,0.00021278771,0.9997873
12682,infection,22,23,127,136,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,1,1,12682,-1,0.000259098,0.9997409
5576,bradycardia,11,12,75,86,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,1,1,5576,-1,0.00021332136,0.9997867
4560,arthritis,20,21,171,180,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,1,1,4560,-1,0.00022647929,0.99977356
3362,prostate cancer,14,16,76,91,"PATIENTS: Seventy men, aged 50-80 years, with advanced androgen-independent prostate cancer.",12627929_4,-1,1,1,3362,-1,0.00020088675,0.9997992
9872,seizures,3,4,18,26,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,1,1,9872,-1,0.00020379662,0.9997962
6065,hemolytic anemia,25,27,156,172,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,1,1,6065,-1,0.00021657585,0.99978346
6909,seizures,25,26,136,144,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,1,1,6909,-1,0.00022393097,0.99977607
13541,fibrosis,9,10,53,61,Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight.,4812392_3,-1,1,1,13541,-1,0.0001882982,0.9998117
6056,anemia,4,5,29,35,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,1,1,6056,-1,0.00019688463,0.9998031
15115,renal toxicity,6,8,45,59,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,-1,1,1,15115,-1,0.00021058427,0.9997894
16013,Myopathy,0,1,0,8,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,1,1,16013,-1,0.00019306217,0.99980694
7240,acute myocardial infarction,10,13,73,100,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,1,1,7240,-1,0.00021166305,0.99978834
7947,thrombosis,10,11,58,68,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1,7947,-1,0.00022919466,0.9997708
2856,convulsion,5,6,32,42,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,1,1,2856,-1,0.00021537243,0.99978465
12278,hepatic injury,23,25,167,181,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,1,1,12278,-1,0.00021877374,0.9997812
2001,angioedema,24,25,147,157,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1,2001,-1,0.0002131209,0.9997869
14681,aplastic anemia,4,6,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,1,1,14681,-1,0.00016760592,0.9998324
4725,tremor,1,2,9,15,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,-1,1,1,4725,-1,0.00021991583,0.9997801
8857,arrhythmia,12,13,69,79,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,1,1,8857,-1,0.00019261573,0.9998074
9022,glomerular sclerosis,18,20,89,109,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,1,1,9022,-1,0.00023765022,0.99976236
5559,myoclonus,7,8,52,61,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,1,1,5559,-1,0.00021585225,0.9997842
12408,cardiotoxicity,7,8,46,60,"None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.",3137399_8,-1,1,1,12408,-1,0.00019449224,0.9998055
11897,tachycardia,7,8,73,84,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,-1,1,1,11897,-1,0.00021269683,0.9997873
15274,glomerulonephritis,9,10,68,86,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,1,1,15274,-1,0.0003738268,0.99962616
9230,proteinuria,25,26,166,177,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,-1,1,1,9230,-1,0.0002175519,0.9997825
6799,proteinuria,17,18,91,102,"Before conversion 8 (32%) patients had no proteinuria, whereas afterwards all patients had proteinuria.",17175308_8,-1,1,1,6799,-1,0.00020991132,0.99979013
4657,convulsions,6,7,48,59,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,-1,1,1,4657,-1,0.00020305374,0.9997969
12696,breast cancer,13,15,66,79,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1,12696,-1,0.00020331568,0.9997967
3169,hypertension,3,4,32,44,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1,3169,-1,0.00020486815,0.99979514
18343,hypertension,18,19,106,118,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,1,1,18343,-1,0.00022593426,0.99977404
4787,cataracts,5,6,42,51,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1,4787,-1,0.00034491238,0.9996551
160,fever,8,9,57,62,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,1,1,160,-1,0.00022516912,0.9997749
17430,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1,17430,-1,0.00020260796,0.9997974
14820,cardiotoxicity,22,23,151,165,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,-1,1,1,14820,-1,0.00019239787,0.99980766
1365,tumors,29,30,186,192,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,1,1,1365,-1,0.00020424988,0.99979573
8807,deaths,1,2,6,12,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,1,1,8807,-1,0.00021501542,0.999785
3206,nephrotoxic,18,19,116,127,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,1,1,3206,-1,0.0002055373,0.9997944
3111,infection,8,9,49,58,There is no evidence of antecedent or concurrent infection in this patient.,1255900_3,-1,1,1,3111,-1,0.000212904,0.99978715
1975,nausea,20,21,102,108,Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea.,11679859_10,-1,1,1,1975,-1,0.00024169024,0.9997583
9217,encephalopathy,14,15,120,134,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,1,1,9217,-1,0.00020135829,0.9997987
13707,Epileptic,0,1,0,9,Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.,6153967_5,-1,1,1,13707,-1,0.00021623375,0.9997838
4389,poisoning,25,26,153,162,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,1,1,4389,-1,0.00022388103,0.9997762
6463,atherosclerosis,7,8,37,52,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,1,1,6463,-1,0.00019776082,0.9998023
14889,bradycardia,1,2,15,26,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,-1,1,1,14889,-1,0.00021732716,0.99978274
2323,death,20,21,116,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,1,1,2323,-1,0.00019742115,0.99980265
3994,depression,11,12,86,96,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,1,1,3994,-1,0.00021351833,0.99978644
8136,nephrotoxicity,3,4,32,46,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,1,1,8136,-1,0.00019113383,0.99980885
16074,chronic renal failure,7,10,42,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1,16074,-1,0.00020281071,0.99979717
2603,catalepsy,5,6,35,44,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,1,1,2603,-1,0.00021384473,0.9997862
128,proteinuria,15,16,91,102,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,1,1,128,-1,0.0002219524,0.9997781
2330,seizures,6,7,34,42,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1,2330,-1,0.00021376337,0.9997862
11662,hypertension,18,19,139,151,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,-1,1,1,11662,-1,0.00021132367,0.9997887
12534,hypotension,11,12,98,109,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,-1,1,1,12534,-1,0.00020238516,0.99979764
8732,jaundice,10,11,61,69,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,1,1,8732,-1,0.00020542719,0.99979454
10402,Extrapyramidal symptoms,0,2,0,23,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,1,1,10402,-1,0.00020970426,0.9997904
11278,ventricular arrhythmias,7,9,62,85,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,1,1,11278,-1,0.0002163086,0.9997837
884,atrophy,7,8,58,65,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,1,1,884,-1,0.0001986125,0.99980146
16077,visual hallucinations,5,7,32,53,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,1,1,16077,-1,0.00017412892,0.9998259
3853,Thromboembolic,0,1,0,14,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,1,1,3853,-1,0.000178035,0.99982196
9207,encephalopathy,12,13,94,108,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,1,1,9207,-1,0.00020932152,0.9997907
14870,hepatitis,3,4,18,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,1,1,14870,-1,0.00020488066,0.99979514
13840,hyperactivity,15,16,129,142,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,-1,1,1,13840,-1,0.00020908097,0.99979097
17259,thrombocytopenia,9,10,51,67,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,1,1,17259,-1,0.0002045188,0.9997955
13822,neuropathy,12,13,48,58,"In 26.5% of all the cases, the aetiology of the neuropathy was undetermined.",6287825_9,-1,1,1,13822,-1,0.00018785564,0.9998122
3632,prostate cancer,7,9,48,63,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,1,1,3632,-1,0.00021798917,0.999782
1185,incontinence,12,13,74,86,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,1,1,1185,-1,0.0001861001,0.999814
13593,Dizziness,0,1,0,9,"Dizziness was less marked than sedation, but increased with the dose.",6103707_7,-1,1,1,13593,-1,0.002289971,0.99771
5514,ischemia,22,23,139,147,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1,5514,-1,0.00021539193,0.99978465
15889,seizures,34,35,215,223,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,1,1,15889,-1,0.00021817193,0.9997818
15181,pain,13,14,79,83,Response to treatment was estimated by the visual analog scale for severity of pain.,7791169_4,-1,1,1,15181,-1,0.00019909257,0.999801
11031,necrosis,5,6,33,41,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,1,1,11031,-1,0.00019594673,0.9998041
2515,dyskinesias,24,25,164,175,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,1,1,2515,-1,0.00020959212,0.9997904
14451,convulsions,10,11,54,65,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,1,1,14451,-1,0.00019969732,0.99980026
9044,pain,12,13,93,97,Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse.,19269743_2,-1,1,1,9044,-1,0.00020616951,0.9997938
18255,mitral regurgitation,16,18,98,118,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,1,1,18255,-1,0.00021480722,0.99978524
3651,convulsions,63,64,384,395,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1,3651,-1,0.0002166566,0.99978334
2732,anemia,11,12,75,81,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,-1,1,1,2732,-1,0.00021789796,0.99978215
8414,nephrosis,19,20,135,144,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,1,1,8414,-1,0.00021306929,0.9997869
9238,Proteinuria,0,1,0,11,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,-1,1,1,9238,-1,0.00021838341,0.99978167
16446,pain,22,23,83,87,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1,16446,-1,0.00021427864,0.9997857
4535,overdose,11,12,71,79,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,1,1,4535,-1,0.00019033691,0.9998097
6321,toxicity,15,16,98,106,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,1,1,6321,-1,0.00020441198,0.9997956
7531,jaundice,37,38,191,199,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,1,1,7531,-1,0.00022765053,0.99977237
13521,fasciculation,8,9,46,59,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,1,1,13521,-1,0.00020170186,0.99979836
145,toxicity,1,2,9,17,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,1,1,145,-1,0.00021967798,0.99978036
13748,arrhythmia,11,12,81,91,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,1,1,13748,-1,0.00020325328,0.9997968
3954,nephropathy,5,6,37,48,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,1,1,3954,-1,0.0001985856,0.99980146
1935,dermatitis,7,8,48,58,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1935,-1,0.00019601718,0.99980396
194,hypothyroidism,10,11,59,73,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,1,1,194,-1,0.00020683443,0.99979323
10023,seizures,20,21,113,121,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,1,1,10023,-1,0.00021294826,0.99978703
11830,seizures,11,12,73,81,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,1,1,11830,-1,0.00020662548,0.99979335
12811,Nephrotoxicity,0,1,0,14,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,1,1,12811,-1,0.00021190071,0.9997881
4929,proteinuria,10,11,67,78,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,1,1,4929,-1,0.0002446134,0.99975544
2168,hypersensitivity,11,12,81,97,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,-1,1,1,2168,-1,0.000199808,0.99980026
5557,glioblastoma,4,5,40,52,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,1,1,5557,-1,0.00018985911,0.99981016
93,cystitis,12,13,101,109,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,-1,1,1,93,-1,0.00022673338,0.9997733
8441,vomiting,23,24,137,145,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,1,1,8441,-1,0.00020400989,0.999796
16481,bradycardia,17,18,86,97,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,1,1,16481,-1,0.00021614715,0.9997838
4858,stroke,32,33,155,161,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1,4858,-1,0.00022280394,0.99977726
11444,eosinophilia,19,20,132,144,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1,11444,-1,0.0028455777,0.99715436
8833,nausea,15,16,80,86,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1,8833,-1,0.00021973181,0.99978024
13715,carcinoma,3,4,19,28,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,13715,-1,0.00021344729,0.99978656
14606,Deaths,0,1,0,6,Deaths from local anesthetic-induced convulsions in mice.,7189975_0,-1,1,1,14606,-1,0.00021633292,0.9997837
3577,myalgia,4,5,26,33,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1,3577,-1,0.00020388018,0.9997961
13794,milk fever,11,13,57,67,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,1,1,13794,-1,0.0037049234,0.99629503
17067,hypotension,46,47,212,223,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,1,1,17067,-1,0.00021053066,0.99978954
7630,rheumatoid arthritis,47,49,350,370,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,7630,-1,0.00019789985,0.9998022
8200,neurotoxicity,30,31,172,185,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,1,1,8200,-1,0.00021959463,0.9997805
18111,stroke,7,8,47,53,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,-1,1,1,18111,-1,0.00021255188,0.9997875
3866,hypertensive,12,13,126,138,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,1,1,3866,-1,0.00022791789,0.99977213
9237,proteinuria,22,23,141,152,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,-1,1,1,9237,-1,0.00021761494,0.9997824
5769,amnesia,11,12,93,100,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,1,1,5769,-1,0.00020056634,0.99979943
16175,Angioedema,0,1,0,10,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,1,1,16175,-1,0.00020739152,0.99979264
11221,weakness,4,5,32,40,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,1,1,11221,-1,0.00021355764,0.99978644
13658,hypotension,11,12,80,91,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,1,1,13658,-1,0.00020913755,0.99979085
17029,hepatotoxic,27,28,132,143,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,1,1,17029,-1,0.00022478084,0.99977523
2453,exencephalic,23,24,160,172,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,2453,-1,0.00021512821,0.9997849
1280,proteinuria,7,8,45,56,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,1,1,1280,-1,0.0002188693,0.9997812
7732,dizziness,8,9,45,54,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,1,1,7732,-1,0.0029498546,0.99705017
701,neurotoxicity,5,6,38,51,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,701,-1,0.00022645855,0.99977356
1982,headache,8,9,53,61,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,-1,1,1,1982,-1,0.00020877457,0.9997912
18124,stroke,12,13,66,72,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,-1,1,1,18124,-1,0.00022573961,0.9997743
5900,pruritus,16,17,62,70,"The grade of sedation (none, mild, moderate, severe), nausea, pruritus, and apnea were recorded after injection of both drugs.",16563323_7,-1,1,1,5900,-1,0.00021527306,0.99978477
16866,hypertension,26,27,163,175,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,-1,1,1,16866,-1,0.00021792497,0.99978215
3646,convulsions,31,32,193,204,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1,3646,-1,0.00021887955,0.9997812
8651,sensorineural hearing loss,12,15,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,-1,1,1,8651,-1,0.00038103136,0.9996189
16215,hypertensive,4,5,20,32,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,1,1,16215,-1,0.00020108583,0.99979895
